<SEC-DOCUMENT>0001485003-24-000005.txt : 20240401
<SEC-HEADER>0001485003-24-000005.hdr.sgml : 20240401
<ACCEPTANCE-DATETIME>20240401084714
ACCESSION NUMBER:		0001485003-24-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240401
DATE AS OF CHANGE:		20240401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		24805767

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>carm-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:343b8f26-08b5-463e-85bb-1b22c4b46cf9,g:eb5f3205-6aed-4489-877d-430d68a8a84b,d:a97881cf99e44bfdaa49bfe02990f0e4-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2023" xmlns:carm="http://carismatx.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>carm-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001485003</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-35">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-36">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-44" name="carm:DerivativeInstrumentConversionTermForRedemptionFeature" id="f-346">P3M</ix:nonNumeric><ix:nonNumeric contextRef="c-52" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-368">P2Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="carm-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:SesenBioStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>carm:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">carm:CollateralCreditCardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">carm:ConvertiblePreferredStockAndExchangeableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">carm:ConvertiblePreferredStockAndExchangeableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">carm:ConversionOfConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">carm:ConversionOfConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="seat"><xbrli:measure>carm:seat</xbrli:measure></xbrli:unit><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">carm:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">carm:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">carm:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Pre2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Post2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:LocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:LocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>carm:target</xbrli:measure></xbrli:unit><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>carm:product</xbrli:measure></xbrli:unit><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="obligation"><xbrli:measure>carm:obligation</xbrli:measure></xbrli:unit><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(Mark One)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the transition period from _________________to _________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36296</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Carisma Therapeutics Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">26-2025616</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(State or other jurisdiction<br/>of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">3675 Market Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Philadelphia</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">PA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">19104</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">267</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">491-6422</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________________________________________________</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name of exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CARM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;&#8201;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">o</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The aggregate market value of the voting and non-voting common equity held by non-affiliates based on the closing sale price as reported on The Nasdaq Stock Market LLC, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June 30, 2023, was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-30">275,726,423</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">41,542,534</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding as of March&#160;15, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2023. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;margin-top:24pt;text-align:center"><span><br/></span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_497">PART I.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8f8e40bbc4b94a42b3092838b537e503_35">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_560">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_560">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i36314fd5b53642f18b987de47735a754_58">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_112">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia67436ff0e154daf9e0780a019696ce1_291368">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814460">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814460">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb123d5983d8459ca77bf2481e16f15b_108">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_974">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_974">tem 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_974">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_974">ybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#icb8612854fdb4bc899cbabd65f5ec6c3_102">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814467">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814467">Properties </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if5e737ab6f0447f5940944311a6059aa_80">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814472">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814472">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i37b9590e9f5545f381aeffddd090fc29_312">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814477">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814477">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie42244f1e3914a36aa6ff1bbc5a72284_83">92</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_505">PART II.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i99e09df4c8454f1492d00d9f553edafb_44">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_599">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_599">Market for Registrant's Common Equity, Related Stockholder Matters</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_599">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_599"> and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idedc72a77be9448ca2de120d5d6f7513_892">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814499">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814499">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i904c9ee508be4188936aabdba77c4d9f_224">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_73">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_73">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2d4dea7d5d904b7db21b116e320e1b02_812">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814505">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814505">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3d8beda0125b485b8e608deacd4c3ee6_116">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628486">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628486">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4281c9492111442eb00ca409116f497e_1454">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628401">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628401">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8ab129e590554d9e9de07ba2d267af47_169">135</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628408">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628408">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i25ce6f05e1054977bf8b9d445d2a980a_2367">135</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628414">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628414">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i2605b46858c34f69b591c912d40f9476_203">135</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628420">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628420">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i428c814163254fc3ab1b7ce960ee6886_127">136</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_512">PART III.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i02ef989efd5d4549802859d72bd457cf_39">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_656">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_656">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i06d532fbf565475f81f2b2dc96c2cd4f_258">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628438">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628438">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i42a1fad063724c4e99820e6f4e1ae018_151">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628444">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628444">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i20e6c748de69440ca58b541527579e0f_161">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628450">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628450">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ide17a71c326e4701887d174c4137ab44_292">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628456">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628456">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i84b00e26c7024fc2ade1cf3a1abe8d27_213">137</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_1099511628466">PART IV.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i75675bb73af14fc4bc6f431ccecf5af2_109">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_121">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_121">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i821e24e285de46d68b37b094e4551312_146">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814366">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814366">tem 1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814366">6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814366">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia97881cf99e44bfdaa49bfe02990f0e4_549755814366">140</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ia05aee446d2f48bfa217090961536dcf_201">141</a></span></div></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K may include, but are not limited to, statements about:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and conduct of our pre-clinical studies and clinical trial of CT-0525 for solid tumors that over-express human epidermal growth factor receptor 2, or HER2;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our plans to conduct discovery and pre-clinical testing of the development of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> chimeric antigen receptor macrophage and monocyte, or CAR-M, therapeutics for up to twelve oncology targets, as well as multiple other targets and indications in connection with our collaboration with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ModernaTX, Inc., or Moderna</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with our Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain additional financing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to replicate in later clinical trials positive results found in pre-clinical studies and early-stage clinical trials of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully enroll patients in our Phase 1 clinical trial of CT-0525 and complete clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r plans to conduct discovery and pre-clinical testing of other product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to realize the anticipated benefits of our research and development programs, strategic partnerships, research and licensing programs and academic and other collaborations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of applying for and receiving, and our ability to maintain, marketing approvals from applicable regulatory authorities for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection and regulatory exclusivity for CT-0525 and any other product candidates we are developing or may develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of CT-0525 and any other product candidates we are developing or may develop, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash and cash equivalents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential advantages of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the potential market opportunity for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization and manufacturing capabilities and strategy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of public health epidemics or pandemics, including the COVID-19 pandemic, and of global economic developments on our business, operations, strategy and goals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of government laws and regulations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic developments; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such other matters as discussed on this Annual Report on Form 10-K, including Part I, Item 1A, &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, forward-looking statements can be identified by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;goals,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those expressed or implied by the forward-looking statements. No forward-looking statement is a promise or a guarantee of future performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report on Form 10-K, unless otherwise stated or the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;Carisma,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Carisma Therapeutics Inc. (formerly Sesen Bio, Inc.) and its consolidated subsidiaries.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to &#8220;Legacy Carisma&#8221; refer to CTx Operations, Inc. (formerly CARISMA Therapeutics Inc.) and references to &#8220;Sesen Bio&#8221; refer to Sesen Bio, Inc. prior to completion of the business combination on March 7, 2023 in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of September 20, 2022, as amended, by and among the Company, Legacy Carisma and Seahawk Merger Sub, Inc., a wholly owned subsidiary of the Company, pursuant to which Seahawk Merger Sub, Inc. merged with and into Legacy Carisma, with Legacy Carisma continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger, or the Merger.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, the Company changed its name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; Following the completion of the Merger, the business conducted by the Company became primarily the business conducted by Legacy Carisma, which is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_497"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span id="i8f8e40bbc4b94a42b3092838b537e503_35"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_560"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. <span id="i36314fd5b53642f18b987de47735a754_58"></span>Business.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_749"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage cell therapy company focused on using our proprietary CAR-M cell therapy platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. Our focus is our proprietary CAR-M cell therapy platform, which redirects macrophages against specific tumor associated antigens and enables targeted anti-tumor immunity by utilizing genetically modified myeloid cells (macrophages and monocytes) to express chimeric antigen receptors, or CARs, enabling these potent innate immune cells to recognize specific tumor associated antigens on the surface of tumor cells. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2023, we completed a business combination in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of September 20, 2022, pursuant to which the Merger was consummated. Pursuant to the Merger Agreement, we changed our name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; Following the completion of the Merger, our business became primarily the business conducted by Legacy Carisma.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2024, following a strategic review of our operating plan for 2024 and future periods, we approved a revised operating plan intended to balance value creation and expense management with our available cash resources. The objective of our revised operating plan is to focus our clinical development efforts on high potential value programs with meaningful near-term milestones and eliminate non-essential expenses and headcount to extend our cash runway. Under this plan, we intend to focus our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology clinical development efforts on our follow-on product candidate CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0525 utilizes a novel approach to CAR-M therapy that engineers patients&#8217; monocytes directly, without ex vivo differentiation into macrophages. In November 2023, we received United States Food and Drug Administration, or FDA, clearance of our Investigational New Drug application, or IND, for CT-0525, and we expect to treat the first patient in the second quarter of 2024. We believe that CT-0525 has favorable attributes compared to our initial clinical stage product candidate, CT-0508, and that the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. We will also continue to focus on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA/lipid nanoparticle, or LNP, CAR-M programs in partnership with Moderna.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we plan to continue ongoing activities under our open label Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities. We have also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases, also remains ongoing.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to pursue additional financing and collaboration opportunities to support development of our product candidates and other research and development programs and will continue to re-assess our expense allocation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Our Product Candidates and Discovery Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our proprietary macrophage and monocyte cell therapy platform, we are developing a pipeline of product candidates, with an initial focus on advancing multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> autologous and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies for the treatment of solid tumors. We are also pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology, fibrosis, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunology programs are wholly owned. Additionally, under a collaboration agreement with Moderna, we are developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies utilizing Moderna's mRNA/LNP, technology. Our current pipeline is summarized below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="carm-20231231_g1.jpg" alt="Pipeline.jpg" style="height:295px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ex Vivo Oncology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CT-0508</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first product candidate to enter clinical development, CT-0508, is the first CAR-Macrophage to be evaluated in a human clinical trial and is intended to treat solid tumors that over-express HER2, a protein that is over-expressed on the surface of a variety of solid tumors, including breast cancer, gastric cancer, esophageal cancer, salivary gland cancer, and numerous others. CT-0508 has been granted &#8220;Fast Track&#8221; status for the treatment of patients with HER2 over-expressing solid tumors by the  FDA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0508 is currently being studied in a multi-center open label Phase 1 clinical trial in the United States. This ongoing first-in-human study evaluates the safety, tolerability, and manufacturing feasibility of CT-0508 along with several customary exploratory secondary endpoints. We have completed enrollment of the first group of patients in this trial, with nine patients having been successfully dosed over a five-day dosing schedule. CT-0508 has been generally well tolerated after infusion with no dose-limiting toxicities to date, was successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients and has shown high CAR expression, viability, and purity. In addition to the first group of patients in this study, we initiated a second group to evaluate bolus dosing of patients and we presented data from five patients in the second group in the third quarter of 2023. While the results from this early clinical trial data are both preliminary and limited, we believe the combined group 1 and group 2 results support the preliminary results from this trial indicating that CT-0508 can potentially be detected within the tumor microenvironment, or TME, and induce anti-tumor adaptive immunity. In group 1, a best overall response, or BOR, of stable disease was seen in 4 out of 9 patients, and in group 2, the BOR was progressive disease. Translational analyses combining group 1 and group 2 demonstrated a correlation between TME activation, T cell activation, and HER2 status with BOR of stable disease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we plan to continue ongoing activities under our open label Phase 1 clinical trial of CT-0508, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CT-0508 and Pembrolizumab Combination Sub-Study</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a sub-study evaluating the co-administration of CT-0508 and pembrolizumab, a programmed cell death protein 1, or PD-1 checkpoint inhibitor, in the clinical setting. We have observed synergistic potential of CT-0508 with a PD-1 checkpoint inhibitor in multiple pre-clinical models. As a result of those studies and the preliminary results from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">group 1 in our monotherapy treatment clinical trial discussed above, we initiated a sub-study in the first quarter of 2023 to evaluate patients with the co-administration of CT-0508 and pembrolizumab. We have enrolled six patients in the sub-study. We expect to report data from this sub-study in the second quarter of 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we plan to continue ongoing activities under our sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also initiated several other sub-studies evaluating CT-0508 in the clinical setting, as further described below. However, these sub-studies have been placed on hold as part of our recently announced revised operating plan and we do not intend to enroll patient in these sub-studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CT-0525</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our follow-on product candidate, CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2, utilizes a novel approach to CAR-M therapy. The patient's monocytes are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> without being differentiated into macrophages, as we currently do for CT-0508. The CAR-Monocyte approach utilizes a single day manufacturing process, which enables the manufacture of up to ten billion cells from a single apheresis. Apheresis is a medical technology in which the blood of the patient is passed through an apparatus that separates out the white blood cells and returns the remainder of the blood to the circulation. The manufacturing approach for CAR-Monocytes leverages an automated, closed-system manufacturing process. In addition, the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. By increasing the cell yield, a CAR-Monocyte enables a larger dose than a CAR-Macrophage. In addition, a CAR-Monocyte has the potential for improved persistence and trafficking, which were observed in pre-clinical studies. We believe that the increased cell yield and the improved persistence and trafficking may improve tumor control. In November 2023, we received FDA clearance of our  IND for CT-0525 and we expect to treat the first patient in the second quarter of 2024. Based on our recently announced revised operating plan, we intend to focus our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> oncology clinical development efforts on CT-0525.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CT-1119</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our pipeline also includes additional tumor targets, encompassing diverse solid tumor indications with significant unmet medical needs. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. CT-1119 incorporates two key enhancements: (1) a next-generation CAR that, in pre-clinical studies, led to a significant increase in tumor killing and cytokine release, and (2) the incorporation of a signal-regulatory protein alpha, or SIRP&#945;, knockdown to overcome the cluster of differentiation, or CD,47 immune checkpoint. We have elected to pause further development of CT-1119 as part of our revised operating plan, pending additional financing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vivo Oncology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M cell therapies, we are developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M cell therapies, wherein immune cells are directly engineered within the patient&#8217;s body. To advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M therapeutics, we established a strategic collaboration with Moderna. In the fourth quarter of 2023, we presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the pre-clinical data demonstrated feasibility, tolerability, and early efficacy of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M against metastatic solid tumors. In December 2023, we announced the nomination of the collaboration's first lead candidate, which will target an antigen present on a solid tumor with significant unmet medical need.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fibrosis and Immunology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to acting as a first line of defense in the innate immune system, macrophages and monocytes are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration. Using our macrophage and monocyte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engineering platform, we are pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. Pre-clinical proof of concept for fibrosis is targeted for the second quarter of 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_854"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to build upon our leadership position in bringing macrophage- and monocyte-based cell therapies to patients with cancer and other serious diseases. To achieve our vision, we have developed our proprietary CAR-M cell therapy platform, a pipeline of assets spanning numerous indications with unmet medical needs, a robust discovery engine, broad intellectual property, robust manufacturing capabilities, and a dedicated executive team with extensive experience in cell therapy and drug development, manufacturing, and commercialization and leading scientific expertise in the field. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We intend to prioritize our clinical development efforts on high potential value programs with meaningful near-term milestones while managing our expense allocation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key pillars of our strategy include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Leverage Leadership in Macrophage- and Monocyte-Based Cell Therapies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Despite the incredible promise shown by cell therapies for hematologic malignancies, the success has not been replicated in the solid tumor setting. Macrophage and monocyte cell therapies hold promise in addressing the limitations of other cell types and transforming the cell therapy treatment paradigm for solid tumors. The inherent biology of macrophages and monocytes offers several potential advantages that directly apply to current barriers for cell therapy efficacy in the solid tumor context. Our proprietary CAR-M platform is designed to enable the therapeutic use of engineered macrophages and monocytes for the treatment of cancer and other serious diseases and disorders. The CAR-M platform incorporates proprietary tumor targeting constructs, vectors to deliver CARs to macrophages and monocytes and novel manufacturing processes. Beyond our CAR-M technologies, we are pursuing multiple platform enhancements for our CAR constructs, editing technologies, and therapeutic delivery vehicles including gene edited induced pluripotent stem cells, or iPSC-derived, macrophages and mRNA-based </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Advance our HER2 program:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Our anti-HER2 clinical candidate CT-0525 is an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> autologous cell therapy product candidate, wherein immune cells from blood drawn from a patient are engineered outside of the body and reinfused into the same patient. We are focused on advancing CT-0525 with a goal of identifying the Phase 2/3 regimen for the product candidate in 2025. We believe that CT-0525 has favorable attributes compared to CT-0508, and that the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Progress Pre-Clinical Oncology Pipeline:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Beyond the HER2 program, we plan to advance additional pipeline candidates targeting diverse solid tumor indications with substantial unmet medical needs. For example, we have a broad strategic collaboration with Moderna focused on the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M therapeutics for up to 12 oncology targets, of which five have already been nominated. The first lead candidate nominated, announced in December 2023, will target an antigen present on a solid tumor with a significant unmet medical need.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Diversify Beyond Oncology:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Leveraging our macrophage and monocyte engineering platform, we are pursuing early research and development opportunities for treating diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. Pre-clinical proof of concept in fibrosis utilizing our engineered platform is expected in the second quarter of 2024.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Forge Strategic Partnerships:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Given the breadth of opportunities enabled by the macrophage and monocyte engineering platform, we may opportunistically enter into strategic partnerships or collaborations to maximize the potential of our platform. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These strategic imperatives collectively position us at the forefront of advancing macrophage- and monocyte-based cell therapies, with a commitment to innovation, clinical progress, and a diversified approach beyond oncology.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_758"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Background</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Limitations of Current CAR-T or CAR-NK Therapies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cellular immunotherapy is a type of immuno-oncology approach whereby human immune cells are utilized to recognize and destroy cancer cells in a targeted manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the incredible promise shown by cell therapies for hematologic malignancies, the success has not been replicated in the solid tumor setting. There are numerous challenges impacting T and NK cell immunotherapy in patients with solid </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumors, such as the inability of cells to appropriately access the TME, overcome immunosuppression in the TME, and overcome target antigen heterogeneity. Importantly, there have been challenges in targeting solid tumors with CAR-T cells without inducing toxicities against normal tissues or inducing severe systemic cytokine release syndrome, or CRS. To date, no CAR therapies for the treatment of solid tumors have received marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Opportunity for Engineered Macrophages in Treating Cancer</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that macrophage and monocyte cell therapies hold promise in addressing the limitations of other cell types and transforming the cell therapy treatment paradigm for solid tumors and other immunologic and inflammatory diseases. The inherent biology of macrophages and monocytes offers several potential advantages that directly apply to current barriers for cell therapy efficacy in the solid tumor context.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macrophages and monocytes are actively recruited into solid tumors, while other immune cells, such as T cells, are often actively excluded. Macrophages are professional phagocytic cells capable of directly killing tumor cells through this unique mechanism. In addition to direct killing, macrophages can secrete pro-inflammatory factors that convert the immunosuppressive TME into an environment that promotes immunity. Importantly, macrophages and monocytes are professional antigen presenting cells, meaning they can directly present tumor-derived antigens to T cells leading to anti-tumor T cell responses, a phenomenon known as epitope spreading. Epitope spreading enables activity against tumor cells which either lack or lose expression of the initial antigen targeted by the CAR&#8201;&#8212;&#8201;a key challenge for cell therapies&#8201;&#8212;&#8201;and ultimately enables macrophages and monocytes to overcome target antigen heterogeneity within the patient&#8217;s cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to acting as a first line of defense in the innate immune system, macrophages and monocytes are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration. The prevalence and diversity of function of macrophages and monocytes make them an attractive potential therapeutic delivery cell. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe an approach which harnesses the direct effector functions of macrophages or monocytes, optimizes their activation status toward an inflammatory phenotype, and redirects phagocytosis with molecular specificity would represent a major advance in cancer immunotherapy and other serious diseases.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CAR-M Pre-clinical data</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M have the potential to address the key challenges involved in treating solid tumors. Pre-clinical studies with CAR-M have demonstrated the ability to infiltrate solid tumors, phagocytose and destroy tumor cells directly, and present tumor-derived antigens leading to activation of the adaptive immune system. CAR-M mount anti-tumor immunity in numerous ways. First, CAR-M leverage the natural tumor-homing ability of macrophages and monocytes, the naturally most abundant immune cells in the TME, to traffic to both primary tumors and metastases, enabling engineered macrophages to act as a &#8220;Trojan horse,&#8221; tricking the tumor into recruiting engineered, anti-tumor CAR-M as if they were normal monocytes or macrophages. Once within the tumor, CAR-M directly kill antigen-expressing tumor cells through phagocytosis and secretion of cytotoxic factors. CAR-M secrete inflammatory cytokines and chemokines that promote a pro-inflammatory environment and lead to the recruitment of T cells and other leukocytes. Finally, CAR-M serve as professional antigen presenting cells for T cells, inducing epitope spreading, systemic anti-tumor immunity, and immune memory against tumor antigens, expanding anti-tumor immunity to target negative tumor cells and potentially preventing antigen negative relapse.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_862"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline of Product Candidates and Discovery Programs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our proprietary CAR-M platform, we are developing a broad pipeline of product candidates, with an initial focus in oncology.</span></div><div style="margin-top:12pt;text-align:center"><img src="carm-20231231_g1.jpg" alt="Pipeline.jpg" style="height:295px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_871"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ex Vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Oncology </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rationale for CAR-M Therapy for HER2+ Solid Tumors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While therapies targeting solid tumors that over-express HER2 have led to improved survival rates in breast, gastric and gastro-esophageal junction cancers, there remains an unmet need in patients with advanced HER2 over-expressing cancers, including metastatic lung, ovarian, colon, bladder, and other cancers, which have exhausted all approved therapies including the approved anti-HER2 therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 20% of breast cancers over-express HER2, a protein that is over-expressed on the surface of a variety of solid tumors. In addition to breast, gastric, and gastroesophageal junction cancers, HER2 is also over-expressed in a number of solid tumor indications including but not limited to bladder cancer, ovarian cancer, lung cancer and colon cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HER2 has several advantages as a target antigen for CAR-M. In addition to being over-expressed in a variety of solid tumor types with significant unmet medical need, HER2 is not shed or internalized, and it is expressed at low levels in non-tumor tissues. As HER2 expression is typically maintained over the course of disease, CAR-M may be developed for treatment of metastatic disease, for example, in the liver and lung, as well as primary tumors. Additionally, HER2 is typically not lost after patients with metastatic cancer progress on available HER2 targeted therapies, rendering HER2 refractory patients potentially eligible for CAR-M therapy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Product Candidate: CT-0508 (anti-HER2 CAR-Macrophage)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0508 is a cell product comprised of autologous, peripheral blood monocyte-derived, pro inflammatory macrophages, transduced with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR. HER2 is a protein on the cell surface that promotes the growth of cancer cells. The anti-HER2 CAR is a first-generation CAR composed of a fully human single-chain variable fragment, or scFv, derived from the monoclonal antibody, or mAb, trastuzumab, which is specific for human HER2. The anti-HER2 scFv is fused to a CAR backbone containing a CD8 hinge, CD8 transmembrane domain, and a CD3&#950; intracellular domain. The CAR is cloned into an adenoviral vector backbone and transduced into monocyte-derived macrophages. Based on the pre-clinical data generated to date, CT-0508 CAR-Macrophages are able to specifically recognize HER2 over-expressing tumor cells, which triggers both direct killing of tumor cells and phagocytosis. Additionally, CAR engagement to HER2 on tumor cells results in the secretion of a broad array of pro-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inflammatory cytokines and chemokines, which contribute to the recruitment and activation of additional immune cells to the TME, including effector T cells and other antigen presenting cells. CT-0508 CAR-Macrophages are antigen presenting cells, and after phagocytosing tumor cells they process tumor-derived antigens and present them to T cells, leading to T cell immunity against tumor antigens. This additional activation of the adaptive immune system amplifies anti-tumor immune response and can lead to long term immune memory not only against HER2, the primary target, but other tumor specific neoantigens as well.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0508 is currently being studied in a multi-center open label Phase 1 clinical trial in the United States. As of the date of this Annual Report on Form 10-K, seven clinical sites are open for screening and enrollment: (i) the University of Pennsylvania Abramson Cancer Center, (ii) the University of North Carolina Lineberger Comprehensive Cancer Center, (iii) the City of Hope National Medical Center, (iv) the MD Anderson Cancer Center, (v) the Sarah Cannon Cancer Research Institute, (vi) Oregon Health and Science University, and (vii) the Fred Hutchinson Cancer Center. The FDA has granted &#8220;Fast Track&#8221; status to CT-0508 for the treatment of patients with HER2 over-expressing solid tumors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we plan to continue ongoing activities under our open label Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">CT-0508 Clinical Data&#8201;&#8212;&#8201;Study 101</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing first-in-human Phase 1 study primarily evaluates the safety, tolerability and manufacturing feasibility of CT-0508 along with several customary exploratory secondary endpoints. We have completed enrollment of the first group of patients in this trial, with nine patients having been successfully dosed over a five-day dosing schedule. CT-0508 has been generally well tolerated after infusion with no dose-limiting toxicities to date, was successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients and has shown high CAR expression, viability, and purity. In addition to the first group of patients in this study, we initiated a second group to evaluate bolus dosing of patients and we presented data from five patients in the second group in the third quarter of 2023. While the results from this early clinical trial data are both preliminary and limited, we believe the combined group 1 and group 2 results support the previously presented preliminary results from this trial indicating that CT-0508 can potentially be detected within the TME and induce anti-tumor adaptive immunity. We have also initiated several sub-studies evaluating CT-0508 in the clinical setting. In addition to monotherapy treatment, we have observed synergistic potential of CT-0508 with a PD-1 checkpoint inhibitor in multiple pre-clinical models. As a result of those studies and the preliminary results from group 1 in our clinical trial, we initiated a sub-study in the first quarter of 2021 to evaluate patients with the co-administration of CT-0508 and pembrolizumab, a PD-1 checkpoint inhibitor. We have enrolled six patients in the sub-study. We anticipate reporting data from this sub-study in the second quarter of 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we plan to continue ongoing activities under our open label Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_905"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional CT-0508 Sub-Studies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CT-0508 Intraperitoneal administration sub-study</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This sub-study has been designed to assess the safety and feasibility of CT-0508 via regional administration into the peritoneal cavity. The target population for this sub-study are subjects at least 18 years of age who meet inclusion criteria per the main protocol, that have HER2 over-expressing gynecological cancers including but not limited to ovarian, fallopian tube, primary peritoneal, and endometrial cancers, who have disease spread mainly within the peritoneal cavity that meet the sub-study specific eligibility criteria. We have elected to place this sub-study on hold for expense reduction purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CT-0508 Biodistribution sub-study</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This open-label sub-study is designed to evaluate the whole body biodistribution of CT-0508 after intravenous administration using radiolabeled CT-0508 and longitudinal positron emission tomography and computed tomography, or PET/CT, imaging. This sub-study includes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Zr-oxine radiolabeling a fraction of the CT-0508 cell product, followed by administration on Day 1 and PET/CT imaging approximately on Day 1, 4, 8, 15, and 28 to assess trafficking and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">biodistribution of CT-0508. The target population for this sub-study are subjects at least 18 years of age that meet inclusion criteria per the main protocol. We have elected to place this sub-study on hold for expense reduction purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CT-0525 (anti-HER2 CAR-Monocyte)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our follow-on product candidate, CT-0525, a CAR-Monocyte, is a cell product comprised of autologous, peripheral blood monocytes, transduced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with a chimeric adenoviral vector, Ad5f35, containing an anti-HER2 CAR. CT-0525 is in clinical development and utilizes a novel </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approach to CAR-M therapy that engineers patients&#8217; monocytes directly, without differentiation into macrophages, as we currently do for CT-0508. CT-0525 will be administered to patients, wherein it will traffic to and enter tumor tissue, differentiating into macrophages </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> rather than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The novel CAR-Monocyte approach enables a single day manufacturing process, enables the ability to manufacture up to ten billion cells from a single apheresis, and leverages an automated, closed-system manufacturing process. By increasing the cell yield, the CAR-Monocyte approach enables a larger dose than with CAR-Macrophages. In addition, CAR-Monocytes have the potential for improved persistence and trafficking, which were observed in pre-clinical studies. The increased cell yield and the improved persistence and trafficking may improve tumor control. In November 2023, we received FDA clearance of our IND for CT-0525 and we expect to treat the first patient in the second quarter of 2024. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CT-0525 Clinical Study Design&#8201;&#8212;&#8201;Study 102</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CT-0525 is currently being studied in a multi-center open label Phase 1 clinical trial in the United States. The Phase 1 clinical trial for CT-0525 is a single-arm, open-label study of systemic intravenous administration of CT-0525. This study is intended to evaluate safety, tolerability, and the manufacturing feasibility of CT-0525. Secondary endpoints will also be evaluated including cellular kinetics, overall response rate, or ORR, and duration of response, or DOR. This study will enroll participants with locally advanced (unresectable) or metastatic solid tumors over-expressing HER2 whose disease has progressed on standard approved therapies. The study will consist of two cohorts: Cohort 1 will receive IV administration of three billion CAR-positive cells, while Cohort 2 will receive IV administration of up to 10 billion CAR-positive cells. In late March 2024, we determined to focus clinical development primarily on CT-0525, as we believe that CT-0525 has favorable attributes compared to CT-0508, and that the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CT-0525: Pre-clinical Development</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In pre-clinical studies, CT-0525 was successfully generated with high cell yield, CAR expression, viability, and purity in a rapid, one day manufacturing process. The manufacturing process enabled the production of 10x10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ten billion) cells, approximately 5-fold higher than the cell number produced in the CT-0508 process. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, CT-0525 demonstrated significantly enhanced persistence with a half-life of 45 days &#8211; an approximately 10-fold increase compared to CT-0508. CT-0525 tumor trafficking was significantly enhanced compared to CT-0508, demonstrating an approximately 40-fold increase in tumor accumulation at early time points. Taken together, the increased dose, trafficking potential, and persistence yields an expected 2,000-fold increased total exposure compared to CT-0508. Mechanistically, CT-0525 differentiated into CAR-Macrophages efficiently and adopted the appropriate inflammatory (M1) phenotype and resisted conversion to undesirable phenotypes in immunosuppressive environments, which may be found in tumors. CT-0525 was able to kill tumors cells as early as two days post transduction and showed enhanced killing as fully differentiated macrophages, seven days post transduction. CT-0525 released a variety of pro-inflammatory cytokines and chemokines that have the potential to activate T cells and induce an anti-tumor immune response. CT-0525 controlled tumor growth in multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> solid tumor models. We believe that CAR-Monocytes represent a potentially promising approach for cancer immunotherapy, with the potential for increased dose, tumor infiltration, persistence, and potency compared to the CAR-Macrophage CT-0508.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CT-1119 (Anti-Mesothelin CAR-Monocyte)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-1119 is a mesothelin-targeted CAR-Monocyte developed for study in patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. We have selected a clinical candidate for CT-1119, which will incorporate two key enhancements: (i) a next-generation CAR that, as demonstrated in pre-clinical studies, leads to a significant increase in tumor killing and cytokine release, and (ii) the incorporation of SIRP&#945; knockdown to overcome the CD47 immune checkpoint. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mesothelin is a well validated tumor associated antigen. Mesothelin has been shown to be aberrantly expressed on the surface of tumor cells and plays an important role in promoting cancer invasion and proliferation. Mesothelin has been demonstrated to be expressed at high levels in mesothelioma, lung cancer, ovarian cancer, pancreatic cancer, and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solid tumors with limited expression in normal tissue. Mesothelin positive solid tumors represent a significant unmet medical need.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to pause further development of CT-1119, pending additional financing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Next-Gen CAR Design</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing additional next generation CAR-M improvements utilizing enhanced CAR constructs to increase potency and functionality of the engineered cells. This includes optimization of each element of the CAR itself&#8201;&#8212;&#8201;the binder (which gives the CAR specificity to a target antigen), the hinge (which connects the binder to the transmembrane domain and gives the CAR length and flexibility), the transmembrane domain (which spans the cell membrane), and the intracellular signaling domains (which are responsible for activation of immune cell function). These changes can lead to increased proinflammatory cytokine release and more potent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> killing relative to the first-generation CAR construct.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIRP&#945; Knockdown</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also developed gene editing technologies for enhancing anti-tumor CAR-M functions. Macrophages naturally express the inhibitory receptor SIRP&#9082;, which suppresses phagocytosis after stimulation with CD47. Solid tumors can over-express CD47 to evade phagocytosis by macrophages. We have previously demonstrated using CRISPR/Cas9 that SIRP&#9082; knockout, or KO, can enhance CAR-M killing and phagocytosis of tumor cells.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have now developed a proprietary single-vector system to simultaneously deliver CAR and targeted gene knockdown. A novel vector was designed to introduce custom shRNA into a synthetic CAR intron under a shared promoter. Expression of this vector concomitantly produces CAR mRNA and SIRP&#9082;-targeting shRNA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We demonstrated that the intronic shRNA vector could deliver HER2-targeting CAR, reduce SIRP&#9082; expression, and enhance anti-tumor functions of primary human CAR-M. Importantly, the one-step vector design was as proficient as transduction followed by CRISPR/Cas9 editing. We also demonstrated that the intronic shRNA vector improved tumor clearance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to unedited CAR-M.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intronic shRNA design is a generalizable technology that is valuable for additional CAR designs, target tumor antigens, and gene knockdown targets. The modular adenoviral vector introduces gene editing capabilities while remaining compatible with pre-existing manufacturing strategies. We have incorporated our proprietary intronic shRNA vector into the CT-1119 platform to enhance anti-tumor functions and overcome the CD47 checkpoint.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_879"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Synergistic Potential of CAR-M Therapy with T cell Checkpoint Inhibitors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Blocking the immune checkpoint molecule PD-1 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">checkpoint inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, has revolutionized cancer treatment for patients with a multitude of solid tumor indications. Pembrolizumab is a potent humanized immunoglobulin G4, or IgG4, mAb, with high specificity of binding to the PD-1 checkpoint inhibitor receptor, inhibiting its interaction with programmed cell death ligand 1, or PD-L1, and programmed cell death ligand 2, or PD-L2. While pembrolizumab is currently indicated for the treatment of patients across several solid tumor indications, the majority of patients have either primary or secondary resistance to immune checkpoint blockade and may benefit from combinatorial therapy that could overcome immune cell exclusion, poor antigen presentation, low T cell infiltration, high tumor-associated macrophages, or TAM, infiltration, a lack of productive co-stimulation, low mutational burden, intra-tumoral, or IT, immunosuppression, and a low frequency of tumor reactive T cell clones.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the data generated during pre-clinical development, CT-0508 is able to specifically recognize cancer cells through the binding of the CAR to HER2 expressed on the surface of the cancer cells. This interaction triggers activation of the CAR-M and results in direct anti-tumor effect by killing and phagocytosis of the tumor cells. In addition, CT-0508 recruits T cells, activates the TME, and as professional antigen presenting cells, can process and present tumor associated antigen and/or neoantigens expressed by the tumor cells, leading to T cell immunity against these specific antigens. However, this indirect anti-tumor effect involves the engagement of T cells that may be actively suppressed, or exhausted, within the TME by a variety of factors including secreted immune-modulatory factors and inhibitory ligands expressed on both immune and tumor cells. Additionally, several studies have demonstrated that patients with low mutational burden, low major histocompatibility complex expression, defective antigen presentation, low CD8+ T cell infiltration, or minimal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Type 1 T helper, or Th1, cytokine signatures tend to be unresponsive to PD-1 checkpoint inhibitor blockade. Therefore, based on the mechanism of action of CT-0508 and the limitations of PD-1 checkpoint inhibitor blockade, the combination of CAR-M therapy with PD-1 checkpoint inhibitor blockade therapy may be beneficial as CT-0508 will drive TME remodeling and enhance antigen presentation (innate immunity) to initiate an anti-tumor T cell response (adaptive immunity) which will be strengthened by inhibiting the PD-1 checkpoint inhibitor pathway.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CT-0508 and pembrolizumab combination sub-study design</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This open-label sub-study assesses the safety and tolerability of co-administering CT-0508 in combination with the PD-1 checkpoint inhibitor, pembrolizumab. The target population for this sub-study are subjects who have HER2 over-expressing solid tumors and meet the eligibility criteria. The sub-study was initiated in the first quarter of 2023 and enrolled six patients with the co-administration of CT-0508 and pembrolizumab. We anticipate reporting data for this sub-study in the second quarter of 2024. Although we plan to continue ongoing activities under our open label Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_830"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In Vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Oncology</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA/LNP Platform </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Moderna, we are developing an mRNA based </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M platform for oncology. This approach is highly differentiated in the cell therapy space&#8201;&#8212;&#8201;not only because it relies on myeloid cells as the engineered effectors, but also because it utilizes direct </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reprogramming of patients&#8217; own cells with a well-validated mRNA/LNP platform. By engineering patients&#8217; own cells directly within their body, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> autologous or allogeneic cell manufacturing is entirely bypassed. Importantly, while this approach enables an off-the-shelf therapy, the engineered cells are autologous, as it is the patients&#8217; own cells being engineered into CAR-M </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or directly within their body. This strategic partnership enables us to apply the learnings gleaned from autologous CAR-M development to expand our pipeline to up to 12 additional oncology candidates, of which five have already been identified as research targets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Studies with the LNP have shown mRNA delivery leads to CAR expression on myeloid cells (monocytes, macrophages, and dendritic cells). Based on clinical data using other (non-CAR) payloads, Moderna has previously demonstrated that the LNP was well-tolerated after systemic administration and could also be re-dosed. Preliminary data have demonstrated that the LNP is efficient in transfecting myeloid cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, preliminary data confirms high CAR expression, viability, and CAR-M function. In the fourth quarter of 2023, we presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the data demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M against metastatic solid tumors. In December 2023, we announced nomination of the collaboration's first lead candidate, which will target an antigen present on a solid tumor with significant unmet medical need.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_838"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fibrosis and Immunology </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fibrosis</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are an oncology focused company, our macrophage and monocyte cell engineering platform offers broad opportunity to develop cell therapies for indications beyond oncology. We have numerous early-stage research programs designed to produce development candidates for liver fibrosis and other immunologic and inflammatory diseases. Our new product candidates will incorporate all the core elements of our macrophage and monocyte cell engineering platform, plus certain indication specific modifications uniquely designed to address the pathology of each indication. While autologous cell therapy may be utilized for proof of concept, these indications have the potential to be combined with our allogeneic or off-the-shelf therapeutic approaches. Pre-clinical proof of concept in fibrosis is expected in the second quarter of 2024.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_790"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Delivery</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, our own manufacturing facilities. We currently rely on and expect to continue to rely on third-party contract manufacturing organizations, or CMOs, for the manufacturing and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">release testing of viral vectors and cell drug products. We also currently rely on third parties for patient leukapheresis material logistics as well as to package, label, store, and distribute the cell drug products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established and will continue to establish arrangements with contract manufacturers to supply clinical materials and manufacturing capabilities for our clinical trials. We currently obtain our supplies from these manufacturers on a purchase order basis and does not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there are several potential replacements, although we may incur some delay in identifying and qualifying such replacements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to continue to expand the scope and number of our collaborations to further develop our manufacturing capabilities and to minimize manufacturing risk. As we scale to commercialization, we expect to increase our capacity with our current suppliers and evaluate other options to secure commercial scale capacity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Process for CT-0525</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A CMO is used to produce viral vector. The CT-0525 drug substance process begins by isolating the monocyte population from a fresh patient leukopak mobilized by donor pretreatment with filgrastim. The resulting monocytes are then transduced in media containing a cytokine and the Ad5f35 vector encoding an anti-HER2 CAR. The resulting drug substance cells are continuously processed, formulated, and transferred into freezing bags to generate drug product. Monocytes from one patient&#8217;s leukopak comprise one batch of CT-0525. The drug product is carefully frozen in a controlled process and then placed into secured storage and maintained at a temperature of &lt;-135 &#186;C. Safety and specification tests are performed and if found acceptable the product is released and shipped to clinical trial sites. The current process from receipt of leukopak to drug product and cryopreservation is one day. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Process for CT-0508</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A CMO is used to produce viral vector. The CT-0508 drug substance process begins by isolating the monocyte population from a single fresh patient leukopak mobilized by donor pretreatment with filgrastim. The resulting monocytes are cultured in the presence of a cytokine and other factors to induce differentiation into macrophages. The resulting macrophages are then transduced with the Ad5f35 vector encoding an anti-HER2 CAR. The resulting cells are then harvested as drug substance. Macrophages derived from a single leukopak from one patient comprise one batch of CT- 0508. Final formulation is performed and transferred into freezing bags to generate drug product. The drug product is carefully frozen in a controlled process and then placed into secured storage and maintained at a temperature of &lt;-135 &#186;C. Safety and specification tests are performed and if found acceptable the product is released and shipped to clinical trial sites. The current process from receipt of leukopak to drug product and cryopreservation is eight days. We plan to continue to invest in process improvements to reduce the overall manufacturing process time and improve costs for the viral vector and cell drug.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_913"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance our proprietary technology, inventions and improvements that we believe are commercially important to the development of our business, including through seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also intend to rely on trade secrets related to our proprietary technology platform and our know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the fields of cancer and other indications including those related to fibrosis and other immunologic and inflammatory diseases, which may be important for the development of our business. We also may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions, where available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend, in part, on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend, and enforce our patents, preserve the confidentiality of our trade secrets and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade secrets that cover these activities. With respect to both our owned and licensed intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we file in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future, nor can we be sure that any of our existing patents or any patents that may be granted us in the future will be commercially useful in protecting our commercial products and methods of manufacturing such products, as well as being held valid if challenged.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently control over 26 granted patents, which are expected to expire at various times between 2033 and 2042, and over 104 patent applications pending in several jurisdictions, including the United States, Europe, Australia, Brazil, Canada, China, Israel, Japan, Korea, Mexico, New Zealand, and Singapore. Intellectual property is a critical component of our business plan for maximizing return on our investments. We are actively developing intellectual property and will continue to maintain and defend United States and international patent rights for our products, technology, and development and improvement of our discovery platforms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To maintain our competitive position in the market, we have spent considerable effort and resources securing intellectual property rights, including several patent rights related to our proprietary CAR technology and myeloid cell engineering technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusively Licensed Intellectual Property&#8201;&#8212; Penn</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to four patent families, and non-exclusive rights to related know-how by virtue of a license agreement with the Trustees of the University of Pennsylvania, or Penn. These patent families are directed to, among other things, methods of efficiently expressing CARs in myeloid cells, including monocytes, macrophages, and dendritic cells and enhancing effector activity, as well as the modified cells and compositions including such modified cells for use in several indications including various oncology targets. The applications will have an expiration date of no earlier than 2034. This licensed patent portfolio includes:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes nine issued U.S. patents and three pending U.S. patent applications relating to modified macrophages, monocytes and dendritic cells comprising CARs. These U.S. patents are expected to expire in 2036, absent any term adjustments or extensions. Corresponding foreign applications have been filed and are pending in Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Russia, Singapore, Thailand and South Africa.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending U.S. patent application relating to modified macrophages, monocytes and dendric cells in protein aggregate-associated disorders. Patent applications in this family are expected to expire in 2039, absent any term adjustments or extensions. Corresponding foreign applications have been filed and are pending in Australia, Canada, China, Europe, Israel, Japan, Korea, New Zealand, and Singapore.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending U.S. patent application relating to activation of antigen presenting cells. Patent applications in this family are expected to expire in 2040, absent any term adjustments or extensions. A corresponding foreign application has been filed in Europe.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">A patent family that includes one issued U.S. patent and one pending U.S. patent application relating to CARs comprising human anti-mesothelin binding domains. Patent applications in this family are expected to expire in 2034, absent any adjustments or extensions. Corresponding foreign applications have been filed and are pending in Australia, Canada, China, Europe and Japan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusively Licensed Intellectual Property&#8201;&#8212;&#8201;NYU</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to one patent family, and non-exclusive rights to related know-how by virtue of a license agreement with New York University, or NYU. The rights granted under the NYU license are to all indications for human use. This licensed patent portfolio includes:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one U.S. patent relating to a chimeric human immunodeficiency virus type 1, or HIV-1, vector with a simian immunodeficiency virus, or SIV, minimal Vpx packaging domain and method of making virions with enhanced infectivity for macrophages and dendritic cells. The U.S. patent is expected to expire in 2033, absent any term adjustments or extensions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Carisma Owned Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently own seven U.S. patent families. This owned patent portfolio includes:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one issued U.S. patent and two pending U.S. patent applications relating to macrophages, monocytes and dendritic cells comprising novel CAR constructs. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending Patent Cooperation Treaty, or PCT, application relating to mRNA transfection of macrophages, monocytes and dendritic cells comprising CARs. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending PCT application relating to modified immune cells for fibrosis and inflammation. Patent applications in this family are expected to expire in 2041, absent any term adjustments or extensions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending PCT application relating to self-polarizing immune cells. Patent applications in this family are expected to expire in 2042, absent any term adjustments or extensions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending PCT application relating to in vivo delivery of, among other things, CARs to macrophages, monocytes, and dendritic cells.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending PCT application relating to methods and constructs for modifying the response of certain cells to environmental and other stimuli.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A patent family that includes one pending PCT application relating to modified constructs including myeloid differentiation primary response protein 88, or MyD88, and/or CD40, domains.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also seek to generate additional intellectual property that covers enhancements to all aspects of the platform, including novel CARs, combinations, gene editing and manufacturing improvements. Where appropriate, we will also look to in-license relevant technology from third parties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term and Patent Term Extensions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO, in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug, biological product or medical device approved pursuant to a pre- market approval may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The length of the patent term extension is related to the length of time the drug is under regulatory review while the patent is in force. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date set for the patent. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be granted an extension and only those claims regarding the approved drug are extended. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark portfolio currently includes registered U.S. trademarks for Carisma in the United States, Europe, Great Britain and Japan. All of our trademarks are renewed on an ongoing basis. In order to supplement the protection of our brand, we also have a registered internet domain name. Going forward, we will consider additional trademarks to enhance our brand and support our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in some circumstances, on trade secrets to protect our unpatented technology. However, trade secrets can be difficult to protect in certain circumstances. We seek to protect our trade secrets and proprietary technology and processes, including through confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached. We may not have adequate remedies for any breach and could lose our trade secrets through such a breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting trade secrets, know-how and inventions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_798"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Moderna Collaboration and License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Moderna, we have established an approach that uses Moderna&#8217;s mRNA/LNP technology, together with our CAR-M platform technology, to create novel </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oncology gene therapies. We believe this approach has the potential to enable a series of off-the-shelf product candidates to target a patient's own myeloid cells against cancer cells directly within their body.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Legacy Carisma and Moderna established this collaboration by entering into a Collaboration and License Agreement, or the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics for up to 12 oncology programs. Under the Moderna License Agreement, the parties initiate research programs during a research term, focused on the discovery and research of products directed to biological targets. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has the right to designate up to 12 research targets as development targets. The first five research targets have been designated and all programs are currently in the discovery phase. Moderna funds the cost of our activities in accordance with an agreed research budget.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna has the right to designate up to 12 research targets as development targets during a specified development target nomination period upon payment of a development target designation milestone payment. Moderna can replace development targets with research targets during a specified period of time. If Moderna exercises its right to designate a development target, Moderna will have a worldwide, exclusive license under patents and know-how controlled by us to develop and commercialize products directed to the applicable development target, subject to certain diligence obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing a specified time after the effective date of the Moderna License Agreement, Moderna will have the right to nominate targets relating to diseases outside the field of oncology for inclusion in research programs in specified circumstances. Such right is subject to the same exclusions as Moderna&#8217;s right to nominate other targets for inclusion in research programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Moderna License Agreement, we and our affiliates are subject to various exclusivity obligations under which we are not permitted to research, develop or commercialize particular products outside of the collaboration, including products for use as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapies in the field of oncology, products directed to any target included in the collaboration, or products containing a polypeptide provided by us to Moderna in connection with a research program that are directed to any development target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Moderna License Agreement, we received a $45.0 million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are also eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. In addition, we are eligible to receive tiered mid-to-high single digit royalties on net product sales, subject to adjustment. Moderna has also agreed to cover the cost of certain milestone payments and royalties we owe as a licensor under one of our intellectual property in-license agreements with Penn that we are sublicensing to Moderna under the Moderna License Agreement, which royalties Moderna may deduct in part from any royalties owed to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Moderna License Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Moderna License Agreement will expire on a country-by-country basis upon the later of (i) the expiration of the last-to-expire valid patent claim of specified patents, (ii) the expiration of regulatory-based exclusivity for such product in such country or (iii) ten years after the first commercial sale with respect to such product in such country. Moderna has the right to terminate the Moderna License Agreement for convenience in its entirety or with respect to a specific product or target on ninety days&#8217; prior notice. Either we or Moderna may terminate the Moderna License Agreement in its entirety if the other party is in material breach and such breach is not cured within the specified cure period, except in the case of Moderna&#8217;s breach of its diligence obligations, termination by us is limited to the applicable target and product. In addition, either we or Moderna may terminate the Moderna License Agreement in the event of specified insolvency events involving the other party. As an alternative to termination in the event of our uncured material breach of certain sections of the agreement, Moderna has the option to continue the collaboration under the agreement with reduced payment obligations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_921"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Penn License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, Legacy Carisma entered into a license agreement, or the Penn License Agreement, with Penn, which was amended in February 2018, January 2019, March 2020 and June 2021. Pursuant to the Penn License Agreement, Penn granted us (i) an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in specified patents related to CAR macrophages, monocytes or dendritic cells, (ii) an exclusive, worldwide license, with specified rights to sublicense, under Penn&#8217;s interest in specified patents related to CAR-M directed to mesothelin, and (iii) a nonexclusive, worldwide license under Penn&#8217;s interest in specified know-how related to CAR-M, with limited rights to sublicense only in combination with specified products or patents. These licensed patents and know-how arose primarily from research conducted by Dr. Saar Gill and Dr. Michael Klichinsky at the University of Pennsylvania, co-founders of Carisma. The foregoing licenses are subject to rights retained by Penn for specified non-commercial uses and rights retained by the U.S. government. Under the Penn License Agreement, we are obligated to use commercially reasonable efforts to pursue development and commercialization of at least one CAR-M product in oncology and non-oncology fields.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for paying Penn an annual license maintenance fee in the low tens of thousands of dollars, payable until our first payment of a royalty. We are required to pay Penn up to $10.9 million per product in development and regulatory milestone payments, up to $30.0 million per product in commercial milestone payments, and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. While the agreement remains in effect, we are required to pay Penn low to mid-single digit percentage tiered royalties on annual net sales of licensed products, which may be subject to reductions. Penn is guaranteed a minimum royalty payment amount in the low hundreds of thousands of dollars for each year after the first commercial sale of a licensed product. We must also pay Penn a percentage in the mid-single digits to low double digits of certain types of income we receive from sublicensees. In addition, we are required to pay Penn an annual alliance management fee in the low tens of thousands of dollars, ending after several years, unless we provide funding to Penn for research and development activities that extend beyond a specified date, in which case we will continue to owe the alliance management fee for each year in which we continue to fund such activities. We also paid Penn an upfront fee in the low hundreds of thousands of dollars for the license to the patents related to the mesothelin binder that is incorporated into the CAR design for our mesothelin product candidate. We are responsible for a pro rata share of costs relating to the prosecution and maintenance of the licensed patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty period for each licensed product will expire on a product-by-product basis upon the later of (i) the expiration of the last-to-expire valid patent claim of the licensed patents covering such product in the country of sale or in the country of manufacture, or (ii) the expiration of regulatory-based exclusivity for such product in the country of sale. The license agreement remains in effect until the later of (i) expiration or abandonment of the last licensed patent or (ii) loss of regulatory exclusivity. We may terminate the agreement for convenience upon thirty days&#8217; prior notice. Penn may terminate the agreement for our material breach, subject to a specified cure period, except for certain breaches for which Penn may terminate immediately. Penn may also terminate if we become the subject of a specified insolvency event.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_930"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NYU License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Legacy Carisma entered into a license agreement with NYU, or the NYU License Agreement. Pursuant to the NYU License Agreement, NYU granted us (i) an exclusive, worldwide license, with specified rights to sublicense, under NYU&#8217;s interest in specified patents related to the Vpx-LV and (ii) a nonexclusive, worldwide license, with specified rights to sublicense, under NYU&#8217;s interest in specified know-how related to the Vpx-LV, in each case to develop, manufacture, use and sell products developed using the Vpx-LV, or Licensed Products. The foregoing licenses are subject to rights retained by NYU to use, and to permit other non-commercial entities to use, the licensed patents and licensed know-how for educational and research purposes, as well as rights retained by the U.S. government. Under the NYU License Agreement, we are obligated to use reasonable diligence to carry out a specified development plan and to obtain regulatory approval for Licensed Products in the United States and each of the other countries in which we or our sublicensees intend to produce, use, and/or sell Licensed Products, as well as to begin the regular commercial production, use, and sale of the Licensed Products in good faith in accordance with the development plan and to continue diligently thereafter to commercialize the Licensed Products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to pay NYU an annual license maintenance fee in the mid tens of thousands of dollars; up to $1,685,000 per Licensed Product in development and regulatory milestone payments; and low single digit percentage tiered royalties on annual net sales of Licensed Products on a country-by-country basis until the later of (i) 12 years after first commercial sale of a Licensed Product in such country or (ii) expiration of the last to expire licensed patent. We must also pay NYU a percentage in the low single digits to low double digits of certain types of income we receive from sublicensees or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assignees of the agreement. We are also responsible for all costs relating to the prosecution, maintenance, and defense of the licensed patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NYU License Agreement remains in effect until the expiration of all royalty terms in all countries. Either party may terminate the NYU License Agreement for the other party&#8217;s uncured material breach or insolvency or bankruptcy.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_938"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry, and in particular the cell therapy field, is characterized by intense investment and competition aimed at rapidly advancing new technologies, intense competition, and a strong emphasis on intellectual property and proprietary products. Our platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products, and numerous other therapies being developed by other biopharmaceutical companies, academic research institutions, governmental agencies, and public and private research institutions. Many of our potential competitors have substantially greater financial, technical, and other resources, such as larger research and development staff, established manufacturing capabilities and facilities, and experienced marketing organizations with well-established sales forces, and any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. In addition, there is substantial patent infringement litigation in the biopharmaceutical industry, and, in the future, we may bring or defend such litigation against our competitors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition, and the availability of coverage and adequate reimbursement from third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike other cell therapy approaches, our CAR-M platform is based on engineering macrophages and monocytes with proprietary vectors, constructs, and processes, enabling a differentiated platform from other cell therapy competitors that primarily focus on T or natural killer cells, or NK cells. While we believe that our scientific expertise, novel technology, and intellectual property position offer competitive advantages, we face competition from multiple other cell therapy technologies and companies. Other companies developing engineered myeloid cell therapies include, among others, Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, Deverra, SIRPant Therapeutics, and others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the broad promise of cell therapies, and the potential of myeloid cell-based approaches to expand cell therapy efficacy into solid tumors, we expect increasing competition from new and existing companies across several fronts, which include, among others:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Myeloid cell therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CellOrigin, Deverra, Inceptor Bio, Myeloid Therapeutics, Resolution Therapeutics, Shoreline Biosciences, Thunder Bio, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Autologous </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T cell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adaptimmune, Autolus, Bristol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myers Squibb, Cabaletta, Gracell, Kite/Gilead, Novartis, Poseida, TScan, Vor, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Allogeneic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T cell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene, Atara, Caribou, Century, Cellectis, Celyad, CRISPR, Fate, Gracell, Kite/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gilead, Legend, Poseida, Precision Bio, Sana, TScan, Vor, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">NK and other cell therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adicet, Artiva, Celularity, Century, Editas, Fate, Fortress, Gamida Cell, ImmunityBio, Nkarta,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKGen, Takeda, among others</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Direct in vivo reprogrammed cell therapies: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioNTech, Ensoma, Interius, Sanofi, Umoja, Orna Therapeutics, among others</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to competition from other cell therapy companies, any products that we develop may also face competition from other types of therapies. Other companies developing non-cell therapies, including gene therapies, in relevant therapeutic areas include Gilead, ALX Oncology, Five-Prime, Immune-Onc, Pionyr, Infinity, NextCure, OncoResponse, Curis, Faron, Apexigen, Pfizer, Dren, and multiple biotechnology and pharmaceutical companies developing other directly competitive technologies such as small molecules, immune agonists, antibodies, bi/tri specific antibodies, antibody drug conjugates, and other solid tumor therapeutics.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete with third parties for retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. We may pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. The acquisition and licensing of technologies and product candidates is a competitive area, and a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow it to make an appropriate return on our investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before it is able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_806"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, or EU, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensure and Regulation of Biologics in the United States</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our product candidates are regulated as biological products, or biologics, under the Public Health Service Act, or the PHSA, and the Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable U.S. requirements at any time during the product development process, including pre-clinical testing, clinical testing, the approval process, or post-approval process, may subject a sponsor to delays in the conduct of the study, regulatory review, and approval, and/or administrative or judicial sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">pre-clinical laboratory tests, animal studies, and formulation studies all performed in accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards and other applicable regulations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">completion of the manufacture, under current good manufacturing practice, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">design of a clinical protocol and submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials to establish the safety, potency, and purity of the product candidate for each proposed indication, in accordance with current IND or good clinical practice, or GCP;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">preparation and submission to the FDA of a Biologic License Application, or BLA, for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the chemistry, manufacturing and controls, or CMC, for the product in clinical development and proposed labelling;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review of the product by an FDA advisory committee, where appropriate or if applicable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the product&#8217;s identity, strength, quality, and purity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of any FDA audits of the pre-clinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of user Prescription Drug User Fee Act, or PDUFA fees, securing FDA approval of the BLA and licensure of the new biologic product; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">compliance with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy, or REMS, and any post-approval studies or other post-marketing commitments required by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-clinical Studies</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any biologic product candidate in humans, the product candidate must undergo pre-clinical testing. Pre-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. These studies are often referred to as IND-enabling studies. The conduct of the pre-clinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the U.S. Department of Agriculture&#8217;s Animal Welfare Act, if applicable. The results of the pre-clinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigational New Drug Application</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any issues surrounding CMC for the proposed product. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin or recommence. As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA raises concerns or questions either during this initial 30-day period, or at any time following allowance of an IND, it may choose to impose a partial or complete clinical hold. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, pre- clinical, and/or CMC. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. This could cause significant delays or difficulties in completing a planned clinical trial or future clinical trials in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expanded Access to an Investigational Drug for Treatment Use</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it evaluates and responds to expanded access requests, sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 clinical trial, or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to and separate from expanded access, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Clinical Trials in Support of a BLA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB. This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB has access.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials are initially conducted in a limited population to test the product candidate for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials are generally conducted in a limited patient population to identify possible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are referred to as &#8220;pivotal.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety and effectiveness after approval. Such trials are typically referred to as post approval or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post marketing clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any post marketing clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting post approval clinical trials could result in withdrawal of approval for products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, with the passage of the Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans. In January 2024, the FDA issued draft guidance setting out its policies for the collection of race and ethnicity data in clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation&#8217;s recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry, clinicaltrials.gov, maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The FDA has issued several pre-notices for voluntary corrective action and several notices of non-compliance during the past two years. While these notices of non-compliance did not result in civil monetary penalties, the failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Studies Outside the United States in Support of FDA Approval</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a clinical development program, a sponsor may conduct trials at sites outside the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, or IEC, and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acceptance by the FDA of study data from clinical trials conducted outside the United States in support of U.S. approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interactions with FDA During the Clinical Development Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. Progress reports detailing the results of clinical trials must be submitted annually within 60 days of the anniversary dates that the IND went into effect and more frequently if serious adverse events occur. These reports must include a development safety update report, or DSUR. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other trials or animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, there are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND and pre-BLA meetings, as well as end of phase meetings such as End of Phase 2, or EOP2, meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product. A Type D meeting is focused on a narrow set of issues, which should be limited to no more than two focused topics, and should not require input from more than three disciplines or divisions. Finally, INitial Targeted Engagement for Regulatory Advice on CBER/CDER ProducTs, or INTERACT, meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Special Regulations and Guidance Governing Gene Therapy Products</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has defined a gene therapy product as one that mediates its effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome and which is administered as nucleic acids, viruses, or genetically engineered microorganisms. The products may be used to modify cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or transferred to cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to administration to the recipient. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy products. Within CBER, the FDA has established the Office of Tissues and Advanced Therapies, or the OTAT, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. In September 2022, the FDA announced renaming of the OTAT to the Office of Therapeutic Products, or the OTP, and elevation of the OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload and new commitments under the PDUFA for fiscal years 2023 to 2027. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has issued various guidance documents regarding gene therapies, including final guidance documents released in January 2020 relating to CMC information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders, as well as draft guidance in January 2021 for Human Gene Therapy for Neurodegenerative Diseases. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, we believes that our compliance with them is likely necessary to gain approval for any gene therapy product candidate we may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the chemistry, manufacturing, and control information that should be included in an IND application; the proper design of tests to measure </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, for a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with good tissue practices, or GTP. These standards are found in FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that T cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Studies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. In May 2023, the FDA issued new draft guidance that further describes the pediatric study requirements under PREA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are completed. The FDA is required to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has taken steps to limit what it considers abuse of this statutory exemption in PREA. Further, Section 505B of the FDCA, as amended by the FDA Reauthorization Act of 2017, or FDARA, requires that any original NDA or BLA submitted on or after August 18, 2020, for a new active ingredient, must contain reports on the molecularly targeted pediatric cancer investigation, unless the requirement is waived or deferred, if the drug that is the subject of the application is: (i) intended for the treatment of an adult cancer, and (ii) directed at a molecular target that the Secretary determines to be substantially relevant to the growth or progression of a pediatric cancer in accordance with FDA guidance. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compliance with cGMP Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, and purity of the finished product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. The Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act, or PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submission and Review of a BLA</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of product candidate development, pre-clinical testing, and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most BLAs is subject to an application user fee, which for federal fiscal year 2024 is $4,048,695 for an application requiring clinical data. The sponsor of a licensed BLA is also subject to an annual program fee, which for federal fiscal year 2024 is $416,734. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following submission of a BLA, the FDA has 60 days to conduct a preliminary review of the application and it must inform the sponsor within that period of time whether the BLA is sufficiently complete to permit substantive review. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. The FDA may request additional information and studies, and the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under the PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond to the sponsor, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its review of a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity of the clinical data submitted to the FDA. With passage of the FDORA, Congress clarified the FDA&#8217;s authority to conduct inspections by expressly permitting inspections of facilities involved in the preparation, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct, or analysis of clinical and non-clinical studies submitted to the FDA as well as other persons holding study records or involved in the study process.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates, and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a risk evaluation and mitigation strategies, or REMS, if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, or ETASU, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The FDA&#8217;s Decision on a BLA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Provincial Health Services Authority, or PHSA, the FDA may approve a BLA if it determines that the product is safe, pure, and potent, and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. Specifically, the FDA must determine that the expected benefits of the proposed product outweigh its potential risks to patients. This &#8220;benefit- risk&#8221; assessment is informed by the extensive body of evidence about the proposed product in the BLA. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of pre-clinical and clinical trial sites to assure compliance with GCPs, the FDA may issue a complete response letter, or CRL, or an approval letter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the application is not approved, the FDA will issue a CRL, which will contain the conditions that must be met in order to secure final approval of the application and will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a CRL may submit to the FDA information that represents a complete response to the issues identified by the FDA, withdraw the application or request a hearing. The FDA will not approve an application until issues identified in the CRL have been addressed. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six-month extension to respond.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. The FDA may limit the approved indication(s) for use of the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may call for post -approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited Review Programs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to expedite the review of applications in several ways. None of these expedited programs changes the standards for approval but each may help expedite the development or approval process governing product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Fast Track designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">they</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Breakthrough therapy designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Priority review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerated approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The agency indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. While this guidance is currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Regenerative advanced therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With passage of the Cures Act, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency, and effectiveness of pharmaceutical products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a biologic product. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the U.S. Department of Health and Human Services, or the HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although physicians may prescribe legally available products for unapproved uses or patient populations, or &#8220;off-label uses, manufacturers may not market or promote such uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. Moreover, with passage of the Pre-Approval Information Exchange Act, or PIE Act, in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. In addition, in October 2023, the FDA published draft guidance outlining the agency&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers. This draft guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of exclusivity begins on the date that the marketing application is approved by the FDA. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Under Omnibus legislation enacted in December 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by FDA. In addition, the FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent exclusivity in the United States and for biologics, if granted, provides for the attachment of an additional six months of regulatory exclusivity to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and Exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2010 Patient Protection and Affordable Care Act, or ACA, which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA. The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing FDA-licensed &#8220;reference product.&#8221; The FDA has approved a number of biosimilar products and interchangeable biosimilar products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposed biosimilar product in terms of safety, purity, and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal and State Data Privacy and Security Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are multiple privacy and data security laws that may impact our business activities, in the United States and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the Health Insurance Portability and Accountability Act, or HIPAA, the HHS, has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans, and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018 California passed into law the California Consumer Privacy Act, or the CCPA, which took effect on January 1, 2020, and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation, or the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency&#8212;the California Privacy Protection Agency&#8212;whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to California, eleven other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws during the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 legislative sessions that will go into effect in 2025 and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Restoration and Extension</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND clearing clinical studies and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FDA Approval of Companion Diagnostics</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic device on issues related to co-development of the products. The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FDA issued additional guidance which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple biological oncology products, when appropriate. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA previously has required </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor must prepare </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For federal fiscal year 2024, the standard fee is $483,560 and the small business fee is $120,890.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Pricing, and Reimbursement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates a sponsor may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates a sponsor may develop are approved, sales of such product candidates will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers, and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover any product candidates a sponsor may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on a sponsor&#8217;s sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be available to enable a sponsor to maintain price levels sufficient to realize an appropriate return on a sponsor&#8217;s investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, ensuring adequate coverage and payment for any product candidates a sponsor may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require a sponsor to conduct a clinical trial that compares the cost effectiveness of any product candidates a sponsor may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in a sponsor&#8217;s commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a product or they may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of a sponsor&#8217;s products, if approved in those countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Law and Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to physicians and teaching physicians and patient privacy laws and regulations and other healthcare laws and regulations that may constrain a sponsor&#8217;s business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act, or the FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal transparency requirements under the ACA, which require certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or the CMS, within the HHS, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring pharmaceutical manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. In addition, certain state and local laws require drug manufacturers to register pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a sponsor&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations that may apply to a sponsor, a sponsor may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of a sponsor&#8217;s operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the U.S. Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government healthcare programs. Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which will remain in effect through 2031 pursuant to the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012, which was enacted in January 2013, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, with passage of the Inflation Reduction Act in August 2022, or IRA, Congress extended the expansion of ACA premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan Act of 2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices a sponsor may obtain for any of a sponsor&#8217;s product candidates for which a sponsor may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the TCJA, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019 Further, on June 17, 2021, the U.S. Supreme Court dismissed a lawsuit after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump administration took executive actions to undermine or delay implementation of the ACA, but those actions were rescinded with issuance of an Executive Order on January 28, 2021, by President Biden which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care and consider actions that will protect and strengthen that access. Under this Executive Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Prices</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, the CMS issued a final rule to rescind it. With issuance of this rule, the CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries&#8217; access to evidence-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue the HHS. Nine states (Colorado, Florida, Maine, New Hampshire, New Mexico, North Dakota, Texas, Vermont and Wisconsin) have passed laws allowing for the importation of drugs from Canada. Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval. On January 5, 2023, the FDA approved Florida&#8217;s plan for Canadian drug importation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed, and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. The IRA, further delayed implementation of this rule to January 1, 2032.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals. The Order directs the HHS to create a plan within 45 days to combat &#8220;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&#8221; On September 9, 2021, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b) improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation first due in 2023; and replaces the Part D coverage gap discount program with a new discounting program beginning in 2025. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. The CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 additional Part D drugs in 2027, 15 additional Part B or Part D drugs in 2028, and 20 additional Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with passage of the IRA in August 2022, Congress authorized Medicare beginning in 2026 to negotiate lower prices for certain costly single- source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year and it only applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition are categorically excluded from Medicare price negotiations. Further, the new legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2023, Merck &amp; Co. filed a lawsuit against the HHS and the CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce (the &#8220;Chamber&#8221;), Bristol Myers Squibb Company, the PhRMA, Astellas, Novo Nordisk, Janssen Pharmaceuticals, Novartis, AstraZeneca and Boehringer Ingelheim, also filed lawsuits in various courts with similar constitutional claims against the HHS and the CMS. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require pharmaceutical manufacturers and other entities in the supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for a sponsor&#8217;s products, once approved, or put pressure on a sponsor&#8217;s product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_814"></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had 107 full-time employees, including a total of 33 employees with M.D. or Ph.D. degrees, all of whom are located in the United States. Of these full-time employees, 93 are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital objectives are focused on attracting, developing, and retaining talent. Cash compensation plans, comprehensive benefits plans and equity grants are designed to attract, retain and to motivate employees, directors, and select consultants to achieve our corporate objectives. We also provide for employer matching contributions equal to 100% of employee deferral contributions up to a deferral rate of 5% of eligible compensation to our Section 401(k) retirement savings plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cost Reduction Measures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have recently taken steps to reduce our operating expenses and conserve cash as we focus our development efforts on high potential value programs with meaningful near-term milestones. As described in Part II, Item 9B of this Annual Report on Form 10-K, in late March 2024, our board of directors approved a reduction in force of 39 full-time employees (representing approximately 37% of our total workforce), including certain employees engaged in research and development activities and certain finance and corporate employees. We believe these changes will provide operating efficiencies for us to continue to support our product development programs as well as any potential collaborations or other strategic relationships we may enter into.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 3675 Market Street, Suite 200, Philadelphia, PA, and our telephone number is (267) 491-6422. Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">httpp://www.carismatx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained on, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or have rights to, or have applied for, trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks and trade names appearing in this Annual Report on Form 10-K are the property of their respective owners. Solely for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">convenience, some of the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K are listed without the &#174; and &#8482; symbols.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available, through our website </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">httpp://www.carismatx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended as soon as reasonably practicable after we electronically file such material with the Securities and Exchange Commission, or the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item <span id="ia67436ff0e154daf9e0780a019696ce1_291368"></span>1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors set forth below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section of this Annual Report on Form 10-K titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; before deciding whether to purchase our securities. The risks and uncertainties we describe below and in the documents mentioned above are not the only ones we face. Additional risks and uncertainties not presently known to us could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception. We expect to continue to incur significant expenses and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding for our continuing operations. Attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and distract from our discovery and product development efforts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never generated revenue from product sales and may never achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reduction in force undertaken to extend our cash runway and focus our resources on our prioritized research and development programs might not achieve our intended outcome.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are heavily dependent on the success of our follow-on product candidate, CT-0525, which will require significant clinical testing before we can seek marketing approval and potentially generate commercial sales. If CT-0525 does not receive marketing approval or is not successfully commercialized, or if there is significant delay in doing so, our business will be harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding for our continuing operations. If we are unable to raise additional capital when needed or on acceptable terms, we could be forced to further delay, reduce or eliminate our discovery or product development programs or commercialization efforts.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cell therapy is a rapidly evolving area of science, and the approach we are taking to discover and develop product cand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">idates by utilizing genetically modified macrophages is novel and may never lead to approved or marketable products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have and may in the future curtail, pause, delay or cease development of a product candidate at any stage of pre-clinical or clinical development based on a variety of factors, including our judgments regarding costs or timing of further development, probability of success of clinical development, regulatory requirements, commercial potential, relative benefits and costs compared to other product candidates in our portfolio, and our overall corporate strategy.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of our product candidates, if approved, may be smaller than we estimate.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business. If we are not able to maintain these third-party relationships or if these arrangements are terminated, we may have to alter our development and commercialization plans and our business could be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely, and expect to continue to rely, on third parties to conduct our manufacturing of our drug substance and drug product, and those third parties may not perform satisfactorily, including failing to meet deadlines to provide adequate drug product for our clinical trials. This may prevent or delay our ability to complete our clinical trials and to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business. If we are not able to maintain these third-party relationships or if these arrangements are terminated, we may have to alter our development and commercialization plans and our business could be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock may be volatile, and the market price of our common stock may drop in the future. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We incur and will continue to incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If at some point we are no longer a &#8220;smaller reporting company&#8221; or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception. We expect to continue to incur significant expenses and operating losses for the foreseeable future, and may never achieve or maintain profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since inception, we have incurred significant operating losses. Our net losses were $86.9 million and $61.2 million for the years ended December 31, 2023 and 2022, respectively. To date, we have not yet commercialized any products or generated any revenue from product sales and have financed our operations primarily with proceeds from sales of our preferred stock, proceeds from our collaboration with Moderna, research tax credits and convertible debt financing. We have devoted substantially all of our financial resources and efforts to pursuing discovery, research and early clinical development of our product candidates. We are in the early stages of development of our follow-on product candidate, CT-0525, and expect to treat the first patient in the second quarter of 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses for the foreseeable future, including costs associated with operating as a public company. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enhance the capabilities of our CAR-M platform;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct a planned clinical trial of CT-0525 for solid tumors that over-express HER2;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct our ongoing Phase 1 clinical trial of CT-0508 with respect to patients currently enrolled or in screening;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct our sub-study of our ongoing Phase 1 clinical trial utilizing CT-0508 in combination with pembrolizumab with respect to patients currently enrolled or in screening;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct discovery and pre-clinical testing of the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M therapeutics for up to twelve oncology targets, as well as multiple other targets and indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct discovery and pre-clinical testing of our autologous cell therapy pipeline to gather information to apply to the development of off-the-shelf engineered macrophage therapeutics;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop iPSC-derived CAR-M, and other macrophage therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reprogrammed mRNA/LNP CAR-M therapies for cancer;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop viral vectors to effectively engineer human monocytes and macrophages, including the Vpx lentiviral vector and our Ad5f35 vector;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct discovery and pre-clinical testing of our other product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approval for CT-0525 or any other product candidate if we successfully complete clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scale up our external manufacturing capabilities and capabilities to support clinical trials of CT-0525 or any other of our product candidates and for commercialization of any product candidate for which we may obtain marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire additional technologies or product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make any payments under our existing or future strategic collaboration agreements, global exclusive rights licensing agreements or sponsored research agreements, including with Moderna, Penn and NYU;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand, enforce and protect our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory, manufacturing, quality control, development and scientific personnel; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including personnel to support our discovery, product development and planned future commercialization efforts and our operations as a public company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Our expenses could increase beyond our expectations if, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are required by regulatory authorities in the United States, Europe or other jurisdictions to perform trials or studies in addition to, or different than, those that we currently expect;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there are any delays in establishing appropriate manufacturing arrangements for or completing the development of any of our product candidates; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there are any third-party challenges to our intellectual property or our needs to defend against any intellectual property-related claim.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain marketing approval for and are successful in commercializing one or more of our product candidates, we expect to incur substantial additional discovery and product development and other expenditures to develop and market additional product candidates or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated revenue from product sales and may never achieve or maintain profitability.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recently initiated clinical development of our follow-on product candidate, CT-0525. Other than completing remaining activities under our ongoing Phase 1 clinical trial of CT-0508 with respect to patients currently enrolled or in screening, we are in the pre-clinical testing stages for our other product candidates. We expect that it will be a number of years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in completing development of, obtaining marketing approval for and eventually commercializing, one or more products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing clinical development of CT-0525, completing discovery, pre-clinical testing and clinical development of CT-0525 in the combination setting and for additional indications, timely filing and receiving acceptance of our IND applications, in order to commence our planned or future clinical trials, successfully enrolling subjects in, and completing, our ongoing and planned clinical trials, scaling up our manufacturing processes and capabilities to support clinical trials of CT-0525 or of other product candidates, obtaining marketing approval for CT-0525 or any other product candidates, manufacturing, marketing and selling any products for which we may obtain marketing approval and maintaining a continued acceptable safety profile of our products following approval. We may never succeed in these activities and, even if we do, we may never generate revenues that are significant enough to achieve profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our discovery and product development efforts, diversify our pipeline of product candidates or even continue our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on the success of our follow-on product candidate, CT-0525, which will require significant clinical testing before we can seek marketing approval and potentially generate commercial sales. If CT-0525 does not receive marketing approval or is not successfully commercialized, or if there is significant delay in doing so, our business will be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated our first clinical trial in 2021, have no products that are approved for commercial sale and may never be able to develop marketable products. We expect that a substantial portion of our efforts and expenditures for the foreseeable future will be devoted to CT-0525 and related combination sub-studies, including CT-0525 in combination with pembrolizumab. Our business currently depends heavily on the successful development, marketing approval and commercialization of CT-0525, and the success of related combination sub-studies. We cannot be certain that CT-0525 or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any combination therapy involving CT-0525 will achieve success in ongoing or future clinical trials, receive marketing approval or be successfully commercialized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were required to discontinue development of CT-0525, or if CT-0525 does not receive marketing approval for one or more of the indications we pursue, fail to achieve significant market acceptance, or fail to receive adequate reimbursement, we may be delayed by many years in our ability to achieve profitability, if ever, and may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding for our continuing operations. If we are unable to raise additional capital on acceptable terms, we could be forced to further delay, reduce or eliminate our discovery or product development programs or commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we conduct our ongoing clinical trial of CT-0525 and pursue related combination strategies, prepare for, initiate and conduct clinical trials of other product candidates, advance our discovery programs and continue our product development efforts. We expect our expenses to increase substantially over time in connection with our ongoing activities, particularly as we advance our pre-clinical activities and clinical trials. In addition, if we obtain marketing approval for CT-0525 or any other product candidate we are developing or develop in the future, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, we will incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise additional capital or obtain adequate funds on acceptable terms, we may be required to further delay, limit, reduce or terminate our discovery and product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and distract from our discovery and product development efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, costs and results of our clinical trials of CT-0525 and other planned and future clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs of our clinical trials of CT-0508 with respect to patients currently enrolled or in screening;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, costs and results of pre-clinical testing and clinical trials of CT-0525 for additional combinations, targets and indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of and development requirements for additional indications for CT-0525 or for any other product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaborations with Moderna or others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to scale up our manufacturing processes and capabilities to support clinical trials of CT-0525 and other product candidates we are developing and develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of CT-0525 and other product candidates we are developing and may develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential changes in the regulatory environment and enforcement rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of license fees and other costs of our technology license arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for CT-0525 and other product candidates we are developing and may develop in the future for which we may receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of revenue, if any, received from commercial sales of CT-0525 and any other product candidates we are developing or develop in the future for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential changes in pharmaceutical pricing and reimbursement infrastructure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of raw materials for use in production of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire additional technologies or product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had cash and cash equivalents of $77.6 million that we believe are sufficient to sustain our planned operations and capital expenditure requirements into the third quarter of 2025. However, we have based this </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. In addition, changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more than currently expected because of circumstances beyond our control. As a result, we could deplete our capital resources sooner than we currently expect. In addition, because the successful development of CT-0525 and any combination studies or other product candidates that we pursue is highly uncertain, at this time we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidate. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting pre-clinical and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. We will not generate commercial revenues unless and until we can achieve sales of products, which we do not anticipate for a number of years, if at all. Accordingly, we will need to obtain substantial additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all, and we may be impacted by the economic climate and market conditions. For example, market volatility resulting from general U.S. or global economic or market conditions, including related to any health epidemics, pandemics or other contagious outbreaks (including any resurgence of the COVID-19 pandemic), could also adversely impact our ability to access capital as and when needed. Alternatively, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We were formed as Carma Therapeutics LLC, a Pennsylvania limited liability company, in April 2016 and converted to a Delaware corporation in May 2017 under the name CARISMA Therapeutics Inc. In connection with the Merger consummated in March 2023, CARISMA Therapeutics Inc. merged with and into a wholly-owned subsidiary of Sesen Bio and was renamed &#8220;CTx Operations, Inc.&#8221; Sesen Bio's name was changed to &#8220;Carisma Therapeutics Inc.&#8221; Following the completion of the Merger, the business conducted by the public company became primarily the business conducted by us. We are a clinical-stage cell therapy company with a limited operating history. Cell therapy product development is a highly speculative undertaking and involves a substantial degree of risk. Our operations prior to the Merger have been limited to organizing and staffing the company, business planning, capital raising, establishing and maintaining our intellectual property portfolio, building our pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations. Our prospects must be considered in light of the uncertainties, risks, expenses and difficulties frequently encountered by companies in their early stages of operations. We have not yet demonstrated our ability to successfully develop any product candidate, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing, obtaining marketing approval for and commercializing products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as our business grows, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. We will need to transition at some point from a company with a discovery and pre-clinical and clinical focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to build our business, we expect our financial condition and operating results to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law may adversely affect us or our investors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form or with what effective dates tax laws, regulations and rulings may be enacted, promulgated or issued, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. Prospective investors should consult </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their tax advisors regarding the potential consequences of changes in tax law on our business and on the ownership and disposition of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards, or NOLs, and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, we had a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future. As a result, we do not know whether or when we will generate taxable income necessary to utilize our NOLs or research and development tax credit carryforwards. As of December 31, 2023, we had federal, state and local NOLs of $317.6&#160;million, $229.4&#160;million and $40.8&#160;million, respectively, and federal research and development tax credit carryforwards totaling $9.9&#160;million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under Section 382 of the Code and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in our equity ownership by certain stockholders over a three-year period, is subject to limitations on our ability to utilize our pre-change NOLs and research and development tax credit carryforwards to offset future taxable income. We have not conducted a study to assess whether any such ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future (which may be outside our control). As a result, if and to the extent we earn net taxable income, our ability to use our pre-change NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Discovery Programs and Research and Development of Our Product Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell therapy is a rapidly evolving area of science, and the approach we are taking to discover and develop product candidates by utilizing genetically modified macrophages is novel and may never lead to approved or marketable products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell therapy has yet to be broadly applied to solid tumors, inflammatory disease, fibrotic disease or neurodegeneration. The discovery, research and development of engineered macrophages to treat disease is an emerging field and our CAR-M platform, which is the first CAR-M to be evaluated in a human clinical trial, is a relatively new technology. Our future success depends on the successful development of this novel therapeutic approach. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. We have only preliminary results from our Phase 1 clinical trial of CT-0508 and expect clinical data updates in the second quarter of 2024. As such, there may be adverse effects or limited favorable results from treatment with any of our current or future product candidates that we cannot predict at this time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success also depends on our successful application of our proprietary macrophage engineering platform in the combination setting and to other indications by reprogramming the target specificity of our CAR-M cell product and developing product candidates against a plethora of tumor associated antigens, including in therapeutic areas beyond oncology. However, our macrophage engineering platform may not allow us to generate new INDs to expand our pipeline on our anticipated timeline or in a cost-efficient manner or at all, which could cause the potential value of our business to decline and materially harm our business prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of macrophage engineering platform will result in the development and marketing approval of any products. Any development problems we experience in the future related to our macrophage engineering platform or any of our discovery programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our clinical trials or pre-clinical studies or commercializing any product candidates we may develop on a timely or profitable basis, if at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are early in our development efforts. If we are unable to commercialize our product candidates or experiences significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are early in our development efforts. We initiated our first Phase 1 clinical trial of CT-0508 in 2020. We received a Study May Proceed notification from the FDA for CT-0525 in November 2023, and expect to treat our first patient in a Phase 1 clinical trial in the second quarter of 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenues from product sales, which we do not expect will occur for a number of years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of CT-0525, including in the combination setting, or one or more of our other product candidates, which may never occur. The success of CT-0525 and our other product candidates will depend on many factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully completing pre-clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully initiating future clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully enrolling patients in our Phase 1 clinical trial of CT-0525 and completing clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scaling up manufacturing processes and capabilities to support clinical trials of CT-0525 and any other product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">applying for and receiving marketing approvals from applicable regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining intellectual property protection and regulatory exclusivity for CT-0525 and any other product candidates we are developing or may develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of CT-0525 and any other product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our products following receipt of any marketing approvals.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially harm our business. As a company, we have limited experience in clinical development. Any predictions about the future success or viability of CT-0525 or any product candidates we are developing or may develop in the future may not be as accurate as they could be if we had a history of conducting clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development involves a lengthy and expensive process, with an uncertain outcome. The results of pre-clinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of CT-0525 or our other product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We initiated our first clinical trial of CT-0508 in 2020, and expect to dose the first patient in a Phase 1 clinical trial of CT-0525 in the second quarter of 2024. Our other product candidates are in pre-clinical development. The risk of failure for CT-0525 and our other product candidates is high. It is impossible to predict when or if CT-0525 or any of our other product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of a product candidate, we must complete pre-clinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Clinical trials may fail to demonstrate that CT-0525 or any of our other product candidates are safe for humans and effective for indicated uses. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can commence clinical trials for a product candidate, we must complete extensive pre-clinical testing and studies, manufacturing process development studies, and analytical development studies that support our planned INDs and other applications to regulatory authorities in the United States or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our pre-clinical testing and studies and cannot predict if the outcome of our pre-clinical testing and studies will ultimately support the further development of our current or future product candidates or whether regulatory authorities will accept our proposed clinical programs. As a result, we may not be able to submit applications to initiate clinical development of product candidates on the timelines we expect, if at all, and the submission of these applications may not result in regulatory authorities allowing clinical trials to begin. Furthermore, product candidates are subject to continued pre-clinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. We cannot guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, among other things, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates or cause regulatory authorities to require additional testing before approving any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any product candidates, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may determine that the planned design of our clinical trials is flawed or inadequate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to establish clinical endpoints that applicable regulatory authorities consider clinically meaningful, or, if we seek accelerated approval, biomarker efficacy endpoints that applicable regulatory authorities consider likely to predict clinical benefit;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-clinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional pre-clinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide, or regulators or IRBs may require us, to suspend or terminate clinical trials of our product candidates for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or IRBs may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our clinical investigators, regulators or IRBs to suspend or terminate the trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators may withdraw their approval of a product or impose restrictions on its distribution; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">business interruptions resulting from any health epidemics, pandemics or other contagious outbreaks (including any resurgence of the COVID-19 pandemic) may result in adverse effects on our business and operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we may:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur unplanned costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approval in some countries and not in others;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will also increase if we experience delays in pre-clinical studies or clinical trials or in obtaining marketing or other regulatory approvals. We do not know whether any of our pre-clinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses or delays. Significant pre-clinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of the FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the regulatory landscape related to clinical trials in the European Union recently evolved. The EU Clinical Trials Regulation, or the EU-CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate Clinical Trial Application, or CTA, to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the EU-CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. The EU-CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. If we are not able to adapt to these and other changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for second-line or third-line use. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. For any of our products that prove to be sufficiently beneficial, we would expect to seek approval potentially as a first-line therapy, but any product candidates we develop, even if approved, may not be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may conduct clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may conduct one or more clinical trials with one or more trial sites that are located outside the United States. The acceptance by the FDA or other regulatory authorities of study data from clinical trials conducted outside their jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">additional foreign regulatory requirements; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">foreign exchange fluctuations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">cultural differences in medical practice and clinical research; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diminished protection of intellectual property in some countries; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruptions or delays in our trials resulting from geopolitical events, such as war or terrorism.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of early-stage clinical trials and pre-clinical studies may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary or interim results of a clinical trial do not necessarily predict final results. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. In particular, the small number of patients in our ongoing or future early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of our Phase 1 clinical trial of CT-0525 may not be predictive of the results of further clinical trials of CT-0525 or any of our other product candidates. Our product candidates may also fail to show the desired safety and efficacy in clinical development despite positive results in pre-clinical studies or having successfully advanced through initial clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our current or future clinical trials may not ultimately be successful or support further clinical development of any of our product candidates and we cannot assure you that any clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to support marketing approval. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in late-stage clinical trials even after achieving promising results in pre-clinical testing and earlier-stage clinical trials, and we cannot be certain that we will not face similar setbacks. Any such setbacks in our clinical development could materially harm our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may announce or publish interim or preliminary results from our clinical trials, including our Phase 1 clinical trials of CT-0508 and CT-0525. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary or interim results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in our clinical trials for CT-0525 or any of our other product candidates, our receipt of necessary marketing approvals could be delayed or prevented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trial for CT-0525 and any other product candidates in the future is critical to our success. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in the trial until its conclusion. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. In particular, our clinical trial of CT-0525 is open for enrollment and the first patient is expected to be treated in the second quarter of 2024. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. We cannot predict how successful we will be at enrolling subjects in future clinical trials. Patient enrollment is affected by a variety of other factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of the disease under investigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for the trial in question;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidate under trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirements of the trial protocols;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of existing treatments for the indications for which we are conducting clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to identify specific patient populations based on specific genetic mutations or other factors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient consents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations as our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost to, or lack of adequate compensation for, prospective patients; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of any health epidemics, pandemics or other contagious outbreaks (including any resurgence of the COVID-19 pandemic).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary marketing approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which could cause the value of our business to decline and limit our ability to obtain additional financing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of CT-0525 or any of our other product candidates, we may need to abandon or limit our further clinical development of those product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first site has been activated for the Phase 1 clinical trial of CT-0525 and the first patient is expected to be treated in the second quarter of 2024. If CT-0525 or any other product candidate is associated with serious adverse events or undesirable side effects in clinical trials or have characteristics that are unexpected in clinical trials or pre-clinical testing, we may need to abandon development of such product candidate or limit development to more narrow uses or subpopulations in which the serious adverse events, undesirable side effects or unexpected characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In pharmaceutical development, many compounds that initially show promise in early-stage or clinical testing are later found to cause side effects that delay or prevent further development of the compound or decrease the size of the patient population for whom the compound could ultimately be prescribed. For example, while CT-0508 has been generally well tolerated based on preliminary clinical results from our Phase 1 clinical trial, such results may not be predictive or indicative of the preliminary clinical results from our Phase 1 clinical trial of our follow-on product candidate, CT-0525, or the successful development, marketing approval and eventual commercialization of CT-0525.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if results of our clinical trials reveal undesirable side effects, we, regulatory authorities or the IRBs at the institutions in which our studies are conducted could suspend or terminate our clinical trials, regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications or we could be forced to materially modify the design of our clinical trials. Treatment-related side effects could also affect patient </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In late March 2024, we determined to suspend enrollment of new patients in Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab, in line with the clinical judgment of the clinical site principal investigator, and pause further development of CT-1119 for expense reduction purposes. If we elect or are forced to suspend or terminate any clinical trial of our product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate revenues from sales of such product candidate will be delayed or eliminated. Any of these occurrences could materially harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We only recently initiated clinical development of our first product candidate, CT-0508, and are initiating our first clinical trial of CT-0525 with the first patient expected to be treated in the second quarter of 2024. We are in the pre-clinical testing stages for our other product candidates. Clinical trials will be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives marketing approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal or limitation by regulatory authorities of approvals of such product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seizure of the product by regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing of the product or the manufacturing process for any component thereof;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirement by regulatory authorities of additional warnings on the label;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirement that we implement a risk evaluation and mitigation strategy or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of regulatory investigations and government enforcement actions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of legal action against us to hold us liable for harm caused to patients; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harm to our reputation and resulting harm to physician or patient acceptance of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because we have limited financial and managerial resources, we focus on discovery programs and product candidates that we identify for specific indications. As a result, we have and may in the future forego or delay the pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. In late March 2024, we determined to focus our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">oncology clinical development efforts on our follow-on product candidate CT-0525, suspend enrollment of new patients in our Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab, in line with the clinical judgment of the clinical site principal investigator, and pause further development of CT-1119 for expense reduction purposes. We may further curtail, pause, delay or cease development of other product candidates at any stage of pre-clinical or clinical development based on a variety of factors, including our judgments regarding costs or timing of further development, probability of success of clinical development, regulatory requirements, commercial potential, relative benefits and costs compared to other product candidates in our portfolio, and our overall corporate strategy. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future discovery and product development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to evaluate CT-0525 in combination with pembrolizumab and may evaluate CT-0525 in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with CT-0525, we may be unable to obtain approval of CT-0525 or market CT-0525.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, we received FDA clearance of our IND for CT-0525 and we expect to treat the first patient in the second quarter of 2024. We also plan to conduct a sub-study of our Phase 1 clinical trial utilizing CT-0525 in combination with pembrolizumab and may evaluate CT-0525 in combination with other drugs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not develop or obtain marketing approval for, nor have we manufactured or sold, any of the currently approved drugs that we may study in combination with CT-0525. If the FDA or similar regulatory authorities outside of the United States revoke their approval of any drug or drugs in combination with which we determine to develop CT-0525, we will not be able to market CT-0525 in combination with such revoked drugs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays, and the FDA or similar regulatory authorities outside of the United States may require us to redesign or terminate the applicable clinical trials. If the drugs we use are replaced as the standard of care for the indications we choose for CT-0525, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which we determine to combine with CT-0525, we may not be able to complete clinical development of CT-0525 on our current timeline or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if CT-0525 were to receive marketing approval or be commercialized for use in combination with other existing drugs, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the drugs used in combination with CT-0525 or that safety, efficacy, manufacturing or supply issues could arise with these existing drugs. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our other product candidates for use in combination with other drugs for cancer or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional potential product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to apply our macrophage engineering platform to address a broad array of indications and targets to generate next-generation therapeutics, including three programs for indications outside of oncology. The discovery efforts that we are conducting may not be successful in identifying product candidates that are useful in treating cancer or other diseases. Our discovery engine may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may not be effective in treating their targeted diseases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If we are unable to identify additional suitable product candidates for pre-clinical and clinical development, it will limit our potential to obtain revenues from sale of products in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse public perception of genetic medicine, and gene therapy in particular, may negatively impact regulatory approval of, or demand for, our potential products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy is unsafe, unethical, or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates that we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of our product candidates, if approved, may be smaller than we estimate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well established in the medical community and doctors may continue to rely on these and similar treatments. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from product sales and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages of our product candidates compared to the advantages and relative risks of alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of sales and marketing efforts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products, if approved, for sale at competitive prices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which the product is approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of competitive products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement, and patients&#8217; willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA, the European Medical Agency, or the EMA, or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">support from patient advocacy groups; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products, if approved, together with other medications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assessment of the potential market opportunity for our product candidates is based on industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and our analysis of these data, research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of our product candidates may be smaller than we expect, and as a result our revenues from product sales may be limited and it may be more difficult for us to achieve or maintain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience as a company in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success for any product for which we may obtain marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that we would build our own focused, specialized sales and marketing organization to support the commercialization in the United States of product candidates for which we receive marketing approval and that can be commercialized with such capabilities. There are risks involved with us establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In general, the cost of establishing and maintaining a sales and marketing organization may exceed the cost-effectiveness of doing so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales, marketing, market access, distribution, customer service, medical affairs and other support personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to equip sales personnel with effective materials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to effectively manage a geographically dispersed sales and marketing team;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our revenues from product sales and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of the market for our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry, and in particular the cell therapy field, is characterized by intense investment and competition aimed at rapidly advancing new technologies. Our platform and therapeutic product candidates are expected to face substantial competition from multiple technologies, marketed products and numerous other therapies being developed by third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as small molecule inhibitors. The competition is likely to come from multiple sources, including biopharmaceutical companies, academic research institutions, governmental agencies and private research institutions that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. The competition is likely to come from multiple sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of a number of companies generally pursuing the development of myeloid cell therapies, including, among others Myeloid Therapeutics, Shoreline Biosciences, Inceptor Bio, Thunder Bio, Resolution Therapeutics, CellOrigin, SIRPant Therapeutics, and others. We are also facing competition from companies pursuing autologous T cell therapies, allogeneic T cell therapies, NK and other cell therapies, direct </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reprogrammed cell therapies and other macrophage-targeted oncology therapeutics.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our development programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other marketing approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technology in the biopharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any products or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have pursued and may in the future pursue the in-license or acquisition of rights to complementary technologies and product candidates on an opportunistic basis. However, we may be unable to in-license or acquire any additional technologies or product candidates from third parties. The acquisition and licensing of technologies and product candidates is a competitive area, and a number of more established companies also have similar strategies to in-license or acquire technologies and product candidates that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to in-license or acquire the relevant technology or product candidate on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. The availability of coverage and adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products, including our product candidates. Government authorities and third-party payors, such as private health insurers and health </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers its costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our product candidates, even if they are approved for sale in the United States, in the European Union or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our product candidates profitably.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products that have been approved for commercial sale, the ongoing, planned and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend any related litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management&#8217;s attention from our primary business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products that we may develop.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of $10.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business. If we are not able to maintain these third-party relationships or if these arrangements are terminated, we may have to alter our development and commercialization plans and our business could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, and expect to continue to rely, on third-party clinical research organizations, in addition to other third parties such as research collaboratives, clinical data management organizations, medical institutions and clinical investigators, to conduct our Phase 1 clinical trial of CT-0525 and any other clinical trials we conduct. We currently have no plans to independently conduct clinical trials of our product candidates or any other product candidates that we may develop. These contract research organizations, or CROs, and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. These third-party arrangements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities might be delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for discovery and product development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities in Europe and other jurisdictions have similar requirements. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully develop and commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned, and the utility of the clinical trial itself </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be jeopardized, which could result in the delay or rejection of any marketing application we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding more CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays can occur, which could materially impact our ability to meet our desired clinical development timelines. Although we plan to carefully manage our relationships with our CROs, investigators and other third parties, we may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party CMOs for the manufacture of both drug substance and finished drug product of our product candidates for pre-clinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third-party CMOs for both drug substance and finished drug product, as well as for commercial manufacture if any of our product candidates receive marketing approval. We also currently rely on these third parties for the manufacture of plasmid and viral vectors, patient leukapheresis material logistics, as well as packaging, labeling, sterilization, storage, distribution and other production logistics. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential failure to manufacture our product candidate or product according to our specifications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential failure to manufacture our product candidate or product according to our schedule or at all;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or active pharmaceutical ingredients, including shortages caused by the purchase of such raw materials or active pharmaceutical ingredients by our competitors or others. Our or our third-party manufacturers' failure to obtain the raw materials or active pharmaceutical ingredients necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party manufacturers are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with current good manufacturing practices, or cGMP, regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If any of our current contract manufacturers cannot perform as agreed, we may be required to replace such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to depend on collaborations with third parties for the research, development and commercialization of certain of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate seeking third-party collaborators for the research, development and commercialization of certain of our product candidates. For example, we entered into a strategic collaboration with Moderna in January 2022 focused on the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M therapeutics for up to twelve product candidates. In collaboration with Moderna, we have established a mRNA/LNP </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M platform for oncology targets, which enables an off-the-shelf approach wherein the patient&#8217;s own myeloid cells are engineered directly within their body via the administration of a LNP encapsulating macrophage reprogramming mRNA CAR constructs, removing the requirement for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cell manufacturing entirely. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies and biotechnology companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such arrangements with third parties will likely limit our control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our discovery programs or any product candidates we may develop, including our collaboration with Moderna, pose the following risks to us:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; for example, our collaboration with Moderna is managed by a joint steering committee, or JSC, which is comprised of representatives from the company and Moderna, with Moderna having final decision-making authority, subject to specified limitations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not perform their obligations as expected;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that divert resources or create competing priorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of any product candidates that achieve marketing approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition or business combination, that may divert resources or create competing priorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis; for example, data, results and know-how generated in the performance of the Moderna collaboration is deemed the confidential information of Moderna, which we may not disclose except under limited circumstances;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator may seek to renegotiate or terminate their relationship with us due to unsatisfactory clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve marketing approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; for example, Moderna has the first right to prosecute, enforce or defend certain patent rights under its agreement with us, and although we may have the right to assume the prosecution, enforcement or defense of such patent rights if Moderna does not, our ability to do so may be compromised by Moderna&#8217;s actions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates; for example, Moderna has the right to terminate its agreement with us for convenience in its entirety or with respect to a specific product or target on ninety days&#8217; prior notice, in connection with a material breach of the agreement by us that remains uncured for a specified period of time or in the event of specified insolvency events involving us; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If a present or future collaborator of ours was to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, or receive it in the timeframe in which we expect to receive it, the development of our product candidates could be delayed, and we may need additional resources to develop our product candidates. All of the risks relating to product development, marketing approval and commercialization described herein also apply to the activities of our collaborators.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future decide to collaborate with biopharmaceutical companies for the development and potential commercialization of any product candidates we may develop. These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to establish additional collaborations. If we are not able to establish or maintain additional collaborations, on commercially reasonable terms, we may have to alter our development and commercialization plans and our business could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To realize the full potential of our macrophage engineering platform and accelerate the development of additional macrophage engineering programs, we plan to continue to selectively pursue collaborations with leading biopharmaceutical companies with particular experience, including development and commercial expertise and capabilities. We face significant competition in attracting appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate, document and execute. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any collaboration we may enter into may limit our ability to enter into future agreements on particular terms or covering similar target indications with other potential collaborators.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market and generate revenue from product sales, which could have an adverse effect on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a number of academic collaborations to supplement our internal discovery and product development programs. If any such collaborator decides to discontinue or devote less resources to such research, our discovery programs could be diminished.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discovery engine is supplemented by academic collaborations to expand our platform, which we rely upon to advance our development and commercialization plans for our product candidates. In August 2020, we entered into a scientific research and licensing agreement with Nathaniel R. Landau, Ph.D. and NYU Langone Health through which we obtained exclusive rights to develop their Vpx lentiviral vector globally for all indications. We also have an ongoing discovery program in neurodegeneration being pursued through a sponsored research agreement with Dr. Saar Gill, Associate Professor of Medicine at the University of Pennsylvania and co-founder of our Company, to develop CAR macrophages and microglia targeted against protein aggregates associated with neurodegenerative disease pathology. In addition, we, from time to time, may enter into academic research collaborations to explore the development of new technologies and indications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While these academic institutions have contractual obligations to us, they are independent entities and are not under our control or the control of our officers or directors. Our research and licensing agreements with academic collaborators generally provide academic collaborators with license maintenance fees, development and regulatory milestone payments, royalties on net sales of products and a portion of sublicense income that we receive. Upon the scheduled expiration of any academic collaboration, we may not be able to renew the related agreement, or any renewal could be on terms less favorable to us than those contained in the existing agreement. Furthermore, either we or the academic institution generally may terminate the sponsored research agreement for convenience following a specified notice period. If any of these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">academic institutions decides to not renew or to terminate the related agreement or decides to devote fewer resources to such activities, our discovery efforts would be diminished, while our royalty obligations, if any, would continue unmodified.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any acquisitions or in-license transactions that we complete could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed three patent families from Penn and one patent family from NYU and may enter into transactions to in-license or acquire other businesses, intellectual property, technologies, product candidates or products. If we determine to pursue a particular transaction, we may not be able to complete the transaction on favorable terms, or at all. Any in-licenses or acquisitions we complete may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an in-license or acquisition or issue our common stock or other equity securities to the stockholders of the target company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. In-license and acquisition transactions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of additional future in-licenses or acquisitions or the effect that any such transactions might have on our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, European Medicines Agency, or EMA, or other comparable foreign regulatory authorities could require the clearance or approval of a companion diagnostic device as a condition of approval for any product candidate that requires or would commercially benefit from such tests. Failure to successfully validate, develop and obtain regulatory clearance or approval for companion diagnostics on a timely basis or at all could harm our product development strategy and we may not realize the commercial potential of any such product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safe and effective use of any of our other product candidates depends on an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves our product candidates. The process of obtaining or creating such diagnostic is time consuming and costly. Companion diagnostics, which provide information that is essential for the safe and effective use of a corresponding therapeutic product, are subject to regulation by the FDA, EMA and other comparable foreign regulatory authorities as medical devices and require separate regulatory approval from therapeutic approval prior to commercialization. The FDA previously has required </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of pre-clinical and clinical data and the submission and review by the FDA, can take several years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our limited experience in developing and commercializing diagnostics, we do not plan to develop companion diagnostics internally and thus will be dependent on the sustained cooperation and effort of third-party collaborators in developing and obtaining approval for these companion diagnostics. We may not be able to enter into arrangements with a provider to develop a companion diagnostic for use in connection with a registrational trial for our product candidates or for commercialization of our product candidates, or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates. We and our future collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by our collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. In addition, we, our collaborators or third parties may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics by physicians.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any companion diagnostic collaborator or third party with whom we contract may decide not to commercialize or to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates, or our relationship with such collaborator or third party may otherwise terminate. We may not be able to enter into arrangements with another provider to obtain supplies of an alternative </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain, maintain and enforce patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain, maintain and enforce protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business and by in-licensing intellectual property related to such technologies and product candidates. If we are unable to obtain, maintain or enforce patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Moreover, the patent applications we own, co-own or license may fail to result in issued patents in the United States or in other foreign countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Moreover, our owned or in-licensed pending and future patent applications may not result in patents being issued which protect our technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the  USPTO, or become involved in opposition, derivation, revocation, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our owned or licensed patent estate includes patent applications, many of which are at an early stage of prosecution. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned or in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to our inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial costs and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position with respect to our current or future product candidates for an adequate amount of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but there is no assurance that any such extensions will be obtained, and the life of a patent, and the protection it affords, is limited. Even if patents covering our current or future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, patent term can also be adjusted due to delays that occur during examination of patent applications, which may extend the term of a patent beyond 20 years. There is a risk that we may take action that detracts from any accrued patent term adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is necessary to pay certain maintenance fees, also referred to as annuities or renewal fees in some countries, throughout the lifetime of a patent at regular intervals. Failure to pay these fees can cause a granted patent to prematurely expire, without an opportunity for revival. There is a risk that we may be unable to maintain patent protection for certain patents in all markets due to finite availability of resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidate(s), which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, we may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we fail to comply with our obligations under any license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in us having to negotiate new or restated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the term of a patent that covers an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Hatch-Waxman Act, as compensation for the loss of a patent term during the FDA regulatory review process for a drug product subject to the provisions of the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years, but patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. There is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions could be for a shorter period than we anticipate. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the maintenance, enforcement or defense of our owned or in-licensed issued patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government retains certain rights in inventions created using its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights&#8221;. March-in rights allow the government, in specified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license itself. We collaborate with a number of universities with respect to certain of our research and development. We cannot be sure that any co-developed intellectual property will be free from government rights pursuant to the Bayh-Dole Act. If, in the future, we co-own or in-license technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we or our licensors are not currently involved in any intellectual property litigation, we may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe, misappropriate or otherwise violate our or our licensor&#8217;s issued patents, the patents of our licensors or other intellectual property. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s product. To counter infringement or misappropriation, we or our licensors may need to file infringement, misappropriation or other intellectual property related claims, which can be expensive and time-consuming and can distract our management and scientific personnel. There can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us, alleging that we infringe, misappropriate or otherwise violate their intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including novelty, non-obviousness, enablement, or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions, such as opposition proceedings. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Similarly, if we or our licensors assert trademark infringement claims, a court may determine that the marks we or our licensors have asserted are invalid or unenforceable, or that the party against whom we or our licensors have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks, which could materially harm our business and negatively affect our position in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse result in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent, and could limit our or our licensor&#8217;s ability to assert those patents against those parties, or other competitors, and curtail or preclude our ability to exclude third parties from developing and commercializing similar or competitive products. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents do not cover such technology. Even if we establish infringement, a court may not order the third party to stop using the technology at issue and instead award only monetary damages to us, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products and have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management, technical personnel and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources in one or more aspects, or for other reasons. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of a third party to commercialize our own technology or products, in which case we would be required to obtain a license from such third party. A license to such intellectual property may not be available or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than us, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the biopharmaceutical industry. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions, such as opposition proceedings before the European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biopharmaceutical industry expands and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal threshold for initiating litigation or contested proceedings is low, so even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our product candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Even if we diligently search third-party patents for potential infringement by our products or product candidates, we may not successfully find patents our products or product candidates may infringe. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party&#8217;s intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringe upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain a license, we could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right, we could be forced to indemnify our customers or collaborators. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign our product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we seek to protect the trademarks and trade names we use in the United States and in other countries, we may be unsuccessful in obtaining registrations or otherwise protecting these trademarks and trade names, which we need to build name recognition in our markets of interest and among potential partners or customers. We rely on both registration and common law protection for our trademarks. Our registered or unregistered trademarks or trade names may be challenged, infringed, diluted or declared generic, or determined to be infringing on other marks. At times, competitors may adopt trademarks and trade names similar to ours, or our collaborators may fail to use our trade names or trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks. If we are unable to protect our rights to trademarks and trade names, we may be prevented from using such marks and names unless we enter into appropriate royalty, license or coexistence agreements, which may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Effective trademark protection may not be available or may not be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sought in every country in which our products are made available. Any name we propose to use for our products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may license our trademarks and trade names to third parties, such as distributors and collaborators. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of or failure to use our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, know-how, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on an annuity service, outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a number of license and research agreements. Some of these agreements provide us with the intellectual property rights required for the development of our product candidates, including the license agreement with Penn. These </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licenses and research agreements and similar agreements in the future may impose diligence, development and commercialization timelines, and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with such obligations, the parties to these agreements may decide to terminate the agreements or require us to grant them certain rights, in which we may not be able to develop, manufacture, or market any products without the rights granted to us by these agreements and may face other penalties. Any such occurrences could adversely affect the value of any product candidate being developed, including CT-0525.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a variety of purposes, we will likely enter into additional licensing and funding arrangements with third parties that may impose similar obligations on us. Termination of these agreements or reduction or elimination of our rights under these agreements may result in us having to negotiate new or restated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects. While we still face all of the risks described herein with respect to such agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks, intellectual property rights that our licenses in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation related issues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment obligations with respect to licensed technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, licensors could retain the right to prosecute and defend the intellectual property rights licensed to us, in which case we would depend on our licensors to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Licensors may determine not to pursue litigation against other companies or may pursue such litigation less aggressively than we would. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications of our in-licenses. If other third parties have ownership rights to patents or patent applications of our in-licenses, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, including of their current or former employers or claims asserting we have misappropriated their intellectual property, or is claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants and contractors have been previously employed at universities or other biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We may have also entered into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. To the extent we become involved in litigation that may require discovery of our trade secrets, know-how and other proprietary technology, we will seek to secure protective orders from the court that bind the parties with access to the discovered information. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. In addition, we cannot be certain that proprietary technical information and related confidential documents that we have shared with our collaborators and/or submitted to governmental agencies, including regulatory agencies for evaluation and supervision of pharmaceutical products, will be kept confidential. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or license;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering our inventions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our owned or in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims of issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research, development, testing or commercialization activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Supreme Court, other federal courts, Congress, the USPTO or similar foreign authorities may change the standards of patentability and any such changes could narrow or invalidate, or change the scope of, our or our licensors&#8217; patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before the relevant patents that we own or license expire;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may harm our business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If approved, our product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, a reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product In addition, the licensure of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still develop and receive approval of a competing biologic, so long as its BLA does not reply on the reference product, sponsor&#8217;s data or submit the application as a biosimilar application. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that any of the product candidates we develop as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing. Nonetheless, the approval of a biosimilar to our product candidates would have a material adverse impact on our business due to increased competition and pricing pressure.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future will ever obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive marketing approval for many reasons, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for our proposed indication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may disagree with our interpretation of data from pre-clinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application, or NDA, to the FDA or other submission or to obtain marketing approval in the United States;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in us failing to obtain marketing approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process and determining when or whether marketing approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA. Risks similar to those outlined above exist with regard to regulatory authorities outside the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary pre-clinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by the EMA and other regulatory authorities outside of the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval requires the submission of extensive pre-clinical and clinical data and supporting </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude us from obtaining marketing approval or prevent or limit commercial use. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional pre-clinical, clinical or other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, under the PREA, a BLA or supplement to a BLA for certain biological products must contain data to assess the safety and effectiveness of the biological product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The applicable legislation in the European Union also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Committee. For any of our product candidates for which we are seeking regulatory approval in the United States or the European Union, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in the European Union and many other foreign jurisdictions, we and our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any jurisdiction, which would materially impair our ability to generate revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom as a result of the withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and EU Customs Union. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, became responsible for supervising medicines and medical devices in Great Britain, or GB, comprising England, Scotland and Wales under domestic law, whereas under the terms of the Northern Ireland Protocol, Northern Ireland is currently subject to EU rules. The United Kingdom and European Union have however agreed to the Windsor Framework which fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the United Kingdom. Once implemented, the changes introduced by the Windsor Framework will see the MHRA be responsible for approving all medicinal products </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">destined for the United Kingdom, or UK, market (i.e., GB and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in obtaining, or an inability to obtain, any marketing authorizations, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may, however, have a significant impact on the pharmaceutical industry and our business in the long term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the Securities and Exchange Commission, or the SEC, and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the FDA have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA, EMA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. In addition, disruptions may result from events similar to the COVID-19 pandemic. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a similar public health emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the United States facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, if a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory requirements governing gene therapy products are periodically updated and may continue to change in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has established the OTAT, within the Center for Biologics Evaluation and Research, or the CBER, to consolidate the review of gene therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review. In September 2022, the FDA announced retitling of the OTAT to the OTP, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elevation of the OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload and new commitments under the Prescription Drug User Fee Act agreement for fiscal years 2023 to 2027. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy clinical trials conducted at institutions that receive funding for recombinant DNA research from the NIH also are potentially subject to review by the Office of Biotechnology Activities&#8217; Recombinant DNA Advisory Committee, or the RDAC; however, the NIH announced that the RDAC will only publicly review clinical trials if the trials cannot be evaluated by standard oversight bodies and pose unusual risks. Although the FDA decides whether individual gene therapy protocols may proceed, the RDAC public review process, if undertaken, can delay the initiation of a clinical trial, even if the FDA has reviewed the trial design and details and approved its initiation. Conversely, the FDA can put an IND on a clinical hold even if the RDAC has provided a favorable review or an exemption from in-depth, public review. If we were to engage an NIH-funded institution to conduct a clinical trial, that institution&#8217;s Institutional Biosafety Committee, or IBC, as well as our IRB would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has issued various guidance documents regarding gene therapies, including final guidance documents released in January 2020 relating to CMC information for gene therapy INDs, gene therapies for rare diseases and gene therapies for retinal disorders. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, we believe that our compliance with them is likely necessary to gain approval for any gene therapy product candidate that we may develop. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things, the proper pre-clinical assessment of gene therapies; the chemistry, manufacturing, and control information that should be included in an IND; the proper design of tests to measure product potency in support of an IND or BLA; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for a 15-year period, including a minimum of five years of annual examinations followed by 10 years of annual queries, either in person or by questionnaire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, for a gene therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with GTP. These standards are found in FDA regulations and guidance that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, ethical, social and legal concerns about gene therapy, genetic testing and genetic research could result in additional regulations or prohibiting the processes that we may use. Federal and state agencies, congressional committees and foreign governments have expressed their intentions to further regulate biotechnology. More restrictive regulations or claims that our product candidates are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance our product candidates through clinical development, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. These regulatory review committees and advisory groups and any new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product for which we obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with any such product following approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product for which we obtain marketing approval, as well as the manufacturing processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market any product for an indication that is not approved, we may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with any product for which we may obtain marketing approval and its manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on such product, manufacturers or manufacturing processes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on the labeling or marketing of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on product distribution or use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">withdrawal of the product from the market;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">recall of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">restrictions on coverage by third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">fines, restitution or disgorgement of profits or revenues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">suspension or withdrawal of marketing approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">refusal to permit the import or export of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">product seizure; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our ability to develop and market new drug products may be impacted by ongoing litigation challenging the FDA&#8217;s approval of mifepristone. Specifically, on April 7, 2023, the U.S. District Court for the Northern District of Texas stayed the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is governed by various conditions adopted under a REMS. In reaching that decision, the district court made a number of findings that may negatively impact the development, approval and distribution of drug products in the United States. Among other determinations, the district court held that plaintiffs were likely to prevail in their claim that FDA had acted arbitrarily and capriciously in approving mifepristone without sufficiently considering evidence bearing on whether the drug was safe to use under the conditions identified in its labeling. Further, the district court read the standing requirements governing litigation in federal court as permitting a plaintiff to bring a lawsuit against the FDA in connection with its decision to approve an NDA or establish requirements under a REMS based on a showing that the plaintiff or its members would be harmed to the extent that FDA&#8217;s drug approval decision effectively compelled the plaintiffs to provide care for patients suffering adverse events caused by a given drug. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2023, the district court decision was stayed, in part, by the U.S. Court of Appeals for the Fifth Circuit. Thereafter, on April 21, 2023, the U.S. Supreme Court entered a stay of the district court&#8217;s decision, in its entirety, pending disposition of the appeal of the district court decision in the Court of Appeals for the Fifth Circuit and the disposition of any petition for a writ of certiorari to or the Supreme Court. The Court of Appeals for the Fifth Circuit held oral argument in the case on May 17, 2023, and, on August 16, 2023, issued its decision. The court declined to order the removal of mifepristone from the market, finding that a challenge to the FDA&#8217;s initial approval in 2000 is barred by the statute of limitations. But the Appeals Court did hold that plaintiffs were likely to prevail in their claim that changes allowing for expanded access of mifepristone that FDA authorized in 2016 and 2021 were arbitrary and capricious. On September 8, 2023, the Justice Department and a manufacturer of mifepristone filed petitions for a writ of certiorari, requesting that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asked the U.S. Supreme Court to review the Appeals Court decision. On December 13, 2023, the Supreme Court granted these petitions for writ of certiorari for the appeals court decision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar restrictions apply to the approval of our products in the EU. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the European Union and are also subject to EU Member State laws. The failure to comply with these and other EU requirements can also lead to significant penalties and sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA, EMA, MHRA and other government agencies. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product. Physicians may nevertheless prescribe our products off-label to their patients in a manner that is inconsistent with the approved label. We intend to implement compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our products for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional scientific communications concerning their products in certain circumstances. For example, in October 2023, the FDA published draft guidance outlining the agency&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers. This draft guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use. In addition, under some relatively recent guidance from the FDA and the PIE Act, signed into law as part of the Consolidated Appropriations Act of 2023, companies may also promote information that is consistent with the prescribing information and proactively speak to formulary committee members of payors regarding data for an unapproved drug or unapproved uses of an approved drug. We may engage in these discussions and communicate with healthcare providers, payors and other constituencies in compliance with all applicable laws, regulatory guidance and industry best practices. We will need to carefully navigate the FDA&#8217;s various regulations, guidance and policies, along with recently enacted legislation, to ensure compliance with restrictions governing promotion of our products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the HHS, the FDA, the Federal Trade Commission, or the FTC, and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the FDCA, the False Claims Act, the Prescription Drug Marketing Act and anti-kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim or caused a false claim to be submitted to the government for payment. The person bringing a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit is entitled to a share of any recovery or settlement. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek PRIME Designation in the European Union for our product candidates, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">process</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the EU, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and where the sponsor intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables a sponsor to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or our collaborators, may seek approval from the FDA or comparable foreign regulatory authorities to use accelerated development pathways for our product candidates. If we, or our collaborators, are not able to use such pathways, we, or they, may be required to conduct additional clinical trials beyond those that are contemplated, which would increase the expense of obtaining, and delay the receipt of, necessary marketing approvals, if we, or they, receive them at all. In addition, even if an accelerated approval pathway is available to us, or our collaborators, it may not lead to expedited approval of our product candidates, or approval at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug, and Cosmetic Act and implementing regulations, the FDA may grant accelerated approval to a product candidate to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies, upon a determination that the product has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. Prior to seeking such accelerated approval, we, or our collaborators, will continue to seek feedback from the FDA or comparable foreign regulatory agencies and otherwise evaluate our, or their, ability to seek and receive such accelerated approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With passage of the FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six months (until the study is completed; and use expedited procedures to withdraw accelerated approval of an NDA or BLA after the confirmatory trial fails to verify the product&#8217;s clinical benefit. Further, the FDORA requires the FDA to publish on its website &#8220;the rationale for why a post-approval study is not appropriate or necessary&#8221; whenever it decides not to require such a study upon granting accelerated approval. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, in March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The FDA indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics.  While this guidance is currently only in draft form and will not be legally binding even when finalized, we will need to consider the FDA&#8217;s guidance closely if we seek accelerated approval for any of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the FDA or comparable foreign regulatory agencies will agree with our, or our collaborators&#8217;, surrogate endpoints or intermediate clinical endpoints in any of our, or their, clinical trials, or that we, or our collaborators, will decide to pursue or submit any additional application for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from the FDA or comparable foreign regulatory agencies, we, or our collaborators, will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval. Furthermore, for any submission of an application for accelerated approval or application under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted for filing or that any expedited development, review or approval will be granted on a timely basis, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period until commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for the FDA to grant orphan drug exclusivity to one of our products, the FDA must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA and comparable foreign regulatory authorities such as the EMA can subsequently approve the same product for the same condition if the FDA or such other authorities conclude that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Congress passed the FDARA. The FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under omnibus legislation signed by former President Trump in December 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDARA in 2017, but have not yet been approved or licensed by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are required by the FDA, EMA or comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates or a group of therapeutic products, and we do not obtain or we face delays in obtaining clearance or approval of a diagnostic test, we may not be able to commercialize the product candidate and our ability to generate revenue may be materially impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required by the FDA, EMA or a comparable regulatory authority to obtain clearance or approval of a companion diagnostic test in connection with approval of any of our product candidates, such companion diagnostic test would be used during our more advanced phase clinical trials as well as in connection with the commercialization of our product candidates. To be successful in developing and commercializing product candidates in combination with these companion diagnostics, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to ensuring the safe and effective use of a novel therapeutic product or new indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared. In </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain circumstances (for example, when a therapeutic product is intended to treat a serious or life-threatening condition for which no satisfactory available therapy exists or when the labelling of an approved product needs to be revised to address a serious safety issue), however, the FDA may approve a therapeutic product without the prior or contemporaneous marketing authorization of a companion diagnostic. In this case, approval of a companion diagnostic may be a post-marketing requirement or commitment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-development of companion diagnostics and therapeutic products is critical to the advancement of precision medicine. Whether initiated at the outset of development or at a later point, co-development should generally be conducted in a way that will facilitate obtaining contemporaneous marketing authorizations for the therapeutic product and the associated companion diagnostic. If a companion diagnostic is required to identify patients who are most likely to benefit from receiving the product, to be at increased risk for serious adverse events as a result of treatment with a particular therapeutic product, or to monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness, then the FDA has required marketing approval of all companion diagnostic tests essential for the safe and effective use of a therapeutic product for cancer therapies. Various foreign regulatory authorities also regulate in vitro companion diagnostics as medical devices and, under those regulatory frameworks, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any future diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization in those countries.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express the specific genomic alteration or mutation alteration that the companion diagnostic was developed to detect. If the FDA, EMA or a comparable regulatory authority requires clearance or approval of a companion diagnostic for any of our product candidates, whether before, concurrently with approval, or post-approval of the product candidate, we, and/or future collaborators, may encounter difficulties in developing and obtaining clearance or approval for these companion diagnostics. The process of obtaining or creating such companion diagnostics is time consuming and costly.  The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to a product candidate to obtain PMA, simultaneously with approval of the therapeutic candidate. The PMA process, including the gathering of pre-clinical and clinical data and the submission and review by the FDA, can take several years or longer. It involves a rigorous pre-market review during which the sponsor must prepare and provide FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing, and labeling. After a device is placed on the market, it remains subject to significant regulatory requirements, including requirements governing development, testing, manufacturing, distribution, marketing, promotion, labeling, import, export, record-keeping, and adverse event reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure by us or third-party collaborators to develop or obtain regulatory clearance or approval of a companion diagnostic could delay or prevent approval or continued marketing of our related product candidates. Further, in April 2020, the FDA issued new guidance on developing and labeling companion diagnostics for a specific group of oncology therapeutic products, including recommendations to support a broader labeling claim rather than individual therapeutic products. We will continue to evaluate the impact of this guidance on our companion diagnostic development and strategy. This guidance and future issuances from the FDA, EMA and other regulatory authorities may impact our development of a companion diagnostic for our product candidates and could result in delays in regulatory clearance or approval or a change in the determination for whether or not a companion diagnostic is still required for our product candidates. We may be required to conduct additional studies to support a broader claim or more narrowed claim for a subset population. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include any of our future approved product candidates covered indications, we may no longer need to continue our companion diagnostic development plans or we may need to alter those companion diagnostic development strategies, which could adversely impact our ability to generate revenue from the sale of our companion diagnostic test.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may rely on third parties for the design, development and manufacture of companion diagnostic tests for our product candidates. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining clearance or approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory clearance or approval processes. Moreover, even if data from pre-clinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory clearance or approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of our product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the co-development or commercialization of our companion diagnostic and therapeutic product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and earnings.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable state and federal fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Kickback Statute - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">False Claims Act -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the federal HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters, and apply regardless of the payor (e.g., public or private);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA and HITECH -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security of individually identifiable health information;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Transparency Requirements -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the ACA, as amended by the Health Care Education Reconciliation Act, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the CMS, within the HHS information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous State, Local and Foreign Laws -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analogous state, local and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader than similar federal laws, can apply to claims involving healthcare items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, as well as tracking and reporting of transfers of value by pharmaceutical manufacturers to physicians and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">healthcare organizations, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any of our collaborators to obtain marketing approval of and commercialize product candidates and affect the prices we, or any of our collaborators, may obtain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, impact pricing and reimbursement and affect our ability, or the ability of any of our collaborators, to profitably sell or commercialize any product candidates for which we, or any of our collaborators, obtain marketing approval. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any of our collaborators, may receive for any FDA approved products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for prescription drugs purchased through a pharmacy by the elderly and disabled and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this statute provides authority for limiting the number of drugs that will be covered in any therapeutic class, subject to certain exceptions. Cost reduction initiatives and other provisions of this statute could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, then-President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031 under the CARES Act. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Under current legislation, the actual reductions in Medicare payments may vary up to 4%.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Appropriations Act, or the Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010 sequester for two years, through the end of calendar year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Appropriation Act&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with passage of the IRA, Congress extended the expansion of the Patient Protection and Affordable Care Act premium tax credits through 2025. Those subsidies were originally extended through 2022 under the American Rescue Plan Act of 2021. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the TCJA, in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, in June 2021, the U.S. Supreme Court dismissed a lawsuit challenging the constitutionality of the ACA after finding that the plaintiffs do not have standing to bring the litigation. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden rescinded those orders and issued a new executive order which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care and consider actions that will protect and strengthen that access. Under this order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the health insurance marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents. This executive order also directs the HHS to create a special enrollment period for the health insurance marketplace in response to the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, on December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022, it will only begin to apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim. Once applicable, it will have a phased implementation depending on the concerned products. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">highest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to scrutiny and considerable legislative and executive actions that could impact the prices we obtain for our drug products, if and when approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States and foreign jurisdictions. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, former President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, the CMS issued a final rule to rescind it. With issuance of this rule, the CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries&#8217; access to evidence-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the PhRMA but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue the HHS. Nine states (Colorado, Florida, Maine, New Hampshire, New Mexico, North Dakota, Texas, Vermont and Wisconsin) have passed laws allowing for the importation of drugs from Canada.  Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval. On January 5, 2023, the FDA approved Florida&#8217;s plan for Canadian drug importation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed, and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. The IRA further delayed implementation of this rule to January 1, 2032. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the IRA was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at 2,000 a year. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2023, Merck &amp; Co. filed a lawsuit against the HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce, or the Chamber, Bristol Myers Squibb Company, the PhRMA, Astellas, Novo Nordisk, Janssen Pharmaceuticals, Novartis, AstraZeneca and Boehringer Ingelheim, also filed lawsuits in various courts with similar constitutional claims against the HHS and CMS. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In other countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the FCPA the Bribery Act, and other anticorruption laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act, and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, United Kingdom, and authorities in the European Union, including </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which is collectively referred to as Trade Control Laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have a material adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. Likewise, any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by the United States, the United Kingdom or other authorities could also have an adverse impact on our reputation, business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, the European Union and the United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in an enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. The HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to potential enforcement by the HHS, we are also potentially subject to privacy enforcement from the FTC. The FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section 5 of the FTC Act, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). The agency is also in the process of developing rules related to commercial surveillance and data security that may impact our business. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that requires us to adhere to very specific privacy and data security practices, which may impact our business. We may also be required to pay fines as part of a settlement (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States are also active in creating specific rules relating to the processing of personal information. In 2018, California passed into law the CCPA which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation, or the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the CPRA, which will significantly expand the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. Most CPRA provisions took effect on January 1, 2023, though the obligations apply to any personal information collected after January 1, 2022. These provisions may apply to some of our business activities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to California, eleven other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or have already passed comprehensive privacy laws during the 2024 legislative sessions that will go into effect in 2025 and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2024. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or the EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20.0 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR places restrictions on the cross-border transfer of personal data from the European Union to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the European Union to other countries. In July 2020, the Court of Justice of the EU, or the CJEU, invalidated the European Union-United States Privacy Shield, or Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. While we are not self-certified under the Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States, generally, and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the CJEU decision, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-US Privacy Shield. The European Union initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022, and the European Commission adopted the adequacy decision in July 2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the European Union to the United States. However, some privacy advocacy groups have already suggested that they will be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2016, the electorate in the United Kingdom. voted in favor of leaving the European Union, commonly referred to as Brexit. As with other issues related to Brexit, there are open questions about how personal data will be protected in the United Kingdom. and whether personal information can transfer from the European Union to the United Kingdom. Following the withdrawal of the United Kingdom from the European Union, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 in the United Kingdom that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under the GDPR, although these transfers currently are permitted by an adequacy decision from the European Commission. The UK government has already determined that it considers all European Union 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom. to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the United Kingdom. as being &#8220;essentially adequate&#8221; for purposes of data transfer from the European Union to the United Kingdom., although this decision may be re-evaluated in the future. The United Kingdom. and the United States. have also agreed to a U.S.-UK &#8220;Data Bridge,&#8221; which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer data from the United Kingdom to the United States. In addition to the United Kingdom., Switzerland is also in the process of approving an adequacy decision in relation to the Swiss-U.S. Data Privacy Framework (which would function similarly to the EU-U.S. Data Privacy Framework and the U.S.-UK Data Bridge in relation to data transfers from Switzerland to the United States). Any changes or updates to these developments have the potential to impact our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our employees, independent contractors, consultants, collaborators and vendors engage in misconduct or other improper activities, including non-compliance with regulatory standards and/or requirements and insider trading, we could sustain significant liability and harm to our reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants, collaborators and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state laws, and requirements of foreign jurisdictions, including the GDPR. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party misconduct, and the precautions that we take to detect and prevent these activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any third-party manufacturer we engage now or in the future fails to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could significantly harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain general liability insurance as well as workers&#8217; compensation insurance to cover costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reduction in force undertaken to extend our cash runway and focus more of our capital resources on our prioritized research and development programs might not achieve our intended outcome.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In late March 2024, our board of directors approved a reduction in force affecting approximately 37% of our total workforce, in order to preserve cash and prioritize investment in our core clinical programs. The reduction in force may result in unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of the reduction in force. In addition, while positions have been eliminated, certain functions necessary to our operations remain, and we might not successfully distribute the duties and obligations of our terminated employees among our remaining employees. The reduction in workforce could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities or initiatives. If we are unable to realize the anticipated benefits from the reduction in force, or if we experience significant adverse consequences from the reduction in force, our business, financial condition and results of operations may be materially adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive officers, as well as the other principal members of our management, scientific and clinical teams. Although we entered into employment agreements with certain of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel is also critical to our success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our discovery programs, development and commercialization objectives and seriously harm our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous biopharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery, research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Failure to succeed in clinical trials may make it even more challenging to recruit and retain qualified scientific personnel. Our success as a public company also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly as we function as a public company and in the areas of product development, clinical, regulatory affairs, manufacturing and quality control and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Future growth will impose significant added responsibilities on members of our management, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">managing our internal development efforts effectively, including the clinical and regulatory review process for CT-0525 and other product candidates we are developing or may develop in the future, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to advance development of and, if approved, commercialize CT-0525 and any other product candidate we are developing or may develop in the future will depend, in part, on our ability to effectively manage any future growth. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. If we do not effectively manage the expansion of our operations, we could experience weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The expansion of our operations could also lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the biopharmaceutical companies, and in particular cell therapy companies, that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can develop product candidates and operate our business will be limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of any of our collaborators, vendors, suppliers, contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber-attacks by malicious third parties. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or email fraud to cause payments or information to be transmitted to an unintended recipient.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience any material system failure, accident, cyber-attack or security that causes interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed, and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, including principal investigators, consultants and vendors and any third parties we may engage in connection with discovery programs, research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and commercialization may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, including principal investigators, consultants and vendors and any other third parties we engage. Misconduct by these parties could include intentional, reckless or negligent conduct or unauthorized activities that include failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide complete and accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state data privacy, security, fraud and other healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report complete financial information or data accurately or disclose unauthorized activities to us. Misconduct by employees and other third parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the EU Data Protection Directive. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance or codes of conduct. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Ownership of Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile, and the market price of our common stock may drop in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock could be subject to significant fluctuations. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials and pre-clinical studies of our product candidates, or those of our competitors or our existing or future collaborators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial and development projections we may provide to the public;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed the financial and development projections of the investment community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of qualified scientific and management personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our business and stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market or macroeconomic conditions or market conditions in the biopharmaceutical sector;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of securities by us or our stockholders in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if we fail to raise an adequate amount of capital to fund our operations and continued development of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to product candidates, including with respect to other products in such markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of technological innovations or new therapies that compete with our products and services; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting and other expenses as a public company that we did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. Some of our management team has not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that we comply with all of these requirements. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a significant portion of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is doing well. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain of our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders have rights, subject to specified conditions, under our resale registration statement on Form S-3 registering 3,730,608 shares of our common stock under which they may sell their shares of common stock in the public market, so long as the resale registration statement on Form S-3 remains effective.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also filed a registration statement registering all shares of common stock that we may issue under our equity compensation plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we are also party to the Sale Agreement with Jefferies, as sales agent, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $100.0 million from time to time through Jefferies under an &#8220;at-the-market offering&#8221; program, or ATM. The number of shares that are sold by Jefferies after we request that sales be made will fluctuate based on the market price of our common stock during the sales period and limits we set with Jefferies. Therefore, it is not possible to predict the number of shares that will ultimately be issued by us, if any, pursuant to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sales agreement. As of December 31, 2023, we have sold 226,533 shares under the ATM for gross proceeds of $0.6 million. From January through March 2024, the Company sold an additional 931,250 shares under the ATM for gross proceeds of $2.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If at some point we are no longer a &#8220;smaller reporting company&#8221; or otherwise no longer qualify for applicable exemptions, we will be subject to additional laws and regulations affecting public companies that will increase our costs and the demands on management and could harm our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as defined in Item 10(f)(1) of Regulation S-K, we may take advantage of certain exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2022 and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. If at some point we are no longer qualified as a smaller reporting company or otherwise no longer qualify for these exemptions, we will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our common stock may be harmed. For example, if we or our independent auditor identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, then we could face additional costs to remedy those deficiencies, the market price of our stock could decline or we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders may have the ability to significantly influence all matters submitted to our stockholders for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, our executive officers, directors and principal stockholders, in the aggregate, beneficially owned 47.7% of our outstanding shares of common stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of the company on terms that other stockholders may desire.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash and cash equivalents and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have broad discretion over the use of our cash and cash equivalents. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to apply these resources effectively could compromise our ability to pursue our growth strategy and we may not be able to yield a significant return, if any, on our investment of these net proceeds. You do not have the opportunity to influence our decisions on how to use our cash resources.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are in the process of unwinding contractual relationships related to a strategic transaction with respect to Vicineum, which may adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, Sesen Bio made the strategic decision to voluntarily pause further development of Vicineum in the United States. and we do not expect to pursue further development of Vicineum for the treatment of non-muscle invasive bladder cancer. Sesen Bio previously entered into various agreements and licenses with licensees, licensors and other counterparties related to the development and/or commercialization of Vicineum. Prior to the consummation of the Merger of the company and Sesen Bio, Sesen Bio began the process of winding down its operations relating to Vicineum. The process of unwinding contractual relationships related to Vicineum is ongoing, and may divert the attention of our management team and employees from day-to-day business, result in liability, impose additional costs and otherwise adversely affect our business and financial condition.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_549755814460"></div><div style="margin-top:12pt;text-align:justify"><span id="ieb123d5983d8459ca77bf2481e16f15b_108"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_974"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div><span id="icb8612854fdb4bc899cbabd65f5ec6c3_102"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cybersecurity Risk Management and Strategy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established processes for assessing, identifying and managing cybersecurity risks, which are built into our overall risk management program and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and patient information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards. We engage certain third parties to enhance and assist with our cybersecurity oversight, including a 24/7 Security Operation Center, or SOC, that monitors network devices and computer systems in real time. We include confidentiality and data protection provisions in certain contracts with third-party service providers to help protect us and our patients from any related vulnerabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that there are currently any known risks from cybersecurity threats that have or are reasonably likely to materially affect us or our business strategy, results of operations or financial condition. However, despite our efforts, we cannot eliminate all risks from cybersecurity threats, or provide assurances that we have not experienced undetected cybersecurity incidents. For more information on the most pertinent risks we may experience from cybersecurity threats, please refer to Part I, Item 1A, &#8220;Risk Factors&#8221; &#8211; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cybersecurity Governance and Oversight</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee of our board of directors provides oversight over cybersecurity risk and updates the full board of directors periodically regarding such oversight. The audit committee reviews and discusses with management the Company&#8217;s major risk exposures, including cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents, if any. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our General Counsel leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. The consultant that operates our SOC updates the General Counsel regarding the detection of cybersecurity risk exposure and provides advice on the prevention, mitigation and remediation of such risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The General Counsel keeps the senior executive leadership team apprised, including our Chief Executive Officer and Chief Financial Officer, on assessments of risk exposure to ensure that the highest levels of management are kept abreast of potential risks we are facing. The General Counsel has significant prior business experience in compliance and risk management and coordinates directly with the third party who operates our SOC on issues involving particular cybersecurity expertise. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to help deter and detect cyber threats, we regularly provide all employees, including part-time and temporary employees, with data protection cybersecurity and incident prevention training throughout the year, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs. </span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_549755814467"></div><div><span id="if5e737ab6f0447f5940944311a6059aa_80"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal facilities consist of office and laboratory space in Philadelphia, Pennsylvania. We occupy approximately 4,369 square feet of office space under a lease that is expected to expire in October 2029 and approximately 3,600 square feet of laboratory space under a lease that expires in April 2024. We believe that our facilities are sufficient to meet our current needs.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_549755814472"></div><div style="margin-top:12pt"><span id="i37b9590e9f5545f381aeffddd090fc29_312"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not a party to any material legal proceedings.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_549755814477"></div><div style="margin-top:12pt"><span id="ie42244f1e3914a36aa6ff1bbc5a72284_83"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_505"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span id="i99e09df4c8454f1492d00d9f553edafb_44"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_599"></div><div><span id="idedc72a77be9448ca2de120d5d6f7513_892"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on the Nasdaq Stock Market under the symbol &#8220;CARM.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of stockholders of record of our common stock as of March&#160;15, 2024 was 42. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business. We do not anticipate paying any cash dividends for the foreseeable future, and future debt financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any securities that were not registered under the Securities Act of 1933, as amended, or the Securities Act, during the twelve months ended December 31, 2023, other than pursuant to transactions previously disclosed in our Current Reports on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> of Equity Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not purchase any of our registered equity securities during the period covered by this Annual Report on Form 10-K. </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_549755814499"></div><div><span id="i904c9ee508be4188936aabdba77c4d9f_224"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span id="i2d4dea7d5d904b7db21b116e320e1b02_812"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated by these forward-looking statements.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_76"></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage cell therapy company focused on using our proprietary CAR-M cell therapy platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. Our focus is our proprietary CAR-M cell therapy platform, which redirects macrophages against specific tumor associated antigens and enables targeted anti-tumor immunity by utilizing genetically modified myeloid cells (macrophages and monocytes) to express CARs, enabling these potent innate immune cells to recognize specific tumor associated antigens on the surface of tumor cells.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first product candidate to enter clinical development, CT-0508, is the first CAR-Macrophage to be evaluated in a human clinical trial and is intended to treat solid tumors that over-express HER2, a protein that is over-expressed on the surface of a variety of solid tumors, including breast cancer, gastric cancer, esophageal cancer, salivary gland cancer, and numerous others. CT-0508 is currently being studied in a multi-center open label Phase 1 clinical trial in the United States. This ongoing first-in-human study evaluates the safety, tolerability, and manufacturing feasibility of CT-0508 along with several customary exploratory secondary endpoints.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late March 2024, following a strategic review of our operating plan for 2024 and future periods, we approved a revised operating plan intended to balance value creation and expense management with our available cash resources. The objective of our revised operating plan is to focus our clinical development efforts on high potential value programs with meaningful near-term milestones and eliminate non-essential expenses and headcount to extend our cash runway. Under this plan, we intend to focus our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology clinical development efforts on our follow-on product candidate CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0525 utilizes a novel approach to CAR-M therapy that engineers patients&#8217; monocytes directly, without </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differentiation into macrophages. In November 2023, we received FDA clearance of our  IND for CT-0525. We expect to treat the first patient in the second quarter of 2024 and to report preliminary data from the study by the end of 2024. We believe that CT-0525 has favorable attributes compared to our initial clinical stage product candidate, CT-0508, and that the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. We will also continue to focus on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA/LNP CAR-M programs in partnership with Moderna. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:-1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we plan to continue ongoing activities under our open label Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities. We have also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases, also remains ongoing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to pursue additional financing and collaboration opportunities to support development of our product candidates and other research and development programs and will continue to re-assess our expense allocation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our proprietary macrophage and monocyte cell therapy platform, we are developing a pipeline of product candidates, with an initial focus on advancing </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> autologous and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies for the treatment of solid tumors. We are also pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. Our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology, fibrosis, and immunology programs are wholly owned. Additionally, under the Moderna License Agreement with Moderna, we are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developing </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies utilizing Moderna's mRNA/LNP technology. As part of the Moderna License Agreement, as further discussed below, we received a $45.0 million up-front cash payment and an investment by Moderna in the form of a $35.0 million convertible promissory note, which converted into shares of common stock in connection with the consummation of the Merger, in addition to future research funding and the opportunity for milestone payments and royalties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our follow-on product candidate, CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2, utilizes a novel approach to CAR-M therapy that engineers patients' monocytes directly, without </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differentiation into macrophages, as we currently do for CT-0508. The CAR-Monocyte approach utilizes a single day manufacturing process, which enables the manufacture of up to ten billion cells from a single apheresis, and leverages an automated, closed-system manufacturing process. In addition, the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. By increasing the cell yield, a CAR-Monocyte enables a larger dose than a CAR-Macrophage. In addition, CAR-Monocyte has the potential for improved persistence and trafficking, which were observed in pre-clinical studies. We believe that the increased cell yield, and the improved persistence and trafficking may improve tumor control. In November 2023, we received FDA clearance of our IND for CT-0525 and we expect to treat the first patient in the second quarter of 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M cell therapies, we are developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M cell therapies, wherein immune cells are directly engineered within the patient&#8217;s body. To advance our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M therapeutics, we established the Moderna License Agreement. In the fourth quarter of 2023, we presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the pre-clinical data demonstrated feasibility, tolerability, and early efficacy of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> CAR-M against metastatic solid tumors. In December 2023, we announced the nomination of the collaboration's first lead candidate, which will target an antigen present on a solid tumor with significant unmet medical need.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to acting as a first line of defense in the innate immune system, macrophages and monocytes are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration. Using our macrophage and monocyte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engineering platform, we are pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis  and other immunologic and inflammatory diseases. Pre-clinical proof of concept for fibrosis is expected in the second quarter of 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have not yet commercialized any products or generated any revenue from product sales and have financed our operations primarily with proceeds from sales of our preferred stock, proceeds from our collaboration with Moderna, research tax credits, convertible debt financing, closing of pre-closing financing, and completion of the Merger. Our operations to date have been limited to organizing and staffing the company, business planning, capital raising, establishing and maintaining our intellectual property portfolio, building our pipeline of product candidates, conducting drug discovery activities, undertaking pre-clinical studies, manufacturing process development studies, conducting early-stage clinical trials, and providing general and administrative support for these operations. We have devoted substantially all of our financial resources and efforts to pursuing discovery, research and development of our product candidates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Financial Operations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our net losses were $86.9 million and $61.2 million for the year ended December 31, 2023 and 2022, respectively. As of December&#160;31, 2023, we had $77.6 million in cash and cash equivalents and an accumulated deficit of $245.1 million. We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we conduct our clinical trial of CT-0525 , complete our ongoing clinical trial of CT-0508 with respect to patients currently enrolled or in screening and advance our discovery programs and continue our product development efforts. If we obtain marketing approval for CT-0525 or any other product candidate we are developing or develop in the future, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe our revised operating plan approved in March 2024 by our board of directors will facilitate cost control to support further development of our product candidates and other research and development programs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we have 40,609,915 shares of common stock issued and outstanding. On March 7, 2023 in connection with the closing of the Merger, we issued 29,880,394 shares of common stock to Legacy Carisma stockholders (including 5,059,338 shares issued to the holder of the convertible promissory note that was entered into concurrently with the Moderna License Agreement (as defined below) and 3,730,608 shares issued in exchange for shares sold in the pre-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">closing financing). Former Sesen Bio stockholders continued to hold 10,374,272 shares of our common stock, reflective of the 1-for-20 reverse stock split that was effected immediately prior to the closing of the Merger.We will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise additional capital or obtain adequate funds on acceptable terms, we may be required to further delay, limit, reduce or terminate our discovery and product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. However, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and distract from our discovery and product development efforts. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considering the anticipated benefits of our revised operating plan, we believe that we have cash and cash equivalents sufficient to sustain our operating expenses and capital expenditure requirements into the third quarter of 2025. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand business, maintain discovery and product development efforts, diversify our pipeline of product candidates or even continue operations.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Moderna Collaboration and License Agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with Moderna, we have established an approach that uses Moderna&#8217;s mRNA/LNP technology, together with our CAR-M platform technology, to create novel </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> oncology gene therapies. We believe this approach has the potential to enable a series of off-the-shelf product candidates to target a patient&#8217;s own myeloid cells against cancer cells directly within their body.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Legacy Carisma and Moderna established this collaboration by entering into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics for up to 12 oncology programs. Under the Moderna License Agreement, the parties initiate research programs during a research term, focused on the discovery and research of products directed to biological targets. Moderna&#8217;s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has the right to designate up to 12 research targets as development targets. The first five research targets have been nominated and all programs are currently in the discovery phase. Moderna funds the cost of our activities in accordance with an agreed research budget.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moderna has the right to designate up to 12 research targets as development targets during a specified development target nomination period upon payment of a development target designation milestone payment. Moderna can replace development targets with research targets during a specified period of time. If Moderna exercises its right to designate a development target, Moderna will have a worldwide, exclusive license under patents and know-how controlled by us to develop and commercialize products directed to the applicable development target, subject to certain diligence obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration is managed by a JSC, which is comprised of representatives from us and Moderna. Decisions of the JSC are made by consensus, with each party having one vote. If the JSC is unable to agree, and the parties&#8217; executives are not able to resolve the dispute, then Moderna has final decision-making authority, subject to specified limitations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing a specified time after the effective date of the Moderna License Agreement, Moderna will have the right to nominate targets relating to diseases outside the field of oncology for inclusion in research programs in specified circumstances. Such right is subject to the same exclusions as Moderna&#8217;s right to nominate other targets for inclusion in research programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Moderna License Agreement, we and our affiliates are subject to various exclusivity obligations under which we are not permitted to research, develop or commercialize particular products outside of the collaboration, including products for use as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapies in the field of oncology, products directed to any target included in the collaboration, or products containing a polypeptide provided by us to Moderna in connection with a research program that are directed to any development target.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Moderna License Agreement, we received a $45.0 million up-front cash payment. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are also eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also will reimburse us for all costs incurred in connection with our research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0 million in research and development costs over the first three years from execution of the Moderna License Agreement). In addition, we are eligible to receive tiered mid-to-high single digit royalties on net  product sales, which may be subject to reductions. Moderna has also agreed to cover the cost of certain milestone payments and royalties we owe to Penn as a licensor under one of our intellectual property in-license agreements that we are sublicensing to Moderna under the Moderna License Agreement, which royalties Moderna may deduct in part from any royalties owed to us. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by us or Moderna.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_82"></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost Reduction Measures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have recently implemented a revised operating plan to reduce our monthly operating expenses and conserve cash. The plan, which we will begin to implement in the second quarter of 2024, includes several measures such as prioritizing CT-0525 as our anti-HER2 product candidate going forward, suspending the enrollment of new patients for CT-0508 in line with the clinical judgment of the clinical site principal investigator, pausing further development of CT-1119, reducing our workforce by 39 full-time employees (representing approximately 37% of our total workforce), including employees engaged in research and development and general and administration activities, and decreasing spending on other non-essential activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe these changes will provide operating efficiencies for us to continue to support our product development programs as well as any potential collaborations or other strategic relationships we may enter into. We expect to incur approximately $2.1 million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. We expect the reduction in workforce to be substantially complete and to pay the majority of these reduction in workforce amounts in the second quarter of 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated from the Moderna License Agreement. Moderna reimburses us for all costs incurred by it in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed. We expect that our revenue for at least the next several years will be derived primarily from Moderna License Agreement, other current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any royalties under the Moderna License Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including discovery efforts and the development of product candidates, and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred to conduct the necessary pre-clinical studies and clinical trials required to obtain regulatory approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of funding research performed by third parties, including pursuant to agreements with CROs, as well as investigative sites and consultants that conduct our pre-clinical studies and clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with CMOs, including manufacturing scale-up expenses and the cost of acquiring and manufacturing pre-clinical study and clinical trial materials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of laboratory supplies and acquiring materials for pre-clinical studies;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility-related expenses, which include direct depreciation costs of equipment and expenses for rent and maintenance of facilities and other operating costs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party licensing fees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to decrease in 2024 as we implement our revised operating plan, including a reduction in workforce, prioritization of CT-0525 and a pause in development of CT-1119. We expect that our expenses will increase again in future years as we continue to advance our clinical trials and potentially progress additional product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our current or future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of any product candidates. The success of CT-0525 and our other product candidates will depend on several factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully completing pre-clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully initiating future clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully enrolling patients in and completing clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scaling up manufacturing processes and capabilities to support clinical trials of CT-0525 and any other product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">applying for and receiving marketing approvals from applicable regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining intellectual property protection and regulatory exclusivity for CT-0525 and any other product candidates the Company is developing or may develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making arrangements with third-party manufacturers, or establishing commercial manufacturing capabilities, for both clinical and commercial supplies of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of CT-0525 and any other product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, enforcing, defending and protecting our rights in our intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not infringing, misappropriating or otherwise violating others&#8217; intellectual property or proprietary rights; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of our products following receipt of any marketing approvals.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development, manufacture or commercialization activities of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, if there are safety concerns or if we determine that the observed safety or efficacy profile would not be competitive in the marketplace, we could be required to expend significant additional financial resources and time on the completion of clinical development. Product commercialization will take several years, and we expect to spend a significant amount in development costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and stock-based compensation expense for employees in executive, finance, accounting, business development and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation and maintenance, and costs not otherwise included in research and development expenses, legal fees related to intellectual property and corporate matters as well as fees for accounting and consulting services.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect that our general and administrative expenses will decrease in 2024, as we implement our revised operating plan, including reducing our workforce and decreasing expenses related to non-essential activities. In addition, our 2023 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expenses included  a significant amount of non-recurring costs related to the Merger that are described below. We expect that our expenses will increase again in future years as we continue to incur costs associated with being a public company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our excess cash. Interest expense consisted of interest on our convertible promissory note that was entered into concurrently with the Moderna License Agreement including non-cash interest expense associated with the amortization of the debt discount. The convertible promissory note was converted into common stock upon the closing of the Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Liability</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of the derivative liability for the redemption feature of our convertible promissory note reflected the non-cash charge for changes in the fair value of the derivative liability that was subject to re-measurement at each balance sheet date through the settlement of the convertible promissory note upon the closing of the Merger at which time the redemption feature was derecognized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses. As of December&#160;31, 2023, we had NOLs for federal income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-37">317.6</ix:nonFraction>&#160;million. We have provided a valuation allowance against the full amount of our deferred tax assets since, in our opinion, based upon our historical and anticipated future losses, it is more likely than not that the benefits will not be realized. As of December&#160;31, 2023, we remained in a full valuation allowance position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The utilization of our NOLs may be subject to a substantial annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Code, respectively, as well as similar state provisions. We have recorded a valuation allowance on all of our deferred tax assets, including deferred tax assets related to NOLs.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2023 and 2022</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(88,731)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,162)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86,879)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,226)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues were $14.9 million and $9.8 million for the years ended December 31, 2023 and 2022, respectively. The increase was related to the research and development activities completed under the Moderna License Agreement that we executed in January 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track outsourced development, outsourced personnel costs and other external research and development costs of our CT-0508, CT-0525, and CT-1119 programs. We do not track internal research and development costs on a program-by-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">program basis. The following table summarizes our research and development expenses for the years ended December 31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0508(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0525</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-1119(1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel costs, including stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other clinical and pre-clinical development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we plan to continue ongoing activities under our open label Phase 1 clinical trial of CT-0508 and our sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities. We have also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the year ended December 31, 2023 were $74.1 million, compared to $56.6 million for the year ended December 31, 2022. The increase of $17.5 million was primarily due to a $8.4&#160;million increase in direct costs associated with pre-clinical development of CT-0525, a $4.4 million increase in personnel costs due to growth in research and development employee headcount, a $2.7&#160;million increase in our facilities and other expenses resulting from increased laboratory space and laboratory supplies from expanded clinical and pre-clinical work, a $1.3&#160;million increase due to costs associated with growth and expansion of pre-clinical activities towards submission of an IND for CT-0525, and a $0.9&#160;million increase in direct costs associated with the pre-clinical development related to CT-1119, partially offset by a $0.2 million decrease in direct costs associated with CT-0508.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel costs, including stock-based compensation (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance, taxes, and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,525&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,378&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, our board of directors approved the revised operating plan which includes the reduction in work force of certain finance and corporate employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses for the year ended December 31, 2023 were $29.5 million, compared to $9.4 million for the year ended December 31, 2022. The increase of $20.1 million was primarily attributable to a $9.2 million increase of personnel costs and a $7.5 million increase in professional fees. The increase in personnel costs was primarily due to non-recurring severance and other costs associated with the Merger of $4.6 million and higher personnel costs as a result of an increase in headcount to support operating as a public company of $4.6 million. The increase in professional fees primarily consisted of $5.3 million in costs associated with activities to support the transitioning to and operating as a public company and protecting our IP portfolio, along with $2.2 million in legal fees and communication fees associated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with the Merger. Insurance and taxes increased $2.1 million as a result of costs associated with operating as a public company, such as director and officer insurance. Facilities and supplies increased $0.8 million due to office expenditures resulting from an increased footprint, and other expenses increased $0.5 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income (Expense), net</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $1.9 million in interest income (expense), net for the year ended December 31, 2023, which was attributable primarily to interest income of $3.7&#160;million, partially offset by $1.3&#160;million the accelerated amortization of the debt discount as a result of the settlement of the convertible promissory note at the closing of the Merger, and $0.5&#160;million interest expense on the outstanding principal balance associated with the convertible promissory note issued to Moderna through March 7, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $(3.1) million in interest income (expense), net for the year ended December 31, 2022, which was attributable primarily to interest expense on the outstanding principal balance associated with the convertible promissory note issued to Moderna, including non-cash interest expense associated with the amortization of the debt discount.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Derivative Liability</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a $0.1 million non-cash charge for the year ended December 31, 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the increase in fair value of the derivative liability associated with the redemption feature of the convertible promissory note with Moderna through settlement in connection with the Merger. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a $1.9 million non-cash charge for the year ended December 31, 2022, for the increase in fair value of the derivative liability associated with the redemption feature of the convertible promissory note with Moderna, which was attributable to the timing in which we expected the accrued settlement event to occur.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, we had $77.6 million in cash and cash equivalents and an accumulated deficit of $245.1 million. To date, we have not yet commercialized any products or generated any revenue from product sales and have financed operations primarily with proceeds from sales of preferred stock, proceeds from our collaboration with Moderna, research tax credits and convertible debt financing. Under the Moderna License Agreement we anticipate receiving $73.9 million over the term of the contract for expected research and development services to be performed by Carisma, inclusive of pass-through costs, to be billed quarterly. Through December 31, 2023, we have generated $24.7&#160;million of collaboration revenues related to research and development services. Under the terms of the Moderna License Agreement, assuming Moderna develops and commercializes 12 products, each directed to a different development target, we are eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, we filed a universal shelf registration statement on Form S-3, which was declared effective on May 2, 2023, or the Registration Statement. Under the Registration Statement, we may offer and sell up to $300.0 million of a variety of securities, including debt securities, common stock, preferred stock, depository shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May 12, 2023, we entered into an Amended and Restated Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or the Sale Agreement, with Jefferies LLC, as sales agent, pursuant to which we may offer and sell shares of our common stock with an aggregate offering price of up to $100.0 million under an &#8220;at-the-market" offering program. As of December&#160;31, 2023, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we have sold 226,533 shares for gross proceeds of $0.6 million. From January through March 2024, the Company sold an additional 931,250 shares for gross proceeds of $2.4 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the year ended December 31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) provided by</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81,177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,357)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we used $81.2 million of net cash in operating activities. Cash used in operating activities reflected our net loss of $86.9 million and a $5.4 million net change in our operating assets and liabilities attributable to the timing in which we pay our vendors for research and development activities that was offset by $11.1 million of non-cash charges related to depreciation and amortization expense, stock-based compensation, reductions in the operating right of use, or ROU assets, amortization of the debt discount on the convertible promissory note, change in fair value of the derivative liability, accretion on marketable securities, and non-cash interest on the finance lease liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we used $5.1 million of net cash in operating activities. Cash provided by our operating activities reflected our net loss of $61.2 million that was offset by $10.9 million of non-cash charges related to depreciation and amortization expense, stock-based compensation, reductions in the operating ROU assets, amortization of the debt discount on the convertible promissory note, change in fair value of the derivative liability, non-cash interest on the finance liability from the failed sale-leaseback and the accretion on marketable securities, and a $45.2 million net change in our operating assets and liabilities which was primarily attributable to the $45.0 million upfront nonrefundable payment received from Moderna pursuant to the Moderna License Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we received $72.4 million of net cash from investing activities. Cash provided by investing activities reflected $108.0 million of proceeds from the sale of marketable securities, partially offset by purchases of marketable securities of $34.5 million and the purchase of property and equipment of $1.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we used $32.6 million of net cash in investing activities. Cash used in investing activities reflected purchases of marketable securities of $90.9 million and $4.7 million of purchases of property and equipment, partially offset by $63.0 million of proceeds from the sale of marketable securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we received $62.2 million of net cash from financing activities, primarily attributable to the $37.9&#160;million in the cash and cash equivalents acquired in connection with the Merger, $30.6 million in proceeds from the issuance of common stock in pre-closing financing, $1.2 million in proceeds from failed-sale leaseback arrangements, $0.6 million from the sale of common stock in connection with the Sale Agreement, partially offset by $5.8&#160;million in payments of financing costs, $1.3 million in payments of principal related to finance lease liabilities, and $1.1 million in payments to our finance liability from failed sale-leaseback arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we received $33.3 million of net cash from financing activities primarily attributable to the $35.0 million in proceeds from convertible promissory note and $1.6 million in proceeds from the failed sale-leaseback arrangements, partially offset by $2.5 million in payments made on deferred financing costs and $0.9 million in payments made on financing leases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we conduct our planned clinical trial of CT-0525, advance our discovery programs and continue our product development efforts. As of December 31, 2023, we had cash and cash equivalents of $77.6 million. We believe that the revised operating plan approved in March 2024 by our board of directors will reduce our spending such that our liquidity is sufficient to sustain our operating expenses and capital expenditure requirements into the third quarter of 2025. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have based our estimate regarding the sufficiency of our cash resources on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially over time in connection with our ongoing activities, particularly as we advance our pre-clinical activities and clinical trials. In addition, if we obtain marketing approval for CT-0525 or any other product candidate we are developing or develop in the future, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. In addition, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise additional capital or obtain adequate funds when needed or on acceptable terms, we may be required to further delay, limit, reduce or terminate our discovery and product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market on our own. In addition, attempting to secure additional financing may divert the time and attention of our management from day-to-day activities and distract us from discovery and product development efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, costs and results of our ongoing clinical trial of CT-0525 and other planned and future clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the costs of our clinical trials of CT-0508 with respect to patients currently enrolled or in screening;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, costs and results of pre-clinical testing and clinical trials of CT-0525 for additional combinations, targets and indications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of and development requirements for additional indications for CT-0525 or for any other product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaborations with Moderna or others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to scale up our manufacturing processes and capabilities to support clinical trials of CT-0525 and other product candidates we are developing and develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of CT-0525 and other product candidates we are developing and may develop in the future;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential changes in the regulatory environment and enforcement rules;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of license fees and other costs of our technology license arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for CT-0525 and other product candidates we are developing and may develop in the future for which we may receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain acceptance of any approved products by patients, the medical community and third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of revenue, if any, received from commercial sales of CT-0525 and any other product candidates we are developing or develop in the future for which we receive marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential changes in pharmaceutical pricing and reimbursement infrastructure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of raw materials for use in production of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire additional technologies or product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting pre-clinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. We will not generate commercial revenues unless and until we can achieve sales of products, which we do not anticipate for a number of years, if at all. Accordingly, we will need to obtain substantial additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or at all, and may be impacted by the economic climate and market conditions. For example, market volatility resulting from general U.S. or global economic or market conditions, including related to any health epidemics, pandemics or other contagious outbreaks (including any resurgence of the COVID-19 pandemic), could also adversely impact our ability to access capital as and when needed. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, we can generate substantial revenues from product sales, we expect to finance our cash needs through a combination of public and private equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing and preferred equity financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our operations and ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments, declaring dividends or other operating restrictions that could adversely impact our ability to conduct business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through additional collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, discovery programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market product candidates that we would otherwise prefer to develop and market on our own, any of which may have a material adverse effect on our business, operating results and prospects. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be required to further delay, limit, reduce or terminate our discovery and product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market on our own.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations and commitments at December 31, 2023 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Less<br/>than<br/>1 Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1 to 3<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4 to 5<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">More<br/>than<br/>5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease commitments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease commitments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total contractual obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">424&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Reflects obligations pursuant to our office and laboratory leases in Philadelphia, Pennsylvania.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Reflects obligations pursuant to a manufacturing and supply agreement pursuant to which we will pay $1.0 million per calendar year, payable in quarterly payments, for reserved capacity starting on the date on which the manufacturing site is declared ready to produce CT-0508 as determined by us. In the event of termination without cause by us, our future commitments will cease and a termination fee equal to $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="carm:TerminationFeePayable" format="ixt:num-dot-decimal" scale="6" id="f-38">4.0</ix:nonFraction> million will be payable by us to Novartis which, pursuant to the terms of the agreement, can be credited in full against amounts due for a substitute product. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Our contracts with CMOs, CROs and other third parties for the manufacture of our product candidates and to support pre-clinical research studies and clinical testing are generally cancelable by us upon prior notice and do not contain any minimum purchase commitments. Payments due upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation are not included in the table above as the amount and timing of such payments are not known. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above does not include any potential milestone or royalty payments that we may be required to make under our license agreement with Penn (as defined below) and under licensing agreements with other third parties not considered material. We excluded these milestone and royalty payments given that the timing and likelihood of any such payments cannot be reasonably estimated at this time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Penn License</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into a license agreement with Penn for certain intellectual property licenses, which was amended in February 2018, January 2019, March 2020 and June 2021. We are responsible for paying Penn an annual license maintenance fee in the low tens of thousands of dollars, payable until our first payment of a royalty. We may be required to pay Penn up to $10.9 million per product in development and regulatory milestone payments, up to $30.0 million per product in commercial milestone payments, and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. While the agreement remains in effect, we are required to pay Penn low- to mid-single digit percentage tiered royalties on annual net sales of licensed products, which may be subject to reductions. Penn is guaranteed a minimum royalty payment amount in the low hundreds of thousands of dollars for each year after the first commercial sale of a licensed product. We must also pay Penn a percentage in the mid-single digits to low double digits of certain types of income we receive from sublicensees. In addition, we are required to pay Penn an annual alliance management fee in the low tens of thousands of dollars, ending after several years, unless we provide funding to Penn for research and development activities that extend beyond a specified date, in which case we will continue to owe the alliance management fee for each year in which we continue to fund such activities. We also paid Penn an upfront fee in the low hundreds of thousands of dollars for the license to the patents related to the mesothelin binder that is incorporated into the CAR design for our mesothelin product candidate. We are responsible for a pro rata share of costs relating to the prosecution and maintenance of the licensed patents.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on our limited historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note 3 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenues from Contracts</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our revenue in accordance with Accounting Standards Codification, or ASC, 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps at inception of the agreement or upon material modification of the agreement: (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price, including variable consideration, if any; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the entity satisfies a performance obligation.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the pattern of satisfaction of the performance obligations under step (v) above to be a critical accounting estimate. More specifically, the determination of the level of achievement of research and development service performance obligations, whose pattern of satisfaction is measured using costs incurred to date as compared to total costs incurred and expected to be incurred in the future is driven by a critical accounting estimate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating the costs expected to be incurred in the future, we use our most recent budget and long-range plan, adjusted for any pertinent information. While this is our best estimate as of the reporting period, costs expected to be incurred in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future require managements judgment as the scope and timing of research and development activities may change significantly over time. We may adjust the scope of our research and development activities based on several factors, such as additional work needed to support advancement of product candidate or change in the number of patients in trials. Further, research and development services may no longer be within the scope of a collaboration agreement, as has been the case with certain of our programs. The timing of when research and development costs are expected to be incurred may change as a result of external factors, such as delays caused by manufacturing or supply chain, or difficulty in enrolling patients; or internal factors, such as prioritization of programs. Our estimate of the scope and timing of research and development services performed relative to the actual scope and timing may have a significant impact on revenue recognition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Accruals</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense research and development costs as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue expenses for pre-clinical studies and activities performed by third parties based upon estimates of the proportion of work completed over the term of the individual trial and patient enrollment rates in accordance with agreements with third parties. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal clinical personnel and external service providers as to the progress or stage of completion of activities or services and the agreed-upon fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Non-refundable advance payments for goods and services, including fees for process development or manufacturing and distribution of pre-clinical supplies that will be used in future research and development activities, are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone payments within our licensing and collaboration arrangements are recognized when achievement of the milestone is deemed probable to occur. To the extent products are commercialized and future economic benefit has been established, commercial milestones that become probable are capitalized and amortized over the estimated remaining useful life of the intellectual property. In addition, we accrue royalty expense and sublicense non-royalty payments, as applicable, for the amount we are obligated to pay, with adjustments as sales are made.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure compensation expense for all stock-based awards based on the estimated fair value of the award on the grant date. We use the Black-Scholes option pricing model to value our stock option awards. We recognize compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period of the award. We have not issued awards where vesting is subject to a market or performance condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model requires the use of subjective assumptions that include the expected stock price volatility and prior to the merger, the fair value of the underlying common stock on the date of grant. See Note 9 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options granted during the years ended December 31, 2023 and 2022.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 to our consolidated financial statements found in this Annual Report on Form 10-K for a description of recent accounting pronouncements applicable to our financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_549755814309"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. We do not engage in off-balance sheet financing arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_549755814505"></div><div><span id="i3d8beda0125b485b8e608deacd4c3ee6_116"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents and marketable securities. Interest income earned on these assets was $3.7&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.5&#160;million for the year ended December 31, 2023 and 2022, respectively. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we may contract with foreign vendors. As such, our operations may be subject to fluctuations in foreign currency exchange rates in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the years ended December 31, 2023 and 2022.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628486"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div><span id="i4281c9492111442eb00ca409116f497e_1454"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628206"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_16">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (KPMG LLP, Philadelphia, PA, Audit Firm ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-39">185</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i89c186fa3a4a4fc39906d97f0a73efad_41465">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_19">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i5af568c1d6374b8cb3e0ab37ff061245_347">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_22">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i71a2c5b885e14e40abf57719723624d6_267">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_25">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_25">Equity (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_25">Deficit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_25">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idf4c614a3bb345f2a54391ad2815b0a3_2177">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_28">Consolidated Statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_28">Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i8b331231bf0942778ddf2679a35fb030_487">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_31">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iba373a31c313448e96adfd3dc5ae16ec_19152">116</a></span></div></td></tr></table></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_16"></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:center"><span id="i89c186fa3a4a4fc39906d97f0a73efad_41465"></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carisma Therapeutics Inc.:</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Carisma Therapeutics Inc. and subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-40">KPMG LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2018</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-41">Philadelphia, Pennsylvania</ix:nonNumeric></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 1, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span id="i5af568c1d6374b8cb3e0ab37ff061245_347"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-42">77,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-43">24,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">27,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">2,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">2,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">80,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">54,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-50">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-51">8,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use assets &#8211; operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-52">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-53">4,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="3" id="f-54">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="f-55">4,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">89,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-57">72,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">3,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">7,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">10,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">2,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">3,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-66">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-68">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-69">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">15,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">19,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible promissory note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="f-74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-75">33,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-78">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-79">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-80">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-81">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-82">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-84">63,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-85">107,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-86"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-87"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="f-88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-89">107,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:16.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-90"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-91">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-92"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-93">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-94"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-95"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-97">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:16.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-100"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-101">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-103">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-104"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-105">40,609,915</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-107">2,217,737</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-108">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-109">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-110">271,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-111">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-113">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-114">245,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-115">158,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Carisma Therapeutics Inc. stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-116">26,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">157,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="3" id="f-118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-119">14,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-120">26,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-121">142,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">89,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">72,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated <span id="i71a2c5b885e14e40abf57719723624d6_267"></span>Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-124">14,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-125">9,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-126">74,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">56,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">29,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">9,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-130">103,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-131">65,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-132">88,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">56,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-134">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="f-135">1,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-136">1,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-137">3,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">86,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">61,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-140"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-141">2.59</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-142"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-143">28.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares of common stock outstanding, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-144"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-145">33,524,197</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-146"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">2,128,069</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-148">86,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">61,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain (loss) on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-150">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-151">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: reclassification to net loss of previous unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-152">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-154">86,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-155">61,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of <span id="idf4c614a3bb345f2a54391ad2815b0a3_2177"></span>Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Convertible preferred stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity (Deficit)</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Additional<br/>paid-in <br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Accumulated<br/>deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Noncontrolling<br/>interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-156">8,700,885</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-157">107,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-158">2,059,072</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-159">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-160">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-162">96,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-163">14,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-164">81,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-165">158,665</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-166">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-167">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-168">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-169">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-170">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-171">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">61,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">61,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-174">8,700,885</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="f-175">107,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-176">2,217,737</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-177">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-178">1,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-179">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-180">158,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-181">14,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-182">142,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-183">128,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-184">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-185">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-186">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-187">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-188">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-189">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Reclassification to net loss of previous unrealized gain on marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-190">399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-191">399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock for cash in pre-closing   financing</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" format="ixt:num-dot-decimal" scale="0" id="f-192">3,730,608</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" scale="3" id="f-193">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" format="ixt:num-dot-decimal" scale="3" id="f-194">30,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" format="ixt:num-dot-decimal" scale="3" id="f-195">30,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-196">5,059,338</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-197">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-198">42,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-199">42,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-200">10,374,272</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-201">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-202">72,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-203">72,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Conversion of convertible preferred stock and non-controlling interests to common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" sign="-" name="carm:ReclassificationsOfTemporaryToPermanentEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-204">8,700,885</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="f-205">107,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" format="ixt:num-dot-decimal" scale="0" id="f-206">18,872,711</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" scale="3" id="f-207">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" format="ixt:num-dot-decimal" scale="3" id="f-208">122,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" format="ixt:num-dot-decimal" scale="3" id="f-209">14,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" format="ixt:num-dot-decimal" scale="3" id="f-210">107,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Sale of common stock under Open Market Sales Agreement, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-211">226,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-212">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-213">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-214">86,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">86,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:fixed-zero" scale="0" id="f-216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-218">40,609,915</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-219">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-220">271,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-222">245,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-224">26,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.               </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of <span id="i8b331231bf0942778ddf2679a35fb030_487"></span>Cash Flows (in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-225">86,879</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-226">61,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustment to reconcile net loss to net cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-227">2,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-228">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Loss on disposal of property and equipment </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-229">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-231">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-232">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reduction in the operating right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-233">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-234">4,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-235">1,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="f-236">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="f-237">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="f-238">1,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accretion on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:AccretionOnMarketableSecurities" scale="3" id="f-239">709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:AccretionOnMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Realized gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" scale="3" id="f-241">399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" format="ixt:fixed-zero" scale="3" id="f-242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:NoncashInterestExpense" scale="3" id="f-243">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:NoncashInterestExpense" scale="3" id="f-244">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-245">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-246">1,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-247">2,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-248">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-249">2,899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-250">4,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-251">1,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-252">47,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-253">4,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-254">4,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other long term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="f-255">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-257">81,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-258">5,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-259">34,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-260">90,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from the sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="carm:PaymentsForProceedsFromMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-261">108,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="carm:PaymentsForProceedsFromMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-262">63,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-263">1,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-264">4,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-265">72,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-266">32,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-267">37,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of reverse recapitalization finance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-269">5,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from the issuance of common stock in pre-closing financing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-271">30,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing" format="ixt:fixed-zero" scale="3" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of principal related to finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-273">1,301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-274">865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from failed sale-leaseback arrangement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:ProceedsFromFailedSaleLeasebackTransaction" format="ixt:num-dot-decimal" scale="3" id="f-275">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:ProceedsFromFailedSaleLeasebackTransaction" format="ixt:num-dot-decimal" scale="3" id="f-276">1,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of finance liability from failed sale-leaseback arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" format="ixt:num-dot-decimal" scale="3" id="f-277">1,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" scale="3" id="f-278">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-279">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-280">2,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of convertible promissory note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="f-282">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-283">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-284">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sale of common stock under Open Market Sales Agreement, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-285">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-287">62,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-288">33,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-289">53,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-290">4,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-291">24,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-292">28,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-293">77,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-294">24,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows (in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-295">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-296">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Supplemental disclosure of non-cash financing and investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of convertible preferred stock and non-controlling interests upon Merger</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:NoncashOrPartNoncashAcquisitionEquityAssumed" format="ixt:num-dot-decimal" scale="3" id="f-297">122,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:NoncashOrPartNoncashAcquisitionEquityAssumed" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NotesReduction" format="ixt:num-dot-decimal" scale="3" id="f-299">42,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:NotesReduction" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain (loss) on marketable securities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" scale="3" id="f-301">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" scale="3" id="f-302">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred financing costs in accrued expenses</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:NonCashDeferredFinancingCostsAccruedExpenses" format="ixt:fixed-zero" scale="3" id="f-303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:NonCashDeferredFinancingCostsAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-304">1,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-305">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-306">6,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new financing lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-307"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-308">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-309">2,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocation of debt proceeds to derivative liability</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1" format="ixt:fixed-zero" scale="3" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1" format="ixt:num-dot-decimal" scale="3" id="f-311">3,820</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_34"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)&#160;&#160;&#160;&#160;<span id="iba373a31c313448e96adfd3dc5ae16ec_19152"></span><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-312" continuedAt="f-312-1" escape="true">Background</ix:nonNumeric></span></div><ix:continuation id="f-312-1" continuedAt="f-312-2"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carisma Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the Company), is a clinical-stage cell therapy company focused on using the Company&#8217;s proprietary chimeric antigen receptor macrophage and monocyte (CAR-M) cell therapy platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company&#8217;s focus is its proprietary CAR-M cell therapy platform, which redirects macrophages against specific tumor associated antigens and enables targeted anti-tumor immunity by utilizing genetically modified myeloid cells (macrophages and monocytes) to express chimeric antigen receptors (CARs), enabling these potent innate immune cells to recognize specific tumor associated antigens on the surface of tumor cells. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company and its board of directors approved a revised operating plan to reduce monthly operating expenses and conserve cash. The plan, which will be implemented in the second quarter of 2024, includes several measures such as prioritizing CT-0525 as the Company's anti-human epidermal growth factor receptor 2 (HER2) product candidate going forward, suspending the enrollment of new patients for CT-0508 in line with the clinical judgment of the clinical site principal investigator, pausing further development of CT-1119, reducing the workforce, including employees engaged in research and development and general and administration activities, and decreasing spending on other non-essential activities. The Company expects the reduction in workforce to be substantially complete and to pay the majority of the workforce reduction costs in the second quarter of 2024. The revised operating plan considers expenses pertaining to severance costs and potential termination and exit fees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s first product candidate to enter clinical development, CT-0508, is the first CAR-Macrophage to be evaluated in a human clinical trial and is intended to treat solid tumors that over-express HER2, a protein that is over-expressed on the surface of a variety of solid tumors, including breast cancer, gastric cancer, esophageal cancer, salivary gland cancer, and numerous others. CT-0508 has been granted &#8220;Fast Track&#8221; status for the treatment of patients with HER2 over-expressing solid tumors by the United States FDA. CT-0508 is currently being studied in a multi-center open label Phase 1 clinical trial in the United States. This ongoing first-in-human study evaluates the safety, tolerability, and manufacturing feasibility of CT-0508 along with several customary exploratory secondary endpoints.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0525 utilizes a novel approach to CAR-M therapy that engineers patients&#8217; monocytes directly, without </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differentiation into macrophages. In November 2023, the Company received FDA clearance of the Company's IND for CT-0525, and expects to treat the first patient in the second quarter of 2024. The Company believes that CT-0525 has favorable attributes compared to its initial clinical stage product candidate, CT-0508, and that the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. The Company will also continue to focus on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA/lipid nanoparticle (LNP) CAR-M programs in partnership with Moderna.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company plans to continue ongoing activities under its open label Phase 1 clinical trial of CT-0508 and its sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities. The Company has also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases, also remains ongoing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using its proprietary macrophage and monocyte cell therapy platform, the Company is developing a pipeline of product candidates with an initial focus on advancing multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> autologous and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies for the treatment of solid tumors. The Company is also pursuing early research and development of multiple assets for the potential treatment </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-312-2" continuedAt="f-312-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology, fibrosis, and immunology programs are wholly owned. Additionally, under a collaboration agreement (the Moderna License Agreement), with ModernaTX Inc. (Moderna) (Note 12), the Company is developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies utilizing Moderna's mRNA/LNP technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's follow-on product candidate, CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2, utilizes a novel approach to CAR-M therapy that engineers patients' monocytes directly, without </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differentiation into macrophages, as the Company currently does for CT-0508. The CAR-Monocyte approach utilizes a single day manufacturing process, which enables the  manufacture of up to ten billion cells from a single apheresis, and leverages an automated, closed-system manufacturing process. In addition, the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. By increasing the cell yield, a CAR-Monocyte enables a larger dose than a CAR-Macrophage. In addition, CAR-Monocyte has the potential for improved persistence and trafficking, which were observed in pre-clinical studies. The Company believes that the increased cell yield, and the improved persistence and trafficking may improve tumor control. In November 2023, the Company received FDA clearance of its IND for CT-0525 and the Company expects to treat the first patient in the second quarter of 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition to the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CAR-M cell therapies, the Company is developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CAR-M cell therapies, wherein immune cells are directly engineered within the patient&#8217;s body. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To advance the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CAR-M therapeutics, the Company established a strategic collaboration with Moderna (Note 12). I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">n the fourth quarter of 2023, the Company presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the pre-clinical data demonstrated feasibility, tolerability, and early efficacy of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CAR-M against metastatic solid tumors. In December 2023, the Company announced the nomination of the collaboration's first lead candidate, which will target an antigen present on a solid tumor with significant unmet medical need.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to acting as a first line of defense in the innate immune system, macrophages and monocytes are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration.  Using the Company's macrophage and monocyte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engineering platform, the Company is pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. Pre-clinical proof of concept for fibrosis is expected in the first half of 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Merger with Sesen Bio</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio, Inc.) consummated a merger with CTx Operations, Inc. (formerly privately-held CARISMA Therapeutics Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and Seahawk Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). Pursuant to the Merger Agreement, the Company changed its name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; At the closing of the Merger, (a) each then outstanding share of Legacy Carisma common stock and convertible preferred stock (including shares of Legacy Carisma common stock issued in connection with the pre-closing financing transaction described below) were converted into shares of Sesen Bio, Inc. (Sesen Bio) common stock at an exchange ratio of <ix:nonFraction unitRef="number" contextRef="c-34" decimals="4" name="carm:ConvertedIntoSharesCommonStockAtExchangeRatio" scale="0" id="f-313">1.8994</ix:nonFraction> shares of Sesen Bio for each share of Legacy Carisma (the Exchange Ratio), and (b) each then outstanding stock option to purchase Legacy Carisma common stock was assumed by Sesen Bio, with necessary adjustments to reflect the Exchange Ratio.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, references herein to &#8220;Carisma,&#8221; the &#8220;Company,&#8221; or the &#8220;Combined Company,&#8221; refer to Carisma Therapeutics Inc. on a post-Merger basis, and references to &#8220;Legacy Carisma&#8221; refer to the business of privately-held CARISMA Therapeutics Inc. prior to the completion of the Merger. References to &#8220;Sesen Bio&#8221; refer to Sesen Bio, Inc. prior to the completion of the Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Merger, the shareholders of Legacy Carisma held <ix:nonFraction unitRef="number" contextRef="c-35" decimals="3" name="carm:BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" scale="-2" id="f-314">74.2</ix:nonFraction>% of the Combined Company and the shareholders of Sesen Bio held <ix:nonFraction unitRef="number" contextRef="c-36" decimals="3" name="carm:OwnershipInterestInReportingEntity" scale="-2" id="f-315">25.8</ix:nonFraction>% of the Combined Company.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-312-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Ratio</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse capitalization under which the historical financial statements of the Company prior to the Merger are Legacy Carisma. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio.</span></div></ix:continuation><div id="ia97881cf99e44bfdaa49bfe02990f0e4_37"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="carm:DevelopmentStageRisksAndLiquidityTableTextBlock" id="f-316" continuedAt="f-316-1" escape="true">Development-Stage Risks and Liquidity</ix:nonNumeric></span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><ix:continuation id="f-316-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-317">245.1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December&#160;31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-318">77.6</ix:nonFraction> million of cash and cash equivalents. Absent any other action, the Company would have required additional liquidity to continue its operations over the next 12 months, which would have raised substantial doubt about its ability to continue as a going concern. As discussed in Note 1, Background, in March 2024, the Company and its board of directors approved a revised operating plan that suspends certain development programs, reduces its workforce and decreases other non-essential activities to extend the Company&#8217;s cash runway. The Company projects this revised operating plan will alleviate the substantial doubt that has been raised by significantly decreasing expenses, thereby reducing ongoing liquidity needs to enable the continuation of operations for at least 12 months from the issuance date of these consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</span></div></ix:continuation><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_40"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-319" continuedAt="f-319-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-319-1" continuedAt="f-319-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-320" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-321" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management&#8217;s estimates include the fair value of the Company&#8217;s common stock and the derivative liability prior to the Merger, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-319-2" continuedAt="f-319-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-322" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. The Company considered the carrying value of its convertible promissory note (Note 8) as of December 31, 2022 to approximate fair value due to its short-term nature. The derivative liability was recorded at its estimated fair value prior to its derecognition in March 2023 upon conversion of the associated convertible promissory notes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-323" continuedAt="f-323-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-324" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement at reporting date using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-325">62,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-327">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-328">7,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; U.S. Treasuries</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-331">27,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-8" name="carm:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-334">Derivative liability &#8211; redemption feature on convertible promissory note</ix:nonNumeric></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-337">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="f-338">no</ix:nonFraction> marketable securities. <ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-339" continuedAt="f-339-1" escape="true">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2022:</ix:nonNumeric></span></div><ix:continuation id="f-339-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-340">27,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-341">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-342">27,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated a redemption feature within the convertible promissory note issued in January 2022 and determined bifurcation of the redemption feature was required. The redemption feature is classified as a liability on the accompanying consolidated balance sheet and is marked-to-market each reporting period with the changes in fair value </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-319-3" continuedAt="f-319-4"><ix:continuation id="f-323-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded in the accompanying statements of operations until it is triggered, terminated, reclassified or otherwise settled. The fair value of the derivative was determined based on an income approach that identified the cash flows using a with-and-without valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the discount factor used was <ix:nonFraction unitRef="number" contextRef="c-8" decimals="2" name="carm:DebtInstrumentConvertibleDiscountFactorPercentage" scale="-2" id="f-343">12</ix:nonFraction>% and a <ix:nonFraction unitRef="number" contextRef="c-44" decimals="2" name="carm:DebtInstrumentConvertibleQualifiedFinancingProbability" scale="-2" id="f-344">90</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-45" decimals="2" name="carm:DebtInstrumentConvertibleQualifiedFinancingProbability" scale="-2" id="f-345">100</ix:nonFraction>% probability of completing a qualified financing prior to the maturity date of the convertible promissory note was assumed. The estimated time of conversion ranged from <span style="-sec-ix-hidden:f-346">three</span> to <ix:nonNumeric contextRef="c-45" name="carm:DerivativeInstrumentConversionTermForRedemptionFeature" format="ixt-sec:durwordsen" id="f-347">twelve months</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-348" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below is a summary of the changes in fair value of the Company&#8217;s derivative liability associated with the redemption feature of the Company&#8217;s convertible promissory note (Level 3 measurement):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-349">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="f-352">3,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-353">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-354">1,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition upon conversion of convertible promissory note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-355">5,823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-358">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023 and 2022, there were no transfers between Level 1, Level 2 and Level 3.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-359" continuedAt="f-359-1" escape="true"><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Upfront license fees</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-319-4" continuedAt="f-319-5"><ix:continuation id="f-359-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Customer options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestone payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-360" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-319-5" continuedAt="f-319-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-361" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-362">one</ix:nonFraction> segment.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-363" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, cas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h equivalents consisted of investments in a money market account. The Company maintained $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="f-364">30,000</ix:nonFraction> as collateral for the Company&#8217;s credit card program at September 30, 2023, which was previously reported as restricted cash on its consolidated balance sheet. There were <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="0" id="f-365">no</ix:nonFraction> amounts restricted as of December 31, 2023 and 2022, as the collateral was released to the Company in the fourth quarter of 2023.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-366" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Marketable Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities consisted of investments in U.S. Treasuries that were classified as available-for-sale. The securities were carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, a component of stockholders' equity (deficit). Realized gains and losses and declines in value determined to be other than temporary were included in the Company's consolidated statements of operations.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-367" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:f-368">two</span> to <ix:nonNumeric contextRef="c-53" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-369">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-370" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-371"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-372">not</ix:nonFraction></ix:nonFraction> recognize any impairment of long-lived assets during th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="carm:DeferredFinancingCostsPolicyPolicyTextBlock" id="f-373" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentGross" format="ixt:num-dot-decimal" scale="6" id="f-374">4.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentGross" format="ixt:num-dot-decimal" scale="6" id="f-375">4.1</ix:nonFraction>&#160;million in deferred financing costs associated with the Merger during the years ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon completion of the Merger, the $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentGross" format="ixt:num-dot-decimal" scale="6" id="f-376">8.3</ix:nonFraction>&#160;million of deferred financing costs were recorded against the gross proceeds received as a result of the Merger.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-377" continuedAt="f-377-1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-319-6" continuedAt="f-319-7"><ix:continuation id="f-377-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="f-378" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Noncontrolling Interest</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that ownership interests in the Company&#8217;s subsidiary are held by entities other than the Company, management reports these as noncontrolling interests on the consolidated balance sheet. Prior to the Merger, an investor had outstanding Class B and Class B-1 shares in the Company&#8217;s Luxembourg subsidiary related to the sale of the Company&#8217;s Series A convertible preferred stock (Series A) and Series B convertible preferred stock (Series B). The shares were nonvoting shares at the subsidiary entity level and were presented as noncontrolling interests in the accompanying consolidated balance sheet at December 31, 2022. In connection with the Merger, the Company's noncontrolling interests exchangeable shares converted into shares of common stock (Note 8).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-379" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-380" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger, and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-381" continuedAt="f-381-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income taxes </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-319-7"><ix:continuation id="f-381-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the deferred tax assets will not be realized. As of December 31, 2023 and 2022, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-382" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-383" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock and exchangeable shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-384">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-385">9,936,148</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-386">6,023,370</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-60" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-387">3,356,937</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of convertible promissory note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-388">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-389">3,258,151</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-390">6,023,370</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-391">16,551,236</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-392" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for fiscal years beginning after December 15, 2022. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to accumulated deficit and did not have a material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued but not yet adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="ia97881cf99e44bfdaa49bfe02990f0e4_43"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-393" continuedAt="f-393-1" escape="true">Merger with Sesen Bio</ix:nonNumeric></span></div><ix:continuation id="f-393-1" continuedAt="f-393-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2023, Legacy Carisma completed the Merger with Sesen Bio as discussed in Note 1. The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) Legacy Carisma stockholders own approximately <ix:nonFraction unitRef="number" contextRef="c-63" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-394">74.2</ix:nonFraction>% of the Combined Company, (ii) Legacy Carisma holds the majority (six of <ix:nonFraction unitRef="seat" contextRef="c-6" decimals="INF" name="carm:NumberOfBoardMembers" format="ixt-sec:numwordsen" scale="0" id="f-395">seven</ix:nonFraction>) of board seats of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-393-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Combined Company and (iii) Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were <ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-396">40,254,666</ix:nonFraction> shares of the Company&#8217;s common stock outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-397" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net assets acquired in the Merger (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 7, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-398">37,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-399">44,588</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-400">1,316</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" scale="3" id="f-401">30</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-402">3,499</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-403">80,308</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-404">8,264</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired less transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-405">72,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March&#160;7, 2023, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-406">4.6</ix:nonFraction> million of severance and personnel costs related to Sesen Bio.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_46"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-407" continuedAt="f-407-1" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="f-407-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-408" continuedAt="f-408-1" escape="true"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-409">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-410">1,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-411">11,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-412">10,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-413">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-414">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-415">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-416">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-417">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="f-418">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-419">12,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-420">11,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-421">6,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-422">3,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-423">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-424">8,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Lab equipment includes failed sale lease-back assets of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:SaleLeasebackTransactionNetBookValue" format="ixt:num-dot-decimal" scale="6" id="f-425">3.4</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:SaleLeasebackTransactionNetBookValue" format="ixt:num-dot-decimal" scale="6" id="f-426">2.6</ix:nonFraction>&#160;million, respectively, as of December 31, 2023 and 2022. Lab equipment includes finance lease ROU assets of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-427"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-428">2.9</ix:nonFraction></ix:nonFraction>&#160;million as of December&#160;31, 2023 and 2022.</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-408-1" continuedAt="f-408-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The accumulated amortization balance includ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-408-2">$<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-429">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-430">0.3</ix:nonFraction>&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2023 and 2022. The accumulated amortization balance includes $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-431">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-432">0.6</ix:nonFraction>&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2023 and 2022.</ix:continuation>  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-433">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-434">1.9</ix:nonFraction>&#160;million for the years ended December 31, 2023, and 2022, respectively.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_415"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-435" continuedAt="f-435-1" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-436" escape="true"><ix:continuation id="f-435-1"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-437">3,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-438">4,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-439">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-440">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-441">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-442">2,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-444">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-445">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-447">7,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-448">10,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ia97881cf99e44bfdaa49bfe02990f0e4_49"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-449" continuedAt="f-449-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-449-1" continuedAt="f-449-2"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2024 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2024 to 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating and finance lease right-of-use (ROU) assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company entered into purchase and sale agreements under which the Company sold lab equipment for $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="carm:ProceedsFromSaleAndLeasebackTransaction" format="ixt:num-dot-decimal" scale="6" id="f-450">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="carm:ProceedsFromSaleAndLeasebackTransaction" format="ixt:num-dot-decimal" scale="6" id="f-451">1.6</ix:nonFraction>&#160;million, respectively. Concurrent with the sale of equipment, the Company entered into various lease agreements, with term end dates ranging from 2025 to 2026, whereby the Company will lease back the equipment. The Company accounts for such transactions as failed sale-leasebacks, due to having continuing involvement with the equipment. The Company carries this laboratory equipment as property and equipment, net on the accompanying consolidated balance sheets and the sale proceeds as a finance liability. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. No gain or loss was recorded on the failed sale-leasebacks. As of December&#160;31, 2023, the Company had a $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-452">1.9</ix:nonFraction> million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-453" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of the lease costs were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-454">5,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-455">4,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-456">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-457">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-458">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-459">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:FinanceLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-460">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:FinanceLeaseCost" scale="3" id="f-461">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-462">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-463">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-464">8,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-465">6,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-449-2" continuedAt="f-449-3"><ix:nonNumeric contextRef="c-1" name="carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" id="f-466" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease term and discount rate information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-467">2.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-468">2.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-469">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-7" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-470">2.2</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-471">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-472">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-473">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-474">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" id="f-475" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-476">5,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-477">4,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-478">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="f-479">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash used in finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:FinancingCashUsedInFinanceLeases" format="ixt:num-dot-decimal" scale="3" id="f-480">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:FinancingCashUsedInFinanceLeases" scale="3" id="f-481">865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-483" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-482" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities were as follows as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal year ending:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-484">1,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-485">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-486">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-487">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-488">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="3" id="f-489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-490">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="3" id="f-491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-492">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="f-494">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-496">2,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-497">939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-498">361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-499">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-500">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-501">872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Sponsored Research Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November 2017 (Penn License Agreement),</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company is required to make annual payments of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="carm:CommitmentsAnnualPaymentsRequiredToBePaid" format="ixt:num-dot-decimal" scale="3" id="f-502">25,000</ix:nonFraction>. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penn is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" format="ixt:num-dot-decimal" scale="6" id="f-503">10.9</ix:nonFraction> million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="carm:AdditionalMilestonePaymentsRequiredToBePaid" format="ixt:num-dot-decimal" scale="6" id="f-504">30.0</ix:nonFraction> million per product in commercial milestones and up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="carm:AdditionalMilestonePaymentsForFirstCarMProduct" format="ixt:num-dot-decimal" scale="6" id="f-505">1.7</ix:nonFraction> million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#8217;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement is for <ix:nonNumeric contextRef="c-81" name="carm:AgreementTerm" format="ixt-sec:durwordsen" id="f-506">five years</ix:nonNumeric> and shall renew automatically for additional <ix:nonNumeric contextRef="c-81" name="carm:RenewalTerm" format="ixt-sec:durwordsen" id="f-507">one-year</ix:nonNumeric> periods unless and until </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-449-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminated by either party. In addition to paying to manufacture the product, the Company will also pay $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="carm:AmountPayablePerCalendarYearForReservedCapacity" format="ixt:num-dot-decimal" scale="6" id="f-508">1.0</ix:nonFraction> million per calendar year, payable in quarterly payments, for reserved capacity starting on the date on which the Novartis site is declared ready to produce CT-0508 as determined by the Company. In the event of termination without cause by the Company, a termination fee equal to $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="carm:TerminationFeePayable" format="ixt:num-dot-decimal" scale="6" id="f-509">4.0</ix:nonFraction> million will be payable by Carisma to Novartis which, pursuant to the terms of the agreement, can be credited in full against amounts due for a substitute product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2023, a purported stockholder filed a complaint in the United States District Court for the District of Delaware against Sesen Bio and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumley v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:23-cv-00131 (D. Del.) (the Plumley Complaint). The Plumley Complaint asserts claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On February 7, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Franchi v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:23-cv-01041 (S.D.N.Y.) (the Franchi Complaint). The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February 9, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Menzer v. Sesen Bio, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., 23-cv-01119 (S.D.N.Y.) (the Menzer Complaint). The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint. In April 2023, the Company executed a confidential fee agreement to resolve the stockholders&#8217; claim for attorney&#8217;s fees and expenses in connection with the Plumley Complaint, Franchi Complaint, and Menzer Complaint.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company settled and paid the confidential fee agreement resulting in $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-510">0.2</ix:nonFraction> million of claim expenses incurred during the year ended December&#160;31, 2023.</span></div></ix:continuation><div id="ia97881cf99e44bfdaa49bfe02990f0e4_55"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-511" continuedAt="f-511-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-511-1"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2023, in connection with the closing of the Mer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#8217; equity (deficit) for the year ended December 31, 2023: (i) the sale of <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-512">3,730,608</ix:nonFraction> shares of common stock in a pre-closing funding at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-64" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-513">8.21</ix:nonFraction> per share for total proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-514">30.6</ix:nonFraction> million, (ii) the issuance of <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-515">5,059,338</ix:nonFraction> shares of common stock upon the settlement of the Company&#8217;s $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-516">35.0</ix:nonFraction> million convertible promissory note, accrued interest and related derivative liability, (iii) the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests into <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" format="ixt:num-dot-decimal" scale="0" id="f-517">18,872,711</ix:nonFraction> shares of common stock, (iv) the issuance of <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-518">10,374,272</ix:nonFraction> shares of common stock to Sesen Bio stockholders as consideration for the Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on May 2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="carm:SaleOfStockStockOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-519">300.0</ix:nonFraction>&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May 12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="carm:SaleOfStockStockOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-520">100.0</ix:nonFraction>&#160;million under an &#8220;at-the-market" offering program. Through December 31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-521">226,533</ix:nonFraction> shares for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="f-522">0.6</ix:nonFraction>&#160;million. From January through March 2024, the Company sold an additional <ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-523">931,250</ix:nonFraction> shares for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="f-524">2.4</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2023, the Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of the Company's common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-525">0.001</ix:nonFraction> par value, from <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-526">100,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-527">350,000,000</ix:nonFraction> shares and authorized <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-528">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-529">0.001</ix:nonFraction> par value.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-530" continuedAt="f-530-1" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-530-1" continuedAt="f-530-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legacy Carisma adopted the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was <ix:nonNumeric contextRef="c-89" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-531">ten years</ix:nonNumeric>, and stock options typically vested over a <ix:nonNumeric contextRef="c-90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-532">four-year</ix:nonNumeric> period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over <ix:nonNumeric contextRef="c-90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-533">four years</ix:nonNumeric>. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sesen Bio, Inc. Amended and Restated 2014 Stock Incentive Plan, as amended (the Sesen Bio 2014 Plan), provides for the grant of incentive and non-qualified</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Compan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">board of directors at the time of grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the Sesen Bio 2014 Plan generally vest over a <ix:nonNumeric contextRef="c-91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-534">four-year</ix:nonNumeric> period at the rate of <ix:nonFraction unitRef="number" contextRef="c-92" decimals="2" name="carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" scale="-2" id="f-535">25</ix:nonFraction>% of the grant vesting on the first anniversary of the date of grant and <ix:nonFraction unitRef="number" contextRef="c-92" decimals="4" name="carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" scale="-2" id="f-536">6.25</ix:nonFraction>% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the Sesen Bio 2014 Plan are exercisable for a period of <ix:nonNumeric contextRef="c-93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-537">ten years</ix:nonNumeric> from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2023, the Company amended and restated the Sesen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bio 2014 Plan to (i) change the name of the plan to the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) and (ii) adopt a new form of stock option agreement and a new form of restricted stock unit agreement for the grant of options and restricted stock units under the 2014 P</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lan. On June 6, 2023, the Company&#8217;s stockholders approved an amendment and restatement of the Company&#8217;s 2014 Plan, which amendment and restatement had previously been adopted by the Company&#8217;s board of directors, subject to stockholder approval. As of December&#160;31, 2023, approximately <ix:nonFraction unitRef="shares" contextRef="c-92" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-538">4.9</ix:nonFraction> million shares of common stock remained available for issuance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sesen Bio 2014 Employee Stock Purchase Plan (the Sesen Bio 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="c-94" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-539">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Sesen Bio 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock. On March 7, 2023, the Company amended and restated the Sesen Bio 2014 ESPP to (i) change the name of the plan to Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan and (ii) restate and integrate a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll prior amendments thereto. As of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-540">0.2</ix:nonFraction> million shares of common stock remained available for issuance.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-530-2" continuedAt="f-530-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-541" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the year ended December 31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic <br/>Value (in <br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-542">3,356,937</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-543">1.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio options assumed in the Merger</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-544">765,223</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="carm:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" scale="0" id="f-545">27.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-546">128,716</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-547">1.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-548">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-549">2,984,152</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-550">6.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-551">114,454</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-552">5.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-553">839,772</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-554">29.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-555">6,023,370</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-556">3.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-557">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-558">5,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-559">2,516,594</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-560">1.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-561">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-562">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-563">6,023,370</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-564">3.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-565">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-566">5,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date per share fair values of options granted during the year ended December 31, 2023 and 2022 were $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-567">4.29</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-568">1.46</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-569" continuedAt="f-569-1" escape="true">The fair values in the year ended December 31, 2023 and 2022 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-569-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-570">2.92</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-97" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-571">4.76</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-572">2.40</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-99" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-573">3.05</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-100" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-574">6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-575">6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-576">57.77</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-97" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-577">103.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-578">54.54</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-99" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-579">56.50</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-582" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:71.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-583">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-584">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-585">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-586">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-587">2,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-588">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-530-3">The Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-589">0.2</ix:nonFraction> million related to the modification of Sesen Bio options assumed in connection with the Merger. Compensation cost for awards not vested as of December&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-590">11.2</ix:nonFraction> million and will be expensed over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-591">3.3</ix:nonNumeric> years</ix:continuation>.</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_61"></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-592" continuedAt="f-592-1" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-593" continuedAt="f-593-1" escape="true"><ix:continuation id="f-592-1" continuedAt="f-592-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-592-2" continuedAt="f-592-3"><ix:continuation id="f-593-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.769%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal tax benefit at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-594">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-595">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-596">8.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-597">7.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" scale="-2" id="f-598">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" scale="-2" id="f-599">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="f-600">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="f-601">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-602">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-603">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-604">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="f-605">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="carm:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" format="ixt:fixed-zero" scale="-2" id="f-606">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="carm:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" scale="-2" id="f-607">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-609">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-610" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-611">72,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-612">27,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs, net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" format="ixt:num-dot-decimal" scale="3" id="f-613">33,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" format="ixt:num-dot-decimal" scale="3" id="f-614">11,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-615">9,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-616">5,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsStartUpCosts" format="ixt:num-dot-decimal" scale="3" id="f-617">4,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:DeferredTaxAssetsStartUpCosts" format="ixt:num-dot-decimal" scale="3" id="f-618">4,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-619">13,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="f-620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsLeaseLiability" scale="3" id="f-621">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-622">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable assets and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsAmortizableAssetsAndOther" scale="3" id="f-623">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:DeferredTaxAssetsAmortizableAssetsAndOther" scale="3" id="f-624">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxAssetsEquityCompensation" scale="3" id="f-625">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:DeferredTaxAssetsEquityCompensation" scale="3" id="f-626">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-627">134,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-628">50,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-629">133,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-630">49,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-631">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-632">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="f-633">645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="carm:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-634">1,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-635">524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-636">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-637">1,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-638">1,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-639">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-641">317.6</ix:nonFraction>&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-642">120.0</ix:nonFraction>&#160;million will begin to expire in 2037, if not utilized. The post-2017 federal NOLs  of $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-643">197.6</ix:nonFraction>&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-644">229.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-645">40.8</ix:nonFraction>&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2038 while the city of Philadelphia NOLs expire after three years with $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-646">29.7</ix:nonFraction>&#160;million expiring in 2023. As of December&#160;31, 2023, the Company also had federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-647">9.9</ix:nonFraction>&#160;million that will begin to expire in 2029, unless previously utilized.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-592-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company's net deferred tax assets as of December&#160;31, 2023. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-648">84.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-649">13.7</ix:nonFraction>&#160;million during the years ended December 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a percentage of apportioned taxable income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2023, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's financial statements. Tax years from 2019 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.</span></div></ix:continuation><div id="ia97881cf99e44bfdaa49bfe02990f0e4_64"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-650" continuedAt="f-650-1" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-650-1">The Company has a collaboration and license agreement with Moderna, a significant shareholder (Note 12).</ix:continuation> </span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_67"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-651" continuedAt="f-651-1" escape="true">Moderna Collaboration and License Agreement</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-651-1" continuedAt="f-651-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics for up to <ix:nonFraction unitRef="target" contextRef="c-113" decimals="INF" name="carm:MaximumOfResearchTargets" format="ixt-sec:numwordsen" scale="0" id="f-652">twelve</ix:nonFraction> oncology programs. Under the Moderna License Agreement, the Company and Moderna initiate research programs during a research term, focused on the discovery and research of products directed to biological targets. Moderna&#8217;s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has the right to designate up to <ix:nonFraction unitRef="target" contextRef="c-113" decimals="INF" name="carm:NumberOfResearchTargetsDesignateAsDevelopmentTargets" format="ixt-sec:numwordsen" scale="0" id="f-653">twelve</ix:nonFraction> research targets as development targets.  The first <ix:nonFraction unitRef="target" contextRef="c-113" decimals="INF" name="carm:NumberOfResearchTargetsDesignated" format="ixt-sec:numwordsen" scale="0" id="f-654">five</ix:nonFraction> research targets have been designated and all programs are currently in the discovery phase. Moderna funds the cost of the Company's activities in accordance with an agreed research budget. The Company is responsible for discovering and optimizing development candidates, and Moderna is responsible for the clinical development thereafter. Pursuant to the Moderna License Agreement, the Company and Moderna formed a joint steering committee (JSC) that is responsible for the coordination and oversight of all research activities to which the Company is responsible for providing. The JSC is comprised of representatives from the Company and Moderna and with Moderna having final decision-making authority, subject to specified limitations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Moderna License Agreement, the Company and its affiliates are subject to various exclusivity obligations under which the Company is not permitted to research, develop or commercialize particular products outside of the collaboration, including products for use as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapies in the field of oncology, products directed to any target included in the collaboration, or products containing a polypeptide provided by the Company to Moderna in connection with a research program that are directed to any development target. Additionally, the Company has granted Moderna an exclusive worldwide royalty free license to the Company&#8217;s intellectual property associated with the product candidates that permits Moderna to conduct its research and development activities. Upon Moderna&#8217;s election of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-651-2" continuedAt="f-651-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="carm:UpfrontNonRefundablePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-655">45.0</ix:nonFraction> million to the Company. Assuming Moderna develops and commercializes <ix:nonFraction unitRef="product" contextRef="c-114" decimals="INF" name="carm:NumberOfProductsDevelopedAndCommercialized" scale="0" id="f-656">12</ix:nonFraction> products, each directed to a different development target, the Company is eligible to receive up to between $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-657">247.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-658">253.0</ix:nonFraction> million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also will reimburse the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="f-659">10.0</ix:nonFraction> million in research and development costs over the first <ix:nonNumeric contextRef="c-114" name="carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts" format="ixt-sec:durwordsen" id="f-660">three years</ix:nonNumeric> from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments royalties the Company owes as a licensor under one of its intellectual property in-license agreements with Penn that the Company is sublicensing to Moderna under the Moderna License Agreement, which royalties Moderna may deduct in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the JSC. The Company determined that there were <ix:nonFraction unitRef="obligation" contextRef="c-118" decimals="INF" name="carm:NumberOfPerformanceObligations" scale="0" id="f-661">2</ix:nonFraction> performance obligations comprised of (i) research and development services and (ii) option rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="carm:UpfrontNonRefundablePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-662">45.0</ix:nonFraction>&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna elects to exercise or elects to not exercise its option right to license and commercialize the underlying research and development target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company included the $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="carm:UpfrontNonRefundablePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-663">45.0</ix:nonFraction> million up-front and nonrefundable payment and $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="carm:VariableConsideration" format="ixt:num-dot-decimal" scale="6" id="f-664">73.9</ix:nonFraction> million of variable consideration for expected research and development services to be performed during the <ix:nonNumeric contextRef="c-119" name="carm:ContractTerm" format="ixt-sec:durwordsen" id="f-665">five-year</ix:nonNumeric> contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the year ended December 31, 2023 and 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-666">14.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-667">9.8</ix:nonFraction> million, respectively, of research and development services as collaboration revenues as the Company is the principal in providing such services. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-668">24.7</ix:nonFraction>&#160;million of collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="f-669" continuedAt="f-669-1" escape="true">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2023 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-669-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transaction <br/>price unsatisfied</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" format="ixt:num-dot-decimal" scale="3" id="f-670">49,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="carm:RevenueRemainingPerformanceObligationOptionRightsAmount" format="ixt:num-dot-decimal" scale="3" id="f-671">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total performance obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="f-672">94,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ia97881cf99e44bfdaa49bfe02990f0e4_10">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="f-651-3"><ix:nonNumeric contextRef="c-1" name="carm:ScheduleOfChangesInDeferredRevenueTableTextBlock" id="f-673" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in deferred revenue (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-674">47,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="carm:ContractWithCustomerLiabilityDeferralOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-676">13,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="carm:ContractWithCustomerLiabilityDeferralOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-677">57,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of unearned revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-678">14,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-679">9,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-680">46,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-681">47,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve months. The noncurrent portion of deferred revenue represents the $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-682">45.0</ix:nonFraction> million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12 months.</span></div></ix:continuation><div id="ia97881cf99e44bfdaa49bfe02990f0e4_70"></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-683" continuedAt="f-683-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-683-1"><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events from the balance sheet date through April&#160;1, 2024, the issuance date of these consolidated financial statements, and has not identified any additional matters requiring disclosure.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628401"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span id="i8ab129e590554d9e9de07ba2d267af47_169"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628408"></div><div><span id="i25ce6f05e1054977bf8b9d445d2a980a_2367"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of December&#160;31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorizations of management and directors; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework provided in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal control over financial reporting were effective as of December 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628414"></div><div><span id="i2605b46858c34f69b591c912d40f9476_203"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director and Officer Trading Arrangements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers <ix:nonNumeric contextRef="c-122" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-684"><ix:nonNumeric contextRef="c-122" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-685">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-122" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-686"><ix:nonNumeric contextRef="c-122" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-687">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the fourth quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Strategic Evaluation and Cost Reduction Measures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 27, 2024, in connection with an assessment of appropriate expense reduction efforts, our board of directors approved an expense reduction plan, which included a reduction in workforce, in order to extend the Company&#8217;s cash runway, reduce operating expenses and further align our workforce with expense allocation on our assets with the greatest strategic interest. Affected employees were informed of the reduction in workforce on or about April 1, 2024. The reduction in workforce represents approximately 39 full-time employees (representing approximately 37% of our total workforce), including certain employees engaged in research and development activities and certain finance and corporate employees. We expect to incur approximately $2.1 million in connection with the reduction in workforce, which primarily represents one-time employee termination benefits directly associated with the workforce reduction. We expect the reduction in workforce to be substantially complete and to pay the majority of these reduction in workforce amounts in the second quarter of 2024. The estimate of costs that we expect to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ. We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the reduction in workforce.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Director Resignation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 27, 2024, Chidozie Ugwumba notified us of his decision to resign from our board of directors, effective April 1, 2024. At the time of his resignation, Mr. Ugwumba was a member of the audit committee. Mr. Ugwumba decided to resign from our board of directors as a result of his other professional commitments and not due to a disagreement on any matter related to our operations, policies or practices. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective April 1, 2024, Michael Torok will become the Chair of the audit committee. Following Mr. Ugwumba&#8217;s resignation, the audit committee is now comprised of Michael Torok (Chair), Regina Hodits, Ph.D., and Sanford Zweifach.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Director Appointment </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 27, 2024, our board of directors elected John Hohneker, M.D. as a director of the Company, effective as of April 1, 2024. Dr. Hohneker was appointed as a Class I director and will serve in accordance with our amended and restated by-laws until our 2024 annual meeting of stockholders and thereafter until his successor is duly elected and qualified or until his earlier death, resignation or removal. Dr. Hohneker will serve on the nominating and corporate governance and science committees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with our non-employee director compensation policy, Dr. Hohneker will receive (i) annual cash compensation of $40,000 for his service as a director and an additional cash retainer for any committees on which he serves and (ii) reimbursement for reasonable out-of-pocket business expenses incurred in connection with attending meetings of our board of directors and committees thereof. In addition, in accordance with our non-employee director compensation policy, Dr. Hohneker was granted a stock option under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan to purchase 38,700 shares of our common stock at a per share exercise price equal to the closing price of our common stock on April 1, 2024, the date of grant. The option will vest as to 2.7778% of the shares of our common stock underlying the option at the end of each successive one-month period over a three-year period following the date of grant, subject to continued service with the company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with his election, we and Dr. Hohneker will enter into our standard form of indemnification agreement, a copy of which is filed as Exhibit 10.8 to this Annual Report on Form 10-K. Pursuant to the terms of the indemnification agreement, we may be required, among other things, to indemnify Dr. Hohneker for certain expenses and costs relating to claims, suits or proceedings arising out of his service as a director of the company. There are no arrangements or understandings between Dr. Hohneker and any other person regarding his election to the board of directors and Dr. Hohneker does not have a direct or indirect material interest in any related party transaction required to be disclosed under Item 404(a) of Regulation S-K.</span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628420"></div><div><span id="i428c814163254fc3ab1b7ce960ee6886_127"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_512"></div><div style="text-align:center"><span id="i02ef989efd5d4549802859d72bd457cf_39"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_656"></div><div><span><br/></span></div><div><span id="i06d532fbf565475f81f2b2dc96c2cd4f_258"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except to the extent provided below, the information required under this Item 10 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We post our Code of Business Conduct and Ethics, which applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, in the &#8220;Governance Overview&#8221; sub-section of the &#8220;Governance&#8221; section of our corporate website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.carismatx.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K.</span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628438"></div><div><span id="i42a1fad063724c4e99820e6f4e1ae018_151"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this Item 11 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628444"></div><div><span id="i20e6c748de69440ca58b541527579e0f_161"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this Item 12 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628450"></div><div><span id="ide17a71c326e4701887d174c4137ab44_292"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this Item 13 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which proxy statement we intend to file with the Securities and Exchange Commission not later than 120 days after the end of the fiscal year ended December 31, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628456"></div><div><span id="i84b00e26c7024fc2ade1cf3a1abe8d27_213"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this Item 14 is incorporated by reference to our definitive proxy statement for our 2024 Annual Meeting of Stockholders, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the end of the fiscal year ended December 31, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_1099511628466"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span id="i75675bb73af14fc4bc6f431ccecf5af2_109"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_121"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span id="i821e24e285de46d68b37b094e4551312_146"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Financial Statements</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a list of financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Financial Statement Schedules</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">Exhibits</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT INDEX</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex3-1.htm">Restated Certificate of Incorporation of Carisma Therapeutics Inc., dated March 7, 2023 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex3-2.htm">Amended and Restated By-Laws of Carisma Therapeutics Inc., dated March 7, 2023 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923069917/tm2318211d1_ex3-1.htm">Certificate of Amendment</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923069917/tm2318211d1_ex3-1.htm"> to Restated Certificate of Incorporation</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923069917/tm2318211d1_ex3-1.htm"> of Carisma Therapeutics Inc., dated June 6, 2023 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on June 9, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923069917/tm2318211d1_ex99-1.htm">Amendment and Restatement of Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on June 9, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_ex1-1.htm">Amended and Restated Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_ex1-1.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_ex1-1.htm">, dated May 12, 2023 (incorporated by reference to Exhibit 1.1 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on May 12, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d32.htm">Collaboration and License Agreement, dated January 7, 2022, by and between Carisma and ModernaTX, Inc. (incorporated by reference to</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d32.htm"> Exhibit 10.32 to</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922120867/sesn-20220930xex10d32.htm"> the Registrant&#8217;s Registration Statement on Form S-4/A (File No. 333-267891), filed on January 18, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d33.htm">License Agreement, dated as of November 10, 2017, by and between Carisma and the Trustees of the University of Pennsylvania, as amended (incorporated by reference to Exhibit 10.33 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-267891), filed on October 14, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465922108912/sesn-20211231xex10d34.htm">License Agreement, dated as of July 24, 2020, by and between Carisma and New York University (incorporated by reference to Exhibit 10.34 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-267891), filed on October 14, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-4.htm">Registration Rights Agreement, dated March 7, 2023 (incorporated by reference to Exhibit 10.4 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-5.htm">Contingent Value Rights Agreement, dated March 7, 2023 (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-6.htm">Form of Indemnification Agreement for Directors and Officers of Carisma Therapeutics Inc. (incorporated by reference to Exhibit 10.6 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-7.htm">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Steven Kelly (incorporated by reference to Exhibit 10.7 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-8.htm">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Richard Morris (incorporated by reference to Exhibit 10.8 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-9.htm">Employment Agreement, dated March 7, 2023, by and between Carisma Therapeutics Inc. and Michael Klichinsky (incorporated by reference to Exhibit 10.9 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-10.htm">CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-11.htm">Form of Nonstatutory Stock Option Agreement under the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.11 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-12.htm">Form of Incentive Stock Option Agreement under the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.12 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-13.htm">Carisma Therapeutics Inc. Amended and Restated 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.13 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001485003/000110465923029687/tm238578d1_8k.htm">2023 Form of Stock Option Agreement under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.14 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx1017.htm">2024 Form of Stock Option Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx1017.htm">u</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx1017.htm">nder the Carisma Therapeutics Inc. 2014 Amended and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx1017.htm">Restated Stock Incentive Plan.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-15.htm">Form of Restricted Stock Unit Agreement under the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (incorporated by reference to Exhibit 10.15 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923029687/tm238578d1_ex10-16.htm">Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.16 to the registrant&#8217;s Current Report on Form 8-K (File No. 001-36296) filed on March 8, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000110465923058778/carm-20230331xex10d18.htm">Lease, dated April 22, 2019, by and between Wexford-SCEC 3675 Market Street, LLC and CARISMA Therapeutics Inc. (incorporated by reference to Exhibit 10.18 to the registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-36296) filed on May 11, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx211.htm">Subsidiaries of the Registrant</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx231.htm">Consent of KPMG LLP, independent registered public accounting firm </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx321.htm">Certifications of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx322.htm">Certifications of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx97.htm">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="carm-20231231xexx97.htm">ompensation Recovery Policy</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-22.5pt"><span><br/></span></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_549755814366"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span id="if53bf8b0bdfa468aad87b6929ca47471_224"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="ia97881cf99e44bfdaa49bfe02990f0e4_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span id="ia05aee446d2f48bfa217090961536dcf_201"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.629%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: April&#160;1, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Steven Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: Steven Kelly</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: President and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.834%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.836%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Steven Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2024</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Steven Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Richard Morris</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2024</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard Morris</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Sanford Zweifach</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director and Chair of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanford Zweifach</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Regina Hodits, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regina Hodits, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Briggs Morrison, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Briggs Morrison, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Bj&#246;rn Odlander, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bj&#246;rn Odlander, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Michael Torok</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Torok</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Chidozie Ugwumba</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;1, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chidozie Ugwumba</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>2
<FILENAME>carm-20231231xexx1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9b44eed83a2447ba9320e8fa936d3f76_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.17</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics Inc.<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">STOCK OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) hereby grants the following stock option pursuant to its Amended and Restated 2014 Stock Incentive Plan.  The terms and conditions attached hereto are also a part hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Grant</font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:48.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of optionee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Incentive Stock Option or Nonstatutory Stock Option&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares of the Company&#8217;s Common Stock subject to this option (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option exercise price per Share&#58;<font style="font-size:7.8pt;position:relative;top:-4.2pt;vertical-align:baseline">1</font></font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Start Date&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Final Exercise Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> 2</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vesting Schedule&#58;</font></div><div style="padding-left:5.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:48.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Number of Options that Vest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CARISMA THERAPEUTICS INC. </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Signature of Participant</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Street Address</font></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:19.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name of Officer</font></div><div style="padding-left:19.85pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div></td></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>City&#47;State&#47;Zip Code</font></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#160;&#160;&#160;&#160;This must be at least 100% of the Grant Date Fair Market Value (as defined in the Plan) of the Common Stock on the date of grant (110% in the case of a Participant that owns more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary (a &#8220;10% Shareholder&#8221;)) for the option to qualify as an incentive stock option (an &#8220;ISO&#8221;) under Section 422 of the Internal Revenue Code.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Final Exercise Date must be no more than 10 years (5 years in the case of a 10% Shareholder) from the date of grant for the option to qualify as an ISO.  The correct approach to calculate the final exercise date is to use the day immediately prior to the date ten years out from the date of the stock option award grant (5 years in the case of a 10% stockholder).  </font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock Option Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporated Terms and Conditions</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This agreement evidences the grant by the Company, on the grant date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth in the Notice of Grant that forms part of this agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company&#8217;s Amended and Restated 2014 Stock Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the number of Shares set forth in the Notice of Grant of common stock, $0.001 par value per share, of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at the exercise price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">per Share set forth in the Notice of Grant.  Unless earlier terminated, this option shall expire at 5&#58;00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The option evidenced by this agreement is intended to be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the maximum extent permitted by law, solely to the extent designated as an incentive stock option in the Notice of Grant.  To the extent not designated as an incentive stock option, or to the extent that the option does not qualify as an incentive stock option, the option shall be a nonstatutory stock option.  Except as otherwise indicated by the context, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This option will become exercisable (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">vest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with the vesting schedule set forth in the Notice of Grant.  For a grant to a newly hired Participant, options will vest and become exercisable, subject to the Participant&#8217;s continued service to the Company on each applicable vesting date, with respect to 25% of the shares of common stock subject to the Option on the first anniversary of the Participant&#8217;s start date with the Company and 1&#47;36 of the shares of common stock subject to the option each month thereafter until the option is fully vested on the fourth anniversary.  For each subsequent annual grant to a Participant, options will vest and become exercisable, subject to the Participant&#8217;s continued service to the Company, on each applicable vesting date, with respect to 1&#47;48 of the shares of common stock subject to the Option each month following the grant date until the option is fully vested on the fourth anniversary.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section&#160;3 hereof or the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Form of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each election to exercise this option shall be in writing, in the form of the Stock Option Exercise Notice attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annex A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, or in such other form (which may be electronic) as is approved by the Company, together with payment in full in the manner provided in the Plan.  The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Continuous Relationship with the Company Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided in this Section&#160;3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, </font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 2 -</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination of Relationship with the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Participant ceases to be an Eligible Participant for any reason, including the Participant&#8217;s death or disability (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date, then, except as provided in paragraph (d) below, the right to exercise this option shall terminate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">twelve months after such cessation (but in no event after the Final Exercise Date), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation.  Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the restrictive covenants (including, without limitation, the non-competition, non-solicitation, or confidentiality provisions) of any employment contract, any non-competition, non-solicitation, confidentiality or assignment agreement to which the Participant is a party, or any other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If, prior to the Final Exercise Date, the Participant&#8217;s employment or other relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other service relationship.  If, prior to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other termination is subsequent to the date of delivery of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s employment or other relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate immediately upon the effective date of such termination of employment or other relationship).  If the Participant is subject to an individual employment or consulting agreement with the Company or eligible to participate in a Company severance plan or arrangement, in any case which agreement, plan or arrangement contains a definition of &#8220;cause&#8221; for termination of employment or other relationship, &#8220;Cause&#8221; shall have the meaning ascribed to such term in such agreement, plan or arrangement.  Otherwise, &#8220;Cause&#8221; shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive.  The Participant&#8217;s employment or other relationship shall be considered to have been terminated for Cause if the Company determines, within 30 days after the Participant&#8217;s resignation, that termination for Cause was warranted.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disqualifying Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If this option is an incentive stock option and the Participant disposes of Shares acquired upon exercise of this option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such disposition.</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 3 -</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Transfer Restrictions&#59; Clawback.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">This option may not be sold, assigned, transferred, pledged, encumbered or otherwise disposed of by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In accepting this option, the Participant agrees to be bound by any clawback policy that the Company has in place or may adopt in the future.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.</font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 4 -</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ANNEX A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Option Exercise Notice</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carisma Therapeutics Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3675 Market Street, Suite 200</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Philadelphia, PA 19104</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Sir or Madam&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby irrevocably exercise the right to purchase </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shares of the Common Stock, $0.001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), of Carisma Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> per share pursuant to the Company&#8217;s Amended and Restated 2014 Stock Incentive Plan and a stock option agreement with the Company dated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Enclosed herewith is a payment of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the aggregate purchase price for the Shares.  The certificate for the Shares should be registered in my name as it appears below or, if so indicated below, jointly in my name and the name of the person designated below, with right of survivorship.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature <br>Print Name&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Address&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name and address of persons in whose name the Shares are to be jointly registered (if applicable)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;- 5 -</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ActiveUS 167816198v.2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>carm-20231231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib00c389cb47b404fa95639b9b912db1e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of the Registrant</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CTx Operations, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delaware, U.S.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CARISMA Therapeutics S.&#224; r.l.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Luxembourg</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>carm-20231231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i79900584c548457fa7d63eac7aad8b4a_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the registration statements (Nos. 333-195170, 333-202677, 333-210523, 333-217686, 333-217687, 333-231644, 333-234697, 333-254264, 333-255941, 333-263070 and 333-271103) on Form S-8 and (Nos. 333-201176, 333-224682, 333-271295 and 333-271296) on Form S-3 of our report dated April 1, 2024, with respect to the consolidated financial statements of Carisma Therapeutics Inc. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Philadelphia, Pennsylvania</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">April&#160;1, 2024</font></div><div><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:60.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>carm-20231231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7dc0a7d5a0274a79a0fbc0b940b2c587_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Steven Kelly, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Carisma Therapeutics Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;1, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>carm-20231231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2f2d5162f4af4839b00d48c4720a4e03_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard Morris, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of Carisma Therapeutics Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;1, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Richard Morris</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Richard Morris</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>carm-20231231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0031240b96e741e782e12967d6087aca_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Carisma Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;1, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Steven Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>carm-20231231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i23c2c30df7694d61aab08956670e0450_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Carisma Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;1, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Richard Morris</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Richard Morris</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>9
<FILENAME>carm-20231231xexx97.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8a4d086d901c46fc9342ed575a6e5b69_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 97</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARISMA THERAPEUTICS INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Dodd-Frank Compensation Recovery Policy</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Compensation Recovery Policy (this &#8220;Policy&#8221;) is adopted by Carisma Therapeutics Inc. (the &#8220;Company&#8221;) in accordance with Nasdaq Listing Rule 5608 (&#8220;Rule 5608&#8221;), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010). This Policy is effective as of October 2, 2023 (the &#8220;Effective Date&#8221;).</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt;text-decoration:underline">Definitions</font></div><div><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:11.07pt">&#8220;Accounting Restatement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> means a requirement that the Company prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. Changes to the Company&#8217;s financial statements that do not represent error corrections are not an Accounting Restatement, including&#58; (A) retrospective application of a change in accounting principle&#59; (B) retrospective revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization&#59; (C) retrospective reclassification due to a discontinued operation&#59; (D) retrospective application of a change in reporting entity, such as from a reorganization of entities under common control&#59; and (E) retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">&#8220;Committee&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;).</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:11.07pt">&#8220;Covered Person&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means a person who served as an Executive Officer at any time during the performance period for the applicable Incentive-Based Compensation.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">&#8220;Erroneously Awarded Compensation&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means the amount of Incentive-Based Compensation that was Received that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had the amount of Incentive-Based Compensation been determined based on the restated amounts, computed without regard to any taxes paid by the Covered Person or by the Company on the Covered Person&#8217;s behalf. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount of Erroneously Awarded Compensation will be based on a reasonable estimate by the Committee of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received. The Company will maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:11.07pt">&#8220;Executive Officer&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Company&#8217;s officers as defined in Rule 16a-1(f) under the Exchange Act. </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:12.17pt">&#8220;Financial Reporting Measures&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means (A) measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures (whether or not such measures are presented within the Company&#8217;s financial statements or included in a filing made with the U.S. Securities and Exchange Commission), (B) stock price and (C) total shareholder return.  </font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt">&#8220;Incentive-Based Compensation&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Incentive-Based Compensation is deemed to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;Received&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the applicable Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period or is subject to additional time-based vesting requirements.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:12.73pt">&#8220;Recovery Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> means the three completed fiscal years immediately preceding the earlier of&#58; (A) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement&#59; or (B) the date a court, regulator, or other legally authorized body directs the Company to </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">prepare an Accounting Restatement. In addition, if there is a change in the Company&#8217;s fiscal year end, the Recovery Period will also include any transition period to the extent required by Rule 5608.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt;text-decoration:underline">Recovery of Erroneously Awarded Compensation</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subject to the terms of this Policy and the requirements of Rule 5608, if the Company is required to prepare an Accounting Restatement, the Company will attempt to recover, reasonably promptly from each Covered Person, any Erroneously Awarded Compensation that was Received by such Covered Person during the Recovery Period pursuant to Incentive-Based Compensation that is subject to this Policy.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:10.5pt;text-decoration:underline">Interpretation and Administration</font></div><div><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">Role of the Committee. This Policy will be interpreted by the Committee in a manner that is consistent with Rule 5608 and any other applicable law and will otherwise be interpreted in the business judgment of the Committee. All decisions and interpretations of the Committee that are consistent with Rule 5608 will be final and binding. </font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Compensation Not Subject to this Policy. This Policy does not apply to Incentive-Based Compensation that was Received before the Effective Date. With respect to any Covered Person, this Policy does not apply to Incentive-Based Compensation that was Received by such Covered Person before beginning service as an Executive Officer.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">Determination of Means of Recovery. Subject to the requirement that recovery be made reasonably promptly, the Committee will determine the appropriate means of recovery, which may vary between Covered Persons or based on the nature of the applicable Incentive-Based Compensation, and which may involve, without limitation, establishing a deferred repayment plan or setting off against current or future compensation otherwise payable to the Covered Person. Recovery of Erroneously Awarded Compensation will be made without regard to income taxes paid by the Covered Person or by the Company on the Covered Person&#8217;s behalf in connection with such Erroneously Awarded Compensation.</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Determination That Recovery is Impracticable. The Company is not required to recover Erroneously Awarded Compensation if a determination is made by the Committee that either (A) after the Company has made and documented a reasonable attempt to recover such Erroneously Awarded Compensation, the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered or (B) recovery of such Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or 411(a) of the Internal Revenue Code and regulations thereunder.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">No Indemnification or Company-Paid Insurance. The Company will not indemnify any Covered Person against the loss of Erroneously Awarded Compensation and will not pay or reimburse any Covered Person for the purchase of a third-party insurance policy to fund potential recovery obligations.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.17pt">Interaction with Other Clawback Provisions. The Company will be deemed to have recovered Erroneously Awarded Compensation in accordance with this Policy to the extent the Company actually receives such amounts pursuant to any other Company policy, program or agreement, pursuant to Section 304 of the Sarbanes-Oxley Act or otherwise.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">No Limitation on Other Remedies. Nothing in this Policy will be deemed to limit the Company&#8217;s right to terminate employment of any Covered Person, to seek recovery of other compensation paid to a Covered Person, or to pursue other rights or remedies available to the Company under applicable law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Adopted by the Board on November 6, 2023.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>carm-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:343b8f26-08b5-463e-85bb-1b22c4b46cf9,g:eb5f3205-6aed-4489-877d-430d68a8a84b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:carm="http://carismatx.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://carismatx.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="carm-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="carm-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="carm-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="carm-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://carismatx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://carismatx.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://carismatx.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>0000006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofCashFlows" roleURI="http://carismatx.com/role/ConsolidatedStatementofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Background" roleURI="http://carismatx.com/role/Background">
        <link:definition>0000008 - Disclosure - Background</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DevelopmentStageRisksandLiquidity" roleURI="http://carismatx.com/role/DevelopmentStageRisksandLiquidity">
        <link:definition>0000009 - Disclosure - Development-Stage Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerwithSesenBio" roleURI="http://carismatx.com/role/MergerwithSesenBio">
        <link:definition>0000011 - Disclosure - Merger with Sesen Bio</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://carismatx.com/role/PropertyandEquipmentnet">
        <link:definition>0000012 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://carismatx.com/role/AccruedExpenses">
        <link:definition>0000013 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://carismatx.com/role/CommitmentsandContingencies">
        <link:definition>0000014 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://carismatx.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://carismatx.com/role/StockbasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://carismatx.com/role/IncomeTaxes">
        <link:definition>0000017 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://carismatx.com/role/RelatedPartyTransactions">
        <link:definition>0000018 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreement" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreement">
        <link:definition>0000019 - Disclosure - Moderna Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://carismatx.com/role/SubsequentEvents">
        <link:definition>0000020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerwithSesenBioTables" roleURI="http://carismatx.com/role/MergerwithSesenBioTables">
        <link:definition>9954473 - Disclosure - Merger with Sesen Bio (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://carismatx.com/role/PropertyandEquipmentnetTables">
        <link:definition>9954474 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://carismatx.com/role/AccruedExpensesTables">
        <link:definition>9954475 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://carismatx.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954476 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://carismatx.com/role/StockbasedCompensationTables">
        <link:definition>9954477 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://carismatx.com/role/IncomeTaxesTables">
        <link:definition>9954478 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreementTables" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables">
        <link:definition>9954479 - Disclosure - Moderna Collaboration and License Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BackgroundDetails" roleURI="http://carismatx.com/role/BackgroundDetails">
        <link:definition>9954480 - Disclosure - Background (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DevelopmentStageRisksandLiquidityDetails" roleURI="http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails">
        <link:definition>9954481 - Disclosure - Development-Stage Risks and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails">
        <link:definition>9954483 - Disclosure - Summary of Significant Accounting Policies - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails">
        <link:definition>9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails" roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails">
        <link:definition>9954487 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1" roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1">
        <link:definition>9954487 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetDetails" roleURI="http://carismatx.com/role/PropertyandEquipmentnetDetails">
        <link:definition>9954488 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetNarrativeDetails" roleURI="http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails">
        <link:definition>9954489 - Disclosure - Property and Equipment, net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://carismatx.com/role/AccruedExpensesDetails">
        <link:definition>9954490 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativesDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails">
        <link:definition>9954491 - Disclosure - Commitments and Contingencies - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofLeaseCostsDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails">
        <link:definition>9954492 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails">
        <link:definition>9954493 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails">
        <link:definition>9954494 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails" roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9954495 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://carismatx.com/role/StockholdersEquityDetails">
        <link:definition>9954496 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationNarrativesDetails" roleURI="http://carismatx.com/role/StockbasedCompensationNarrativesDetails">
        <link:definition>9954497 - Disclosure - Stock-based Compensation - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockOptionActivityDetails" roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails">
        <link:definition>9954498 - Disclosure - Stock-based Compensation -Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails">
        <link:definition>9954499 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9954500 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9954501 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" roleURI="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails">
        <link:definition>9954502 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativesDetails" roleURI="http://carismatx.com/role/IncomeTaxesNarrativesDetails">
        <link:definition>9954503 - Disclosure - Income Taxes - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreementNarrativesDetails" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails">
        <link:definition>9954504 - Disclosure - Moderna Collaboration and License Agreement - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails">
        <link:definition>9954505 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails" roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails">
        <link:definition>9954506 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="carm_DeferredTaxAssetsEquityCompensation" abstract="false" name="DeferredTaxAssetsEquityCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_Post2017Member" abstract="true" name="Post2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" abstract="false" name="PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AdditionalMilestonePaymentsForFirstCarMProduct" abstract="false" name="AdditionalMilestonePaymentsForFirstCarMProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="carm_Pre2018Member" abstract="true" name="Pre2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_MaximumOfResearchTargets" abstract="false" name="MaximumOfResearchTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" abstract="false" name="AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_VariableConsideration" abstract="false" name="VariableConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_LocalJurisdictionMember" abstract="true" name="LocalJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NoncashOrPartNoncashAcquisitionEquityAssumed" abstract="false" name="NoncashOrPartNoncashAcquisitionEquityAssumed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ModernaLicenseAgreementMember" abstract="true" name="ModernaLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_CarismaTherapeuticsIncLegacyStockholdersMember" abstract="true" name="CarismaTherapeuticsIncLegacyStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets" abstract="false" name="NumberOfResearchTargetsDesignateAsDevelopmentTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_AgreementTerm" abstract="false" name="AgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="carm_ReclassificationsOfTemporaryToPermanentEquityShares" abstract="false" name="ReclassificationsOfTemporaryToPermanentEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" abstract="false" name="CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_CarismaTherapeuticsInc.Member" abstract="true" name="CarismaTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ConvertiblePreferredStockAndExchangeableSharesMember" abstract="true" name="ConvertiblePreferredStockAndExchangeableSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_DeferredFinancingCostsPolicyPolicyTextBlock" abstract="false" name="DeferredFinancingCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="carm_PennLicenseAgreementMember" abstract="true" name="PennLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_FinancingCashUsedInFinanceLeases" abstract="false" name="FinancingCashUsedInFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_SesenBioStockholdersMember" abstract="true" name="SesenBioStockholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_DebtInstrumentConvertibleDiscountFactorPercentage" abstract="false" name="DebtInstrumentConvertibleDiscountFactorPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_LeasesWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeasesWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_DevelopmentStageRisksAndLiquidityAbstract" abstract="true" name="DevelopmentStageRisksAndLiquidityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_FinanceLeaseCostAbstract" abstract="true" name="FinanceLeaseCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_SesenBioIncMember" abstract="true" name="SesenBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ConversionOfConvertiblePromissoryNoteMember" abstract="true" name="ConversionOfConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_ProceedsFromFailedSaleLeasebackTransaction" abstract="false" name="ProceedsFromFailedSaleLeasebackTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_CollateralCreditCardProgramMember" abstract="true" name="CollateralCreditCardProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_AmountPayablePerCalendarYearForReservedCapacity" abstract="false" name="AmountPayablePerCalendarYearForReservedCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" abstract="false" name="ProceedsFromIssuanceOfCommonStockPreClosingFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_RevenueRemainingPerformanceObligationOptionRightsAmount" abstract="false" name="RevenueRemainingPerformanceObligationOptionRightsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" abstract="false" name="ScheduleOfChangesInDeferredRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="carm_LeasesWeightedAverageDiscountRateAbstract" abstract="true" name="LeasesWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_DeferredTaxAssetsStartUpCosts" abstract="false" name="DeferredTaxAssetsStartUpCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NoncashInterestExpense" abstract="false" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DeferredTaxAssetsAmortizableAssetsAndOther" abstract="false" name="DeferredTaxAssetsAmortizableAssetsAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ResearchAndDevelopmentServicesMember" abstract="true" name="ResearchAndDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_CommitmentsAnnualPaymentsRequiredToBePaid" abstract="false" name="CommitmentsAnnualPaymentsRequiredToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_AdditionalMilestonePaymentsRequiredToBePaid" abstract="false" name="AdditionalMilestonePaymentsRequiredToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_SaleOfStockStockOfferingAmount" abstract="false" name="SaleOfStockStockOfferingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" abstract="false" name="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_RenewalTerm" abstract="false" name="RenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" abstract="false" name="PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_TrusteesOfUniversityOfPennsylvaniaMember" abstract="true" name="TrusteesOfUniversityOfPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ContractWithCustomerLiabilityDeferralOfRevenue" abstract="false" name="ContractWithCustomerLiabilityDeferralOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" abstract="false" name="MinimumCommitmentToReimburseResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_DevelopmentStageRisksAndLiquidityTableTextBlock" abstract="false" name="DevelopmentStageRisksAndLiquidityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" abstract="false" name="StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ModernaMember" abstract="true" name="ModernaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_ConvertedIntoSharesCommonStockAtExchangeRatio" abstract="false" name="ConvertedIntoSharesCommonStockAtExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" abstract="false" name="AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="carm_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_NumberOfResearchTargetsDesignated" abstract="false" name="NumberOfResearchTargetsDesignated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" abstract="false" name="StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" abstract="true" name="ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_TwoThousandSeventeenStockIncentivePlanMember" abstract="true" name="TwoThousandSeventeenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_TerminationFeePayable" abstract="false" name="TerminationFeePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" abstract="false" name="BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="carm_TwoThousandFourteenStockIncentivePlanMember" abstract="true" name="TwoThousandFourteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="carm_DerivativeInstrumentConversionTermForRedemptionFeature" abstract="false" name="DerivativeInstrumentConversionTermForRedemptionFeature" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" abstract="false" name="NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_StateJurisdictionMember" abstract="true" name="StateJurisdictionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_NumberOfBoardMembers" abstract="false" name="NumberOfBoardMembers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" abstract="false" name="PeriodOfReimbursementOfResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="carm_ContractTerm" abstract="false" name="ContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="carm_ProceedsFromSaleAndLeasebackTransaction" abstract="false" name="ProceedsFromSaleAndLeasebackTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="carm_AccretionOnMarketableSecurities" abstract="false" name="AccretionOnMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_PaymentsForProceedsFromMarketableSecurities" abstract="false" name="PaymentsForProceedsFromMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NonCashDeferredFinancingCostsAccruedExpenses" abstract="false" name="NonCashDeferredFinancingCostsAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_UpfrontNonRefundablePaymentReceived" abstract="false" name="UpfrontNonRefundablePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" abstract="false" name="RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_OwnershipInterestInReportingEntity" abstract="false" name="OwnershipInterestInReportingEntity" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="carm_DebtInstrumentConvertibleQualifiedFinancingProbability" abstract="false" name="DebtInstrumentConvertibleQualifiedFinancingProbability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" abstract="false" name="Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="carm_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_NumberOfProductsDevelopedAndCommercialized" abstract="false" name="NumberOfProductsDevelopedAndCommercialized" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>carm-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:343b8f26-08b5-463e-85bb-1b22c4b46cf9,g:eb5f3205-6aed-4489-877d-430d68a8a84b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_47496b0b-7998-4927-8e1f-968961ecd438" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ad478b06-83f7-4f02-8972-75ca25c0a9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_47496b0b-7998-4927-8e1f-968961ecd438" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ad478b06-83f7-4f02-8972-75ca25c0a9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8c6d2cfc-65ba-4645-9a27-d65de3c68241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_47496b0b-7998-4927-8e1f-968961ecd438" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8c6d2cfc-65ba-4645-9a27-d65de3c68241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4394b609-84ce-4d55-98c6-57e263d71fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_47496b0b-7998-4927-8e1f-968961ecd438" xlink:to="loc_us-gaap_CommonStockValue_4394b609-84ce-4d55-98c6-57e263d71fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_328193d5-fe19-4bd8-9928-1abf7d82198f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_47496b0b-7998-4927-8e1f-968961ecd438" xlink:to="loc_us-gaap_PreferredStockValue_328193d5-fe19-4bd8-9928-1abf7d82198f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_aa0f6275-3703-4494-a869-cc07f6d4a2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_47496b0b-7998-4927-8e1f-968961ecd438" xlink:to="loc_us-gaap_AdditionalPaidInCapital_aa0f6275-3703-4494-a869-cc07f6d4a2cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c257758-d08c-44f3-b2af-3407410fde99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_be23618a-5c5f-42d8-89c4-50b22eee6796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c257758-d08c-44f3-b2af-3407410fde99" xlink:to="loc_us-gaap_Liabilities_be23618a-5c5f-42d8-89c4-50b22eee6796" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccea4611-1ef4-4f90-95e0-a858952513e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c257758-d08c-44f3-b2af-3407410fde99" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ccea4611-1ef4-4f90-95e0-a858952513e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2e686390-c3a9-4edf-947c-458263731275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c257758-d08c-44f3-b2af-3407410fde99" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_2e686390-c3a9-4edf-947c-458263731275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_76eae9c9-cf2d-4287-9689-89f43b7998f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5c257758-d08c-44f3-b2af-3407410fde99" xlink:to="loc_us-gaap_CommitmentsAndContingencies_76eae9c9-cf2d-4287-9689-89f43b7998f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_00a71584-09a8-487b-87e3-30d06a4482ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_93e53a45-c6e8-4f3f-87e8-bf8ea246cd26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00a71584-09a8-487b-87e3-30d06a4482ce" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_93e53a45-c6e8-4f3f-87e8-bf8ea246cd26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_75d490e9-5dca-4e15-a3b1-0acf134be129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00a71584-09a8-487b-87e3-30d06a4482ce" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_75d490e9-5dca-4e15-a3b1-0acf134be129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_298a1cea-0fe9-4ebb-a425-e24a71bb8acd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00a71584-09a8-487b-87e3-30d06a4482ce" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_298a1cea-0fe9-4ebb-a425-e24a71bb8acd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_ee8b64b6-cc89-409f-8eb9-85ccb0e5c642" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00a71584-09a8-487b-87e3-30d06a4482ce" xlink:to="loc_us-gaap_DeferredRevenueCurrent_ee8b64b6-cc89-409f-8eb9-85ccb0e5c642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4ae63f2f-8abf-4b48-a58a-3eeff97b7428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00a71584-09a8-487b-87e3-30d06a4482ce" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4ae63f2f-8abf-4b48-a58a-3eeff97b7428" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_68828e88-bb4a-4928-961f-03ddae535fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_00a71584-09a8-487b-87e3-30d06a4482ce" xlink:to="loc_us-gaap_AccountsPayableCurrent_68828e88-bb4a-4928-961f-03ddae535fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f2173003-bf5c-4b6c-9863-211c61cadc49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd20428b-8024-4ce9-b367-41e3d3705049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f2173003-bf5c-4b6c-9863-211c61cadc49" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd20428b-8024-4ce9-b367-41e3d3705049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1f7f8151-b048-4d37-82f9-7ced4a316119" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f2173003-bf5c-4b6c-9863-211c61cadc49" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1f7f8151-b048-4d37-82f9-7ced4a316119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16cd6cdb-802e-48b4-9541-f36eef530c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f2173003-bf5c-4b6c-9863-211c61cadc49" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_16cd6cdb-802e-48b4-9541-f36eef530c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f8d1d31-e2fd-417d-b625-8145618732d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b78b0e8d-7dd8-4256-a08e-945e74d310ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f8d1d31-e2fd-417d-b625-8145618732d2" xlink:to="loc_us-gaap_MinorityInterest_b78b0e8d-7dd8-4256-a08e-945e74d310ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5ecdbc3-ec4e-424e-88e5-d511743268ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f8d1d31-e2fd-417d-b625-8145618732d2" xlink:to="loc_us-gaap_StockholdersEquity_d5ecdbc3-ec4e-424e-88e5-d511743268ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_60d64451-e1b3-4e77-830d-02fcb9da9993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f41cbe80-51c9-4801-9f11-0b0f5156491b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_60d64451-e1b3-4e77-830d-02fcb9da9993" xlink:to="loc_us-gaap_AssetsCurrent_f41cbe80-51c9-4801-9f11-0b0f5156491b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8bc2248a-dafb-4ab8-a423-54e1c342fc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_60d64451-e1b3-4e77-830d-02fcb9da9993" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8bc2248a-dafb-4ab8-a423-54e1c342fc89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf48e3f1-1032-499f-aebb-677f6ce80229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_60d64451-e1b3-4e77-830d-02fcb9da9993" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf48e3f1-1032-499f-aebb-677f6ce80229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_3a449b69-3be2-4906-9469-ba288365b81f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_60d64451-e1b3-4e77-830d-02fcb9da9993" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_3a449b69-3be2-4906-9469-ba288365b81f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_40dfebe7-4074-4b2d-9ace-7d0f3a48c5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_424fae82-29fe-4653-8f56-f68333d42c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40dfebe7-4074-4b2d-9ace-7d0f3a48c5d9" xlink:to="loc_us-gaap_LiabilitiesCurrent_424fae82-29fe-4653-8f56-f68333d42c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_35d94a4d-46b8-49f6-b935-527af73b35c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40dfebe7-4074-4b2d-9ace-7d0f3a48c5d9" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_35d94a4d-46b8-49f6-b935-527af73b35c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_6b54d71a-322f-4544-ad4c-fe40b1cef526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40dfebe7-4074-4b2d-9ace-7d0f3a48c5d9" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_6b54d71a-322f-4544-ad4c-fe40b1cef526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5bd8d819-0cdb-4331-abb7-da703b5586fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40dfebe7-4074-4b2d-9ace-7d0f3a48c5d9" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5bd8d819-0cdb-4331-abb7-da703b5586fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51745ad5-192d-4823-81f0-fbff27d2ab82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40dfebe7-4074-4b2d-9ace-7d0f3a48c5d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_51745ad5-192d-4823-81f0-fbff27d2ab82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a026cdd3-19c4-4121-acca-2a4ece1b0849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40dfebe7-4074-4b2d-9ace-7d0f3a48c5d9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a026cdd3-19c4-4121-acca-2a4ece1b0849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_232ed2a6-edda-4e5b-827c-06daec0e0359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_40dfebe7-4074-4b2d-9ace-7d0f3a48c5d9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_232ed2a6-edda-4e5b-827c-06daec0e0359" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f0acc08-9eec-4c3f-9d95-03ce128e8c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a08e16c0-fba3-4444-b456-3f98ce55250a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f0acc08-9eec-4c3f-9d95-03ce128e8c14" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a08e16c0-fba3-4444-b456-3f98ce55250a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0900a255-f26c-4014-9752-ef70be444d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f0acc08-9eec-4c3f-9d95-03ce128e8c14" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0900a255-f26c-4014-9752-ef70be444d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b760fbd-f2fb-4db1-976f-f2e18db8bee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0f0acc08-9eec-4c3f-9d95-03ce128e8c14" xlink:to="loc_us-gaap_NetIncomeLoss_0b760fbd-f2fb-4db1-976f-f2e18db8bee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d4b938bf-4c59-44a8-9dbb-615d2c1371eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_37b22680-5d79-46bc-8a92-40b8ed0b4326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d4b938bf-4c59-44a8-9dbb-615d2c1371eb" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_37b22680-5d79-46bc-8a92-40b8ed0b4326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_6c79f06a-793a-436c-9cd8-d00deb1ceb50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d4b938bf-4c59-44a8-9dbb-615d2c1371eb" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_6c79f06a-793a-436c-9cd8-d00deb1ceb50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4e74b337-daea-420f-a564-3279753dc581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d4b938bf-4c59-44a8-9dbb-615d2c1371eb" xlink:to="loc_us-gaap_OperatingIncomeLoss_4e74b337-daea-420f-a564-3279753dc581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f24cb9bd-32bd-4834-a8de-7f04e33f8b10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b1892bd3-7c54-477b-8ae8-724e577f6b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f24cb9bd-32bd-4834-a8de-7f04e33f8b10" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b1892bd3-7c54-477b-8ae8-724e577f6b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7b0fcc29-8e7d-49cf-b720-77b873e79e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f24cb9bd-32bd-4834-a8de-7f04e33f8b10" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7b0fcc29-8e7d-49cf-b720-77b873e79e87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6bf69432-8861-4306-937c-fe61648cb25e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0a4c50f9-2368-4bda-bc4c-c1907ff670b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6bf69432-8861-4306-937c-fe61648cb25e" xlink:to="loc_us-gaap_OperatingExpenses_0a4c50f9-2368-4bda-bc4c-c1907ff670b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_d2b95c66-5c18-46d5-9b79-f111af3efd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6bf69432-8861-4306-937c-fe61648cb25e" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_d2b95c66-5c18-46d5-9b79-f111af3efd6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59aa9586-70f0-460b-8cec-365b142c2d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_424701db-b5fd-4ff8-810d-a0f329819fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59aa9586-70f0-460b-8cec-365b142c2d2b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_424701db-b5fd-4ff8-810d-a0f329819fa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentsForProceedsFromMarketableSecurities_f6a2526a-535e-40d1-a969-dd8be3b2b966" xlink:href="carm-20231231.xsd#carm_PaymentsForProceedsFromMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59aa9586-70f0-460b-8cec-365b142c2d2b" xlink:to="loc_carm_PaymentsForProceedsFromMarketableSecurities_f6a2526a-535e-40d1-a969-dd8be3b2b966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_075bf6f4-1ce0-4c86-84ab-b182e7e3ecc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_59aa9586-70f0-460b-8cec-365b142c2d2b" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_075bf6f4-1ce0-4c86-84ab-b182e7e3ecc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f4ce37fd-9255-4188-999d-2d19ffd5d008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a9619fb-5527-4221-8f93-1066df77a00a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f4ce37fd-9255-4188-999d-2d19ffd5d008" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9a9619fb-5527-4221-8f93-1066df77a00a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6a0b1e5e-f69f-4058-9609-0159865bfa82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f4ce37fd-9255-4188-999d-2d19ffd5d008" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6a0b1e5e-f69f-4058-9609-0159865bfa82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_226a7ed0-6a8b-4acd-9b3c-8bbebec9723d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f4ce37fd-9255-4188-999d-2d19ffd5d008" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_226a7ed0-6a8b-4acd-9b3c-8bbebec9723d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_03660f17-d4b9-48f9-952e-e829affe7f16" xlink:href="carm-20231231.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_03660f17-d4b9-48f9-952e-e829affe7f16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_661f8ead-88a9-4a2b-b89f-8411fe1d44d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_661f8ead-88a9-4a2b-b89f-8411fe1d44d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1ad58418-7af1-4704-9c5d-42b9054fa48d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1ad58418-7af1-4704-9c5d-42b9054fa48d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_882ebc8b-60e5-42c2-a3c8-0345a13d614d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_882ebc8b-60e5-42c2-a3c8-0345a13d614d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_252649f9-b0b0-4a0d-bff5-17764db4826f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_252649f9-b0b0-4a0d-bff5-17764db4826f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_c21920f0-c241-4a1c-af0a-a64d9242f61d" xlink:href="carm-20231231.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_c21920f0-c241-4a1c-af0a-a64d9242f61d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8036d783-27c9-4f95-b9e3-45af3c42431e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8036d783-27c9-4f95-b9e3-45af3c42431e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromFailedSaleLeasebackTransaction_e5281417-e0c6-419b-98ab-a1d4024e0ae3" xlink:href="carm-20231231.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_carm_ProceedsFromFailedSaleLeasebackTransaction_e5281417-e0c6-419b-98ab-a1d4024e0ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_4d6e07cd-818a-4d1b-8ce7-cc29d2b97193" xlink:href="carm-20231231.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_4d6e07cd-818a-4d1b-8ce7-cc29d2b97193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_7db53656-53c5-4e85-8845-1f6e09cb3f21" xlink:href="carm-20231231.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07a87e7-fcf8-49b7-8b26-c1fd8f705ea2" xlink:to="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_7db53656-53c5-4e85-8845-1f6e09cb3f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_106e5886-85b1-40d0-9700-c8f161f1bec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_ProfitLoss_106e5886-85b1-40d0-9700-c8f161f1bec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f12f36a9-8381-4a49-8374-9f8e2430229b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f12f36a9-8381-4a49-8374-9f8e2430229b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashInterestExpense_3ebaf156-99d8-4408-b00f-dcf64e6fed27" xlink:href="carm-20231231.xsd#carm_NoncashInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_carm_NoncashInterestExpense_3ebaf156-99d8-4408-b00f-dcf64e6fed27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_01a0dc6e-acf5-47e2-8d9c-52bd01a598ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_01a0dc6e-acf5-47e2-8d9c-52bd01a598ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6bf7b157-e975-4731-b6f6-175b905fa2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6bf7b157-e975-4731-b6f6-175b905fa2c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_f4e34f4e-fac1-45d7-a18f-0cedd6a6624b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_f4e34f4e-fac1-45d7-a18f-0cedd6a6624b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_49f35953-f35b-4251-8838-365f9ed4ac62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_DepreciationAndAmortization_49f35953-f35b-4251-8838-365f9ed4ac62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_28b61b49-a25d-49fe-85f6-a5bf129cb557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_28b61b49-a25d-49fe-85f6-a5bf129cb557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_e224abe9-c8a8-4f9d-9823-e2f403e0aacc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_e224abe9-c8a8-4f9d-9823-e2f403e0aacc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_57d6c65c-d0b5-42be-8c6c-aa34ac5c064f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_57d6c65c-d0b5-42be-8c6c-aa34ac5c064f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a0c34777-e9e6-496c-8dcd-e7c29bc9a317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a0c34777-e9e6-496c-8dcd-e7c29bc9a317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_f22ea8af-cf6b-45d0-8bcd-e3872c9b85a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_f22ea8af-cf6b-45d0-8bcd-e3872c9b85a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a2a65e97-6a0a-4c30-b07b-a3a606bf6af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a2a65e97-6a0a-4c30-b07b-a3a606bf6af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_aba1e578-231a-4aa4-9c50-891347461ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_aba1e578-231a-4aa4-9c50-891347461ab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aabf7828-6c0b-41bc-b66d-52842ccf2c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_us-gaap_ShareBasedCompensation_aabf7828-6c0b-41bc-b66d-52842ccf2c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccretionOnMarketableSecurities_99784449-d2a7-4bb9-b4cd-ba1eb3b599ca" xlink:href="carm-20231231.xsd#carm_AccretionOnMarketableSecurities"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb910e32-315f-4fab-88c2-159f1a88afe4" xlink:to="loc_carm_AccretionOnMarketableSecurities_99784449-d2a7-4bb9-b4cd-ba1eb3b599ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_45cc27aa-3c3d-4b3d-9b23-c6724b5e7fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2becbfda-2bcb-41fe-8e80-551ee747233c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_45cc27aa-3c3d-4b3d-9b23-c6724b5e7fcc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2becbfda-2bcb-41fe-8e80-551ee747233c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6d0d7995-f60c-4884-a954-983e47a5088b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_45cc27aa-3c3d-4b3d-9b23-c6724b5e7fcc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6d0d7995-f60c-4884-a954-983e47a5088b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_109d9d5c-d9c7-4056-8d1a-68daf8668280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_d88856c5-e79e-4f00-8b55-e6a3975e765b" xlink:href="carm-20231231.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_109d9d5c-d9c7-4056-8d1a-68daf8668280" xlink:to="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_d88856c5-e79e-4f00-8b55-e6a3975e765b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_727f13b1-5055-439a-b2e3-7b787f62f30c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_109d9d5c-d9c7-4056-8d1a-68daf8668280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_727f13b1-5055-439a-b2e3-7b787f62f30c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f366cc7-4de6-44e7-b274-5d726c3cdc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_109d9d5c-d9c7-4056-8d1a-68daf8668280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f366cc7-4de6-44e7-b274-5d726c3cdc9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_ff36e05b-5186-439f-96b7-a36caa09497e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_109d9d5c-d9c7-4056-8d1a-68daf8668280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_ff36e05b-5186-439f-96b7-a36caa09497e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_44b0bb96-9e9e-466d-8561-58ee436dc5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_109d9d5c-d9c7-4056-8d1a-68daf8668280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_44b0bb96-9e9e-466d-8561-58ee436dc5ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1" xlink:type="simple" xlink:href="carm-20231231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9119fba4-865a-4ca2-93f0-b30b2e08d33a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_19f32ae2-fa6b-4758-b207-c6302148949d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9119fba4-865a-4ca2-93f0-b30b2e08d33a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_19f32ae2-fa6b-4758-b207-c6302148949d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_bff63df0-d7c8-4cef-9325-ea5f146267f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9119fba4-865a-4ca2-93f0-b30b2e08d33a" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_bff63df0-d7c8-4cef-9325-ea5f146267f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#PropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8088299b-8c40-4bb6-b364-a1eb32030efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_1b661381-cc72-4c9f-b412-12f9a55a53bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8088299b-8c40-4bb6-b364-a1eb32030efe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_1b661381-cc72-4c9f-b412-12f9a55a53bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_855f43a4-e5e8-416a-bdfc-c9946c9f6e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8088299b-8c40-4bb6-b364-a1eb32030efe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_855f43a4-e5e8-416a-bdfc-c9946c9f6e8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bb4dbaab-2b0d-4f18-9d77-03ca02f6a319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_663098cb-f3f3-413d-8b69-fd85be440ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bb4dbaab-2b0d-4f18-9d77-03ca02f6a319" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_663098cb-f3f3-413d-8b69-fd85be440ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d359fc52-5150-45cc-9191-9d01635496f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bb4dbaab-2b0d-4f18-9d77-03ca02f6a319" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d359fc52-5150-45cc-9191-9d01635496f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_0375fa71-0783-4ae1-b827-eb0b8a557087" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bb4dbaab-2b0d-4f18-9d77-03ca02f6a319" xlink:to="loc_us-gaap_InterestPayableCurrent_0375fa71-0783-4ae1-b827-eb0b8a557087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent_100bfb36-b663-453a-a89f-917ba6c8470f" xlink:href="carm-20231231.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bb4dbaab-2b0d-4f18-9d77-03ca02f6a319" xlink:to="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent_100bfb36-b663-453a-a89f-917ba6c8470f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5928ccbf-982d-4522-a6fd-3f169c825310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bb4dbaab-2b0d-4f18-9d77-03ca02f6a319" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5928ccbf-982d-4522-a6fd-3f169c825310" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingenciesScheduleofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCost_4b607039-cc4c-48f4-b2de-151ff37b6ab4" xlink:href="carm-20231231.xsd#carm_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_634a217f-bd77-45f5-bfd1-b68ccbe69f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_carm_FinanceLeaseCost_4b607039-cc4c-48f4-b2de-151ff37b6ab4" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_634a217f-bd77-45f5-bfd1-b68ccbe69f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_aa3fd929-cc6c-4209-9b87-e85aa6c28b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_carm_FinanceLeaseCost_4b607039-cc4c-48f4-b2de-151ff37b6ab4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_aa3fd929-cc6c-4209-9b87-e85aa6c28b3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_bc8b15e3-2b5b-49b4-bbba-c8d6cc1fad73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCost_c0dce45a-12cf-4e58-b4c5-4619c42f006d" xlink:href="carm-20231231.xsd#carm_FinanceLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bc8b15e3-2b5b-49b4-bbba-c8d6cc1fad73" xlink:to="loc_carm_FinanceLeaseCost_c0dce45a-12cf-4e58-b4c5-4619c42f006d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_aec4785e-2be2-48c3-8cc9-31c0deb33cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bc8b15e3-2b5b-49b4-bbba-c8d6cc1fad73" xlink:to="loc_us-gaap_OperatingLeaseCost_aec4785e-2be2-48c3-8cc9-31c0deb33cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_89e28e1e-8e44-4b4e-b96e-e1cc01f7e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bc8b15e3-2b5b-49b4-bbba-c8d6cc1fad73" xlink:to="loc_us-gaap_VariableLeaseCost_89e28e1e-8e44-4b4e-b96e-e1cc01f7e5c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f150409-3785-4170-b054-56cd576b0ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cde4d888-1ecf-4185-8625-a7ad966b4ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f150409-3785-4170-b054-56cd576b0ac3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cde4d888-1ecf-4185-8625-a7ad966b4ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4fdd5a0e-522c-45a3-b222-28a839a0c40d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f150409-3785-4170-b054-56cd576b0ac3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4fdd5a0e-522c-45a3-b222-28a839a0c40d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_0c41049e-d241-4138-b3a5-9c216df9068c" xlink:href="carm-20231231.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f150409-3785-4170-b054-56cd576b0ac3" xlink:to="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_0c41049e-d241-4138-b3a5-9c216df9068c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_60a6c7e0-3e74-4d1a-b749-9c001b0912aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f150409-3785-4170-b054-56cd576b0ac3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_60a6c7e0-3e74-4d1a-b749-9c001b0912aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_cd8a0a83-d85e-409c-aba7-e2b4ea22d047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f150409-3785-4170-b054-56cd576b0ac3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_cd8a0a83-d85e-409c-aba7-e2b4ea22d047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_0b51bc6e-0d89-4e81-8cb2-f5d55dbec42f" xlink:href="carm-20231231.xsd#carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f150409-3785-4170-b054-56cd576b0ac3" xlink:to="loc_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_0b51bc6e-0d89-4e81-8cb2-f5d55dbec42f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_250e9239-746a-4d5d-afce-0cb247d56535" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1f150409-3785-4170-b054-56cd576b0ac3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_250e9239-746a-4d5d-afce-0cb247d56535" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_16c0b982-3016-47eb-8abd-d0981a8479fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_53add541-cca8-4498-9eb7-c3b827b40efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_16c0b982-3016-47eb-8abd-d0981a8479fd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_53add541-cca8-4498-9eb7-c3b827b40efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ee263c08-de4e-4ebb-ba4f-af03ada3a938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_16c0b982-3016-47eb-8abd-d0981a8479fd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ee263c08-de4e-4ebb-ba4f-af03ada3a938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ccff63c3-ae4e-401c-bdc5-0b9a784931c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6614082c-18e1-4520-a038-fc11445fbb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ccff63c3-ae4e-401c-bdc5-0b9a784931c7" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6614082c-18e1-4520-a038-fc11445fbb4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset_3602c798-b280-4b4d-84c9-7e1e29c58382" xlink:href="carm-20231231.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ccff63c3-ae4e-401c-bdc5-0b9a784931c7" xlink:to="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset_3602c798-b280-4b4d-84c9-7e1e29c58382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5707175a-e53f-4235-8257-9b61d0331e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_262232e2-02eb-454d-bb3f-2db2c5f3a270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5707175a-e53f-4235-8257-9b61d0331e9e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_262232e2-02eb-454d-bb3f-2db2c5f3a270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7e1967dc-e0f4-49ac-9139-c72217619807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_5707175a-e53f-4235-8257-9b61d0331e9e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7e1967dc-e0f4-49ac-9139-c72217619807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsLeaseLiability_6f3f0e87-0c74-4256-baac-5309bdb1bfec" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:to="loc_carm_DeferredTaxAssetsLeaseLiability_6f3f0e87-0c74-4256-baac-5309bdb1bfec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3176d466-e177-4431-b7e6-cdf1b8f17b24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3176d466-e177-4431-b7e6-cdf1b8f17b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_603bf7e1-43f0-466c-a0f0-a90e74445eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_603bf7e1-43f0-466c-a0f0-a90e74445eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d251830f-eec4-48da-baa4-18faace5e8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d251830f-eec4-48da-baa4-18faace5e8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_93c859d2-9661-450e-ab8a-b707f92df55b" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:to="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_93c859d2-9661-450e-ab8a-b707f92df55b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsStartUpCosts_7fc936b6-e0ca-47d3-bcd8-3a28b90eac54" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsStartUpCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:to="loc_carm_DeferredTaxAssetsStartUpCosts_7fc936b6-e0ca-47d3-bcd8-3a28b90eac54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsEquityCompensation_1124afaa-0ced-4447-82c1-b689584005bf" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsEquityCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:to="loc_carm_DeferredTaxAssetsEquityCompensation_1124afaa-0ced-4447-82c1-b689584005bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther_3824b97f-8a5f-4480-aa35-acc7ff4f32ca" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_94e5af9a-3e71-4067-b3c7-00a41f4e99ee" xlink:to="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther_3824b97f-8a5f-4480-aa35-acc7ff4f32ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"/>
  <link:calculationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f9e03af6-6ef1-46b8-a01d-a48eef11a261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_14d1786f-9f3f-4ebf-bedb-f3035e18f78a" xlink:href="carm-20231231.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_f9e03af6-6ef1-46b8-a01d-a48eef11a261" xlink:to="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_14d1786f-9f3f-4ebf-bedb-f3035e18f78a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_5521cf4f-db51-4e46-badc-f5a1c1fe1b17" xlink:href="carm-20231231.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_f9e03af6-6ef1-46b8-a01d-a48eef11a261" xlink:to="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_5521cf4f-db51-4e46-badc-f5a1c1fe1b17" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>carm-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:343b8f26-08b5-463e-85bb-1b22c4b46cf9,g:eb5f3205-6aed-4489-877d-430d68a8a84b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8c7c1a5e-21c6-4d11-9c11-f72c648f53b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e1f45f70-5c05-452b-9d0a-ee07d1587aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8c7c1a5e-21c6-4d11-9c11-f72c648f53b7" xlink:to="loc_us-gaap_StatementTable_e1f45f70-5c05-452b-9d0a-ee07d1587aef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_caa57308-382d-49ce-8115-14fc738eed84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e1f45f70-5c05-452b-9d0a-ee07d1587aef" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_caa57308-382d-49ce-8115-14fc738eed84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_caa57308-382d-49ce-8115-14fc738eed84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_caa57308-382d-49ce-8115-14fc738eed84" xlink:to="loc_us-gaap_EquityComponentDomain_caa57308-382d-49ce-8115-14fc738eed84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_caa57308-382d-49ce-8115-14fc738eed84" xlink:to="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e10ed4a4-0ccc-443b-a670-21a7e08251cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_CommonStockMember_e10ed4a4-0ccc-443b-a670-21a7e08251cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b6d9c87e-189f-4ec3-8ff6-3e8528fed4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b6d9c87e-189f-4ec3-8ff6-3e8528fed4eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4730d72f-50cb-4eb8-8cf0-59f1d5cbec1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4730d72f-50cb-4eb8-8cf0-59f1d5cbec1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f54c1563-934a-434c-997a-ee18d904da72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_RetainedEarningsMember_f54c1563-934a-434c-997a-ee18d904da72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b723f0b0-20ed-4609-962a-b8390f856fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b723f0b0-20ed-4609-962a-b8390f856fd8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8c7c1a5e-21c6-4d11-9c11-f72c648f53b7" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_00be95e3-9b24-4259-be6a-5b265c19919c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_00be95e3-9b24-4259-be6a-5b265c19919c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_b30bdd5a-89d0-4906-bf8e-4c84ee7266cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_b30bdd5a-89d0-4906-bf8e-4c84ee7266cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares_3ac192cc-cd83-4e48-a3b0-0942b4a82743" xlink:href="carm-20231231.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares_3ac192cc-cd83-4e48-a3b0-0942b4a82743" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_46022314-cb44-4812-97f6-d8720e325d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_46022314-cb44-4812-97f6-d8720e325d67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_40888aee-fa73-4e55-ad2c-29dca172d759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_c01da847-111d-45b2-8902-ce174caf9df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8c7c1a5e-21c6-4d11-9c11-f72c648f53b7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_55b8b66d-6652-4f9a-96c4-ed0fad80266d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_SharesIssued_55b8b66d-6652-4f9a-96c4-ed0fad80266d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ca14ca8-5d76-4b92-9081-833d7ad6283c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ca14ca8-5d76-4b92-9081-833d7ad6283c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0cb04dfe-f752-412b-a36b-0e416a190c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0cb04dfe-f752-412b-a36b-0e416a190c44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b7f62b2a-2a1c-4c91-9646-e4a9dbca65ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b7f62b2a-2a1c-4c91-9646-e4a9dbca65ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a13fcd19-f63f-43c3-9ef9-7ce07dc5fab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a13fcd19-f63f-43c3-9ef9-7ce07dc5fab3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d9f3e126-cbb4-488b-b7dc-019e6797813b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d9f3e126-cbb4-488b-b7dc-019e6797813b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_3784d862-5b5e-4180-912f-211027bfc6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_3784d862-5b5e-4180-912f-211027bfc6cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_837aa6d4-c621-42f4-962b-c39040037e18" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_837aa6d4-c621-42f4-962b-c39040037e18" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_f60c4f90-6625-4cd6-8591-082c4799c373" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_f60c4f90-6625-4cd6-8591-082c4799c373" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_da0f8338-6d02-4795-9f5d-ad523219ff25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_da0f8338-6d02-4795-9f5d-ad523219ff25" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c5c5725d-1dec-4a59-a671-bb40cd1a95f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c5c5725d-1dec-4a59-a671-bb40cd1a95f8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e4a1d09a-5108-4b29-ade1-a0677a9f7df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e4a1d09a-5108-4b29-ade1-a0677a9f7df5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fceac2b7-aaee-4df8-8f38-eea84b33997c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fceac2b7-aaee-4df8-8f38-eea84b33997c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_bfaef723-cb4a-4593-81b8-5215528c0c1b" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_bfaef723-cb4a-4593-81b8-5215528c0c1b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_b204b826-ad59-4127-b96f-ad6443a51f8d" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_b204b826-ad59-4127-b96f-ad6443a51f8d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_650064c2-5f40-4c6b-b4ad-a584a9e3e0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_650064c2-5f40-4c6b-b4ad-a584a9e3e0bb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_661325ff-fc64-4e02-8a19-df2d83534ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_661325ff-fc64-4e02-8a19-df2d83534ac7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a8d2085d-9326-4298-9071-2bb63f2a4531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_ProfitLoss_a8d2085d-9326-4298-9071-2bb63f2a4531" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_22a52bee-fac1-4005-97ad-811b81f4c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_440926a4-4e3a-40a6-aea4-98d058af7985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/BackgroundDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#BackgroundDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/BackgroundDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:to="loc_dei_LegalEntityAxis_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af" xlink:to="loc_dei_EntityDomain_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_99f3e308-c1da-43c1-bc79-360a329f3816" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af" xlink:to="loc_dei_EntityDomain_99f3e308-c1da-43c1-bc79-360a329f3816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_2a76d164-0e94-42d4-8022-18a9380a070f" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_99f3e308-c1da-43c1-bc79-360a329f3816" xlink:to="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_2a76d164-0e94-42d4-8022-18a9380a070f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioStockholdersMember_ab3949a5-e5c3-4dd4-b333-31171d6343c6" xlink:href="carm-20231231.xsd#carm_SesenBioStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_99f3e308-c1da-43c1-bc79-360a329f3816" xlink:to="loc_carm_SesenBioStockholdersMember_ab3949a5-e5c3-4dd4-b333-31171d6343c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_27de8ba8-607c-444e-9205-ab86326ff187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_27de8ba8-607c-444e-9205-ab86326ff187" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27de8ba8-607c-444e-9205-ab86326ff187_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27de8ba8-607c-444e-9205-ab86326ff187" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27de8ba8-607c-444e-9205-ab86326ff187_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c966d1b-24fc-425d-9d8b-4abd34510d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27de8ba8-607c-444e-9205-ab86326ff187" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c966d1b-24fc-425d-9d8b-4abd34510d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember_497c25b2-c274-4678-a400-e829a273895a" xlink:href="carm-20231231.xsd#carm_SesenBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c966d1b-24fc-425d-9d8b-4abd34510d96" xlink:to="loc_carm_SesenBioIncMember_497c25b2-c274-4678-a400-e829a273895a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_dcd22394-4d55-4045-b4c4-65195b6f989b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:to="loc_srt_OwnershipAxis_dcd22394-4d55-4045-b4c4-65195b6f989b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_dcd22394-4d55-4045-b4c4-65195b6f989b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_dcd22394-4d55-4045-b4c4-65195b6f989b" xlink:to="loc_srt_OwnershipDomain_dcd22394-4d55-4045-b4c4-65195b6f989b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_72cb544a-4fdf-43ff-badd-10431276013e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_dcd22394-4d55-4045-b4c4-65195b6f989b" xlink:to="loc_srt_OwnershipDomain_72cb544a-4fdf-43ff-badd-10431276013e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsInc.Member_c5a71af4-0fd3-4dff-94ae-41afdb24ad41" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_72cb544a-4fdf-43ff-badd-10431276013e" xlink:to="loc_carm_CarismaTherapeuticsInc.Member_c5a71af4-0fd3-4dff-94ae-41afdb24ad41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConvertedIntoSharesCommonStockAtExchangeRatio_1c60f761-a5e3-4fa4-9edd-64caad302d56" xlink:href="carm-20231231.xsd#carm_ConvertedIntoSharesCommonStockAtExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:to="loc_carm_ConvertedIntoSharesCommonStockAtExchangeRatio_1c60f761-a5e3-4fa4-9edd-64caad302d56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare_144e845b-1756-41b3-bbc1-b26519f27331" xlink:href="carm-20231231.xsd#carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:to="loc_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare_144e845b-1756-41b3-bbc1-b26519f27331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_OwnershipInterestInReportingEntity_c1128342-165d-4e2c-bbfe-77ec9018017c" xlink:href="carm-20231231.xsd#carm_OwnershipInterestInReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:to="loc_carm_OwnershipInterestInReportingEntity_c1128342-165d-4e2c-bbfe-77ec9018017c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a342c1b8-f200-4ce6-a6d6-7d8d38660a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a342c1b8-f200-4ce6-a6d6-7d8d38660a6c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_adcef9bb-b9c7-419e-a62a-c78cae07b37a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_adcef9bb-b9c7-419e-a62a-c78cae07b37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_adcef9bb-b9c7-419e-a62a-c78cae07b37a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_adcef9bb-b9c7-419e-a62a-c78cae07b37a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_adcef9bb-b9c7-419e-a62a-c78cae07b37a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a770675e-6eed-4ab8-ba29-58c76848ed6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_adcef9bb-b9c7-419e-a62a-c78cae07b37a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a770675e-6eed-4ab8-ba29-58c76848ed6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6dbefa45-bdf8-4dc9-aa18-7fb496398efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a770675e-6eed-4ab8-ba29-58c76848ed6e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6dbefa45-bdf8-4dc9-aa18-7fb496398efa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a1c519d-d555-4c60-a7d9-87bd1d019cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a1c519d-d555-4c60-a7d9-87bd1d019cd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a1c519d-d555-4c60-a7d9-87bd1d019cd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a1c519d-d555-4c60-a7d9-87bd1d019cd8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a1c519d-d555-4c60-a7d9-87bd1d019cd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a1c519d-d555-4c60-a7d9-87bd1d019cd8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_759a087b-5e0c-469f-ace5-2d32e2cd07ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_759a087b-5e0c-469f-ace5-2d32e2cd07ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_19aaf6f6-1830-43e2-a7dd-d769210ae5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_19aaf6f6-1830-43e2-a7dd-d769210ae5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_858a7e53-2bae-45f6-8a66-5f9949c8d3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_858a7e53-2bae-45f6-8a66-5f9949c8d3c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_783106b2-759c-44ed-9569-1026cde302df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a342c1b8-f200-4ce6-a6d6-7d8d38660a6c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_783106b2-759c-44ed-9569-1026cde302df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1936f964-ce78-4754-bc30-4498063859a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_783106b2-759c-44ed-9569-1026cde302df" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1936f964-ce78-4754-bc30-4498063859a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e971f083-6c26-4d41-accf-d0da020af22b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_783106b2-759c-44ed-9569-1026cde302df" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e971f083-6c26-4d41-accf-d0da020af22b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7da1145b-076b-4edf-b4aa-4a9650aaff56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a342c1b8-f200-4ce6-a6d6-7d8d38660a6c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7da1145b-076b-4edf-b4aa-4a9650aaff56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f106ce90-596a-4cff-8412-c21227f6647e" xlink:href="carm-20231231.xsd#carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7da1145b-076b-4edf-b4aa-4a9650aaff56" xlink:to="loc_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f106ce90-596a-4cff-8412-c21227f6647e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4e999b51-b573-4a1d-85d6-f2f6490be48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7da1145b-076b-4edf-b4aa-4a9650aaff56" xlink:to="loc_us-gaap_DerivativeLiabilities_4e999b51-b573-4a1d-85d6-f2f6490be48b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f745fd77-53c2-435e-a881-4d157183fd20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f745fd77-53c2-435e-a881-4d157183fd20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_88016f20-573a-4cfc-b536-dff672dc4c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f745fd77-53c2-435e-a881-4d157183fd20" xlink:to="loc_us-gaap_FinancialInstrumentAxis_88016f20-573a-4cfc-b536-dff672dc4c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88016f20-573a-4cfc-b536-dff672dc4c9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_88016f20-573a-4cfc-b536-dff672dc4c9f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_88016f20-573a-4cfc-b536-dff672dc4c9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c82e83e1-5ffb-4bf7-a14b-b1bc97eeca3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_88016f20-573a-4cfc-b536-dff672dc4c9f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c82e83e1-5ffb-4bf7-a14b-b1bc97eeca3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f5df2280-923a-4725-a850-a0f55e8fda64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c82e83e1-5ffb-4bf7-a14b-b1bc97eeca3e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f5df2280-923a-4725-a850-a0f55e8fda64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_fdeec0be-fc49-435d-a218-527d524d6244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_fdeec0be-fc49-435d-a218-527d524d6244" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d663732-dc65-4389-b7f6-36d270ae4896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d663732-dc65-4389-b7f6-36d270ae4896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_86739d4e-ec63-44e4-8098-75e600b5843d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_86739d4e-ec63-44e4-8098-75e600b5843d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1e5b777f-edfc-4ea8-9882-b393a562b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fe825569-dd93-4b01-a35e-dd1eefb1d3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1e5b777f-edfc-4ea8-9882-b393a562b1c6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fe825569-dd93-4b01-a35e-dd1eefb1d3fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fe825569-dd93-4b01-a35e-dd1eefb1d3fe" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0ccf2db9-6462-4d5c-8886-f3f28db32cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0ccf2db9-6462-4d5c-8886-f3f28db32cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f8f05f6d-0c20-4b0d-a4fe-e080003d957d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0ccf2db9-6462-4d5c-8886-f3f28db32cb2" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f8f05f6d-0c20-4b0d-a4fe-e080003d957d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1e5b777f-edfc-4ea8-9882-b393a562b1c6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4614a765-dd27-4ab1-93d3-119deb85b554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4614a765-dd27-4ab1-93d3-119deb85b554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9c02d73d-b449-4045-b321-c55e5beda5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9c02d73d-b449-4045-b321-c55e5beda5f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_063ff217-3b67-412a-8739-88abac95ed17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_063ff217-3b67-412a-8739-88abac95ed17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_677a7f9c-3556-4cf2-8108-6480463b04b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_677a7f9c-3556-4cf2-8108-6480463b04b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a52aa0c0-f41e-40f8-9fe9-727b8e481145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f938b7c4-e96e-46be-9801-df5c6a5fa6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f938b7c4-e96e-46be-9801-df5c6a5fa6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f938b7c4-e96e-46be-9801-df5c6a5fa6c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f938b7c4-e96e-46be-9801-df5c6a5fa6c3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f938b7c4-e96e-46be-9801-df5c6a5fa6c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039f087a-9df8-4587-a27b-8c282b1944c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f938b7c4-e96e-46be-9801-df5c6a5fa6c3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039f087a-9df8-4587-a27b-8c282b1944c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember_9076b64d-873d-49b5-9e00-12fe4fa670c9" xlink:href="carm-20231231.xsd#carm_SesenBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039f087a-9df8-4587-a27b-8c282b1944c6" xlink:to="loc_carm_SesenBioIncMember_9076b64d-873d-49b5-9e00-12fe4fa670c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bb9e89f5-86fd-4334-9918-86d17b152435" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:to="loc_srt_RangeAxis_bb9e89f5-86fd-4334-9918-86d17b152435" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bb9e89f5-86fd-4334-9918-86d17b152435_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bb9e89f5-86fd-4334-9918-86d17b152435" xlink:to="loc_srt_RangeMember_bb9e89f5-86fd-4334-9918-86d17b152435_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_93b36d4d-57ff-4f2b-bc46-b882a4b271c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bb9e89f5-86fd-4334-9918-86d17b152435" xlink:to="loc_srt_RangeMember_93b36d4d-57ff-4f2b-bc46-b882a4b271c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_81cdcebd-0659-49c4-9c46-b52649f53941" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_93b36d4d-57ff-4f2b-bc46-b882a4b271c2" xlink:to="loc_srt_MinimumMember_81cdcebd-0659-49c4-9c46-b52649f53941" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7c1db72f-4f8e-4f3c-8c5d-a35aec4abb8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_93b36d4d-57ff-4f2b-bc46-b882a4b271c2" xlink:to="loc_srt_MaximumMember_7c1db72f-4f8e-4f3c-8c5d-a35aec4abb8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e1a140ca-2b69-4de2-8a06-4d903a593c30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e1a140ca-2b69-4de2-8a06-4d903a593c30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e1a140ca-2b69-4de2-8a06-4d903a593c30_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e1a140ca-2b69-4de2-8a06-4d903a593c30" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e1a140ca-2b69-4de2-8a06-4d903a593c30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_322cf49e-a5b2-4fe8-bbea-a2cfe0aa5925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e1a140ca-2b69-4de2-8a06-4d903a593c30" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_322cf49e-a5b2-4fe8-bbea-a2cfe0aa5925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollateralCreditCardProgramMember_9e47c1c5-8857-4e06-ac42-8f300e55c141" xlink:href="carm-20231231.xsd#carm_CollateralCreditCardProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_322cf49e-a5b2-4fe8-bbea-a2cfe0aa5925" xlink:to="loc_carm_CollateralCreditCardProgramMember_9e47c1c5-8857-4e06-ac42-8f300e55c141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DebtInstrumentConvertibleDiscountFactorPercentage_2ddc64a8-f2f9-439a-941a-9d2e67292936" xlink:href="carm-20231231.xsd#carm_DebtInstrumentConvertibleDiscountFactorPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_carm_DebtInstrumentConvertibleDiscountFactorPercentage_2ddc64a8-f2f9-439a-941a-9d2e67292936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DebtInstrumentConvertibleQualifiedFinancingProbability_9e9070a9-24e7-49e9-a8a0-3ff9fb9ffc0d" xlink:href="carm-20231231.xsd#carm_DebtInstrumentConvertibleQualifiedFinancingProbability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_carm_DebtInstrumentConvertibleQualifiedFinancingProbability_9e9070a9-24e7-49e9-a8a0-3ff9fb9ffc0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DerivativeInstrumentConversionTermForRedemptionFeature_6855cd6e-b706-42a8-baeb-0db8fed2ccdd" xlink:href="carm-20231231.xsd#carm_DerivativeInstrumentConversionTermForRedemptionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_carm_DerivativeInstrumentConversionTermForRedemptionFeature_6855cd6e-b706-42a8-baeb-0db8fed2ccdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4f3584d8-e7a7-43d3-ae35-27883ef77002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4f3584d8-e7a7-43d3-ae35-27883ef77002" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_25e8194c-b95d-4af8-be66-eb66e84f6392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_25e8194c-b95d-4af8-be66-eb66e84f6392" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fe67d3bd-c1b9-4e5b-b583-c563396821ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fe67d3bd-c1b9-4e5b-b583-c563396821ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dbadfc50-6984-4b52-acd4-c0f86d99997f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dbadfc50-6984-4b52-acd4-c0f86d99997f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentGross_8548dae0-ab8b-4ca6-93ee-cf1de2c4fd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentGross_8548dae0-ab8b-4ca6-93ee-cf1de2c4fd1f" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e8db448-5a93-4206-a7f3-ad349bab0e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8bc352d9-f7ae-4d29-b9ca-00c1762cfa91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e8db448-5a93-4206-a7f3-ad349bab0e0d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8bc352d9-f7ae-4d29-b9ca-00c1762cfa91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8d3ab075-e81e-4eac-9d4c-79cf218a94c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8bc352d9-f7ae-4d29-b9ca-00c1762cfa91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8d3ab075-e81e-4eac-9d4c-79cf218a94c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8d3ab075-e81e-4eac-9d4c-79cf218a94c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8d3ab075-e81e-4eac-9d4c-79cf218a94c8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8d3ab075-e81e-4eac-9d4c-79cf218a94c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8d3ab075-e81e-4eac-9d4c-79cf218a94c8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConvertiblePreferredStockAndExchangeableSharesMember_7f92273c-8e3c-4daa-918f-43f7259b7d5f" xlink:href="carm-20231231.xsd#carm_ConvertiblePreferredStockAndExchangeableSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:to="loc_carm_ConvertiblePreferredStockAndExchangeableSharesMember_7f92273c-8e3c-4daa-918f-43f7259b7d5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ad967698-df49-4b20-8b1a-4102ab17a8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ad967698-df49-4b20-8b1a-4102ab17a8e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConversionOfConvertiblePromissoryNoteMember_577fdd0e-5b2b-4cd7-911a-441c6f9c5bc8" xlink:href="carm-20231231.xsd#carm_ConversionOfConvertiblePromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:to="loc_carm_ConversionOfConvertiblePromissoryNoteMember_577fdd0e-5b2b-4cd7-911a-441c6f9c5bc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28882482-c33b-470a-8607-df01b7620bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e8db448-5a93-4206-a7f3-ad349bab0e0d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28882482-c33b-470a-8607-df01b7620bb5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5615082b-8ddb-4e72-ad73-1a0b126e95a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5615082b-8ddb-4e72-ad73-1a0b126e95a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5615082b-8ddb-4e72-ad73-1a0b126e95a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5615082b-8ddb-4e72-ad73-1a0b126e95a6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5615082b-8ddb-4e72-ad73-1a0b126e95a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96c21590-b9b2-4827-817f-a9342d71f8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5615082b-8ddb-4e72-ad73-1a0b126e95a6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96c21590-b9b2-4827-817f-a9342d71f8f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_41b515d1-70e6-4219-9729-069507d907cb" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96c21590-b9b2-4827-817f-a9342d71f8f5" xlink:to="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_41b515d1-70e6-4219-9729-069507d907cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_359f8634-7d08-4340-aa52-571c4103baa8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:to="loc_dei_LegalEntityAxis_359f8634-7d08-4340-aa52-571c4103baa8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_359f8634-7d08-4340-aa52-571c4103baa8_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_359f8634-7d08-4340-aa52-571c4103baa8" xlink:to="loc_dei_EntityDomain_359f8634-7d08-4340-aa52-571c4103baa8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ffc6836b-a4f8-4289-a3ce-daafc73b9386" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_359f8634-7d08-4340-aa52-571c4103baa8" xlink:to="loc_dei_EntityDomain_ffc6836b-a4f8-4289-a3ce-daafc73b9386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsInc.Member_7716793b-700e-48ae-8cc6-8c2cfd7589cf" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_ffc6836b-a4f8-4289-a3ce-daafc73b9386" xlink:to="loc_carm_CarismaTherapeuticsInc.Member_7716793b-700e-48ae-8cc6-8c2cfd7589cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_362e11ae-c33f-4e5c-8590-f7b82e90431b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_362e11ae-c33f-4e5c-8590-f7b82e90431b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfBoardMembers_a13f227a-36fd-4def-af93-986a0d8d7319" xlink:href="carm-20231231.xsd#carm_NumberOfBoardMembers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_carm_NumberOfBoardMembers_a13f227a-36fd-4def-af93-986a0d8d7319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e0fd06ac-84a4-4576-8140-5bb0c14b4dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e0fd06ac-84a4-4576-8140-5bb0c14b4dca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f77060a-75d1-4b05-9b63-658b5e732337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f77060a-75d1-4b05-9b63-658b5e732337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_3aa09d04-c164-46dd-b8ce-c5be1f86e330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_3aa09d04-c164-46dd-b8ce-c5be1f86e330" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_cfd17e84-4e86-4d37-af41-1e0a21926397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_cfd17e84-4e86-4d37-af41-1e0a21926397" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_c4893dae-2f7b-47d9-8de8-f618b77bd0a4" xlink:href="carm-20231231.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_c4893dae-2f7b-47d9-8de8-f618b77bd0a4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_30030e8a-928e-4e5b-9408-558b333a0574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_30030e8a-928e-4e5b-9408-558b333a0574" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6ea1376f-955b-48fd-8fc6-ce8c044c6712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6ea1376f-955b-48fd-8fc6-ce8c044c6712" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_10a1e41f-b10f-41b3-8826-0d8700e6cd94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_10a1e41f-b10f-41b3-8826-0d8700e6cd94" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f3c501c8-f878-4def-8772-96fb4c33c69d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f3c501c8-f878-4def-8772-96fb4c33c69d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_656dfc6e-38f7-4a40-be56-115510f1574b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_SeveranceCosts1_656dfc6e-38f7-4a40-be56-115510f1574b" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#PropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_726f2a2e-0a34-4f53-ab45-c5820e60f8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_726f2a2e-0a34-4f53-ab45-c5820e60f8ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_07a09548-35bf-4ce4-89dd-abc3040395dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_726f2a2e-0a34-4f53-ab45-c5820e60f8ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_07a09548-35bf-4ce4-89dd-abc3040395dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07a09548-35bf-4ce4-89dd-abc3040395dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_07a09548-35bf-4ce4-89dd-abc3040395dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_07a09548-35bf-4ce4-89dd-abc3040395dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_07a09548-35bf-4ce4-89dd-abc3040395dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_787680bf-a3d8-4e6a-b8e2-a410048f1a60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_787680bf-a3d8-4e6a-b8e2-a410048f1a60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8e6bbdd7-8dec-47df-87ce-e920a83bb45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_EquipmentMember_8e6bbdd7-8dec-47df-87ce-e920a83bb45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5aae9396-f68b-484b-be67-00d35f6b8051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5aae9396-f68b-484b-be67-00d35f6b8051" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c23dae70-e06b-4117-8849-1902862340ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c23dae70-e06b-4117-8849-1902862340ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_f3bee8a1-25f5-48f1-a596-c878d2673f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_ConstructionInProgressMember_f3bee8a1-25f5-48f1-a596-c878d2673f9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_82bd2150-484d-49d4-a5bc-9bfb2ff3ff7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_82bd2150-484d-49d4-a5bc-9bfb2ff3ff7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_4fc26646-1194-4c04-83bc-1ae47b1f7a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_4fc26646-1194-4c04-83bc-1ae47b1f7a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f2d15017-5b46-441b-b515-e8b7bb6d3682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f2d15017-5b46-441b-b515-e8b7bb6d3682" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue_92b643c3-54e0-4693-8da8-0a2f92aac25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_SaleLeasebackTransactionNetBookValue_92b643c3-54e0-4693-8da8-0a2f92aac25d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_ddf073f4-d19e-445e-9fef-e7a96371a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_ddf073f4-d19e-445e-9fef-e7a96371a5db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_81d78293-bd2b-4119-a89c-2249cccf7d66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_81d78293-bd2b-4119-a89c-2249cccf7d66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_88c984e2-55bd-48cd-ad8b-f488e8e00486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_88c984e2-55bd-48cd-ad8b-f488e8e00486" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingenciesNarrativesDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ecad0977-c20a-4360-8d03-620696ca2d14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ecad0977-c20a-4360-8d03-620696ca2d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecad0977-c20a-4360-8d03-620696ca2d14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecad0977-c20a-4360-8d03-620696ca2d14" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecad0977-c20a-4360-8d03-620696ca2d14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d743551-3271-43a1-bbc8-77bd61f85ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecad0977-c20a-4360-8d03-620696ca2d14" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d743551-3271-43a1-bbc8-77bd61f85ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PennLicenseAgreementMember_4e306a8d-2f30-4615-8300-612b64aa2dff" xlink:href="carm-20231231.xsd#carm_PennLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d743551-3271-43a1-bbc8-77bd61f85ba5" xlink:to="loc_carm_PennLicenseAgreementMember_4e306a8d-2f30-4615-8300-612b64aa2dff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_bd924036-d43f-4829-9d2f-99a4cb21b74b" xlink:href="carm-20231231.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d743551-3271-43a1-bbc8-77bd61f85ba5" xlink:to="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_bd924036-d43f-4829-9d2f-99a4cb21b74b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc183c8-f3bd-445a-bafd-31b68939aa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc183c8-f3bd-445a-bafd-31b68939aa5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0fc183c8-f3bd-445a-bafd-31b68939aa5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc183c8-f3bd-445a-bafd-31b68939aa5c" xlink:to="loc_us-gaap_RelatedPartyDomain_0fc183c8-f3bd-445a-bafd-31b68939aa5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e7a9551e-bc6f-46e6-a441-36dc2dc3afee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc183c8-f3bd-445a-bafd-31b68939aa5c" xlink:to="loc_us-gaap_RelatedPartyDomain_e7a9551e-bc6f-46e6-a441-36dc2dc3afee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember_20788659-084d-4a74-9613-4fcb633881ff" xlink:href="carm-20231231.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e7a9551e-bc6f-46e6-a441-36dc2dc3afee" xlink:to="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember_20788659-084d-4a74-9613-4fcb633881ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbe3ca1e-ba52-4920-b2db-fa6c8febc529" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_srt_RangeAxis_cbe3ca1e-ba52-4920-b2db-fa6c8febc529" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbe3ca1e-ba52-4920-b2db-fa6c8febc529_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cbe3ca1e-ba52-4920-b2db-fa6c8febc529" xlink:to="loc_srt_RangeMember_cbe3ca1e-ba52-4920-b2db-fa6c8febc529_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0716a1a2-1fdd-4bd6-86ac-48ae1b90de9b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cbe3ca1e-ba52-4920-b2db-fa6c8febc529" xlink:to="loc_srt_RangeMember_0716a1a2-1fdd-4bd6-86ac-48ae1b90de9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_80f6aa6b-530b-4589-aba2-d94cca370e77" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0716a1a2-1fdd-4bd6-86ac-48ae1b90de9b" xlink:to="loc_srt_MaximumMember_80f6aa6b-530b-4589-aba2-d94cca370e77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6a9a087-c55f-46f7-88ac-0b696ca0c3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6a9a087-c55f-46f7-88ac-0b696ca0c3da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6a9a087-c55f-46f7-88ac-0b696ca0c3da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6a9a087-c55f-46f7-88ac-0b696ca0c3da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a6a9a087-c55f-46f7-88ac-0b696ca0c3da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6dc5d9f-5469-4931-92d6-0eff17eaa1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6a9a087-c55f-46f7-88ac-0b696ca0c3da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6dc5d9f-5469-4931-92d6-0eff17eaa1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_448813c4-e555-4783-a987-1cc6240a7e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6dc5d9f-5469-4931-92d6-0eff17eaa1ef" xlink:to="loc_us-gaap_EquipmentMember_448813c4-e555-4783-a987-1cc6240a7e4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromSaleAndLeasebackTransaction_1017b70f-3f39-4cbe-9a1f-b567415032c8" xlink:href="carm-20231231.xsd#carm_ProceedsFromSaleAndLeasebackTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_ProceedsFromSaleAndLeasebackTransaction_1017b70f-3f39-4cbe-9a1f-b567415032c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_e749a769-86d3-4f1b-8326-86c6c7450509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_us-gaap_FinanceLeaseLiability_e749a769-86d3-4f1b-8326-86c6c7450509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid_60c68a5b-ab5d-4d71-894f-a6efd359d5c4" xlink:href="carm-20231231.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid_60c68a5b-ab5d-4d71-894f-a6efd359d5c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_71990959-4014-484e-96fb-8571212d2e20" xlink:href="carm-20231231.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_71990959-4014-484e-96fb-8571212d2e20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid_08c69b3e-3a65-4fb9-9f8b-cc0884b6783a" xlink:href="carm-20231231.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid_08c69b3e-3a65-4fb9-9f8b-cc0884b6783a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct_1f739649-bb5a-4f63-a3a7-e4125a996f22" xlink:href="carm-20231231.xsd#carm_AdditionalMilestonePaymentsForFirstCarMProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct_1f739649-bb5a-4f63-a3a7-e4125a996f22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AgreementTerm_ca10a3aa-6723-4567-908b-269a86967a2a" xlink:href="carm-20231231.xsd#carm_AgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AgreementTerm_ca10a3aa-6723-4567-908b-269a86967a2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RenewalTerm_06969abe-33ec-4066-885c-adc05e31b982" xlink:href="carm-20231231.xsd#carm_RenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_RenewalTerm_06969abe-33ec-4066-885c-adc05e31b982" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayablePerCalendarYearForReservedCapacity_bd05c829-31a2-4171-ab5f-7d4f96d2f8a9" xlink:href="carm-20231231.xsd#carm_AmountPayablePerCalendarYearForReservedCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AmountPayablePerCalendarYearForReservedCapacity_bd05c829-31a2-4171-ab5f-7d4f96d2f8a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TerminationFeePayable_2824579b-9a72-4676-9daf-a906d7307d9f" xlink:href="carm-20231231.xsd#carm_TerminationFeePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_TerminationFeePayable_2824579b-9a72-4676-9daf-a906d7307d9f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2e70fcdd-fdab-4680-82f8-1fcc504a34df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2e70fcdd-fdab-4680-82f8-1fcc504a34df" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_053c8a1a-86f4-4258-bc10-05d7b06ce37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_053c8a1a-86f4-4258-bc10-05d7b06ce37f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_053c8a1a-86f4-4258-bc10-05d7b06ce37f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_053c8a1a-86f4-4258-bc10-05d7b06ce37f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_053c8a1a-86f4-4258-bc10-05d7b06ce37f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d850cc5-53b9-4978-a006-d80a4dc1f868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_053c8a1a-86f4-4258-bc10-05d7b06ce37f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d850cc5-53b9-4978-a006-d80a4dc1f868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AtTheMarketOfferingMember_597c09e7-bbbf-443a-a945-38c02b83df9b" xlink:href="carm-20231231.xsd#carm_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d850cc5-53b9-4978-a006-d80a4dc1f868" xlink:to="loc_carm_AtTheMarketOfferingMember_597c09e7-bbbf-443a-a945-38c02b83df9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6b31389e-0925-4e87-b30b-3d7b980ca0e4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:to="loc_srt_CounterpartyNameAxis_6b31389e-0925-4e87-b30b-3d7b980ca0e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b31389e-0925-4e87-b30b-3d7b980ca0e4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6b31389e-0925-4e87-b30b-3d7b980ca0e4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b31389e-0925-4e87-b30b-3d7b980ca0e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_835d48a1-ce50-430d-84cc-a9ddb88811ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6b31389e-0925-4e87-b30b-3d7b980ca0e4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_835d48a1-ce50-430d-84cc-a9ddb88811ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_JefferiesLLCMember_4a56368d-8344-4112-a976-5196e3668dc0" xlink:href="carm-20231231.xsd#carm_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_835d48a1-ce50-430d-84cc-a9ddb88811ac" xlink:to="loc_carm_JefferiesLLCMember_4a56368d-8344-4112-a976-5196e3668dc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7cbc7e90-793a-4683-af03-65c2b4f6cd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7cbc7e90-793a-4683-af03-65c2b4f6cd4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7cbc7e90-793a-4683-af03-65c2b4f6cd4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cbc7e90-793a-4683-af03-65c2b4f6cd4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7cbc7e90-793a-4683-af03-65c2b4f6cd4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_443d40b4-6131-4ae4-8354-aa51ecae9925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cbc7e90-793a-4683-af03-65c2b4f6cd4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_443d40b4-6131-4ae4-8354-aa51ecae9925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5d9c779e-53ca-4112-986a-c1e53991afac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_443d40b4-6131-4ae4-8354-aa51ecae9925" xlink:to="loc_us-gaap_SubsequentEventMember_5d9c779e-53ca-4112-986a-c1e53991afac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_75f78343-8fc9-4b5f-a478-b59b9773c0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_75f78343-8fc9-4b5f-a478-b59b9773c0cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_76b71a32-ee7c-4e63-a922-158bc93b3855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_76b71a32-ee7c-4e63-a922-158bc93b3855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e06e041-5afe-4428-b4dd-8d7aebd168b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e06e041-5afe-4428-b4dd-8d7aebd168b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a742222a-bfd5-4b92-8674-e677d3a62235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a742222a-bfd5-4b92-8674-e677d3a62235" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3c96d38e-007a-4c7c-a6aa-b858536affaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3c96d38e-007a-4c7c-a6aa-b858536affaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_9f8c3774-3a5a-45a8-90fd-86232858b454" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_9f8c3774-3a5a-45a8-90fd-86232858b454" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd2edfab-992b-4b62-8682-57c3d88f7436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd2edfab-992b-4b62-8682-57c3d88f7436" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockStockOfferingAmount_ab9c4df6-2db5-4a12-b5e8-b17610c604ef" xlink:href="carm-20231231.xsd#carm_SaleOfStockStockOfferingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_carm_SaleOfStockStockOfferingAmount_ab9c4df6-2db5-4a12-b5e8-b17610c604ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91dc2dbf-8a90-46e6-abd7-587b8dc2ba77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91dc2dbf-8a90-46e6-abd7-587b8dc2ba77" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_1059c215-e45f-4566-b342-b38334233e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_1059c215-e45f-4566-b342-b38334233e23" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_91437bc1-b8c8-4014-8cc6-4c0d220e3ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_91437bc1-b8c8-4014-8cc6-4c0d220e3ba8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cf111579-4a91-4f26-9968-cff925e3a352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cf111579-4a91-4f26-9968-cff925e3a352" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_29cfc2ec-b934-4caa-8924-c7a8b9cba264" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_29cfc2ec-b934-4caa-8924-c7a8b9cba264" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_358ea61c-e4cb-4646-aceb-a56470c310ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_358ea61c-e4cb-4646-aceb-a56470c310ed" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationNarrativesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensationNarrativesDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/StockbasedCompensationNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:to="loc_us-gaap_PlanNameAxis_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b" xlink:to="loc_us-gaap_PlanNameDomain_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b" xlink:to="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandSeventeenStockIncentivePlanMember_df32ce8f-d489-4f34-a779-126e32ebdada" xlink:href="carm-20231231.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:to="loc_carm_TwoThousandSeventeenStockIncentivePlanMember_df32ce8f-d489-4f34-a779-126e32ebdada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenStockIncentivePlanMember_fc2ab69f-38d8-466a-a81e-6ee667157095" xlink:href="carm-20231231.xsd#carm_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:to="loc_carm_TwoThousandFourteenStockIncentivePlanMember_fc2ab69f-38d8-466a-a81e-6ee667157095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_7cb366b2-4e00-49aa-92ce-d9e6ee9b4b73" xlink:href="carm-20231231.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:to="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_7cb366b2-4e00-49aa-92ce-d9e6ee9b4b73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7ad7ad34-f2b7-4536-b767-14d4b9be9440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:to="loc_us-gaap_AwardTypeAxis_7ad7ad34-f2b7-4536-b767-14d4b9be9440" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ad7ad34-f2b7-4536-b767-14d4b9be9440_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7ad7ad34-f2b7-4536-b767-14d4b9be9440" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7ad7ad34-f2b7-4536-b767-14d4b9be9440_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eeea4ff2-2dcc-4e1a-aa48-9d4729ed9c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7ad7ad34-f2b7-4536-b767-14d4b9be9440" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eeea4ff2-2dcc-4e1a-aa48-9d4729ed9c2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a2d0b5d2-68a6-4084-95fe-9252c9f12067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eeea4ff2-2dcc-4e1a-aa48-9d4729ed9c2d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a2d0b5d2-68a6-4084-95fe-9252c9f12067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83199a4d-589d-4493-bc4b-71e49b7832d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:to="loc_srt_RangeAxis_83199a4d-589d-4493-bc4b-71e49b7832d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83199a4d-589d-4493-bc4b-71e49b7832d0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_83199a4d-589d-4493-bc4b-71e49b7832d0" xlink:to="loc_srt_RangeMember_83199a4d-589d-4493-bc4b-71e49b7832d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_798a579c-0688-43eb-94d5-debc1d8d46d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_83199a4d-589d-4493-bc4b-71e49b7832d0" xlink:to="loc_srt_RangeMember_798a579c-0688-43eb-94d5-debc1d8d46d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4272a006-ef39-4eb9-82b6-7954c6bac2aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_798a579c-0688-43eb-94d5-debc1d8d46d1" xlink:to="loc_srt_MaximumMember_4272a006-ef39-4eb9-82b6-7954c6bac2aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3e2a1280-d626-4dfb-b050-a00f039e2868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3e2a1280-d626-4dfb-b050-a00f039e2868" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73ca2317-f43f-4a92-8754-1871f26777b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73ca2317-f43f-4a92-8754-1871f26777b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear_a8e0fe5f-2825-4154-91f3-d798b46d7882" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear_a8e0fe5f-2825-4154-91f3-d798b46d7882" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear_077bfd31-ba7c-495f-9ceb-fe287389f490" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear_077bfd31-ba7c-495f-9ceb-fe287389f490" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b65a1b3a-5454-4d22-83dc-9ea4d97c731d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b65a1b3a-5454-4d22-83dc-9ea4d97c731d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_cdca4d04-a372-472e-924f-2b0a1e800bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_cdca4d04-a372-472e-924f-2b0a1e800bd3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cee74a89-49e4-46e6-968b-579c77c6cc08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:to="loc_us-gaap_AwardTypeAxis_cee74a89-49e4-46e6-968b-579c77c6cc08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cee74a89-49e4-46e6-968b-579c77c6cc08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cee74a89-49e4-46e6-968b-579c77c6cc08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cee74a89-49e4-46e6-968b-579c77c6cc08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcd7a7bf-b175-4638-ba4c-2a3ac5ad24f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cee74a89-49e4-46e6-968b-579c77c6cc08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcd7a7bf-b175-4638-ba4c-2a3ac5ad24f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5e9aa9c-a58d-4a57-be3e-5d6f8966696d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcd7a7bf-b175-4638-ba4c-2a3ac5ad24f5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5e9aa9c-a58d-4a57-be3e-5d6f8966696d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4309b7de-e432-462b-8ddd-7a5040ab6a18" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:to="loc_srt_RangeAxis_4309b7de-e432-462b-8ddd-7a5040ab6a18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4309b7de-e432-462b-8ddd-7a5040ab6a18_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4309b7de-e432-462b-8ddd-7a5040ab6a18" xlink:to="loc_srt_RangeMember_4309b7de-e432-462b-8ddd-7a5040ab6a18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9d3f511-7199-4749-97c1-8eada2646336" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4309b7de-e432-462b-8ddd-7a5040ab6a18" xlink:to="loc_srt_RangeMember_e9d3f511-7199-4749-97c1-8eada2646336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1740608c-f1a5-462e-be5d-8c790ff75ae1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e9d3f511-7199-4749-97c1-8eada2646336" xlink:to="loc_srt_MinimumMember_1740608c-f1a5-462e-be5d-8c790ff75ae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85b71591-2333-4c6f-b8a7-07c3a6312184" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e9d3f511-7199-4749-97c1-8eada2646336" xlink:to="loc_srt_MaximumMember_85b71591-2333-4c6f-b8a7-07c3a6312184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eace6a67-56d0-44b7-9270-00b4310f7748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eace6a67-56d0-44b7-9270-00b4310f7748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c41bcb3-90ea-4de9-8078-45395530b844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c41bcb3-90ea-4de9-8078-45395530b844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4c81c3d6-bc09-412c-9e43-4d2715dca8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4c81c3d6-bc09-412c-9e43-4d2715dca8a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ef2e2b9f-0785-49c7-b683-76f2e85fdbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ef2e2b9f-0785-49c7-b683-76f2e85fdbb2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9c16f6fb-d33e-4117-9029-c1e90841afbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9c16f6fb-d33e-4117-9029-c1e90841afbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c16f6fb-d33e-4117-9029-c1e90841afbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c16f6fb-d33e-4117-9029-c1e90841afbd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c16f6fb-d33e-4117-9029-c1e90841afbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bb3c9ff4-343b-4986-b9b8-6afd08f72983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c16f6fb-d33e-4117-9029-c1e90841afbd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bb3c9ff4-343b-4986-b9b8-6afd08f72983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d1b3dd5e-0f11-48e1-a83b-b967207e5184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bb3c9ff4-343b-4986-b9b8-6afd08f72983" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d1b3dd5e-0f11-48e1-a83b-b967207e5184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a538b553-e6b9-4006-9678-58ca375921e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bb3c9ff4-343b-4986-b9b8-6afd08f72983" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a538b553-e6b9-4006-9678-58ca375921e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_680fdb2d-da53-463d-b067-f06c4458c8da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_680fdb2d-da53-463d-b067-f06c4458c8da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_680fdb2d-da53-463d-b067-f06c4458c8da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_680fdb2d-da53-463d-b067-f06c4458c8da" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_680fdb2d-da53-463d-b067-f06c4458c8da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d05b5ea-44b6-46cc-9cf2-2eaf75e515a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_680fdb2d-da53-463d-b067-f06c4458c8da" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d05b5ea-44b6-46cc-9cf2-2eaf75e515a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember_53ce9777-9f03-477c-a30b-460ddb6d2b01" xlink:href="carm-20231231.xsd#carm_SesenBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d05b5ea-44b6-46cc-9cf2-2eaf75e515a8" xlink:to="loc_carm_SesenBioIncMember_53ce9777-9f03-477c-a30b-460ddb6d2b01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_eb866600-208f-4683-9dfb-12f62b9c6335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_eb866600-208f-4683-9dfb-12f62b9c6335" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5bee7ca8-9379-428c-84ff-296e645b56bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5bee7ca8-9379-428c-84ff-296e645b56bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4bd7d408-8b4c-4695-8ed0-d02b7c7934e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4bd7d408-8b4c-4695-8ed0-d02b7c7934e0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesNarrativesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#IncomeTaxesNarrativesDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/IncomeTaxesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_203ed72a-822a-4eaf-94fa-24f1e6c61765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:to="loc_us-gaap_TaxPeriodAxis_203ed72a-822a-4eaf-94fa-24f1e6c61765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_203ed72a-822a-4eaf-94fa-24f1e6c61765_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_203ed72a-822a-4eaf-94fa-24f1e6c61765" xlink:to="loc_us-gaap_TaxPeriodDomain_203ed72a-822a-4eaf-94fa-24f1e6c61765_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_203ed72a-822a-4eaf-94fa-24f1e6c61765" xlink:to="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Pre2018Member_6d7d5b43-4d09-448b-b277-f610962d6f93" xlink:href="carm-20231231.xsd#carm_Pre2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:to="loc_carm_Pre2018Member_6d7d5b43-4d09-448b-b277-f610962d6f93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Post2017Member_ba788ba5-07d2-450c-9bfd-fe6b42201713" xlink:href="carm-20231231.xsd#carm_Post2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:to="loc_carm_Post2017Member_ba788ba5-07d2-450c-9bfd-fe6b42201713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2023Member_af8fd588-56bc-4aff-87e7-3ec2a0fd492b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:to="loc_us-gaap_TaxYear2023Member_af8fd588-56bc-4aff-87e7-3ec2a0fd492b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4c86e82d-f043-4e0a-9019-8710708c288e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4c86e82d-f043-4e0a-9019-8710708c288e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4c86e82d-f043-4e0a-9019-8710708c288e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4c86e82d-f043-4e0a-9019-8710708c288e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4c86e82d-f043-4e0a-9019-8710708c288e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4c86e82d-f043-4e0a-9019-8710708c288e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_92c9cca2-dc05-4d8d-ac90-144c234dcb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:to="loc_us-gaap_DomesticCountryMember_92c9cca2-dc05-4d8d-ac90-144c234dcb2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StateJurisdictionMember_3ba0c389-5b53-4709-99c8-43a4553274db" xlink:href="carm-20231231.xsd#carm_StateJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:to="loc_carm_StateJurisdictionMember_3ba0c389-5b53-4709-99c8-43a4553274db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LocalJurisdictionMember_4f02a611-71b5-4815-a18d-84fde14bb1c3" xlink:href="carm-20231231.xsd#carm_LocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:to="loc_carm_LocalJurisdictionMember_4f02a611-71b5-4815-a18d-84fde14bb1c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_525e5b0c-7aa2-498c-8f9a-7601496c59c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_525e5b0c-7aa2-498c-8f9a-7601496c59c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_525e5b0c-7aa2-498c-8f9a-7601496c59c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_525e5b0c-7aa2-498c-8f9a-7601496c59c1" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_525e5b0c-7aa2-498c-8f9a-7601496c59c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ed0532e-9da3-403b-801d-defef7c165a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_525e5b0c-7aa2-498c-8f9a-7601496c59c1" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ed0532e-9da3-403b-801d-defef7c165a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_088b07bb-a33f-431e-97af-f2ebb244df20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ed0532e-9da3-403b-801d-defef7c165a8" xlink:to="loc_us-gaap_ResearchMember_088b07bb-a33f-431e-97af-f2ebb244df20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ac922876-6a6f-43c0-a449-e80b6b7a27dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ac922876-6a6f-43c0-a449-e80b6b7a27dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d7e77441-d5b9-4f9f-811f-716debe7c2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d7e77441-d5b9-4f9f-811f-716debe7c2d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d3bac769-a59d-48ea-836e-d738cfd3f362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d3bac769-a59d-48ea-836e-d738cfd3f362" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#ModernaCollaborationandLicenseAgreementNarrativesDetails"/>
  <link:definitionLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9f936e05-65bf-4e5e-8ea3-9a325a3e0504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9f936e05-65bf-4e5e-8ea3-9a325a3e0504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f936e05-65bf-4e5e-8ea3-9a325a3e0504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f936e05-65bf-4e5e-8ea3-9a325a3e0504" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f936e05-65bf-4e5e-8ea3-9a325a3e0504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a8e3f21-95f3-43d1-b7a0-d32d3bc812a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f936e05-65bf-4e5e-8ea3-9a325a3e0504" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a8e3f21-95f3-43d1-b7a0-d32d3bc812a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborationAndLicenseAgreementMember_73ea4697-97bb-4010-b9f4-1bae2604947d" xlink:href="carm-20231231.xsd#carm_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a8e3f21-95f3-43d1-b7a0-d32d3bc812a7" xlink:to="loc_carm_CollaborationAndLicenseAgreementMember_73ea4697-97bb-4010-b9f4-1bae2604947d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaLicenseAgreementMember_a0cd4318-97b7-4cee-b002-2cd5193ae5a8" xlink:href="carm-20231231.xsd#carm_ModernaLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a8e3f21-95f3-43d1-b7a0-d32d3bc812a7" xlink:to="loc_carm_ModernaLicenseAgreementMember_a0cd4318-97b7-4cee-b002-2cd5193ae5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b82ffb2-ce69-492b-8274-b42ba2476c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b82ffb2-ce69-492b-8274-b42ba2476c8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5b82ffb2-ce69-492b-8274-b42ba2476c8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b82ffb2-ce69-492b-8274-b42ba2476c8a" xlink:to="loc_us-gaap_RelatedPartyDomain_5b82ffb2-ce69-492b-8274-b42ba2476c8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2d458ac5-3faa-4930-8cce-287a2ed8d509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b82ffb2-ce69-492b-8274-b42ba2476c8a" xlink:to="loc_us-gaap_RelatedPartyDomain_2d458ac5-3faa-4930-8cce-287a2ed8d509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaMember_89c39bbf-1694-4469-b228-d1064023cc1a" xlink:href="carm-20231231.xsd#carm_ModernaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2d458ac5-3faa-4930-8cce-287a2ed8d509" xlink:to="loc_carm_ModernaMember_89c39bbf-1694-4469-b228-d1064023cc1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f50c88c-f332-4e58-8f3b-aab6f0656ad2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_srt_RangeAxis_0f50c88c-f332-4e58-8f3b-aab6f0656ad2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f50c88c-f332-4e58-8f3b-aab6f0656ad2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0f50c88c-f332-4e58-8f3b-aab6f0656ad2" xlink:to="loc_srt_RangeMember_0f50c88c-f332-4e58-8f3b-aab6f0656ad2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6542e4f-f311-4fe6-98dd-acd4bdd2bca5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0f50c88c-f332-4e58-8f3b-aab6f0656ad2" xlink:to="loc_srt_RangeMember_d6542e4f-f311-4fe6-98dd-acd4bdd2bca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e601e886-8099-41bb-a2c8-b5187a208169" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d6542e4f-f311-4fe6-98dd-acd4bdd2bca5" xlink:to="loc_srt_MinimumMember_e601e886-8099-41bb-a2c8-b5187a208169" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e5fa80f8-246e-4066-885e-cba734d26ffb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d6542e4f-f311-4fe6-98dd-acd4bdd2bca5" xlink:to="loc_srt_MaximumMember_e5fa80f8-246e-4066-885e-cba734d26ffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4c34190-cf27-4413-8680-8ed69ca325b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_srt_ProductOrServiceAxis_e4c34190-cf27-4413-8680-8ed69ca325b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e4c34190-cf27-4413-8680-8ed69ca325b9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e4c34190-cf27-4413-8680-8ed69ca325b9" xlink:to="loc_srt_ProductsAndServicesDomain_e4c34190-cf27-4413-8680-8ed69ca325b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cff1dfdd-d66e-456c-a724-95efa9d4825e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e4c34190-cf27-4413-8680-8ed69ca325b9" xlink:to="loc_srt_ProductsAndServicesDomain_cff1dfdd-d66e-456c-a724-95efa9d4825e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentServicesMember_6d45e61c-6857-4e85-a7cf-8fc84c73e504" xlink:href="carm-20231231.xsd#carm_ResearchAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cff1dfdd-d66e-456c-a724-95efa9d4825e" xlink:to="loc_carm_ResearchAndDevelopmentServicesMember_6d45e61c-6857-4e85-a7cf-8fc84c73e504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MaximumOfResearchTargets_3113a1d9-c26c-449e-9582-b9208efaeefb" xlink:href="carm-20231231.xsd#carm_MaximumOfResearchTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_MaximumOfResearchTargets_3113a1d9-c26c-449e-9582-b9208efaeefb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets_37df9400-1f43-43c0-a0f9-3ca929c802ff" xlink:href="carm-20231231.xsd#carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets_37df9400-1f43-43c0-a0f9-3ca929c802ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsDesignated_82206ef5-5791-43b8-8bcc-04166566d519" xlink:href="carm-20231231.xsd#carm_NumberOfResearchTargetsDesignated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_NumberOfResearchTargetsDesignated_82206ef5-5791-43b8-8bcc-04166566d519" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_UpfrontNonRefundablePaymentReceived_f6da1584-cfc0-457a-8ac7-9db3e11a5a68" xlink:href="carm-20231231.xsd#carm_UpfrontNonRefundablePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_UpfrontNonRefundablePaymentReceived_f6da1584-cfc0-457a-8ac7-9db3e11a5a68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfProductsDevelopedAndCommercialized_1eb77a6b-ccab-4673-b54e-18ec3f2baa16" xlink:href="carm-20231231.xsd#carm_NumberOfProductsDevelopedAndCommercialized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_NumberOfProductsDevelopedAndCommercialized_1eb77a6b-ccab-4673-b54e-18ec3f2baa16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_77753b9d-abec-4ad4-a770-a2d774b41437" xlink:href="carm-20231231.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_77753b9d-abec-4ad4-a770-a2d774b41437" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_884520a6-4926-46c9-bece-cccd6b5024a2" xlink:href="carm-20231231.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_884520a6-4926-46c9-bece-cccd6b5024a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_0a35ba77-1438-4523-9acd-2d2ffa984d9e" xlink:href="carm-20231231.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_0a35ba77-1438-4523-9acd-2d2ffa984d9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPerformanceObligations_07c74e64-1dcf-483d-aaa5-452349486ad2" xlink:href="carm-20231231.xsd#carm_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_NumberOfPerformanceObligations_07c74e64-1dcf-483d-aaa5-452349486ad2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_VariableConsideration_bf75ab8d-e22c-4659-8282-25ff408fe3a9" xlink:href="carm-20231231.xsd#carm_VariableConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_VariableConsideration_bf75ab8d-e22c-4659-8282-25ff408fe3a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractTerm_11f8faf2-6d62-47c0-886e-e5ccb4767b5f" xlink:href="carm-20231231.xsd#carm_ContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_ContractTerm_11f8faf2-6d62-47c0-886e-e5ccb4767b5f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73508273-2f75-48d3-929e-dd03a7b15dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73508273-2f75-48d3-929e-dd03a7b15dec" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_49f7c319-d18e-4c0c-8a7a-1510f495dd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_49f7c319-d18e-4c0c-8a7a-1510f495dd4d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_706050cb-a42d-4a6a-a4dd-a63ca9f1c53d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_706050cb-a42d-4a6a-a4dd-a63ca9f1c53d" xlink:type="arc" order="13"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>carm-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:343b8f26-08b5-463e-85bb-1b22c4b46cf9,g:eb5f3205-6aed-4489-877d-430d68a8a84b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c2f5a45-63e6-4d0f-ba2b-a71acc29f204_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_6eb19cc8-1a95-4f68-bdc1-8349522537f9_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:to="lab_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_7e0f133f-8d4f-4299-b841-5a0914b42574_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2fa02083-748a-422e-91d4-f18b4ba2e4d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a1439c6b-91c5-4307-81f6-71c946847a2b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c76db58f-281c-43b8-88cb-9bfc6fe0723d_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_928a232c-2971-44c2-824c-2e7e1e042136_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_747be335-b243-41e8-b6ab-5ddda492bf68_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_6aaf1faa-9497-4b54-aa1b-0e500e284e9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance at issuance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_df826bce-a7db-4ee8-8165-90894fa7b310_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_097f9be2-7c37-4f8b-90da-568f2a31f5cd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Terms</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_83d76e0b-0a42-468b-b7d5-38991a1b5f98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_7f565c4f-412c-4d0c-915e-cc29adc12ad6_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct_6e9669f6-fd0b-46ba-90cf-a431841787fc_terseLabel_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments for first CAR-M product</link:label>
    <link:label id="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct_label_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payments for the First CAR-M Product</link:label>
    <link:label id="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct_documentation_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional amount required to be paid in development and regulatory milestone payments for the first CAR-M product directed to mesothelin.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:href="carm-20231231.xsd#carm_AdditionalMilestonePaymentsForFirstCarMProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:to="lab_carm_AdditionalMilestonePaymentsForFirstCarMProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b4e08e6-59a2-4594-9583-65d52148fb7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid_09abdbab-af50-45ca-9d6a-fb62151f8c9a_terseLabel_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments</link:label>
    <link:label id="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid_label_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payments Required to be Paid</link:label>
    <link:label id="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid_documentation_en-US" xlink:label="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of additional milestone payments required to be paid per product in commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:href="carm-20231231.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:to="lab_carm_AdditionalMilestonePaymentsRequiredToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_RenewalTerm_e8ccfb3b-7917-4d9c-8d4d-482d47e4f929_terseLabel_en-US" xlink:label="lab_carm_RenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_carm_RenewalTerm_label_en-US" xlink:label="lab_carm_RenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Renewal Term</link:label>
    <link:label id="lab_carm_RenewalTerm_documentation_en-US" xlink:label="lab_carm_RenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The renewal term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RenewalTerm" xlink:href="carm-20231231.xsd#carm_RenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_RenewalTerm" xlink:to="lab_carm_RenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8d07a37f-350f-4226-8191-4a5d5518a6f6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_aa278405-a690-471b-933a-798204207c9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Assets Acquired in the Merger</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_24bac690-f5f1-4ac0-bc85-423d2eef8bbd_negatedLabel_en-US" xlink:label="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of finance liability from failed sale-leaseback arrangements</link:label>
    <link:label id="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_label_en-US" xlink:label="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Finance Liability, Failed Sale Leaseback Transaction</link:label>
    <link:label id="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_documentation_en-US" xlink:label="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow in a failed sale-leaseback recognized in financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:href="carm-20231231.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:to="lab_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_f5a39975-78b8-4e6c-a773-ae1d9969f58f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_42d0a331-9298-4741-a7f2-41ffe4820f1b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0c25ff34-d44a-42ee-a546-211ece1656e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable as of September 30, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ba0dedf2-8244-477d-a273-527a1659762e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34729ea2-f2ca-421e-acef-f7db823a06da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_e12f34f4-9db7-4e5c-a0ba-30487c2eb3d7_terseLabel_en-US" xlink:label="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:href="carm-20231231.xsd#carm_LeasesWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_carm_LeasesWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock_91cdcc32-5bff-4904-a219-36e2ce4538d2_terseLabel_en-US" xlink:label="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs</link:label>
    <link:label id="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Financing Costs, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:href="carm-20231231.xsd#carm_DeferredFinancingCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:to="lab_carm_DeferredFinancingCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ac0b4f4a-1d29-475a-bf45-c81d064d7c51_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bbe2a8e3-f160-486c-a9f2-7790aef90e17_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b55b98be-1eb9-4a7d-8d8c-df5b99d84beb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable as of September 30, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_1fa9fb20-1a9d-441b-8860-a929d621db02_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_a31e0422-b497-4276-9943-5725c865296f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_d9e7a012-1f54-4712-8637-95f5847763ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_e45003bc-e0c6-44c0-ad7f-51f59b7cac60_terseLabel_en-US" xlink:label="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum commitment to reimburse research and development costs</link:label>
    <link:label id="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Commitment to Reimburse Research and Development Costs</link:label>
    <link:label id="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum commitment to reimburse research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:href="carm-20231231.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:to="lab_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_85230e40-1a2b-427c-88dd-be4d88264618_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a5e42d45-0009-4293-8bb3-a7a3efaefa43_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock under Open Market Sales Agreement, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LeasesWeightedAverageDiscountRateAbstract_57ba87fe-3d35-48ae-9aba-64ee57a6f164_terseLabel_en-US" xlink:label="lab_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_carm_LeasesWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_carm_LeasesWeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:href="carm-20231231.xsd#carm_LeasesWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:to="lab_carm_LeasesWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_46b2b8a5-eabd-4a02-9366-a1a77b1fff72_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a75c39a2-6c2b-4905-87a8-bfb981ad7da6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear_a13d5eff-9bad-40bb-9f18-c282f6e92ec1_terseLabel_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting on first anniversary (as a percent)</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear_label_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Percentage, First Year</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear_documentation_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of stock awards vesting on the first anniversary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" xlink:to="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_f40add37-1775-416e-a59a-b882898a62c8_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_794ab0a0-3a10-411c-a186-5302a6740355_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_1980b0eb-3fee-4226-b2fe-d4213d1a922f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e2e9a9b4-c00d-4610-b5dd-f836ccbe55a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c59ee00f-08b5-49e4-aa30-dcf52267af26_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a73f42d1-9c99-4445-b0f2-081641f55c44_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_99025d90-0afb-452b-818d-0a9d077e1d3d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_f75f4f95-5d5e-4d4e-8ed9-8dff586cc7a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_ac1429af-6c84-43ce-9a0f-539af7f38f3f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Merger with Sesen Bio</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_f34b7537-0093-4785-aaa9-60d473deb078_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_288e8bd4-e3b6-4eb0-b0f5-1d13d10b9bd9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityAbstract_adc8c403-0538-46c1-b722-4f35266605b0_terseLabel_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity</link:label>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityAbstract_label_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity</link:label>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityAbstract_documentation_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:href="carm-20231231.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:to="lab_carm_DevelopmentStageRisksAndLiquidityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f58fcde-8d5b-4524-abe8-b6aa6ab63e24_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_9de54178-c1fd-4216-a47a-e2d7a99b517e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3109ae31-90af-41c9-823e-5ad19d93d011_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DebtInstrumentConvertibleDiscountFactorPercentage_121ea302-9c81-4467-9773-384d7cd346c7_terseLabel_en-US" xlink:label="lab_carm_DebtInstrumentConvertibleDiscountFactorPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount factor percentage</link:label>
    <link:label id="lab_carm_DebtInstrumentConvertibleDiscountFactorPercentage_label_en-US" xlink:label="lab_carm_DebtInstrumentConvertibleDiscountFactorPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Discount Factor Percentage</link:label>
    <link:label id="lab_carm_DebtInstrumentConvertibleDiscountFactorPercentage_documentation_en-US" xlink:label="lab_carm_DebtInstrumentConvertibleDiscountFactorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Discount Factor Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DebtInstrumentConvertibleDiscountFactorPercentage" xlink:href="carm-20231231.xsd#carm_DebtInstrumentConvertibleDiscountFactorPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DebtInstrumentConvertibleDiscountFactorPercentage" xlink:to="lab_carm_DebtInstrumentConvertibleDiscountFactorPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cfea90ad-2172-494a-9a9c-eff3c998d882_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TwoThousandFourteenStockIncentivePlanMember_99b8fe71-a7e2-41f9-a374-ce2779d85bf4_terseLabel_en-US" xlink:label="lab_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Stock Incentive Plan</link:label>
    <link:label id="lab_carm_TwoThousandFourteenStockIncentivePlanMember_label_en-US" xlink:label="lab_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_carm_TwoThousandFourteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Two Thousand Fourteen Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:href="carm-20231231.xsd#carm_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:to="lab_carm_TwoThousandFourteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5ccc1405-a8c4-446b-ae74-eb111f39f96a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f41b20f2-3981-4ad3-9a72-9998a6479c8a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2022 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_87bac4e1-c6e2-4529-89e0-f7ada0deb435_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of September 30, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_57c984bc-0b2e-4bac-927b-d461d5cdeb4a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4f8ff86f-2aa5-4d66-87d4-7c53c7c601a8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid_d7d57fda-f502-468c-a284-e7453d6f82b6_terseLabel_en-US" xlink:label="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual payments to be made</link:label>
    <link:label id="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid_label_en-US" xlink:label="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments, Annual Payments Required to be Paid</link:label>
    <link:label id="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid_documentation_en-US" xlink:label="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of annual payments required to be paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:href="carm-20231231.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:to="lab_carm_CommitmentsAnnualPaymentsRequiredToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_cf28857d-9f3d-4840-a266-e97e08c6f12f_terseLabel_en-US" xlink:label="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</link:label>
    <link:label id="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_label_en-US" xlink:label="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash Acquired in Reverse Recapitalization, Financing Activities</link:label>
    <link:label id="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_documentation_en-US" xlink:label="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:href="carm-20231231.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:to="lab_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_62632048-05d3-4e74-8eca-8b162d3948b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_d436880a-0304-4063-a20c-83eb7727f50c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities &#8211; U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20c8de94-98d8-4763-8f83-4b6378c87acb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ae3c0fad-d429-457d-9dc9-a17b2debfa1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c402a268-24b8-4e4d-bcca-630a882f35ba_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f491c7a8-4842-4c14-b208-3439d5ce1144_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_be932ef7-f583-475b-bcc8-6c8fbf143674_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ec8c065d-64da-46cb-bf4e-be54015a1f6e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_6a957d2c-ce59-43b0-8d3b-2dbd3d9043b8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_63ff78e7-5721-411a-8133-efbd51607f2d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_00660fe3-0930-4f2a-9816-89fda44a8269_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_cd1804d9-63db-4354-84e8-65776143f88a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_50e422e8-aadc-47b0-84e4-629597df54b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ba19ae5e-29cb-463d-a87f-5100b7b93f87_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_5226f593-ce29-468c-840b-804520819b98_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8812a416-f2d0-4e93-b799-748f6806062d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1e475be9-3ab5-4172-a46d-c0fbe0b92292_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b2d8bbec-b707-4c53-8ae1-f057a0dced7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e6faec47-3857-4487-9301-b0a16c14eb8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification to net loss of previous unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_97777325-7df2-40f5-ad1b-a24585073236_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassification to net loss of previous unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8b6f36bc-6022-426c-8c43-e1f0fc0ccd4d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ec0dd5c0-b856-43fe-a419-022f6b132a91_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the ending of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8041e156-4ced-4797-9a32-6082a87018b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_339ab60c-4cff-4a98-8eb9-255ddb669a50_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AmountPayablePerCalendarYearForReservedCapacity_106edabf-bd57-4c83-aa8a-bc5ad43d6237_terseLabel_en-US" xlink:label="lab_carm_AmountPayablePerCalendarYearForReservedCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount payable per calendar year for reserved capacity</link:label>
    <link:label id="lab_carm_AmountPayablePerCalendarYearForReservedCapacity_label_en-US" xlink:label="lab_carm_AmountPayablePerCalendarYearForReservedCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Payable Per Calendar Year For Reserved Capacity</link:label>
    <link:label id="lab_carm_AmountPayablePerCalendarYearForReservedCapacity_documentation_en-US" xlink:label="lab_carm_AmountPayablePerCalendarYearForReservedCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount payable per calendar year for reserved capacity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayablePerCalendarYearForReservedCapacity" xlink:href="carm-20231231.xsd#carm_AmountPayablePerCalendarYearForReservedCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AmountPayablePerCalendarYearForReservedCapacity" xlink:to="lab_carm_AmountPayablePerCalendarYearForReservedCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_3919db5f-565e-4e19-8609-42189a3d24f4_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible promissory note</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_VariableConsideration_6a7f3211-2de9-4d43-a4ad-e340ad89043b_terseLabel_en-US" xlink:label="lab_carm_VariableConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable consideration</link:label>
    <link:label id="lab_carm_VariableConsideration_label_en-US" xlink:label="lab_carm_VariableConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Consideration</link:label>
    <link:label id="lab_carm_VariableConsideration_documentation_en-US" xlink:label="lab_carm_VariableConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of variable consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_VariableConsideration" xlink:href="carm-20231231.xsd#carm_VariableConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_VariableConsideration" xlink:to="lab_carm_VariableConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_302cc9de-28d1-4202-92fd-d03d23cbcdb1_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash in pre-closing financing</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Values, Pre-closing Financing Transaction</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued pursuant to preclosing financing during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:to="lab_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c3d7f3cd-0ca9-42e4-912d-ae3b2242b2e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_a15c1d74-66ca-44a1-a3fa-796cdfa0affe_negatedLabel_en-US" xlink:label="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of reverse recapitalization finance costs</link:label>
    <link:label id="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_label_en-US" xlink:label="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Finance Costs, Reverse Recapitalization, Financing Activities</link:label>
    <link:label id="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_documentation_en-US" xlink:label="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for payment of reverse recapitalization finance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:href="carm-20231231.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:to="lab_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent_6ffe0310-29dc-4f4b-93d6-03dc32fae9de_terseLabel_en-US" xlink:label="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Expense, Current</link:label>
    <link:label id="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="carm-20231231.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_carm_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares_7492326f-df81-496d-88d6-658e33bee86f_terseLabel_en-US" xlink:label="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</link:label>
    <link:label id="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares_label_en-US" xlink:label="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity, Shares</link:label>
    <link:label id="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares_documentation_en-US" xlink:label="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of stock classified as temporary equity reclassified or converted to permanent equity during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:href="carm-20231231.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:to="lab_carm_ReclassificationsOfTemporaryToPermanentEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_235dc2f6-a299-4de3-ab6f-8d8357354510_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3602661d-6838-43e6-898d-574e01454273_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a94efd6d-042f-47a5-8e82-8c08e240b636_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_af0177be-6228-483a-9827-20f13d3fba46_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_43a1ff19-dce0-4067-8d92-f5193db8f8cc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_1eaf001f-2b26-4672-b325-6e23d3681b75_terseLabel_en-US" xlink:label="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of reimbursement of research and development costs</link:label>
    <link:label id="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period of Reimbursement of Research and Development Costs</link:label>
    <link:label id="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of reimbursement of research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:href="carm-20231231.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:to="lab_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_583feedb-7e61-4b08-aa01-cf7e77a6534f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f4f6417e-da48-4b53-9e28-8212c0597e9c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_24354c56-ad3c-4537-90c5-718a1f503018_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f09886bc-c2a2-4232-9992-89dc73bbd994_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_feabf944-add7-4003-96d0-fd9ae3b028fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e5b643e9-9fa6-499b-bffa-657300f08caa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dee6f778-4164-4e30-93ae-31de0746348b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0ebd81a2-2379-4e8a-af80-ae2f593a9ca7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a9897a74-b5bd-4f91-adcf-5d1d42453253_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4540868c-eb6e-4101-acd4-ea7d4f55c38b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_4a71f291-13d9-478f-946f-0e61ba216c12_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_6c85e098-9a37-4de9-b993-2b749727be2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognition upon conversion of convertible promissory note</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8c6a3607-ff1b-4598-8615-0c5735fbaaaf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_98d5df90-c2b4-43e2-a40a-446ef2484622_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_339123b9-42df-4b0d-a2f7-08c1fd98cb6c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TerminationFeePayable_70863f4f-7ea2-4cf2-a595-2e440a39c659_terseLabel_en-US" xlink:label="lab_carm_TerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination fee payable</link:label>
    <link:label id="lab_carm_TerminationFeePayable_label_en-US" xlink:label="lab_carm_TerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Termination Fee Payable</link:label>
    <link:label id="lab_carm_TerminationFeePayable_documentation_en-US" xlink:label="lab_carm_TerminationFeePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of termination fee payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TerminationFeePayable" xlink:href="carm-20231231.xsd#carm_TerminationFeePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TerminationFeePayable" xlink:to="lab_carm_TerminationFeePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_6cb6e093-3b57-4a81-a123-3e2939104753_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9894032c-c0f0-4fb9-ac09-5867c16ee817_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of derivative liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7ea69200-f986-45f8-a8f1-6695991ba453_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_1d39fb93-ccb6-4be5-9b22-b55b3b1ba48c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9a7ef2b-95f9-4400-9032-1e3502a7487d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_88e59d3f-81aa-45d8-8025-5a36c42d41d3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Maturities, Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ConvertedIntoSharesCommonStockAtExchangeRatio_7b503370-16be-498c-b5a1-f671096f3601_terseLabel_en-US" xlink:label="lab_carm_ConvertedIntoSharesCommonStockAtExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock at an exchange ratio</link:label>
    <link:label id="lab_carm_ConvertedIntoSharesCommonStockAtExchangeRatio_label_en-US" xlink:label="lab_carm_ConvertedIntoSharesCommonStockAtExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Converted Into Shares Common Stock at an Exchange Ratio</link:label>
    <link:label id="lab_carm_ConvertedIntoSharesCommonStockAtExchangeRatio_documentation_en-US" xlink:label="lab_carm_ConvertedIntoSharesCommonStockAtExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio of converted into shares common stock at an exchange ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConvertedIntoSharesCommonStockAtExchangeRatio" xlink:href="carm-20231231.xsd#carm_ConvertedIntoSharesCommonStockAtExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ConvertedIntoSharesCommonStockAtExchangeRatio" xlink:to="lab_carm_ConvertedIntoSharesCommonStockAtExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_0dbf4c0b-b560-4ff4-ae25-ad9e8fb6c8d5_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of debt proceeds to derivative liability</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Debt Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_456d7f85-35b1-48d4-810c-662b9417d6a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0b7382cd-9cb2-4d43-8d38-122ffdd8a67c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e2b6bb29-15a9-4720-944a-386a9c202bd2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cd41ac2c-b942-4e62-82e3-03961acf7f37_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a8f25136-1a8b-412a-8542-f0be49abb00d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Anti-Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StateJurisdictionMember_9af5a081-8cf9-41a2-a23d-adfcd46d6395_terseLabel_en-US" xlink:label="lab_carm_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_carm_StateJurisdictionMember_label_en-US" xlink:label="lab_carm_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State Jurisdiction [Member]</link:label>
    <link:label id="lab_carm_StateJurisdictionMember_documentation_en-US" xlink:label="lab_carm_StateJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">State Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StateJurisdictionMember" xlink:href="carm-20231231.xsd#carm_StateJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StateJurisdictionMember" xlink:to="lab_carm_StateJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ModernaLicenseAgreementMember_3863cfae-77c9-40f3-af25-5f4046da32eb_terseLabel_en-US" xlink:label="lab_carm_ModernaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna License Agreement</link:label>
    <link:label id="lab_carm_ModernaLicenseAgreementMember_label_en-US" xlink:label="lab_carm_ModernaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Moderna License Agreement [Member]</link:label>
    <link:label id="lab_carm_ModernaLicenseAgreementMember_documentation_en-US" xlink:label="lab_carm_ModernaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to moderna license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaLicenseAgreementMember" xlink:href="carm-20231231.xsd#carm_ModernaLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ModernaLicenseAgreementMember" xlink:to="lab_carm_ModernaLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_7a59be8a-d4fc-4c85-b433-1163721a385d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5c9428c5-9808-4ec1-b98e-ec9f98a03e43_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_78e071ae-869f-42fa-b959-62805ec64aba_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DebtInstrumentConvertibleQualifiedFinancingProbability_b6a626b5-1439-4907-b120-01fdd960e39e_terseLabel_en-US" xlink:label="lab_carm_DebtInstrumentConvertibleQualifiedFinancingProbability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of convertible qualified financing (as a percent)</link:label>
    <link:label id="lab_carm_DebtInstrumentConvertibleQualifiedFinancingProbability_label_en-US" xlink:label="lab_carm_DebtInstrumentConvertibleQualifiedFinancingProbability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Qualified Financing, Probability</link:label>
    <link:label id="lab_carm_DebtInstrumentConvertibleQualifiedFinancingProbability_documentation_en-US" xlink:label="lab_carm_DebtInstrumentConvertibleQualifiedFinancingProbability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Qualified Financing, Probability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DebtInstrumentConvertibleQualifiedFinancingProbability" xlink:href="carm-20231231.xsd#carm_DebtInstrumentConvertibleQualifiedFinancingProbability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DebtInstrumentConvertibleQualifiedFinancingProbability" xlink:to="lab_carm_DebtInstrumentConvertibleQualifiedFinancingProbability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57820d7f-18c7-498b-ab5e-fd735e219874_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e0802e1b-cd40-4143-955d-c727638a0cbf_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b49c7ef5-3956-43ad-abc1-c400572701be_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5ed42c1d-65b7-43ce-a776-f97a879ecbf2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_b4bc13a3-d121-428d-8a09-0c54b8c642e7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11796a6a-1ba5-42bf-9e69-cf8b1833c943_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e9f097d7-fa20-45a8-82b2-910fc506aa10_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_77d641ec-add1-4caf-b7ff-46065ac305c2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LocalJurisdictionMember_3d2853ed-bb4b-4293-90f3-76d4d2b2bb29_terseLabel_en-US" xlink:label="lab_carm_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local</link:label>
    <link:label id="lab_carm_LocalJurisdictionMember_label_en-US" xlink:label="lab_carm_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Jurisdiction [Member]</link:label>
    <link:label id="lab_carm_LocalJurisdictionMember_documentation_en-US" xlink:label="lab_carm_LocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Local Jurisdiction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LocalJurisdictionMember" xlink:href="carm-20231231.xsd#carm_LocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LocalJurisdictionMember" xlink:to="lab_carm_LocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b0bb0193-4a4d-4783-ab35-9d96c15e1cb5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of September 30, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f3fb3ee2-5cbe-4c3a-92e6-50f154b17f84_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_f1d7cd8c-033b-4060-a6b2-3969fa740e77_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_33395d36-537d-489c-ae93-0fcd35c46100_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_845cbe7b-aa2d-4dfa-af77-e1aa409de1b0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ea81585f-14eb-4a8b-865f-a23d0a938d73_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7c0b0929-ba96-4f8c-971f-63e3d1e1cbba_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7a152794-9137-491d-ae08-3d61ce977963_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_db29ef77-0ca1-4716-b213-347b2c180d76_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_67fadd97-529c-4b25-8729-3d86551248d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_262b6f62-cad9-4d13-9c73-106274f80a65_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_944485a7-fe3b-4077-966a-865dfa63c4b5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a93de756-6b80-4709-a616-cec9372b43af_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_c3604e39-c55a-4a24-8674-15f4472fd763_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_c298fac8-d27a-48ca-bd0e-cff92455e1d8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_5a32c019-518a-42b4-9702-b2e26a060718_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_cd05abc3-4568-4daa-ab73-07e8904fe2e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e64138b3-f0a2-40a1-96af-183073ecd07a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9f3df7e3-e7e7-4198-ab55-7f7b692192fb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_68c43df8-454c-45e6-80e8-23b1288214d1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_a12f739c-407b-460b-ac86-543b95302282_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7169c6d1-7b77-491b-9922-52895c02458a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b8a7c9db-56f1-492b-bff7-48ace6b2e9d8_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1db6c142-d640-4632-a7b0-a60352a7e564_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2687d70f-e0bc-455c-b993-cdb52c2b22c3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5eca9462-db44-4a9a-95f4-aeb684091259_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_8e17e039-8a11-4ba8-9f85-0e4fe6988c34_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f2914d60-29fb-4879-97c1-aff161f1095f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_63257849-928a-4d4c-83df-901416e9aef4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_eace60eb-42f6-4997-ad42-18348da6bc67_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_d1b40ae3-53d8-4eb6-b8ef-d6840b8ff2b9_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance and personnel costs paid</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_JefferiesLLCMember_46ac59d1-b9e5-47d0-ae3f-6fd94edc1b95_terseLabel_en-US" xlink:label="lab_carm_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_carm_JefferiesLLCMember_label_en-US" xlink:label="lab_carm_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_carm_JefferiesLLCMember_documentation_en-US" xlink:label="lab_carm_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_JefferiesLLCMember" xlink:href="carm-20231231.xsd#carm_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_JefferiesLLCMember" xlink:to="lab_carm_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3e073fb3-2cd6-4015-8c70-724bd1c3707d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Using The Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_209afb34-23a2-4f37-91f2-17e0affcdf0e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9f0f834e-a664-4578-8d3a-7c6019c859f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_790ca461-e67d-405c-8597-fa6b321e9383_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6fce1217-d460-4fb4-8566-9dc6883701f6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_f7aead61-708d-461b-9025-b8a93c9dc8d0_terseLabel_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Term and Discount Rate Information</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_label_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating and Finance Lease, Lease term and Discount Rate Information [Table Text Block]</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_documentation_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of ease term and discount rate information relating to operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:href="carm-20231231.xsd#carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:to="lab_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AgreementTerm_5baa2a52-bb56-4518-9a66-341c0fdf09a0_terseLabel_en-US" xlink:label="lab_carm_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_carm_AgreementTerm_label_en-US" xlink:label="lab_carm_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_carm_AgreementTerm_documentation_en-US" xlink:label="lab_carm_AgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AgreementTerm" xlink:href="carm-20231231.xsd#carm_AgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AgreementTerm" xlink:to="lab_carm_AgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8e4ab3a9-343c-4d9a-81fd-44b5685f3035_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period compensation cost of unvested awards to be expensed</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b28929ef-54ca-4b12-b0f9-faaf556b48e0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0073151a-b27d-4178-a4ba-b751376f2dc0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5b34d80d-f638-4481-a59c-745093abdaec_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future compensation cost for awards not vested</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7e88494d-05fd-4cf2-9b09-4767aa58ea48_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_cc010923-8adc-4018-b447-5dd992d1eb0a_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2eced655-7a2e-45b3-b0ab-310da78dac2f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_OwnershipInterestInReportingEntity_dff45710-a847-4c64-9002-f111ee728972_terseLabel_en-US" xlink:label="lab_carm_OwnershipInterestInReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership interest held after the merge</link:label>
    <link:label id="lab_carm_OwnershipInterestInReportingEntity_label_en-US" xlink:label="lab_carm_OwnershipInterestInReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Interest In the Reporting Entity</link:label>
    <link:label id="lab_carm_OwnershipInterestInReportingEntity_documentation_en-US" xlink:label="lab_carm_OwnershipInterestInReportingEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ownership interest in the reporting entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_OwnershipInterestInReportingEntity" xlink:href="carm-20231231.xsd#carm_OwnershipInterestInReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_OwnershipInterestInReportingEntity" xlink:to="lab_carm_OwnershipInterestInReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4f8cad7b-2509-4c13-8977-8424e3f88853_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_e247d4ec-86ea-4bcb-8fb3-514f25eaa089_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear_f53e90a5-51f2-4d6f-a039-ed9708d56a06_terseLabel_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting at the end of each three-month period after first anniversary (as a percent)</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear_label_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Percentage, Each Three Month Period After First Year</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear_documentation_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of stock awards vesting at the end of each three-month period after the first anniversary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" xlink:to="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_Pre2018Member_ed8b94f2-8cd6-4b0e-8dff-c871b2991172_terseLabel_en-US" xlink:label="lab_carm_Pre2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-2018</link:label>
    <link:label id="lab_carm_Pre2018Member_label_en-US" xlink:label="lab_carm_Pre2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-2018 [Member]</link:label>
    <link:label id="lab_carm_Pre2018Member_documentation_en-US" xlink:label="lab_carm_Pre2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Pre2018Member" xlink:href="carm-20231231.xsd#carm_Pre2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_Pre2018Member" xlink:to="lab_carm_Pre2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_bca57a91-33ed-40b8-8f8f-638e3705ffdf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_096145d3-cb0a-454a-abbf-7aa5a3a04c1f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8bc1f960-3441-4941-b192-c76880e2801b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6c0e5741-ac27-4fbc-b093-5d5d6a6252d2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionNetBookValue_4637f74a-1595-46fa-9aa3-fe52b4381e35_terseLabel_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale lease-back asset</link:label>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionNetBookValue_label_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Net Book Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:to="lab_us-gaap_SaleLeasebackTransactionNetBookValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2a31c02f-f71a-43a1-8254-0603afd50c2e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0f353441-bbec-4378-9826-c395a29c7962_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af91fadd-54a4-4b36-8bd2-7e34a9b5b7a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsEquityCompensation_49d69010-f2e2-4684-9f1d-610bebebbe18_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsEquityCompensation_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Equity Compensation</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsEquityCompensation_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsEquityCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Equity Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsEquityCompensation" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsEquityCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsEquityCompensation" xlink:to="lab_carm_DeferredTaxAssetsEquityCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c1be81db-11e5-4803-9d85-2173f3e858f6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c3f54b7e-7620-4184-aef7-85ef74029844_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_b60aa4ab-676f-4707-ae8b-8445e8c05d4e_terseLabel_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option rights</link:label>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_label_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Option Rights, Amount</link:label>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_documentation_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:href="carm-20231231.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:to="lab_carm_RevenueRemainingPerformanceObligationOptionRightsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_e9fd5196-0af5-40e2-9136-038293117c84_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State and local tax rate change</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_63d13d7a-8ae6-4235-9ce1-191a1d1ddde9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_1898f47a-f1a6-479a-baef-29710aab2294_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_e2fdb703-bd4a-4bb9-a04c-c7cc34f595dd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5f964340-ecb5-41dc-a97c-5fceb71b30a4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue_64fcdce7-bbe5-45b4-8231-0f2ec1a4f037_terseLabel_en-US" xlink:label="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferral of revenue</link:label>
    <link:label id="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue_label_en-US" xlink:label="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer Liability, Deferral of Revenue</link:label>
    <link:label id="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue_documentation_en-US" xlink:label="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of revenue deferred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:href="carm-20231231.xsd#carm_ContractWithCustomerLiabilityDeferralOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:to="lab_carm_ContractWithCustomerLiabilityDeferralOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8aa0801a-b968-4e9e-a498-a7a4db2eff88_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4ce2a754-735e-4ad5-9442-4b52a9603b45_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in a pre-closing funding (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_182df780-92e5-4ddc-9439-df4e13bf15df_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2f7d45ae-df3b-48fb-a834-2d594614dd8d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f7b23216-e7c7-4164-8ef4-22d0ebad990e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents &#8211; money markets accounts</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets_47dd05a0-01ad-45bd-a2a7-41daa0d4245b_terseLabel_en-US" xlink:label="lab_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of research targets, designate as development targets</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets_label_en-US" xlink:label="lab_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Research Targets, Designate as Development Targets</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets_documentation_en-US" xlink:label="lab_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Research Targets, Designate as Development Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets" xlink:href="carm-20231231.xsd#carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets" xlink:to="lab_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0ad67e17-5349-4483-bb01-302651bb5967_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_854253c4-d9ed-4717-b5a4-32c673b1e6e1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger with Sesen Bio</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_84333b76-a64e-4093-a2e2-8cc51225f27f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability &#8211; redemption feature on convertible promissory note</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ProceedsFromFailedSaleLeasebackTransaction_ffd73498-5003-4046-ba5c-a575ccefb1b7_terseLabel_en-US" xlink:label="lab_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from failed sale-leaseback arrangement</link:label>
    <link:label id="lab_carm_ProceedsFromFailedSaleLeasebackTransaction_label_en-US" xlink:label="lab_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Failed Sale Leaseback Transaction</link:label>
    <link:label id="lab_carm_ProceedsFromFailedSaleLeasebackTransaction_documentation_en-US" xlink:label="lab_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:href="carm-20231231.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:to="lab_carm_ProceedsFromFailedSaleLeasebackTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_33d5d6e9-c45f-47ad-94ac-fa111e15619f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_97458d26-34de-4412-878b-1979dd9e717d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ConvertiblePreferredStockAndExchangeableSharesMember_5f084749-121a-4663-bef1-a231d107c723_terseLabel_en-US" xlink:label="lab_carm_ConvertiblePreferredStockAndExchangeableSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock and exchangeable shares</link:label>
    <link:label id="lab_carm_ConvertiblePreferredStockAndExchangeableSharesMember_label_en-US" xlink:label="lab_carm_ConvertiblePreferredStockAndExchangeableSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock and Exchangeable Shares [Member]</link:label>
    <link:label id="lab_carm_ConvertiblePreferredStockAndExchangeableSharesMember_documentation_en-US" xlink:label="lab_carm_ConvertiblePreferredStockAndExchangeableSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to convertible preferred stock and exchangeable shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConvertiblePreferredStockAndExchangeableSharesMember" xlink:href="carm-20231231.xsd#carm_ConvertiblePreferredStockAndExchangeableSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ConvertiblePreferredStockAndExchangeableSharesMember" xlink:to="lab_carm_ConvertiblePreferredStockAndExchangeableSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64b659fb-d70d-4f0e-b9c4-83ab805921e2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2011ddda-57bd-4015-92bd-74382a0df72c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember_a7b11897-64b5-4b78-afc8-cb5d8083bb09_terseLabel_en-US" xlink:label="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CARISMA Therapeutics Inc, Legacy, Stockholders</link:label>
    <link:label id="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember_label_en-US" xlink:label="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CARISMA Therapeutics Inc, Legacy, Stockholders [Member]</link:label>
    <link:label id="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember_documentation_en-US" xlink:label="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stockholders of legacy CARISMA Therapeutics, prior to the merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:to="lab_carm_CarismaTherapeuticsIncLegacyStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ContractTerm_deb8d093-f9f1-4d79-b70a-9605822cc1d4_terseLabel_en-US" xlink:label="lab_carm_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_carm_ContractTerm_label_en-US" xlink:label="lab_carm_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Term</link:label>
    <link:label id="lab_carm_ContractTerm_documentation_en-US" xlink:label="lab_carm_ContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractTerm" xlink:href="carm-20231231.xsd#carm_ContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ContractTerm" xlink:to="lab_carm_ContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ResearchAndDevelopmentServicesMember_711eb5cf-3686-4669-ab15-4f9091e976fe_terseLabel_en-US" xlink:label="lab_carm_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Services</link:label>
    <link:label id="lab_carm_ResearchAndDevelopmentServicesMember_label_en-US" xlink:label="lab_carm_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Services [Member]</link:label>
    <link:label id="lab_carm_ResearchAndDevelopmentServicesMember_documentation_en-US" xlink:label="lab_carm_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to research and development services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentServicesMember" xlink:href="carm-20231231.xsd#carm_ResearchAndDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ResearchAndDevelopmentServicesMember" xlink:to="lab_carm_ResearchAndDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_1153abe8-d28f-4be8-ab37-de0e6ed03064_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_b480dc66-3855-4df1-90f9-967a9bf1352d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_50fe08cd-deed-45f2-8e8f-e471e37648ab_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_efdb0606-38a8-49cc-9368-eacc81b2a36c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_d8da061c-66bb-4335-a0a6-ee50f6ac0053_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2ac6a824-b402-4312-bdf0-8521e08b4e38_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_79edcc36-61bb-4eee-a1b1-6006bcb4c066_terseLabel_en-US" xlink:label="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount receivable per product</link:label>
    <link:label id="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_label_en-US" xlink:label="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Receivable Per Product in Development Target Designation, Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label id="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_documentation_en-US" xlink:label="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount receivable per product in development target designation, development, regulatory and commercial milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:href="carm-20231231.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:to="lab_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_b74b4617-d991-4d0c-8eee-a855ac549bc9_terseLabel_en-US" xlink:label="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Agreement</link:label>
    <link:label id="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_label_en-US" xlink:label="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing and Supply Agreement with Novartis Pharmaceuticals Corporation [Member]</link:label>
    <link:label id="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_documentation_en-US" xlink:label="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to manufacturing and supply agreement with Novartis Pharmaceuticals Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:href="carm-20231231.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:to="lab_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_ee7bc6ea-11c2-470e-99e8-8123d3d94285_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_44c3f0eb-0fef-49e8-8899-43028d1107a1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f583e7c3-d6fb-4fdc-9171-b8dde5c77bfe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_6c4cda99-e557-4bf1-93ca-418627a539b7_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_fc8392d3-0c89-4de5-89de-f25c4d662086_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash financing and investing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8954acdc-8554-474e-8d6a-79b34a5b1f1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d2a092bb-15dc-4ddd-a608-4dee979fd8cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_782d44c8-5951-4904-81b7-ebd1e3825d49_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-Controlling Interests</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:to="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_23b83947-9eb1-43ba-86f9-e91107e22f34_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3ad39342-129c-4d63-81f6-9f84f36d3a32_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_126eb681-c9d1-4b1a-b439-4b05eb2f11c3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b943d207-eccc-47cf-88be-6b954d2cb876_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2063cd58-3481-412c-99ce-9ddf105def10_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_93f820c0-5ebf-45f7-924d-9e43fab378b7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1a6f2412-929a-4843-be77-50790949cacf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets for Federal Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a1e033c2-1633-406e-95cb-212cf1ed4cd3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_6fcc4c27-64d4-4d2b-8e2b-cb13870a92cf_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_b56df83e-638c-4bf1-8395-b0dcc5e1ca6c_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6c47d744-2c1f-4b93-a162-bd2c21f3d9c3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_902cdf3b-26fc-4750-8d36-7cf1311efac7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_168270ef-aa3a-4e06-a2fe-09cc914175b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_abe76a84-d5ad-4c9a-9641-724b987750a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_48ad3de4-b653-4020-9283-0a79db61bcfd_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity common stock, shares outstanding immediately after merger</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember_a0504ceb-0aae-422c-8103-3213272f7030_terseLabel_en-US" xlink:label="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penn</link:label>
    <link:label id="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember_label_en-US" xlink:label="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trustees of the University of Pennsylvania [Member]</link:label>
    <link:label id="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember_documentation_en-US" xlink:label="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Trustees of the University of Pennsylvania .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:href="carm-20231231.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:to="lab_carm_TrusteesOfUniversityOfPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TwoThousandSeventeenStockIncentivePlanMember_40f6da40-e50e-4372-98c0-893d6f7c5abb_terseLabel_en-US" xlink:label="lab_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Stock Incentive Plan</link:label>
    <link:label id="lab_carm_TwoThousandSeventeenStockIncentivePlanMember_label_en-US" xlink:label="lab_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Seventeen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_carm_TwoThousandSeventeenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Two Thousand Seventeen Stock Incentive, a Legacy Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:href="carm-20231231.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:to="lab_carm_TwoThousandSeventeenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_01e88e3d-900e-4dcc-93fa-a51e9a77deb0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_c5691d1b-43d6-4f1d-8c56-2a900d906828_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_742f9e76-ddcf-4177-beaa-c0c337ed2b71_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_cefba149-cd22-4280-9387-c0837f8f0740_terseLabel_en-US" xlink:label="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_label_en-US" xlink:label="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash, Unrealized Gain (Loss) on Marketable Securities</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_documentation_en-US" xlink:label="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:href="carm-20231231.xsd#carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:to="lab_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_FinanceLeaseCost_b803db9d-9a47-4ec3-b32a-11e6a54fd983_totalLabel_en-US" xlink:label="lab_carm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_carm_FinanceLeaseCost_label_en-US" xlink:label="lab_carm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:label id="lab_carm_FinanceLeaseCost_documentation_en-US" xlink:label="lab_carm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of finance lease cost expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCost" xlink:href="carm-20231231.xsd#carm_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_FinanceLeaseCost" xlink:to="lab_carm_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2ac39179-dd9b-40bd-b9ad-6e059f02b688_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_707c9e29-4e16-46ae-ad4e-85016ce94cf6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e4e35af-ebdf-4033-9e24-0a47cafbd24e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_97d75966-44bc-4139-a701-40a51ac86c35_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec2d375c-a586-462f-a7d0-02eed4139ad9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total provision</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_0ef55fab-d50a-4dba-8eb9-0cfd4df9f4aa_negatedTerseLabel_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Return to provision</link:label>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_label_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision, Percent</link:label>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_documentation_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:href="carm-20231231.xsd#carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:to="lab_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_5b923b03-6469-4294-b5aa-65e65c2803bf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_fdb51f42-bf21-4faa-b6c0-a51daf8582dd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_8c86ede5-a850-48b2-83db-9ef858ff5362_terseLabel_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_665c8345-a01c-40cc-afcc-f3a8d9f3da6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at September 30, 2023</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d03f734e-d589-4e56-b560-756da750d092_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_251d8768-044f-493a-9852-bc596f4a4b84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0b7e113d-e803-4d46-99ff-5cada95b1e8b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Background</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b45b650a-47f4-42bd-81ad-014a6a3ef924_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_a2a8ee81-4d61-4329-92f2-cf3cd8f723d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at September 30, 2023 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fd41968a-915b-486c-9a22-f8a6ccc24a35_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_65f5097d-b1fc-4fac-b08b-50214f2c3247_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_291e3c89-bfb9-4ee3-8d1a-cb8a060bb39c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_670c4b45-4432-40bc-8b32-c8f5d823df81_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cde8f344-a93f-4ae0-b6e0-8a45aa2c5c59_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8edf7b0d-87d5-4aa6-ab27-f104d00ce538_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_33780bc0-3e67-427c-a94d-53ac3c392164_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityTableTextBlock_c4ea5d82-62c9-4671-8e89-8f5b8a7ab231_terseLabel_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity</link:label>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityTableTextBlock_label_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development-Stage Risks and Liquidity [Table Text Block]</link:label>
    <link:label id="lab_carm_DevelopmentStageRisksAndLiquidityTableTextBlock_documentation_en-US" xlink:label="lab_carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure on risks of development-stage and liquidity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:href="carm-20231231.xsd#carm_DevelopmentStageRisksAndLiquidityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:to="lab_carm_DevelopmentStageRisksAndLiquidityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_49a4cab3-6cb3-4d3e-bd5c-23f6a84a91d5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1af2953f-f181-447d-89cc-0b0de58399b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_51ad60cc-a2dd-46bc-89ae-2478758af8f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_6d166d0b-aadc-40d4-8951-347b8b2d37fe_negatedLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b4c77ee7-5163-42f1-8c32-cb86351a76a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_231117a9-b21c-446d-ad74-123a27a84f0d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_5ab1b6a9-e1c1-4eb6-a28e-917810526750_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_15cd15b0-0f29-4f9e-b286-8043b06811fb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock $0.001 par value, 350,000,000 shares authorized, 40,609,915 and 2,217,737 shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_415143e2-7643-4b7a-a89b-3c51d3d9d8cb_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_Post2017Member_e13ee57d-56ac-4f17-a44c-8c56bae16e3e_terseLabel_en-US" xlink:label="lab_carm_Post2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-2017</link:label>
    <link:label id="lab_carm_Post2017Member_label_en-US" xlink:label="lab_carm_Post2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-2017 [Member]</link:label>
    <link:label id="lab_carm_Post2017Member_documentation_en-US" xlink:label="lab_carm_Post2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Post2017Member" xlink:href="carm-20231231.xsd#carm_Post2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_Post2017Member" xlink:to="lab_carm_Post2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75502985-9f11-46d9-a97f-5d51d4170b8c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_c55207a3-902f-4fba-9ba2-cfa922937f08_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f3322b47-d969-470b-bdb1-0ae31d9ae6eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in the operating right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_e6c4b940-d048-4ead-9c90-dbcd05be175a_terseLabel_en-US" xlink:label="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="carm-20231231.xsd#carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8a182e01-21fc-4623-8d43-c8308c0980e9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_37a2d56c-f932-4409-8792-cd848520e616_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_9b2c3795-557e-4ed7-b448-128f60b4c117_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of principal related to finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_b146ca80-392f-4e93-8df7-d4364f240f45_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash in pre-closing financing (in shares)</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing, Financing Transaction</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued during the period pursuant to pre-closing financing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:to="lab_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_6e3807e1-0da7-4d66-bde5-ae19ab0ac752_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Maturities, Financing Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_UpfrontNonRefundablePaymentReceived_ede6680e-abc0-4ded-a3a3-8b1919d07d89_terseLabel_en-US" xlink:label="lab_carm_UpfrontNonRefundablePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront non-refundable payment received</link:label>
    <link:label id="lab_carm_UpfrontNonRefundablePaymentReceived_label_en-US" xlink:label="lab_carm_UpfrontNonRefundablePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Non-Refundable Payment Received</link:label>
    <link:label id="lab_carm_UpfrontNonRefundablePaymentReceived_documentation_en-US" xlink:label="lab_carm_UpfrontNonRefundablePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront non-refundable payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_UpfrontNonRefundablePaymentReceived" xlink:href="carm-20231231.xsd#carm_UpfrontNonRefundablePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_UpfrontNonRefundablePaymentReceived" xlink:to="lab_carm_UpfrontNonRefundablePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_aeedd1f5-6a86-4519-b0a4-ac7392a5cb1b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ModernaMember_0cb356f5-7ccb-4cf8-b387-031f8e140424_terseLabel_en-US" xlink:label="lab_carm_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna</link:label>
    <link:label id="lab_carm_ModernaMember_label_en-US" xlink:label="lab_carm_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Moderna [Member]</link:label>
    <link:label id="lab_carm_ModernaMember_documentation_en-US" xlink:label="lab_carm_ModernaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Moderna, a significant shareholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaMember" xlink:href="carm-20231231.xsd#carm_ModernaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ModernaMember" xlink:to="lab_carm_ModernaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_32661866-5f46-40b5-ba21-1a9fef6b0873_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_afc39887-3338-46b3-a251-e407bacd4d66_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ce474cd7-c169-48c9-bc6c-b4d8f1cae590_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_1243fffa-8ebe-4e34-a886-ea13c90b2a8a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_c016066c-9996-4880-865e-162e7ece3979_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_9d7ad810-501c-4931-83fc-0770ffe7a50a_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6b647d7e-ed07-44d7-97b4-d5f30659cc66_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5e940c2b-60d1-4d1f-b8e1-14f8a67825e9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_SesenBioIncMember_856c2189-2947-4c6e-be5b-fead15ad9965_terseLabel_en-US" xlink:label="lab_carm_SesenBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sesen Bio, Inc.</link:label>
    <link:label id="lab_carm_SesenBioIncMember_label_en-US" xlink:label="lab_carm_SesenBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sesen Bio, Inc [Member]</link:label>
    <link:label id="lab_carm_SesenBioIncMember_documentation_en-US" xlink:label="lab_carm_SesenBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the entity Sesen Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember" xlink:href="carm-20231231.xsd#carm_SesenBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_SesenBioIncMember" xlink:to="lab_carm_SesenBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AccretionOnMarketableSecurities_f867a4e7-a0b2-4cf0-9b26-89f11698a497_negatedLabel_en-US" xlink:label="lab_carm_AccretionOnMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion on marketable securities</link:label>
    <link:label id="lab_carm_AccretionOnMarketableSecurities_label_en-US" xlink:label="lab_carm_AccretionOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion on Marketable Securities</link:label>
    <link:label id="lab_carm_AccretionOnMarketableSecurities_documentation_en-US" xlink:label="lab_carm_AccretionOnMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accretion on marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccretionOnMarketableSecurities" xlink:href="carm-20231231.xsd#carm_AccretionOnMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AccretionOnMarketableSecurities" xlink:to="lab_carm_AccretionOnMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7f479f74-2b83-49d5-a4e1-62b9bfda875d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross_cef347f3-6c18-4b0b-afd5-3b1587499652_terseLabel_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sesen Bio options assumed in the Merger (in shares)</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross_label_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed In Merger in Period, Gross</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross_documentation_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross number of share options (or share units) assumed in a merger during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" xlink:to="lab_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d8e53a2a-884e-4ab6-a3a8-3077b2714435_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_aa539d77-e086-4156-8322-29c9700ea2b9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b1878d6d-c2ae-4f37-840d-6157fd40a118_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aa105174-2efc-4416-bb46-5212d58e4c6d_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_48f4b0e9-0a7e-4772-8433-608f38f4b94d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3206c5bf-6d8c-4aed-bac4-6437b7a537de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State and local tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_80a6cc1f-09ef-4304-be22-1a491d26c3d7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_d8483eb5-930d-4e11-bd78-13f21b436563_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development costs, net of amortization</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:to="lab_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0fa2e379-7d51-4c83-976e-fcc651cc0dc7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_448d1a1a-8df2-4eea-814d-44990ffdec09_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AuditInformationAbstract_label_en-US" xlink:label="lab_carm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_carm_AuditInformationAbstract_documentation_en-US" xlink:label="lab_carm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AuditInformationAbstract" xlink:href="carm-20231231.xsd#carm_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AuditInformationAbstract" xlink:to="lab_carm_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_4cd3d042-cbc5-4f02-9f85-651edaae0a97_terseLabel_en-US" xlink:label="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_label_en-US" xlink:label="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredRestrictedCash</link:label>
    <link:label id="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_documentation_en-US" xlink:label="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of restricted cash from business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:href="carm-20231231.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:to="lab_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8989b51a-eff1-42d4-ae61-f39d6b6a5277_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CollaborationAndLicenseAgreementMember_fccdf525-7987-47f6-92e0-5b9f37d164e5_terseLabel_en-US" xlink:label="lab_carm_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreement</link:label>
    <link:label id="lab_carm_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_carm_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreement [Member]</link:label>
    <link:label id="lab_carm_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_carm_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborationAndLicenseAgreementMember" xlink:href="carm-20231231.xsd#carm_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CollaborationAndLicenseAgreementMember" xlink:to="lab_carm_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ce188a9c-fa59-4d7b-9414-584cd6c2a1e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable as of September 30, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a6066c07-4562-4654-8697-c2bbd857a4a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_99b7b279-df17-491f-8bee-06d0c12c0930_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_1f86f2b1-b58c-4dfb-a927-3b0541dff160_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1c7f908e-3575-49c5-987c-ff33957ece4f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CollateralCreditCardProgramMember_ff1b8df7-cdd6-423c-b5a2-c25d602944c5_terseLabel_en-US" xlink:label="lab_carm_CollateralCreditCardProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral, credit card program</link:label>
    <link:label id="lab_carm_CollateralCreditCardProgramMember_label_en-US" xlink:label="lab_carm_CollateralCreditCardProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral, Credit Card Program [Member]</link:label>
    <link:label id="lab_carm_CollateralCreditCardProgramMember_documentation_en-US" xlink:label="lab_carm_CollateralCreditCardProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collateral, Credit Card Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollateralCreditCardProgramMember" xlink:href="carm-20231231.xsd#carm_CollateralCreditCardProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CollateralCreditCardProgramMember" xlink:to="lab_carm_CollateralCreditCardProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_68e28fe7-c37a-44d6-bdb8-b0d48b30995d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Carisma Therapeutics Inc. stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsLeaseLiability_7ffba56e-72c0-42fc-8d6a-3b59b87b80e6_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsLeaseLiability" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsLeaseLiability" xlink:to="lab_carm_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_abb9a061-d113-4019-bdd9-b2a1fe570fcd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ccf17ee3-c8a4-4bb4-a06a-303c316f466d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_71bcb885-b2ed-4f37-adbd-f07e67bd4c75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_851dc525-b835-4b83-80f0-c03b7536adea_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_31494b0a-a9fc-4f94-9fee-471eba5cac35_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1d277605-bb99-4735-a331-656f6813f34b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of unearned revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_3eb35f43-3854-4139-8dd8-68eff789a095_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_88012262-709b-4b7d-89b8-8118a40a409e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9aac37d2-2d5d-4727-b498-1a1b3a788d93_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_eaeddf3e-e761-4d1c-8ff0-27fe4ae06ade_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2023Member_87ccede8-4a79-4d25-845a-964f2f594c2a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiring in 2023</link:label>
    <link:label id="lab_us-gaap_TaxYear2023Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2023Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2023Member" xlink:to="lab_us-gaap_TaxYear2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_FinancingCashUsedInFinanceLeases_99d9cdf2-1ea4-46cf-973c-c6483236285b_terseLabel_en-US" xlink:label="lab_carm_FinancingCashUsedInFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing cash used in finance leases</link:label>
    <link:label id="lab_carm_FinancingCashUsedInFinanceLeases_label_en-US" xlink:label="lab_carm_FinancingCashUsedInFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing cash used in finance leases</link:label>
    <link:label id="lab_carm_FinancingCashUsedInFinanceLeases_documentation_en-US" xlink:label="lab_carm_FinancingCashUsedInFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for payment on finance lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinancingCashUsedInFinanceLeases" xlink:href="carm-20231231.xsd#carm_FinancingCashUsedInFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_FinancingCashUsedInFinanceLeases" xlink:to="lab_carm_FinancingCashUsedInFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2c3127bc-9588-4257-8369-cc19725aabb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_959a138e-6fb7-4e45-b496-d1d1b9b83f38_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_9696b693-0dd6-4129-b654-f84b3dd0503d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6ecfe8d6-ea0f-48bc-98b2-55cf907df227_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5eb3e6ce-8729-4d36-89c7-07c8e45bbf55_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b8318d5b-26a6-486a-b27a-2a93a5563cc0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1e681060-6c31-4f1c-b086-eb965aec083f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PennLicenseAgreementMember_7bea0ec3-6f10-480c-90b5-6a0db8098ca1_terseLabel_en-US" xlink:label="lab_carm_PennLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penn License Agreement</link:label>
    <link:label id="lab_carm_PennLicenseAgreementMember_label_en-US" xlink:label="lab_carm_PennLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Penn License Agreement [Member]</link:label>
    <link:label id="lab_carm_PennLicenseAgreementMember_documentation_en-US" xlink:label="lab_carm_PennLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Penn License Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PennLicenseAgreementMember" xlink:href="carm-20231231.xsd#carm_PennLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PennLicenseAgreementMember" xlink:to="lab_carm_PennLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4225b7e0-f106-467f-b3b1-1c98035a6a4e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e97285a7-6625-4f1a-88ef-d8a8fb22f66f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_cd79e097-9722-446d-8289-4d17d97fd42c_terseLabel_en-US" xlink:label="lab_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="carm-20231231.xsd#carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_34e20613-aa94-4d5e-aaf0-c03627339e9b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8ca697ce-34fb-4454-95db-a39d90034084_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_59b9fc18-a02e-4d36-9cc9-78ed2d1577b4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_ca014e26-1d3b-48f4-b9d6-ebf337a34cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount to the market price (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be4ad4bd-011b-4372-8fdb-334d0a6ccaf5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_322c75a5-75f6-4fba-b106-a220fa0e846a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2022 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dd58c4d6-2b7c-4fbd-a878-068bf7e798ee_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of September 30, 2023 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0da7b037-3165-4457-b8f6-50d47482bd88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_bd0b4646-6440-4ce9-924e-15890fdef38e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale leaseback transaction, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_label_en-US" xlink:label="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Leaseback Transaction, Accumulated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:to="lab_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b20547c2-1994-4c62-87ae-8b711852e653_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d242fde9-9b73-4a54-9e51-f3afe95871d2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b39c9c9e-6943-4446-a3de-f93512a0dac3_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_adbe845e-16c3-47db-9fd2-779788a6a5f2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_dd8b6ae1-4b4c-4610-bb03-f4bdca455160_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther_c42c3c9b-b658-452a-8eb3-396ff6ef74cc_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortizable assets and other</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Amortizable Assets And Other</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Amortizable Assets And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:to="lab_carm_DeferredTaxAssetsAmortizableAssetsAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7470aeef-2c89-444a-8bee-8e791e55e687_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5bcd61d2-1b16-48b4-ae78-157d161ad7a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_354f983a-f2c5-4644-8663-15c8844fc86e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_869c26b0-4668-47c7-a442-4d61bc6ea815_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7164b9cb-faf0-4013-bf8b-5b21f0f64110_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_068a6cc8-0199-48d8-a538-3794c9c5529b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_70008443-f52b-4b35-b825-96e732ada06e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_PaymentsForProceedsFromMarketableSecurities_a831ecf7-c7d8-4da8-abff-464446bbd74c_negatedLabel_en-US" xlink:label="lab_carm_PaymentsForProceedsFromMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of marketable securities</link:label>
    <link:label id="lab_carm_PaymentsForProceedsFromMarketableSecurities_label_en-US" xlink:label="lab_carm_PaymentsForProceedsFromMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Marketable Securities</link:label>
    <link:label id="lab_carm_PaymentsForProceedsFromMarketableSecurities_documentation_en-US" xlink:label="lab_carm_PaymentsForProceedsFromMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentsForProceedsFromMarketableSecurities" xlink:href="carm-20231231.xsd#carm_PaymentsForProceedsFromMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_PaymentsForProceedsFromMarketableSecurities" xlink:to="lab_carm_PaymentsForProceedsFromMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfResearchTargetsDesignated_4bb73011-97f6-4772-adbb-97f429358c7f_terseLabel_en-US" xlink:label="lab_carm_NumberOfResearchTargetsDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of research targets designated</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsDesignated_label_en-US" xlink:label="lab_carm_NumberOfResearchTargetsDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Research Targets Designated</link:label>
    <link:label id="lab_carm_NumberOfResearchTargetsDesignated_documentation_en-US" xlink:label="lab_carm_NumberOfResearchTargetsDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Research Targets Designated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsDesignated" xlink:href="carm-20231231.xsd#carm_NumberOfResearchTargetsDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfResearchTargetsDesignated" xlink:to="lab_carm_NumberOfResearchTargetsDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NoncashInterestExpense_73708bc9-041d-4589-ae7f-a78d9e38cceb_terseLabel_en-US" xlink:label="lab_carm_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_carm_NoncashInterestExpense_label_en-US" xlink:label="lab_carm_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Interest Expense</link:label>
    <link:label id="lab_carm_NoncashInterestExpense_documentation_en-US" xlink:label="lab_carm_NoncashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expense (income) related to the increase (decrease) in interest expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashInterestExpense" xlink:href="carm-20231231.xsd#carm_NoncashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NoncashInterestExpense" xlink:to="lab_carm_NoncashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b6bb0561-7dee-4a69-9dba-f4384f390514_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_19acee5b-2eb4-4079-b389-07f141a82666_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_8d1581a7-cb0d-472a-958f-45b027380ead_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfPerformanceObligations_f84aa254-58cf-40ce-967d-41e8b60b2b60_terseLabel_en-US" xlink:label="lab_carm_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_carm_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_carm_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Performance Obligations</link:label>
    <link:label id="lab_carm_NumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_carm_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPerformanceObligations" xlink:href="carm-20231231.xsd#carm_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfPerformanceObligations" xlink:to="lab_carm_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e72da551-a355-45f7-83eb-19047b12a125_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_c87a5c73-b36f-4e7d-92a8-50b68327337e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_e4742d6c-0f4d-405e-add8-ea77db0af8d2_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_17326d43-873d-482f-bb7a-8f5d9d44c8ca_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ee11aa07-4094-41ee-a492-a9c77ef41fda_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_fda5cbee-9902-47d0-be93-10726365aa17_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dfcbd705-f34b-4634-8650-7958e6e83bd0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_69fdc8da-57d0-47ef-9e4e-a1079db55f05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0104e127-52e1-45c0-ad52-3979275bbc36_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_836c923b-7f4f-40be-b6d0-10aa6a69ff03_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ddf72a18-f635-4bdf-a7e1-725db9dc7538_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f01543fd-a290-4bc7-b6c3-4dee91d83d40_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f2fa06eb-ba44-4545-a75d-b9aa51a94319_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets &#8211; operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_87e5d4f3-5e2f-4b09-844f-bfcd274ed620_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_aec8853a-fcf5-4b39-9723-beab86822239_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_15ec5d9f-6b8a-4cd3-92b2-384863559b87_terseLabel_en-US" xlink:label="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Employee Stock Purchase Plan</link:label>
    <link:label id="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Two Thousand Fourteen Employee Stock Purchase Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:href="carm-20231231.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfProductsDevelopedAndCommercialized_eff2014d-3797-4521-8421-08aad9c6f968_terseLabel_en-US" xlink:label="lab_carm_NumberOfProductsDevelopedAndCommercialized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products developed and commercialized</link:label>
    <link:label id="lab_carm_NumberOfProductsDevelopedAndCommercialized_label_en-US" xlink:label="lab_carm_NumberOfProductsDevelopedAndCommercialized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products Developed and Commercialized</link:label>
    <link:label id="lab_carm_NumberOfProductsDevelopedAndCommercialized_documentation_en-US" xlink:label="lab_carm_NumberOfProductsDevelopedAndCommercialized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of products developed and commercialized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfProductsDevelopedAndCommercialized" xlink:href="carm-20231231.xsd#carm_NumberOfProductsDevelopedAndCommercialized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfProductsDevelopedAndCommercialized" xlink:to="lab_carm_NumberOfProductsDevelopedAndCommercialized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_a6022926-1826-4f20-ad78-e7132de2a627_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_435e9210-5526-4d03-9daa-de748759a291_negatedTerseLabel_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_label_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:label id="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_documentation_en-US" xlink:label="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:href="carm-20231231.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="lab_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c733e9da-25ec-4606-82e2-1ab5b6491c3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_SaleOfStockStockOfferingAmount_d7c081d7-bb34-447c-b1c1-78c4605a1afb_terseLabel_en-US" xlink:label="lab_carm_SaleOfStockStockOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock offering, amount</link:label>
    <link:label id="lab_carm_SaleOfStockStockOfferingAmount_label_en-US" xlink:label="lab_carm_SaleOfStockStockOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Stock Offering, Amount</link:label>
    <link:label id="lab_carm_SaleOfStockStockOfferingAmount_documentation_en-US" xlink:label="lab_carm_SaleOfStockStockOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Stock Offering, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockStockOfferingAmount" xlink:href="carm-20231231.xsd#carm_SaleOfStockStockOfferingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_SaleOfStockStockOfferingAmount" xlink:to="lab_carm_SaleOfStockStockOfferingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bdfa7184-62e7-43bb-a60b-4be09bd7556b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_b099e146-1791-4aa6-95be-cd8b38a6e27d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at September 30, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c5c14941-d8f7-4bf2-840d-ede8bc1274c4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_29e4bc4d-060a-4a97-b17a-f775661814fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0fdd6d9c-10f0-4b2b-985e-a69106c99f96_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_7b0651c5-be84-4d2e-aa54-486da24ef2e7_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9c33c814-690b-423d-9041-4041b16a500a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_cefc53a1-fd1d-4ecf-bd8e-9f9ef7061ba6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9e5cb7bb-7654-4eb3-bc2f-567e2944cf1f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset_502b3034-413b-485a-8175-3a8095ad3bce_negatedTerseLabel_en-US" xlink:label="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:label id="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="carm-20231231.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_carm_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_34db85f5-36a2-445d-9c65-a6e1e7f80502_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e7c8aff9-825b-4244-bc46-9b7c2e9ca4a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f005b10e-ad4f-4c7b-8953-a4bff12b57f7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentGross_e764c06c-c0c0-45e8-9d3e-9f9f7f27bc44_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost, Gross, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b6e53a57-f825-420f-a7db-68414efb0c1d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_faa64b08-7d08-4a0b-80c4-f1b766cb8626_terseLabel_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_label_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Research and Development, Amount</link:label>
    <link:label id="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_documentation_en-US" xlink:label="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:href="carm-20231231.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:to="lab_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_5956427c-e25a-486e-b43f-4a23c208b261_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_6efaa5b6-f675-4a7c-a73e-5b8a04fe93bc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_2dc55fec-0c07-4246-bcc2-65059cfddf66_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c9133945-46d7-4701-8f0b-96c1ae33f0a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Security, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_9689428c-b964-4b61-8dfb-9490f3e42627_terseLabel_en-US" xlink:label="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_label_en-US" xlink:label="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events</link:label>
    <link:label id="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_documentation_en-US" xlink:label="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount required to pay per product in development upon the achievement of certain clinical, regulatory and commercial milestone events.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:href="carm-20231231.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:to="lab_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_834a6934-8684-49d9-99bd-80702cc5a77f_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_15ec72c6-7f00-446a-b830-93663d8c008d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice_e6ea4769-7625-460a-bccd-51fe3991e96a_terseLabel_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sesen Bio options assumed in the Merger (in USD per share)</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice_label_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Assumed in Merger, Weighted Average Exercise Price</link:label>
    <link:label id="lab_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options for shares assumed in a merge during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" xlink:to="lab_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_4b03be87-372c-439d-a079-9abca4ae59c9_terseLabel_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_label_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating and Finance Lease, Supplemental Cash flow Information [Table Text Block]</link:label>
    <link:label id="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_documentation_en-US" xlink:label="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of supplemental cash flow information relating to operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:href="carm-20231231.xsd#carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="lab_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e4b2ba8b-1222-4511-b58d-29f953c2caab_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_87d16ead-2cd0-4cfa-af0f-afc52c872f88_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_34fc80e2-9ff4-40ec-a321-121de7dc1972_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bacc8-2ec1-4abb-8436-df1fa82484e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_b8dcf9bb-1b71-4459-825c-67e3428214d8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ProceedsFromSaleAndLeasebackTransaction_e4793392-1342-4d9c-9a55-6bad4a41174f_terseLabel_en-US" xlink:label="lab_carm_ProceedsFromSaleAndLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale and leaseback transactions</link:label>
    <link:label id="lab_carm_ProceedsFromSaleAndLeasebackTransaction_label_en-US" xlink:label="lab_carm_ProceedsFromSaleAndLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Leaseback Transaction</link:label>
    <link:label id="lab_carm_ProceedsFromSaleAndLeasebackTransaction_documentation_en-US" xlink:label="lab_carm_ProceedsFromSaleAndLeasebackTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Leaseback Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromSaleAndLeasebackTransaction" xlink:href="carm-20231231.xsd#carm_ProceedsFromSaleAndLeasebackTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ProceedsFromSaleAndLeasebackTransaction" xlink:to="lab_carm_ProceedsFromSaleAndLeasebackTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e01f1faa-605c-4876-8b97-28a6be60b60c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_61f26e97-923b-4ea1-b3d1-080a420be9ce_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_e95e3b99-9d55-40d6-b5ec-14412d2ee6ba_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_25379b4d-55d1-4800-b65c-b69b8bc45e04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_25309125-6f16-49f1-bccd-2cdb079b23c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_546e6970-eebb-4cd1-ba0f-9d4f9117cea2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_92d0f2ba-90a6-433b-9699-99a593fea7e4_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare_02cd0c65-5068-47e2-84d1-02eb68197b68_terseLabel_en-US" xlink:label="lab_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange ratio of shares of Sesen Bio for each share of Legacy Carisma</link:label>
    <link:label id="lab_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare_label_en-US" xlink:label="lab_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Ratio Conversion Of Acquired Entity's to Acquiring Entity's Share</link:label>
    <link:label id="lab_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare_documentation_en-US" xlink:label="lab_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The ration of conversion of the acquired entity shares to acquiring entity's share in a merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" xlink:href="carm-20231231.xsd#carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" xlink:to="lab_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_SesenBioStockholdersMember_81ef5ff2-af2b-46e9-9753-1e988ca5d04c_terseLabel_en-US" xlink:label="lab_carm_SesenBioStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sesen Bio Stockholders</link:label>
    <link:label id="lab_carm_SesenBioStockholdersMember_label_en-US" xlink:label="lab_carm_SesenBioStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sesen Bio Stockholders [Member]</link:label>
    <link:label id="lab_carm_SesenBioStockholdersMember_documentation_en-US" xlink:label="lab_carm_SesenBioStockholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stockholders of Sesen Bio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioStockholdersMember" xlink:href="carm-20231231.xsd#carm_SesenBioStockholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_SesenBioStockholdersMember" xlink:to="lab_carm_SesenBioStockholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a7638c61-d1ab-4750-909c-10af21c1783a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a964462a-3621-4134-809d-e01744fe7d1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding as of September 30, 2023</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_ad192db3-4442-4bf6-b375-3d277afd4457_terseLabel_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests to common stock</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_label_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger</link:label>
    <link:label id="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_documentation_en-US" xlink:label="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:to="lab_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_af3777f6-2084-480a-802f-a10ed5628b8b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_aac43cf0-ce69-4755-98da-f1ff266b6e38_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_c2ce20fc-3ccb-4e8b-8b93-97f0e91dd043_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_6fe6b8c7-4d18-4c4c-aaab-84c103db7529_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_01730b18-cbca-451b-9e1a-7b1db7f44817_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ad0b8447-d44b-427e-98fb-6d00251ff799_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_CarismaTherapeuticsInc.Member_53e4d84d-55fb-4a9c-82d5-2ca6777f2073_terseLabel_en-US" xlink:label="lab_carm_CarismaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carisma Therapeutics Inc.</link:label>
    <link:label id="lab_carm_CarismaTherapeuticsInc.Member_label_en-US" xlink:label="lab_carm_CarismaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carisma Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_carm_CarismaTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_carm_CarismaTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Carisma Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsInc.Member" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_CarismaTherapeuticsInc.Member" xlink:to="lab_carm_CarismaTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DerivativeInstrumentConversionTermForRedemptionFeature_5546d7aa-6f01-4dfe-b914-1fda42fc5b49_terseLabel_en-US" xlink:label="lab_carm_DerivativeInstrumentConversionTermForRedemptionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative instrument, conversion range, term</link:label>
    <link:label id="lab_carm_DerivativeInstrumentConversionTermForRedemptionFeature_label_en-US" xlink:label="lab_carm_DerivativeInstrumentConversionTermForRedemptionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument, Conversion Term for Redemption Feature</link:label>
    <link:label id="lab_carm_DerivativeInstrumentConversionTermForRedemptionFeature_documentation_en-US" xlink:label="lab_carm_DerivativeInstrumentConversionTermForRedemptionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instrument, Conversion Term for Redemption Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DerivativeInstrumentConversionTermForRedemptionFeature" xlink:href="carm-20231231.xsd#carm_DerivativeInstrumentConversionTermForRedemptionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DerivativeInstrumentConversionTermForRedemptionFeature" xlink:to="lab_carm_DerivativeInstrumentConversionTermForRedemptionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b91f3802-c6c7-4c22-bc2a-7576a7de385b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0ceffb80-1aa5-45ae-96ab-448b997d0aca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable as of September 30, 2023 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_3b1af51d-0930-49d0-86cd-306ae602f8f6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_6a401c99-7456-4148-8b2a-3c0eb9c5c78b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_170b075f-60e6-49dc-bb30-65bfebcc7da5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_44737cd1-d3c0-4108-b383-8b941e103871_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_eda672df-fb8a-49f9-be0b-84fe67b9b483_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_f3317c3b-6cbc-4e3e-8f68-36c7e5c2f950_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bb8d8a02-ec95-4af5-b029-778b9071862e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_05662feb-33b6-4227-baaf-ac6ffab500ac_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests to common stock</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_4d3ec421-4407-4a7a-b8f5-f3c676f98b3b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ce3153db-e838-4c0a-a78a-8fddd86d8ae4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_ebec5196-767b-4366-b0e5-afac8cec3516_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4b34135a-8977-4380-846f-55a17e1b250f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_3b485bb7-a368-40c2-8c08-fd8c56b2024c_terseLabel_en-US" xlink:label="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Deferred Revenue</link:label>
    <link:label id="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_label_en-US" xlink:label="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Deferred Revenue [Table Text Block]</link:label>
    <link:label id="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_documentation_en-US" xlink:label="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of changes in deferred revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:href="carm-20231231.xsd#carm_ScheduleOfChangesInDeferredRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:to="lab_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9aed24fe-ea6e-489e-8c87-1983d6dab97e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock under Open Market Sales Agreement, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_def9fcaa-9b36-41c2-b7ef-5679b82247f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bfff2ab-98b6-43e0-9307-f88bfb8ea168_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_59a9c2e5-ec81-4f6c-8ddd-02bc6f4a816a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net assets acquired less transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_DeferredTaxAssetsStartUpCosts_1dac39b8-f13f-4307-87ff-3d368f19f8b9_terseLabel_en-US" xlink:label="lab_carm_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Start-up costs</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsStartUpCosts_label_en-US" xlink:label="lab_carm_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Start Up Costs</link:label>
    <link:label id="lab_carm_DeferredTaxAssetsStartUpCosts_documentation_en-US" xlink:label="lab_carm_DeferredTaxAssetsStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Start Up Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsStartUpCosts" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_DeferredTaxAssetsStartUpCosts" xlink:to="lab_carm_DeferredTaxAssetsStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fc0ee81c-bf73-4bfb-bcd5-0124ee5d6a4e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development services as collaboration revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_82563beb-5c04-49a4-a669-57aec54bbb40_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_392781d2-4ca1-42ec-aa6f-2c9b64142c63_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_474b753d-4e72-4af8-9241-d3bece7ad036_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_854a0cb8-b6af-49e4-aaed-8ae57844cac4_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_5ce3c436-476c-4837-b8b0-6fd780bad97b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_390bcab8-fc34-444e-bc04-e83d0263acef_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_cb315bd5-c689-48d4-83c7-b1363c6bb7a6_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:to="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_05aaafe3-40e5-4cba-8efd-b8c82f90b869_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6f6fe5fa-b468-4fa7-90a4-4c5ea334487f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d5f9bc47-7f83-4c40-86c0-672776785b60_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4d9bd5bc-b42d-4142-ab2a-2984c3c2c5f9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_f760e08a-d271-4833-90c9-13c38f4e4b69_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_1a96c98b-dd8d-45ba-a4a2-3e17c8cf24f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_MaximumOfResearchTargets_f5a36924-a9c3-49cb-bd5e-80571d922d91_terseLabel_en-US" xlink:label="lab_carm_MaximumOfResearchTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum of research targets</link:label>
    <link:label id="lab_carm_MaximumOfResearchTargets_label_en-US" xlink:label="lab_carm_MaximumOfResearchTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum of Research Targets</link:label>
    <link:label id="lab_carm_MaximumOfResearchTargets_documentation_en-US" xlink:label="lab_carm_MaximumOfResearchTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum number of research targets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MaximumOfResearchTargets" xlink:href="carm-20231231.xsd#carm_MaximumOfResearchTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_MaximumOfResearchTargets" xlink:to="lab_carm_MaximumOfResearchTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_b854829c-d603-4ccd-84e2-c1f776a9c0de_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_666d3fff-735a-4da7-b4fc-9973233f7163_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0307cf7f-25ff-466d-8d2b-6c76e4e0404c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_14bacc2b-23ab-45c5-8f9a-bf3938c4ad76_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_312c799a-40ec-4986-a0bc-d81a5280505f_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_94b136f6-facd-45ef-8c41-6e94aa790ef1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_00349884-ab6c-4825-a213-19d312a105f0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b093e411-493c-48a7-8e0b-e60217a47de8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2e5d4ddd-4482-4661-bc61-2815457bb2f4_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_1bbbd551-76c1-453b-b8ae-85ab6a635b6f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b7b953f1-2584-4819-b611-0d6fb08487d9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_37b3d553-95bf-4590-84a2-11f566fbdf98_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_4db11d8d-d716-4100-b5de-f056693062eb_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_faa9dab5-5396-49ea-80d0-921039438d1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d758907c-0f44-4760-8c66-c5dac8470fc7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_AtTheMarketOfferingMember_8591c28a-8871-4cb6-b343-10464a55f3df_terseLabel_en-US" xlink:label="lab_carm_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:label id="lab_carm_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_carm_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Offering [Member]</link:label>
    <link:label id="lab_carm_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_carm_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AtTheMarketOfferingMember" xlink:href="carm-20231231.xsd#carm_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_AtTheMarketOfferingMember" xlink:to="lab_carm_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_3f5470dd-dba1-4dc5-a278-edce2a647d59_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_67860019-b32c-4c81-af0c-b6dbcd146c63_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_3fa21ef4-9d87-4f26-92a9-295df8638702_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_92ef3601-e70c-4b8a-aaeb-97519043fd91_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_35d6cad0-b1fe-42a5-842f-da9950761a2d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at September 30, 2023</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_6ad520c0-5f5f-4ceb-84ff-0e43bb83c50b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_13191b4a-7069-48c7-bc34-f49453cb41cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible promissory note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_092aa6f0-ebbf-4751-b4a7-62dcf736d4bd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_b6649c42-a7ef-4322-baaf-3688d0ecd5d9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_adb99014-1060-4bba-b1d0-b00cae4d5ce2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_dd762309-7635-47ec-bfa2-58842235afed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_6b469e9b-a929-4a94-8e6f-a7f2ca7aeb2f_terseLabel_en-US" xlink:label="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible preferred stock and non-controlling interests upon Merger</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_label_en-US" xlink:label="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Equity Assumed</link:label>
    <link:label id="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_documentation_en-US" xlink:label="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:href="carm-20231231.xsd#carm_NoncashOrPartNoncashAcquisitionEquityAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:to="lab_carm_NoncashOrPartNoncashAcquisitionEquityAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NumberOfBoardMembers_7a761b83-7a38-4243-98b0-a8f528bb6959_terseLabel_en-US" xlink:label="lab_carm_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of board seats</link:label>
    <link:label id="lab_carm_NumberOfBoardMembers_label_en-US" xlink:label="lab_carm_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Board Members</link:label>
    <link:label id="lab_carm_NumberOfBoardMembers_documentation_en-US" xlink:label="lab_carm_NumberOfBoardMembers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Board Members</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfBoardMembers" xlink:href="carm-20231231.xsd#carm_NumberOfBoardMembers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NumberOfBoardMembers" xlink:to="lab_carm_NumberOfBoardMembers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_f0176c80-926b-40bc-a8f1-68d4bbe401e2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash used in finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b2ad73fd-de0a-4402-af7c-59050d3bb7fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_dac3dbf5-438c-4240-9be1-c462489edade_netLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total future minimum payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_b4ff0645-ad09-474a-b19b-f7e04d2c96b0_totalLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_e1314265-121f-4378-8346-b5fdccaae1b5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_bedc2023-1684-4000-8268-b12938aa0343_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e13fa5d7-1798-4516-bedd-190da4c02898_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_cb68b8f5-e6e0-41c1-9066-96e84ff879cf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationAbstract_9642824d-010e-4466-b85b-83f0af7594ea_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligations:</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Performance Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuePerformanceObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract" xlink:to="lab_us-gaap_RevenuePerformanceObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_be84bbd2-b46d-47af-ab25-503999ae241d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_abc65ccc-89d1-4877-80de-892026057cd2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_262deea1-386e-494e-9254-1cc3912ed5dc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6617384f-0f1d-4bf4-aef3-3ed5e92feaff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fef15f17-07ad-4470-9e0b-47825b6aa29d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_03e78432-d630-4bb6-90d2-7a886f0c3771_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_bab5f054-565a-424d-8972-d8f2b9a4985d_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_FinanceLeaseCostAbstract_e811be2f-5bc8-4b29-839f-75d1a784602a_terseLabel_en-US" xlink:label="lab_carm_FinanceLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_carm_FinanceLeaseCostAbstract_label_en-US" xlink:label="lab_carm_FinanceLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Cost [Abstract]</link:label>
    <link:label id="lab_carm_FinanceLeaseCostAbstract_documentation_en-US" xlink:label="lab_carm_FinanceLeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCostAbstract" xlink:href="carm-20231231.xsd#carm_FinanceLeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_FinanceLeaseCostAbstract" xlink:to="lab_carm_FinanceLeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_47dbfd38-ae0e-4d82-88bd-6e4cbc4bcb0b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Background</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3e7fcbed-2c0c-4327-a0d7-1236f75b5397_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b000c208-75e8-481c-9856-151988765ab0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_NonCashDeferredFinancingCostsAccruedExpenses_7cd177cb-6f36-4a5a-a59d-166d7d273b73_terseLabel_en-US" xlink:label="lab_carm_NonCashDeferredFinancingCostsAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs in accrued expenses</link:label>
    <link:label id="lab_carm_NonCashDeferredFinancingCostsAccruedExpenses_label_en-US" xlink:label="lab_carm_NonCashDeferredFinancingCostsAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Deferred Financing Costs, Accrued Expenses</link:label>
    <link:label id="lab_carm_NonCashDeferredFinancingCostsAccruedExpenses_documentation_en-US" xlink:label="lab_carm_NonCashDeferredFinancingCostsAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Deferred Financing Costs, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NonCashDeferredFinancingCostsAccruedExpenses" xlink:href="carm-20231231.xsd#carm_NonCashDeferredFinancingCostsAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_NonCashDeferredFinancingCostsAccruedExpenses" xlink:to="lab_carm_NonCashDeferredFinancingCostsAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_64f8f76a-ac62-4b34-b613-b5b94293cb10_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_f1528aad-34e6-4c8b-99f9-44e8fdf1b368_terseLabel_en-US" xlink:label="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock in pre-closing financing</link:label>
    <link:label id="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_label_en-US" xlink:label="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Pre-Closing Financing</link:label>
    <link:label id="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_documentation_en-US" xlink:label="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock, Pre-Closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:href="carm-20231231.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:to="lab_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_70b8a9a7-35ed-48d4-ade5-ad26c87355ed_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Moderna Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_afa53c9e-02b5-4caf-a71f-a4d4877dc0f1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9c58f306-f1f6-4287-bcd5-bf217b11af49_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c0e6a1ee-51ad-493d-ab92-02af445fa19d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_34bd0bda-8ad0-4928-a3c0-b503d4d3aef0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReduction_8c93e932-ddd7-46dd-a028-385ecbbe0b28_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</link:label>
    <link:label id="lab_us-gaap_NotesReduction_label_en-US" xlink:label="lab_us-gaap_NotesReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReduction" xlink:to="lab_us-gaap_NotesReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_carm_ConversionOfConvertiblePromissoryNoteMember_8071c2c8-cbe9-41a8-b87f-a74904e24d2c_terseLabel_en-US" xlink:label="lab_carm_ConversionOfConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible promissory note</link:label>
    <link:label id="lab_carm_ConversionOfConvertiblePromissoryNoteMember_label_en-US" xlink:label="lab_carm_ConversionOfConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Convertible Promissory Note [Member]</link:label>
    <link:label id="lab_carm_ConversionOfConvertiblePromissoryNoteMember_documentation_en-US" xlink:label="lab_carm_ConversionOfConvertiblePromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to conversion of convertible promissory note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConversionOfConvertiblePromissoryNoteMember" xlink:href="carm-20231231.xsd#carm_ConversionOfConvertiblePromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_carm_ConversionOfConvertiblePromissoryNoteMember" xlink:to="lab_carm_ConversionOfConvertiblePromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_42c855bd-1eab-443f-90ab-7a0c03d507e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_34ae15a3-e31f-46fd-9714-34003a92b683_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_8a146bdc-8174-4da3-948d-a2187f7f436d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>carm-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:343b8f26-08b5-463e-85bb-1b22c4b46cf9,g:eb5f3205-6aed-4489-877d-430d68a8a84b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://carismatx.com/role/Cover" xlink:type="simple" xlink:href="carm-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_87346cdd-576a-47cd-992d-d48508ca8331" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_DocumentType_87346cdd-576a-47cd-992d-d48508ca8331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_79ed0d0e-7904-4413-adc7-d8d4edcdcf57" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_DocumentAnnualReport_79ed0d0e-7904-4413-adc7-d8d4edcdcf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ba59f26f-c6e5-429e-bb0c-ab162ec24082" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_DocumentPeriodEndDate_ba59f26f-c6e5-429e-bb0c-ab162ec24082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_42db1048-5864-4723-ac7b-f2a82fdba688" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_CurrentFiscalYearEndDate_42db1048-5864-4723-ac7b-f2a82fdba688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b256876f-ffb4-4a61-b810-f7bba4bf5af0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_DocumentTransitionReport_b256876f-ffb4-4a61-b810-f7bba4bf5af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c8132b98-d8e0-4fc5-95dd-6447ce9a4bcc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityFileNumber_c8132b98-d8e0-4fc5-95dd-6447ce9a4bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a707575c-f034-4dec-a580-de405b91e7d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityRegistrantName_a707575c-f034-4dec-a580-de405b91e7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f0ceb541-a831-4f6f-bf46-9eff2a430a93" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f0ceb541-a831-4f6f-bf46-9eff2a430a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3ead001b-20bd-439a-8844-1e2f79bd0f5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityTaxIdentificationNumber_3ead001b-20bd-439a-8844-1e2f79bd0f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e2a5e49c-e87c-4ffa-9bec-5c92abc27e79" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityAddressAddressLine1_e2a5e49c-e87c-4ffa-9bec-5c92abc27e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_bcfcd150-b97c-4ba9-a3a3-6753e2831b9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityAddressAddressLine2_bcfcd150-b97c-4ba9-a3a3-6753e2831b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_66087be8-74e4-4187-aefe-3cde8f998e5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityAddressCityOrTown_66087be8-74e4-4187-aefe-3cde8f998e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1068c295-c16d-470c-b447-4ee62b397a51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityAddressStateOrProvince_1068c295-c16d-470c-b447-4ee62b397a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1c347c4b-9334-4eea-bd5a-110e55c42229" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityAddressPostalZipCode_1c347c4b-9334-4eea-bd5a-110e55c42229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6000e9d1-abf0-43ef-b956-516c0179e044" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_CityAreaCode_6000e9d1-abf0-43ef-b956-516c0179e044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_cfc22d48-c7ef-4de7-8276-7a57c1cfcd6c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_LocalPhoneNumber_cfc22d48-c7ef-4de7-8276-7a57c1cfcd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c92f5f60-9aac-4022-befa-7e7c404cb633" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_Security12bTitle_c92f5f60-9aac-4022-befa-7e7c404cb633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_87a9f539-0a77-4eff-9d0d-f895c5f02f36" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_TradingSymbol_87a9f539-0a77-4eff-9d0d-f895c5f02f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_478db33e-8324-4074-9ef7-4036562bbdfb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_SecurityExchangeName_478db33e-8324-4074-9ef7-4036562bbdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_97aeb9c1-2900-4ac9-b3ca-0d0907e5aa95" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_97aeb9c1-2900-4ac9-b3ca-0d0907e5aa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1b8b0229-9698-4361-b4f1-1fcc8bc7724f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityVoluntaryFilers_1b8b0229-9698-4361-b4f1-1fcc8bc7724f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a285b344-d2ca-4419-a672-7e2c1cae88fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityCurrentReportingStatus_a285b344-d2ca-4419-a672-7e2c1cae88fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_69ac4ad1-88f6-4977-880f-314c5dbfdace" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityInteractiveDataCurrent_69ac4ad1-88f6-4977-880f-314c5dbfdace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b131a934-9d5d-4266-b623-725b5e43dc8f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityFilerCategory_b131a934-9d5d-4266-b623-725b5e43dc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b98fedc5-4967-41ef-8585-ba8451d544a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntitySmallBusiness_b98fedc5-4967-41ef-8585-ba8451d544a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7d9f43f8-8d3c-4f22-ba7e-156ba49117f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityEmergingGrowthCompany_7d9f43f8-8d3c-4f22-ba7e-156ba49117f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5eb17888-ad06-4085-a80d-9e4e7991798f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5eb17888-ad06-4085-a80d-9e4e7991798f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_ac48ffa9-8ea8-42b4-9bb7-532d4784416f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_ac48ffa9-8ea8-42b4-9bb7-532d4784416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_56e9ccf2-b1e5-45df-80b7-22b4d898dfad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityShellCompany_56e9ccf2-b1e5-45df-80b7-22b4d898dfad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_34cc5bd4-a823-4b3f-a0f6-31d29ca8ac70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityPublicFloat_34cc5bd4-a823-4b3f-a0f6-31d29ca8ac70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ab7e8352-c207-4bc5-85d7-71e36d422251" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ab7e8352-c207-4bc5-85d7-71e36d422251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_830708c9-fce2-43b5-9463-3e712fc4c7ca" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_830708c9-fce2-43b5-9463-3e712fc4c7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5f0cda3c-440a-4010-b7db-7fa4a6b74f20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_EntityCentralIndexKey_5f0cda3c-440a-4010-b7db-7fa4a6b74f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_388d0347-a7a8-4b62-8fcc-33ca7ba75d36" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_AmendmentFlag_388d0347-a7a8-4b62-8fcc-33ca7ba75d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7453c482-7539-4a72-8580-04fdb4f46ebc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_DocumentFiscalYearFocus_7453c482-7539-4a72-8580-04fdb4f46ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5441b754-2afe-41e5-81fd-5b8273f7441a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a0a9a90-66d7-479f-965a-17b1c28e2060" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5441b754-2afe-41e5-81fd-5b8273f7441a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AuditInformation" xlink:type="simple" xlink:href="carm-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_carm_AuditInformationAbstract_9d28579f-1359-4b76-93c3-9036429af2c7" xlink:href="carm-20231231.xsd#carm_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_0779451c-63f2-43da-9771-d33f0e44c2db" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_AuditInformationAbstract_9d28579f-1359-4b76-93c3-9036429af2c7" xlink:to="loc_dei_AuditorFirmId_0779451c-63f2-43da-9771-d33f0e44c2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_32f24429-5771-43ce-9b66-4d5fb9b0c2d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_AuditInformationAbstract_9d28579f-1359-4b76-93c3-9036429af2c7" xlink:to="loc_dei_AuditorName_32f24429-5771-43ce-9b66-4d5fb9b0c2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_4502638e-2a85-4be8-b6f2-8ea143f96596" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_AuditInformationAbstract_9d28579f-1359-4b76-93c3-9036429af2c7" xlink:to="loc_dei_AuditorLocation_4502638e-2a85-4be8-b6f2-8ea143f96596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0657e92f-72d7-47b2-b94b-2748e02eb3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a1094759-d385-414b-83ae-b84cf476944b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0657e92f-72d7-47b2-b94b-2748e02eb3ef" xlink:to="loc_us-gaap_AssetsAbstract_a1094759-d385-414b-83ae-b84cf476944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2fe1749e-a7d9-44c3-9d7c-def7a3276227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a1094759-d385-414b-83ae-b84cf476944b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2fe1749e-a7d9-44c3-9d7c-def7a3276227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0109a5f5-6edc-477b-b6f5-4ddb414a8ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2fe1749e-a7d9-44c3-9d7c-def7a3276227" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0109a5f5-6edc-477b-b6f5-4ddb414a8ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_6607aeb6-e979-4da8-b95a-42d426ec1eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2fe1749e-a7d9-44c3-9d7c-def7a3276227" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_6607aeb6-e979-4da8-b95a-42d426ec1eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639f1092-d1f4-4309-9b7f-81058fcd1d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2fe1749e-a7d9-44c3-9d7c-def7a3276227" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_639f1092-d1f4-4309-9b7f-81058fcd1d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2d71e7d9-1991-4858-a959-7a52480e1ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2fe1749e-a7d9-44c3-9d7c-def7a3276227" xlink:to="loc_us-gaap_AssetsCurrent_2d71e7d9-1991-4858-a959-7a52480e1ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b56dedb8-3c48-4d00-b5b7-5f733109caff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a1094759-d385-414b-83ae-b84cf476944b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b56dedb8-3c48-4d00-b5b7-5f733109caff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_34d27fe0-b34d-4fdc-a275-1992e8ee40eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a1094759-d385-414b-83ae-b84cf476944b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_34d27fe0-b34d-4fdc-a275-1992e8ee40eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_3da1d5dc-9a4f-4ef1-a730-8aff985607f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a1094759-d385-414b-83ae-b84cf476944b" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_3da1d5dc-9a4f-4ef1-a730-8aff985607f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1ea032b5-3566-4d20-8a35-b79d5f7e7a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a1094759-d385-414b-83ae-b84cf476944b" xlink:to="loc_us-gaap_Assets_1ea032b5-3566-4d20-8a35-b79d5f7e7a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0657e92f-72d7-47b2-b94b-2748e02eb3ef" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_36c6a05b-2df3-4c73-9426-df47b1dab112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:to="loc_us-gaap_AccountsPayableCurrent_36c6a05b-2df3-4c73-9426-df47b1dab112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7475bf68-87c9-47c2-a715-7614c12f762b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7475bf68-87c9-47c2-a715-7614c12f762b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_cac1ed38-2904-47d2-b5ac-acdac7191934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:to="loc_us-gaap_DeferredRevenueCurrent_cac1ed38-2904-47d2-b5ac-acdac7191934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_184bfa77-ad82-4e76-b602-6b416b876688" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_184bfa77-ad82-4e76-b602-6b416b876688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_08881287-3ab8-4c82-864c-38bf41b105f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_08881287-3ab8-4c82-864c-38bf41b105f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b0a937b2-381e-41e1-a47c-ae1f632691ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b0a937b2-381e-41e1-a47c-ae1f632691ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c39ebda2-57ea-41fa-a6e1-3083f98484bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_705be8ba-0aec-45c6-98fa-bf8f0477463c" xlink:to="loc_us-gaap_LiabilitiesCurrent_c39ebda2-57ea-41fa-a6e1-3083f98484bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_3876f7f0-d909-4c29-9b48-5d998fbeee58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_3876f7f0-d909-4c29-9b48-5d998fbeee58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_7b1b204e-00a5-4445-9d93-eb81abc8d132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_7b1b204e-00a5-4445-9d93-eb81abc8d132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_929f6f69-3c19-4c3c-b021-088bf320352d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_929f6f69-3c19-4c3c-b021-088bf320352d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17c0cb03-8849-4920-a079-76cf4156c79d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_17c0cb03-8849-4920-a079-76cf4156c79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_64686472-c621-4f56-9476-5c8d90754f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_64686472-c621-4f56-9476-5c8d90754f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9e0e317b-e985-4d37-b8a8-d6aa6e8d5f86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9e0e317b-e985-4d37-b8a8-d6aa6e8d5f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8377b952-3132-4795-b115-566c199677d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_Liabilities_8377b952-3132-4795-b115-566c199677d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b28a9ba2-6ae1-4ccc-8497-a24e2edbfa16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b28a9ba2-6ae1-4ccc-8497-a24e2edbfa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3f3c95d7-6a3a-449c-8493-dd72f4057c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_3f3c95d7-6a3a-449c-8493-dd72f4057c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_98b3e7da-dd64-4d62-bdeb-3e18dd4d73c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:to="loc_us-gaap_PreferredStockValue_98b3e7da-dd64-4d62-bdeb-3e18dd4d73c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2f37afcd-e7fb-4267-a809-dc3d533e2163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:to="loc_us-gaap_CommonStockValue_2f37afcd-e7fb-4267-a809-dc3d533e2163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_8563ece0-7b72-45c8-822e-2bff8ef5b771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:to="loc_us-gaap_AdditionalPaidInCapital_8563ece0-7b72-45c8-822e-2bff8ef5b771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1f0f77d7-56e3-490d-9d17-6db2bd697961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1f0f77d7-56e3-490d-9d17-6db2bd697961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62fa6cd8-2953-44f9-bd9d-361294bcebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62fa6cd8-2953-44f9-bd9d-361294bcebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4d17e23b-08be-4b87-8ca6-5da9b555d069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:to="loc_us-gaap_StockholdersEquity_4d17e23b-08be-4b87-8ca6-5da9b555d069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_7d9b885b-67e7-42f4-b956-0c5c71fd7656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:to="loc_us-gaap_MinorityInterest_7d9b885b-67e7-42f4-b956-0c5c71fd7656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb96e23-17e5-4cbb-9096-a21dd0323203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_b94fff1f-756c-4ef5-af6f-59120dc16584" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5fb96e23-17e5-4cbb-9096-a21dd0323203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a17cb026-f8b7-4a83-be11-254446a11b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e1569618-c929-40ee-9430-7da2b3b6153f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a17cb026-f8b7-4a83-be11-254446a11b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8125a2f8-8db6-4d37-ad39-876353551ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8125a2f8-8db6-4d37-ad39-876353551ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_74389218-a3a5-4f83-ab25-e258c42c9993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_74389218-a3a5-4f83-ab25-e258c42c9993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_44bb3c62-182c-4163-ac77-8b4a89bd19c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_44bb3c62-182c-4163-ac77-8b4a89bd19c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cf58248f-0348-4ec6-b703-75ba5037c853" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cf58248f-0348-4ec6-b703-75ba5037c853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_07bcfc3b-1659-45f9-9002-01c1888b4b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_07bcfc3b-1659-45f9-9002-01c1888b4b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_26f91151-4b96-4f63-8080-ef48598bba7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_26f91151-4b96-4f63-8080-ef48598bba7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8d996024-1960-4962-804f-0e9595772e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:to="loc_us-gaap_CommonStockSharesIssued_8d996024-1960-4962-804f-0e9595772e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_83256a5d-3043-4a06-8380-a765ad7108c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_562aaa70-a43a-4435-8d10-1e2a0d6df51c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_83256a5d-3043-4a06-8380-a765ad7108c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c3d16c75-248a-46ce-a4f1-62922d4b2bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c3d16c75-248a-46ce-a4f1-62922d4b2bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_44cb4934-c32b-4dc8-bb29-e1b31e4991da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:to="loc_us-gaap_OperatingExpensesAbstract_44cb4934-c32b-4dc8-bb29-e1b31e4991da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_04fa4237-be43-459a-9080-9a2b1300a353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44cb4934-c32b-4dc8-bb29-e1b31e4991da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_04fa4237-be43-459a-9080-9a2b1300a353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cecb324f-8705-4277-a781-8429830c6586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44cb4934-c32b-4dc8-bb29-e1b31e4991da" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cecb324f-8705-4277-a781-8429830c6586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3972b01c-40bc-47c8-a04d-f68bd433a079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_44cb4934-c32b-4dc8-bb29-e1b31e4991da" xlink:to="loc_us-gaap_OperatingExpenses_3972b01c-40bc-47c8-a04d-f68bd433a079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2726ee63-06bf-43a4-8608-5576194e1e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:to="loc_us-gaap_OperatingIncomeLoss_2726ee63-06bf-43a4-8608-5576194e1e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_0b87faf4-3be5-4fce-9dd4-a8da6df97c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_0b87faf4-3be5-4fce-9dd4-a8da6df97c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0a657e72-c327-4d10-adfe-de7e644f9420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_0a657e72-c327-4d10-adfe-de7e644f9420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7e661bf2-63b5-4282-9696-02ac9f7c871c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:to="loc_us-gaap_NetIncomeLoss_7e661bf2-63b5-4282-9696-02ac9f7c871c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f7dd221a-f139-406a-8421-79a19e23db95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f7dd221a-f139-406a-8421-79a19e23db95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d711a058-7e2c-4f1e-9852-a08c0c9c4bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7dd221a-f139-406a-8421-79a19e23db95" xlink:to="loc_us-gaap_EarningsPerShareBasic_d711a058-7e2c-4f1e-9852-a08c0c9c4bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_79f97b24-f331-43ec-8b67-c711976aa32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7dd221a-f139-406a-8421-79a19e23db95" xlink:to="loc_us-gaap_EarningsPerShareDiluted_79f97b24-f331-43ec-8b67-c711976aa32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_080f7e57-abf2-4e64-ac34-5a2d707dd63a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7dd221a-f139-406a-8421-79a19e23db95" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_080f7e57-abf2-4e64-ac34-5a2d707dd63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86a76779-d676-4314-a2c9-65afe0ccb3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f7dd221a-f139-406a-8421-79a19e23db95" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_86a76779-d676-4314-a2c9-65afe0ccb3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_7f618263-bc59-474d-8d51-161e57e655c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1e920d60-8565-4540-a0df-fb16d4cee933" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_7f618263-bc59-474d-8d51-161e57e655c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_755e3641-a692-47ca-83a8-3c7e665596af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_7f618263-bc59-474d-8d51-161e57e655c5" xlink:to="loc_us-gaap_NetIncomeLoss_755e3641-a692-47ca-83a8-3c7e665596af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7a0fc4e5-1098-4e2d-b1da-4fd4127d9eef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_7f618263-bc59-474d-8d51-161e57e655c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7a0fc4e5-1098-4e2d-b1da-4fd4127d9eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_382f956c-1ebd-4915-b569-c3b85588385b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_7f618263-bc59-474d-8d51-161e57e655c5" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_382f956c-1ebd-4915-b569-c3b85588385b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f33f58ee-47b0-4393-bd88-f6bc51a8b9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_7f618263-bc59-474d-8d51-161e57e655c5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f33f58ee-47b0-4393-bd88-f6bc51a8b9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8fb02dc3-0a3a-4d70-82fc-792af14e4844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e1f45f70-5c05-452b-9d0a-ee07d1587aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8fb02dc3-0a3a-4d70-82fc-792af14e4844" xlink:to="loc_us-gaap_StatementTable_e1f45f70-5c05-452b-9d0a-ee07d1587aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_caa57308-382d-49ce-8115-14fc738eed84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1f45f70-5c05-452b-9d0a-ee07d1587aef" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_caa57308-382d-49ce-8115-14fc738eed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_caa57308-382d-49ce-8115-14fc738eed84" xlink:to="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e10ed4a4-0ccc-443b-a670-21a7e08251cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_CommonStockMember_e10ed4a4-0ccc-443b-a670-21a7e08251cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b6d9c87e-189f-4ec3-8ff6-3e8528fed4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b6d9c87e-189f-4ec3-8ff6-3e8528fed4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4730d72f-50cb-4eb8-8cf0-59f1d5cbec1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4730d72f-50cb-4eb8-8cf0-59f1d5cbec1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f54c1563-934a-434c-997a-ee18d904da72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_RetainedEarningsMember_f54c1563-934a-434c-997a-ee18d904da72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b723f0b0-20ed-4609-962a-b8390f856fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1302fbc9-ee37-45df-ac90-863715e653a5" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b723f0b0-20ed-4609-962a-b8390f856fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8c7c1a5e-21c6-4d11-9c11-f72c648f53b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1f45f70-5c05-452b-9d0a-ee07d1587aef" xlink:to="loc_us-gaap_StatementLineItems_8c7c1a5e-21c6-4d11-9c11-f72c648f53b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8c7c1a5e-21c6-4d11-9c11-f72c648f53b7" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_00be95e3-9b24-4259-be6a-5b265c19919c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_00be95e3-9b24-4259-be6a-5b265c19919c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_b30bdd5a-89d0-4906-bf8e-4c84ee7266cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_b30bdd5a-89d0-4906-bf8e-4c84ee7266cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares_3ac192cc-cd83-4e48-a3b0-0942b4a82743" xlink:href="carm-20231231.xsd#carm_ReclassificationsOfTemporaryToPermanentEquityShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_carm_ReclassificationsOfTemporaryToPermanentEquityShares_3ac192cc-cd83-4e48-a3b0-0942b4a82743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_46022314-cb44-4812-97f6-d8720e325d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_46022314-cb44-4812-97f6-d8720e325d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_40888aee-fa73-4e55-ad2c-29dca172d759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_40888aee-fa73-4e55-ad2c-29dca172d759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_c01da847-111d-45b2-8902-ce174caf9df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_223a8ffd-2546-47da-85b0-abac98f93010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_c01da847-111d-45b2-8902-ce174caf9df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8c7c1a5e-21c6-4d11-9c11-f72c648f53b7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_55b8b66d-6652-4f9a-96c4-ed0fad80266d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_SharesIssued_55b8b66d-6652-4f9a-96c4-ed0fad80266d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ca14ca8-5d76-4b92-9081-833d7ad6283c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ca14ca8-5d76-4b92-9081-833d7ad6283c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0cb04dfe-f752-412b-a36b-0e416a190c44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0cb04dfe-f752-412b-a36b-0e416a190c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b7f62b2a-2a1c-4c91-9646-e4a9dbca65ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b7f62b2a-2a1c-4c91-9646-e4a9dbca65ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a13fcd19-f63f-43c3-9ef9-7ce07dc5fab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a13fcd19-f63f-43c3-9ef9-7ce07dc5fab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d9f3e126-cbb4-488b-b7dc-019e6797813b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d9f3e126-cbb4-488b-b7dc-019e6797813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_3784d862-5b5e-4180-912f-211027bfc6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_3784d862-5b5e-4180-912f-211027bfc6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_837aa6d4-c621-42f4-962b-c39040037e18" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction_837aa6d4-c621-42f4-962b-c39040037e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_f60c4f90-6625-4cd6-8591-082c4799c373" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction_f60c4f90-6625-4cd6-8591-082c4799c373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_da0f8338-6d02-4795-9f5d-ad523219ff25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_da0f8338-6d02-4795-9f5d-ad523219ff25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c5c5725d-1dec-4a59-a671-bb40cd1a95f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c5c5725d-1dec-4a59-a671-bb40cd1a95f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e4a1d09a-5108-4b29-ade1-a0677a9f7df5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e4a1d09a-5108-4b29-ade1-a0677a9f7df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fceac2b7-aaee-4df8-8f38-eea84b33997c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_fceac2b7-aaee-4df8-8f38-eea84b33997c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_bfaef723-cb4a-4593-81b8-5215528c0c1b" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_bfaef723-cb4a-4593-81b8-5215528c0c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_b204b826-ad59-4127-b96f-ad6443a51f8d" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger_b204b826-ad59-4127-b96f-ad6443a51f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_650064c2-5f40-4c6b-b4ad-a584a9e3e0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_650064c2-5f40-4c6b-b4ad-a584a9e3e0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_661325ff-fc64-4e02-8a19-df2d83534ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_661325ff-fc64-4e02-8a19-df2d83534ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a8d2085d-9326-4298-9071-2bb63f2a4531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_ProfitLoss_a8d2085d-9326-4298-9071-2bb63f2a4531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_22a52bee-fac1-4005-97ad-811b81f4c60b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_SharesIssued_22a52bee-fac1-4005-97ad-811b81f4c60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_440926a4-4e3a-40a6-aea4-98d058af7985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7e9b7066-e1a8-4b41-92ee-761afc276263" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_440926a4-4e3a-40a6-aea4-98d058af7985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="carm-20231231.xsd#ConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60bbff37-6bec-487a-a1cd-02b656e5388d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60bbff37-6bec-487a-a1cd-02b656e5388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7966a8a1-2245-467b-915b-1229408d4c13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60bbff37-6bec-487a-a1cd-02b656e5388d" xlink:to="loc_us-gaap_ProfitLoss_7966a8a1-2245-467b-915b-1229408d4c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60bbff37-6bec-487a-a1cd-02b656e5388d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9f290a11-b3d5-4c32-82db-ab058253e50f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_us-gaap_DepreciationAndAmortization_9f290a11-b3d5-4c32-82db-ab058253e50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1cd0dc77-9e0c-4f58-8c5c-d2d46bb03456" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1cd0dc77-9e0c-4f58-8c5c-d2d46bb03456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3ce8f1b2-2d27-43de-80c9-e5dd1b529156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_us-gaap_ShareBasedCompensation_3ce8f1b2-2d27-43de-80c9-e5dd1b529156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f00b5373-dced-472a-8b76-80ac2908a268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f00b5373-dced-472a-8b76-80ac2908a268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_877166f0-d9b3-42d3-a3ad-2748200c0652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_877166f0-d9b3-42d3-a3ad-2748200c0652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ba762e71-0c24-4b4e-a0ea-b8c78e16ba53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_ba762e71-0c24-4b4e-a0ea-b8c78e16ba53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccretionOnMarketableSecurities_fcda9321-8c13-4595-a805-b299882f4092" xlink:href="carm-20231231.xsd#carm_AccretionOnMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_carm_AccretionOnMarketableSecurities_fcda9321-8c13-4595-a805-b299882f4092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_884a8966-ea0b-41ae-9f93-d5019dd0ab6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_884a8966-ea0b-41ae-9f93-d5019dd0ab6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashInterestExpense_205b626b-4a16-4ba6-aecc-259badf74b4a" xlink:href="carm-20231231.xsd#carm_NoncashInterestExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_carm_NoncashInterestExpense_205b626b-4a16-4ba6-aecc-259badf74b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dd15ad6-4387-47eb-8976-f8768e74e5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_390e39b5-b59b-4a2c-8b69-731d482c5da5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dd15ad6-4387-47eb-8976-f8768e74e5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_856f3579-6016-428f-b45f-32242f9384cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dd15ad6-4387-47eb-8976-f8768e74e5ad" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_856f3579-6016-428f-b45f-32242f9384cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c009f2d6-8113-4b7b-9cf8-320a77372d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dd15ad6-4387-47eb-8976-f8768e74e5ad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c009f2d6-8113-4b7b-9cf8-320a77372d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1d56e8da-4316-435e-a43e-aedeb0555297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dd15ad6-4387-47eb-8976-f8768e74e5ad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1d56e8da-4316-435e-a43e-aedeb0555297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_23b2b774-49de-4139-b93d-44559ee580cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dd15ad6-4387-47eb-8976-f8768e74e5ad" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_23b2b774-49de-4139-b93d-44559ee580cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_56953956-d9cd-49f9-94da-d4ece59a4531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dd15ad6-4387-47eb-8976-f8768e74e5ad" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_56953956-d9cd-49f9-94da-d4ece59a4531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_94e1ded9-1c95-49ab-97c1-3ba2f6e2fab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9dd15ad6-4387-47eb-8976-f8768e74e5ad" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_94e1ded9-1c95-49ab-97c1-3ba2f6e2fab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_006daf3e-4ce7-4bac-b452-c78f92727b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_60bbff37-6bec-487a-a1cd-02b656e5388d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_006daf3e-4ce7-4bac-b452-c78f92727b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d6e9d42d-5325-4610-9a51-ff14b107effb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d6e9d42d-5325-4610-9a51-ff14b107effb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9de803c4-6992-455c-8df9-6679e33430ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d6e9d42d-5325-4610-9a51-ff14b107effb" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9de803c4-6992-455c-8df9-6679e33430ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentsForProceedsFromMarketableSecurities_dccbfa9c-8149-41e4-a081-468e9c44c2e4" xlink:href="carm-20231231.xsd#carm_PaymentsForProceedsFromMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d6e9d42d-5325-4610-9a51-ff14b107effb" xlink:to="loc_carm_PaymentsForProceedsFromMarketableSecurities_dccbfa9c-8149-41e4-a081-468e9c44c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26253334-c577-4dd1-8b43-9b288367167c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d6e9d42d-5325-4610-9a51-ff14b107effb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_26253334-c577-4dd1-8b43-9b288367167c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3b61df33-34b5-4db5-9d1f-6df849567aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d6e9d42d-5325-4610-9a51-ff14b107effb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3b61df33-34b5-4db5-9d1f-6df849567aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_ff98431a-00cd-46fc-8c02-04cc7c5f6636" xlink:href="carm-20231231.xsd#carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities_ff98431a-00cd-46fc-8c02-04cc7c5f6636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_9d5f87c1-7739-4a47-829b-31d75193424b" xlink:href="carm-20231231.xsd#carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities_9d5f87c1-7739-4a47-829b-31d75193424b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_6dae59bf-f2d6-4d26-be66-06195db84a68" xlink:href="carm-20231231.xsd#carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing_6dae59bf-f2d6-4d26-be66-06195db84a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_4593a75e-0ab8-45bc-9249-507b269adefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_4593a75e-0ab8-45bc-9249-507b269adefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromFailedSaleLeasebackTransaction_4410561a-ecfa-4bc8-bb9c-70f01fb11730" xlink:href="carm-20231231.xsd#carm_ProceedsFromFailedSaleLeasebackTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_carm_ProceedsFromFailedSaleLeasebackTransaction_4410561a-ecfa-4bc8-bb9c-70f01fb11730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_880a59c6-3aa8-49a5-b447-f036b56c25d2" xlink:href="carm-20231231.xsd#carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction_880a59c6-3aa8-49a5-b447-f036b56c25d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_b0306720-8713-4b3f-b169-78553e3c5e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_b0306720-8713-4b3f-b169-78553e3c5e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_4e288777-8d37-48f7-9fdc-4a2caeacbe9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_4e288777-8d37-48f7-9fdc-4a2caeacbe9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c025924b-fa4a-4d53-baa2-771151641527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c025924b-fa4a-4d53-baa2-771151641527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e32d9279-5c6b-43b8-b717-d84653bac578" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e32d9279-5c6b-43b8-b717-d84653bac578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5824d4af-5f99-48d0-905a-8ca916d99d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_985e65ef-8051-4682-aa5d-6559a95c04cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5824d4af-5f99-48d0-905a-8ca916d99d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_73d80a38-acec-493a-9e44-497f077bcca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_73d80a38-acec-493a-9e44-497f077bcca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35bac974-0e09-4054-a5b8-0e71ee0eb2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35bac974-0e09-4054-a5b8-0e71ee0eb2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aead7aeb-1e60-4fcb-8f22-d65eb8e4acf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aead7aeb-1e60-4fcb-8f22-d65eb8e4acf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dc21295-da32-423e-90dd-507782bc73bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dc21295-da32-423e-90dd-507782bc73bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_991a17fd-a9d8-40b2-b479-dbf198889a45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dc21295-da32-423e-90dd-507782bc73bd" xlink:to="loc_us-gaap_InterestPaidNet_991a17fd-a9d8-40b2-b479-dbf198889a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_411bd6cf-6337-497d-80f9-bc31dfc6bb7d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_2d3d4511-4411-4e1f-badb-42c4bdfae3fd" xlink:href="carm-20231231.xsd#carm_NoncashOrPartNoncashAcquisitionEquityAssumed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:to="loc_carm_NoncashOrPartNoncashAcquisitionEquityAssumed_2d3d4511-4411-4e1f-badb-42c4bdfae3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReduction_7362d226-5de8-46b4-90d9-f7f8c9f605fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:to="loc_us-gaap_NotesReduction_7362d226-5de8-46b4-90d9-f7f8c9f605fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_aede538b-01d4-4237-942c-0a5a17125622" xlink:href="carm-20231231.xsd#carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:to="loc_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities_aede538b-01d4-4237-942c-0a5a17125622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NonCashDeferredFinancingCostsAccruedExpenses_8563b5dc-3e4a-4eca-b188-bd833ab82a8d" xlink:href="carm-20231231.xsd#carm_NonCashDeferredFinancingCostsAccruedExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:to="loc_carm_NonCashDeferredFinancingCostsAccruedExpenses_8563b5dc-3e4a-4eca-b188-bd833ab82a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_80ce4bad-2bf7-4dfe-8c52-866a7b8563b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_80ce4bad-2bf7-4dfe-8c52-866a7b8563b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_f05ba0df-56df-4a68-9103-499adf2c269f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_f05ba0df-56df-4a68-9103-499adf2c269f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_752a3890-63bb-4ef6-91ae-1b308ce017c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_50c5e482-ea94-4548-84e0-d30a71f42758" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1_752a3890-63bb-4ef6-91ae-1b308ce017c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/Background" xlink:type="simple" xlink:href="carm-20231231.xsd#Background"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/Background" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6543e60d-a64d-499d-96f9-f4e0e26a1fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bd7340f5-3b52-4d2d-b0e6-18284d84ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6543e60d-a64d-499d-96f9-f4e0e26a1fe3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bd7340f5-3b52-4d2d-b0e6-18284d84ef52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/DevelopmentStageRisksandLiquidity" xlink:type="simple" xlink:href="carm-20231231.xsd#DevelopmentStageRisksandLiquidity"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/DevelopmentStageRisksandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_a998715b-ca5b-4d7e-af6d-05ee3717a397" xlink:href="carm-20231231.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityTableTextBlock_f23ef9bc-f10f-4d38-9108-e8b4a62a8cce" xlink:href="carm-20231231.xsd#carm_DevelopmentStageRisksAndLiquidityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_a998715b-ca5b-4d7e-af6d-05ee3717a397" xlink:to="loc_carm_DevelopmentStageRisksAndLiquidityTableTextBlock_f23ef9bc-f10f-4d38-9108-e8b4a62a8cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a5cbd6c0-4795-4f7d-b33e-ab8ab11b0420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a9621774-3186-4768-a78b-fed4b415d0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5cbd6c0-4795-4f7d-b33e-ab8ab11b0420" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a9621774-3186-4768-a78b-fed4b415d0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBio" xlink:type="simple" xlink:href="carm-20231231.xsd#MergerwithSesenBio"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/MergerwithSesenBio" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c9c82694-28b8-4835-8be2-048f4c288154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e71984c3-8abd-4162-93f8-9b84a4310c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c9c82694-28b8-4835-8be2-048f4c288154" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_e71984c3-8abd-4162-93f8-9b84a4310c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="carm-20231231.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bacb3a39-ecb5-4c0d-8572-7b8e44c2b6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7d9532b5-408b-4c78-bcc3-8c96920eef7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bacb3a39-ecb5-4c0d-8572-7b8e44c2b6a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_7d9532b5-408b-4c78-bcc3-8c96920eef7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="carm-20231231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3bf68627-c3a7-4c72-9ebd-defbda4443fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_20b0823b-9628-4fff-9b47-6991538c4efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3bf68627-c3a7-4c72-9ebd-defbda4443fb" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_20b0823b-9628-4fff-9b47-6991538c4efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15953f74-c97f-4e74-bf85-a594d60672bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0285671b-a3f9-4528-b6c6-a4dbbaa2b794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15953f74-c97f-4e74-bf85-a594d60672bb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0285671b-a3f9-4528-b6c6-a4dbbaa2b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="carm-20231231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8d4cda21-4c5a-4ae8-97be-95ae94337b30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ac09e20a-3090-4749-ae02-2600d15d7392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8d4cda21-4c5a-4ae8-97be-95ae94337b30" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ac09e20a-3090-4749-ae02-2600d15d7392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be834b42-15d0-4d9b-946a-c6aed2986662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6eb2ac15-2015-42b0-b62c-546261e77b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be834b42-15d0-4d9b-946a-c6aed2986662" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6eb2ac15-2015-42b0-b62c-546261e77b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="carm-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_92ef00d3-7ee5-4664-9f29-14c0ab5c9993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ef127562-e4df-4c11-ad75-68bc37f9b36f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92ef00d3-7ee5-4664-9f29-14c0ab5c9993" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ef127562-e4df-4c11-ad75-68bc37f9b36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="carm-20231231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6528420f-16a3-45f3-b2da-ceebc0a02619" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ab8ecbe2-2786-4d10-a07f-579139161e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6528420f-16a3-45f3-b2da-ceebc0a02619" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ab8ecbe2-2786-4d10-a07f-579139161e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreement" xlink:type="simple" xlink:href="carm-20231231.xsd#ModernaCollaborationandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_35a51be3-ab06-4869-8118-0d8de34110dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7a4011b5-7754-4d55-b0bd-00dfa8ff3cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_35a51be3-ab06-4869-8118-0d8de34110dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7a4011b5-7754-4d55-b0bd-00dfa8ff3cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="carm-20231231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6d11323a-eea3-48b9-9977-f7024a579bef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_b7f4913f-5480-4d32-a6b2-133c4b309af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6d11323a-eea3-48b9-9977-f7024a579bef" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_b7f4913f-5480-4d32-a6b2-133c4b309af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82d10097-6c36-4bb7-929a-3ea4c4c0e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_82d10097-6c36-4bb7-929a-3ea4c4c0e66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_296aba82-efd9-440c-8b19-ac5540daf9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_UseOfEstimates_296aba82-efd9-440c-8b19-ac5540daf9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7b534ab4-545e-4422-bf59-b8f421b64485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7b534ab4-545e-4422-bf59-b8f421b64485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e1e835c5-eaeb-4606-9e5c-b0c64ebcce67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e1e835c5-eaeb-4606-9e5c-b0c64ebcce67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_227b39cb-a6c7-4dd4-95cb-2b94ca46d447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_227b39cb-a6c7-4dd4-95cb-2b94ca46d447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c1506bb0-0726-40e3-986b-7f66e4bf2154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c1506bb0-0726-40e3-986b-7f66e4bf2154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e1ac3981-003e-4528-a016-74f802359ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e1ac3981-003e-4528-a016-74f802359ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7a5bc659-e8e3-4209-a378-7aa1fa170b90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7a5bc659-e8e3-4209-a378-7aa1fa170b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_ca4c5b4d-e7a1-418f-8efc-86817d898848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_ca4c5b4d-e7a1-418f-8efc-86817d898848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c0188a47-f4a6-4c51-93fb-2546b118fd73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c0188a47-f4a6-4c51-93fb-2546b118fd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bf8f6ff1-34a2-48f8-885c-da81406ce0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bf8f6ff1-34a2-48f8-885c-da81406ce0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredFinancingCostsPolicyPolicyTextBlock_03d39738-520c-4508-8eda-87dcd1b8fbc9" xlink:href="carm-20231231.xsd#carm_DeferredFinancingCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_carm_DeferredFinancingCostsPolicyPolicyTextBlock_03d39738-520c-4508-8eda-87dcd1b8fbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_0ee13887-9317-496f-9c06-ba0962158fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_0ee13887-9317-496f-9c06-ba0962158fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_328003af-20d6-4041-aea0-b578ba7575ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_328003af-20d6-4041-aea0-b578ba7575ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7bdf549d-94e9-4690-acf7-4847004dc92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7bdf549d-94e9-4690-acf7-4847004dc92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d0daba97-19ff-4b17-902b-4bb38ed0b9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d0daba97-19ff-4b17-902b-4bb38ed0b9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6062fd33-a767-4f8e-82c4-a5a87ab8527c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6062fd33-a767-4f8e-82c4-a5a87ab8527c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9cb3dcbc-b263-4d4e-b441-e0c80dc7e790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9cb3dcbc-b263-4d4e-b441-e0c80dc7e790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a0b06fb1-a0bd-44e1-b5ed-43e363ae1740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c811f8c-baa8-4fa2-aa44-ce0b2f8cca26" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a0b06fb1-a0bd-44e1-b5ed-43e363ae1740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c7e4a4f-2b3c-41d6-b8d6-fd95636228df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_39eddb30-f815-4b95-b258-3a79c52dcf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c7e4a4f-2b3c-41d6-b8d6-fd95636228df" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_39eddb30-f815-4b95-b258-3a79c52dcf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_fa26278d-a76e-4214-a99f-8d02d6247244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c7e4a4f-2b3c-41d6-b8d6-fd95636228df" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_fa26278d-a76e-4214-a99f-8d02d6247244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_dda5356e-ad1b-4e4a-b355-532be24e7d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c7e4a4f-2b3c-41d6-b8d6-fd95636228df" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_dda5356e-ad1b-4e4a-b355-532be24e7d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ba625971-2b7d-496d-8382-8c91f06f7a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c7e4a4f-2b3c-41d6-b8d6-fd95636228df" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ba625971-2b7d-496d-8382-8c91f06f7a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioTables" xlink:type="simple" xlink:href="carm-20231231.xsd#MergerwithSesenBioTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_95543b80-fc6b-44e7-ac4f-15dbe42c7fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c08333c8-bb60-4908-a725-fd38153852de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_95543b80-fc6b-44e7-ac4f-15dbe42c7fb2" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c08333c8-bb60-4908-a725-fd38153852de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="carm-20231231.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9f4e919a-e547-483a-ba52-b3cde788426a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d3045962-c0fc-4896-956b-b03a4738b5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9f4e919a-e547-483a-ba52-b3cde788426a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_d3045962-c0fc-4896-956b-b03a4738b5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="carm-20231231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e02b2d18-d508-4192-971f-946d70140cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_779a3b49-5297-47e3-81e2-55e6e4c78fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e02b2d18-d508-4192-971f-946d70140cde" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_779a3b49-5297-47e3-81e2-55e6e4c78fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f564f792-2867-463c-9c15-ad373602ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1035b4c0-4f14-4412-9cfd-3a10f6bb93ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f564f792-2867-463c-9c15-ad373602ce22" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1035b4c0-4f14-4412-9cfd-3a10f6bb93ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_95c96c88-30f8-4df5-8160-61edb561733d" xlink:href="carm-20231231.xsd#carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f564f792-2867-463c-9c15-ad373602ce22" xlink:to="loc_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock_95c96c88-30f8-4df5-8160-61edb561733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_ee4d2904-1ced-43c8-bf04-cc4a0153d789" xlink:href="carm-20231231.xsd#carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f564f792-2867-463c-9c15-ad373602ce22" xlink:to="loc_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_ee4d2904-1ced-43c8-bf04-cc4a0153d789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_321f3038-c910-4f04-9e7b-4eb114049e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f564f792-2867-463c-9c15-ad373602ce22" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_321f3038-c910-4f04-9e7b-4eb114049e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_b4612f41-269a-4e80-8a3f-363f822f0a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f564f792-2867-463c-9c15-ad373602ce22" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_b4612f41-269a-4e80-8a3f-363f822f0a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac9ae642-baea-4746-b3a7-01e944bc42e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6b6794f5-3297-4d82-bc11-1a1f3d701508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac9ae642-baea-4746-b3a7-01e944bc42e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6b6794f5-3297-4d82-bc11-1a1f3d701508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c04cce98-7676-43c6-bf43-06f171a2642d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac9ae642-baea-4746-b3a7-01e944bc42e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c04cce98-7676-43c6-bf43-06f171a2642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_32e0580e-cdd1-4278-b391-e9465d42af1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac9ae642-baea-4746-b3a7-01e944bc42e5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_32e0580e-cdd1-4278-b391-e9465d42af1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="carm-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_02d830f5-4a3f-4f4c-9c05-4657ec0c58c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e58fa0e2-69dd-4a13-9ca0-f0f644e5669b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02d830f5-4a3f-4f4c-9c05-4657ec0c58c7" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e58fa0e2-69dd-4a13-9ca0-f0f644e5669b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3c6d5ad4-ad37-45a2-b806-bf4b8f0610f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02d830f5-4a3f-4f4c-9c05-4657ec0c58c7" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3c6d5ad4-ad37-45a2-b806-bf4b8f0610f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables" xlink:type="simple" xlink:href="carm-20231231.xsd#ModernaCollaborationandLicenseAgreementTables"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6390cb92-1e72-4043-88e0-e5e7d0293593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_0ec0db49-a21f-46cd-b432-11c32cfd15be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6390cb92-1e72-4043-88e0-e5e7d0293593" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_0ec0db49-a21f-46cd-b432-11c32cfd15be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_2b4cb99e-4005-4899-a74d-9def91d026f7" xlink:href="carm-20231231.xsd#carm_ScheduleOfChangesInDeferredRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6390cb92-1e72-4043-88e0-e5e7d0293593" xlink:to="loc_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock_2b4cb99e-4005-4899-a74d-9def91d026f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/BackgroundDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#BackgroundDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/BackgroundDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b8bcb50-75d9-41e7-88bc-f4219873e795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8b8bcb50-75d9-41e7-88bc-f4219873e795" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:to="loc_dei_LegalEntityAxis_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_99f3e308-c1da-43c1-bc79-360a329f3816" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c6beab3d-af9d-4474-8f56-9c8d1bb1b4af" xlink:to="loc_dei_EntityDomain_99f3e308-c1da-43c1-bc79-360a329f3816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_2a76d164-0e94-42d4-8022-18a9380a070f" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_99f3e308-c1da-43c1-bc79-360a329f3816" xlink:to="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_2a76d164-0e94-42d4-8022-18a9380a070f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioStockholdersMember_ab3949a5-e5c3-4dd4-b333-31171d6343c6" xlink:href="carm-20231231.xsd#carm_SesenBioStockholdersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_99f3e308-c1da-43c1-bc79-360a329f3816" xlink:to="loc_carm_SesenBioStockholdersMember_ab3949a5-e5c3-4dd4-b333-31171d6343c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_27de8ba8-607c-444e-9205-ab86326ff187" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_27de8ba8-607c-444e-9205-ab86326ff187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c966d1b-24fc-425d-9d8b-4abd34510d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27de8ba8-607c-444e-9205-ab86326ff187" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c966d1b-24fc-425d-9d8b-4abd34510d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember_497c25b2-c274-4678-a400-e829a273895a" xlink:href="carm-20231231.xsd#carm_SesenBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4c966d1b-24fc-425d-9d8b-4abd34510d96" xlink:to="loc_carm_SesenBioIncMember_497c25b2-c274-4678-a400-e829a273895a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_dcd22394-4d55-4045-b4c4-65195b6f989b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:to="loc_srt_OwnershipAxis_dcd22394-4d55-4045-b4c4-65195b6f989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_72cb544a-4fdf-43ff-badd-10431276013e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_dcd22394-4d55-4045-b4c4-65195b6f989b" xlink:to="loc_srt_OwnershipDomain_72cb544a-4fdf-43ff-badd-10431276013e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsInc.Member_c5a71af4-0fd3-4dff-94ae-41afdb24ad41" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_72cb544a-4fdf-43ff-badd-10431276013e" xlink:to="loc_carm_CarismaTherapeuticsInc.Member_c5a71af4-0fd3-4dff-94ae-41afdb24ad41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_850c2354-3759-4ae1-83f7-5de3881266d1" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConvertedIntoSharesCommonStockAtExchangeRatio_1c60f761-a5e3-4fa4-9edd-64caad302d56" xlink:href="carm-20231231.xsd#carm_ConvertedIntoSharesCommonStockAtExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:to="loc_carm_ConvertedIntoSharesCommonStockAtExchangeRatio_1c60f761-a5e3-4fa4-9edd-64caad302d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare_144e845b-1756-41b3-bbc1-b26519f27331" xlink:href="carm-20231231.xsd#carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:to="loc_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare_144e845b-1756-41b3-bbc1-b26519f27331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_OwnershipInterestInReportingEntity_c1128342-165d-4e2c-bbfe-77ec9018017c" xlink:href="carm-20231231.xsd#carm_OwnershipInterestInReportingEntity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8f235c5b-833f-415a-b674-65adfd2792ac" xlink:to="loc_carm_OwnershipInterestInReportingEntity_c1128342-165d-4e2c-bbfe-77ec9018017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#DevelopmentStageRisksandLiquidityDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_be40db2b-7bae-4f00-8013-942caad6cb10" xlink:href="carm-20231231.xsd#carm_DevelopmentStageRisksAndLiquidityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59435b32-98f2-4a8c-bc73-616a95364ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_be40db2b-7bae-4f00-8013-942caad6cb10" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59435b32-98f2-4a8c-bc73-616a95364ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_bfaa2d77-d93a-49af-be93-3c43ad9fa1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_DevelopmentStageRisksAndLiquidityAbstract_be40db2b-7bae-4f00-8013-942caad6cb10" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_bfaa2d77-d93a-49af-be93-3c43ad9fa1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_961c88bb-283a-4f50-9bfa-94ae27198a43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_961c88bb-283a-4f50-9bfa-94ae27198a43" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_adcef9bb-b9c7-419e-a62a-c78cae07b37a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_adcef9bb-b9c7-419e-a62a-c78cae07b37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a770675e-6eed-4ab8-ba29-58c76848ed6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_adcef9bb-b9c7-419e-a62a-c78cae07b37a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a770675e-6eed-4ab8-ba29-58c76848ed6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6dbefa45-bdf8-4dc9-aa18-7fb496398efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a770675e-6eed-4ab8-ba29-58c76848ed6e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6dbefa45-bdf8-4dc9-aa18-7fb496398efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a1c519d-d555-4c60-a7d9-87bd1d019cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a1c519d-d555-4c60-a7d9-87bd1d019cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9a1c519d-d555-4c60-a7d9-87bd1d019cd8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_759a087b-5e0c-469f-ace5-2d32e2cd07ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_759a087b-5e0c-469f-ace5-2d32e2cd07ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_19aaf6f6-1830-43e2-a7dd-d769210ae5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_19aaf6f6-1830-43e2-a7dd-d769210ae5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_858a7e53-2bae-45f6-8a66-5f9949c8d3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_60ae50f9-ae5f-4254-86d4-4df02b354016" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_858a7e53-2bae-45f6-8a66-5f9949c8d3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a342c1b8-f200-4ce6-a6d6-7d8d38660a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99591b49-22b4-4c99-b85d-ebd0b4b7372c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a342c1b8-f200-4ce6-a6d6-7d8d38660a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_783106b2-759c-44ed-9569-1026cde302df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a342c1b8-f200-4ce6-a6d6-7d8d38660a6c" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_783106b2-759c-44ed-9569-1026cde302df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1936f964-ce78-4754-bc30-4498063859a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_783106b2-759c-44ed-9569-1026cde302df" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1936f964-ce78-4754-bc30-4498063859a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e971f083-6c26-4d41-accf-d0da020af22b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_783106b2-759c-44ed-9569-1026cde302df" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e971f083-6c26-4d41-accf-d0da020af22b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7da1145b-076b-4edf-b4aa-4a9650aaff56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a342c1b8-f200-4ce6-a6d6-7d8d38660a6c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7da1145b-076b-4edf-b4aa-4a9650aaff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f106ce90-596a-4cff-8412-c21227f6647e" xlink:href="carm-20231231.xsd#carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7da1145b-076b-4edf-b4aa-4a9650aaff56" xlink:to="loc_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_f106ce90-596a-4cff-8412-c21227f6647e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4e999b51-b573-4a1d-85d6-f2f6490be48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7da1145b-076b-4edf-b4aa-4a9650aaff56" xlink:to="loc_us-gaap_DerivativeLiabilities_4e999b51-b573-4a1d-85d6-f2f6490be48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_61dfc010-35a5-42e2-9361-dca825e327d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f745fd77-53c2-435e-a881-4d157183fd20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61dfc010-35a5-42e2-9361-dca825e327d2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f745fd77-53c2-435e-a881-4d157183fd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_88016f20-573a-4cfc-b536-dff672dc4c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f745fd77-53c2-435e-a881-4d157183fd20" xlink:to="loc_us-gaap_FinancialInstrumentAxis_88016f20-573a-4cfc-b536-dff672dc4c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c82e83e1-5ffb-4bf7-a14b-b1bc97eeca3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_88016f20-573a-4cfc-b536-dff672dc4c9f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c82e83e1-5ffb-4bf7-a14b-b1bc97eeca3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_f5df2280-923a-4725-a850-a0f55e8fda64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c82e83e1-5ffb-4bf7-a14b-b1bc97eeca3e" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_f5df2280-923a-4725-a850-a0f55e8fda64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_f745fd77-53c2-435e-a881-4d157183fd20" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_fdeec0be-fc49-435d-a218-527d524d6244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss_fdeec0be-fc49-435d-a218-527d524d6244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d663732-dc65-4389-b7f6-36d270ae4896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8d663732-dc65-4389-b7f6-36d270ae4896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_86739d4e-ec63-44e4-8098-75e600b5843d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b54a5d68-ef9b-4716-8ce0-fa7d30a1bc90" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_86739d4e-ec63-44e4-8098-75e600b5843d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dfb8e51d-c9a6-4719-afae-928c3e4c7d69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fe825569-dd93-4b01-a35e-dd1eefb1d3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dfb8e51d-c9a6-4719-afae-928c3e4c7d69" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fe825569-dd93-4b01-a35e-dd1eefb1d3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fe825569-dd93-4b01-a35e-dd1eefb1d3fe" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0ccf2db9-6462-4d5c-8886-f3f28db32cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2e835f00-a7f1-4346-9e1e-1d76ddbd1fb9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0ccf2db9-6462-4d5c-8886-f3f28db32cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f8f05f6d-0c20-4b0d-a4fe-e080003d957d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0ccf2db9-6462-4d5c-8886-f3f28db32cb2" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_f8f05f6d-0c20-4b0d-a4fe-e080003d957d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1e5b777f-edfc-4ea8-9882-b393a562b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_fe825569-dd93-4b01-a35e-dd1eefb1d3fe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1e5b777f-edfc-4ea8-9882-b393a562b1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1e5b777f-edfc-4ea8-9882-b393a562b1c6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4614a765-dd27-4ab1-93d3-119deb85b554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4614a765-dd27-4ab1-93d3-119deb85b554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9c02d73d-b449-4045-b321-c55e5beda5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_9c02d73d-b449-4045-b321-c55e5beda5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_063ff217-3b67-412a-8739-88abac95ed17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_063ff217-3b67-412a-8739-88abac95ed17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_677a7f9c-3556-4cf2-8108-6480463b04b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_677a7f9c-3556-4cf2-8108-6480463b04b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a52aa0c0-f41e-40f8-9fe9-727b8e481145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_6f6fa5a6-32e6-423b-8241-adfa93301f77" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a52aa0c0-f41e-40f8-9fe9-727b8e481145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ec59decb-4655-49b3-a765-f3073f02d06c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec59decb-4655-49b3-a765-f3073f02d06c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f938b7c4-e96e-46be-9801-df5c6a5fa6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f938b7c4-e96e-46be-9801-df5c6a5fa6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039f087a-9df8-4587-a27b-8c282b1944c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f938b7c4-e96e-46be-9801-df5c6a5fa6c3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039f087a-9df8-4587-a27b-8c282b1944c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember_9076b64d-873d-49b5-9e00-12fe4fa670c9" xlink:href="carm-20231231.xsd#carm_SesenBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_039f087a-9df8-4587-a27b-8c282b1944c6" xlink:to="loc_carm_SesenBioIncMember_9076b64d-873d-49b5-9e00-12fe4fa670c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bb9e89f5-86fd-4334-9918-86d17b152435" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:to="loc_srt_RangeAxis_bb9e89f5-86fd-4334-9918-86d17b152435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_93b36d4d-57ff-4f2b-bc46-b882a4b271c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bb9e89f5-86fd-4334-9918-86d17b152435" xlink:to="loc_srt_RangeMember_93b36d4d-57ff-4f2b-bc46-b882a4b271c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_81cdcebd-0659-49c4-9c46-b52649f53941" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_93b36d4d-57ff-4f2b-bc46-b882a4b271c2" xlink:to="loc_srt_MinimumMember_81cdcebd-0659-49c4-9c46-b52649f53941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7c1db72f-4f8e-4f3c-8c5d-a35aec4abb8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_93b36d4d-57ff-4f2b-bc46-b882a4b271c2" xlink:to="loc_srt_MaximumMember_7c1db72f-4f8e-4f3c-8c5d-a35aec4abb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e1a140ca-2b69-4de2-8a06-4d903a593c30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e1a140ca-2b69-4de2-8a06-4d903a593c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_322cf49e-a5b2-4fe8-bbea-a2cfe0aa5925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_e1a140ca-2b69-4de2-8a06-4d903a593c30" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_322cf49e-a5b2-4fe8-bbea-a2cfe0aa5925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollateralCreditCardProgramMember_9e47c1c5-8857-4e06-ac42-8f300e55c141" xlink:href="carm-20231231.xsd#carm_CollateralCreditCardProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_322cf49e-a5b2-4fe8-bbea-a2cfe0aa5925" xlink:to="loc_carm_CollateralCreditCardProgramMember_9e47c1c5-8857-4e06-ac42-8f300e55c141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5e5befde-eec6-478c-a1ed-df64ba67ed63" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DebtInstrumentConvertibleDiscountFactorPercentage_2ddc64a8-f2f9-439a-941a-9d2e67292936" xlink:href="carm-20231231.xsd#carm_DebtInstrumentConvertibleDiscountFactorPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_carm_DebtInstrumentConvertibleDiscountFactorPercentage_2ddc64a8-f2f9-439a-941a-9d2e67292936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DebtInstrumentConvertibleQualifiedFinancingProbability_9e9070a9-24e7-49e9-a8a0-3ff9fb9ffc0d" xlink:href="carm-20231231.xsd#carm_DebtInstrumentConvertibleQualifiedFinancingProbability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_carm_DebtInstrumentConvertibleQualifiedFinancingProbability_9e9070a9-24e7-49e9-a8a0-3ff9fb9ffc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DerivativeInstrumentConversionTermForRedemptionFeature_6855cd6e-b706-42a8-baeb-0db8fed2ccdd" xlink:href="carm-20231231.xsd#carm_DerivativeInstrumentConversionTermForRedemptionFeature"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_carm_DerivativeInstrumentConversionTermForRedemptionFeature_6855cd6e-b706-42a8-baeb-0db8fed2ccdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_4f3584d8-e7a7-43d3-ae35-27883ef77002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_4f3584d8-e7a7-43d3-ae35-27883ef77002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_25e8194c-b95d-4af8-be66-eb66e84f6392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_25e8194c-b95d-4af8-be66-eb66e84f6392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fe67d3bd-c1b9-4e5b-b583-c563396821ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fe67d3bd-c1b9-4e5b-b583-c563396821ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dbadfc50-6984-4b52-acd4-c0f86d99997f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dbadfc50-6984-4b52-acd4-c0f86d99997f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentGross_8548dae0-ab8b-4ca6-93ee-cf1de2c4fd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e779778b-3213-4019-b38b-6eedceaa6be0" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentGross_8548dae0-ab8b-4ca6-93ee-cf1de2c4fd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cc0e242a-b764-4049-b632-ab54fb7b1932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8bc352d9-f7ae-4d29-b9ca-00c1762cfa91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cc0e242a-b764-4049-b632-ab54fb7b1932" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8bc352d9-f7ae-4d29-b9ca-00c1762cfa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8d3ab075-e81e-4eac-9d4c-79cf218a94c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8bc352d9-f7ae-4d29-b9ca-00c1762cfa91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8d3ab075-e81e-4eac-9d4c-79cf218a94c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8d3ab075-e81e-4eac-9d4c-79cf218a94c8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConvertiblePreferredStockAndExchangeableSharesMember_7f92273c-8e3c-4daa-918f-43f7259b7d5f" xlink:href="carm-20231231.xsd#carm_ConvertiblePreferredStockAndExchangeableSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:to="loc_carm_ConvertiblePreferredStockAndExchangeableSharesMember_7f92273c-8e3c-4daa-918f-43f7259b7d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ad967698-df49-4b20-8b1a-4102ab17a8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ad967698-df49-4b20-8b1a-4102ab17a8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ConversionOfConvertiblePromissoryNoteMember_577fdd0e-5b2b-4cd7-911a-441c6f9c5bc8" xlink:href="carm-20231231.xsd#carm_ConversionOfConvertiblePromissoryNoteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c1e932-72fc-4459-8801-5cbf4211c1c7" xlink:to="loc_carm_ConversionOfConvertiblePromissoryNoteMember_577fdd0e-5b2b-4cd7-911a-441c6f9c5bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e8db448-5a93-4206-a7f3-ad349bab0e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8bc352d9-f7ae-4d29-b9ca-00c1762cfa91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e8db448-5a93-4206-a7f3-ad349bab0e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28882482-c33b-470a-8607-df01b7620bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e8db448-5a93-4206-a7f3-ad349bab0e0d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28882482-c33b-470a-8607-df01b7620bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cbd41f0f-068a-4ce4-8753-4ecd712e130d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_cbd41f0f-068a-4ce4-8753-4ecd712e130d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5615082b-8ddb-4e72-ad73-1a0b126e95a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5615082b-8ddb-4e72-ad73-1a0b126e95a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96c21590-b9b2-4827-817f-a9342d71f8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5615082b-8ddb-4e72-ad73-1a0b126e95a6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96c21590-b9b2-4827-817f-a9342d71f8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_41b515d1-70e6-4219-9729-069507d907cb" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsIncLegacyStockholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96c21590-b9b2-4827-817f-a9342d71f8f5" xlink:to="loc_carm_CarismaTherapeuticsIncLegacyStockholdersMember_41b515d1-70e6-4219-9729-069507d907cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_359f8634-7d08-4340-aa52-571c4103baa8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:to="loc_dei_LegalEntityAxis_359f8634-7d08-4340-aa52-571c4103baa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ffc6836b-a4f8-4289-a3ce-daafc73b9386" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_359f8634-7d08-4340-aa52-571c4103baa8" xlink:to="loc_dei_EntityDomain_ffc6836b-a4f8-4289-a3ce-daafc73b9386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CarismaTherapeuticsInc.Member_7716793b-700e-48ae-8cc6-8c2cfd7589cf" xlink:href="carm-20231231.xsd#carm_CarismaTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_ffc6836b-a4f8-4289-a3ce-daafc73b9386" xlink:to="loc_carm_CarismaTherapeuticsInc.Member_7716793b-700e-48ae-8cc6-8c2cfd7589cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_320be909-d527-4c93-b3ce-ff313c74399a" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_362e11ae-c33f-4e5c-8590-f7b82e90431b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_362e11ae-c33f-4e5c-8590-f7b82e90431b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfBoardMembers_a13f227a-36fd-4def-af93-986a0d8d7319" xlink:href="carm-20231231.xsd#carm_NumberOfBoardMembers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_carm_NumberOfBoardMembers_a13f227a-36fd-4def-af93-986a0d8d7319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e0fd06ac-84a4-4576-8140-5bb0c14b4dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e0fd06ac-84a4-4576-8140-5bb0c14b4dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f77060a-75d1-4b05-9b63-658b5e732337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2f77060a-75d1-4b05-9b63-658b5e732337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_3aa09d04-c164-46dd-b8ce-c5be1f86e330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_3aa09d04-c164-46dd-b8ce-c5be1f86e330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_cfd17e84-4e86-4d37-af41-1e0a21926397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_cfd17e84-4e86-4d37-af41-1e0a21926397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_c4893dae-2f7b-47d9-8de8-f618b77bd0a4" xlink:href="carm-20231231.xsd#carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash_c4893dae-2f7b-47d9-8de8-f618b77bd0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_30030e8a-928e-4e5b-9408-558b333a0574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_30030e8a-928e-4e5b-9408-558b333a0574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6ea1376f-955b-48fd-8fc6-ce8c044c6712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_6ea1376f-955b-48fd-8fc6-ce8c044c6712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_10a1e41f-b10f-41b3-8826-0d8700e6cd94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_10a1e41f-b10f-41b3-8826-0d8700e6cd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f3c501c8-f878-4def-8772-96fb4c33c69d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_f3c501c8-f878-4def-8772-96fb4c33c69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_656dfc6e-38f7-4a40-be56-115510f1574b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_10df976a-2422-4d1b-b41b-959f7b33ff5a" xlink:to="loc_us-gaap_SeveranceCosts1_656dfc6e-38f7-4a40-be56-115510f1574b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1" xlink:type="simple" xlink:href="carm-20231231.xsd#MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#PropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fabacf6f-4fd8-4aaf-a626-0c97b1650a07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_726f2a2e-0a34-4f53-ab45-c5820e60f8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fabacf6f-4fd8-4aaf-a626-0c97b1650a07" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_726f2a2e-0a34-4f53-ab45-c5820e60f8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_07a09548-35bf-4ce4-89dd-abc3040395dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_726f2a2e-0a34-4f53-ab45-c5820e60f8ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_07a09548-35bf-4ce4-89dd-abc3040395dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_07a09548-35bf-4ce4-89dd-abc3040395dd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_787680bf-a3d8-4e6a-b8e2-a410048f1a60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_787680bf-a3d8-4e6a-b8e2-a410048f1a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_8e6bbdd7-8dec-47df-87ce-e920a83bb45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_EquipmentMember_8e6bbdd7-8dec-47df-87ce-e920a83bb45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5aae9396-f68b-484b-be67-00d35f6b8051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5aae9396-f68b-484b-be67-00d35f6b8051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c23dae70-e06b-4117-8849-1902862340ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c23dae70-e06b-4117-8849-1902862340ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_f3bee8a1-25f5-48f1-a596-c878d2673f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a19bc68e-2374-467d-b7ca-0647df0d455c" xlink:to="loc_us-gaap_ConstructionInProgressMember_f3bee8a1-25f5-48f1-a596-c878d2673f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_726f2a2e-0a34-4f53-ab45-c5820e60f8ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_82bd2150-484d-49d4-a5bc-9bfb2ff3ff7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_82bd2150-484d-49d4-a5bc-9bfb2ff3ff7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_4fc26646-1194-4c04-83bc-1ae47b1f7a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_4fc26646-1194-4c04-83bc-1ae47b1f7a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f2d15017-5b46-441b-b515-e8b7bb6d3682" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_f2d15017-5b46-441b-b515-e8b7bb6d3682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionNetBookValue_92b643c3-54e0-4693-8da8-0a2f92aac25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionNetBookValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_SaleLeasebackTransactionNetBookValue_92b643c3-54e0-4693-8da8-0a2f92aac25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_ddf073f4-d19e-445e-9fef-e7a96371a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_ddf073f4-d19e-445e-9fef-e7a96371a5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_81d78293-bd2b-4119-a89c-2249cccf7d66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_81d78293-bd2b-4119-a89c-2249cccf7d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_88c984e2-55bd-48cd-ad8b-f488e8e00486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_fa9f56c0-cf29-46be-9df5-2d3c75d30273" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_88c984e2-55bd-48cd-ad8b-f488e8e00486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#PropertyandEquipmentnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_45e26c6f-fe58-4a55-8cef-c67c87f1ac9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_11b59d95-6cc0-4859-8409-c80cf499976d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_45e26c6f-fe58-4a55-8cef-c67c87f1ac9a" xlink:to="loc_us-gaap_DepreciationAndAmortization_11b59d95-6cc0-4859-8409-c80cf499976d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_377fd428-498c-4e20-a5cd-8094ceb9f7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent_e8e06aa9-1538-40ba-bbec-33afc336e19a" xlink:href="carm-20231231.xsd#carm_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_377fd428-498c-4e20-a5cd-8094ceb9f7e6" xlink:to="loc_carm_AccruedResearchAndDevelopmentExpenseCurrent_e8e06aa9-1538-40ba-bbec-33afc336e19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6e03c607-e0a6-4dcc-8392-59a420339c33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_377fd428-498c-4e20-a5cd-8094ceb9f7e6" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6e03c607-e0a6-4dcc-8392-59a420339c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f926fea1-39c1-4122-9a1a-c4e4b06e7b73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_377fd428-498c-4e20-a5cd-8094ceb9f7e6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f926fea1-39c1-4122-9a1a-c4e4b06e7b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_c0cc6a45-9ce3-4d49-8f61-6771ab37030c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_377fd428-498c-4e20-a5cd-8094ceb9f7e6" xlink:to="loc_us-gaap_InterestPayableCurrent_c0cc6a45-9ce3-4d49-8f61-6771ab37030c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_83090331-1add-4d4a-9e1a-566ad5f78c15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_377fd428-498c-4e20-a5cd-8094ceb9f7e6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_83090331-1add-4d4a-9e1a-566ad5f78c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_debd223d-0e87-43d6-8e99-65943eca6aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_377fd428-498c-4e20-a5cd-8094ceb9f7e6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_debd223d-0e87-43d6-8e99-65943eca6aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingenciesNarrativesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3408281e-b10a-4ace-bd68-0e6fa7bfabc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3408281e-b10a-4ace-bd68-0e6fa7bfabc3" xlink:to="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ecad0977-c20a-4360-8d03-620696ca2d14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ecad0977-c20a-4360-8d03-620696ca2d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d743551-3271-43a1-bbc8-77bd61f85ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecad0977-c20a-4360-8d03-620696ca2d14" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d743551-3271-43a1-bbc8-77bd61f85ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PennLicenseAgreementMember_4e306a8d-2f30-4615-8300-612b64aa2dff" xlink:href="carm-20231231.xsd#carm_PennLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d743551-3271-43a1-bbc8-77bd61f85ba5" xlink:to="loc_carm_PennLicenseAgreementMember_4e306a8d-2f30-4615-8300-612b64aa2dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_bd924036-d43f-4829-9d2f-99a4cb21b74b" xlink:href="carm-20231231.xsd#carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d743551-3271-43a1-bbc8-77bd61f85ba5" xlink:to="loc_carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember_bd924036-d43f-4829-9d2f-99a4cb21b74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc183c8-f3bd-445a-bafd-31b68939aa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc183c8-f3bd-445a-bafd-31b68939aa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e7a9551e-bc6f-46e6-a441-36dc2dc3afee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0fc183c8-f3bd-445a-bafd-31b68939aa5c" xlink:to="loc_us-gaap_RelatedPartyDomain_e7a9551e-bc6f-46e6-a441-36dc2dc3afee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember_20788659-084d-4a74-9613-4fcb633881ff" xlink:href="carm-20231231.xsd#carm_TrusteesOfUniversityOfPennsylvaniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e7a9551e-bc6f-46e6-a441-36dc2dc3afee" xlink:to="loc_carm_TrusteesOfUniversityOfPennsylvaniaMember_20788659-084d-4a74-9613-4fcb633881ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbe3ca1e-ba52-4920-b2db-fa6c8febc529" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_srt_RangeAxis_cbe3ca1e-ba52-4920-b2db-fa6c8febc529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0716a1a2-1fdd-4bd6-86ac-48ae1b90de9b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cbe3ca1e-ba52-4920-b2db-fa6c8febc529" xlink:to="loc_srt_RangeMember_0716a1a2-1fdd-4bd6-86ac-48ae1b90de9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_80f6aa6b-530b-4589-aba2-d94cca370e77" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0716a1a2-1fdd-4bd6-86ac-48ae1b90de9b" xlink:to="loc_srt_MaximumMember_80f6aa6b-530b-4589-aba2-d94cca370e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6a9a087-c55f-46f7-88ac-0b696ca0c3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6a9a087-c55f-46f7-88ac-0b696ca0c3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6dc5d9f-5469-4931-92d6-0eff17eaa1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a6a9a087-c55f-46f7-88ac-0b696ca0c3da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6dc5d9f-5469-4931-92d6-0eff17eaa1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_448813c4-e555-4783-a987-1cc6240a7e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6dc5d9f-5469-4931-92d6-0eff17eaa1ef" xlink:to="loc_us-gaap_EquipmentMember_448813c4-e555-4783-a987-1cc6240a7e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6a584f78-4927-424d-b174-c4cab5addaf3" xlink:to="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ProceedsFromSaleAndLeasebackTransaction_1017b70f-3f39-4cbe-9a1f-b567415032c8" xlink:href="carm-20231231.xsd#carm_ProceedsFromSaleAndLeasebackTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_ProceedsFromSaleAndLeasebackTransaction_1017b70f-3f39-4cbe-9a1f-b567415032c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_e749a769-86d3-4f1b-8326-86c6c7450509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_us-gaap_FinanceLeaseLiability_e749a769-86d3-4f1b-8326-86c6c7450509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid_60c68a5b-ab5d-4d71-894f-a6efd359d5c4" xlink:href="carm-20231231.xsd#carm_CommitmentsAnnualPaymentsRequiredToBePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_CommitmentsAnnualPaymentsRequiredToBePaid_60c68a5b-ab5d-4d71-894f-a6efd359d5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_71990959-4014-484e-96fb-8571212d2e20" xlink:href="carm-20231231.xsd#carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents_71990959-4014-484e-96fb-8571212d2e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid_08c69b3e-3a65-4fb9-9f8b-cc0884b6783a" xlink:href="carm-20231231.xsd#carm_AdditionalMilestonePaymentsRequiredToBePaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AdditionalMilestonePaymentsRequiredToBePaid_08c69b3e-3a65-4fb9-9f8b-cc0884b6783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct_1f739649-bb5a-4f63-a3a7-e4125a996f22" xlink:href="carm-20231231.xsd#carm_AdditionalMilestonePaymentsForFirstCarMProduct"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AdditionalMilestonePaymentsForFirstCarMProduct_1f739649-bb5a-4f63-a3a7-e4125a996f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AgreementTerm_ca10a3aa-6723-4567-908b-269a86967a2a" xlink:href="carm-20231231.xsd#carm_AgreementTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AgreementTerm_ca10a3aa-6723-4567-908b-269a86967a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RenewalTerm_06969abe-33ec-4066-885c-adc05e31b982" xlink:href="carm-20231231.xsd#carm_RenewalTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_RenewalTerm_06969abe-33ec-4066-885c-adc05e31b982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountPayablePerCalendarYearForReservedCapacity_bd05c829-31a2-4171-ab5f-7d4f96d2f8a9" xlink:href="carm-20231231.xsd#carm_AmountPayablePerCalendarYearForReservedCapacity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_AmountPayablePerCalendarYearForReservedCapacity_bd05c829-31a2-4171-ab5f-7d4f96d2f8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TerminationFeePayable_2824579b-9a72-4676-9daf-a906d7307d9f" xlink:href="carm-20231231.xsd#carm_TerminationFeePayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_carm_TerminationFeePayable_2824579b-9a72-4676-9daf-a906d7307d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2e70fcdd-fdab-4680-82f8-1fcc504a34df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_f0a40be2-1775-4231-a92c-9eff3dae889e" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_2e70fcdd-fdab-4680-82f8-1fcc504a34df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingenciesScheduleofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63294122-61de-41e6-a3c6-e7ca8ef5ad92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_6186b8d9-9926-4101-a363-17a7b44fb56d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63294122-61de-41e6-a3c6-e7ca8ef5ad92" xlink:to="loc_us-gaap_OperatingLeaseCost_6186b8d9-9926-4101-a363-17a7b44fb56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCostAbstract_05aaa320-bfa4-4846-8db0-c95d1d1ee833" xlink:href="carm-20231231.xsd#carm_FinanceLeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63294122-61de-41e6-a3c6-e7ca8ef5ad92" xlink:to="loc_carm_FinanceLeaseCostAbstract_05aaa320-bfa4-4846-8db0-c95d1d1ee833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_6dc2922b-7b52-4c07-bc29-28727c3a52a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_05aaa320-bfa4-4846-8db0-c95d1d1ee833" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_6dc2922b-7b52-4c07-bc29-28727c3a52a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_35510480-9c30-4189-9dbe-60345ac590ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_05aaa320-bfa4-4846-8db0-c95d1d1ee833" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_35510480-9c30-4189-9dbe-60345ac590ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinanceLeaseCost_a4334f95-5a37-47a4-a612-491d4c69c05e" xlink:href="carm-20231231.xsd#carm_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_05aaa320-bfa4-4846-8db0-c95d1d1ee833" xlink:to="loc_carm_FinanceLeaseCost_a4334f95-5a37-47a4-a612-491d4c69c05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ebda71db-23fe-403d-b1e6-a4e5bfca702f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_FinanceLeaseCostAbstract_05aaa320-bfa4-4846-8db0-c95d1d1ee833" xlink:to="loc_us-gaap_VariableLeaseCost_ebda71db-23fe-403d-b1e6-a4e5bfca702f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f56221e0-fbd6-4450-9134-ec5aab0fa415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63294122-61de-41e6-a3c6-e7ca8ef5ad92" xlink:to="loc_us-gaap_LeaseCost_f56221e0-fbd6-4450-9134-ec5aab0fa415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a47901b9-1197-442e-bf03-15b7d797cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_62ead7ee-5881-4a53-a4c0-fb54a56dfa8e" xlink:href="carm-20231231.xsd#carm_LeasesWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a47901b9-1197-442e-bf03-15b7d797cdf7" xlink:to="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_62ead7ee-5881-4a53-a4c0-fb54a56dfa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_79691782-0181-44e4-a88c-ae0d7d4724b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_62ead7ee-5881-4a53-a4c0-fb54a56dfa8e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_79691782-0181-44e4-a88c-ae0d7d4724b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_696315d5-ed6b-4c45-bacc-8ce8abf4e21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_LeasesWeightedAverageRemainingLeaseTermAbstract_62ead7ee-5881-4a53-a4c0-fb54a56dfa8e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_696315d5-ed6b-4c45-bacc-8ce8abf4e21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LeasesWeightedAverageDiscountRateAbstract_ddd0b026-646c-419a-a567-165301ee2504" xlink:href="carm-20231231.xsd#carm_LeasesWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a47901b9-1197-442e-bf03-15b7d797cdf7" xlink:to="loc_carm_LeasesWeightedAverageDiscountRateAbstract_ddd0b026-646c-419a-a567-165301ee2504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_21341aba-a251-4e37-93a7-48cc1c0d4a06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_LeasesWeightedAverageDiscountRateAbstract_ddd0b026-646c-419a-a567-165301ee2504" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_21341aba-a251-4e37-93a7-48cc1c0d4a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_4c030ecf-db63-4d67-900c-2feefd3fc88d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_LeasesWeightedAverageDiscountRateAbstract_ddd0b026-646c-419a-a567-165301ee2504" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_4c030ecf-db63-4d67-900c-2feefd3fc88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71d7635c-da18-4ae7-9124-4749eb9f859f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f8e2fdfa-f8e3-47fb-9d1c-a54d5ab82899" xlink:href="carm-20231231.xsd#carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71d7635c-da18-4ae7-9124-4749eb9f859f" xlink:to="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f8e2fdfa-f8e3-47fb-9d1c-a54d5ab82899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_aab91318-2411-414c-97c8-e041fdfe706d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f8e2fdfa-f8e3-47fb-9d1c-a54d5ab82899" xlink:to="loc_us-gaap_OperatingLeasePayments_aab91318-2411-414c-97c8-e041fdfe706d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_23aafd7a-360e-482e-8a2f-a5b15a4d6a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f8e2fdfa-f8e3-47fb-9d1c-a54d5ab82899" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_23aafd7a-360e-482e-8a2f-a5b15a4d6a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_FinancingCashUsedInFinanceLeases_35d1faac-3644-427d-81ed-f4ac82120bff" xlink:href="carm-20231231.xsd#carm_FinancingCashUsedInFinanceLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_f8e2fdfa-f8e3-47fb-9d1c-a54d5ab82899" xlink:to="loc_carm_FinancingCashUsedInFinanceLeases_35d1faac-3644-427d-81ed-f4ac82120bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80f85603-848f-4186-af74-def508827926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80f85603-848f-4186-af74-def508827926" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dd5f9d15-3c2b-4add-b716-83d3ffd42f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dd5f9d15-3c2b-4add-b716-83d3ffd42f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_365debf7-c3a0-4805-9d7f-301a449b6314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_365debf7-c3a0-4805-9d7f-301a449b6314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1683fd36-d47b-4158-a52c-4cb499e9bbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1683fd36-d47b-4158-a52c-4cb499e9bbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4b46d11c-3cab-40f7-a02a-e8488e7e8e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4b46d11c-3cab-40f7-a02a-e8488e7e8e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1cac95f6-6870-40f9-92d8-9b14b4d059b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1cac95f6-6870-40f9-92d8-9b14b4d059b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_26347c70-8b50-4f88-abff-153302bab523" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_26347c70-8b50-4f88-abff-153302bab523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_58c56bff-f493-4284-92bd-da77252ae26b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_58c56bff-f493-4284-92bd-da77252ae26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6df3f433-43d3-450c-a2cd-1e3bbbbfa328" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6df3f433-43d3-450c-a2cd-1e3bbbbfa328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e580a4d7-c134-4368-ac07-3630475ac01d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e9998b5a-f2a0-422b-8db9-d5baf1ca5f1f" xlink:to="loc_us-gaap_OperatingLeaseLiability_e580a4d7-c134-4368-ac07-3630475ac01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_80f85603-848f-4186-af74-def508827926" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_768242f5-5d4a-402a-a48f-c989d4bdd284" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_768242f5-5d4a-402a-a48f-c989d4bdd284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c95df143-0c6c-40b5-9415-7a18ee870870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c95df143-0c6c-40b5-9415-7a18ee870870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_b2c89c4c-def4-4f33-962a-69693c88a85b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_b2c89c4c-def4-4f33-962a-69693c88a85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c0e92682-6a8a-4445-8186-069a7a5a6434" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c0e92682-6a8a-4445-8186-069a7a5a6434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_5afc5fc9-ff44-41d7-b6dc-ff65dd821367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_5afc5fc9-ff44-41d7-b6dc-ff65dd821367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_cda156ec-f586-4ca4-9bea-4ac5bcdccde7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_cda156ec-f586-4ca4-9bea-4ac5bcdccde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1c40b3a8-e825-4b32-9e90-4f15ca740856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1c40b3a8-e825-4b32-9e90-4f15ca740856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_045ed93e-8573-4727-8b66-e792a96e735c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_045ed93e-8573-4727-8b66-e792a96e735c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d6f7793a-50ec-4c0c-a581-0d200907f773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5e963b45-fc28-4c8d-9306-e643f8e894be" xlink:to="loc_us-gaap_FinanceLeaseLiability_d6f7793a-50ec-4c0c-a581-0d200907f773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8806a1c5-ac91-4d5e-9fc3-4fd26efed201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8806a1c5-ac91-4d5e-9fc3-4fd26efed201" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_053c8a1a-86f4-4258-bc10-05d7b06ce37f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_053c8a1a-86f4-4258-bc10-05d7b06ce37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d850cc5-53b9-4978-a006-d80a4dc1f868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_053c8a1a-86f4-4258-bc10-05d7b06ce37f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d850cc5-53b9-4978-a006-d80a4dc1f868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AtTheMarketOfferingMember_597c09e7-bbbf-443a-a945-38c02b83df9b" xlink:href="carm-20231231.xsd#carm_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d850cc5-53b9-4978-a006-d80a4dc1f868" xlink:to="loc_carm_AtTheMarketOfferingMember_597c09e7-bbbf-443a-a945-38c02b83df9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6b31389e-0925-4e87-b30b-3d7b980ca0e4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:to="loc_srt_CounterpartyNameAxis_6b31389e-0925-4e87-b30b-3d7b980ca0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_835d48a1-ce50-430d-84cc-a9ddb88811ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6b31389e-0925-4e87-b30b-3d7b980ca0e4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_835d48a1-ce50-430d-84cc-a9ddb88811ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_JefferiesLLCMember_4a56368d-8344-4112-a976-5196e3668dc0" xlink:href="carm-20231231.xsd#carm_JefferiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_835d48a1-ce50-430d-84cc-a9ddb88811ac" xlink:to="loc_carm_JefferiesLLCMember_4a56368d-8344-4112-a976-5196e3668dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7cbc7e90-793a-4683-af03-65c2b4f6cd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7cbc7e90-793a-4683-af03-65c2b4f6cd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_443d40b4-6131-4ae4-8354-aa51ecae9925" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cbc7e90-793a-4683-af03-65c2b4f6cd4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_443d40b4-6131-4ae4-8354-aa51ecae9925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5d9c779e-53ca-4112-986a-c1e53991afac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_443d40b4-6131-4ae4-8354-aa51ecae9925" xlink:to="loc_us-gaap_SubsequentEventMember_5d9c779e-53ca-4112-986a-c1e53991afac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_eb2a5c08-0b6f-4849-81e7-8f87b64ac3ee" xlink:to="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_75f78343-8fc9-4b5f-a478-b59b9773c0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_75f78343-8fc9-4b5f-a478-b59b9773c0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_76b71a32-ee7c-4e63-a922-158bc93b3855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_76b71a32-ee7c-4e63-a922-158bc93b3855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e06e041-5afe-4428-b4dd-8d7aebd168b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6e06e041-5afe-4428-b4dd-8d7aebd168b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a742222a-bfd5-4b92-8674-e677d3a62235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a742222a-bfd5-4b92-8674-e677d3a62235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3c96d38e-007a-4c7c-a6aa-b858536affaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3c96d38e-007a-4c7c-a6aa-b858536affaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_9f8c3774-3a5a-45a8-90fd-86232858b454" xlink:href="carm-20231231.xsd#carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests_9f8c3774-3a5a-45a8-90fd-86232858b454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd2edfab-992b-4b62-8682-57c3d88f7436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_cd2edfab-992b-4b62-8682-57c3d88f7436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SaleOfStockStockOfferingAmount_ab9c4df6-2db5-4a12-b5e8-b17610c604ef" xlink:href="carm-20231231.xsd#carm_SaleOfStockStockOfferingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_carm_SaleOfStockStockOfferingAmount_ab9c4df6-2db5-4a12-b5e8-b17610c604ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91dc2dbf-8a90-46e6-abd7-587b8dc2ba77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91dc2dbf-8a90-46e6-abd7-587b8dc2ba77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_1059c215-e45f-4566-b342-b38334233e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_1059c215-e45f-4566-b342-b38334233e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_91437bc1-b8c8-4014-8cc6-4c0d220e3ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_91437bc1-b8c8-4014-8cc6-4c0d220e3ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cf111579-4a91-4f26-9968-cff925e3a352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cf111579-4a91-4f26-9968-cff925e3a352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_29cfc2ec-b934-4caa-8924-c7a8b9cba264" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_29cfc2ec-b934-4caa-8924-c7a8b9cba264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_358ea61c-e4cb-4646-aceb-a56470c310ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_15607d9f-afa2-4b01-bdc1-068d3ec0a616" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_358ea61c-e4cb-4646-aceb-a56470c310ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationNarrativesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensationNarrativesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e61cc54b-5c86-4c7c-930f-aa96c0ac1122" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e61cc54b-5c86-4c7c-930f-aa96c0ac1122" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:to="loc_us-gaap_PlanNameAxis_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4f4bc5e1-af8e-46a0-9234-8ebbcd2c2b8b" xlink:to="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandSeventeenStockIncentivePlanMember_df32ce8f-d489-4f34-a779-126e32ebdada" xlink:href="carm-20231231.xsd#carm_TwoThousandSeventeenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:to="loc_carm_TwoThousandSeventeenStockIncentivePlanMember_df32ce8f-d489-4f34-a779-126e32ebdada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenStockIncentivePlanMember_fc2ab69f-38d8-466a-a81e-6ee667157095" xlink:href="carm-20231231.xsd#carm_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:to="loc_carm_TwoThousandFourteenStockIncentivePlanMember_fc2ab69f-38d8-466a-a81e-6ee667157095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_7cb366b2-4e00-49aa-92ce-d9e6ee9b4b73" xlink:href="carm-20231231.xsd#carm_TwoThousandFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4a95b2ed-6069-452c-8d8c-dd21ff422791" xlink:to="loc_carm_TwoThousandFourteenEmployeeStockPurchasePlanMember_7cb366b2-4e00-49aa-92ce-d9e6ee9b4b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7ad7ad34-f2b7-4536-b767-14d4b9be9440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:to="loc_us-gaap_AwardTypeAxis_7ad7ad34-f2b7-4536-b767-14d4b9be9440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eeea4ff2-2dcc-4e1a-aa48-9d4729ed9c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7ad7ad34-f2b7-4536-b767-14d4b9be9440" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eeea4ff2-2dcc-4e1a-aa48-9d4729ed9c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a2d0b5d2-68a6-4084-95fe-9252c9f12067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eeea4ff2-2dcc-4e1a-aa48-9d4729ed9c2d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a2d0b5d2-68a6-4084-95fe-9252c9f12067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83199a4d-589d-4493-bc4b-71e49b7832d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:to="loc_srt_RangeAxis_83199a4d-589d-4493-bc4b-71e49b7832d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_798a579c-0688-43eb-94d5-debc1d8d46d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_83199a4d-589d-4493-bc4b-71e49b7832d0" xlink:to="loc_srt_RangeMember_798a579c-0688-43eb-94d5-debc1d8d46d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4272a006-ef39-4eb9-82b6-7954c6bac2aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_798a579c-0688-43eb-94d5-debc1d8d46d1" xlink:to="loc_srt_MaximumMember_4272a006-ef39-4eb9-82b6-7954c6bac2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9a0b979a-ff29-42d2-b511-f8825049f103" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3e2a1280-d626-4dfb-b050-a00f039e2868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3e2a1280-d626-4dfb-b050-a00f039e2868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73ca2317-f43f-4a92-8754-1871f26777b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_73ca2317-f43f-4a92-8754-1871f26777b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear_a8e0fe5f-2825-4154-91f3-d798b46d7882" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear_a8e0fe5f-2825-4154-91f3-d798b46d7882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear_077bfd31-ba7c-495f-9ceb-fe287389f490" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear_077bfd31-ba7c-495f-9ceb-fe287389f490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b65a1b3a-5454-4d22-83dc-9ea4d97c731d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b65a1b3a-5454-4d22-83dc-9ea4d97c731d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_cdca4d04-a372-472e-924f-2b0a1e800bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fb54ab5-cffd-4891-bedb-1dbaab15d08b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_cdca4d04-a372-472e-924f-2b0a1e800bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensationScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c33455d-5c47-4ce0-9437-2aafb9b5571a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c33455d-5c47-4ce0-9437-2aafb9b5571a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1749a2b0-6d04-4d01-b059-0bad6e9f193f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1749a2b0-6d04-4d01-b059-0bad6e9f193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross_b888b6fd-49eb-46e9-8a36-33ff8229f69d" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross_b888b6fd-49eb-46e9-8a36-33ff8229f69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_07da582d-dd54-40ec-a2bb-60f986a78692" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_07da582d-dd54-40ec-a2bb-60f986a78692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635cfe91-dfde-4414-bbeb-95a9008d8a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635cfe91-dfde-4414-bbeb-95a9008d8a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_38b8136b-b8cd-4399-bcd2-d69a615a908c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_38b8136b-b8cd-4399-bcd2-d69a615a908c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8e9e6cc4-916e-4bfd-b877-63773844ce5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8e9e6cc4-916e-4bfd-b877-63773844ce5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4ead651d-4fc3-45c3-bc67-ce4e3db5f73f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4ead651d-4fc3-45c3-bc67-ce4e3db5f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_81e93638-fb76-4919-a758-32af53d5d62d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_81e93638-fb76-4919-a758-32af53d5d62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_079016a1-e632-435e-98c2-f2f8204638a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_e770cc79-a0b4-419d-a578-81a5818d3dc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_079016a1-e632-435e-98c2-f2f8204638a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c33455d-5c47-4ce0-9437-2aafb9b5571a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_62c7b064-634e-4cfb-9484-53d0d9e78350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_62c7b064-634e-4cfb-9484-53d0d9e78350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice_89cfb246-8377-4c94-8040-d25ee18de834" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice_89cfb246-8377-4c94-8040-d25ee18de834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a279df1b-804c-49c5-9452-5b420a064384" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a279df1b-804c-49c5-9452-5b420a064384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6af4bc32-e15f-40c4-bcff-5b07f1923a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6af4bc32-e15f-40c4-bcff-5b07f1923a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_79cb1bb3-e065-4a26-b267-ba563717486c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_79cb1bb3-e065-4a26-b267-ba563717486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_cf441b3a-dbcd-45c6-9239-92af24c9fe1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_cf441b3a-dbcd-45c6-9239-92af24c9fe1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4dc9f13b-aba1-4ae1-a935-d5f7d0c54859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4dc9f13b-aba1-4ae1-a935-d5f7d0c54859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f54a9464-5606-4246-9f44-1bbc79fa4226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f54a9464-5606-4246-9f44-1bbc79fa4226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cced1caa-c41b-4bb6-9b1c-c1e86752f3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_cced1caa-c41b-4bb6-9b1c-c1e86752f3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb8f4bb2-9f2c-4f34-96ef-3f2b76493e37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e8920d14-7634-4b6c-80d7-43d301ecc0d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb8f4bb2-9f2c-4f34-96ef-3f2b76493e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19c9c903-d11d-4ada-a249-ac8809867444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c33455d-5c47-4ce0-9437-2aafb9b5571a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19c9c903-d11d-4ada-a249-ac8809867444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b28bb84c-b8b7-4b07-95ca-de87ffcda957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19c9c903-d11d-4ada-a249-ac8809867444" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b28bb84c-b8b7-4b07-95ca-de87ffcda957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d9d535b6-176f-4256-ab59-f1f221123a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19c9c903-d11d-4ada-a249-ac8809867444" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d9d535b6-176f-4256-ab59-f1f221123a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d4279489-ccbe-4af7-bef6-444d3acc673f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_19c9c903-d11d-4ada-a249-ac8809867444" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d4279489-ccbe-4af7-bef6-444d3acc673f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_74e9657c-34ed-4fe0-8568-2d5b0e270579" xlink:href="carm-20231231.xsd#carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8c33455d-5c47-4ce0-9437-2aafb9b5571a" xlink:to="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_74e9657c-34ed-4fe0-8568-2d5b0e270579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5819bbf1-ebba-48f7-9411-a47922acbfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_74e9657c-34ed-4fe0-8568-2d5b0e270579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5819bbf1-ebba-48f7-9411-a47922acbfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_06131f3e-87a6-4768-9c45-cdc9f1598a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_74e9657c-34ed-4fe0-8568-2d5b0e270579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_06131f3e-87a6-4768-9c45-cdc9f1598a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28a8711c-fe74-416f-ab56-72319d253792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_74e9657c-34ed-4fe0-8568-2d5b0e270579" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28a8711c-fe74-416f-ab56-72319d253792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_38722c7b-f3e4-485b-958e-36a9f9356a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_74e9657c-34ed-4fe0-8568-2d5b0e270579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_38722c7b-f3e4-485b-958e-36a9f9356a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8495878f-77a4-401c-8aad-d8c482864edc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8495878f-77a4-401c-8aad-d8c482864edc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cee74a89-49e4-46e6-968b-579c77c6cc08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:to="loc_us-gaap_AwardTypeAxis_cee74a89-49e4-46e6-968b-579c77c6cc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcd7a7bf-b175-4638-ba4c-2a3ac5ad24f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cee74a89-49e4-46e6-968b-579c77c6cc08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcd7a7bf-b175-4638-ba4c-2a3ac5ad24f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5e9aa9c-a58d-4a57-be3e-5d6f8966696d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fcd7a7bf-b175-4638-ba4c-2a3ac5ad24f5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5e9aa9c-a58d-4a57-be3e-5d6f8966696d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4309b7de-e432-462b-8ddd-7a5040ab6a18" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:to="loc_srt_RangeAxis_4309b7de-e432-462b-8ddd-7a5040ab6a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9d3f511-7199-4749-97c1-8eada2646336" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4309b7de-e432-462b-8ddd-7a5040ab6a18" xlink:to="loc_srt_RangeMember_e9d3f511-7199-4749-97c1-8eada2646336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1740608c-f1a5-462e-be5d-8c790ff75ae1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e9d3f511-7199-4749-97c1-8eada2646336" xlink:to="loc_srt_MinimumMember_1740608c-f1a5-462e-be5d-8c790ff75ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_85b71591-2333-4c6f-b8a7-07c3a6312184" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e9d3f511-7199-4749-97c1-8eada2646336" xlink:to="loc_srt_MaximumMember_85b71591-2333-4c6f-b8a7-07c3a6312184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7c7ce0f-b1a2-4da6-99c7-c2dbe45300f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eace6a67-56d0-44b7-9270-00b4310f7748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_eace6a67-56d0-44b7-9270-00b4310f7748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c41bcb3-90ea-4de9-8078-45395530b844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c41bcb3-90ea-4de9-8078-45395530b844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4c81c3d6-bc09-412c-9e43-4d2715dca8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4c81c3d6-bc09-412c-9e43-4d2715dca8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ef2e2b9f-0785-49c7-b683-76f2e85fdbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8a9149b2-52a4-43fd-a5bd-da1b3e0e1091" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ef2e2b9f-0785-49c7-b683-76f2e85fdbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_531bb9f8-94ad-4dc6-b270-8ff688ca8e46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_531bb9f8-94ad-4dc6-b270-8ff688ca8e46" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9c16f6fb-d33e-4117-9029-c1e90841afbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9c16f6fb-d33e-4117-9029-c1e90841afbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bb3c9ff4-343b-4986-b9b8-6afd08f72983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9c16f6fb-d33e-4117-9029-c1e90841afbd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bb3c9ff4-343b-4986-b9b8-6afd08f72983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d1b3dd5e-0f11-48e1-a83b-b967207e5184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bb3c9ff4-343b-4986-b9b8-6afd08f72983" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d1b3dd5e-0f11-48e1-a83b-b967207e5184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a538b553-e6b9-4006-9678-58ca375921e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bb3c9ff4-343b-4986-b9b8-6afd08f72983" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a538b553-e6b9-4006-9678-58ca375921e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_680fdb2d-da53-463d-b067-f06c4458c8da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_680fdb2d-da53-463d-b067-f06c4458c8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d05b5ea-44b6-46cc-9cf2-2eaf75e515a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_680fdb2d-da53-463d-b067-f06c4458c8da" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d05b5ea-44b6-46cc-9cf2-2eaf75e515a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_SesenBioIncMember_53ce9777-9f03-477c-a30b-460ddb6d2b01" xlink:href="carm-20231231.xsd#carm_SesenBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d05b5ea-44b6-46cc-9cf2-2eaf75e515a8" xlink:to="loc_carm_SesenBioIncMember_53ce9777-9f03-477c-a30b-460ddb6d2b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b3b3abc1-4eaf-400a-871d-f75483120af5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_eb866600-208f-4683-9dfb-12f62b9c6335" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_eb866600-208f-4683-9dfb-12f62b9c6335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5bee7ca8-9379-428c-84ff-296e645b56bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_5bee7ca8-9379-428c-84ff-296e645b56bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4bd7d408-8b4c-4695-8ed0-d02b7c7934e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2e1e5b0b-2bd3-4325-86d6-2e12937af32a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4bd7d408-8b4c-4695-8ed0-d02b7c7934e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f46e8058-9dbe-42dc-8914-a1051c317365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f46e8058-9dbe-42dc-8914-a1051c317365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_035cbf97-bb4c-408a-b170-e6c88cb8d987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_035cbf97-bb4c-408a-b170-e6c88cb8d987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_5cd4968c-77b1-4dfb-ab63-4b9167bfcb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal_5cd4968c-77b1-4dfb-ab63-4b9167bfcb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_d36c0b6a-7ef7-4f9e-86f4-1f7330b92214" xlink:href="carm-20231231.xsd#carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:to="loc_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences_d36c0b6a-7ef7-4f9e-86f4-1f7330b92214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_c4761823-57ed-47ff-ad65-1da51ee7ae33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_c4761823-57ed-47ff-ad65-1da51ee7ae33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051ac048-809a-4fa2-b62d-4bc994f31cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_051ac048-809a-4fa2-b62d-4bc994f31cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_9ca3ce96-3535-485c-9001-6ffe7572da3d" xlink:href="carm-20231231.xsd#carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:to="loc_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent_9ca3ce96-3535-485c-9001-6ffe7572da3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b342fd03-2b83-4492-9ec9-3e560ec4a4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_383e172f-2f22-4f4b-9393-f73a3274aaf3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b342fd03-2b83-4492-9ec9-3e560ec4a4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_650e06c5-8fb4-4e95-b74b-2441f1b73836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_650e06c5-8fb4-4e95-b74b-2441f1b73836" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d2c9d3f2-e44e-42a3-b794-87d139a4fbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d2c9d3f2-e44e-42a3-b794-87d139a4fbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_49823fcf-282a-401d-94c5-071cb4474fca" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization_49823fcf-282a-401d-94c5-071cb4474fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b6538cf1-4f2f-4028-bc1a-92d1ad679140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b6538cf1-4f2f-4028-bc1a-92d1ad679140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsStartUpCosts_d3285c2b-27de-4714-93ef-9965488bb30b" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsStartUpCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_carm_DeferredTaxAssetsStartUpCosts_d3285c2b-27de-4714-93ef-9965488bb30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_aa97abed-d9d4-4a06-9680-841dd349c35f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_aa97abed-d9d4-4a06-9680-841dd349c35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsLeaseLiability_ea47daf3-50ac-4d6e-ac9b-c2957b898f1c" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_carm_DeferredTaxAssetsLeaseLiability_ea47daf3-50ac-4d6e-ac9b-c2957b898f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther_3443df9b-9d50-4a86-bdae-6941fde963f3" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsAmortizableAssetsAndOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_carm_DeferredTaxAssetsAmortizableAssetsAndOther_3443df9b-9d50-4a86-bdae-6941fde963f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxAssetsEquityCompensation_d6235f1c-b577-4343-8029-7bbb610ea979" xlink:href="carm-20231231.xsd#carm_DeferredTaxAssetsEquityCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_carm_DeferredTaxAssetsEquityCompensation_d6235f1c-b577-4343-8029-7bbb610ea979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a5dddfaf-e89d-487d-8715-cf33232ea48a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a5dddfaf-e89d-487d-8715-cf33232ea48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e6c8580-cef8-4cd8-b316-f87e61b72aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e6c8580-cef8-4cd8-b316-f87e61b72aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2d5b8850-71e3-4be5-b8e1-6f4a372ece94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_bf3a1abf-8fcd-4d4a-af55-b0cda64a4c57" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2d5b8850-71e3-4be5-b8e1-6f4a372ece94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2b7d6d98-ec3c-4d64-a5e2-86840c3a5c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_650e06c5-8fb4-4e95-b74b-2441f1b73836" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2b7d6d98-ec3c-4d64-a5e2-86840c3a5c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset_16473e9f-99fd-46b0-b361-b9a5bab99f51" xlink:href="carm-20231231.xsd#carm_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2b7d6d98-ec3c-4d64-a5e2-86840c3a5c58" xlink:to="loc_carm_DeferredTaxLiabilitiesRightOfUseAsset_16473e9f-99fd-46b0-b361-b9a5bab99f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4444643b-55d7-40a9-aa3f-b191cac053a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2b7d6d98-ec3c-4d64-a5e2-86840c3a5c58" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4444643b-55d7-40a9-aa3f-b191cac053a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_32adfad0-16b7-410e-848a-987b457a2624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2b7d6d98-ec3c-4d64-a5e2-86840c3a5c58" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_32adfad0-16b7-410e-848a-987b457a2624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d18ad81e-1c2f-4dc6-8778-3ebb8f5ea922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_2b7d6d98-ec3c-4d64-a5e2-86840c3a5c58" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d18ad81e-1c2f-4dc6-8778-3ebb8f5ea922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/IncomeTaxesNarrativesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#IncomeTaxesNarrativesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/IncomeTaxesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_040d3782-21fc-4aca-b969-0c2df6071d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_040d3782-21fc-4aca-b969-0c2df6071d27" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_203ed72a-822a-4eaf-94fa-24f1e6c61765" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:to="loc_us-gaap_TaxPeriodAxis_203ed72a-822a-4eaf-94fa-24f1e6c61765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_203ed72a-822a-4eaf-94fa-24f1e6c61765" xlink:to="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Pre2018Member_6d7d5b43-4d09-448b-b277-f610962d6f93" xlink:href="carm-20231231.xsd#carm_Pre2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:to="loc_carm_Pre2018Member_6d7d5b43-4d09-448b-b277-f610962d6f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_Post2017Member_ba788ba5-07d2-450c-9bfd-fe6b42201713" xlink:href="carm-20231231.xsd#carm_Post2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:to="loc_carm_Post2017Member_ba788ba5-07d2-450c-9bfd-fe6b42201713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2023Member_af8fd588-56bc-4aff-87e7-3ec2a0fd492b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_f02b1cc5-c324-4d0b-8338-d987963bd92a" xlink:to="loc_us-gaap_TaxYear2023Member_af8fd588-56bc-4aff-87e7-3ec2a0fd492b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4c86e82d-f043-4e0a-9019-8710708c288e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4c86e82d-f043-4e0a-9019-8710708c288e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4c86e82d-f043-4e0a-9019-8710708c288e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_92c9cca2-dc05-4d8d-ac90-144c234dcb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:to="loc_us-gaap_DomesticCountryMember_92c9cca2-dc05-4d8d-ac90-144c234dcb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_StateJurisdictionMember_3ba0c389-5b53-4709-99c8-43a4553274db" xlink:href="carm-20231231.xsd#carm_StateJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:to="loc_carm_StateJurisdictionMember_3ba0c389-5b53-4709-99c8-43a4553274db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_LocalJurisdictionMember_4f02a611-71b5-4815-a18d-84fde14bb1c3" xlink:href="carm-20231231.xsd#carm_LocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3c33bf1e-db5a-4960-9851-c51be4248bde" xlink:to="loc_carm_LocalJurisdictionMember_4f02a611-71b5-4815-a18d-84fde14bb1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_525e5b0c-7aa2-498c-8f9a-7601496c59c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_525e5b0c-7aa2-498c-8f9a-7601496c59c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ed0532e-9da3-403b-801d-defef7c165a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_525e5b0c-7aa2-498c-8f9a-7601496c59c1" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ed0532e-9da3-403b-801d-defef7c165a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_088b07bb-a33f-431e-97af-f2ebb244df20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_7ed0532e-9da3-403b-801d-defef7c165a8" xlink:to="loc_us-gaap_ResearchMember_088b07bb-a33f-431e-97af-f2ebb244df20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f09b954f-99fc-4312-80a8-54dea258953f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ac922876-6a6f-43c0-a449-e80b6b7a27dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ac922876-6a6f-43c0-a449-e80b6b7a27dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d7e77441-d5b9-4f9f-811f-716debe7c2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d7e77441-d5b9-4f9f-811f-716debe7c2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d3bac769-a59d-48ea-836e-d738cfd3f362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b88e87d1-5bd3-49fb-b515-3d6d8944ccd5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d3bac769-a59d-48ea-836e-d738cfd3f362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#ModernaCollaborationandLicenseAgreementNarrativesDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b524bff-532c-4075-bd67-ac65e5a404d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b524bff-532c-4075-bd67-ac65e5a404d9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9f936e05-65bf-4e5e-8ea3-9a325a3e0504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9f936e05-65bf-4e5e-8ea3-9a325a3e0504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a8e3f21-95f3-43d1-b7a0-d32d3bc812a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9f936e05-65bf-4e5e-8ea3-9a325a3e0504" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a8e3f21-95f3-43d1-b7a0-d32d3bc812a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_CollaborationAndLicenseAgreementMember_73ea4697-97bb-4010-b9f4-1bae2604947d" xlink:href="carm-20231231.xsd#carm_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a8e3f21-95f3-43d1-b7a0-d32d3bc812a7" xlink:to="loc_carm_CollaborationAndLicenseAgreementMember_73ea4697-97bb-4010-b9f4-1bae2604947d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaLicenseAgreementMember_a0cd4318-97b7-4cee-b002-2cd5193ae5a8" xlink:href="carm-20231231.xsd#carm_ModernaLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a8e3f21-95f3-43d1-b7a0-d32d3bc812a7" xlink:to="loc_carm_ModernaLicenseAgreementMember_a0cd4318-97b7-4cee-b002-2cd5193ae5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b82ffb2-ce69-492b-8274-b42ba2476c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b82ffb2-ce69-492b-8274-b42ba2476c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2d458ac5-3faa-4930-8cce-287a2ed8d509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5b82ffb2-ce69-492b-8274-b42ba2476c8a" xlink:to="loc_us-gaap_RelatedPartyDomain_2d458ac5-3faa-4930-8cce-287a2ed8d509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ModernaMember_89c39bbf-1694-4469-b228-d1064023cc1a" xlink:href="carm-20231231.xsd#carm_ModernaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2d458ac5-3faa-4930-8cce-287a2ed8d509" xlink:to="loc_carm_ModernaMember_89c39bbf-1694-4469-b228-d1064023cc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f50c88c-f332-4e58-8f3b-aab6f0656ad2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_srt_RangeAxis_0f50c88c-f332-4e58-8f3b-aab6f0656ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d6542e4f-f311-4fe6-98dd-acd4bdd2bca5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0f50c88c-f332-4e58-8f3b-aab6f0656ad2" xlink:to="loc_srt_RangeMember_d6542e4f-f311-4fe6-98dd-acd4bdd2bca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e601e886-8099-41bb-a2c8-b5187a208169" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d6542e4f-f311-4fe6-98dd-acd4bdd2bca5" xlink:to="loc_srt_MinimumMember_e601e886-8099-41bb-a2c8-b5187a208169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e5fa80f8-246e-4066-885e-cba734d26ffb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d6542e4f-f311-4fe6-98dd-acd4bdd2bca5" xlink:to="loc_srt_MaximumMember_e5fa80f8-246e-4066-885e-cba734d26ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e4c34190-cf27-4413-8680-8ed69ca325b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_srt_ProductOrServiceAxis_e4c34190-cf27-4413-8680-8ed69ca325b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cff1dfdd-d66e-456c-a724-95efa9d4825e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e4c34190-cf27-4413-8680-8ed69ca325b9" xlink:to="loc_srt_ProductsAndServicesDomain_cff1dfdd-d66e-456c-a724-95efa9d4825e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ResearchAndDevelopmentServicesMember_6d45e61c-6857-4e85-a7cf-8fc84c73e504" xlink:href="carm-20231231.xsd#carm_ResearchAndDevelopmentServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cff1dfdd-d66e-456c-a724-95efa9d4825e" xlink:to="loc_carm_ResearchAndDevelopmentServicesMember_6d45e61c-6857-4e85-a7cf-8fc84c73e504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_69374878-e229-4101-8b1f-dade43d3d7bc" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MaximumOfResearchTargets_3113a1d9-c26c-449e-9582-b9208efaeefb" xlink:href="carm-20231231.xsd#carm_MaximumOfResearchTargets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_MaximumOfResearchTargets_3113a1d9-c26c-449e-9582-b9208efaeefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets_37df9400-1f43-43c0-a0f9-3ca929c802ff" xlink:href="carm-20231231.xsd#carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets_37df9400-1f43-43c0-a0f9-3ca929c802ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfResearchTargetsDesignated_82206ef5-5791-43b8-8bcc-04166566d519" xlink:href="carm-20231231.xsd#carm_NumberOfResearchTargetsDesignated"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_NumberOfResearchTargetsDesignated_82206ef5-5791-43b8-8bcc-04166566d519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_UpfrontNonRefundablePaymentReceived_f6da1584-cfc0-457a-8ac7-9db3e11a5a68" xlink:href="carm-20231231.xsd#carm_UpfrontNonRefundablePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_UpfrontNonRefundablePaymentReceived_f6da1584-cfc0-457a-8ac7-9db3e11a5a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfProductsDevelopedAndCommercialized_1eb77a6b-ccab-4673-b54e-18ec3f2baa16" xlink:href="carm-20231231.xsd#carm_NumberOfProductsDevelopedAndCommercialized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_NumberOfProductsDevelopedAndCommercialized_1eb77a6b-ccab-4673-b54e-18ec3f2baa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_77753b9d-abec-4ad4-a770-a2d774b41437" xlink:href="carm-20231231.xsd#carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments_77753b9d-abec-4ad4-a770-a2d774b41437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_884520a6-4926-46c9-bece-cccd6b5024a2" xlink:href="carm-20231231.xsd#carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts_884520a6-4926-46c9-bece-cccd6b5024a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_0a35ba77-1438-4523-9acd-2d2ffa984d9e" xlink:href="carm-20231231.xsd#carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts_0a35ba77-1438-4523-9acd-2d2ffa984d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_NumberOfPerformanceObligations_07c74e64-1dcf-483d-aaa5-452349486ad2" xlink:href="carm-20231231.xsd#carm_NumberOfPerformanceObligations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_NumberOfPerformanceObligations_07c74e64-1dcf-483d-aaa5-452349486ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_VariableConsideration_bf75ab8d-e22c-4659-8282-25ff408fe3a9" xlink:href="carm-20231231.xsd#carm_VariableConsideration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_VariableConsideration_bf75ab8d-e22c-4659-8282-25ff408fe3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractTerm_11f8faf2-6d62-47c0-886e-e5ccb4767b5f" xlink:href="carm-20231231.xsd#carm_ContractTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_carm_ContractTerm_11f8faf2-6d62-47c0-886e-e5ccb4767b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73508273-2f75-48d3-929e-dd03a7b15dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73508273-2f75-48d3-929e-dd03a7b15dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_49f7c319-d18e-4c0c-8a7a-1510f495dd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_49f7c319-d18e-4c0c-8a7a-1510f495dd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_706050cb-a42d-4a6a-a4dd-a63ca9f1c53d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0025bb8c-c550-4cca-9a37-9caa1ea7dfe8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_706050cb-a42d-4a6a-a4dd-a63ca9f1c53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_17fb9dbc-3b39-4082-8bf1-07d3a4db4876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationAbstract_22697820-b1be-40c0-9835-cb5cdfcf3810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuePerformanceObligationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_17fb9dbc-3b39-4082-8bf1-07d3a4db4876" xlink:to="loc_us-gaap_RevenuePerformanceObligationAbstract_22697820-b1be-40c0-9835-cb5cdfcf3810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_a6dc6f23-359b-4cba-8eac-0901d2622d58" xlink:href="carm-20231231.xsd#carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract_22697820-b1be-40c0-9835-cb5cdfcf3810" xlink:to="loc_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount_a6dc6f23-359b-4cba-8eac-0901d2622d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_d262cbe1-edec-4cea-974c-041f780c50fc" xlink:href="carm-20231231.xsd#carm_RevenueRemainingPerformanceObligationOptionRightsAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract_22697820-b1be-40c0-9835-cb5cdfcf3810" xlink:to="loc_carm_RevenueRemainingPerformanceObligationOptionRightsAmount_d262cbe1-edec-4cea-974c-041f780c50fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_17705bda-a110-473d-aaa3-70cbf77dabdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuePerformanceObligationAbstract_22697820-b1be-40c0-9835-cb5cdfcf3810" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_17705bda-a110-473d-aaa3-70cbf77dabdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails" xlink:type="simple" xlink:href="carm-20231231.xsd#ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a7181e02-87fe-471c-89cf-d300b9c50cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_29ddf83a-3b2d-4cdd-8e51-7ebe95958e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a7181e02-87fe-471c-89cf-d300b9c50cf6" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_29ddf83a-3b2d-4cdd-8e51-7ebe95958e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_20876c2d-ae5a-47a2-8465-066753989cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_29ddf83a-3b2d-4cdd-8e51-7ebe95958e4d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_20876c2d-ae5a-47a2-8465-066753989cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_carm_ContractWithCustomerLiabilityDeferralOfRevenue_804c6be9-6010-4d22-8575-10177e9cc894" xlink:href="carm-20231231.xsd#carm_ContractWithCustomerLiabilityDeferralOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_29ddf83a-3b2d-4cdd-8e51-7ebe95958e4d" xlink:to="loc_carm_ContractWithCustomerLiabilityDeferralOfRevenue_804c6be9-6010-4d22-8575-10177e9cc894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8a36d359-63e3-467c-a100-f03f1f278f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_29ddf83a-3b2d-4cdd-8e51-7ebe95958e4d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8a36d359-63e3-467c-a100-f03f1f278f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5bef0f91-52fc-4cb0-949b-857ca76fb7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_29ddf83a-3b2d-4cdd-8e51-7ebe95958e4d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5bef0f91-52fc-4cb0-949b-857ca76fb7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>carm-20231231_g1.jpg
<TEXT>
begin 644 carm-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" <K$ @# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS \;_'#]
MLFR\::_;Z1IOC!M)AU"XCLVA\%1R(81(PCVO]D.X;<8.3GKFOT_HKJP]949.
M4H*7J<N)HRKP48S<?-'XZ^)/VX/VF?!NK2:7X@\3W^AZG&JL]GJ7AVRMYE!&
M02CVP(!'(XKJ=/\ VBOVS]6L+:^L;7Q=>V5S&LT%S;^"89(Y4895U86F&4@@
M@C@YKE_^"D7_ "=9K_\ UY6?_HE:_4K]G_\ Y(3\._\ L7M/_P#2=*^@J5J4
M,)3Q/L8WETLO,^:IT:T\9/#>VE:*O>[\O\SYDF^-GQG\+_L+>(/&WBFZU#1/
MB+::B(XI]4T:&UF2$SQ(/W#PA""K, 2GX\5F?\$\OVF/B3\<_'7BO3_&_B/^
MV[.QTV.>WC^PVUOL<RA2<Q1H3QV)(KU[_@H9_P FF^,?]^T_]*8J^-?^"8OC
M[PQX!^(?C*Y\3^(])\.6]QI<<<,VK7T5JDC"8$JID8 G'.!7-AE#$8?$5.17
MOIIM[JV.O%.IAJ^&I^T=NNN_O/<_5FORU_:B_;3^,WPZ_: \9^&O#WC'^S]%
MT^\6*VM?[+LI?+7RT.-SPLQY)ZDU^@O_  TA\)?^BH^"_P#PH+3_ ..5^/W[
M7NNZ;XF_:6\>:IH^H6NJZ;<WZO!>6,ZS0RKY2#*NI(89!Z'M664T.;%VJPNK
M/=:;Q.C-L1RX2]*=GS+9ZVM+M\C]B_B%XFU+0_@?XC\06-SY&KVGAZXOH+CR
MU;9,MLSJ^T@J<, <$8]J_*_PW^W!^TSXRU:+2] \3WVN:G*&:.RTWP[97$SA
M1EB$2V+$  D\< 5^GOQ8_P"3:?%__8IW?_I(U?E;^P+XHT;P;^TWX>U37]7L
M=#TR*VO%DO=2N4MX4+6[A07<A022 .>2:VR^G"4L0Y13Y5=)K_%^=CFS.K4C
M3PJC)KF=FT^_(OPNST?_ (7U^VU_T#/&G_A#1?\ R'6EX8^.?[9USXDTF'4-
M-\8BPDNX4N#)X)C11&7 ?+?9!@8SSGBOT"_X:0^$O_14?!?_ (4%I_\ '*OZ
M#\</ASXIU:WTO1?'_A?5]3N"5ALK#6;:>:4@$D*BN6/ )X'0&H6+MK]6C]W_
M  "W@N966*E]_P#P3SG]M[XG^)OA!\ -3\2>$=2_LG6H;RUB2Z\B*;"O( PV
MR*R\CVK\_?"/[8W[57Q DN8_"^L:QXD>U"M.ND>%[2Z,0;.TN([8[<X.,]<&
MOMG_ (*4?\FJZS_V$++_ -&BOG__ ()'_P#(P?$G_KUL?_0YJK+HTUA*U:<%
M)Q?5>4?\PS)U)8RC1A-Q4H]'_>D<-<_M$?MHZ;;R75W8^+H+:$;Y))_!,21J
MHZEF^R# _&NZ_9O_ ."F7B*^\9:9X>^)]O87.EWTJVRZW9P^1+;R,0%>50=C
M)G&=H4C)/.,5^C>H:E::3:275]=0V5K&I9YKB01HH R26)P!7X8_M&:EHWC3
M]H?QI=^#D2YTK4-7?[%]D7Y9V8@%D ZAWW$8Z[A6V"G1Q]1T944E;=?+_/3T
M.?'4ZV7TE6A7;=[6>O1O\+:^I^Z]>+_M??&:Y^!?P'U_Q'IMPMMKLFRRTQV1
M7Q<2' ;:P(;:H=\$$?+R*]6\-VUQ9^'=+M[LDW4-K%',2<G>$ ;GOSFOS=_X
M*L_%+^U/&7ACP#:RY@TN ZE>*.AFE^6,'W5 Q_[:5X="A[7$QHIW5_P6K^]+
M\3WJV(]CAI5VK-+\7HOQ9XP?^"@7[0BP+,?'3B%F*+)_8EAM+  D _9^H!'Y
MBOU)_9C^+!^-GP.\*^*YY%DU&XMO)U#: O\ I49*2G X&64L .S"OA#QE^S'
M_97_  3GT'7Q:8U^VO!XFN"%^;R+C;'M]<"+R&/^Z:Z?_@E#\5/+N?%OP[NI
ML"0+K-BK'N-L<X'X>4<>S5]#BJ5"O0J^Q@E*F^BWMO\ +7\#YS"5:^'K476F
MW&HNK>EWI\]%]Y^B6H2O!I]S(AVND3,IQT(!(K\>K#]NS]H[7M=CTK2/%]SJ
M6H7$QBM[.ST&QFFE;/"JBVY9C[ 5^P6K?\@J]_ZXO_Z":_$O]D?_ ).L^'O_
M &&T_P#9J\_**<*DZO/%.R6^O\QZ6<U)TZ5-TY-7;VTZ(]@N_P!HC]M#3+=[
MF\L_%UO;1C<\D_@F)$ ')R3:# KJ/@%_P4Z\56?BFQTKXHQ6>J:%<R"*75[6
MV$%S:$G'F,J?(Z#N H;&2"<8/Z;U^+_[?VDZ%HW[4GBR'08X88W$$UW%;@!%
MN7B5I.!T))#'W8UTX2M0QE7V$Z*5T]OZ_KYG+BZ%?!4O;TZ[;36C_K^EZ'ZB
M_M2>/M7^'_[/'B[Q5X6U%;/5;.SCGL[U(XYE7=(@W!7#*P*L>H/6OS6\)_MI
M?M1>/+^6Q\,Z_JGB*]BC\Z2VTGPU9W4B(" 7*QVQ(7) STY%?8WQ.GN[G_@F
M?%+?;C=-X2TXN7^\?]3@GWQBOE#_ ()G^./#G@/XT>(+[Q-K^E^';*70I(8[
MG5KV.UC=S/"0@:1@"V 3CKP:6"HPIK$*45)P;M=7V0L=7J5/JSC)QY][/O;\
MKFI_POK]MK_H&>-/_"&B_P#D.NV^"7QF_:WUKXO>#[#Q=I_BR/PQ<:G!%J37
M?@^.VB%N7 <O*+5=@QGYMPQZU]O?\-(?"7_HJ/@O_P *"T_^.5K>%_C#X"\;
M:I_9OAWQOX<U_4=AD^QZ7JUO<S;!U;8CDX&1SCO6#Q>G^[1^[_@&_P!3;T6*
ME]__  3P;_@H3\;/&GP.^&?AS5O!.L_V)J%WJXM9YOLL-QOC\F1MN)48#E0<
M@9XJO_P3S^.'C;XY> ?%.I>-]:_MN]LM32WMY?LD%OLC,2L1B)$!Y)Y(S7'_
M /!6+_DC/A#_ +#X_P#2>:JO_!)G_DEOC?\ [#,?_HA:*-.#RZK-Q5T]^N\2
MZ]2:S.E34GRM;=-I'W2W"D^U?E7\+_VVOC3XB_:(\-^&-0\9_:-#O/$<-A/:
M_P!EV2[X&N A3<L(8?+QD'/O7ZIO]UOI7X=_!3_D[7P?_P!C?;_^E0J<HIPJ
M5IJ<4U9;^H\YJ3I8>,J<FG?IIT9^FG[<'C3XN>"_!?AVX^$-OJUQJTVH-'>K
MI.CKJ3B'RR1N1HI-HW8YP/3-?%.N?M,?MC^%])N-4UE?%.DZ9;+NGO+[P9!#
M#$,@99VM %&2!R>]?K17A7[<?_)J?Q#_ .O*/_T='7)A\5&BE"5-2N]WYV1V
M8G"3KRYHU91TV3/SP\)_MI?M1>/+^6Q\,Z_JGB*]BC\Z2VTGPU9W4B(" 7*Q
MVQ(7) STY%>T_ 3XR?M9Z[\9/".G^--/\51>%;B_1-1>\\(1VL(A.<[I1:J4
M'ON%</\ \$I/^2[>)?\ L7I/_2B"OU3KV<?6I86HJ<:,7=7V7F>%E]&MC*;J
M2K25G;=]E_F?EW^UA^V?\9/AG^T+XR\,^&_&']FZ)I]Q$EM:_P!F6<OEJ8(V
M(W/"S'YF)Y)ZU^EWA?4);_PKI%[=R!IIK*&:60@*"QC!8\<#DFOQF_;L_P"3
MLOB'_P!?4'_I-%7Z,?M7?$"Z^'/[&%]?6$K07U[I=GID,J'#+YRHCD'L=A>N
M/$48_4<.X17-+E5^[:Z_,[\/6E_:&)4Y/EBY?))O9>2/GC]J+_@I%K?_  DU
MYX3^$30PVUO+]GD\1&%9Y;F0'!%NC J%SP&(8MU&."?-X_A[^VEKNF_\)$MW
MX\2"1?.\H^(/LTF.O_'J9U<?[NS\*G_X)?\ POT[QI\:-5\1:G;1W<?AFR6>
MUCD (6ZD?:DF#W55D(]#@]0*_5^M\1.GEO+1I03E:[;U_K\CGP\*N:<U:M-Q
MC?1)V/RX^ /_  44\=_#SQA%X;^+9FUC1EF^RW-S=6WDZCIK X+, H,@4YW*
MPW^AXVG]0;.\@U"T@NK:5+BVG198IHV#*ZL,A@1U!!!KY?\ VBOV!?#7[0?Q
M*@\73Z[/X<D:U6"^@L+1&>[=2=LA=FP&VX7[IR%'I7O_ ,,_ EO\,? .A^%+
M34+W5+32;9;6&ZU%E:=HU^Z&*JH^4848'0#KUKS\55P]>G&I!<L^J6W]?YZG
MHX2EB</5E3G+FI]&]_3^NVAT]%%%>6>L%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S5^WW\8/%WP4^"]AK
MW@S5O[&U6768;1[C[-#/F)HIF*[949>J+SC/%?2M?''_  5._P"3<]+_ .QA
MM_\ T1/6U%)UJ:>SE'\T8UFU1J-;J,O_ $EGR9X1_:]_:O\ B!'<R>%]3USQ
M)':E5G;2/"MK="(MG:',=J=I.#C/7!JUKO[87[5WPY\F[\53:OI5L[A5&N>%
M8+2.0]=N3;H3D>AS7MO_  2/_P"1=^)7_7W8_P#H$U?9'QVTG0M:^#7C.U\2
M1PR:*=*N'N#/C:@6,L'!/1E(!![$"O?QV)HX2M*G[&+2MT5]4F?-Y?A:V.H1
MJNO)-MK=VT;7?R/"_P!B_P#;<C_:,DNO#7B2RM=(\9VL)N$^Q[A;WT(.&9%8
MDJZY&5R<@Y'&0.$_X*'?M+?$CX%^-?"5AX(\1_V):7VGRSW$?V&VN-[B3:#F
M6-R./3%?'?["4UW#^U?\/_L9;>US,D@7O&;>7?GVVY_*O=O^"M'_ "4;P'_V
M"9O_ $=6E;"4J6845%>[*]UTV?X?J*CC*U7+J\I/WHVL^OQ1_'?Y'&>'?VGO
MVPO%VD0:KH3>)M:TN?=Y5]IW@ZWN()-K%6VNEH5.&!!P>""*76OVMOVM?A[;
MIJ?B@:YING;POF:WX2AM8&/9=YMTY/L<U]M_\$\O^31_!/\ OWW_ *6SUWO[
M2_B[PIX5^"?C%O%EW9Q6%QI=Q;K:W+KNN)&C8)&BDY9BV,8^O;-88K%TJ%>=
M)4(OE;6VK_#<WPN#JXBC&H\1)77?1?B>+_L6_MR-^T-J-SX4\56%KI?B^&%K
MF"6QW+;WL2XW85B2LBY!(R01DC&,5]/>-O&FC?#OPIJ?B/Q!>QZ?I&G0F:XN
M).P'0 =V)P !R20*_'S_ ()^Z7?ZE^U?X+>R21EM?M-Q<NF0$B%O(I+8[$LJ
M_5A7T[_P5A^(EW8:#X,\$VTK1VVH22ZE>*K8WB/:L2GU&YG/U4>E3C\%!8JG
M2HZ<_P"&]W]R^\K+\=-X2I6KZ\GX[67WO\3R#XH?M_\ Q=^-?C#^POAI%>>'
MM/N)&BLM/TBW$^HW0[%W 9@V 3B/  SDMC-17GPZ_;2\*V!U^:]\=R00KYQC
M3Q$+Q\=?^/99W8_[NS\*^@?^"6?PCT_1_AGJOQ!N;5)-9UB[DLK:X906BM8L
M!@I[;I-V?78OI7W+5XG$4\#/V%"FM-V];D8;#5<?#ZQB*DE?9+2Q^;?[,O\
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MMJWBC5-;\-K=%A;G5_"MK:B;;C=L\RU&[&1G'3(K]>Z_//\ X*Y?\@[X9?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^.W_!2+_DZS7_^O*S_ /1*U^I7[/\ _P D)^'?_8O:?_Z3I7Y:_P#!
M2+_DZS7_ /KRL_\ T2M?J5^S_P#\D)^'?_8O:?\ ^DZ5[U;_ )%='Y?DSYVC
M_P C:K_A_P#D3R__ (*&?\FF^,?]^T_]*8J_-S]DO]E[_AJ+Q-KND?\ "3?\
M(S_9=FMWYWV#[7YF7"[<>;'CKG.37Z1_\%#/^33?&/\ OVG_ *4Q5\I_\$F/
M^2F>.?\ L$1?^CA6F63E3P=><=T__;8D9K"-3%8>$MG_ /)'3_\ #HC_ *JQ
M_P"6Y_\ ==?$?QK^&?\ PISXK^(O!G]I?VO_ &/<B#[=Y'D>;E%;.S<VW[V,
M;CTK]\*_$?\ ;8_Y.L^(G_817_T5'6^5XW$8C%*G4E=6;V7>/^9CFF!P^'PO
MM*4;/F2W>UI>?D?K5\6/^3:?%_\ V*=W_P"DC5^.?[.'P5_X:"^+&F>"O[9_
ML'[;%/+]N^R_:=GEQ,^-F],YVX^]QFOV,^+'_)M/B_\ [%.[_P#21J_)G]BG
MXE^&_A'^T)H?B;Q9J/\ 96B6UO=)+=>1+-M9X'51MC5F.6(' J,M<E+%..]M
M/7WK?B/-;.GA%+9O7T]R_P"!]0?\.B/^JL?^6Y_]UUWOP)_X)M_\*4^+'A[Q
MK_PL3^V?[)E>3[#_ &)Y'F[HW3&_[0VW[^?NGI7IO_#PGX ?]#]_Y1M0_P#D
M>@?\%"/@ Q 'C[G_ + VH?\ R/7/]8S.7NVEK_=_X!U+#Y7%IIQT_O?\$Q/^
M"E'_ ":KK/\ V$++_P!&BOS=_9V_9=\5_M,W>N6_A>_T>QDT>.*2?^UII8PX
MD+!0GEQ/D_(<YQVK](/^"DSB3]E/5W4Y5K^R(/\ VU%> _\ !(__ )&#XD_]
M>MC_ .AS5OELY4L%7J1W3_2)AF=.-?'4(2V<?_;I'QY\:/@5XO\ @#XK&@^+
M[!;6>1/-M[JW?S+>YCS@O&_&<'J" 1W S7W9_P $_P#]FWX0:U96?Q#T[7;K
MQEXCTV0!K+4+9;5=+N,95C &?<PYVN79>X 8<?2/[6G[/%G^T7\*;S1PL<7B
M&RW76D7;<>7.!]PG^XX^4_@>U?E5^SG\9M;_ &6?C9%J%W!<06T,[:=KVEL,
M,\(?$BE?[Z$;E]UQT)KJP^)J9A0E24N6HNW7^MGV?EH<F(PM/+<1"JX\U-]^
MC_K57W6FZN?MS>WD.G6<]W<R+#;P1M+)(W 55&23] *_"OXB>/++XU?M!:EX
ME\07YTW1=8UE6GNFC=S;66\*#M4%B5B X ).*_3[]N;XV67A/]EF_P!0T6_C
MG?Q;%'8:;<0MQ)#.NYW4CMY(;G_:%?"G[#O[)>D_M-:OXFE\2WFJ:?H.D01*
MLNER1QR27$C$JNZ2-QM"HQ(QGE>:XLI@J'M,54T4=/R;_0[LXJ.NJ6$I.[GK
M^B_]N_,^X/$7[:O[-OB/P/J'A2?QNJZ1>:>^G-"-%U#"Q-&4P!]G[#I]*_-'
M]GOXE)\$_CYX9\2P7@GTVQU'R;FX1659;1R8Y&VD \HQ8 C.0*_0?_AU+\)?
M^AB\:?\ @;:?_(M?&/[;'[,.G_LS^.M&LM!NM0OO#^JV1F@GU-T>83(Q61"4
M1%P 4(X_BKJP-3!PJN%.4FYZ-/K:[[=KG'CZ>-G14ZD8I4]5;ILN_>Q^R&I2
M)-HUU)&P=&MV964Y!!4X(K\#_ 6K>)]"^)&EZAX+2YD\56]YOTY+.U%U,9@3
MC;$58.?;::_7C]C7XJ?\+8_9<T6\GF\[4]*M9-(O<G)\R%=JD^[1F-OJQK\Q
M?V1_^3K/A[_V&T_]FK++*3P^)Q%-]$O_ &[\S;-*RQ&#H55U;_)?D>OWGQI_
M;6U:W>UDT_QPB2#:6A\'+ PSZ.MJI7Z@BH?@7_P3[^)?Q6\:1:Q\1K2\\-Z
M\XN;^XU27-_?9;<R*F2X9N[R8QG(W$8K]9J*XEF;IW]C3C%OJD=KRI5+*M5E
M)+HV>!_MJ6-OI?[(OCJSM(5M[6WTZ&&&&,85$66,*H'H  *_+[]E']F[_AIW
MQWJ7AO\ X2+_ (1K['IS7_VK[#]KWXDC39M\Q,??SG/;I7ZD?MQ_\FI_$/\
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MX;_;L_Y.R^(?_7U!_P"DT5?K+XD^'-C\7/@ WA#4&\NVU;1(8/-QDQ/Y2E'
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MO)'<4445YAZ@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVT_X!I_\$X[^"\_9/\-10[=]K=7L,VWKO^T._/OM=?PQ7TW7Y*_L$?M>Z;\
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M 4444 %%%<]X^\?:#\+_  E?^)_$U_\ V9H=@%:YNO)DEV!G5%^6-68Y9@.
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MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=+AQYEY?SK#$N> "S$#)/0=ZQ-C6HKY^;]OCX"K??9#\08/-W;=PTZ\,>?\
MKIY.W'OG%>U>%?%^A^.-%AU?P[J]EK>ES9"7FGSK-&2.HW*2,CN.HK:5&K37
M-.+2]#&%:E4?+"2;\F:]%%%8FP4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !117A'BC]N3X(^#?$>IZ#K'C7['JNFW$EI=6
M_P#95\_ERHQ5EW+ 5."#R"15PISJ/E@KOR,YU(4X\TVDO,]WHKYU_P"'A/P
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M)(%:?5<1_P ^W]S,OKF&_P"?D?O1[O14<T\=K#)--(L4,:EWD<A550,DDGH
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M3;JW2$"-0HP'@<YP.?FKWSP?X8M?!/A/1?#UC)-+9:390V,$EP0TC)&@12Q
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M]H-Q#'97]LJV[;MRB,FW+ *<8R2>!S7UUI]J]C8VUO)<S7CPQK&UQ<;?,E(
M!=MH"[CU. !D\ 58HK:IB*M9*-25TC*GAZ5&3E3C9O<^8/CA_P $]OAG\9-6
MN=;MENO"&NW!9YKC2-GD3R'DO)"PQG/)*%2>2<FO$K3_ ()%VB7BM<_%&::U
MW?-%#H0C<C/0.;A@#[[?PK]#**VI8[$48\D)Z??^9A6P.&KRYZD-?N_(\4^
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M2-QC#'H!VYKZM\<?\$H?!K>';QO"'BK7X-<6,M;KK$D$]N[@9"MY<4;*#TW
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M7AYU?A<5?TYI'V3??\$H?A=)9S+9>)_%T%T5(CDGN+65%;L646ZEA[!A]:^
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M)XR?X=_L2^'O$\4?FS:3X'M[V-",AG2S5E!]L@5^?/\ P4P_Y.DU#_L%V?\
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MIXFIAZ/U9VTU^Y6_4\NG4PM/$5_K,;^\[?>[GT5_PZE^$O\ T,7C3_P-M/\
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MUFC5NQ9! A8>P8?6OCS]D;]L#_AE>'Q/'_PB7_"3_P!M-;MG^TOLGD^4)/\
MIE)NSYGMC'?->]ZM_P %<K^:QF33?AC;VEX5(CFNM;:>-6QP2BP(6'MN'UK;
M'0QTJS>'ORZ=5V5]_,YL!4P$:"6)MS7?1OKIMY'R=H>M>(OV4OVA9#9WI.I^
M&=5:TN3;L52\A23;(A']UU'0],CN*_67]LJ03?LJ_$20# ;2BPS[NE?FG\ _
MV>_'?[67Q>'B/5["Z3P_>ZBVH:SKT\)C@<%]\D<1/#NWW0JYVY!. *_2W]LQ
M1'^RQ\1E485=*( _X&M<6:27)1C-IU$O>M\OUN>CE,7[2M.FFJ;?NW^?Z6N?
MF!^Q7\ /#W[1WQ6U#PSXEO-3L;"WTB6_232I8XY3(LL* $R1N-N)&[9X'-?;
M?_#J7X2_]#%XT_\  VT_^1:_/+]G_P#: \0_LX^,[KQ-X:L],OK^XL7L'CU6
M*22(1LZ.2!'(AW9C7OCD\5]!_P##UKXM?]"[X+_\ KO_ .2J]3&T\9.HGAY6
M5OQU/'P-7!4Z;6)C>5^W30^IO O_  34^&/P_P#&FA^)M.UWQ;-?Z1>Q7T$=
MU>6K1,\;AE#A;8$KD<X(/O7UG7P?^R'^WCX_^/WQHLO"'B'2/#=GILUI<7#2
MZ9;7"3!HTR "\[C&>O%?>%?-8Z.)A*,,0[NUU_7R/J<!+"U(RGAHV5[/\_U"
MOEO]O[]H^^^!/POMM/\ #]Q]F\4^(WDMK:X4_/:P*!YLR^C?,JJ>Q;/:OJ2O
MRO\ ^"K6L377QN\,Z<Q_T>TT)9$&?XI)I-Q_)%_*L,'25?$PIRV;U^2;_0Z,
M95E0PU2K'=+3YM+\+W,7]B3]C&']HUM0\8>,KR[B\*VMR8%BMY-L^H7  9\N
M02$&X9(Y)8@$8)KZU^(W_!-+X1>(_"]S:^%].NO"6MB,FVOHK^>X0R8X$B3.
MX*D]=NT^AKL/V =-@T[]DWP-Y(7,Z74\A7NS74N<^_ 'X5]"UZ&88RLL1*$)
M.*B[:>1YN6X.A+#0J3BI.2OKKO\ EH?D'^QOK'Q%^!/[1@TBWT/6=0TEM1.B
M^(;33[.6XA&US&93M4C,;?,&Z[=PZ,:^U_\ @I1_R:KK/_80LO\ T:*^I:^6
MO^"E'_)JNL_]A"R_]&BL*F+>+KT92C9J45?O[R.BE@U@Z%>,97BXR:7;W6?/
M_P#P2/\ ^1@^)/\ UZV/_H<U?I+7YM?\$C_^1@^)/_7K8_\ H<U?I+6^<?[U
M\E^1CDW^ZKU85^'_ .V-_P G3?$;_L+O_):_<"OP_P#VQO\ DZ;XC?\ 87?^
M2U>1?[^O1_G$,[_W+_MY?E(_5#]L+_DT[X@?]@?_ -F2OQB\$^,M5^'OB[2?
M$NAW+6FJZ7<)<V\H_O*>A'=2,@CN"17[._MA?\FG?$#_ + __LR5^6_[-O[/
M[_M :+\1+"P!_P"$BTG2H]1TL G$LBR8:(C_ &U) ]#M]ZZ,JJ1HQK5)[*U_
MQ//S2G*LL/3AN[V_ _7OX&_%[2OCG\,=%\8:251+V+%Q;;LM;7"\21-_NMT/
M<$'O7Y9_\%(O^3K-?_Z\K/\ ]$K6S_P3W_:*D^"_Q4?P=K\S6WAKQ'.MM(L_
MRBSO0=L<A!^Z&/[MO^ D_=K&_P""D7_)UFO_ /7E9_\ HE:JEA?JN91Y?ADF
MU^&GR_*P5,7]:RV:G\<;)_>M?G^=S]/O%7_)MVK?]BI+_P"DAK\LO^">'_)V
MG@[_ *YWO_I)+7ZF^*O^3;M6_P"Q4E_])#7Y9?\ !/#_ ).T\'?]<[W_ -))
M:G _Q,9Z/_V\O,OX6"]?_D#[J_X*$?M(7_P/^&MGHOAVY^R^)_$ADABND.'M
M;=0/-E7T<EE53VR2.17R5^Q#^Q3;?M"6]YXS\:7-U%X5@N3!!:VTFR;4)A@N
M6<@E8QD D<L2<$;>9_\ @JEK$]Y^T!HVGN?W%GH,+1KGC+S3%C^@_*ON+]A7
M38-+_91^'Z0;2);66=RHZL\\C'\<G'X5G1?U3+O;P^.;M?[_ -%][;-:]L9F
M2P\_@@KV^2O^+^Y' ?$S_@FC\)O$GA:ZM_"6GW/A'75C)M;R.^GN8FD X$J3
M.^5)Z[=I_E7R'^Q#X@^(?P6_:"71H=#UJ^T*YOSH^OVME9RW$,3!R@F)52 8
MWYW?W=P[U^NM%<-',*M-2A5]^,NC?]?UJ=]?+J51QG2]R47ND%?F+_P56^*7
M]L>//#?@.UES;Z/;G4+M0>//FX0'W6,9_P"VE?IEJ%_!I6GW-[=2+#:VT332
MR-T5%!+$_0 U^)MBMW^UC^UK'Y@<IXHU[>X[Q6:MDC_@$"?^.U>5455Q2E+:
M"N_R7ZOY$9M6='"N,=YZ+\W^B^9S?Q=^"FK_  <TOP'J%^7 \3:+'J\9QM\I
MF8GR_JJ&(GW>OV-_9C^**_&+X%^$?$[2"2]N+-8+WG)%S%^[ESZ992WT85X5
M_P %,OA4GB7X 66O6%L!/X4NDD"QI]VUD B=1Z 'RC]%KS#_ ()0_%3!\6_#
MN[F'.W6;!&/^['.!_P"03C_>KT*E3^T,%.?VH2;^6_Y-?<>92I?V;C:</LSB
ME\]OQ:^7,?6O[7W_ ";%\2O^P--_(5^>O_!+G_DY2Z_[ -U_Z,AK]"OVOO\
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M;XI?\('^SY-HEO+LU#Q1<+IZ@'GR%^>8_3 5?^!U]*^!_P#D2O#_ /V#[?\
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M$OFL1(1_N#8Q]FKZ:_X*I?%/^WOB7H'@:UFW6N@VIN[I5/'VB;& ?=8U4_\
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M#)!.;<F1"C %<-G@\U\^?!'_ (*8^ OB/J-II'BO3Y_ VJW#"-+B>83V#,2
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MI'XGI\'?@CXM\4^8J75I9-'9[CC-S)^[B'_?;*?H#7(_L*_\FG?#S_KTF_\
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M$O\ T,7C3_P-M/\ Y%H_X=2_"7_H8O&G_@;:?_(M?.O_  ]:^+7_ $+O@O\
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M$I[VU"BBBH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*YWP9^T!\:?V,?B1_P (YXEFU"YLK1E^U>'=6N#/;RPGHUN^3LR,D-&<9'S
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MW>)U('/<QO@]\X&/>CRYAA(45*U2'?KT_&R]'IYGSTU/+L9.ORWIU-[='O\
MA=^J]+'[%:AJ%MI-A<WMY,EM:6T;3332'"HBC+,3V  )K\,_&5Y<?M#_ +2F
MIR:2C22>*?$)CM JG/ER3;8R1VPF"?3!KT[Q]^U-\>?VM+!O"NGZ9+)IMQA;
MG2_"6FS;9QGCS6+2/M]06"^HXKZP_8;_ &&[KX-WR>._'D<+>+C&4L--C<2+
MIRL"'=V!VM*02ORY"@GDD_+KA:2RMRQ%=KFM9+\?T7HON,\76>:*.&PZ?+>[
M?;I^%WZG0_\ !2>U2Q_91EMHAB*'4K&-1[ D#^5?//\ P2[^&_A+XA3?$A?%
M/A?1O$@M4T_[/_:UA%=>3N-QNV>8IVYVKG'7 ]*^HO\ @H;X2USQM^SC=Z9X
M=T74->U)M3M9!9Z9:R7,Q4,V6V("<#N<5Y%_P2Z^&WB[X?W'Q'/BCPMK7AL7
M2Z?]G_M?3IK7SMIN-VSS%&[&Y<XZ9'K7/@ZELOQ%WJW\_L&^.IWQ^'26BBOS
MD>=?\% _V-M,^&UK%\1/ .F?V?H1D$6K:;;9\NT=C\DT8_A0GY2HX4[<8!X[
MO_@GK^V5J/BW4(OACX[U%K[43&3HFJW3YEF"C)MI&/WF !*L>3@@D_+7WAX@
MT#3_ !5H=_H^JVL=[IM] ]O<6\HRLD;## _@:_'?XN_LC_%#X*?&*ZB\&^&?
M$NNV%C<I?:/K6C:;/<[5W;H\O&I D0C!'J,XP158&M#%4WA,2_1O^NGXK3H3
MCZ$\+4CC,*O*277_ (?KV=GNS]+_ -L__DUOXC_]@MO_ $-:^'?^"4<$<_QB
M\8K(BN#X?93N&>#<19%?5_C[Q'XI^-O[$'B6:[\'ZYIGC*[THVUSH,VF3QW+
M7*LH8Q1,NYD;[RX!X..H->"_\$QOA1XQ\!?$CQA>^*/!^N^'(IM)2&"?5M-G
MM5D/G*2JF10"> <#TJ<+%4J.)IS:O:WKN/&-UZN%J03M>_IK'<^4]6UK5OV7
M_P!H+QS::6OE36;:GHZ+N('DSQR)&_X!XY![J*^FO^"4/@-;S5/B#XLGBRD-
MI#I,+^OF$R2C/TCB_.N>_P""A?[.OC+5_P!H.?Q#X3\&ZYXAL-8L()YY]'TV
M:Z1)T!B96,:D [40X/K7UG_P3]^%FH_"_P#9SLX-:TNZT?6M5O;F_NK.^@:&
M>/YO*0.C ,/DB4X(_BKHKXB,LK<[^_**CYZ7O_[=]YRPP\XYG[.WN*3FOFDU
M_P"V_<?G+^QRHC_:\\"JHPJZM(!_W[DK]L*_(W]F+X%_$+PQ^UIX5U/4/ /B
MC3M%M=8F9]0O-'N8X$CVR ,TC(% .1SGO7ZY5AFLXS5)Q=]/\CT,M@X5*Z:M
M[W^84445\^>Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'X?_MC?\G3?$;_L+O\ R6OVYLO^/.#_ *YK_*OQ
M\_:P^!?Q*\1?M'>/M4TCX>^*M3TZYU-Y(+RST2YFAE7"_,KJA##W!KKU^.W[
M;"1A%TOQH% VC_BAH^G_ ("5]14H_6L%AX0DDXK6[[J/^1\I&O\ 5<?B)S@V
MG)[+^\SZO_X*4^.+3PO^S3J&D23JM]K]W;VEO"?O.J2++(<>@"#GU8>M?/\
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MN*^=/^"3O@>YN_B!XR\7-&PLK'3ETU)".&EED60@'U"PC/\ O#UKR;3?A/\
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M]CT2Y:%HC=EA('";2N.=V<8YJ,EDHXJ\G;3]4:9[%SP5HJ[NORD?L@ %  &
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MX\=2VUUXL6,K8Z;;L)(M/W+AG9^CRX)7Y?E4$X+9!#AA*&%C*>*DI=DG_7_
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M+?#NI>']1D2/2[&WU:SDMI3'D23.%D4':2(@#C'RL*]#"3CA_K&+;UNTOO\
MU;_ X,;">)6'PB6C5W]WZ)/[SQ__ (7U^VU_T#/&G_A#1?\ R'7R[\0-+\:>
M'?&4VH>+](U3P]XCOIFU(C4-/:PD=V<L95C*( -X/W0!D''2OW[KXF_X*9_
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M2P0Y4.B$9'<9KU,MDHXJ+;[_ ),\O-(N6$FDNWYH_1KX*?\ )&_ ?_8 L/\
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MA0)!!'EMID^7//)QQQPSRV<(N;G'37?_ (!WT\SIU)J"A+5VV_X)\;_M_?\
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MJXB\7VZBVU0ZW<K<WUJ6!X1@JH(VYPZ(NX AN1@>I?MQ_P#)J?Q#_P"O*/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>/\ [7?C2?P!^S;X]UBUF-O=C3FM8)%.&5YF$((]QOS^%?G3_P $S? UIXN_
M:074+V%9TT#3)M1A5UR!,62)&^H\QB/0@'M7WU^W=H<VO?LI^/(K=2TEO;Q7
M9 _NQ31N_P"2JQ_"OA[_ ()7Z[#IO[0&L:?+(J/J.@S)"&/+NDL3[1[[0Q_X
M":^@RS3#8B2^*S^[E_X+/G,UUQ&&B]K_ *K_ (!^KM>-_'C]E#P)^T5JVAZC
MXMCO_/TE)(H_L$ZP^<CD';(=I8@$9&",;F]:]DKC_'GQ>\%_"^ZTFW\6^)+#
MP\^JNZ6C:A)Y:2% "V7/RJ!N'+$#FO"IN<9IT_BZ6_KL?05%&4'&I\/6^Q+\
M,?AAX>^#W@ZT\+^%K26RT:U9WBAEN))R&=BS'<[$C)).!QR>*^4/^"I?Q2_X
M1OX2Z/X+M9@MWXBN_-N%!Y^S0$,?SD,?_?)K[/TO5K'7+"&^TZ\M]0LIEW17
M-K*LD;CU5E)!'TK\;_V_/BI_PL[]I#7D@F\W3-! T>UVME<QD^:P^LA?\ *]
M#!4Y8G&1Y];>\_E_P;'GXZK'"X.3AI?W5;S_ .!<^@?V#?V<8/''[,OQ,O=1
M@ F\81R:792,/NI"I*N/^VY_.(5\]?L/_$>?X,_M/:'#J):SM=2F?0=1CDXV
M&1@J[O3;,L>?0 U]-_!;_@HI\'_A'\*?"_@^'P_XPD.DV,<$LD=C:;9)L;I7
M&;GHSEC^-?#_ ,>/&OAWQO\ &;Q)XK\&07^FZ1J5Y]O@AOHTBGAE8!I.$=P/
MWFXC#=".E?1TE5GC*RJQ?LY*WW:?BG<^7K2HPP5%TI+VD'?[]7]S21^\E?B[
M^WX-W[6GC@>KVH_\EHJ_5S]G?XG)\8O@MX2\6!P]S?62B[Q_#<I\DP_[[5L>
MV*_*3]OK_D[;QM_UTM?_ $FBKR,II.GF7LI[I-/[XGNYG45;+O:1V;B_P9E_
M"OQMXG_8O_:,#ZG!)'+ILYL=7LHS\MW:.06*^H*[9$/J%]Z_0K]OW7K#Q5^Q
MCJ^LZ5=1WNFW[Z=<VUQ&<K)&]Q&RL/J#7!?\%(/V;_\ A-/ =G\3-#M=^M:%
M;+'J<<8YGLASO]S&23_NEO[HKX_\._M%277[)'C#X2:U.SM#<6M]H<CG/R?:
MHVFM_P ,F1?J_H*ZG;,(4ZR^.$HI^G,O^'^]=#SX-Y=*I2E_#J0DUZ\KT_3[
MF?37_!(W_CR^)O\ UTT_^5Q7E_\ P50_Y.$T?_L 0?\ HZ:O4/\ @D;_ ,>7
MQ-_ZZ:?_ "N*\O\ ^"J'_)PFC_\ 8 @_]'35=7_D<+T7_I J'_(EG_7VT?>7
M[%?_ ":Q\.?^P;_[4>NC_:.^'UC\3_@CXQT"_A243:=-+ S#F*>-"\3CT(91
M^M<Y^Q7_ ,FL?#G_ +!O_M1Z])^)%_#I?P[\47ERXCM[?2[J61CV58F)/Y"O
MG,P;CB*TENI2_-GTF6)2PU"+V<8_DC\D/^"=_C6Y\(_M1^'+6-V6UUN*XTVY
M0=&4QF1./:2-/UKZ&_X*Y?\ (.^&7_774/Y6]?*W[#VES:O^U5\/8H0V8KU[
MABIQA8X9'.?;"_K7U3_P5R_Y!WPR_P"NNH?RMZ^GQJ7]H89]=?RE_P $^7RY
MOZCB%T_X'_#'IW_!+G_DVFY_[#]U_P"BX:_//5?^3N+S_L>'_P#2\U^AG_!+
MG_DVFY_[#]U_Z+AK\\]5_P"3N+S_ +'A_P#TO-7A?^1K4]/_ )$QQ'_(HI_X
MG_[<?N57Q#_P52^'MEJWPCT+Q>L*+JFD:BMH9\89K>96RI]<.J$>F3ZU]O5\
MC_\ !3[48+/]F?[/(^V6[UFUCB7N2 [G]%-?*8>3C7IN._-'\6D_P/L<1%2P
M]52_EE^";7XGG7_!)GQM<7OA3QWX4FD9K?3[JWU"W4\[?.5TD ]!F%#CW-?2
M_P"V!\4O^%0_L]^+=:AE\K49[?\ L^Q/?SYOD4CW4%F_X#7R-_P20TN9M6^)
M.I886ZP6-OG/!8M,WY@+^M5O^"KGQ3^V>(/"GP^M9<QV43:M>JI_Y:/E(@?<
M*'/_  ,5[./H*OF*I+[5K^EM?O2^]GBY=B'A\N=:_P -[>M]/_)F<5_P2_\
MA:OC#XT:GXIO(!+8>&[%MF]<J;B<&-1_W[$WZ5X_\3-+OOV7?VK-1_LU&B;P
M[KBW]BI& ]N6$L:_0QL%/XU[C^QC^V9\,OV:_A?=:+K.C>)KW7]0OWO+RXTZ
MTMWAVX"1HK/.K$!5SRHY8UY9^VO\>/ _[1'C[2/%/A#3M9TZZ2Q^QZ@NK00Q
M>9L8F-E\N5\G#,#G'1>M>O>O_:'-R^Y;E\N]_ONOF>(E0_LUPYESWYO/M;[M
M?D?L;X:\067BSP[I>MZ=*)M/U*UBN[>0?Q1R*&4_D16E7R3_ ,$T_BI_PG?P
M 7P_<S>9J/A:Y:R(8Y8V[YDA/T&70>T=?6U?)8NC]7KRI=GIZ=/P/L<'7^LX
M>%7JUKZ[/\3\T/\ @K9_R.GP\_[!]U_Z,2OI3_@G'_R:?X9_Z^KW_P!*9*^:
M_P#@K9_R.GP\_P"P?=?^C$KZ4_X)Q_\ )I_AG_KZO?\ TIDKUE_R)U_B?_I4
MCRI?\CF7^%?^DQ/:_C%_R2/QM_V!+W_T0]?CG^QG\1O#WPH_:(\->)_%6H?V
M7H=FET)[KR))MA>WD1?EC5F.68#@=Z_8SXQ?\DC\;?\ 8$O?_1#U^,/[*OPD
MT?XY?''0/!NO7-]::7J"W#2S:=(B3#RX'D7:71EZJ,Y4\9I9/:V(YMN57]+3
MN3G=[8;EWYG;U]RQ^HG_  \)^ '_ $/W_E&U#_Y'K;\$_MJ?!GXC>*M.\-^'
M?&7]H:UJ,GE6MK_9=[%YC8)QN>%5' /4BO'_ /AU+\)?^AB\:?\ @;:?_(M=
M3\+?^"=7PW^$GQ T7Q?H^M^*;G4M)F,\$5]=VSPLVTKA@MNI(PQZ$5SN&76T
ME+\/\CI4\ROK&-OG_F?4U%%%>.>T%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/;LNWXO\$:XG+W55&C3LJ<-^[_#LM_-G!?\ #O;X ?\ 0@_^5G4/_DBOF?\
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M-R%7C..*\RUO]@_X&>(M:O\ 5M1\#_:-0O[B2ZN)O[7OEWR.Q9VPLX R23@
M"NNEF%.GC)XBSLU\^GGY'!4RVK/ PPUU=._6W7R\SRMO^"K?PGVG;X<\9EL<
M V5H!_Z4U\@?M4_M4:Y^U]XJT+0]!T"ZL]'M9BNG:3&?/NKNX?"[V"C[V. J
MYQEN3FOT&_X=[_ #_H0?_*SJ'_R17IGPW^ ?P\^$+%_"'A#3-$N"I0W<4.^Y
M*GJIF<ER..F[%1#$8&C)5*<)-K:YI/#YA7@Z=2I%)[VW_0X#]CCX$']F_P""
M$%CK!CBUV^9M4UA]P*PN5&(]PX(C10">F=Q'!K\M?B!K6H?M1?M/7LUD6>7Q
M-K:6=EG)\N N(HC]%C"D_0U^W&O:'9^)M#O](U&-YK"^@>VN(XY7B9HW4JP#
MH0RY!/((->2> ?V-/@[\+_%EAXF\->#5T_6[$LUM=-J-W/Y992A.R25E)PQZ
MCC/'-1A<=&GB9XJLKR:TM_6VB1IBL!*IA886@[13UO\ \-YMOY'.0_\ !//X
M!1PQH_@5I750#(VL7X+''4XGQS[5P/[0'_!/WX567P;\67O@GPDVF>*+*R>[
MLITU*[F):/YV39)*RG<JLO([\5]ETV2-98V1U#(PPRL,@@]JX'B\3NJCOZL]
M".#PNSIJWHC\B/\ @FS\5/\ A ?VA(-#N9O+TWQ3;MI[*3\HN%R\#?7(9!_U
MTK]>:\%TO]A7X'Z'K]IK5AX)-IJEI<I>07$6KWRF.56#JRCS\## '&,5[U77
MF&*I8N<:E--.UG?^OZT./+L+5P<94ZC35[K^OZZGYH?\%;/^1T^'G_8/NO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BOA+XC?M,?$G0
M?B%XHTRQ\1^18V6J75M!%]AMFV1I,RJN3&2< #DG-<]_PU;\4_\ H:?_ "GV
MO_QJOI8Y#BIQ4E*.OF_\C\NK>(F54:DJ4J=2\6UM'I_V^?H=17YX_P##5OQ3
M_P"AI_\ *?:__&J/^&K?BG_T-/\ Y3[7_P"-57^KV*_FC][_ ,C+_B)&4_\
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M ,^JGW1_^3/T.HK\\?\ AJWXI_\ 0T_^4^U_^-4?\-6_%/\ Z&G_ ,I]K_\
M&J/]7L5_-'[W_D'_ !$C*?\ GU4^Z/\ \F?H=17YX_\ #5OQ3_Z&G_RGVO\
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MHK\\?^&K?BG_ -#3_P"4^U_^-4?\-6_%/_H:?_*?:_\ QJC_ %>Q7\T?O?\
MD'_$2,I_Y]5/NC_\F?H=17YX_P##5OQ3_P"AI_\ *?:__&J/^&K?BG_T-/\
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M%/\ Z&G_ ,I]K_\ &J/]7L5_-'[W_D'_ !$C*?\ GU4^Z/\ \F?H=17YX_\
M#5OQ3_Z&G_RGVO\ \:H_X:M^*?\ T-/_ )3[7_XU1_J]BOYH_>_\@_XB1E/_
M #ZJ?='_ .3/T.HK\\?^&K?BG_T-/_E/M?\ XU1_PU;\4_\ H:?_ "GVO_QJ
MC_5[%?S1^]_Y!_Q$C*?^?53[H_\ R9^AU%?GC_PU;\4_^AI_\I]K_P#&J/\
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M?_C5'^KV*_FC][_R#_B)&4_\^JGW1_\ DS]#J*_/'_AJWXI_]#3_ .4^U_\
MC5'_  U;\4_^AI_\I]K_ /&J/]7L5_-'[W_D'_$2,I_Y]5/NC_\ )GZ'45^>
M/_#5OQ3_ .AI_P#*?:__ !JC_AJWXI_]#3_Y3[7_ .-4?ZO8K^:/WO\ R#_B
M)&4_\^JGW1_^3/T.HK\\?^&K?BG_ -#3_P"4^U_^-4?\-6_%/_H:?_*?:_\
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M_*?:_P#QJC_5[%?S1^]_Y!_Q$C*?^?53[H__ "9^AU%?GC_PU;\4_P#H:?\
MRGVO_P :H_X:M^*?_0T_^4^U_P#C5'^KV*_FC][_ ,@_XB1E/_/JI]T?_DS]
M#J*_/'_AJWXI_P#0T_\ E/M?_C5'_#5OQ3_Z&G_RGVO_ ,:H_P!7L5_-'[W_
M )!_Q$C*?^?53[H__)GZ'45^>/\ PU;\4_\ H:?_ "GVO_QJC_AJWXI_]#3_
M .4^U_\ C5'^KV*_FC][_P @_P"(D93_ ,^JGW1_^3/T.HK\\?\ AJWXI_\
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MG_T-/_E/M?\ XU1_J]BOYH_>_P#(/^(D93_SZJ?='_Y,_0ZBOSQ_X:M^*?\
MT-/_ )3[7_XU1_PU;\4_^AI_\I]K_P#&J/\ 5[%?S1^]_P"0?\1(RG_GU4^Z
M/_R9^AU%?GC_ ,-6_%/_ *&G_P I]K_\:H_X:M^*?_0T_P#E/M?_ (U1_J]B
MOYH_>_\ (/\ B)&4_P#/JI]T?_DS]#J*_/'_ (:M^*?_ $-/_E/M?_C5'_#5
MOQ3_ .AI_P#*?:__ !JC_5[%?S1^]_Y!_P 1(RG_ )]5/NC_ /)GZ'45^>/_
M  U;\4_^AI_\I]K_ /&J/^&K?BG_ -#3_P"4^U_^-4?ZO8K^:/WO_(/^(D93
M_P ^JGW1_P#DS]#J*_/'_AJWXI_]#3_Y3[7_ .-4?\-6_%/_ *&G_P I]K_\
M:H_U>Q7\T?O?^0?\1(RG_GU4^Z/_ ,F?H=17YX_\-6_%/_H:?_*?:_\ QJC_
M (:M^*?_ $-/_E/M?_C5'^KV*_FC][_R#_B)&4_\^JGW1_\ DS]#J*_/'_AJ
MWXI_]#3_ .4^U_\ C5'_  U;\4_^AI_\I]K_ /&J/]7L5_-'[W_D'_$2,I_Y
M]5/NC_\ )GZ'45^>/_#5OQ3_ .AI_P#*?:__ !JC_AJWXI_]#3_Y3[7_ .-4
M?ZO8K^:/WO\ R#_B)&4_\^JGW1_^3/T.HK\\?^&K?BG_ -#3_P"4^U_^-4?\
M-6_%/_H:?_*?:_\ QJC_ %>Q7\T?O?\ D'_$2,I_Y]5/NC_\F?H=17YX_P##
M5OQ3_P"AI_\ *?:__&J/^&K?BG_T-/\ Y3[7_P"-4?ZO8K^:/WO_ "#_ (B1
ME/\ SZJ?='_Y,_0ZBOSQ_P"&K?BG_P!#3_Y3[7_XU1_PU;\4_P#H:?\ RGVO
M_P :H_U>Q7\T?O?^0?\ $2,I_P"?53[H_P#R9^AU%?GC_P -6_%/_H:?_*?:
M_P#QJC_AJWXI_P#0T_\ E/M?_C5'^KV*_FC][_R#_B)&4_\ /JI]T?\ Y,_0
MZBOSQ_X:M^*?_0T_^4^U_P#C5'_#5OQ3_P"AI_\ *?:__&J/]7L5_-'[W_D'
M_$2,I_Y]5/NC_P#)GZ'45^>/_#5OQ3_Z&G_RGVO_ ,:H_P"&K?BG_P!#3_Y3
M[7_XU1_J]BOYH_>_\@_XB1E/_/JI]T?_ ),_0ZBOSQ_X:M^*?_0T_P#E/M?_
M (U1_P -6_%/_H:?_*?:_P#QJC_5[%?S1^]_Y!_Q$C*?^?53[H__ "9^AU%?
MGC_PU;\4_P#H:?\ RGVO_P :H_X:M^*?_0T_^4^U_P#C5'^KV*_FC][_ ,@_
MXB1E/_/JI]T?_DS]#J*_/'_AJWXI_P#0T_\ E/M?_C5'_#5OQ3_Z&G_RGVO_
M ,:H_P!7L5_-'[W_ )!_Q$C*?^?53[H__)GZ'45^>/\ PU;\4_\ H:?_ "GV
MO_QJC_AJWXI_]#3_ .4^U_\ C5'^KV*_FC][_P @_P"(D93_ ,^JGW1_^3/T
M.HK\\?\ AJWXI_\ 0T_^4^U_^-4?\-6_%/\ Z&G_ ,I]K_\ &J/]7L5_-'[W
M_D'_ !$C*?\ GU4^Z/\ \F?H=17YX_\ #5OQ3_Z&G_RGVO\ \:H_X:M^*?\
MT-/_ )3[7_XU1_J]BOYH_>_\@_XB1E/_ #ZJ?='_ .3/T.HK\\?^&K?BG_T-
M/_E/M?\ XU1_PU;\4_\ H:?_ "GVO_QJC_5[%?S1^]_Y!_Q$C*?^?53[H_\
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M_#5OQ3_Z&G_RGVO_ ,:H_P!7L5_-'[W_ )!_Q$C*?^?53[H__)GZ'45^>/\
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MG_GU4^Z/_P F?H=17YX_\-6_%/\ Z&G_ ,I]K_\ &J/^&K?BG_T-/_E/M?\
MXU1_J]BOYH_>_P#(/^(D93_SZJ?='_Y,_0ZBOSQ_X:M^*?\ T-/_ )3[7_XU
M1_PU;\4_^AI_\I]K_P#&J/\ 5[%?S1^]_P"0?\1(RG_GU4^Z/_R9^AU%?GC_
M ,-6_%/_ *&G_P I]K_\:H_X:M^*?_0T_P#E/M?_ (U1_J]BOYH_>_\ (/\
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M45^>/_#5OQ3_ .AI_P#*?:__ !JC_AJWXI_]#3_Y3[7_ .-4?ZO8K^:/WO\
MR#_B)&4_\^JGW1_^3/T.HK\\?^&K?BG_ -#3_P"4^U_^-4?\-6_%/_H:?_*?
M:_\ QJC_ %>Q7\T?O?\ D'_$2,I_Y]5/NC_\F?H=17YX_P##5OQ3_P"AI_\
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MI_\ 0T_^4^U_^-4?\-6_%/\ Z&G_ ,I]K_\ &J/]7L5_-'[W_D'_ !$C*?\
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M]K_\:H_U>Q7\T?O?^0?\1(RG_GU4^Z/_ ,F?H=17YX_\-6_%/_H:?_*?:_\
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M (B1E/\ SZJ?='_Y,_0ZBOSQ_P"&K?BG_P!#3_Y3[7_XU1_PU;\4_P#H:?\
MRGVO_P :H_U>Q7\T?O?^0?\ $2,I_P"?53[H_P#R9^AU%?GC_P -6_%/_H:?
M_*?:_P#QJC_AJWXI_P#0T_\ E/M?_C5'^KV*_FC][_R#_B)&4_\ /JI]T?\
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M3_Z&G_RGVO\ \:H_U>Q7\T?O?^0?\1(RG_GU4^Z/_P F?H=17YX_\-6_%/\
MZ&G_ ,I]K_\ &J/^&K?BG_T-/_E/M?\ XU1_J]BOYH_>_P#(/^(D93_SZJ?=
M'_Y,_0ZBOSQ_X:M^*?\ T-/_ )3[7_XU1_PU;\4_^AI_\I]K_P#&J/\ 5[%?
MS1^]_P"0?\1(RG_GU4^Z/_R9^AU%?GC_ ,-6_%/_ *&G_P I]K_\:H_X:M^*
M?_0T_P#E/M?_ (U1_J]BOYH_>_\ (/\ B)&4_P#/JI]T?_DS]#J*_/'_ (:M
M^*?_ $-/_E/M?_C5'_#5OQ3_ .AI_P#*?:__ !JC_5[%?S1^]_Y!_P 1(RG_
M )]5/NC_ /)GZ'45^>/_  U;\4_^AI_\I]K_ /&J/^&K?BG_ -#3_P"4^U_^
M-4?ZO8K^:/WO_(/^(D93_P ^JGW1_P#DS]#J*_/'_AJWXI_]#3_Y3[7_ .-4
M?\-6_%/_ *&G_P I]K_\:H_U>Q7\T?O?^0?\1(RG_GU4^Z/_ ,F?H=17YX_\
M-6_%/_H:?_*?:_\ QJC_ (:M^*?_ $-/_E/M?_C5'^KV*_FC][_R#_B)&4_\
M^JGW1_\ DS]#J*_/'_AJWXI_]#3_ .4^U_\ C5'_  U;\4_^AI_\I]K_ /&J
M/]7L5_-'[W_D'_$2,I_Y]5/NC_\ )GZ'45^>/_#5OQ3_ .AI_P#*?:__ !JC
M_AJWXI_]#3_Y3[7_ .-4?ZO8K^:/WO\ R#_B)&4_\^JGW1_^3/T.HK\\?^&K
M?BG_ -#3_P"4^U_^-4?\-6_%/_H:?_*?:_\ QJC_ %>Q7\T?O?\ D'_$2,I_
MY]5/NC_\F?H=17YX_P##5OQ3_P"AI_\ *?:__&J/^&K?BG_T-/\ Y3[7_P"-
M4?ZO8K^:/WO_ "#_ (B1E/\ SZJ?='_Y,_0ZBOSQ_P"&K?BG_P!#3_Y3[7_X
MU1_PU;\4_P#H:?\ RGVO_P :H_U>Q7\T?O?^0?\ $2,I_P"?53[H_P#R9^AU
M%?GC_P -6_%/_H:?_*?:_P#QJC_AJWXI_P#0T_\ E/M?_C5'^KV*_FC][_R#
M_B)&4_\ /JI]T?\ Y,_0ZBOSQ_X:M^*?_0T_^4^U_P#C5'_#5OQ3_P"AI_\
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M^]_Y!_Q$C*?^?53[H_\ R9^AU%?GC_PU;\4_^AI_\I]K_P#&J/\ AJWXI_\
M0T_^4^U_^-4?ZO8K^:/WO_(/^(D93_SZJ?='_P"3/T.HK\\?^&K?BG_T-/\
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M?^?53[H__)GZ'45^>/\ PU;\4_\ H:?_ "GVO_QJC_AJWXI_]#3_ .4^U_\
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M?GC_ ,-6_%/_ *&G_P I]K_\:H_X:M^*?_0T_P#E/M?_ (U1_J]BOYH_>_\
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M .4^U_\ C5'_  U;\4_^AI_\I]K_ /&J/]7L5_-'[W_D'_$2,I_Y]5/NC_\
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MWXI_]#3_ .4^U_\ C5'^KV*_FC][_P @_P"(D93_ ,^JGW1_^3/T.HK\\?\
MAJWXI_\ 0T_^4^U_^-4?\-6_%/\ Z&G_ ,I]K_\ &J/]7L5_-'[W_D'_ !$C
M*?\ GU4^Z/\ \F?H=17YX_\ #5OQ3_Z&G_RGVO\ \:H_X:M^*?\ T-/_ )3[
M7_XU1_J]BOYH_>_\@_XB1E/_ #ZJ?='_ .3/T.HK\\?^&K?BG_T-/_E/M?\
MXU1_PU;\4_\ H:?_ "GVO_QJC_5[%?S1^]_Y!_Q$C*?^?53[H_\ R9^AU%?G
MC_PU;\4_^AI_\I]K_P#&J/\ AJWXI_\ 0T_^4^U_^-4?ZO8K^:/WO_(/^(D9
M3_SZJ?='_P"3/T.HK\\?^&K?BG_T-/\ Y3[7_P"-4?\ #5OQ3_Z&G_RGVO\
M\:H_U>Q7\T?O?^0?\1(RG_GU4^Z/_P F?H=17YX_\-6_%/\ Z&G_ ,I]K_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUI\5/^$%\ G1[*;R]8UL- I4X:.#_EH_MD$*/]XGM7DYO6EC,3# T>CU]?\
M@+]3[3@[!4LCRJKGN,5G):=^5;6\YNUOEW/#/%WQ\TO6OVBM/\2ZBMS=^%]!
MD:*SAM%5V?:K8D 9E'S28;.?NJOI7J6M?MN^#[C1[Z*PTO7DOG@=8&F@A""0
MJ0I8B8D#..@->9?LF_!OP_\ $P>(KSQ-IC:C9VGDPVZ^?+$!(VXL<HRYP OY
MUUG[3GP;^'WPR^&XOM&T'[%JUU>1VT$WVRXDV]78[7D(/RH1R.];8BG@/;T\
M%.,FXV6EK:ZW>OG=GGY?B.(EE^(SRA5IQA4<IOFOS>[I9:6MI:*N?)A)/)Y-
M%?:WP3^ ?PT\??"WP_K=YX<\^^N("MS)]NN5W2HQ1CA9 !DKG '>O _VG/AW
MI/PU^)0T[0[0V6F3V45S'"9'D"DEE;YG))Y7/7O7MTLRHUL2\*DU)7WM;3YG
MPN-X7QF!RV&:SG%TYJ+5F[^]JKWBEZZGDM%36=G/J%Y!:VT33W,[K%%$@RSL
M3@ #U)-?=O@O]D7P)I_A;38?$&C_ -J:T(@;NY^V3H&D/) ".HP,X''('-:X
MW'4L#%2JWU['+D?#^,X@J3AA;+D5VY72UV6B>KUZ=&?!E%>I_M$6/@O0O'3Z
M'X+TI+&WTT&*[N%N99O.G_B4;W; 3IQCG=Z"O4/@?^R#_;UA;:[XV::VM9E$
MD&D1$I(ZGH96ZJ"/X1SR,D=*4LPHT\.L34O%/9/?[AT>'<;B<QGEN%M4E!V;
M3?*N^K2V>FVKVN?+E%?IAIOP/^'^E6J6\/@W17C08#7-DD[_ (M(&8_B:R_%
M7[-_P\\66;PR>&[33)<$)<:4@M70GN @VG_@0(]J\9<0T.:S@[?(^WEX;9@J
M=XUX.7;6WWV_0_..BO1OC=\%]1^#?B-+6:0WNE70+V5\%V^8!U5AV=<C/KD'
MV'G-?2T:T,1352F[IGY;C,'7R^O+#8F/+..Z_KIV85>T/1+WQ)K%GI6G0-<W
MUY*L,,2]68G ^@]^U4:^D/V(O",6K>.M6UV= XTFV"0Y'W9)21N'N%5Q_P "
MJ,376&HSK/[*_P"&_$ZLIP$LTQU'!1=N=V]%NW\E=GTE\&/@IHWPAT&.&WB2
MYUJ9!]LU)E^>1NI5?[J ]![9.35CXB?'+P=\+Y!;ZWJ@%^5WK8VJ&68CMD#A
M<]MQ&:T/BSXW'PZ^'>MZ^ K36L&(%;H96(6,'VW,,^V:_,_5=4N]<U*YU"_N
M)+N]N9#+--(<L[$Y)-?"X#!3S:I.OB).R_%]O*Q^^\19[1X1PU+ 9=37.UHG
MLEM=[-MO\FV?=.A_MF?#S6+P07!U31U/ FOK52G_ )#=R/Q%>RJ^E^+-$RIM
M=7TF^B[;989XV'XA@:_*>OIG]BOXE7=AXHN/!MU.SZ=?1/<6D;'/E3*,L%]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF>YX;5\5SU\/RMT=[]%+:WS6_HBS\.OAOHGPN\/KI&AVYBA+F2660[I)G/\
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M%YX0U&\FO[#[*US:&=R[0,A4%%)_A(;IT!7CJ:^4Z^DOV'?#LUYX\UG6MO\
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M-J48OW;/\&DOS/UGCV,<5DF%QE16GS1_\FBVU]Z7W'WSX/\ ^12T3_KQ@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOU1\'_\ (I:)_P!>,'_HM:_/C]I+_DN'BW_KY7_T6E>O:/\ MR_V3I-C8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]#_L._\ )6-6_P"P
M)-_Z/MZ*/V'?^2L:M_V!)O\ T?;T5^;Y[_OC]$?T[X?_ /(DC_BD>2_%[_DK
M'C7_ +#=[_Z/>N2KJ?BM,MQ\4?&,J@A9-9O'&>N#.YKEJ_0J'\*'HC^;\<[X
MNJU_-+\V%%%%;'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444O&W
MJ<^F* $HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1T__ +Y;_&C_ (9W^&__ $*.G_\ ?+?XUZ+13^M8C_GX_O8O[(R[_H&A_P"
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M_P :/^&=_AO_ -"CI_\ WRW^->BT4?6L1_S\?WL/[(R[_H&A_P" 1_R/.O\
MAG?X;_\ 0HZ?_P!\M_C1_P ,[_#?_H4=/_[Y;_&O1:*/K6(_Y^/[V']D9=_T
M#0_\ C_D>=?\,[_#?_H4=/\ ^^6_QH_X9W^&_P#T*.G_ /?+?XUZ+11]:Q'_
M #\?WL/[(R[_ *!H?^ 1_P CSK_AG?X;_P#0HZ?_ -\M_C1_PSO\-_\ H4=/
M_P"^6_QKT6BCZUB/^?C^]A_9&7?] T/_  "/^1YU_P ,[_#?_H4=/_[Y;_&C
M_AG?X;_]"CI__?+?XUZ+11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_ /0H
MZ?\ ]\M_C1_PSO\ #?\ Z%'3_P#OEO\ &O1:*/K6(_Y^/[V']D9=_P! T/\
MP"/^1YU_PSO\-_\ H4=/_P"^6_QH_P"&=_AO_P!"CI__ 'RW^->BT4?6L1_S
M\?WL/[(R[_H&A_X!'_(\Z_X9W^&__0HZ?_WRW^-'_#._PW_Z%'3_ /OEO\:]
M%HH^M8C_ )^/[V']D9=_T#0_\ C_ )'G7_#._P -_P#H4=/_ .^6_P :/^&=
M_AO_ -"CI_\ WRW^->BT4?6L1_S\?WL/[(R[_H&A_P" 1_R/.O\ AG?X;_\
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MXUZ+11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_ /0HZ?\ ]\M_C1_PSO\
M#?\ Z%'3_P#OEO\ &O1:*/K6(_Y^/[V']D9=_P! T/\ P"/^1YU_PSO\-_\
MH4=/_P"^6_QH_P"&=_AO_P!"CI__ 'RW^->BT4?6L1_S\?WL/[(R[_H&A_X!
M'_(\Z_X9W^&__0HZ?_WRW^-'_#._PW_Z%'3_ /OEO\:]%HH^M8C_ )^/[V']
MD9=_T#0_\ C_ )'G7_#._P -_P#H4=/_ .^6_P :/^&=_AO_ -"CI_\ WRW^
M->BT4?6L1_S\?WL/[(R[_H&A_P" 1_R/.O\ AG?X;_\ 0HZ?_P!\M_C1_P ,
M[_#?_H4=/_[Y;_&O1:*/K6(_Y^/[V']D9=_T#0_\ C_D>=?\,[_#?_H4=/\
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M_LC+O^@:'_@$?\CSK_AG?X;_ /0HZ?\ ]\M_C1_PSO\ #?\ Z%'3_P#OEO\
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M:Q'_ #\?WL/[(R[_ *!H?^ 1_P CSK_AG?X;_P#0HZ?_ -\M_C1_PSO\-_\
MH4=/_P"^6_QKT6BCZUB/^?C^]A_9&7?] T/_  "/^1YU_P ,[_#?_H4=/_[Y
M;_&C_AG?X;_]"CI__?+?XUZ+11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_
M /0HZ?\ ]\M_C1_PSO\ #?\ Z%'3_P#OEO\ &O1:*/K6(_Y^/[V']D9=_P!
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MX;_]"CI__?+?XUZ+11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_ /0HZ?\
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M[V']D9=_T#0_\ C_ )'G7_#._P -_P#H4=/_ .^6_P :/^&=_AO_ -"CI_\
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M11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_ /0HZ?\ ]\M_C1_PSO\ #?\
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M4=/_ .^6_P :/^&=_AO_ -"CI_\ WRW^->BT4?6L1_S\?WL/[(R[_H&A_P"
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M_P :/^&=_AO_ -"CI_\ WRW^->BT4?6L1_S\?WL/[(R[_H&A_P" 1_R/.O\
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MZ?\ ]\M_C1_PSO\ #?\ Z%'3_P#OEO\ &O1:*/K6(_Y^/[V']D9=_P! T/\
MP"/^1YU_PSO\-_\ H4=/_P"^6_QH_P"&=_AO_P!"CI__ 'RW^->BT4?6L1_S
M\?WL/[(R[_H&A_X!'_(\Z_X9W^&__0HZ?_WRW^-'_#._PW_Z%'3_ /OEO\:]
M%HH^M8C_ )^/[V']D9=_T#0_\ C_ )'G7_#._P -_P#H4=/_ .^6_P :/^&=
M_AO_ -"CI_\ WRW^->BT4?6L1_S\?WL/[(R[_H&A_P" 1_R/.O\ AG?X;_\
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MXUZ+11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_ /0HZ?\ ]\M_C1_PSO\
M#?\ Z%'3_P#OEO\ &O1:*/K6(_Y^/[V']D9=_P! T/\ P"/^1YU_PSO\-_\
MH4=/_P"^6_QH_P"&=_AO_P!"CI__ 'RW^->BT4?6L1_S\?WL/[(R[_H&A_X!
M'_(\Z_X9W^&__0HZ?_WRW^-'_#._PW_Z%'3_ /OEO\:]%HH^M8C_ )^/[V']
MD9=_T#0_\ C_ )'G7_#._P -_P#H4=/_ .^6_P :/^&=_AO_ -"CI_\ WRW^
M->BT4?6L1_S\?WL/[(R[_H&A_P" 1_R/.O\ AG?X;_\ 0HZ?_P!\M_C1_P ,
M[_#?_H4=/_[Y;_&O1:*/K6(_Y^/[V']D9=_T#0_\ C_D>=?\,[_#?_H4=/\
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M_LC+O^@:'_@$?\CSK_AG?X;_ /0HZ?\ ]\M_C1_PSO\ #?\ Z%'3_P#OEO\
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M:Q'_ #\?WL/[(R[_ *!H?^ 1_P CSK_AG?X;_P#0HZ?_ -\M_C1_PSO\-_\
MH4=/_P"^6_QKT6BCZUB/^?C^]A_9&7?] T/_  "/^1YU_P ,[_#?_H4=/_[Y
M;_&C_AG?X;_]"CI__?+?XUZ+11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_
M /0HZ?\ ]\M_C1_PSO\ #?\ Z%'3_P#OEO\ &O1:*/K6(_Y^/[V']D9=_P!
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MX;_]"CI__?+?XUZ+11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_ /0HZ?\
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M[V']D9=_T#0_\ C_ )'G7_#._P -_P#H4=/_ .^6_P :/^&=_AO_ -"CI_\
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M11]:Q'_/Q_>P_LC+O^@:'_@$?\CSK_AG?X;_ /0HZ?\ ]\M_C1_PSO\ #?\
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M4=/_ .^6_P :/^&=_AO_ -"CI_\ WRW^->BT4?6L1_S\?WL/[(R[_H&A_P"
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M_P :/^&=_AO_ -"CI_\ WRW^->BT4?6L1_S\?WL/[(R[_H&A_P" 1_R/.O\
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MZ?\ ]\M_C1_PSO\ #?\ Z%'3_P#OEO\ &O1:*/K6(_Y^/[V']D9=_P! T/\
MP"/^1YU_PSO\-_\ H4=/_P"^6_QH_P"&=_AO_P!"CI__ 'RW^->BT4?6L1_S
M\?WL/[(R[_H&A_X!'_(Y+PO\)O"'@G4CJ&AZ!9Z;>F,Q>?"IW;202.3["BNM
MHK"=2=1\TW=^9WT</1PT>2A!179))?@%%%%0;A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\VE4A"2C)V;O^&Y[K17Q[;_\%2O@[-J@M7L/%5O 7V_;I-/A,(']["S%\?\
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M GP[_P" T_\ \>H_X;B\=_\ 0)\._P#@-/\ _'J/["QG9?>'_$0,D_FE_P"
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M#O\ X#3_ /QZC^PL9V7WA_Q$#)/YI?\ @)]PT5\/?\-Q>._^@3X=_P# :?\
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M3X=_\!I__CU']A8SLOO#_B(&2?S2_P# 3[AHKX>_X;B\=_\ 0)\._P#@-/\
M_'J/^&XO'?\ T"?#O_@-/_\ 'J/["QG9?>'_ !$#)/YI?^ GW#17P]_PW%X[
M_P"@3X=_\!I__CU'_#<7CO\ Z!/AW_P&G_\ CU']A8SLOO#_ (B!DG\TO_ 3
M[AHKXIL?VYO%D>?MF@:-/Z>0)HO3U=O>O2?"/[;GA35Y!'KVEWOA]SC]XA^U
M1#YL<E0&Z8/"GOZ#.%3)\;35^2_IK_P3T,+QKD>*ER*ORO\ O)K\=OQ/HVBL
M[0/$6E^*M,CU'1]0M]2L9/NSVL@=<]P2.A'<'D=ZT:\9IQ=GN?:PG&I%3@[I
M]4%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBLGQ1XLT7P3HL^K^(-5L]%TN 9DO+Z98HU]!N8CD]AU-
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M6D^'+:=_*BFU:^BM4D?&=JM(P!..<"DDV[(;=E=F[17G7_#2'PE_Z*CX+_\
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M4\2>./[*_MO^RO$.J'[!]I^S^;YAFB_UFQ\8WY^Z>F/>OI'_ (>[_P#5)_\
MRX__ +DKROX&V<%__P %*+B"Z@CN8'\1:UNCF0,IQ%=$9!]Z_4RY\"^&[RWD
M@N/#VE3P2#:\<EE$RL/0@KR*WQ-2C3I4%5I\SY%U:,J%*O4Q&(=*IR^^^B?7
MS/SZU3_@K'K^M6YL_#7PPM[;5IODA:XU1[T;CT_=)#&6^FZL/X#?LF_$O]HO
MXR+\3/C!97>F:0;I;V>/4H?(GOV3&R%(" 4B "@D@#;PN2<C>_;>_90D^#-U
M!\7OA(EQX<CLY =2M-(=HOL)/ N(=IRB'.UE' R#C&<?0'[#_P"UJO[1'A&;
M2->>.+QUH\:F["@(M[#G N$4=#G <#@$@C 8 5&=.G0>)P,+/9[MQ]/P_#3M
MG*%2IB%A<?.\7JK62EZ_U\]5?Z>Z<"EKQ[]K+P[X]\5?!#6-.^&DM]!XODFM
MFMGTW4!8S!1,IDQ,70+\@;(W#(XYKX'_ .%"_MM?]!/QI_X7,7_R97CX;#1Q
M$7*511L[:^BU/:Q6*EAY*,:;E=7TZ:M6_"_S/U9K\H/V\O\ D^#3/]W2O_0A
M7TE^Q%\-_P!H'P7X_P!>NOB[=Z_<:++IGE6BZMXB34HQ<>:ARJ+/)M.T-\V!
MW&>:^;?V\O\ D^#3/]W2O_0A7IX"BJ./IQC)2\UZ,\K,*\J^6U92@X^3]4>@
M?\%//!MWX)^)7@+XJZ./(N2RVLDR_P -S;OYL#'W*EA](Z^__A]XRL_B'X%T
M#Q/8'_1-7L8;V,9SM#H&VGW!)!]Q7E/[;GPQ_P"%J?LW^*["&'S=1TZ'^UK,
M*,MYD&6('NR>8O\ P*O(O^";OQGM;S]G#6],U:Y"?\(3+-)(S'E;-U:96/T8
M3#Z**XDU5R]WWI.__;LO^#I\CNDG1S"+6U56_P"WH_\  _%GG?[8DC_M$?MG
M?#_X2VDAETW2C&+\(<A3)B:X/U$")^)-<)_P52ACM_CEX2BB18XH_#L2HBC
M4"XG  KTK_@G9HMW\5_C1\3?C/JT;,\T\EK:%^=LD[^8X'^Y&L:_1Z\X_P""
MK'_)>/"W_8OQ_P#I3/7JX5.CC,)A>L;M_P"*2;9YU=^VPN+Q725DO\,912^_
M4_1_XC^/+?X8?"O7?%ETGFQ:/IKW?E_WV5,JOXM@?C7YH?LD_ RY_;2^+'B?
MQW\2+RYU'1[.99+N-9&0WD[Y*0!@<I$BKR%((&T#&<C[?_;>AGF_9#\<K;AB
MXLK=FV_W!/$6_P#'0:\D_P""4,T#? _Q5$I7[2OB%VD ^]M-M!MS[9#?K7!@
MW[.AB*\?B5DO*[5W^/X'3B8^VGAJ$OA=V_.RT_KS9] :E^R7\&M4T%M)E^&O
MAN*V:/R_-MM/CAN ,8R)T DS[[LU^=GCS0=8_P"">O[5&FWN@WUS<>%KP+<I
M&[9-U8,^V6WD[,R8.#ZA&ZU^MU?FI_P5NFA;Q9\.8E93<+97C.O\04R1!2?;
M(;\C49=7J?6HTY.\9733ZZ-_H:YEAZ:PDZD5:4+--:6]Y+]3ZO\ VU;R'4OV
M1_'=W;N);>XTZ&6-QT96EC(/Y&OA[]@7]F'3/VAI-0UGQQ)=:AX1\.2"VL](
M6=HXI[B3+R;BI!"@;20I!8LN3@8/UU^T)#-;_P#!/J]BN0RW">%].64.<L&
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M20 #QSBOU%\ ^#;'X=^"-"\,::NVQTFRBLXN,%@BA=Q]R02?<FOS2_X*$?\
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MHC'"N <J.0>O6O5J\7$*$:TU2^&[MZ=#W,,ZCH0=7XK*_KU"BBBN<Z0HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$_0&OE#]L3_@H-I7C;PM>>!/A9)=7D6IK]GO]<:%HM\3<-# C .2V<%B!QD
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MRD,"" 000017)?"/]G/X>_ FXU*;P-H+Z&^HJB70^WW-PLH0DK\LLC@$;FY
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M)X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]@?L.>.)KS
M3=<\*7,A=;,K>VBD$[48E91GL VP@>KM7U17P!^R!J36/QPTR$, +RVN("",
MY C,F!Z<QC\J^_Z_-<[I*EC&U]I)_I^A_47 >,EB\EA&;NZ;<?DK-?<G;T04
M445X)^AA117AG[7/[2%G^SK\-9;RW,=SXKU/=;:-8,-Q>7',K*.J)D$^IVCO
M51C*<E&*NWL3*481<I.R6YX[^V9\5=;^*WC;3?V=OAS-OUG6&4^(+Z-SLM+?
M&XQ.1T&WYW]MJ\[L5YM_P2WTD:#\5OBOI@E\X64,5L)"N-^R>1<X[9Q7T)^Q
M'^SE=_"7PG>>+_%RM=?$;Q4?M>HW%Q\TMO&YWB$GLQ)W/C^+ YV UX7_ ,$U
M_P#DNWQI_P"NG_MU+7OTG&E"KAJ>MHMM]Y:?@ME]Y\]54JU2EB9Z7DE%=HZ_
MB]W\D?:OQN^*=E\%OA7XB\97R"6/3+8O% 3CSIF(6*/_ ($[*/H2:^ _V5?V
M;K[]L;Q-J_Q=^+E]=:II$EVT-O8+(T8O'7JH8',<$>0H5""2",C:=WMO_!4W
M4KBS_9YTNUB8K#=Z[ DV.ZK%*P!_X$ ?PKUW]B[3;?2_V6_AS%;($1],$[8[
MO([.Y_[Z8UR89O#X6IB(_$Y**?96N_F]ON.S%1^L8JGAI? HN3\W>R7RW.DM
M/V;?A/8V"V<7PT\)_9PNW:^BV[D_5F0DGW)S7Q[^V1^Q)IGP[T&?XI_"9;CP
MWJ&B.+V\TVRE8(B*<F>W.<QLG4J#MP#@#&#^A-9/BW3X-6\*ZS8W2JUM<V4T
M,JL,@HR$'/X&N".+K4'[6,G=:^ODSOE@Z&(7L9Q5GIMMYH\<_8O_ &@)?VA/
M@S::KJ3*?$>F2G3]4V@*))54%90!T#J0>.-VX#@5[S7YO_\ !)6^FA\0?$O3
MU8O:&"RFW#[NY7F4'\0Q_*OT@KMS*C&CB9*&SL_O_P""<>659U<-%U-U=?=_
MP#PC]MBX\:?\,^Z[8> ]+U+5-=U1X[%DTJ%I9X[=R?-8!>>5!7(_OUR/[%?[
M*GAKX9?"71=7U[PO#-XWU2+[5?3:Q9@W%IN)VP*L@S%M7&X#!+9SV ^I:CGG
MCM89)II%AAC4N\DC!550,DDGH *Y(8B5.C*E'3F=V^MDMO3J=<\/&K6A5EKR
MJR72[>_KT/B#_@H]^SWX,B^$-S\0-*TBRT+Q'I=U )+BQB6#[9')($*R!0 S
M L&#'GY2,XKU;X&_'*^_X8FTWXC>(&:[O],T2YDFDER6N&MFDC1F]2_EKD]R
M37S%^U%\9M5_;2^)FD?!WX5QMJ&@6MWYU[JJY\F=U^4S$]H(P3@_QL1C/RY^
MB_VEO ]G\(?V$/$?A31A))9Z3I$%DK]&DS/&))&]V+,Q^IKNJ1E# QHU?BE*
M\>ZC:WRN]3@IN-3,'5HKW8QM)]'*]_G9?Y'B'_!//X,Z?\8KSQ9\8OB!:0^)
M]7N=3>WM!J48FC64*LDLVUL@GYT5?[NTX[8]C_;C_9C\)^//@UXA\2:=H=EI
MOBO0;1]0@OK*W6*2:.,;I(I-H&\% V,YVD#'?-C_ ()LV\</[*NB.C*6EO[U
MWVCD'SBN#[X4?I7OOQ/C6;X:^+$=0R-I-V"I[CR7J,QK3I8ENF[<EK>5D7EE
M"%7#Q517]IOYW9X=^P;\9+[XH?LUV=SJ3R:AK/AYY=+G8G=).(T5XCZDF-T7
M/<J37A/[)G[-.L_%3XT^.?B)\;?".H"\CN%ELM/\063+;SRR,^6VN-LBQ*BJ
MJ\J-P]%K:_X)*S.WP_\ 'T1/[M=4MV"^A,1!/Z#\J^\ZZ,94^J8NLJ:UDEKV
MO9NWJ<N"I_7,'1]H](MZ=[-I7]/^'/,_BA^SI\/_ (K>$;K0M8\,:8B-"T=O
M=VUK'%/:-CY7B=0"N#CCH<8((XKY&_X):>+-5L=6^(O@"XNFO=)TN5+NV8$E
M(Y/,:*3:>P?:AQ_LD]S7JG[;G[7MC\'_  Y=^"_"]P+_ .(6K1?9TBMOG.GI
M(,>8^/\ EH0?D3KD@GC&;G[ ?[-E]\!_AK=ZIXBA:W\6>)&CGNK9_O6D* ^5
M$W^U\S,WH6 _AK+#\U/"U9U'[LK)+N[[KT[]=C?$<M3%4H4U[\=6^RML_7HN
MF_4^E/$7B#3O">A7^LZM=QV.F6$#W%S<S-A8XU&6)/T%?D;^TKK_ (J_:<T?
MQ-\:+L2:9X#T6^BT30+&8$F7>WS,!T!P SMZLJC.WCZ4_:>\=:O^U9\9+'X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^,/\ @JGI<MY\ =$O$!,=GKT)DP>@:&903^./SKK/^";-_#>?
MLJZ)%$VY[6_O891_=8S%\?\ ?+J?QKT[]J+X5/\ &?X%>*_"UN@?4)[;S['/
M_/Q$1)&/Q*[?^!&OB?\ X)B?'*U\&^(-=^%GB*;^SI-2N?M6FBY^3_2U 26
MYZ.P5"!ZHPZD ^UA;UL%6HKXDU+Y:?Y,\3%OV..H5I?"TX_/5_JOQ/TMHHJC
MKFN:?X9T:]U;5;N*PTVRA:>XNIVVI%&HRS$^@%>*>WN7J*_*#X>_$#QA^TY^
MW,^H^%=<UK1=#O-06XN/[/O);<#3+8*/W@0C[ZJJX/\ %+BOU?KMQ&%EAXP<
MWK)7MV_K]#BP^*CB9U%!:1=K]'Z?UU*FK?\ (*O?^N+_ /H)K\LO^"6__)RG
MB'_L7KK_ -*;:OU-U;_D%7O_ %Q?_P!!-?EE_P $M_\ DY3Q#_V+UU_Z4VU=
MF6_!B?\ !_\ )''F>^&_Q_Y'ZL5\S_&?]O[X>_ WXB:EX-U[1O$UWJE@L32S
M:=:V[PGS(UD7:7G1NC#.5'.:^F*\9^(G['OPA^+'BV\\3^*O"/\ :NN7@19[
MK^TKR'>$0(ORQS*HPJ@<#M7FT'252]9-QMTWOT_4]*NJKIM46E+SV/%O^'K7
MPE_Z%WQI_P" 5I_\E5G?\%$_%-M\0_V/O"/BC389XM/U74K#48H[E565(Y;:
M9E#@$@-\P!P2,]S7JW_#O;X ?]"#_P"5G4/_ )(IG[8'P=MM4_9"UWPIX;LV
MAM_#]C!/I]HK-*RQ6I4[ 6)9CY:L,DDFNV=3!QE3E1334HMW[)Z]3AIT\;*-
M2%9IIQDE;NU9=!G_  3P=6_9'\%A6!*R7P;!Z'[9,<'\Q7TA7Q)_P2S^)UCK
MGPBU7P3)<HNKZ)?27,=NS?,UK-@AP.X$F\''3<OJ*^S]8UBR\/Z3>:GJ5U%9
M:?9Q-/<7,S!4CC499F)Z  5.9Q<,74<NKO\ ?J/*Y*IA*?+Z'Y;>+(CJ7_!4
MJ!8>2OB>R8\'_EG#$6_]!-?='[5'[,MO^T]X5TG1;GQ%<>'DTZZ:[1X;99UD
M<H4&Y2R] 3T/>OA_]C^UF^/G[=>O?$!(7;2K&YO=9+NIPHDW16Z'T;#@@?\
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MN_%7Q/I^N6-K*LIT[39)IS>;>BRRRJA5,@9 !)'&1UK]"D18T5$4*JC 51@
M>E.HKJQ&*JXFWM'HMCDP^$I86_LUJ]PHHHKD.P**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXI_;FT]X_B%H%Z58)-I?DA
MOX24FD) ]_W@_,5]K5\Y_ML>"WUKP!IVOV\1DFT>YVS%5'$$HP6)Z\.(_P#O
MHFO:R>JJ6-A?KI]Y\/QIA98K(ZZ@KN-I?<]?PN?$=%%%?IQ_*04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWO:_E:_EV-,5%O$OVT92IV7+:^]M;I=WWZ'SE^UU^SSX*_9O^(7@#P]X5O\
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MC.1N/.1/^S/\)_VIO@)XPT'PLUA!-\,X]5$FH>3=:?+'Y+L!+)&783@8^;:
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MO45M1K3H352F[-&-:C"O!TZBNF?E_HOQ,_;1^#<2:-=>&=?\200+LC^U:/\
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M&  !/P *?_PKC]NG_G[U[_PHM/\ _C]?I[173_:,O^?4/N_X)R?V;%:*K/\
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M<U4X^:-I 8EB/LBR*"/[V\]Z^W?V5O%(\9?LY_#S5-_F.VC002-ZR1+Y3_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M87%U:V7O$R^+WOP;2_([#_AZU\)?^A=\:?\ @%:?_)5'_#UKX2_]"[XT_P#
M*T_^2JU/V9?V3?A%XR^ /@36]:\"Z;J&JWVEQ3W-U*9-TKD<L<-BO3?^&*?@
M?_T3G2?SE_\ BZNK]1HU)4W"5TVM^Q-'Z_6IQJ*<;-)[=SQ[_AZU\)?^A=\:
M?^ 5I_\ )5?7?A?Q!;^+/#.D:Y9I+'::G9PWL*3@"14D0.H8 D X89P3]:\E
M_P"&*?@?_P!$YTG\Y?\ XNO8])TNUT/2[/3;"!;:QLX4MX(4SB.-%"JHSV
M%<->6&E%>QBT_,[L/'%1G>O)->2ZGRGXR_X*9?"_P1XLUGP]?:#XNEO=*O);
M*>2WL[5HV>-RC%2;D$C(.,@'VK'_ .'K7PE_Z%WQI_X!6G_R57RK\+?"6C>.
MO^"B.H:)X@TVWU?2+KQ%K GL[I \<FU+EER.^&4'\*_1S_AD?X,?]$T\._\
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MW=H0H'N3BO;?#7BK1O&6CPZKH&JV6M:9-GR[S3[A9HFQU 921D>G:OG75/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDW:G&*TTWO+\-3\@/C%HG[0_P/\ %6DZ'X[^*7B/3M+U9_+BUQ?$5_<:>5R
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M^A6_\J%K_P#':_0ZBC_6'%?RQ^Y_YA_Q#?*?^?M3[X__ "!^>/\ PRE\4_\
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M7Q3_ .A6_P#*A:__ !VOT.HH_P!8<5_+'[G_ )A_Q#?*?^?M3[X__('YX_\
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M_$-\I_Y^U/OC_P#('YX_\,I?%/\ Z%;_ ,J%K_\ ':/^&4OBG_T*W_E0M?\
MX[7Z'44?ZPXK^6/W/_,/^(;Y3_S]J??'_P"0/SQ_X92^*?\ T*W_ )4+7_X[
M1_PRE\4_^A6_\J%K_P#':_0ZBC_6'%?RQ^Y_YA_Q#?*?^?M3[X__ "!^>/\
MPRE\4_\ H5O_ "H6O_QVC_AE+XI_]"M_Y4+7_P".U^AU%'^L.*_EC]S_ ,P_
MXAOE/_/VI]\?_D#\\?\ AE+XI_\ 0K?^5"U_^.T?\,I?%/\ Z%;_ ,J%K_\
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MA:__ !VC_AE+XI_]"M_Y4+7_ ..U^AU%'^L.*_EC]S_S#_B&^4_\_:GWQ_\
MD#\\?^&4OBG_ -"M_P"5"U_^.T?\,I?%/_H5O_*A:_\ QVOT.HH_UAQ7\L?N
M?^8?\0WRG_G[4^^/_P @?GC_ ,,I?%/_ *%;_P J%K_\=H_X92^*?_0K?^5"
MU_\ CM?H=11_K#BOY8_<_P#,/^(;Y3_S]J??'_Y _/'_ (92^*?_ $*W_E0M
M?_CM'_#*7Q3_ .A6_P#*A:__ !VOT.HH_P!8<5_+'[G_ )A_Q#?*?^?M3[X_
M_('YX_\ #*7Q3_Z%;_RH6O\ \=H_X92^*?\ T*W_ )4+7_X[7Z'44?ZPXK^6
M/W/_ ##_ (AOE/\ S]J??'_Y _/'_AE+XI_]"M_Y4+7_ ..T?\,I?%/_ *%;
M_P J%K_\=K]#J*/]8<5_+'[G_F'_ !#?*?\ G[4^^/\ \@?GC_PRE\4_^A6_
M\J%K_P#':/\ AE+XI_\ 0K?^5"U_^.U^AU%'^L.*_EC]S_S#_B&^4_\ /VI]
M\?\ Y _/'_AE+XI_]"M_Y4+7_P".T?\ #*7Q3_Z%;_RH6O\ \=K]#J*/]8<5
M_+'[G_F'_$-\I_Y^U/OC_P#('YX_\,I?%/\ Z%;_ ,J%K_\ ':/^&4OBG_T*
MW_E0M?\ X[7Z'44?ZPXK^6/W/_,/^(;Y3_S]J??'_P"0/SQ_X92^*?\ T*W_
M )4+7_X[1_PRE\4_^A6_\J%K_P#':_0ZBC_6'%?RQ^Y_YA_Q#?*?^?M3[X__
M "!^?FG_ +(OQ-O)%6;1K>Q!;!>XOH2 /4[&8X^G->E>"_V&9C+%/XJ\0(L8
M(+V>EQDEA@<>:^,<Y'"GZU]<T5A5SS&5%9-1]%_G<]#"\ Y+AI*4XRJ?XI:?
M^2J)SG@KX=^'/AWI_P!C\/Z5!I\9 #R(,RR>[N<LWXFNCHHKPI2E-N4G=GZ!
M1HT\/!4J,5&*V25DOD%%%%0;!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN:'X&TW3M6L=/,MM=1&3=&VY1D98CN:Y54P%_@E]YU^SS#_GY'[CS[_@D?\
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M.Y4;G<A1EB ,GJ0*_2[_ (:0^$O_ $5'P7_X4%I_\<K\JM-^%-C\;OVXM?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1+^\U1^/[JW C53UYYQGH:^R_@=^S_X._9[\+MHOA*P:(S$/=ZA<L)+J[<#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=C10!QV?'?IHG_D6C/COTT3_ ,BUV-% ''9\=^FB?^1:,^._31/_ "+78T4
M<=GQWZ:)_P"1:,^._31/_(M=C10!QV?'?IHG_D6C/COTT3_R+78T4 <=GQWZ
M:)_Y%HSX[]-$_P#(M=C10!QV?'?IHG_D6C/COTT3_P BUV-% ''9\=^FB?\
MD6C/COTT3_R+78T4 <=GQWZ:)_Y%HSX[]-$_\BUV-% ''9\=^FB?^1:,^._3
M1/\ R+78T4 <=GQWZ:)_Y%HSX[]-$_\ (M=C10!QV?'?IHG_ )%HSX[]-$_\
MBUV-% ''9\=^FB?^1:,^._31/_(M=C10!QV?'?IHG_D6C/COTT3_ ,BUV-%
M''9\=^FB?^1:,^._31/_ "+78T4 <=GQWZ:)_P"1:,^._31/_(M=C10!QV?'
M?IHG_D6C/COTT3_R+78T4 <=GQWZ:)_Y%HSX[]-$_P#(M=C10!QV?'?IHG_D
M6C/COTT3_P BUV-% ''9\=^FB?\ D6C/COTT3_R+78T4 <=GQWZ:)_Y%HSX[
M]-$_\BUV-% ''9\=^FB?^1:,^._31/\ R+78T4 <=GQWZ:)_Y%HSX[]-$_\
M(M=C10!QV?'?IHG_ )%HSX[]-$_\BUV-% ''9\=^FB?^1:,^._31/_(M=C10
M!QV?'?IHG_D6C/COTT3_ ,BUV-% ''9\=^FB?^1:,^._31/_ "+78T4 <=GQ
MWZ:)_P"1:,^._31/_(M=C10!QV?'?IHG_D6C/COTT3_R+78T4 <=GQWZ:)_Y
M%HSX[]-$_P#(M=C10!QV?'?IHG_D6C/COTT3_P BUV-% ''9\=^FB?\ D6C/
MCOTT3_R+78T4 <=GQWZ:)_Y%HSX[]-$_\BUV-% ''9\=^FB?^1:,^._31/\
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M2NZHH X7/BO_ *;?DE&?%?\ TV_)*[JB@#A<^*_^FWY)1GQ7_P!-OR2NZHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <MXI^*O@KP-J,.G^)/&&@^'[^9!+%
M:ZIJ<%M+(A)4,JNP)&01D=P:Z*\OK?3[.:[NIXK:TAC:66>9PD<: 9+,QX
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M;\4:-XQTF+5- U>QUS3)2RQWNFW*7$+E3A@'0E3@@@\]16I7S)_P3C_Y-/\
M#/\ U]7O_I3)7TW6^*HJA6E23O9F.&K.O1C5:M<***_/#XR?'/QKJ_[?WA3P
M ^MS6_A'3/$&FB/3+7]W',6$<A:7',AW-P&.!@8 /-+#4)8FJJ47;2_R5O\
M,6*Q$<+1=:2O8_0^BBBN8Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MURT\51G6A!TDH\RM;=.ZMKUUM<ZJF$KPH3G[9N7*[W^%JSOITTV.T_X)Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZQ9ZD;AONBWF18Y'R>RDR9_W37L7_!+KX;>+OA_<?$<^*/"VM>&Q=+I_V?\
MM?3IK7SMIN-VSS%&[&Y<XZ9'K7M/[9'[(]I^TQX9M;G3[F'2_&6E*PL;R?/E
M31GDP2X!(4GD, 2ISP037K8C$PH9G[5ZQ:2=NS2_5?F>/A\-.OECI+22=UZK
M_@-_,^BU=9%5E(96&0P.01ZU\E?\%./%MEH?[-LNCS2J+W6M2MX;>+^(B-_-
M=OH @'_ A7@?@_XG_M??L\:5'X.;X?7GBVSLU$-I-=:1/J:PQCA52>U< J.P
M<D@8' &*Y+XP?L__ +0_QN\*ZO\ $OXA:?J$VHVBQ0Z1X8LK4RW)625 VRVB
MW&)%4L26^<E1G@9KBIX*-.M"<JBY$T[WWU5M/7?L=M3'2G1G35*7.XM-6VNG
M?7TV[Z'V+_P3C_Y-/\,_]?5[_P"E,E?3=?/'[ _A?6?!W[,OAW2]?TB^T/4X
MKF\:2RU*V>WF0-<.5)1P&&001QT-?0]<N8-2Q51KN=F7IQPM-/L%?EG\3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI[X^6/[.?PJO?%%Q M[J+N+33;%FVB>X8$J#WVJ S''9<=2*^"/AS\%OC?\
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M,+_]:OH:60XJHKS:C_7D?FV,\0\IP\G"BI5/-*R_%I_@?I-17YB?\+>\=_\
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M_A;WCO\ Z'7Q%_X-9_\ XNC_ (6]X[_Z'7Q%_P"#6?\ ^+H_U=J_\_%^(?\
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M?IW17YB?\+>\=_\ 0Z^(O_!K/_\ %T?\+>\=_P#0Z^(O_!K/_P#%T?ZNU?\
MGXOQ#_B)>$_Z!Y?>C].Z*_,3_A;WCO\ Z'7Q%_X-9_\ XNC_ (6]X[_Z'7Q%
M_P"#6?\ ^+H_U=J_\_%^(?\ $2\)_P! \OO1^G=%?F)_PM[QW_T.OB+_ ,&L
M_P#\71_PM[QW_P!#KXB_\&L__P 71_J[5_Y^+\0_XB7A/^@>7WH_3NBOS$_X
M6]X[_P"AU\1?^#6?_P"+H_X6]X[_ .AU\1?^#6?_ .+H_P!7:O\ S\7XA_Q$
MO"?] \OO1^G=%?F)_P +>\=_]#KXB_\ !K/_ /%T?\+>\=_]#KXB_P#!K/\
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M_A;WCO\ Z'7Q%_X-9_\ XNC_ (6]X[_Z'7Q%_P"#6?\ ^+H_U=J_\_%^(?\
M$2\)_P! \OO1^G=%?F)_PM[QW_T.OB+_ ,&L_P#\71_PM[QW_P!#KXB_\&L_
M_P 71_J[5_Y^+\0_XB7A/^@>7WH_3NBOS'A^,7CR&0.OC3Q 2/[^IS,/R+8K
ML?#?[6/Q(\/,/,U>+6(0<^3J5NKC_OI=K_\ CU9SX>Q"5X33^]'10\2,NG*U
M:C.*[Z/]4?H/17@'PS_;#\+^+I(;+7X_^$8U!\+YDT@:U9N<GS,#8./XN!G&
M3UKWR&:.XA26)UEBD4,CH<JP(R"#W%?/5\-6PLN6M&S/T?+\TP6:T_:X.HIK
M\5ZK=?,?1117,>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<!\<OC/H?P%^'.
MI>+==+20VX$=O:1D"2ZG;[D29[GN>P!/:C5NR#;5G>2S)!&\DKK'&@W,['
M'<FN%NOC]\,+&\:TN?B/X2M[I3M,$NN6JN#TQM,F<U^;.B:7\;_^"C'BR^N+
MC5?[%\$6DX#JS.FFVAZB-(QS/, <Y///+*"HKVVU_P""2OAA=+\NY^(&KRZE
MC_CXBL8DASZ^66)Q_P #KUW@Z5"RQ-2TNR5[>IXZQM7$7>%IWCW;LGZ+<^[-
M-U2SUJRBO-/NX+ZTE&8[BVD62-QZAE)!JU7Y(?$'X6?%[_@GGXNL?$7AWQ$U
M_P"&KN8(+RW1EM+E@,^3=VY8@$C=CD\9*L"./TC_ &=_CEI/[0OPOT[Q9IB?
M9I7)M[ZQ9MS6MRH&^//<<AE/=64\'@8U\(H4U7HRYH?BO5?U^1M0QCG4]A6A
MR3WMNFO)_P!?F>F45^:OB;_@E?XRU[Q)JVIQ^--"B2]NYKE8VAF)4.Y8 \=L
MUY%^T)^P3XD_9Z^'4OB_5/$VE:K:QW,5L;>TBE5R7) .6&,#%:4\+AZBBO;6
M;MI9[OIN9U<5B:;DU0O%7UYELNNW8_8>BOQW_9Z_8+\2?M#?#M/%VE^)M+TJ
MU:ZEM1;W<4K/E,9.5&,'->N>&_\ @E9XRT3Q%I>HR>-="D2SNHKAD6&;+!'#
M$#CVK:>!P].?).O9K^Z_\S"&/Q-6G[2GA[I_WE_D?I91117B'NA17EG[2'Q\
MTC]G3X9W?BC4H_METS"VT_3U?:UU<,"57/90 68]@#WP*^%O!,/[6'[8D$_B
MG2?&,O@WPZTC+:217\NE6KX."D0MU:20*>-SY&01NR"!V8?"RKQ<[J,5NW^7
MJ<6(Q4<.U"SE)[)?GZ'Z>45^85Q\;OVC?V)_&6FVOQ)NI_&?A6Z? DN[DW<=
MRO\ %Y-TP\Q) ,_*_P#WR1@U^D'@7QII7Q&\'Z1XFT.X^U:3JELES;R=#M8=
M&'9@<@CL013KX65&"J)J47U7Y>HJ&+C6FZ4HN,UT?;OZ&[17QW_P4R^+&N_#
M;X5^&;3PUKFH>']5U3523=:9=O;3>3%$Q9=Z$'!9X\CZ5\Y>%?@1^U]XR\,Z
M3KVG>._$?V#4[6.\M_.\8SHYCD4,I*F3(.".#6E#!^VI.K*:BKVU,\1C/8U5
M1A!R=KZ>MC]4:*_,+_AF/]LK_H>]>_\ "UG_ /CE?HS\-=-U?1_AWX8L-?FD
MN==M=,MH;^:68S/)<+$HD8N22Y+ G=WZU%?#PHQYHU%+T+H8FI6GRRI./FSI
M**^'_P!LC]M?Q%X/\;P_"WX41?:?%TCI#=W\<(N)(I9,;+>&,@@R<C)((&0
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MW#F6Z2UWND_UL?0%%%%<!Z(4444 %%%% !1110 4444 %%%% !1110 4444
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MQCJ]92G+,L,VG[\-UT:[V_KJNQT1IPRO%)6_=SV?6+[7[?IZ,^N_VM/VI?\
MAEOP_H&J?\(Q_P )-_:MU);>5]O^R>5M0-NSY4F[/3&!7S+_ ,/=_P#JD_\
MY<?_ -R5]Z^+? 'A?Q];V\'B?PWI'B."W8O#%JUC%=+&Q&"RB12 2.XKF?\
MAF_X2_\ 1+O!?_A/6G_QNO-P]3#0A:M3YGZV/3Q%+%3FG0J<J]+G'_LF?M/_
M /#47A;6]9_X1K_A&?[-O5M/)^W_ &OS,H'W;O*CQUQC!KX3^&/_ "D\NO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7NG[/_P"TMJ/PVO+;1M>GEO\ PHQV!6&^2QS_ !)W
M*>J?BO.0WA=%<^(P]/$TW3JJZ/2R[,L3E>(CB<)/EDON:[-=4?K%9WD.H6D%
MU;2K-;S(LD<B'*NK#((]B#4U?*G[&/Q=DOH9O NJ3&22!&N-,DD;GRQC?"/I
MRP]BW8"OJNORS&866#K.E+I^*/ZWR7-:6=8&&,I:7W79K=?Y>5F%%%%<1[@4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !115/6-8LO#^E7FIZE=16.GV<33W%S.P5(HU&69B>@ % ]]$7**P? O
MCK0_B5X3T_Q+X;OO[2T34%9[:Z\IXO,4,5)VNJL/F4CD#I6]52BXMQDK-$1E
M&<5*+NF%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_:_C%O']E;@2?V/'XAN[IQM&<K'<*B$CT4D^F:[\91CB91JUIJG)I73Z>?\
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MG/["'UB.)7Q)6_X?^NB/C+]B+]C'QM^S7X_U[7/$^J:!?6E_IGV*)-)N)Y)
M_FH^6$D*#&%/0GMQ7V;1158C$3Q,^>IN1AL-3PL'"GLW<*^"OVEO^"=OB/Q]
M\8)O&WPUUC1= 6]9;RY@U">>!H;P')EB,43_ 'B QZ$-D]^/O6BIH5ZF'J*I
M3=F77H4\33=*HKIG.?#N'Q/:^"-&@\9R:?/XGAMUCOY]+D=[>:1>/,4NB$;@
M Q&T8)(&0,UT=%%92ES2<NYK"/)%1O>P5\1>#_V(?'7A_P#;&F^+%QJOAY_#
MKZW>ZD+6*YG-WY<PE"C:80FX;QD;\=>37V[16M&M/#R<X;M-?)F=:C#$14)[
M)I_-7_S$(# @C(K\\(/^"9.OQ_M +XA;5/#[?#Y=<_M#^S_.F^UFU\WS!#L\
MG9G^#[^,<^U?HA158?$5,+-SI.S(Q.&IXN'LZJNKW"OB?Q-^Q/XXUK]LR'XM
MP:KX?7PVFM6FHFUDN)Q>>7$D:L-HA*;B4./GQTY%?;%%30K3P\_:4][6^^W^
M0\1AX8JG[*IM>_W77ZG*?%#X9Z#\8/ VJ>$_$EL;G2M0CVOL.V2-@<K(AQPR
MD @^W.1Q7P@/^"<7Q>^&FNW<WPM^*\&F65P<-))>7>FSLH)VK((%=7QGJ2/7
M Z5^C5%70Q-7#W]F]'NN@L1A:6)M[1:K9[-'PKX5_P""=/B?QKJ]EJ7QN^*.
MI>,8K5LKI=K=SS*>0<>?,=RJ<8(1%//#"KO@W]ACQ7\+/VLK;XB>#[GPU:>"
M(+QFCTF2XGCN([:2$QR(JB%E)&YBN7YP,D9-?;M%;_VA7O>^EFK6TL]]#G>7
M8=QLUK=.]];K;4S/$GAO2_&&@WVB:U8PZEI5]$T%S:W"[DD0]01_7J.M?!WC
M#_@F7XC\*>*)=;^#GQ%E\.LY/E07T\]M-;J>2HN8 69<XZH#@#))YK]!**YJ
M.(J8=N5-VOOYG57P]+$14:JO;;R]#\\=%_X)K_$'Q]X@MK[XP?%*36;:W.-M
MG=W.H7#IW19;E5\O/KM;Z5]X>!? NA_#7PGIWAKPWI\>F:-I\?E06\>3@9R2
M2>68DDECR2236]16E;%U:\5"3T71:(RH8.CAY.<%J^KU9\8_LO?L8^-O@G^T
M)K_CO7-4T"ZTC4(+R.*'3[B=[@&6977<KPJN %.<,>?6OLZBBLJM:=;EY_LJ
MR]$;4J,*/-R?:;;]6>9?'K]GGPC^T3X3&B^*+9Q+ 2]EJ5J0MQ:.1@E&(((.
M!E2"#@=P"/C&/_@G5\;/AU=7-O\ #?XOQ:=I<S;GVZA>Z4[_ .\D D4G&.<U
M^C=%:4,55PZ<8/1]-T9U\+2Q+4JBU779GP;\,/\ @F()/$R>(OBUXQD\779<
M2S:?9M(5N&'_ #UN9#YCK[!5/^UVK[KL;&WTNRM[.S@CM;2WC6*&"% J1HHP
MJJ!P    !4]%*MB:N(LJCT6RZ!0PM+#W=-:O=[L_(Y_AOHOQ<_X**>)/"/B&
M*672-4UG4XYA#(4D4BWF=&5NQ5E5AG(XY!'%>OWO_!/;XW>#7FT?X>_&-K3P
MG(S%;6;5+[3R QY#10JZ,<=3D9]!7$_#/_E*A>?]A[5/_22>OU(KU:V(J8>C
MAE!Z.G&Z>JZGE4L-3Q&(Q/.M5.5FM'N?(O[-/_!//P[\&=?MO%?BG5/^$Q\5
MV[^;;YBV6EI)U\Q5)+22 Y(=L8SD*" :^J?$6GR:OX?U2PA95FNK66!&D)"A
MF0J"<#IDUHT5X^(K5,4[U7<]G#4*>$_@JW4^0?V&_P!D'QE^S/XA\57_ (HU
M+0[^'5;6&"!=(GFD961V8EO,B3 P1TS7U]1158C$3Q,^>IN3A\/#"P]G3V/B
M_P 9?L7^-O$/[9EG\6[;5- 3PW#JME?-:RW$XO"D*1JP"B$IN)0X^?'3D5])
M?&[X*^'?CYX!N_"GB2*3[-*PE@NH"!-:S+G;(A((R,D8/!!([UWU%*5><X0@
MWI#;^OD..'A"I4J):SW_ *^9^<6G_P#!/'XY_#._NH?AQ\7+73=+G;<S)J%[
MIKRGH"\4*2*3CON-=_X%_P""<U]X@\06FO\ QL^(6I?$"YM_NZ:MS.\77.UI
MY6\PI_LJJ?7M7V]174\QQ#ZJ_>RO]YQK+<,M+.W:[M]Q\6? ']BOQI\"/VFM
M3\:Z?J'AQ_!-X]Y +&*>=+J.UE;?&H3R=F598QC?C /-?1GQGT?X=_$3P_<>
M ?'6IZ7&-4B$L5C<WT<-UP2%FB#'=E6SA@",@CGD5Z/7R!_P4'_99U[X[:!H
MOB+PA"M[XBT)9(GT\R!&NK=R&Q&3QO5AD D9#'O@'+VSQ-2FJ\K):7[=G]_7
MYFZHK#4ZCH1NWK;H^Z^[H>27'_!-SXK?#O6[J?X5_%>/3+*X/,DE[=Z9<%/X
M5<VZN'QGKQ]!5+XB?L+GX:_!OQ]\1?B?XQG\:^+X-+86G[V5H89V(17:60[Y
MFRPQD*!D\,<8@\)_\%(OB)\'=$M?#7Q%^&LVHZM8Q+ MS=SRZ7<.JC ,J/"^
MYN/O *#Z5@_$+XL_'#]OE;+PKX:\$2:#X/>=9)W7S#;,RGAKB[=54JO4(H!)
M'1B!CW'''-V<ER_SZ;>N^QX,98!*ZB^;?D][?TVW_P"&Z'M7_!)ZPEA^#WB^
M[9<0SZYY:'U*01Y_]"%?2'[0'[./A#]HWPLFD^)K>2*ZMB7L=4M2%N;1CUVD
M@@J<#*G@X'0@$6/V=_@K8_ 'X3Z/X/LYA=RVX::\O NW[1<.<R/CL,X ']U1
M7I5>-C:ZJXJ56F^UGZ*USVL#0='"1HU%WNO5WL?G)#_P3L^-WP[N+BV^'/Q?
MBT_2IFW-LU&^TIG]VC@$BD].<UTGPQ_X)B2S^*8_$7Q<\9-XKN/,$LVGV;2N
M+EAT\VYD(=EXY 4'_:K[WHJ_[2Q-M]>]E<S_ +,PU_AT[7=B"QL;?2[*WL[.
M".UM+>-8H8(4"I&BC"JH'     %3T45YM[ZL]1))604444AA1110 4444 %%
M%% !1110 4444 %?-?[<'B^32_!.C>'X)C&=5N6EG53]^*$ [3[;W0_5*^E*
M^)OVYKUY/B1H5H1\D6DK*/J\TH/_ * *]K)Z:J8V%^EV?"\;8J6&R.MR/65H
M_>]?PNCYPHHHK]./Y4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$^;DER?%9V]>A\D_#_X6?M0_M-Z';^-M7^*]YX!TK45,^GV=C/-:L\1Y5A#
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M&GU&HT[-<R5W&^OG]WJ9_7Z2:NGRMV4K::[??Z'VY1117G'I!2-]T_2OB?\
M: _;2\9WWQ8?X3_ W1(==\30NT%WJ4D8E$<H^^D:L0BA/XI)"5!R,<9K U'X
MD_M=_L_V2^*_'EEIGCSPG" ^HVUI';++:1_Q'= B,I'][$BC'/'-=BP=2=-2
M<E'FVN[7_KSL<$\9"$W",7+EWLKV]?\ @7'?\$ZOB3XN\;_%7XI6GB+Q3K6O
MVEFJ?9H-4U":Y2#]_(/D5V(7@ <>E?>U?F[_ ,$K[Y-4^*'Q2O8U9([BWAF5
M6Z@-/(0#^=>Y_M6?MD:M\*_&VF?#?X=Z#'XF^(&HB/Y)U9XK<R']VFQ2"[L/
MFY8!1@G.<5W8VA*6(A1A'WG%?\$Y<)B(1H5*TY>[S/7ROH?5]%?!E]I?[=?V
M!M536M&5\>9_8L$>G&1>^T%HBI_[^'ZUV_[&W[8WB#XQ>+M9^'OQ!T:'2?&>
MEQ/*);>)H1,(V"2QR1L3LD4D'C@C/"XYY7@I<LI0E&5M6D];'0L;'FC&<)1O
MHFUI?^NYTG[<G[3VN_LV>#M$D\.:;9W6JZW-+!'=7I+):A%4EO+&-Y.[C) &
M.0>E?1>B7$EYHMA/*V^66WC=VQC+%02:_+?_ (*/:7\5[/Q1:W/C/6+*]\%3
MZG='PW:0)$);>/"Y#E8U8_+M^\S5]H?LIZ-\<M'M]4D^+OB#3=8TN2TMSI"6
M20*8<!M^[RX8S]W9U)Z&M?J\/J,:O,KMM_EIZKJC/ZQ/ZZZ/*[)>5MWKZ/I^
M1]"T5\(>*OVR?BM\</B9J_@G]G[P]9S6FF%EGU^]".2%;;YH,A$<:$YVA@[-
MC('45B>./%G[:GP1TF7Q3KFH:3XIT*Q7SKR.WM+.2.*,=2ZQQQ2[1W*G@<DB
ML8X.;2<Y*-]DWK_7J:RQD5*481E*VC:5U_P?D?H57Q;^U-\&?BM\7H_B!?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXX2FU_6K/SK_ .'1'_56/_+<_P#NNNW^"7_!-/\ X4[\5/#GC/\ X6-_:_\
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M;S0V)/L,)Z&6>X90)7 )VJH!P3A>IK])OA#\,-*^#?PYT/P?HP)LM,@$?G,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M< @G@OV0?V0-=;Q9_P +D^,,DVH>-+R3[98Z=>'+VSL.)IAT$@'"Q](QC@,
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M/PS#\)_A:\_BS4-:NXDN[JQA?RV"N&6&+(!D9G"DD#: .ISQ[/J'PGF^"?\
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M)8UDD?W)=V/XUX-_P5._Y-STO_L8;?\ ]$3UG_LB_MK>#--^&&A>"OB)J?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% $-U:07UO);W,,=Q!(-KQ2H&5AZ$'@UPLO[/?PLGN#<2?#7P?).3N,K:#:E
ML^N?+SFO0**J,I1UB[$RC&6DE<K:?IMII-G%:6-K#96D0VQP6\8C1!Z!0,"K
M-%%3N5L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN;5,16GB)4*'*N6WQ7UNKZ)'UO;:[IMYHR:O;ZA:SZ2\/VA;^.96@,6,^8)
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M&E?"/X?:YXNUI]MAI=NTS(" TK=$C7_:9B%'N:_-[X(_!_Q7_P %!/BAJOQ
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MN(VQ2J#R>I&:]0HJHRE"2E%V:)E&,XN,E=,^=?\ AWM\ /\ H0?_ "LZA_\
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MBG+$5JBY9S;7JQ0P]&F^:$$GY)'%?$OX+^!_C%8Q6GC+PS8:\D0(BDN$*S1
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M)KY>9@?\%6_$DVJ:S\./!5I^\FE,U\T2]2[LL47'X25]\>"?#</@WP;H.@0
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MS1_PP[X[_P"@MX=_\"9__C-?<-%']NXSNON#_B'^2?RR_P# CX>_X8=\=_\
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MMX=_\"9__C-?<-%']NXSNON#_B'^2?RR_P# CX>_X8=\=_\ 06\._P#@3/\
M_&:/^&'?'?\ T%O#O_@3/_\ &:^X:*/[=QG=?<'_ !#_ "3^67_@1\/?\,.^
M._\ H+>'?_ F?_XS1_PP[X[_ .@MX=_\"9__ (S7W#11_;N,[K[@_P"(?Y)_
M++_P(^'O^&'?'?\ T%O#O_@3/_\ &:/^&'?'?_06\._^!,__ ,9K[AHH_MW&
M=U]P?\0_R3^67_@1\/?\,.^._P#H+>'?_ F?_P",T?\ ##OCO_H+>'?_  )G
M_P#C-?<-%']NXSNON#_B'^2?RR_\"/A[_AAWQW_T%O#O_@3/_P#&:/\ AAWQ
MW_T%O#O_ ($S_P#QFON&BC^W<9W7W!_Q#_)/Y9?^!'P]_P ,.^._^@MX=_\
M F?_ .,T?\,.^._^@MX=_P# F?\ ^,U]PT4?V[C.Z^X/^(?Y)_++_P "/A[_
M (8=\=_]!;P[_P"!,_\ \9H_X8=\=_\ 06\._P#@3/\ _&:^X:*/[=QG=?<'
M_$/\D_EE_P"!'P]_PP[X[_Z"WAW_ ,"9_P#XS1_PP[X[_P"@MX=_\"9__C-?
M<-%']NXSNON#_B'^2?RR_P# CX>_X8=\=_\ 06\._P#@3/\ _&:/^&'?'?\
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M_B'^2?RR_P# CX>_X8=\=_\ 06\._P#@3/\ _&:/^&'?'?\ T%O#O_@3/_\
M&:^X:*/[=QG=?<'_ !#_ "3^67_@1\/?\,.^._\ H+>'?_ F?_XS1_PP[X[_
M .@MX=_\"9__ (S7W#11_;N,[K[@_P"(?Y)_++_P(^'O^&'?'?\ T%O#O_@3
M/_\ &:/^&'?'?_06\._^!,__ ,9K[AHH_MW&=U]P?\0_R3^67_@1\/?\,.^.
M_P#H+>'?_ F?_P",T?\ ##OCO_H+>'?_  )G_P#C-?<-%']NXSNON#_B'^2?
MRR_\"/A[_AAWQW_T%O#O_@3/_P#&:/\ AAWQW_T%O#O_ ($S_P#QFON&BC^W
M<9W7W!_Q#_)/Y9?^!'P]_P ,.^._^@MX=_\  F?_ .,T?\,.^._^@MX=_P#
MF?\ ^,U]PT4?V[C.Z^X/^(?Y)_++_P "/A[_ (8=\=_]!;P[_P"!,_\ \9H_
MX8=\=_\ 06\._P#@3/\ _&:^X:*/[=QG=?<'_$/\D_EE_P"!'P]_PP[X[_Z"
MWAW_ ,"9_P#XS1_PP[X[_P"@MX=_\"9__C-?<-%']NXSNON#_B'^2?RR_P#
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MS1_PP[X[_P"@MX=_\"9__C-?<-%']NXSNON#_B'^2?RR_P# CX>_X8=\=_\
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MMX=_\"9__C-?<-%']NXSNON#_B'^2?RR_P# CX>_X8=\=_\ 06\._P#@3/\
M_&:/^&'?'?\ T%O#O_@3/_\ &:^X:*/[=QG=?<'_ !#_ "3^67_@1\/?\,.^
M._\ H+>'?_ F?_XS1_PP[X[_ .@MX=_\"9__ (S7W#11_;N,[K[@_P"(?Y)_
M++_P(^'O^&'?'?\ T%O#O_@3/_\ &:/^&'?'?_06\._^!,__ ,9K[AHH_MW&
M=U]P?\0_R3^67_@1\/?\,.^._P#H+>'?_ F?_P",T?\ ##OCO_H+>'?_  )G
M_P#C-?<-%']NXSNON#_B'^2?RR_\"/A[_AAWQW_T%O#O_@3/_P#&:/\ AAWQ
MW_T%O#O_ ($S_P#QFON&BC^W<9W7W!_Q#_)/Y9?^!'P]_P ,.^._^@MX=_\
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M9SXBC[>"A>S337JG_E=?,****YSH"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.N:YI_AG1K
MW5M5NXK#3;*%I[BZG;:D4:C+,3Z 5>HH ^)?A;X)OOVR/CF/C)XIM)(/AQX?
ME-OX3TJZ0C[:R-_Q\,I_AW#<?5@J\A#G[:HHKHJUO:*,8JT8Z)?G\WNV<]*C
M[-RG)WE+=_DO1+1(****YSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D[S5/%T=W.M
MOHMG) KL(W:X ++G@GGTJ+^UO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_
MQH_M;QI_T K+_P "1_C78T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\ P)'^
M-=C10!QW]K>-/^@%9?\ @2/\:/[6\:?] *R_\"1_C78T4 <=_:WC3_H!67_@
M2/\ &C^UO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "
M1_C78T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%
M9?\ @2/\:/[6\:?] *R_\"1_C78T4 <=_:WC3_H!67_@2/\ &C^UO&G_ $ K
M+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C78T4 <=_:WC3_
M * 5E_X$C_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%9?\ @2/\:/[6\:?]
M *R_\"1_C78T4 <=_:WC3_H!67_@2/\ &C^UO&G_ $ K+_P)'^-=C10!QW]K
M>-/^@%9?^!(_QH_M;QI_T K+_P "1_C78T4 <=_:WC3_ * 5E_X$C_&C^UO&
MG_0"LO\ P)'^-=C10!QW]K>-/^@%9?\ @2/\:/[6\:?] *R_\"1_C78T4 <=
M_:WC3_H!67_@2/\ &C^UO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M
M;QI_T K+_P "1_C78T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\ P)'^-=C1
M0!QW]K>-/^@%9?\ @2/\:/[6\:?] *R_\"1_C78T4 <=_:WC3_H!67_@2/\
M&C^UO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C7
M8T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%9?\
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MO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C78T4
M<=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%9?\ @2/\
M:/[6\:?] *R_\"1_C78T4 <=_:WC3_H!67_@2/\ &C^UO&G_ $ K+_P)'^-=
MC10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C78T4 <=_:WC3_ * 5E_X$
MC_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%9?\ @2/\:/[6\:?] *R_\"1_
MC78T4 <=_:WC3_H!67_@2/\ &C^UO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?
M^!(_QH_M;QI_T K+_P "1_C78T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\
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M0!QW]K>-/^@%9?\ @2/\:/[6\:?] *R_\"1_C78T4 <=_:WC3_H!67_@2/\
M&C^UO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C7
M8T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%9?\
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MO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C78T4
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M^!(_QH_M;QI_T K+_P "1_C78T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\
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M0!QW]K>-/^@%9?\ @2/\:/[6\:?] *R_\"1_C78T4 <=_:WC3_H!67_@2/\
M&C^UO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C7
M8T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%9?\
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MO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C78T4
M<=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%9?\ @2/\
M:/[6\:?] *R_\"1_C78T4 <=_:WC3_H!67_@2/\ &C^UO&G_ $ K+_P)'^-=
MC10!QW]K>-/^@%9?^!(_QH_M;QI_T K+_P "1_C78T4 <=_:WC3_ * 5E_X$
MC_&C^UO&G_0"LO\ P)'^-=C10!QW]K>-/^@%9?\ @2/\:/[6\:?] *R_\"1_
MC78T4 <=_:WC3_H!67_@2/\ &C^UO&G_ $ K+_P)'^-=C10!QW]K>-/^@%9?
M^!(_QH_M;QI_T K+_P "1_C78T4 <=_:WC3_ * 5E_X$C_&C^UO&G_0"LO\
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M* .%_MCQ/_S[S?\ @-_]:C^V/$__ #[S?^ W_P!:NZHH X7^V/$__/O-_P"
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MS?\ @-_]:C^V/$__ #[S?^ W_P!:NZHH X7^V/$__/O-_P" W_UJ/[8\3_\
M/O-_X#?_ %J[JB@#A?[8\3_\^\W_ (#?_6J]H>I:[<:I!'>0R);'=O9H=H^Z
M<<X]<5UE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJZQ-&-5:7_IA17B/[9WQ/_X5/^SGXMU2*;R=0O+?^S+(J?F\Z?Y,CW52[?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLFK6IT(\U1V1]?T4R*031HXX# ,,^]/K$U335T%%%% PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***P_%WCC0/ .F+J'B+5[31[1Y%ACDNI OF2,<*
MB#JS$]%4$TTFW9";25V;E%%%(84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5^1_@_1;7Q)_P4@UO2+Z,365_XCUBUGC/1HWCN
M%8?D37ZX5^3WPQ_Y2>77_8UZI_Z#<5Z^5I2K33_DE^AY.:-JA!K^>/Y2.O\
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M13_[>E*/_MI^L=E_QYP?]<U_E4]4)-0M])T-KZ\F6WM+:W\Z:9SA415RS'V
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M3_Y)/_Y$^M**^2_^&]/^I&_\J_\ ]HH_X;T_ZD;_ ,J__P!HH_L;'?\ /O\
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M\5_F'^N_#_\ T$_^23_^1/K2BODO_AO3_J1O_*O_ /:*/^&]/^I&_P#*O_\
M:*/[&QW_ #[_ !7^8?Z[\/\ _03_ .23_P#D3ZTHKY+_ .&]/^I&_P#*O_\
M:*/^&]/^I&_\J_\ ]HH_L;'?\^_Q7^8?Z[\/_P#03_Y)/_Y$^M**^2_^&]/^
MI&_\J_\ ]HH_X;T_ZD;_ ,J__P!HH_L;'?\ /O\ %?YA_KOP_P#]!/\ Y)/_
M .1/K2BODO\ X;T_ZD;_ ,J__P!HH_X;T_ZD;_RK_P#VBC^QL=_S[_%?YA_K
MOP__ -!/_DD__D3ZTHKY+_X;T_ZD;_RK_P#VBC_AO3_J1O\ RK__ &BC^QL=
M_P ^_P 5_F'^N_#_ /T$_P#DD_\ Y$^M**^2_P#AO3_J1O\ RK__ &BC_AO3
M_J1O_*O_ /:*/[&QW_/O\5_F'^N_#_\ T$_^23_^1/K2BODO_AO3_J1O_*O_
M /:*/^&]/^I&_P#*O_\ :*/[&QW_ #[_ !7^8?Z[\/\ _03_ .23_P#D3ZTH
MKY+_ .&]/^I&_P#*O_\ :*/^&]/^I&_\J_\ ]HH_L;'?\^_Q7^8?Z[\/_P#0
M3_Y)/_Y$^M**^2_^&]/^I&_\J_\ ]HH_X;T_ZD;_ ,J__P!HH_L;'?\ /O\
M%?YA_KOP_P#]!/\ Y)/_ .1/K2BODO\ X;T_ZD;_ ,J__P!HH_X;T_ZD;_RK
M_P#VBC^QL=_S[_%?YA_KOP__ -!/_DD__D3ZTHKY+_X;T_ZD;_RK_P#VBC_A
MO3_J1O\ RK__ &BC^QL=_P ^_P 5_F'^N_#_ /T$_P#DD_\ Y$^M**^2_P#A
MO3_J1O\ RK__ &BMG1?VZ?#]Q(BZKX:U&Q4_>:UF2XV]/79D=:F63XZ*NZ?X
MK_,TI\:9#4ERQQ*^<9+\7%'TW17#> _C7X,^)'R:)K<,EV.MG<9AG_!&P6'3
ME<CGK7<UY=2G.E+EJ)I^9]9A\30Q=-5</-3B^J::_ ****S.D**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +&2;_TFMJ^U*Y,T_P![G\OR1VY3_N</G^;/RU_8=_Y/P\7?]QC_ -*!5O\
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M3G%OIH^AS8/"XS#THJG-+KMK<_,#]@7XO0?"G]I"PM#<2#0/$A.CRM, IR[
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M  A'[/X\0W,6S4/%-VUZ2PPPMXR8XA]#AW'M)7S/_P %6/\ DO'A;_L7X_\
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M,O\ @E)_R0/Q)_V,DW_I-;5T4Y*6&Q3CLY+\T<LHRC7PD9[I/[^4^U*_+/\
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M?$<$:QORNRWB5E7'H3'^IK]5J_*K]JJ&[_9U_;PTSX@36TK:1>7MKK4;(O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]?ZV/SAM?V /VAO!\#:1X3^,<%EX?!(2"+6M1L5*GKF&-&49R>-QKTK]G_\
MX)LZ+X \3V_BKX@:XOC36H9!<16*1%;1)LYWR,Y+3'/(R%&>H-?:E%=#S'$-
M-7LWU25_O.=9;ADU[MTNC;:^X****\P]0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQS]JKXA2> _A7=16KLFHZN_V"%T8J8U()D?CG[H*\=W
M!KV.OC?]NS6GF\3>%])W_);V<EUL]Y'VY/\ WZ_G[UZV5T57Q<(RVW^X^0XM
MQT\OR:O5INTFN5?]O.WY7/E^BBBOU(_DD**** "BBB@ HHHH **** "BBB@
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M\M_AG_RE0O/^P]JG_I)/7ZD5^6_PS_Y2H7G_ &'M4_\ 22>NC*_XU3_KW/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6Z_ ^#XXP\L1D=;E6L>67W-7_"[/C:BBBOTT_E8**** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y3\:/VH/AS\ UCB\6Z\L&I2IYD.E
MVD9GNI%['8OW0<'#.5!P>:]5/YU^1/P1_P"$-^+W[9/B2X^-=]%Y<US=M!;Z
MG<>5;RW:2A(K=VR,*J!@JD@$HJ\YP>[!X=8B<E)Z13;MOIT7]?F<&,Q+PU-.
M*UDTE?;7JSZST_\ X*F_!^]ODMYM-\5V$3-@W5Q80&-1ZD).S8^BDU]-?#?X
MI^%/B[X=37/!^N6NN::S;&DMR0T;==LB, R-CG:P!P0:XS7OV3_@UXKT"73Y
M/AUX:M[:XCPMSIFG16LZ@CADFB4-GOG/YU\V_L@_LJ_%+]G?]H/7;IX(1\/+
MD7%FUQ+?1M)=0JQ:VE\I"2'! ^\!@.];\N$K1DH7A)*ZN]'Y>IS\V,HRBYVG
M%NSLM5Y^A]W,P522< <DFOFWXG?\%!_@Y\,=4FTU]7O/$VH0.4FA\/VXN%C8
M=1YKLD9/^ZQQWKSC_@IS\=M2\ > ]'\$:)=26=YXD\Q[Z>(E7%HF 8P1TWLV
M#[*P[U;_ &/_ -A+P3X:^'FC^)O'6A6OB?Q1JULEX;;5(A+;64;J&6(0M\K-
M@C<S X/ QCF*&'I^Q>)KM\M[)+=O_+?^K7TQ&(J>V6%PZ7-:[;V2_P _\U\N
MI\!_\%)/@QXVU*.RN;[5?"LDC!(Y->LUCB8DXYDB>14'NY4#UKZAM;N"_M8;
MFVFCN+:9!)%-$P9'4C(92."".<BOF7]H3]@WX=?%#P=??\(QX<TWPAXJ@A9[
M"ZTF!;6%W R(Y8D 1E;&-V-PSD'J#X=_P3#^-FL0ZYKOPCU^>:2.SBDO-,CG
M.6MF1PL\ ]LL& Z J_K6GL*&(I3GA[J4=6GV[K^OTOE[?$8:K"&(LXRT37?L
MU^7_  ]N(_X*D?\ )P_@S_L"0?\ I5-7Z8Z]KUOX5\+:AK5VDDEKIUG)=RI"
M 79(T+,%!(!. <9(K\SO^"I'_)P_@S_L"0?^E4U?HI\7/^2.^,O^P%>?^D[U
M&);CEM!KO4_,TP\5+-JT7U5/\CB?V<_VL/"/[3CZ\OA?3M:L#HH@-Q_:\$,>
M[S?,V[/+E?./+;.<=1UKU;Q)XFTKP?H=WK&N:C;:5I5HADGO+N01QQKZDG_)
MK\^?^"1?_'Q\4?\ <TW^=U6)_P %"OB!K?Q@_: \.?!G0;G;9VT]M \(8A);
MZX(VL^.H1'3Z;GKHQ&!7U[ZK1T6C]-$V_P"NZ.?#X]K!/%5M;=NO9?UT/>O$
M'_!4+X-:+JCVEK%XDUR%3C[;I^GQK"?<":6-_P#QVN'_ &T/V@/ OQZ_9%U*
M_P#!NMQZ@;?5K(7-G(ABN;<EFQOC;D X.&&5.#@G%>]_"_\ 8G^$?PW\*V^E
M2^#=)\37FP?:=3UVRCNYIY,?,P\P$1CT5, >YR3\8_\ !0?]D70?@[I]EXZ\
M#6SZ7H=]<BRU+2HW9HH9&!='3)R$8J05Z A<8S@*FL%*M"$+IIJS?5IIZKSV
M05)8Y4)SFHM.+NENDTUOY;L^JO\ @G'_ ,FG^&?^OJ]_]*9*^FZ^9/\ @G'_
M ,FG^&?^OJ]_]*9*^FZYLQ_WNIZG7E_^Z4_0Y?XG?$+3OA3X!UOQ=J\-U<:;
MI,!N)XK)%:9ER!A0S*">>Y%?D1XR_:*\-^(?VS+/XMVUEJJ>&X=5LKYK66*(
M7A2%(U8!1(4W$H<?/CIR*_9/5M'L/$&FW&G:I8V^I:?<+LFM;N)98I%]&1@0
M1]17Y3_$;P;H%G_P4DT[P]!H>FPZ VO:;$VE1VD:VI1HH2RF(#;@DG(QSDUU
M90X?6&FM>5_==7_0X\Z4_JMT_=NK_I^I^@_[._[37A?]IC2=8U#PQ8:O80Z7
M.EO,NKPQ1LS,I8%?+D?(P.Y%8/P?_;.\$_&SXH:EX$T/2]?M=7T^.>26;4+>
M!+<B*0(VUDF9LDL,94<>E>P>&/ _ASP3#/#X=T#2] BG8/+'I=E';+(P& 6"
M*,D#UK\T?^"?O_)ZGC'_ *]-4_\ 2J.L:-*CB)U7%-)1;6O5+_,WK5:^'A24
MFG)R2>G1M_H?J37@7QC_ &T/!/P1^)VG>!==TO7[O5[Z*":.;3[>!X )9&1=
MS/,K9!4YPIX]:]]K\L_^"A'_ ">AX2_Z\M,_]*9*RP%&&(Q,*4]G_D:YC7GA
ML).M3W7^:/TP\<>+K/P#X-UOQ+J$4\UCI-G+>SQVRJTK)&I9@H8@$X'&2![U
MY!\/_P!MCX9^.OAGK'CR:[O?"_A_2[S[#*^NQ1I+)+L5PL21/(7)#< <\'CC
M-=C^TM_R;W\1_P#L 7O_ *):OS)_8._9UM?VC/%VHV_BB>ZF\$^'0MY-IL4[
M1K<7,WRJN005!6(EF7#811D9R+P>'IUZ=651VY;:_-W^_9>9.-Q-3#SI1IJ_
M,Y*WR5OSN_(^P%_X*D?!TZO]C-GXH%OOV?V@=/B\C']['G>9C_@&?:OHO2_C
M3X'UCX<CQ[:^)M/;PAY1E;59)-D: '!5@V"KYXV$!L\8S7E/Q=_8G^$OBCX9
MZOIVF^#-*T#48+.1['4M.@\F:*54)1F9<&09 R'SGZ\U^=O[&?PJU#]H?QTG
MP^U+6+ZW\!6C-K^IV%O*565T"Q+CT9BZKN[+G'.*Z*>'PN*A-TFXN%F[ZZ:_
MCHSEJXG%8.I!5DI*=TK::Z::]+M?GTU^W]5_X*C?!S3]6:T@MO$VIVZM@7]K
MI\8A;W DF1\?\ S7T5\*?C%X1^-GAD:[X.UB+5K$-Y<H5626!\9V21L RGZC
MGJ,CFN"UK]B?X+:QX1ET!? 6EV$31>7'?6<92\C..'$^=[$=?F)![YKXF_X)
MSWU[\._VK?%?@?[2TEG-;7EE.G($DMM+\CX]0!)_WV:F%'"XBG-4;J45?6VJ
M6Y4Z^*PU2#K<KC)I:7T;V/U)9A&I9B%51DDG  KYI^)?_!0[X-_#;4Y=.&K7
MOBB]A;9+'X>MUG1#Z>:[I&W_  %C7F/_  5 ^.NI>"O".B^ =%N9+.?Q"LD^
MHS0L5?[*A"B+(Z!V)SZA".A-=!^R7^P?X'\'_#_2->\<:!:>*/%>IVR74L.J
MQ":WLE=0RPK"V4+ $;F8$YSC ZX4,/3]C]9KM\M[)+=_\#?^M^C$8BK[987#
MI<UKMO9+_/;^KVZ+P!_P4@^#'CK4H[&XU'4O"DTK!(WU^T6*)B?62-Y$0>[E
M1[U]/V]Q%=V\<\$J302J'CDC8,KJ1D$$=01WKY<_:/\ V"_A]\3/!=_+X2\.
MZ?X2\66T+26,VDP+;03,!GRI8D 0ANFX#<#@YQD'Q_\ X)??''5KRXUWX4Z]
M<2S+IT!OM*6<Y:W57"30<]@65@O;YZT]A0Q%*=3#W4HZM/MW7]?I?/V^(PU6
M%/$V<9Z)KOV:_K\[?2?Q>_;"\&_!?XH:)X#UO3-=NM7U=8'@FT^"%[=1+*8E
MWL\RL,,ISA3QZ]*Y'XD?\%&OA%\-_%5SH#RZQXBN;60Q7%QH=K'+;Q.#@KO>
M5-V.Y3</>OD;_@J5))#^T5HDD+M'*FA6[(Z'#*PGFP0>QS7VA\#_ -BSX8^!
M_A=I&F:WX,T?Q%K<]JDNI:AJUG'<S-.R@N$9P3&H)P N. "<G)-QH8>&%IXB
MK>[NK+KK^GZHF=?$2Q=3#4K))1=WTT5_5MO\&>K>!_C%X4^(/PWA\>:9J8A\
M+R123-?:A&UJL:H2LA;S ,!2K MTX.":\"\7?\%-O@SX7U)[.T?7O$RH2K7.
MD6">5D=<&:2,D>X!![&O/?\ @IAN^&?P#\#>"_"UO_8_A26]-M+;6Q(39%'N
MBB)/)!)+<GDIDY-=K^QK\$?@-XE^"_A^\T_0?#?C#7);2.35Y-6MXKVYANBH
M\Q&CD#>4 V0   0 ><Y,TZ%#V<L3)-PYK)=?5O\ K\1U,17]I#"P:4W&[?3T
M2.W^$_[>GPA^+FK6^DV>LW&@:O<N(X++7H!;F5CT59%9H\D\!=^2>@-?1%?"
MO[8W_!/^R\76.F:U\(?"]GINOBY$5[IMG+':6LD)4GS0K,J(RL ,+C(;H<5]
M7? K2_%>A_"+PMIOC<QOXHLK-;:]DBF\X.4)56+]V*!23ZDUA6AAY4E5HNSO
M9Q>_JO(WHSQ,:KI5TFK74EMZ/S.\HHHKSST0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQ!X;TGQ
M;I4VF:YI=GK&FS<26=_;I/$_U1@0:TJ* / =6_8+^ VM7CW-Q\/;:.1SDK:7
M]W;)^"1RJH_ 5WGPW_9]^''PBD\WPCX/TO1KK:5^V)%YESM/5?.<M)CVW8KT
M*BMW7K2CRN;MZLP6'HQESJ"OWL@HHHK W*FK:38Z]IMUIVIV5OJ.GW49BGM+
MN)98ID(P5=&!# CL1BLCPC\.?"?P_6Z7POX7T;PV+HJ;@:1I\-KYVW.W?Y:C
M=C)QGIDUT5%4I-)I/<EQ3:;6P4445)04444 %<M:_"KP39>*F\3V_@_0(/$K
M2-*=9BTR!;PNP*LWG!=^2"03GD$UU-%-2<=4Q.*DK-!1112&<SXN^&/@[Q_-
M;S>*/"6A^))K92D$FKZ;#=-$I.2%,BG:"0.GI71001VL,<,,:PPQJ$2.-0JJ
MH&  !T %244^9VY;Z"Y5?FMJ%9OB+PUI'B[29M*UW2K+6M,FQYMEJ-ND\,F"
M"-R."IP0#R.HK2HI#,?POX.T#P/IIT[PYH>F^']/,AE-II=I';1%R "VQ !D
M@#G'85L444VW)W8E%15DBMJ&FVFK6<MI?6L-[:2C;)!<1B2-QZ%2,$5R>C_!
M'X=>'=234=*\ ^%],U"-MR7=GHUM%*I]0ZH"#^-=K13C*4=G84HQE\2N%%%%
M24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445A^.O%UEX
M!\&:YXDU%MMCI-G+>S>ZHA; ]SC'XTF[*XTKNR/E?]M#XU:[X@\5Z+\ _AS<
M%?%GB9ECU6\C)S96K@DKD?=)0,[$<A!_M"OI/X1_"[1?@S\/='\(Z#%LL=/A
M"F1@ \\AY>5_]IFR3]<#@"OCC_@G#X8O/B5XT^(?QN\2+]IU;4;U[&TE?GRV
M;$D^W/0!3"B^@#"OM'XH>*X_ OPW\4>(I6V)I>F7%WGW2-F _,"O1Q:^JTUA
MUNM9>;MHO1+1?,\W!OZY4>(^S?ECZ7LWZM[^21^37Q \&W?[2'Q?_:$\561D
MD/AV&;4+;9SO6&XCB _[\1RD#U K]'_V-_C%_P +K^ /AS6;B;SM7LX_[,U+
M)RWVB( %C[NI1_\ @=?.W_!*WP2MY\/?B%XDU"+[0-:OTTY_-&?,2.,L_P"!
M-QS]*QOV.;ZX_9P_:X\>?!C4I6CTG59'ETSS> SH#)"P_P!^!F!]2BBO5KQ4
MHRP*U=.,6ODO>_!KYH\FA+EE'']*DY)^C?N_BG\F?7'[5?C(^ _V=?'^L)((
MITTJ6WA;/224>4F/?+BO&?\ @F!X._X1_P#9SEU=TQ+KNK3W(8CDQQA85'TW
M1O\ G5'_ (*E^,O[#^ NEZ"C8EUS5HU9<]8H5,A_\>\NN_T?Q79_LG_L4Z%J
MMY"IN-(T&W*6K?+YU[,H81GZRR'/L":\RE>&"J26\Y*/JDK_ )NQZE7]YCJ4
M7M",I>C;M^2N>L?$GXS>!_@_91W7C+Q/I^@)*"T4=S)F:4#J4B7+OC_9!KD/
M /[87P<^)FLQZ3X?\=V$^HRL$BM[R*:S:5CT5//1-['T7)KY"_9G_9#N/VJ%
MN?B_\9-4U#48]8G=[+3HI3$;B-6*[F8<I$""J(FWA<YQ@'L_VJ/^"?OPVT'X
M0Z]XG\"6%QX9UC0K5[_REO9KB&Y1!N=6$SL5.T'!4CGJ#6CH86@_95YOFZVM
M9>M]7;R,XXC%8A>TP\%R]+WO+TMM?I<^[*YKPQ\3_!OC;4+FP\.^+=#U^^M5
M+SVNEZE#<RQ*#M)=48E1GCGO7C_[!_Q;U+XP?L[Z1?ZU</>:QI<\FE7-U(<O
M/Y>TH['NWEN@)/)()[U\Q?'?3)_V,OVSM"^)FF0M#X-\43,U_%$IV*'(%W'@
M#KDK,H]?I6<,'_M,L+-ZZV\WNOO1I+&?[+'%05UI?R6S^YGZ,ZEJ=GHNGW-_
MJ%W!86-M&TL]U<R+'%$@&2S,Q 4 =2:Y>Q^-'P^U31]1U:R\=^&;S2M-V?;;
MZ#6+=X+7><)YKA]J;CP-Q&3TKXE_:J^,VM?M7?$K3_@7\)[E+[2&D636=6MV
M)@DVD%MSCCR8^"2/O/@#) S]'2?L?^!-._9RD^%;76H:;H/R7>I:EI[QQ75W
M-&0[2NSHXY*#C'"J .!64J$:5%5:SLY/1?W>K?XV[_EK'$2JUG2H*ZBM7Y](
MKS[]OS^4-0^*WAGXB?\ !2*QUW4O%^DQ>"?#J_Z)J5UJ<2V),=J<&.1GV$M,
M^>#SCVK](-&UK3_$6EVVIZ3?VNIZ==)YD%Y9S+-#*I_B5U)##W!K\FOV,/V0
M_"O[2VK>.+C6+_6[#P[H\T<-A)I\T*32EVD(WL\3*<(BYP!RWX5^JO@7P=8?
M#WP9H?AC2O,.G:19Q65NTQ!D9(U"@L0 "QQDD <D\5W9A"E2A3HQ;YHI*WKK
M=^;NC@R^=:K4J5II6DWK?MHDO)6>INUY_P#'CXP:9\"?A=K7C#4QYJV<>VVM
MLX-Q<-Q'&/J>I[ $]J] K\Z?^"KGBZ[OM8^'W@BV<B&42ZC)'V>1F$46?I^\
M_P"^J\S#T7B*\**^T_\ @O\ !?>>KB*RPU"==_95_P!%^+5SF?V=?V;O$7[;
M7BO4/BO\6=4O'\/27!CMK:%C&;S:QS%$?^64"'Y?EY)W8((+5]S:7^RG\'-'
MTM-/@^&7A>2!%V![K3(KB;'O+(&<GW+9KL?AKX)L_AO\/_#WA?3XUCM=)L8K
M1=HQN*J S'W9LL?<FO/OB)^V'\(?A1XLN_#/BGQ>NF:W:!#/:KIUW/LWJ&7+
M1Q,O*D'&>]=N(Q%3$5/98>_*MDNRZZ'!A\/3H4O;8BW.]6WW?37[CXO_ &WO
MV2K;X$:AH'Q'^%,5[I*-J"0R6%B[NUI<G+12P'E@"5(V\@';C@XK] _@WXNU
M/QY\*_"^O:UIMQI&L7UC')>V5U T$D<X&V3Y& (!8$C(Z$&O*/\ AX3\ /\
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M:Z:V5UJ^W1>K/UE_:6_Y-[^(_P#V +W_ -$M7R-_P2/ _P"$=^)1QS]JL?\
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M$B2POLFMY5SMEC;!PPR>H(()!!!(K\^/'?\ P2X\?^$]2;4?A[XLLM82%C)
MEP[V%ZA[!6&Y"?\ :W)]!7MO_!3/X6^*/%?PWTOQ1X;N-0E@T1I%U33K.5]L
MEN^")C&O#>65Y.. Q/0&LW]G/_@I%X F^'NDZ3\1KVZ\/>(--MDM9;S['+<V
M]X$7:L@\I696( W J!D\$]JP?UB%%U<-*[OK'?Y_EM^@L:\-.M&CB8V5KJ6W
MR_/?]3Y[D^-W[5/[)MQ;CQ=_:UUI._:%\2(-1M)6YP@NE8L#@'"K*.G2OT6_
M9O\ CMIW[1/PLL/%UC:G3YVD>UO;%GW_ &>X3&Y0V!D$%6!QT8=\U\<_MK?M
MS?#_ .*'PIO_  %X&^T>)+G5I(1+J$EI)!# J2*_R"0*[.2H ^4#!//:OH'_
M ()^_!_6?@]^S_;V_B"WDL=5UJ]DU:2QF4K);*Z1HB.#T;;&&(/(W8/(-=&(
M7M<)*M7IJ$[V72_R^_[CFP[]EBXT</4<X6N];V[:GTK1117SQ]&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ?P_G]GUIBZLZ.,E55G?;KIT^=DC+!TH5\%&B[JV_37K\KL^,/V??V8?V@_
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MK]%@,# &!7Y__L7^&[[]H3]I+QM\?=9M7CTJ"XDM=&28$_O&0(N/^N<&%/\
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MK]:**/\ 6/\ Z<_^3?\  #_B&/\ U&?^4_\ [<_)>BOUHHH_UC_Z<_\ DW_
M#_B&/_49_P"4_P#[<_)>BOUHHH_UC_Z<_P#DW_ #_B&/_49_Y3_^W/R7HK]:
M**/]8_\ IS_Y-_P _P"(8_\ 49_Y3_\ MS\EZ*_6BBC_ %C_ .G/_DW_   _
MXAC_ -1G_E/_ .W/R7HK]:**/]8_^G/_ )-_P _XAC_U&?\ E/\ ^W/R7HK]
M:**/]8_^G/\ Y-_P _XAC_U&?^4__MS\EZ*_6BBC_6/_ *<_^3?\ /\ B&/_
M %&?^4__ +<_)>BOUHHH_P!8_P#IS_Y-_P  /^(8_P#49_Y3_P#MS\EZ*_6B
MBC_6/_IS_P"3?\ /^(8_]1G_ )3_ /MS\EZ*_6BBC_6/_IS_ .3?\ /^(8_]
M1G_E/_[<_)>BOUHHH_UC_P"G/_DW_ #_ (AC_P!1G_E/_P"W/R7HK]:**/\
M6/\ Z<_^3?\  #_B&/\ U&?^4_\ [<_)>BOUHHH_UC_Z<_\ DW_ #_B&/_49
M_P"4_P#[<_)>BOUHHH_UC_Z<_P#DW_ #_B&/_49_Y3_^W/R7HK]:**/]8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5R?Q8\#0_$SX:>)_"LY 35M/FM Q_A9E(1
MOP;!_"NLHI/56&G9W/CO_@F7XFG_ .%2^)/ NI P:SX3UJ:":U;[T22$D _]
MM%G'X5]B445U8BM]8JNK:U[?EK]YRX:C]7I*DG=*_P!U]/NV"BBBN8Z0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_?B'_P".T?\ #7_@W_H&ZY_WXA_^.U\@T4?ZVYGW7W!_J3E'\LO_  (^OO\
MAK_P;_T#=<_[\0__ !VC_AK_ ,&_] W7/^_$/_QVOD&BC_6W,^Z^X/\ 4G*/
MY9?^!'U]_P -?^#?^@;KG_?B'_X[1_PU_P"#?^@;KG_?B'_X[7R#11_K;F?=
M?<'^I.4?RR_\"/K[_AK_ ,&_] W7/^_$/_QVC_AK_P &_P#0-US_ +\0_P#Q
MVOD&BC_6W,^Z^X/]2<H_EE_X$?7W_#7_ (-_Z!NN?]^(?_CM'_#7_@W_ *!N
MN?\ ?B'_ ..U\@T4?ZVYGW7W!_J3E'\LO_ CZ^_X:_\ !O\ T#=<_P"_$/\
M\=H_X:_\&_\ 0-US_OQ#_P#':^0:*/\ 6W,^Z^X/]2<H_EE_X$?7W_#7_@W_
M *!NN?\ ?B'_ ..T?\-?^#?^@;KG_?B'_P".U\@T4?ZVYGW7W!_J3E'\LO\
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MO_ CZ^_X:_\ !O\ T#=<_P"_$/\ \=H_X:_\&_\ 0-US_OQ#_P#':^0:*/\
M6W,^Z^X/]2<H_EE_X$?7W_#7_@W_ *!NN?\ ?B'_ ..T?\-?^#?^@;KG_?B'
M_P".U\@T4?ZVYGW7W!_J3E'\LO\ P(^OO^&O_!O_ $#=<_[\0_\ QVC_ (:_
M\&_] W7/^_$/_P =KY!HH_UMS/NON#_4G*/Y9?\ @1]??\-?^#?^@;KG_?B'
M_P".T?\ #7_@W_H&ZY_WXA_^.U\@T4?ZVYGW7W!_J3E'\LO_  (^OO\ AK_P
M;_T#=<_[\0__ !VC_AK_ ,&_] W7/^_$/_QVOD&BC_6W,^Z^X/\ 4G*/Y9?^
M!'U]_P -?^#?^@;KG_?B'_X[1_PU_P"#?^@;KG_?B'_X[7R#11_K;F?=?<'^
MI.4?RR_\"/K[_AK_ ,&_] W7/^_$/_QVC_AK_P &_P#0-US_ +\0_P#QVOD&
MBC_6W,^Z^X/]2<H_EE_X$?7W_#7_ (-_Z!NN?]^(?_CM'_#7_@W_ *!NN?\
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M&_\ 0-US_OQ#_P#':^0:*/\ 6W,^Z^X/]2<H_EE_X$?7W_#7_@W_ *!NN?\
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M^_$/_P =KY!HH_UMS/NON#_4G*/Y9?\ @1]??\-?^#?^@;KG_?B'_P".T?\
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M\@T4?ZVYGW7W!_J3E'\LO_ CZ^_X:_\ !O\ T#=<_P"_$/\ \=H_X:_\&_\
M0-US_OQ#_P#':^0:*/\ 6W,^Z^X/]2<H_EE_X$?7W_#7_@W_ *!NN?\ ?B'_
M ..T?\-?^#?^@;KG_?B'_P".U\@T4?ZVYGW7W!_J3E'\LO\ P(^OO^&O_!O_
M $#=<_[\0_\ QVC_ (:_\&_] W7/^_$/_P =KY!HH_UMS/NON#_4G*/Y9?\
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M?_CM'_#7_@W_ *!NN?\ ?B'_ ..U\@T4?ZVYGW7W!_J3E'\LO_ CZ^_X:_\
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M'_#7_@W_ *!NN?\ ?B'_ ..U\@T4?ZVYGW7W!_J3E'\LO_ CZ^_X:_\ !O\
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M@;KG_?B'_P".U\@T4?ZVYGW7W!_J3E'\LO\ P(^OO^&O_!O_ $#=<_[\0_\
MQVC_ (:_\&_] W7/^_$/_P =KY!HH_UMS/NON#_4G*/Y9?\ @1]??\-?^#?^
M@;KG_?B'_P".T?\ #7_@W_H&ZY_WXA_^.U\@T4?ZVYGW7W!_J3E'\LO_  (^
MOO\ AK_P;_T#=<_[\0__ !VC_AK_ ,&_] W7/^_$/_QVOD&BC_6W,^Z^X/\
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M_?B'_P".T?\ #7_@W_H&ZY_WXA_^.U\@T4?ZVYGW7W!_J3E'\LO_  (^OO\
MAK_P;_T#=<_[\0__ !VC_AK_ ,&_] W7/^_$/_QVOD&BC_6W,^Z^X/\ 4G*/
MY9?^!'U]_P -?^#?^@;KG_?B'_X[1_PU_P"#?^@;KG_?B'_X[7R#11_K;F?=
M?<'^I.4?RR_\"/K[_AK_ ,&_] W7/^_$/_QVC_AK_P &_P#0-US_ +\0_P#Q
MVOD&BC_6W,^Z^X/]2<H_EE_X$?7W_#7_ (-_Z!NN?]^(?_CM'_#7_@W_ *!N
MN?\ ?B'_ ..U\@T4?ZVYGW7W!_J3E'\LO_ CZ^_X:_\ !O\ T#=<_P"_$/\
M\=H_X:_\&_\ 0-US_OQ#_P#':^0:*/\ 6W,^Z^X/]2<H_EE_X$?7W_#7_@W_
M *!NN?\ ?B'_ ..T?\-?^#?^@;KG_?B'_P".U\@T4?ZVYGW7W!_J3E'\LO\
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MO_ CZ^_X:_\ !O\ T#=<_P"_$/\ \=H_X:_\&_\ 0-US_OQ#_P#':^0:*/\
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MBC_6W,^Z^X/]2<H_EE_X$?7W_#7_ (-_Z!NN?]^(?_CM'_#7_@W_ *!NN?\
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M&_\ 0-US_OQ#_P#':^0:*/\ 6W,^Z^X/]2<H_EE_X$?7W_#7_@W_ *!NN?\
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M^_$/_P =KY!HH_UMS/NON#_4G*/Y9?\ @1]??\-?^#?^@;KG_?B'_P".T?\
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M\@T4?ZVYGW7W!_J3E'\LO_ CZ^_X:_\ !O\ T#=<_P"_$/\ \=H_X:_\&_\
M0-US_OQ#_P#':^0:*/\ 6W,^Z^X/]2<H_EE_X$?7W_#7_@W_ *!NN?\ ?B'_
M ..T?\-?^#?^@;KG_?B'_P".U\@T4?ZVYGW7W!_J3E'\LO\ P(^OO^&O_!O_
M $#=<_[\0_\ QVC_ (:_\&_] W7/^_$/_P =KY!HH_UMS/NON#_4G*/Y9?\
M@1]??\-?^#?^@;KG_?B'_P".T?\ #7_@W_H&ZY_WXA_^.U\@T4?ZVYGW7W!_
MJ3E'\LO_  (^OO\ AK_P;_T#=<_[\0__ !VC_AK_ ,&_] W7/^_$/_QVOD&B
MC_6W,^Z^X/\ 4G*/Y9?^!'U]_P -?^#?^@;KG_?B'_X[1_PU_P"#?^@;KG_?
MB'_X[7R#11_K;F?=?<'^I.4?RR_\"/K[_AK_ ,&_] W7/^_$/_QVC_AK_P &
M_P#0-US_ +\0_P#QVOD&BC_6W,^Z^X/]2<H_EE_X$?7W_#7_ (-_Z!NN?]^(
M?_CM'_#7_@W_ *!NN?\ ?B'_ ..U\@T4?ZVYGW7W!_J3E'\LO_ CZ^_X:_\
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M'_#7_@W_ *!NN?\ ?B'_ ..U\@T4?ZVYGW7W!_J3E'\LO_ CZ^_X:_\ !O\
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M]^(?_CM'_#7_ (-_Z!NN?]^(?_CM?(-%'^MN9]U]P?ZDY1_++_P(^OO^&O\
MP;_T#=<_[\0__':/^&O_  ;_ - W7/\ OQ#_ /':^0:*/];<S[K[@_U)RC^6
M7_@1]??\-?\ @W_H&ZY_WXA_^.T?\-?^#?\ H&ZY_P!^(?\ X[7R#11_K;F?
M=?<'^I.4?RR_\"/K[_AK_P &_P#0-US_ +\0_P#QVC_AK_P;_P! W7/^_$/_
M ,=KY!HH_P!;<S[K[@_U)RC^67_@1]??\-?^#?\ H&ZY_P!^(?\ X[1_PU_X
M-_Z!NN?]^(?_ ([7R#11_K;F?=?<'^I.4?RR_P# CZ^_X:_\&_\ 0-US_OQ#
M_P#':/\ AK_P;_T#=<_[\0__ !VOD&BC_6W,^Z^X/]2<H_EE_P"!'U]_PU_X
M-_Z!NN?]^(?_ ([1_P -?^#?^@;KG_?B'_X[7R#11_K;F?=?<'^I.4?RR_\
M CZ^_P"&O_!O_0-US_OQ#_\ ':/^&O\ P;_T#=<_[\0__':^0:*/];<S[K[@
M_P!2<H_EE_X$?7W_  U_X-_Z!NN?]^(?_CM'_#7_ (-_Z!NN?]^(?_CM?(-%
M'^MN9]U]P?ZDY1_++_P(^OO^&O\ P;_T#=<_[\0__':/^&O_  ;_ - W7/\
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M'_X[7R#11_K;F?=?<'^I.4?RR_\  CZ^_P"&O_!O_0-US_OQ#_\ ':/^&O\
MP;_T#=<_[\0__':^0:*/];<S[K[@_P!2<H_EE_X$?='PW^/&@?%#7)]*TJSU
M*WN(;9KIFO(HU3:&52 5=CG+CMZT5X3^R!_R4K4_^P1+_P"CH:*_3<@QU;,<
M$J]?XKM:>1^1\2Y=0RO,'AL,GRV3UUW/,_B?_P E*\6_]A>[_P#1SUS-=-\3
M_P#DI7BW_L+W?_HYZYFOPG%?[Q4]7^9_1F"_W6E_A7Y!1117*=H4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA(8N$;*5]'Y-K] HHHK@/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH48_J37V+\,/^2;^%O\ L&6W_HI:^8R'),-C<1B*&)N_9NVCMU:_0^MS_/\
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MY;0S(97 !*2%0<\8*DX[J.U>9G62X*&#CF&72]Q]+]'I=7UT>Z?X6/3R//\
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MO234O2._WVT/K\7F\*64/,X=8IKU>R^]ZE*X_9'\76L$DTNJZ"D4:EW9KB;
M &2?]57B3#:Q .X9ZCO7V]^TAXN_X17X7W\<;[;K4R+&+Z,"7/\ WP&'U(KX
M@KJXBP>$R_%+#X5/17=W?5]/N_,\[A7,,=FF%GB<8U:]HV5MMW^GR"BBBOEC
M[4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /<OV0/^2E:G_V")?_ $=#11^R
M!_R4K4_^P1+_ .CH:*_<.$O^18O\3/YYXV_Y&\O\,3S/XG_\E*\6_P#87N__
M $<]<S73?$__ )*5XM_["]W_ .CGKF:_&<5_O%3U?YG[S@O]UI?X5^04445R
MG:6--L9=4U"ULH!NFN)5A0>K,0!^IK]']-L8],T^ULX5"Q6\2Q(HZ!5  _E7
MPS\ ]#&O?%KP_$R%XH)C=/[>6I<$_P# @OYU]S:E?1Z9I]U>3';%;Q-*Y/8*
M"3_*OUW@ZDJ&"K8J>B;_  BO^"S\4X^Q#J8FAA8]$W_X$[+\CX9^/FN_V_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!TG@/XA:S\.=:&I:/.$=ALE@E!:*9?[K#//U'(]:^AM%_;&T>6
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >Y?L@?\E*U/_L$2_P#HZ&BC]D#_ )*5J?\
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M)C]YXG17MG_#(_C7_G[T?_P(D_\ C='_  R/XU_Y^]'_ / B3_XW1_869_\
M/B7W!_K%E'_03'[SQ.BO;/\ AD?QK_S]Z/\ ^!$G_P ;H_X9'\:_\_>C_P#@
M1)_\;H_L+,_^?$ON#_6+*/\ H)C]YXG17MG_  R/XU_Y^]'_ / B3_XW1_PR
M/XU_Y^]'_P# B3_XW1_869_\^)?<'^L64?\ 03'[SQ.BO;/^&1_&O_/WH_\
MX$2?_&Z/^&1_&O\ S]Z/_P"!$G_QNC^PLS_Y\2^X/]8LH_Z"8_>>)T5[9_PR
M/XU_Y^]'_P# B3_XW1_PR/XU_P"?O1__  (D_P#C=']A9G_SXE]P?ZQ91_T$
MQ^\\3HKVS_AD?QK_ ,_>C_\ @1)_\;H_X9'\:_\ /WH__@1)_P#&Z/["S/\
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M$2?_ !NC_AD?QK_S]Z/_ .!$G_QNC^PLS_Y\2^X/]8LH_P"@F/WGB=%>V?\
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M]'_\")/_ (W1_869_P#/B7W!_K%E'_03'[SQ.BO;/^&1_&O_ #]Z/_X$2?\
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MC]YXG17MG_#(_C7_ )^]'_\  B3_ .-T?\,C^-?^?O1__ B3_P"-T?V%F?\
MSXE]P?ZQ91_T$Q^\\3HKVS_AD?QK_P _>C_^!$G_ ,;H_P"&1_&O_/WH_P#X
M$2?_ !NC^PLS_P"?$ON#_6+*/^@F/WGB=%>V?\,C^-?^?O1__ B3_P"-T?\
M#(_C7_G[T?\ \")/_C=']A9G_P ^)?<'^L64?]!,?O/$Z*]L_P"&1_&O_/WH
M_P#X$2?_ !NC_AD?QK_S]Z/_ .!$G_QNC^PLS_Y\2^X/]8LH_P"@F/WGB=%>
MV?\ #(_C7_G[T?\ \")/_C='_#(_C7_G[T?_ ,")/_C=']A9G_SXE]P?ZQ91
M_P!!,?O/$Z*]L_X9'\:_\_>C_P#@1)_\;H_X9'\:_P#/WH__ ($2?_&Z/["S
M/_GQ+[@_UBRC_H)C]YXG17MG_#(_C7_G[T?_ ,")/_C='_#(_C7_ )^]'_\
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M_GQ+[@_UBRC_ *"8_>>)T5[9_P ,C^-?^?O1_P#P(D_^-T?\,C^-?^?O1_\
MP(D_^-T?V%F?_/B7W!_K%E'_ $$Q^\\3HKVS_AD?QK_S]Z/_ .!$G_QNC_AD
M?QK_ ,_>C_\ @1)_\;H_L+,_^?$ON#_6+*/^@F/WGB=%>V?\,C^-?^?O1_\
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MO/$Z*]L_X9'\:_\ /WH__@1)_P#&Z/\ AD?QK_S]Z/\ ^!$G_P ;H_L+,_\
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M_@1)_P#&Z/["S/\ Y\2^X/\ 6+*/^@F/WGB=%>V?\,C^-?\ G[T?_P ")/\
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M=']A9G_SXE]P?ZQ91_T$Q^\\3HKVS_AD?QK_ ,_>C_\ @1)_\;H_X9'\:_\
M/WH__@1)_P#&Z/["S/\ Y\2^X/\ 6+*/^@F/WGB=%>V?\,C^-?\ G[T?_P "
M)/\ XW1_PR/XU_Y^]'_\")/_ (W1_869_P#/B7W!_K%E'_03'[SQ.BO;/^&1
M_&O_ #]Z/_X$2?\ QNC_ (9'\:_\_>C_ /@1)_\ &Z/["S/_ )\2^X/]8LH_
MZ"8_>>)T5[9_PR/XU_Y^]'_\")/_ (W1_P ,C^-?^?O1_P#P(D_^-T?V%F?_
M #XE]P?ZQ91_T$Q^\\3HKVS_ (9'\:_\_>C_ /@1)_\ &Z/^&1_&O_/WH_\
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M'_#(_C7_ )^]'_\  B3_ .-T?V%F?_/B7W!_K%E'_03'[SQ.BO;/^&1_&O\
MS]Z/_P"!$G_QNC_AD?QK_P _>C_^!$G_ ,;H_L+,_P#GQ+[@_P!8LH_Z"8_>
M>)T5[9_PR/XU_P"?O1__  (D_P#C='_#(_C7_G[T?_P(D_\ C=']A9G_ ,^)
M?<'^L64?]!,?O/$Z*]L_X9'\:_\ /WH__@1)_P#&Z/\ AD?QK_S]Z/\ ^!$G
M_P ;H_L+,_\ GQ+[@_UBRC_H)C]YXG17MG_#(_C7_G[T?_P(D_\ C='_  R/
MXU_Y^]'_ / B3_XW1_869_\ /B7W!_K%E'_03'[SQ.BO;/\ AD?QK_S]Z/\
M^!$G_P ;H_X9'\:_\_>C_P#@1)_\;H_L+,_^?$ON#_6+*/\ H)C]YXG17MG_
M  R/XU_Y^]'_ / B3_XW1_PR/XU_Y^]'_P# B3_XW1_869_\^)?<'^L64?\
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M ,^)?<'^L64?]!,?O/$Z*]L_X9'\:_\ /WH__@1)_P#&Z/\ AD?QK_S]Z/\
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MX9'\:_\ /WH__@1)_P#&Z/["S/\ Y\2^X/\ 6+*/^@F/WGB=%>V?\,C^-?\
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M<'^L64?]!,?O/$Z*]L_X9'\:_P#/WH__ ($2?_&Z/^&1_&O_ #]Z/_X$2?\
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MZ/\ ^!$G_P ;H_L+,_\ GQ+[@_UBRC_H)C]YXG17MG_#(_C7_G[T?_P(D_\
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M_P!8LH_Z"8_>>)T5[9_PR/XU_P"?O1__  (D_P#C='_#(_C7_G[T?_P(D_\
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MXU_Y^]'_ / B3_XW1_869_\ /B7W!_K%E'_03'[SQ.BO;/\ AD?QK_S]Z/\
M^!$G_P ;H_X9'\:_\_>C_P#@1)_\;H_L+,_^?$ON#_6+*/\ H)C]YXG17MG_
M  R/XU_Y^]'_ / B3_XW1_PR/XU_Y^]'_P# B3_XW1_869_\^)?<'^L64?\
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M ,^)?<'^L64?]!,?O/$Z*]L_X9'\:_\ /WH__@1)_P#&Z/\ AD?QK_S]Z/\
M^!$G_P ;H_L+,_\ GQ+[@_UBRC_H)C]YXG17MG_#(_C7_G[T?_P(D_\ C='_
M  R/XU_Y^]'_ / B3_XW1_869_\ /B7W!_K%E'_03'[SQ.BO;/\ AD?QK_S]
MZ/\ ^!$G_P ;H_X9'\:_\_>C_P#@1)_\;H_L+,_^?$ON#_6+*/\ H)C]YXG1
M7MG_  R/XU_Y^]'_ / B3_XW1_PR/XU_Y^]'_P# B3_XW1_869_\^)?<'^L6
M4?\ 03'[SQ.BO;/^&1_&O_/WH_\ X$2?_&Z/^&1_&O\ S]Z/_P"!$G_QNC^P
MLS_Y\2^X/]8LH_Z"8_>>)T5[9_PR/XU_Y^]'_P# B3_XW1_PR/XU_P"?O1__
M  (D_P#C=']A9G_SXE]P?ZQ91_T$Q^\\3HKVS_AD?QK_ ,_>C_\ @1)_\;H_
MX9'\:_\ /WH__@1)_P#&Z/["S/\ Y\2^X/\ 6+*/^@F/WDW[('_)2M3_ .P1
M+_Z.AHKO/@;\!_$WPV\;-JVI75@UHUK) RVLSLS%BI (* 8RN>O845^M\,X>
MMA< J5>#C*[T9^)<6XJAC,S=;#34HN*U1]!4445]6?&!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445G>(/$6E^%-'NM6UK4;72M,M4WSWEY*L44:^K,Q % &C17RAX
MN_X*9_!?PQ?-;6<^N>)@I*M-I&G@1@CT,[Q9^HR*F\&?\%*O@MXLO$MKN^U?
MPNSL%5]:L,(23CEH6D"CW; '<UV+!XAQYE3?W'$\;AHRY745_4^J:*I:/K6G
M^(M+MM2TJ^M]2TZZ0207=I*LL4JGHRLI((]Q5VN1IIV9V)IJZ"BBBD,***\_
M^+GQZ\"? JUTZY\<:[_8D.H.\=JWV2>X\QE +#$4;XP".N.M.*<FHQ5VQ2DH
MIRD[)'H%%9GAGQ)IWC#P[IFNZ1<?:]*U*VCO+2XV,GF12*&1MK ,,@@X(!]1
M7G_@?]I[X9_$CQY=^#/#GB7^T?$MIYWG6/V"ZBV^4VV3YWB5#@^C<]LU:IS;
M<5%W6_E;>Y#JP24G)6>WG?:QZG11169H%%9/BSQ5I?@?PSJ?B#6[K[%I&FV[
MW5W<>6\GEQJ,LVU 6.!V )KE_A+\=O WQTL=0O? ^N?VW;:?*L-R_P!DGM_+
M=@2!B5$)X!Z9JU"4DY):+?R(E.,9*+=F]O/T.^HHJAK^NV/A?0M1UG4Y_LVF
MZ?;R7=S-L9_+B12SMM4$G !. ":@TWT1?HKYU_X>$_ #_H?O_*-J'_R/1_P\
M)^ '_0_?^4;4/_D>NKZKB/\ GV_N9Q_7,-_S\C]Z/HJBOG7_ (>$_ #_ *'[
M_P HVH?_ "/6]X$_;/\ @Y\3/%FG^&?#?C#^TM;U!F2VM?[,O(O,(4L1N>%5
M'"D\D=*/JN(W]F_N8UB\.W95(_>CVRBBBN4Z@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BN6^)7Q0\,?"#PK-XD\7:JNCZ-#(D37#122G>YPJ
MA(U9B2?0'H3T%8?PC_:%^'WQV_M/_A!O$2:XVF^7]J7[+/;M'OW;3B5$)!VM
MR,]*TC3G*+G&+:6[Z(SE4A&2A*23>RZL]%HHHK,T"BBB@ HHHH **@AOK:YG
MN((;B*6:W8+-&C@M&2,@,!T)!!Y[&N4^*GQ@\(_!3PY%KWC35O[&TJ6X6T2X
M^S33YE968+MB1FZ(W.,<4TFVDNHFTDV]D=E17/> /'^@_%#PE8>)_#%__:>A
MWP8V]UY,D6\*[(WRR*K##*1R!TKH:<HN+<9*S0HRC.*E%W3"BBBI*"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\W^+/[
M1?PZ^"$2?\)CXHM-,NI%W1V*;I[IQV(AC!;'^T0![UX!<?\ !5+X0PW;0II'
MBZXC!P+B.PMPA]\-<!L?A712P]:LKTXMHYJN)HT':I-)GV/17DGP=_:J^&7Q
MTF%IX5\2PRZMMW'2KQ&M[K &3M1P-^!U*%@.YKUNLZE.=)\LU9FM.I"K'FIN
MZ\@HHKD_B;\5?"OP;\+OXB\8ZLNC:.LJ0?:&ADE)D;[JA(U9B>#T'0$U"3;2
M74MM)-O9'645Y[\(_C_X!^.T.I2^!O$":XNFLBW0^RSV[1%P2GRRHA(.UN0"
M.#7H55.$J;Y9JS\R85(5(\T'=>045%<W$=G;RSRMLBB0N[8)PH&2>*^>O^'A
M/P _Z'[_ ,HVH?\ R/3ITYU;JG%NW97)J5:=%)U))7[NQ]%45\Z_\/"?@!_T
M/W_E&U#_ .1ZMZ;^WM\!=6NDMX/B#;I(QP#<Z?>0)^+20JH_$UM]5Q'_ #[?
MW,Q^MX?_ )^1^]'O]%9GASQ-I'C#2(-5T+5+/6=,GSY5Y83K/$^#@X=20<&M
M.N9IQ=F=2:DKH****0PHKP[QE^VQ\%_A_P"*-2\.:_XS^P:SITI@NK;^R[V3
MRW')&Y(2IZ]B:]4\#^.-$^)'A73O$OAR_74]$U",R6UTJ.@=0Q4_*X# @@C!
M /%:NE4C!5'%\KZVT^\R5:G*;IJ2YETOKIY&[1145U=16-K-<W$BQ00HTDDC
M=%4#))^@%8WMJS97>B):*\%\/_MT_ _Q5X@TW1-+\;_:M4U&YCL[6#^R;Y?,
MED8(B[F@"C+$#)('O7O5;3I5*5N>+5^ZL8TZU.K?V<D[=G<****R-0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **BN;B.SMY9Y6V11(7=L$X4#)/%>:
M_"7]ICX;?'/4[[3_  1XC_MN\L81/<1_8;FWV(6V@YEC0'GL"35QA*:;BKVW
M\B)3C!I2=K[>?H>GT445!84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'+8R)$R?X0KX]37TQ\/OVEOA;\4FAB\,^.-(U"ZF.([*2?[/<O\ 2&4+(?\
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MOV[_ /1<=32H5,/C:=.HM;_YEU,13Q."J5*;TL_R/K7]FG_DW?X9?]BWI_\
MZ3I7DGP-_8?_ .%,_'C5_B3_ ,)I_;']H?;/^)9_97D>7Y\F_P#UOG-G;T^Z
M,^U>M_LT_P#)N_PR_P"Q;T__ -)TKXH_8Y^*WC;Q1^VEXHT/6?&&OZMHL/\
M:OE:;?:G/-;)LG 3;&S%1M' P..U=/+4EB<1[.5M)W\UU1S<U*.&PWM(WUA;
MR=M&?I#17D7[3W[1&E_LV_#:7Q%>0?VAJ5Q)]ETW3M^W[1,03\Q[(H!+'\.I
M%?#O@>T_:R_:^AD\4:9XQN/"'A]W86LR7\NDVCX."L2VZF20 \;V!&01N)!Q
MPX?"RKQ=1M1BNK_([L1BXX>2II.4GLE^?H?=/[5W_)M7Q,_[ %Y_Z*-?+_\
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M>*Y/'-SXOT>U_>7K1ZE+JL4,8(R9(KI X7U9!P,DD=:ZO[/<6HU:D8R?1O\
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M71>?;^NZ/TPHK\RY/CQ^T7^Q7XNTRR^*#R>,_"5T^U9KB87(F48W&&Z($@D
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ML?6O[-/_ ";O\,O^Q;T__P!)TK\__P!AW_D_#Q=_W&/_ $H%?H!^S3_R;O\
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M!_PI_P#X*)WWA?26,>E2:EJ6DF%.AM]DDD:G_=9(_P#OFNJ_X*V?\CI\//\
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MV>]0U:*,?;=4UF;SY<<E8T147/H,L?\ @1KJO^"CBA?V3/$H   NK$ #H/\
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M)QS7+C*,J&)M7;DGK?NOZT.K!5HU\+^X2BU=6Z)_UJ?-'_#UKX2_]"[XT_\
M *T_^2J]N_9U_:B\*_M-66N77A?3]8L(](DBCG&KPQ1EC(&*[/+E?(^0YSCM
M7+?\.]O@!_T(/_E9U#_Y(KTGX1_ /P'\";?4H/ VA?V'%J3QO=+]LGN/,9 P
M4_O9'Q@,W3'6BK+ NFU2C+FZ7VW]>PJ,,P52+JRCR];7OL_+O8_.&;_E*$/^
MQM7_ -!%>G_\%4/A_<:/JO@;XG:6&@NH)/[,N+B,89)$)FMVSZ@B7\A7F$W_
M "E"'_8VK_Z"*^__ -K;X8_\+;_9\\8:#'%YM^MH;VR'?SX?WB ?[VTK_P "
M-==2M]7A@ZW\L5]UDG^%SEI4/K-7&T/YI-?.[M^-CK/AC\2K'X@?"70/&_FQ
MQ6=_IB7T[9^6)MF95/\ NL&!_P!VOB+]A:QF^.O[4WQ)^,FH1EK:UDDCL=Z_
M=><E8P/=($*_\#%>6?"G]IH^%?V#_'W@YKO9K4-\NF:>N[#"WO0S28^@CN3_
M ,#%?;7[ _PN_P"%8_LV>'?/B\O4M=SK-UQS^] \H'Z1"/CUS3J4?J3Q%1=?
M=C_V][S_ /);?,FG6^NQPU)Z_:E_V[[J^^5_D?&G[1G_ "DQT7_L/Z!_*VK]
M/_%7A72?&WA^]T/7;"+4])O$\NXM)P2DBY!P<>X%?F!^T9_RDQT7_L/Z!_*V
MK[,_;V^)VM?"S]G'6;_0)Y+/4K^XATU;R$X>!)"=[*>QVJ5![%LUSUXN6#P<
M5NU;YOE1UX>2CB\5-[*S^239!:_%;]G']D2+4/#>GZYI?AMY[IKF[TW3VN+^
M43;54[PGF&,X5?E.T#TYKB_%'_!4CX2:/O32K#Q%K\H'R-!9I#$3Z%I)%8?]
M\FO&?V#_ -C'P!\8?AO-XY\;I/X@EGO9K6'34NWABA"8RTAC*N7).<;@,$<'
M-?:_A_\ 9W^$/PPM6U*P\#>'-+6Q0SG4+BSCDD@51DOYT@+# &<YJL1##8>;
MC6E*<EOT6WGJ9X>>*Q$%*A&,(/;=O?RLC\X/V/?%T?Q _;ZM/$T-C_9D6L7N
MJ7RV>_?Y(D@G?9NP,XSUP*]J_P""M?BJXATGX>^'$9EM;B:ZOY5!X9HQ&B?D
M)'_.O'_V6O%UGXR_X*)#7[1LV>K:MJ]S;,%(W(\-PRG';*\U[9_P5E\$W-]X
M5\#>*X8GDM]/N;BPN&4$A/.5&0GT&8F'U(KMK<L<5@^:/*N5:=OBLOD['#0Y
MGA\;RRYI<SU[[7?S5SZJ_9=\'V7@;]GOP!I=C$D:'1[>ZE*#&^:9!+(Y]RSF
MNW\;>#]-^('A'6/#>L1&;3-5M9+2X52 VQU()4D'##J#C@@5YO\ LA_$;3_B
M9^SOX*U"QG26:STZ'3+R-2-T-Q BQNK#MG:&'^RRGO7=_$[QYI_PP^'^O^*=
M3FC@M-+M)+@F0\.P'R(/4LV% [DUX>-YEB*G-O=_F>]E]GAJ7+V7Y'(? /\
M9I\'_LWZ;J=GX2.HN-2:-[J34+KS6=D#!3@!5'WCT S^%?GI^QWH$6N?M^:E
M+-&)%TZ^UB\4,. P:1%/X&0&OK_]B/\ :F\7_M-VOB2X\0^'M,TJTTGR8TO-
M-\U4GE?<2@5V;&U5!/S?Q#UKY8_8=_Y/P\7?]QC_ -*!7L4(UJ=:NJS][DE^
M6GX'BXB5"K0H>P5H>TCY=7?_ ()^I5?E'XTL8_C9_P %+/['UK_2=-CUY+4V
M\O*F"UBW&/'HQC;(_P!HU^KE?E#\9KT_LZ_\%%$\5:I&T>D3:K#JOG;<YM9T
MV3./7:6E_%:X\I_WO3?EE;UT.[-_]SUVYHW]-?UM^!^KH 4  8 Z"O%OVS/!
M=AXX_9I\=VU]"DC66G2:C;.PYCFA!D5@>W0CZ,17L=C?6^J65O>6<\=U:7$:
MRPSPL&21&&592."""""*\&_;H^)^F_#?]G'Q5'=W,::CKEJ^E6%N2-\KRC:Q
M [A4+,3VP/45Y24N9*/Q75O6^GXGK<T.7FE\-M?3K^!X7_P29\475[X$\=Z!
M*[/::?J%O=P*3D*9HV5P/^_*G\37D^C^";+Q[_P5"U+3]1A6XLH-<N+]XG *
ML8(#*@(/4;U7BO9?^"4/@NYTGX8>+O$L\31Q:QJ,=O;EN-Z0(<L/;=*RY]5-
M>&-\1[#X5_\ !3'5M=U6=;72_P"W9K.ZGD.%B2:$Q;V/95+@D]@#7U>^:5?9
M[^S=O6T?U/C]LII>TV]HK^EYW_ _5JOB'_@JQX-M-1^#_AOQ+Y*_VAIFK"U$
MV!N\F:-RRY]-T:&OMQ761592&5AD,#D$>M? W_!5SXEZ=#X/\+> X+F.75;B
M^_M6X@4@M%"B.B%AVW-(<>NPU\YA%)XFFH;\R_X/X7/J,6XK#57/;E?Y:?C8
M]T_8_P#$USXK_8U\*7EVS/-#I5S9;F.25@DEA3_QU%_*OC7_ ()4^&K+5/C7
MXCU:YC62YTO1C]FW#.QI)45F'H=H9?HQK[=_9C\!W7PW_9+\,:)?1M#>KH\U
MW/$X(:-YR\Q0CL1YF#[@U\<?\$F/^2F>.?\ L$1?^CA7M0DO:XYPV_X,SP*D
M7[' *??_ .0L?IW7Y8?&BUBTO_@I]I/V5?)\SQ!H\K;>,LZ0%C^.3^=?J?7Y
M:_'C_E)[HG_8<T3_ -%V]<.4_P"^K_#+\XGHYOK@I_+\S]*/'GP_\.?$SP[+
MH?BG2H-9TB1UD>UN<["R]&X(Y%>&V?[17[.7[,>CKX-TCQ-IVFVEG)(XT[21
M<:B4D9B7#2(),-G/#-QC'&,5R7_!3;XH:WX!^"NFZ3HMS)9?\)%?-9W=Q"2K
M^0L99HP1TW' /J 1WK@OV,_V%?AEXT^#>A>-?&-I+XIU+65>=;?[7)#;6JK(
MR! (F4LWR_-N)&> !CF</1C["5:M)J%[675V^XO$UY?6(T*,4YVO=[)7MZ_=
M_G;K?%W_  5/^%VEPSQ:)HGB'Q!<;2(R8([:!SZ%F<N!_P  -?/G_!+^[74/
MVG/$UTD(MTFT&[D$(.0@-U;G;T'3.*^_/^%5_"/X"^'=0\46O@_P[X>@TFV>
MYDU);&,3QJJD\2D%\GH!G))%? /_  3%U1=0_:A\1W3#8UYH=Y(JX[M<P-C\
MLUWX-T)0K^Q@U:.K;\GI8\_&*O&=#V\UK-627IK<U?\ @J!KEYXG^/G@WP>K
M,MK;:=$\:YX,MQ.RLV/I&@_"OTL\*^&[#P;X9TK0M+@6VT[3;:.TMX4& J(H
M4#\A7YN?\%3O!][H'Q:\&^.((V-K=6*VGFX)5)X)6< GW60$?[IK]$_AOX\T
MSXG> ]#\4Z/.MQ8:I:I<(RD':2/F0XZ,K94CL017'5_Y%U'DVO*_K?3]3LIZ
M9G6Y]W&-O2VOZ?,Y']J+P38_$#]G_P =:3?Q)(HTJ>ZA9QGRYHD,D;CT(91^
M&:^3_P#@D?\ \B[\2O\ K[L?_0)J^H/VO/B18?#']GKQGJ-Y<1Q7%Y82Z=91
MMUEN)D**H'?&2Q]E)KY?_P""1_\ R+OQ*_Z^['_T":C"<WU/$OI[OW\RO^%A
M8WE^NX1?:O/[N5V_&_XGSU^TQ\0M)OOVZ-5U?QA!<:IX9T36+>WGLK:-7=[:
MW"[HE5V53N8-D$@?,:^N!_P5:^$B@ >'?&8 Z#[#:?\ R57S'^T'I>F_!W]O
MZ35O%^D6NI^%+[5(-3F@O[99X)K2=0LK%&!#;&,G&.J5^D%C^S[\'-4LK>\L
M_AKX'NK2XC66&>'0;-DD1AE64B/!!!!!%=E25!8/#NK%M<O1];*_S.2G&N\=
MB52DD[]5TN[6\K?H?$?[4G[>7PI^/OP7UOPC:Z!XHAU68QSV%Q?6=LL4,Z."
M&++<,P!7<IP#PQKU'_@E3XJN-6^"?B+1)Y3)'I.L$P*?X(Y8U;:/;>KG_@1K
MO/VD[+X'?LW_  YE\3ZC\)?!6IW3S);66EKHUG"]U(QY ;R6P%7<Q.#TQWKI
M/V/?'7A7XG?#6Z\2^$?AS9_#G3[B\:!K:SMH(ENGC49D!B10P!8J"1G*L*Q]
MI3^IU51IOE;6K>ST_0V]G5^N4G7J)R2=DEJUK^OZGN]-==RL/48IU%>#)*2:
M9[Y^9-[_ ,$H/&EU>3S#QOH*B21G ,$W&3GTKYU^-7[,.K_!/XN:!X!U#6;+
M4;[6$MWCN[9'6*/SIFB&01G@KFOW K\\?VVOA?XR\5_M>?#_ %G1/"6NZQI%
MK%IPGU#3]-FGMXBMV[,&D12JX4@G)X!S7TF S"M4Q$*=67NOT[,^<S'+Z$</
M5K0C[^_7JUT.0_X=,^-?^AXT'_OQ/_A7W7^S+\([[X%_!70/!6HWUOJ5YIK7
M!>ZM598W\R>248#<\!P/PKU*BO+K8ZOB(>SJ.ZWV/2HY?A\//VE.-GZL****
MX#T0HHHH **** "BBB@ HHHH **** "N ^)OQJ\/_#&$Q7DIO=69=T>G6Y^<
MCU8]$'UY/8&N9_:"^-Q^'EBNCZ.Z/X@NXRQDX(M(SP'([L>=H]LGL#\<75U-
M>W$D]Q-)//(=SRRL69CZDGDFO@<^XE6 D\+A-:G5](_YO\%Y['Z5PWPF\R@L
M7C6U3>RZR_R7XOI;<]7\7?M.>,_$A>.SN(]"M2Q*I8C]YCL#(>?Q&.M>:ZEX
MEU?6&+7^JWM\Q!&ZYN'D.#UZD]:SJ*_*<1C\5BY<U>HY>K_38_9\+EN#P4>7
M#THQ]%K]^X4445P'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMKYLXG@:<H48-O\ =NZV\M]/)=@HHHKSST3\U_VFOV%?B'I_QT_X3/X-Z/\
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MH2E&+W2>GW'"?!7X-^'O@/\ #^Q\)^&XG6TMR9)KB;!EN9FQOED(ZL<#V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !1110 4444 %%%% !7T]^QG<LUGXLM^=L<EK(.>,L)0>/\
M@(KYAKZM_8ZTEH/"^OZB4PMS=I K>OEIG\OWG\Z^MX6C)YK3:Z*5_P#P%GQ7
M&,HQR6JI=7&W_@2?Y7/H.BBBOW8_G$**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF[]N7]I!O@'\*S;
M://M\8Z_NM-,"X+0+@>9/C_9! 7_ &F7T-?2-?F4NH?\-9?\%%[>&<F[\+^%
M[AQ'$<F/R+,DYQZ27&,^H85VX.A'$5DI_"DY2]%_G^5SBQE>6'HN4/B;48^K
MV^X^N?V+_@*?@7\';2/4HR?%FN$:EK,TG,GFL,K$2>3L4X/^T7/>OAS]O+_D
M^#3/]W2O_0A7ZOU^4'[>7_)\&F?[NE?^A"O1R^M*OF,:DMVW^7Z'EYE1CA\L
MG3CT2_-7?S/U?HHHKP3Z$_//_@KE_P @[X9?]==0_E;U]6?L@?\ )L7PU_[
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MPGWA _#;Q!=;_$&@P;M-FE;YKJR&!LYZM%D#_<*_W2:^T-6_Y!5[_P!<7_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT54TG4[?6M+L]0LY5FM+N%+B&1#D.C*&4CV((JW7DM.+LSUHR4DI+9GYY_\
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M3DH[7.ZDW*G%RWL@HHHK,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F2_ZM_H:?3)?]6_T-
M95?X<O1C6Y^/O[!OPGTGXK_M-O'KEK'?Z7HL%QJKVDRAHYI$D5(U8'J T@;!
MX.W!XK]@)K:*YMY+>6))8)$,;Q.H*LI&"".XQVK\O/\ @EW_ ,G&>,O^P)<?
M^E4-?J17T.;R<JD(O;E_S/$RR*3K26_._P!#\:OA'\%=#\:?MQ2>!+BU#^&K
M77[_ 'VG.UK>W,KK$<?PG8JGV)K]C[6S@L;6*UMH([>VA01QPQ(%1% P% '
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M"&'\-1B:CJX3VN&M&#^))6L_/^NW<UPU-4<9[+%-RFM8MN]UY>?_  >QA?\
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M_P!3A_Y3/_MU'_#&/_4X?^4S_P"W4?ZL9O\ \^?_ ":/_P D'^M^2?\ /_\
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M33YGP^;\<5*\'1RZ+@G]I[_);+UU^1!8V-OI=G!:6D$=M:P((XH8E"JB@8
M'05/117Z.DHJR/RIMR=WN%%%%,04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_G,9/5SP0S8)/%?II15QQM.D^>A249=[MV]#.6!J5ER8BJY1[62OZOJ>=?M
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MBBO*/6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M444 %%%% !1110 4444 %%%% !117RQ^W-^UP_[//AFUT3PXT,GC?6(V:!I
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MG/I]%%:5*DJDN:;NS.G3C2CRP5D%%%%9F@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'E'QW_9O\.?M$)H-MXJU/6H]*TFY^U#2]/N(XK>Z?@?OLQLY^7*_*RX#
M-CDYKU"QL;?2[&WL[.".UM+>-8H8(5"I&BC"JH'     J>BKYY<BA?1:D<D>
M=U+:[?(****@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK]DDFW_79FNOB_\ ;OFL/[?73+A-/*^=]A-AI8DV]=OD$>?G_9QNKT3]F/\
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M_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\
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M?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\
MY^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_
M^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<
M)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\
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M_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\
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M?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\
MY^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_
M^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<
M)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\
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M_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\
M G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "?_KT =W17"?V/XG_
M .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B
M?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "?_KT =W1
M7"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_
M .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "
M?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\
MY^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_
M^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<
M)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\
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M_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\
M G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "?_KT =W17"?V/XG_
M .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B
M?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "?_KT =W1
M7"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_
M .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "
M?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\
MY^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_
M^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<
M)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\
MZ]']C^)_^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_
M^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#G
MXF_\"?\ Z]']C^)_^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y
M^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG
M]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#K
MT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z
M] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "?_KT =W17"?V/XG_ .?B
M;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GX
MF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "?_KT =W17"?V
M/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O1
M_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;_P "?_KT
M =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_B?\ Y^)O
M_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']C^)_^?B;
M_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!W=%<)_8_
MB?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\"?\ Z]']
MC^)_^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_  )_^O0!
MW=%<)_8_B?\ Y^)O_ G_ .O1_8_B?_GXF_\  G_Z] '=T5PG]C^)_P#GXF_\
M"?\ Z]']C^)_^?B;_P "?_KT =W17"?V/XG_ .?B;_P)_P#KT?V/XG_Y^)O_
M  )_^O0!W=%<)_8_B?\ Y^)O_ G_ .O5_0]-UVWU2"2\FD>V7=O5I]P^Z<<9
M]<4 =91110 4444 %%%% !7G/[1G_)!_'O\ V!KG_P!%FO1J\Y_:,_Y(/X]_
M[ US_P"BS6=3X)>AZN4_\C##_P"./_I2/@#]B70TUK]HSPZ\H5H[&.XNRC#[
MQ6%U7'N&96_X#7ZBU^;/_!/V%)?CT[,N6CTBX=.>AW1C/Y$U^DU<. 7[KYGZ
M1XH5'//(Q>T:<5^,G^H4445Z1^1'Y4?MA0O;_M(^-5D7:QF@<#.>&MHF!_(B
MOT7_ &?M'.@_ _P+9L2771[:5]V.&>,.PX]"Q'X5^>?[:G_)S7C+_MS_ /2*
M"OTM^'\*6W@+PU#&NV./3+9%7.< 1* *\G"K]_4?];G[IQM6E_JWE$/YH1?W
M4X_YF_1117K'X6?,/_!0RW6?X%V#L2##KEO(N.Y\F=>?P8UPW_!-6ZW6/Q!M
M]N/+DL9-V>NX7 QC_@/ZUW__  4&_P"2#V__ &&;?_T7+7G/_!-+_FHW_<-_
M]NJ\F7^^Q]/T9^X83WO#S$WZ37_I<#[3U;4$TG2[R^D&8[6%YF'LJDG^5?D[
M\ =%7XB?'[PI;:HQF%YJ@NKDJ=GF%-TS#@<9*XXQUXQU'ZN^(+ ZMH.I60!)
MN;:6$!2 ?F0C@GCO7Y4_LOZROA?]H3P5<W), &H?97W-LVF5&AY)Z<OR/PIX
MS^)33VO_ )#\/;QRO-IT?XB@K=_AG;\3]9J***]4_#@HHHH ^5?^"B'A6WU3
MX2Z1KACS>Z5J:QI)Z13(0Z]>[)$?^ USW_!-K7);CPSXWT<L3!:7=M=HO8-*
MCHQ_*!?RKL_^"@>L6VG_  +ALI6_TB_U6".% 1GY5=V8C.=H"XR,\LOK7 ?\
M$U],=+'Q]J+(OER265O&_P#%E1,S#V'SI^7M7E2_WU6[?H?M^';GX>5_:_9F
MN7_P..WWR_$^LOB9KDOAGX<>*]8@8I/I^DW=W&R]0T<+N"/Q%?F5^R1X-M/'
M'Q_\+66H0?:+&WDDOI8^Q,,;/'G@@KY@3(/!&1WK]*?C)HYU_P"$GC33E1I)
M+G1KN.-8U+,7,+;< <DYQQWK\[/V(]<BT7]HKP^DS!$OHKBT#,.C-$S*/Q90
M/Q_&EBM:U-/;_@E\$RE3X=S:I0_B<KVW^"5OUL?J)1117K'X:%%%% '@_P"V
MQX4MO$O[/NNW$L0>YTEX;ZW?869&$@1L<\91V![8^E?,7_!.G_DMFM_]B]/_
M .E-M7UA^V!K$6B_LY^,9)&4-<0Q6L:L1EVDF1< 9&2 2?HI/:OD_P#X)T_\
MELUO_L7I_P#TIMJ\FM;ZW _=.'I5)<#Y@I?"I2M]T+GZ*U^6/[9GB!M?_:*\
M4YQY5D8;*/ [)$F[/_ BU?J=7Y4?MA:8=*_:.\9QE-JRS0W"]<'?!&Y(S[D_
MB"*O,+^R7J</A6H/.*S>_LW;_P "C<['P#^W1XG^'7@S1_#6E^&=#-EIMNL"
M-)YVYR.6=OWGWF8ECCC).,5O_P##QSQM_P!"SH'Y3_\ QROK#X?_  K^&GBK
MP)X=UF/P%X5E74-.M[K?_8MMD[XU8Y^3KD]ZW_\ A1GPW_Z)]X5_\$MM_P#$
M4HT,196J:%XKB+A9UZCKY6W.[O>76^O7N?&'_#QSQM_T+.@?E/\ _'*/^'CG
MC;_H6= _*?\ ^.5]G_\ "C/AO_T3[PK_ ."6V_\ B*/^%&?#?_HGWA7_ ,$M
MM_\ $57L<3_S\.;_ %BX1_Z%3_\  O\ @GPCX^_;H\4_$3P9K'AK4?#>AI9Z
MG;M;R/&LI=,]&7<Y&X'!''4"N>_8GUR71OVC/#4:,1%?)<VDRJ/O*8'8#_OM
M$/X5^A__  HSX;_]$^\*_P#@EMO_ (BKFC_"7P/X?U*#4-+\&>']-OX"3%=6
M>EP12QD@@E75 1P2.#WJ/JM5SC.<[V.R7&N24<MQ&78' NFJL9+=6NU9/Y:#
MOBM_R2[QC_V!KS_T0]?E9\ =(&N_&[P+9NBRQMK-K))'(H961)%=@0>""%(_
MQK]4_BM_R2[QC_V!KS_T0]?F)^RK"]Q^T-X'6-=S"_WGG'"HQ)_(&IQFM6FO
MZW._P^J.EDF:5%NDW]T)'ZRT445ZY^"!7Y9_MJ?\G->,O^W/_P!(H*_4RORS
M_;4_Y.:\9?\ ;G_Z105YF8?PEZ_YG[)X5_\ (ZJ_]>I?^EP/T!_9KT9=!^ ?
M@.V01@2:3#=?NUVC,R^<>/7,G)[G)KTNN2^$,*6OPG\%0QKMCCT2R15SG $"
M "NMKOIJT$O(_+<RJ.MCJ]1[N<G][84445H>:?D7X18:3^T7HK6Z@"V\5P&-
M6R1\MXN >_:OUTK\E_\ FZ+_ +G+_P!O:_6BO*P&TUYG[=XG/FE@)]7!_H?G
M[_P4>UR6X^(_A71RQ,%II+7:+V#2S.C'\H%_*OH7]A_PO;^'?V>]%NHU3[1J
MTT][.RCDGS&C4$]\)&OZU\Z_\%'-,>+XI>&=0*,([C1A;AS]TF.>1B![CS1G
MZBOIC]B_7(=;_9S\+B/:)++S[255*_*RS.1G'0E64\\_-GG.2J7^]SO_ %L:
M9XW'@3 *C\+DK_\ D[_]*_$]OHHHKUC\-"BBB@#\B/B?X9B\&_'CQ!HUNI6U
MM-<=8%8Y(C,NY 3DY^4CFOUWK\E?C5K4&O\ [1WBB]MB&@;7GC1U8,KA)=FX
M$<$';D>QK]:J\K VYJEN_P#F?M_B/*I+"97*K\3@[^MH7"BBBO5/Q **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OR9_:?T?4/V5_P!MBT\=V=JS:7>Z
M@FO6P7@3*QQ=0Y[')D'L'6OUFKRO]HO]GGP]^T=X"D\/ZUFTNX6,VGZI$@:6
MSFQC< ?O*>C+GD>A ([,'B/JM=56KK9^C_K]#BQF'^MT)4KV>Z?FOZ:_'H=W
MX-\8:3X^\+Z9XBT*\CU#2-1@6XM[B,Y#*>Q]"#D$'D$$'I6S7Y3:3H_[2O[!
M^K7EOI&F3>(/"4DAD;R;:2_TN;C_ %A"8>!L8SDH3C^( 5TLO_!57Q_J5NMC
MI7P^TC^VV^0,7N)U+=.(5VM^&ZNR>7RJ/FPK4H^NJ]3BAF4:<>7%IPDO)V?I
M;^O,^WOVF_C9IWP'^$&M^(KJXC346A:VTRW9L-/=.I" #N ?F/H%-?%'_!*W
MX67>K>,_$_Q(OHF-I9P'3;2:0?ZRXD*O*P/JJ  _]=:Y[0_V;?CW^VAXVM?$
M7Q.EO/#6@1G FU2#[.8HB<F.UM."">/G8 '&2S$8/Z4_#GX>:%\*O!FE^%O#
M=DMCI&GQ".*,<LQZL[G^)V.23W)K3W,!0G#F3J3T=MDOZ;^_RUCW\PKPGRM4
MX:J^[?\ DOZWT^,?^"M7_)/_  #_ -A2X_\ 10KZ=_93_P"3:_AI_P!@&T_]
M%BO /^"GG@#Q1X^\#^"8/#'AO5_$<]OJ,SS1:38RW31J8@ S"-20">YKZ*_9
MITF^T']G[X>Z=J=E<:=J%KHEK%/:7<312Q.(P"KHP!4@]B*PYE_9_+?7G_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9Q;@&F8=B1N5/?G^$U:_9#^.'BKXV>$]3N_$FD10"PF$,>K0G8EXS;F*"/&
M8QLR0W.\<9S7P]\*OA#XU_:=\=7%X\]Q=0O<(^KZ]>-N$2DC."?OOM'RH/0#
MY1S7Z?\ @7P+HOPW\+V7A_P_9+8Z;:KA47EG;N[G^)B>237/0G5KU'4VB?6\
M38#)^',JAE$4JN+;YI3ZPVT]&M%%WTO)I.Q4^*W_ "2[QC_V!KS_ -$/7YG_
M +(?_)QW@G_KXE_]$25^F'Q6_P"27>,?^P->?^B'K\S_ -D/_DX[P3_U\2_^
MB)*SQ?\ &I_UU/5X%_Y)_-O\+_\ 2)'ZM4445ZQ^%!7Y9_MJ?\G->,O^W/\
M](H*_4RORS_;4_Y.:\9?]N?_ *105YF8?PEZ_P"9^R>%?_(ZJ_\ 7J7_ *7
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M< =6 /BOQ"_X*(>%=+LYH?!^D7NN:AT2XOD^SVH_VL9+M_NX7ZU\^>!_!'Q
M_;.^)1U36[NX.DQ2;+O5-F+>RBR7\B!2<;N<!1D_,&;N3E5Q2?N4=9,]K)>"
MJU-_VCGR]CAJ>K4OBE;I;=7V[O9*YXAI-Q+=>(K.::1III+I'>21BS,Q<$DD
M]237[55^0?Q$\,V/@WXW:SH6F(T>GZ=K+6L"R.68(DF!DGJ>*_7RL<O7*YI^
M7ZGT7BE6AB(9?6I_#*,VO1\C"BBBO7/P8**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVO\ @/18])T)B?):UL;.&"09(^22]),F,8)4XR.W2K>@_MY_&3X#^,K7P_\
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M3;J%%'4R?9!O1?5L@#UKZ;_8U_; @_:<T?4K+4M.AT;Q;I*I)=6]LY,%Q$W
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M\D)(]BQ?':JCQ9E<G9R:^3(EP7G$5=03_P"WE^MCZOHKQSP;^U)X1\23"WU
MS>'[DC@WF&A8^@D7I_P(**]?@N(KJ%989$EB895XV#*1[$5]'A<=AL='GPU1
M27E^JW1\KC,OQ>7SY,53<'Y]?1[/Y$E%%%=QYX4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^!?_ -E4X;!PQ$'*551\F7C<PJ82HH1H2GINMCW>BO"/^$7\=_W=0_\  O\
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M^,_UXQO_ $*:WW/_ .1/M.BOE#X<^ ?C!9^-M'GO)M4M;".Y1[I[S4=\1A#
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M/L#-R 7S!; ?2%';ZXKGO@Q^TV?#/_!/GQMI+7>S7='G;1+ ;OG\N\RR,/\
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M50'U&92?J!7B7[+-]HUU_P %$C-H45K::))JNKBPAM%5(5A\FXV",*  NT#
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M%3]GSQ?87EO')=6%C+J5C,P^:&>%"ZE3VR 5/LQKYC_X)'_\B[\2O^ONQ_\
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M,;+2U/[O3;=SY0]V_OM[GIV H^,GQ/NOB=XLEN2Y&E6K/%80X("QY^^1_>;
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MH:TY:Q?YI^:_%$M%%%?3'R04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2,P522< <DFEKXT_;\_:2OO"^GVOPF\#M-=>-_$NV"?[$<
MRVT$AVK&N.1)+G [A<GN#6E.G.M-4Z:U9G4JPHPE5J.T5N?./[:W[;GB'QA\
M2&T+X<^*-3T'PUHC-";[1KR2U?4)^CN7C8$QC&%'0\MSD8_2SX0WUQJ7PG\%
M7EY/+=7=QHEE+-<3N7DD=H$+,S'DDDDDGKFORD_:X_9QL_V<?AM\+-*<1S^)
M-02]NM8O$YW3?N,1*?[D8.T>IW-_%7ZJ?!3_ )(WX#_[ %A_Z3QU[>*A1C@H
M>QU2DU?O:Z;^;/!PLZ\L?)UM+QO;M>UEZVW\SM****\ ^B"ORF_;@US5/VC?
MVII? _AP_:H_#5A<6\,8Y5IHH7N+@\=SL$?U05^E'QA^(=K\*/A?XF\6W>#'
MI5E).B$_?DQB-/\ @3E1^-? W_!+_P !7?C3XE>-OB=K(^U/"C6B32+GS+JX
M;S)G'N%&#_UUKU,!'E=3$_\ /N+M_B>B_P"#ZGE9A+FC3PR_Y>22?^%6;_3[
MF>G_ /!+CXP#Q1\+=4\!WDV[4/#<_GVJL>6M)F+8'^[)OSZ!UK[;K\GO#-X_
M[&_[?=S8R'[+X;O;\VKY.U/[/NR&C;Z1L4)_ZY&OUAJ\QC&<H8F&U17^?7_@
M^;,\MDZ<9X6>]-V^71_Y>045D>+?%FD^!?#>HZ_KM]%IND:?"9[FZF/RHH_4
MD\  <DD 5\$^)_\ @IEXS\:>*9M(^#WPV.N)&24>^MKB]N)T!QO^SVY4H/JS
M=1TZ5P4,/4Q#:IK;?LCT*^(I8:*E4=K[=V?=/Q+_ .2<^*O^P3=_^B7K\_O^
M"1__ ",'Q)_Z];'_ -#FKH=+_P""AVLFSUKP9\9? T_@C5=0TVXB@O8[:>W1
M7>-E026\V752>-X9N>H R1SW_!(__D8/B3_UZV/_ *'-7LX?#U,/0Q/.M'&-
MGT>K/'Q&)I8BMAO9O52E=;-:1/TEHKS[XW_'+PM\ ?!,WB3Q3=-'#N\JVLX
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MZSD\0Z'\)K2V\(XWK>7FFWUT@0=S<(\<?X[:]X_90_;RT7]HC6O^$7U?2?\
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M&P.'=SG+GOZ<5J?M'?M2>$/V:O#\-WKKR7^L7@/V#1;0CS[C'5B3PB ]6/X
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M<YDE<G+R.>[,Q)/UXP,"ORA^+WPQN/C+^WAXN\&VE\FF76J:O<)#=2(65'6
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M<@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>"_!>C?#SPOIWAWP_80Z;I&GQ"&"WA4  #J3ZL3DECR223R:_,+]HAD^&?\
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MW$$@!66.%Y9F1@>H(CP1Z&OT&_85_P"33OAY_P!>LW_I3+7Q=\#O^4H&M?\
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M%Y)".V68X'.!@=J[RBBN6I4E5FYS=VSJITXTH*G!62"BBBLS0**** "BBB@
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M^3****_!3^D@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *]Y_8]M&?QYK%T/N1Z8T9^K2QD?^@&O!J^L_P!D
M+PO)I_A'5=;FB*'4KA8H68?>CB!&X>V]G'U2OJ.&:$JV:4K;1NW\E_G8^.XM
MQ$</D]:^\K17S?\ E<]]HHHK][/YM"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?O)[^2[?Y_\  /YZXKSZ.;8A4:#_ '4-O-]7^B_X(4445]B?"!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>./ /AWXE>';C0?
M%&CVNMZ3<??MKI-PR.C*>JL.S*01V-;]% 'R!K?_  2W^#FK7[W%K=^*-&B8
MY%K8ZA$T:^P,L,C?FQKTKX._L5_"CX):E!JNBZ"^H:Y!S%JFL3&YFC/J@P$1
MO]I5!]Z]UHKK>,Q$H\KF[>IQK!X:,N=4U?T"BBBN0[ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "F2_P"K?Z&GTR7_ %;_ $-95?X<O1C6Y^,?[''P2T[X[?M%
M#1=<1I] T]9]4O[8,5$Z1N%6,D=B\BYQSMW8K]=KGX5^#;OPJ_AF3PKHY\/M
M'Y7]FK8QK %QCA N ?<<BOS@_P""7?\ R<9XR_[ EQ_Z50U^I%?1YO.3G"G?
M3E7ZGA99"/-6J6UYVOD?BI\,?@?:^,/VMY_A6MY<P^'CK=U:77ERE6EM+9WD
M*D]R1$ #V)![5^P.B_"KP;X=\+CPYIWA;2+70O+\IM/6SC,3KC!W@CYR>Y;)
M/>OS=_9E_P"4E&N_]A77/_09J_4RIS&K.5.A%O>";\V_^&)RVE"-;$RBK<LW
M%>25G^I^3VA^';3X&_\ !2K3]$\.1FQTI=>CMX;>,DJD-U"-T?)^Z/-('H /
M2OT!_:^_Y-B^)7_8&F_D*^$_B?\ \I2-+_[&+2__ $5#7W9^U]_R;%\2O^P-
M-_(5GC&Y8;#3EJW%?DC3!I0Q>*A'1<WYW/R]_97_ &AOBA\#]/\ $4'P\\(V
MWB>'4987O'N-,NKOR60.$ ,,B[<AFZYSCBO9=<_X*0?'_P ,VZW&L?#W0-)@
M8[5EOM$U"%2?0%K@#-=U_P $C_\ D7?B5_U]V/\ Z!-7WSJFEV6N:=<Z?J-I
M#?6-RABFMKB,21R(1@JRG@@^]=V88BG3Q,HSI*3TU^2/.RS#5*N$C*%5Q5Y:
M+_$_^'/RMD_:)_:6_;*TW4/#/A73;>'377RM07P_$+2/8W\,L\TA*J1G@.-P
MR.>E?7/[%?[&D?[-NGWNMZ]=6^I^-=2B$$DEKDPV<&0QBC) +$L 6; ^Z !@
M$M\>?M0?!WQ#^Q+\:M,\=?#RZGTWP]?S-)I\B,66WDZR6<H_B0CD ]5R.JDU
M^BO[.'QXTK]H?X7Z?XIT]5MKS_CWU&P#;C:W*@;D]U.0RGNK#OFHQ,_]E]IA
M$E3EOW3[/^O+9Z[8:G_M?L\8VZD=8W>C7=>?];K3@?\ @H9_R:;XQ_W[3_TI
MBK@?^"7%M#>_LVZY;W$23P3:_<QR1R*&5U,$ ((/4$5WW_!0S_DTWQC_ +]I
M_P"E,5<+_P $K_\ DW;5O^QAN/\ T1!7'A]<NKI_S+\HG9BO^1AAO1_^W'RQ
M\;? NO\ [!?[3>F^*_"J2#PW=3-=Z<&8^7+ 3B>RD/L#@9YP4;J./T_\%_$3
M1OBO\,;/Q7H%Q]HTO4[)IHS_ !(=I#1L.S*P*D>H-<[^TE\"M,_:$^%>I^%[
MT1PWV/M&FWK+DVURH.QO]T\JP[AC7Y__ +$OQUU/]GWXC:_\(_'!DT_3-0N)
M;58[@X%AJ &P<_W),!2>F=AZ9-.7_"A@Y0?\6FG;SC_G^O\ B%_R+L9&HM*5
M1J_]V7^3_KX2;_@EC_R<%XL_[ ,W_I3!7ZER2)#&\DC!(U!9F8X  ZDU^6G_
M  2Q_P"3@O%G_8!F_P#2F"OLO]NGXM?\*E_9U\0SV\WDZKK _LBR*MA@TH(=
MA[K&'/U K7-HREB(1CNTDO5MF>4RC&E5E+92;?HDKGP_X#\S]L']OUM7E5KK
MP]:7[7V#\R+8VF!"OT=A&#[R&OU+\7>&;+QIX5U?0-2C$MAJEI+9SH1G*.I4
M_P Z_)+]F7]E'XU^/?"+>-_ASXIA\'VEY))9^<NKW-C/<*C#=S"ARFX8Y/53
MQQ7L_P#PQ]^US_T6>;_PK]3_ /C==&.P]&2AA_:J*@K6Z^OY'+@<16BYXGV3
M;F[W6UNB^6IYW^P_XPOOV=_VM-3^'^MR^1:ZK<2Z%=!_E7[3&[?9Y,?[3 J/
M::OUAK\4OVD/@!\4?V??$6B^)O&^M1ZSJVJSF:'6K6^FNI?.AV$>9+*BMO V
MD=>%]J_7#X$_%"V^,GPC\,>+[9EW:C9JUPB_\L[A?DF3\'5A],5EF,%5I4\3
M&2E]EM=_ZO\ @:Y;-TJU3#2BXI^]%/M_5OQ/D3_@IQKMUXNU_P"%_P *M+;=
M>ZO?BZ>,'^)V$$&1Z9>7\J^YO#>@VOA;P[I>C6*>79:=:Q6D"^B1H%4?D!7P
M1X5_XOW_ ,%-M5U+BXT?P3$X0]5!MU$2_C]HE9A_NU^A-<-;]WA:-+J[R?SV
M^Y(]"C^\Q=:KTC:"^6LOO;/R@F_Y2A#_ +&U?_017ZOU^4$W_*4(?]C:O_H(
MK]7ZUQG^[8;_  K\D88/_>\7_C?YL*J:M_R"KW_KB_\ Z":MU4U;_D%7O_7%
M_P#T$UX=7^'+T9[U/XX^I^7O_!+'_DX+Q9_V 9O_ $I@KLO^"D_[-T^B:K!\
M8_"D,EN3)&NM"U^5H9@0(KH8Y&2 K$=PI[DUQO\ P2Q_Y."\6?\ 8!F_]*8*
M_3WQ!H&G^*M#O]'U6UCO=-OH'M[BWE&5DC888'\#7U&85IX?%TZM/=)?/5Z?
MUZGR^7T88G#5J-39R?RT6OR_X!X?^Q?^TC#^T1\*H)[Z9!XMT<+::O", NV/
MDG _NR $^S!AV%?%'QD_Y2=:;_V,FC_^@6]<]=P^(O\ @GC^U4LD7GWGAF<Y
M4=!J&FR-ROIYB$?]](#T/-[Q[XDTWQC_ ,%&?#FN:/=)?:7J&NZ+<VUQ'T>-
MH[<@_KT[5U8:C!8R.)H_!.+^3O&Z_KS70X\56G]1GA:_QP:^:UL_Z\GU/U/\
M<?\ (EZ__P!@^X_]%M7XN_LH_M(_\,Q>.]2\2?\ "._\)+]LTYK#[+]N^R;,
MR1OOW>6^?N8QCOUK]HO''_(EZ_\ ]@^X_P#1;5^7'_!+WP_I?B/XW>(K?5M,
ML]4@30)'6*]@295;[1 ,@," <$\^]>=E;BHXAR5URK_VX]'-TY2PRB[/F>O_
M ( >G?\ #W?_ *I/_P"7'_\ <E<!\4_^"C7Q$^-NCS^#_!7A)?#SZLC6S_8)
M9+_4)%;@I$51-N1D$A">>"*_2K_A5?@K_H4-!_\ !9!_\36UI.@Z9H,/DZ9I
MUIIT/_/.T@6)?R4"L?K&#6JH?^3,W^K8UZ/$?^2H^0?^">O[)FK?!73=1\:>
M,;3[#XGU> 6UMI[$&2SM<AF\S'1W95)7^$* <$D#[-HHKCQ.(GBJCJ3.W"X:
M&%IJG#_APHHHKE.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KFO&OPY\/_$"S$&MZ='<LHQ'<*-LT?.<*XY ]NA]*Z6BL
MJM*G6@Z=6*<7T9M1K5,/-5:,G&2V:T9\H>,OV1-8L9C+X;U&'4[;&?(O#Y4R
MGT!^ZWU.WZ=Z\SU+X*^.M)9EG\+ZBY4X/V:+SQ^!CW9ZU]]T5\7B>$,!6DY4
MG*'DG=?CK^)]]A>.,RH14:RC4\VK/\-/P/SU_P"%8>,O^A2US_P6S?\ Q-'_
M  K#QE_T*6N?^"V;_P")K]"J*X?]2L/_ ,_I?<CT?^(@8K_GQ'[V?GK_ ,*P
M\9?]"EKG_@MF_P#B:/\ A6'C+_H4M<_\%LW_ ,37Z%44?ZE8?_G]+[D'_$0,
M5_SXC][/SU_X5AXR_P"A2US_ ,%LW_Q-'_"L/&7_ $*6N?\ @MF_^)K]"J*/
M]2L/_P _I?<@_P"(@8K_ )\1^]GYZ_\ "L/&7_0I:Y_X+9O_ (FC_A6'C+_H
M4M<_\%LW_P 37Z%44?ZE8?\ Y_2^Y!_Q$#%?\^(_>S\]?^%8>,O^A2US_P %
MLW_Q-'_"L/&7_0I:Y_X+9O\ XFOT*HH_U*P__/Z7W(/^(@8K_GQ'[V?GK_PK
M#QE_T*6N?^"V;_XFC_A6'C+_ *%+7/\ P6S?_$U^A5%'^I6'_P"?TON0?\1
MQ7_/B/WL_/7_ (5AXR_Z%+7/_!;-_P#$T?\ "L/&7_0I:Y_X+9O_ (FOT*HH
M_P!2L/\ \_I?<@_XB!BO^?$?O9^>O_"L/&7_ $*6N?\ @MF_^)H_X5AXR_Z%
M+7/_  6S?_$U^A5%'^I6'_Y_2^Y!_P 1 Q7_ #XC][/SU_X5AXR_Z%+7/_!;
M-_\ $T?\*P\9?]"EKG_@MF_^)K]"J*/]2L/_ ,_I?<@_XB!BO^?$?O9^>O\
MPK#QE_T*6N?^"V;_ .)H_P"%8>,O^A2US_P6S?\ Q-?H511_J5A_^?TON0?\
M1 Q7_/B/WL_/7_A6'C+_ *%+7/\ P6S?_$UHZ;\$?'>J,%A\+WZ' /\ I*"
M<^\A6OOFBJCP5A;^]5E;Y?\ !(EQ_C&O<HQ3^;_R/D_PC^R'K5])'+XAU*#3
M(,_-;VO[Z8CTS]T'WYKZ+\#_  [T'X=Z=]DT6Q2 L!YMPV&FFQ_??J>IXZ#/
M %=+17U&7Y+@LM?-0A[W=ZO_ ('RL?'YEQ!F&;+EQ%3W?Y5HO^#\[A1117NG
MSH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO(5EAE0]5=&!##V(HJXA5*-&DE\"M^7^04<.Z>(K5F])N_Y_YGP1_P $C_\
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MF2YTG2X+61T)!*%HT!*Y ..G KGPN(6'A5BU?G5OS_S.C&89XF5&2=N1W_\
M2?\ (ZNBBBN$] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^#?B1_P5
M(_X5]\1/%/A;_A67V_\ L/5;K3/M?]O^7YWDS-'OV?9CMW;<XR<9QDUSO_#W
M?_JD_P#Y<?\ ]R5Z:RW%25U#\5_F>5+-,)%M.?X/_(_12BOSK_X>[_\ 5)__
M "X__N2C_A[O_P!4G_\ +C_^Y*?]F8O^3\5_F+^U<'_/^#_R/T4HK\Z_^'N_
M_5)__+C_ /N2C_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\
MZ_\ A[O_ -4G_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P
M?\_X/_(_12BOSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#
M^U<'_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\
MN2C^S,7_ "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\
MN/\ ^Y*/[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH
M_P"'N_\ U2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)_
M_+C_ /N2C_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\
MA[O_ -4G_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X
M/_(_12BOSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'
M_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^
MS,7_ "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\
M^Y*/[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'
MN_\ U2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)__+C_
M /N2C_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_
M -4G_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_
M12BOSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\
M@_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^S,7_
M "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\ ^Y*/
M[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'N_\
MU2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)__+C_ /N2
MC_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G
M_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_12BO
MSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\ @_\
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M?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G_P#+C_\
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M_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_12BOSK_X>[_]4G_\N/\
M^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\ @_\ (_12BOSK_P"'N_\
MU2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^S,7_ "?BO\P_M7!_S_@_\C]%
M**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\ ^Y*/[,Q?\GXK_,/[5P?\_P"#
M_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'N_\ U2?_ ,N/_P"Y*/[,Q?\
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M?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G_P#+C_\ N2C_ (>[_P#5)_\
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M /N2C^S,7_)^*_S#^U<'_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\
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M>[_]4G_\N/\ ^Y*/[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\
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M^U<'_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\
MN2C^S,7_ "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\
MN/\ ^Y*/[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH
M_P"'N_\ U2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)_
M_+C_ /N2C_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\
MA[O_ -4G_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X
M/_(_12BOSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'
M_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^
MS,7_ "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\
M^Y*/[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'
MN_\ U2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)__+C_
M /N2C_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_
M -4G_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_
M12BOSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\
M@_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^S,7_
M "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\ ^Y*/
M[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'N_\
MU2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)__+C_ /N2
MC_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G
M_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_12BO
MSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\ @_\
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M?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G_P#+C_\
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M_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_12BOSK_X>[_]4G_\N/\
M^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\ @_\ (_12BOSK_P"'N_\
MU2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^S,7_ "?BO\P_M7!_S_@_\C]%
M**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\ ^Y*/[,Q?\GXK_,/[5P?\_P"#
M_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'N_\ U2?_ ,N/_P"Y*/[,Q?\
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M?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G_P#+C_\ N2C_ (>[_P#5)_\
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M /N2C^S,7_)^*_S#^U<'_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\
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M>[_]4G_\N/\ ^Y*/[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\
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M^U<'_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\
MN2C^S,7_ "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\
MN/\ ^Y*/[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH
M_P"'N_\ U2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)_
M_+C_ /N2C_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\
MA[O_ -4G_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X
M/_(_12BOSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'
M_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^
MS,7_ "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\
M^Y*/[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'
MN_\ U2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)__+C_
M /N2C_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_
M -4G_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_
M12BOSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\
M@_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^S,7_
M "?BO\P_M7!_S_@_\C]%**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\ ^Y*/
M[,Q?\GXK_,/[5P?\_P"#_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'N_\
MU2?_ ,N/_P"Y*/[,Q?\ )^*_S#^U<'_/^#_R/T4HK\Z_^'N__5)__+C_ /N2
MC_A[O_U2?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G
M_P#+C_\ N2C_ (>[_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_12BO
MSK_X>[_]4G_\N/\ ^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\ @_\
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M?_RX_P#[DH_LS%_R?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G_P#+C_\
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M_P#5)_\ RX__ +DH_LS%_P GXK_,/[5P?\_X/_(_12BOSK_X>[_]4G_\N/\
M^Y*/^'N__5)__+C_ /N2C^S,7_)^*_S#^U<'_/\ @_\ (_12BOSK_P"'N_\
MU2?_ ,N/_P"Y*/\ A[O_ -4G_P#+C_\ N2C^S,7_ "?BO\P_M7!_S_@_\C]%
M**_.O_A[O_U2?_RX_P#[DH_X>[_]4G_\N/\ ^Y*/[,Q?\GXK_,/[5P?\_P"#
M_P C]%**_.O_ (>[_P#5)_\ RX__ +DH_P"'N_\ U2?_ ,N/_P"Y*/[,Q?\
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M?BO\P_M7!_S_ (/_ "/T4HK\Z_\ A[O_ -4G_P#+C_\ N2C_ (>[_P#5)_\
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M /N2C^S,7_)^*_S#^U<'_/\ @_\ (_12BOSK_P"'N_\ U2?_ ,N/_P"Y*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAH^N^7ON".<).BHJMC@!DP3U85Y?]J87FY>;YVT/664XMQYN7Y7U/N+X&?\
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M/Z_J'Q#_ +$O-4L8;R33CH7G&W\Q0P0O]H7) (S\HYKY;_:.^#MC\!?BI?\
M@NS\2?\ "426$,37-W]B^RA)77?Y87S'SA2ASGJQ&.*PCBZ,ZKHQE>2OT?3<
MWE@Z\*2KRC[KMK===O,\QHHHKL.(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$DG^V=0ZG_MO3?\ AWM\ /\ H0?_ "LZA_\ )%?GA>?\%!OC]%>3HOCW"J[
M#^QM/Z _]<*B_P"'A/Q__P"A^_\ *-I__P CU:P./MI5_P#)I?Y#GC\OC)J5
M'7_#'_,TO^"@7P;\'_!'XO:/HG@K1_[%TRXT:.[D@^TS3[I3-*I;=*[,.$48
M!QQ70?\ !+O_ ).6G_[ -U_Z,AKYW^*WQD\8?&[7[?6_&NK_ -M:G;VXM(Y_
MLT,&V(,S!=L2*IY=CDC/-?1'_!+O_DY:?_L W7_HR&O5]G4I8*4*KO)1EKOW
M/&E5I5L?"=&/+%RCI:W:^WF??W[:W_)K'Q%_[!W_ +42ORC_ &0_^3G/AK_V
M&H/YU^KG[:W_ ":Q\1?^P=_[42ORC_9#_P"3G/AK_P!AJ#^=>7DFU3Y'I<0_
M##TE^A^Y5?F-^TU_P4A\:IX_U70/AG=6NA:)I=PUL-4:UCN;B\="5=AY@9%C
M)'R@+D@9SS@?I7KCR1Z+J#19\U;>0IC^]M.*_GF9B[%F)9B<DGJ:XLIP\*]6
M;J*ZBE^-_P#+\3TLXQ-3#T8QINSDWKZ6_P _P/U;_87_ &V-4^/6I7G@WQI%
M;#Q1;6QNK74+6,1)>Q*0'#IG"R#(;Y< @G@;>>S_ ."@_P ([3XE_L[ZUJ?D
M(=8\,(=5M)R/F6-<>>F?1H\G'JB^E?GI^P#<26_[6G@3RW9/,>Z1L'[RFTFR
M#7ZX_&J&WN/@[XZBNSMMGT*^65O1?L[Y/3TJ\UI0P=>%6BK:7T[IO_(,GJ3Q
MM&5&L[ZV^37_  Y^5O\ P39_Y.KT3_KPO?\ T2:_8-V55+.0%7DD]!CO7X^?
M\$V?^3J]$_Z\+W_T2:_4GX]:Q+X>^!_C_4X)##-:Z#?2QR+U5A Y!'T-:9[?
MVT+;\O\ [=(Y>';.E53>G/\ ^V0/E?Q1_P %5O!VA^/)])L/"&I:SX=MYFAD
MUJ&[C223:2"\4!7#J<9!:120>@KY#UB:;]M;]L8K9M<6VG^(-26*)I!^\M["
M%.6QR WE1EL<C<:^=Z^NO^"7MK!<?M,2/, 9(=#NI(<C.&WQ*3[?*S?G7LT\
M'1P,77@O>C%_/K^AX]3'5\=)4)NT927RUMO\^O6Q^J&GZ?H/PQ\$Q6MK'!HW
MAS0[+"J/EC@@B3))/L 23WY-?F#\9?\ @IK\1O$7BFZ7P!/;^$_#L$K+;,UG
M%<75P@. \IE5E7/7:H&,XRW6OO;]LBZGL_V7OB1);LRR-I,D9*_W6*JW_CI-
M?A[7B950AB*DZE9<S5M_.]V^Y[F;8B>%ITZ5#W4[[=E:R78_5_\ 8A_;BO/C
MUJT_@WQG;VEKXJB@-Q9WEFICCOHUQO4H2=L@'S?+P1G 7;SL?\%$O@#8_%#X
M-WWBVTM5'BCPM"UW'<*,/-:#F:)CW 7+CT*D#&XY_/7]BB\N+']JCX=26H)D
M;43$P#8^1XG5_P#QTMQWK]G_ !S:V]]X)\06UV ;6;3[B.4-TV&-@WZ9J,UA
M' U8UZ*MU^:_1K]2LHJRQU*>'KN_3Y/]4U?[C\V_^"3_ (9T[4OB=XRUNXC6
M34-,TV**U+<[!-(?,8>^(P,^C$=Z^U?VM/''Q.\ _"\:E\*_#W]OZV;I8[D)
M;&YEMH"K9ECA!R[;M@Z-@$DJ1R/RC_97_:$N_P!F[XJ6WB1+9]0TFXB-GJ=E
M&0'EMV()*9XWJ5##/7!&0#FOU_\ A3^T5\._C59PR^$_%-C?74B;VTV2017D
M?KN@;#C!XR 0>Q-=.;4:GMHU[<T4E^#V9S9/6I^QG0<N63?YI*Z\S\T?#G_!
M1CXZ>"/%N/%-[#KD$,H6ZT;4]+AM'49^90T4:.C8X!;<!W!K[,US_@HS\!Y-
M!=9M6OM76Y@VSZ=#I,Q8AE^:-O,5$/4@\X-?1WBKP+X;\=60L_$GA_2]?M0<
MB'4[..X0'U <'!KY:^-?_!-/X<>.M/N[OP6DG@C7R&>,0NTMC*YYP\3$E!V'
MEE0,YVMC%<<L1@L195:?)_AM^.G_  3OCA\=AKNC5Y_\5_P=_P#)'Y6^+)-'
MF\4:O)X?2XBT%[N5K".\4"9;<N3&K@,PW!< X)Y%?LM^P?\ \FG^ /\ KWG_
M /2F6OQO\;>#=5^'OB[5O#6N6QM-6TNX:VN(NH#*>H/=2,$'N"#7[(?L'_\
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MI_\ L W7_HR&OT+_ &P+6WO/V8?B3'<@&-=&FD&?[Z@,G_CP6OST_P""7?\
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MI7T[W-S<2G+22.Q9F/U)-?IE^R7^V=\'/AE^SWX0\,^)?&']FZW80RI<VO\
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ME9-7I4J$E4FD[]6ET1^8%?NA^R=_R;3\,_\ L VO_HL5^%]?JY^SU^V_\%/
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M[C'EA<C!VEF&?NFN.ICL57IN@J5I/1[_ )=#NIY?A*%55W5]U:I:?+7J8?\
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M/(J*Q_'9GZDU^>?_  2?^(5Y:>-O%_@EDEET^]LEU5".4AEB=8V)]-ZR*/\
MMF*_0[XD>-K3X;^ ?$/BF^_X]=(L9KQUS@OL0D*/<G 'N:\/,Z;P^)FX[25_
MO=VOO7X'T.55/K&%@I;Q=ON5D_\ P%Z_,_*K_@I-\5/^$^_:$FT.VF\S3?"U
MNNGJ%(*_:&P\Y'ODJA]XZ^4*T/$.NWGBC7]2UG4)/.O]0N9+NXD_O22,68_F
M36?7U^$H_5Z$*75+7UZ_B?&8RO\ 6<1.KT;T]%HOP"BBBNLX@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[/_
M ."4O_)P_B+_ +%:X_\ 2NSHH_X)2_\ )P_B+_L5KC_TKLZ*^(S;_>7Z(^\R
M?_=5ZL^=?VD/^3A_BC_V-.J?^E<M>=5Z+^TA_P G#_%'_L:=4_\ 2N6O.J^R
MI?PX^B/B*W\27JPHHHK4R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'V?_P2
ME_Y.'\1?]BM<?^E=G11_P2E_Y.'\1?\ 8K7'_I79T5\1FW^\OT1]YD_^ZKU9
M\Z_M(?\ )P_Q1_[&G5/_ $KEKSJO1?VD/^3A_BC_ -C3JG_I7+7G5?94OX<?
M1'Q%;^)+U84445J9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1H4\/'DI*R"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^=_CU^W)X$_9W\<1^%?$FD^
M(KW4'LX[T2:7;021;'9E R\R'.4/;'3FO./^'K7PE_Z%WQI_X!6G_P E5\V?
M\%-HUF_:DTQ'&Y&T6S4CU!FFK[RA_8I^"#0H3\.=*)*CO+_\77MQI8:EAJ=:
MM%MROL^S/"E6Q57%U*%&22C;==T>0?\ #UKX2_\ 0N^-/_ *T_\ DJM/PM_P
M4Z^%WB[Q-I&AV>@^+X[O4[N&RA>>SM1&KR.$4L1<D@989P#]*]._X8I^!_\
MT3G2?SE_^+JWI/['OP:T/5+/4;#P!IEM?6<R7$$R&3='(C!E8?/U! -9JI@+
MZPE]YK[/,/\ GY'[CV.BBBO(/8"BBB@ HHHH **** /"OVAOVP_!G[-.MZ1I
M?B?3-=OKC4[=KF%M)MX9$55;:0QDF0@Y] :]NL;M+^SM[F,,(YHUD4-U (R,
M^_->(_M#?L>>#/VEM;TC5/$^IZ[87&F6[6T*Z3<0QHRLVXEA)"Y)SZ$5[=8V
MB6%G;VT98QPQK&I;J0!@9]^*Z9>R]A&WQW=^UNGX'.O:^WE?X+*W>]M?QN3T
M445S'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y[\=/C=H?[
M/_@*7Q;XBM-0O--CN([8Q:9'')-N<D X=T&..>:]"KY1_P""FG_)KMY_V%K/
M_P!":M*<5*I"+V;2^]I&=23C2G-;J,G]R;/=/@K\8=&^._P]L?&.@6U]::9>
M22QQQ:E&B3 QN4;(1W7JIQ\W2NZKYD_X)Q_\FG^&?^OJ]_\ 2F2OINNC&4HT
M<1.G#9,PPE65:A"I/=H****XSK"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#;LT/Q5IFFG0;;7]9N"^FQS><(EN$D#)NVKN&YL_='0<<5UG_!4GQ%/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>ZZ;['I7[-W[<GC#]H3X\WOA2P\*Z8/",;7%R-23S4N+>T0D1-)EBI=B8UP
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ML^%])T[1-+MQ(^HZ>95Q*[ 1PX=F!)4.Q(/\/3FOFG]L33[W]GO]M[1?B/\
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M/WE^7_ /3****\ ^B"BBL_Q!X@TWPKHM[K&KWL.G:991-/<75PX5(D49+$T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OR=_X*+?\ )X&G?]>&G_\ HQJ_6*OR=_X*+?\
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MX6A^&/@37]3DU5;B;4-5\5:IJ$CS0P,$6./[0^YXT!4G"?.2W' ;/UA^RO\
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M\E?VB-1M-(_X*/07U_<PV5C:^(]&FGN;B01QQ1J+<L[,3A5 !))X %?K57Y
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MD^N+Y7LXN_WQ'G-E@^;JI*WK9_U\C]=:***\4]L**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7YZ_P#!6KQL\>E> ?"$3-Y<TUQJ
MUPO;**(HC[_ZR;Z<>M?H57Y6?\%7I)S\>O#",&^S+X:A9/EXW&ZN=W/<X"<=
MN/6O6RN*EBHWZ7/'S:3CA)6ZV_,^*J***^Z/S\**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OTC_ ."2_C>>
MYT3Q[X1FE9H+2>WU*U0OG'F!XY<#L/W<73U_/\W*^U?^"4-VZ?'KQ/; +Y<G
MAJ:0GOE;JV _]#/Z5YN914L+.YZF63<,7"W70_5.BBBO@3]$"OFS]O'X9?$+
MXP?".S\+^ +%;][C4$FU&)KN.W+PHI*KF1E!^<JV,_P5])T5<)<DU-=&G]VI
M$X\\90?5-??H>:?LZ_!_3?@C\)/#_ANRT^*QO4M8Y=3==I>>[9 97=A]X[L@
M<D   < 5\O?\%5/ OAUOAOX>\7M#!;>*(M32QCN44"6X@:-V*,1]X*5##/3)
MQUK[.\<>.="^&_A>_P#$7B34H=*T>R3?-<SG 'HH'5F)X"C)).!7YQWTGBG_
M (*4?'6U^SVMUHGPH\.2[6EDX*QD@L<]#<2@  #(1<=<'=Z6%]IB,5]8D[).
M\GV\OGM;L>;BO9X;"_5XJ[:Y8KJWW^6]^Y]?^'?C1<^!OV,=$^(WB$-<ZA:^
M&+>Z<3'#7,YC58\GU=BG_?5?)_[$?[.T?[2WB37_ (Q_%,-XBBDU!DM;*ZYB
MNYP 7>1>\:9553[O!!&%P?>?^"C%A%H'[(MSINF0BUT^WO+"V6"(85(4<!5^
M@VK^0KJ/^"?44$7[)7@@P!1O^V,Y7NWVN;.??_"MX5%&C7Q=-6<I<J\D_>_X
M'W'-4IN5;#X.KJE'F?FU[OZ7^;/H'3]-M-)L8K.QM8;*SA79';V\8CC11V"@
M8 ^E?*G[:7[&GAKXJ>!M8\4>&](M]*\<Z="]XLMC&(QJ(4;FBE48#,0#M?KD
M $XKZTILBJT;*PRI&#GTKQ55J4G[2F[277^OQ/;E3IU(^SJ*\7T_K^D?(W_!
M.#X_7WQ9^%=[X;UV[>\UWPN\<*W$SEI)[1P?*+$\DJ59"?0+GDU]=U^9O_!,
MX_9OVDOB3;6)W:7_ &?/@YXPMX@C/Y%J_3*O3S*,57YXJW,D[>IYF6RE[%TI
M._(W&_H>8?M,:#XN\5_ [Q7HG@:$3>)-2M?LD"FX6#Y'8"7#L0 ?+W@<]37G
M_P"PY^SB_P  _A0G]NZ-#I_CC4II7U.3S(YG5!(1%$)$)&S8%; /5CGGI]'U
M7U#4+72;&XO;VXBM+.W1I9KB=PB1H!DLS'@ #N:X8UY4Z4Z:VE:_RZ>G4[YT
M(U*L*CWC>WSZ^I\\?M_>!?#OBO\ 9K\4:EK-O M_HL*W>G7S*/,BFWJ BMUP
M^=I'0Y'H*Y#]AKXCWVB_L2SZ_K#-+;^&UU VS2G[UO"#(JY] 2RC_= KQ/\
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MU1^BE%?F%_PKC]NG_G[U[_PHM/\ _C]'_"N/VZ?^?O7O_"BT_P#^/U7U"/\
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MB9XF_;NTOXB:;X:^T^#H=5TNYDU+[?:IB.%(1*WEM*)."C<;<G'&:^E_VNO
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M#V<Z,V[O9'Z$?&#XO>'?@EX%U#Q/XCO8[:VMXV,-N7 ENI<?+%&/XF)_+J>
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MP"< #/L*UP$:,>:K4DE)?"GMZ_Y>:,\PE6?+2I1;B_B:WMV\O/R?J?<GP.^
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MUBC]:HU%+W5'KOL]_,PEAJWU/$4G'WG*Z2VWCMY'U91117SA].?F]H_CK3_
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MC3LNB35EYV2/JROS7^$.I0? W_@I1XQT[7G%A;^(IKNWMIYOE0_:72X@Y/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% !1110 4444 %%%% !15C3=-N]8OH+*PM9KZ]G<1PV]M&9))&/154
MDGV%?<_[,7_!-/5O$\EOXA^*ZRZ)HY&^+P_#(4O9_P#KLP_U*]/E!+G)SLQS
MS5\13P\>:HSJP^&JXF7+35_R.8_X)\_LES_%;Q9;_$#Q+;2P>$-#N4FLDD3
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MF>9]_C[OOTYK[.HHK>I6E4C3@_L)17HNYA3HQISJ36\W=^OD%%%%8&X4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?,G_  4>_P"33?$__7U8_P#I3'63_P $R/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M= AW'35EFCEC?:0L0,88D +EL$8SUJGJX\NS5[_UU%\*ES;IV_KR+^E_MF^
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M#O&WBZV\/:;!JQNKF0QPSR6JB)R 3GARP& 3DJ/?%*/O;#?N[G1>!OC1HGQ
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M@>A![BO*?B5^TMX6^%OB9M#U2SU6ZO%B29FLH8F10V< EI%.<<].XK$_8_\
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MK6JFG%V9*=U=!17G&L?'OPOX>\>7OA74VNK&YL[?[3-?3*@M578'QNW[B<$
M#;R>!7'?\-G> /[1^S>5K'D[]OVS[*GE8_O8W[\?\!S[5*:=K%;'O%%>:>-O
MVB/!/@73;&[N=2;43?1+/;6^G*)9'C/1^2 H_P!X@\'T-1?#7]HSP?\ %#5#
MIFG2W5CJ1!:.UU")8VE &3M*LRD@=LY]N*I:MI=!/179ZA15/5]8LM!TVXU#
M4;J*RLK==\L\S!44>Y->)ZA^V=X L;UX(H=8OXU.!<V]J@C;W&^16_2INKV'
M;2Y[Q17*?#_XG^'/B=ISW>@:@MUY>!- X*31$]-R'G\>AQP:SO''QDT/X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:./_ +[-=%2_/4A'=V:]=OU3,*=N6,WLFT_2[9W7@W1+BZ_9X^)GC34!F_\
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MFU*3:\]_Z^X[OPO>27W[)9ED9G?_ (1NY3+')PL3J/T KE?V*?"=A%X+U/Q
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M[[:%2_ARMY?=?4^C/%_P]T+QIX7FT+4-.MVLS&4A"Q@&W.,!H\#Y2/;Z=*\
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MVNB'[7;Y)XC8.649Z#*9QZL:S_V4?"UK\0M?\3^.O$$$>IZC]KV0?:%#K&[
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M"]=H)R3T K@?V-?"=SH/PUNM2NHS$=6NO.A5A@F)5"JWT)W8J*>]3M9???\
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MLH_P8\VW7UZW\S67\5VWZ>G0\:_8W\4"'Q%XL\*VMXU[HT1-Y8R.&'RB386
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MPRJ\8+$'UVJP_&N._;0^(FE7&AZ?X3L[J*ZU$70NKE8F#>0JJRA6QT8ENG7
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MWEKIUY>7:VTR[D=_M&U=P/! W$X/H*]T_:+\*Z7K7P?U][FRA:73[5KBUDV
M-"RX(VGL#C!'H:\M_9]_Y.6^)O\ OW?_ *5K7M'QT_Y([XO_ .P=+_*L/^8:
M'^$VAKB'?^;_ ".6_9*OIKWX*:8LSEQ!//"F3T4.2!^IKSW]E?\ Y+!\2O\
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M_>!8?\!KZ%T7QIH?B#P^FMV.J6LVELGF-<^:H6,8R0Y)^4CN#TK&'\)^KO\
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M0C:GSQ.'X'3)7=]:I_M6>*+75_BSX;\+ZS?26/AFT$5Q?,BLV-['<V%!)(0
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MV<(O]0LX[JZN]@\R5I%#8+==HS@#IQ[FN2_;1_Y)+;?]A2'_ - DKU+X5_\
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M[_Y(P?\ K_N/Y+7E_P"QOX"TKQ%K_B'6]2M(;V736CCMHYT#JCN6)?!XR @
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MI<^F]8\&Z)K^@OHM]I=K/I;)Y8M3$ B#'&T ?*1V(QBOG']F&ZN/ _Q=\:>
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M4SX:_P#)XWC#_KG<?^TZ/VF9H[/X]?#6YG=8;>-[=GED("J!= DD]@!3I_\
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MD=W(H &. J"NL_:\_P"2(R?]?=O_ #-8SMR.W\W_ ,B7"_/&^_*_U.X^!O\
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MXZ\>E8OQXTJW\/?M(?#S4M/ACM+B^N+<SM"NWS&%P%+-CJ2K8SWQ7;_L;_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK<M=VDB_:9'567YI'5LC#'C&!VQ7?2>#]-O/"<?AS4HO[6TU;9+9UO0&:55
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M]413G[/>72!#]?+1#^M>[44+W=AO7<J:5I-EH>GP6&G6L-E90+LB@@0(B#T
M%6Z**-Q'GVK_  2T/6OB=9>.I[O4%U>TV;(8Y(Q =H(&5*%N_P#>KT&BBCI;
MH&[N%%%% ')_$+X6^'/BAIJ6>OV/G^428;B-BDT)/7:P_D<@^E>=^'_V/? &
MAZG'>2_VGJXC.X6^H7"&+/;(1%)^A./6O<**%[KN@>JLQD4201I'&BQQH JH
MHP% Z #L*\X^(_[/?@WXG7AOM3LYK34F #WVGR".1P.FX$%6^I&?>O2J*3UU
M8T[;'C?@[]D_P%X/U2._\B\UF>)@T0U299$1AT.Q54'_ ($#7LE%%5=[$VZG
ME_Q&_9S\&?$S43J.H6UQ8:D_^LN].D$;RXZ;@RLI/OC/O1\./V<_!OPRU :C
MI]M<7^I+_J[O49%D>+UVA550??&?>O4**4?=V&_>W$90ZE6 92,$$9!KQ;Q3
M^R-X \3:E)>1Q7^BO(2SQ:9.J1DGN%=&"_1<#VKVJBE97N.[V/.?AO\  'P?
M\+[K[9I5E+<ZE@J+Z^D\V50>H7 "K]0 >:U/C!8Z'J7PVUV#Q)=S6.BF$-<3
MVQ D 5E8!<J1DL .G>NRJ"\LK?4;62VNX(KJVD&UX9D#HX]"#P12FG.-@C:+
MN>5_LLZ/-H_P9TD31/#]JEFN8TD^]Y;.=A/U !_&O6Z15"*%4!5 P .@I:UE
M+F=R(JR."^*'P9T7XM3:/+J]U?VS:6[O#]BD10Q8J3NW(V?N#ICO5_XG?#+2
M_BQX=CT;5Y[RVM4G6X#V3HK[E# #+*PQ\Q[5UU%9\JM;IN7=WN9_A_18/#>A
MZ?I5LTCV]C;QVT;2D%RJ*%!)  S@=@*Y'Q#\%]$\2_$;2O&MU=:A'JNFB,0P
MPR((&V%B-P*%C]X]&%=]157?-S=25I'E6Q0US0]/\2:5<:;JEI%?6%PNR6"9
M<JP_H?0CD&O%+O\ 8O\  -Q>-/'<:U:Q%LBVAND,8]@6C+8_X%7O5%397N5=
MVL<_X)\!Z%\.]'73- L$L;7.Y\$L\C?WG8\L?K^%8?P_^#>B_#?7]=U?3+J_
MGN=8D\RX6[D1D4[V;Y J*1RQZDUWE%5=WYNHNG+T.&^)7P8\+_%:&'^W+-Q=
MPKMBO;5_+F1<YQG!!'LP(&37+>#?V5/ O@O41?1Q7NJW2<Q/J4RN(F_O*JHJ
MY'8D'!YKV*BI22V'ON<;\+OA7I/PET2ZTO1[B\N;>XN3=.U\Z.X8JJX!55&,
M*.U4?B5\#?"?Q59)M9LY(K^-=BW]FXCFV_W22"&'^\#CM7H%%-^]N)>[L>):
M/^R#X"TFSOH<:E>S7,+0K=74Z-) &&"T8"!0V.Y4XKT7P5\/=.\!^"8O"]A-
M=3:?&LJ"2Y=6EQ(S,W(4#JQQQ7444/5-/J"T::Z:G#?"GX0:-\'].OK+1KF^
MN8KR432-?2([ @8XVHO%1>!O@OHGP_\ %VN>(M.NM0FO=7+F>.ZD1HUW/O.P
M*@(Y]2>*[ZBG=WYNNP=.7H8WC'PK:>-O#&HZ%?2316E]%Y4CV[!9 ,@_*2",
M\=P:Q_"/@NT^$7@&72]#6ZU.*R2:XABNI%\V5SE]FY4 &3P/E[]Z[&BIUL[:
M7'VOT/E_P[H'PT_:GFO-3N;*?POXFCEVW%O9WB"6=<#$F&3#<Y!(7/')Z5RG
MQY^'/P_^$W@@:'H3-?\ BF_NHP7N)EFN4B7).0H 0$X' !/OBO:_&W[*_@3Q
MMJDNHO;WFD7<S%YFTN98UD8]6*LK*#] *L^ ?V9? _P_U*+4;:UN=3OX6W0W
M&I2B0Q'U5555S[D9':BR=EM_70&VKO<[#X8Z'-X;^'?AO2[A2EQ:V$,<JMU5
M]@W#\#FNGHHJY2YI.7<B,>6*CV.!?X,:(_Q47Q^;K4/[95=@@\Q/L^/*\O[N
MS=T_VNM=5XG\/V_BSP[J.C7;RQVM] ]O*\) <*PP2I((S]0:U**BRY>7H6G:
M7,MSE/AI\-],^%?AH:'I,]W<6GG//OO'5I-S8R,JJC''I6?XW^#FB^/O%F@>
M(=0NK^&]T5UDMX[:1%C8K('&\,A)Y'8CBN[HJKNZEU1-E9QZ,IZQH]CX@TVX
MT[4K6*]L;A"DL$R[E8>XKQ/4/V,? %Y?//%-K%C&QR+:WND,:^PWQLV/^!5[
MQ14V5[E7TL<KX!^&'AOX9Z>]IX?TY;3S,>=.Q+RRD?WG//X#@9.!65X^^"^B
M?$7Q-HFNZE=:A!=Z0RM EK(BQMAPXW!D8GD=B*[^BJN[J75$VT:[A7 ^%?@Q
MHG@_Q]K7B^SNM0EU+5O,\^*>1#"N]PYV@(".0.I-=]12V=^HWJK,YCQ[\-O#
MWQ+TM;'Q!IZWB1DM%*"4EA8]T8<CMQT.!D&O+;']C#P#:7JSRSZS>QJ<FVGN
MD$9]B4C5L?\  J]YHI)6=T-ZJQ0T/0M/\-:7;Z;I=G%8V%NNV*"%<*H_Q]3U
M-<!\3OV=_"?Q6U2/4M4%Y9Z@J"-KG3Y51I%'0,&5@<>N,UZ=13?O.[$O=T1Y
MAKW[/GA[Q'\/=%\'7=_JHTW29/,@FCEC$[?> #$QE2,.>BCH*]%TK3H]'TNS
ML(69H;6%($:0@L550H)P.N!5JBG=Z^8=O(X/5O@WHNL?$[3_ !U-=7ZZM8QK
M''#'(@@( 8#*E"W\9Z,.U=1XD\,:5XPT>?2]9L8M0L)A\\,HX]B".01ZC!%:
ME%+IR]!W=^;J>!W'[%O@*:Z:9+O6[>,G(@CNHR@]LM&6Q^->K> _ASX?^&NE
MM8>']/2SB<AI9"2TDK#N[GD]^.@SP!7344[V5A;NYP&M?!?1->^)FG>.+BZU
M!-6L518X8Y$$!V[L;@4+?Q'HPKOZ**73EZ ]7=GBWBS]DGP'XJU:;4 FH:/+
M,Q>2/39D2-F)R3M=&Q]!@>U:.C_LP^ ]%\.ZEI4%A,\E_ 8)=1FD#W2J?[C$
M;4/T7GOFO6**5K+E6P[N]SSVW\!V7PU^#VLZ!IUU>7=E;V%VT37KHTBAD=BN
M551C)/;O7@'[.'P7\,?%CX6ZB-;MI%NH-5=8KVU<1S(IBB)7)!!&>Q!QVKZV
MU;38M9TJ]T^9G6&ZA>!VC(#!64J2,@\X-<O\+?A5I/PCT.YTK1[B]N;>XN#<
MLU\Z.X8JJX!55&,*.U4MY.75+\R7M%1Z-_BCF_A_^S+X)^'>J1ZG:V]UJ>H1
M-NAN-3E60PGU5555S[D$CMBO3[W4+738?.N[F&UAR%\R9PBY/09/<U8KGO'W
M@?3OB-X5O- U5ITL[K:6>V8+(I5@P()!'4=P:4F[:#BE?4^=?CY#H_QC^,O@
MOPMHTL-]<Q;AJ%Y:R!UCA+!BA(XRJJY^K 5]3V]O':P1PPHL<4:A$11@*H&
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M@@]*[BBENDNP[ZM]SS'2/V??#^C?#75?!$-_JLFD:C-Y\DDDL9F1LH<*1&%
M_=CJIZFNN\!^"K'X=^%;'P_ILMQ/9V881R73*TAW,6.2J@=6/:N@HJK[^?Z$
MV1PGQ+^#NC?%2[T6XU:YO[=])D:6 6<B*&+%"=VY&R/D'3'>N[HHI+160PKX
MQ^ ?PWT'XF^*OB+IFO6?VB%9P\4J,4DA;S9!N1AT/MT/<&OLZN ^'/P7T3X8
MZUK6IZ7=:A<3ZLVZ=;R1&5?F9OEVHI'+'J31&W-=[6?Z [\MEO='*>%?V1_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;VL45M<;U?S(U4!6W+P<@ Y'%5-3^(7A71;QK34/$VCV%VIPT%U?Q1N#[JS
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M!T%%16MU#?6\<]M-'<02#<DL3!E8>H(X-2T %8>L>.O#7AVZ^RZKXATK3+G
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M^K6,.K3C=%8R7*+/(.>5C)W$<'H.QJE?_$+PKI5\UE>^)='L[Q3M-O<7\22
M^FTMF@#H**;'(DT:R1LKHPW*RG((/0@TRZNH;&WDGN9H[>",;GEE8*JCU)/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP;W)KB_V5;S4/"?Q(\9^ IKQ[O3[$R/%N)PKQRA"RCMN# GZ"OJ2OEOX&_\
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M7'_H5</^TA_R<)\,O^NMM_Z55O**]M"/1VO\UJ<Z?[J<NJO^#.LOOV0_!/\
MPB=S;E+VXUTPL_\ :SW+F1I<9SLSLP6[8S@]<\U0_8M\27VJ>!=6TN[F::+2
M[L+;[R241USL'L""<>]?0LG^K;Z&OF3]B>58-!\9R/PB7<;'Z!'-91E:4[[6
M3_$T<;QCWO\ HRY)\"?$?Q6^*^K:O\1$FA\-VY(TVS@NT*NF["J-K$H-HRW
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M.\BJP7<K L2PS@@C.#GIUKH?V*?^/WQW_P!=X/YRUL?MN_\ ).]%_P"PF/\
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M*EHYV[+\RZFL(7[O\CP^^\%77Q#_ &I/$^@PW\^G6EU/+]NFMSAS;@*S(/\
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M/T')IR7+%<KMIO\ J-/FF[J^NWZ'0^"=7D_:*_9YOK34=KZJ\4EE+)@ &XC
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MUV&A^T$()'4%&3)[\*1ZY.*^KZ\2UGP9\*_VD]0OIK6ZDFU?3]L5S=V"O;S
M'(4,)$VO]TC.#C&,U,6XR;75:B=G&SZ/3^O,T?VEOB#I?A7X9ZQILMU$VK:I
M;FUMK-6!D;?PS[>H4#)S]!7/_L6S-)\)[Q&.5CU24+^,<9K+\:?!CP)\!_AO
MXAURWBFOM5DM7M+2XU.59'6252@"*JJH/).<9 !YZUV/[*7AV;P_\&=,:="D
ME_+)>[6Z[6("G\54'\:JGO-^2_/;]29WM!>;_+<]@HHHI#/-OVCO^2)>*_\
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MDJ2.OY5H?M :QJOQ,^+FC?"S3;U['3F"27[QY^<E2YW#N%09 Z$GZ8A\._\
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MQ,!]5<U],UT3W7HOR1DNMN[_ #/)OVBM#\<>*O"MIHW@R(E;J4B_F2Y2%Q$
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M^%;'Q%XX^U:_K6J6Z3D2W+QI!&5'EJH0@\+MZG Z #%6?VV/^25:=_V%XO\
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M*I*C@_U,?^Z/Y5)4O<4/A04444BPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$LI>S=FCPQR.653G\*YSXM?!C6_'GQ2\'^)=/NK"&QT=X6N([F1UE;9-YAV
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M^HFDUR]#@_B]\'](^,&@I8Z@[6EY;DO:7T2AGA8]1C^)3@9''0<BO*;/X/\
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M=43%<J<>A\U:E^S]\3OB//;VWC[QW:SZ/$X<V^FH<MC_ &1'&N?]H@XSTKZ
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M"*,O]&:OI2BI225NA3;>O4Y+X8_#/2?A7X8BT;259QN\R>YEQYD\A'+-CZ
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M):771GS9J7P#^*7Q%:"R\=^/;231HV#-!IJ$E\>JB.-2?=MV/2O>O!_A'3/
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M44EI'E]?Q&]9<W]:'C/PN^#.M^"?B]XP\57UU82Z?K#3FWCMY':5=\XD&\%
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MYO\ '3X7ZEX1U/PU/KGB*3Q)XMUFX;SV).Q$4HJ*@/.,L>P'8 8KU?2O@/\
M%?X<^=8>!_'MDFBLQ9(=1CY3/)PIBD4'U*XSUQ6[X!_9SU"'QC!XO\>^(6\3
MZ[;D-!$F[R8F!RK9.,@'D*%4 \\UK&W-%]%WW]"7>S75]MO4]TC4I&JGJ !3
MJ**D$K*R"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNJWFN?"KPS?W]S)>7MQ:+)+/,VYG8D\DT1]Y-]K+[QOW;7ZG;4444""BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF5YXL.ZLQ">=(,C<1GA4&>G1C7167@G]HC3K."TMO%NAPV\$:Q11K##A548
M'^C=@*F/O0DW]K3Y+_@E2O&44NFOS>WX%#]D#Q+<>']8\3?#[5&,=W9SO/!&
MQZ,IV2J/R4_G7H7[6'_)#]:_ZZV__HY:^=?$UAXU^!_Q>T'QCXLGM;R\O9S+
M-<6( 25!A)5("* Q1NP[YKZ%_:FN8KSX#ZK<0.LL,K6SHZG(93*A!'X45+RI
M1D]]$_5-#I^[5:6VK1Y?\)?@GJ?QJ\"Z5J'BSQ%J%IX?AA%KINE:>P0;(_D\
MQMP9<E@?X23Z@8%4K?3]7_9E^-GA_1;+6KC4/#&M21J;><\;7?RSN7IO4X.Y
M0,C\17O7[.O_ "1/PG_UZG_T8U>/_M3?\EF^&W_72/\ ]*%KHVQ$8KJ[/S,%
M[U&3?177D3_ME?#73/[''C?S[O\ M7S(+'R=Z^1Y?SG.-N[=_P "Q[5VO[-_
MP?T;P3X9T_Q/8W-]+?ZUI4+7$=Q(AB4LJN=@" CGU)XJM^V5_P D=_[B,'\G
MKT+X/_\ ))?"'_8(MO\ T4M<\=*=1KO^:=RYN\X)]OR:L>'?L4_\?OCO_KO!
M_.6J_B;6O$O[17Q<U/P=H^L2Z)X3TDLEU+;D@RA6VL6P1O);A5)P ,U8_8I_
MX_?'?_7>#^<M1_LANMC\0/B)I]R-FH>:IVM]["2R!_U9:M)2E%/^6_X()-Q5
M1K?FM]X_QE^RS=_#S17\0?#W7]:.N60\UK8L&DN .H3RU4Y_V2&STKH?B=KV
MN>(_V4=3O/$FFS:5K9C@2Y@FB,9++<QC?M/0,,''N:]XU;5;30]+N]1OIA;V
M5K$TTTK D(BC).!R>!VKQGXZ>-=%\>_LZ>)M4T&^&H6.^&+SEC=/F$\61A@#
MW':L:C]QKT^6II!>_%_TP^&?_)I2_P#8%OOYS5XE\ OAOKWQC\-R:1=ZS<Z1
MX)TVX9I(K/A[J=\$C)X.% Y((&1@<DU[;\,_^32E_P"P+??SFJM^QC=03?"6
M>&-E,T6I2^:HZC*H03^'\JZ&DZU6_9?FS%-^RIV_K0\]^('PYUW]EVXLO%7@
MW7+R[T(SK%=V-XP(YZ!PH"LK<C.T%3C'6O>O%?Q U*X^$'_"3>$=-GU34KZT
MCDLK>&(RLC.!DE0.=F3QZKBL#]K*]@M?@CK$<VW?<2V\46?[_FJW'_ 5:N9T
MSXD3_!;]EWPOJ1MEN=3GB$5I#-G;ND9W5FP<[0G/'7@<9K+FO3ES=&E]ZV-;
M6G%KJG^'4QO!W[+]W\1]%AU[XC>(-=;5[P>8+,2!'MU)X5O,5L''\( QTKG+
MS1=8_9C^+WABPTK7KN_\.:Q,BO:W#8!4R!'#+]TL P(8 ?SSU/AOX>_&+XH:
M39ZUJ_Q#E\.VM]&L\-O8*RR+&PRN5C* 9!!^\3SSS7F'Q:^&:?#/XD>#;:77
M[WQ#J=Y-'/<W-Z><><H7 ))'1NI-;15JT([7=K?H9OWJ<GOIN>L?MC?#?3+[
MPS)XUDGNQJMDD%E'"KKY!0RDDD;=V?G/\6.G%:G[,WPGT+P?X5T_QQ%>7OV[
M4=,/VE)Y$,"*6#$J @8?<'5CWK7_ &N?^2):G_U\V_\ Z,%6?AY;S7?[,-E!
M;@F>309DC ZEBC@?K6,7R4JDH[I_FFV:RBISIQ?5?J>2Z3'XC_:T\8:N\VL7
M.A^!M.D");6YP9,YVC'1G(&2S9VYP!5WQY\ ]1^!NBS>+_A_XEU2)M. ENK.
M[=6\V,$9/RJJL!U*LIXSSQ7%?LY_"_6_B!X>U6;1?B)J7A)K:Z"36-BLF'R@
M*R';,G)P1T_AZUZ?K7[-_BA=)NSJ_P ;-7&E^4PN?MHE\GR\?-OW7.W;CKGB
MJE'D24='_6Y$6IN\M4>D^%_C)9:Y\&V\=3Q+$MO:R27-NC=)DR"@)]6 Q_O"
MO#/A]\,=:_:=^U^+?&NO7MOI#3M%9V-DP &.NP,"J*.!]TEB#D]STNJ?#VW\
M$_LL^+=*T?Q';^*;9I/M0O+-%" ;XBZ_*[C@*3U[UW'[*=Y!=?!#0TA8%H'G
MBE _A?S6;!_!@?QJK1E.4K;)?CN_T)O)0BN[?X;'SS^T1\,];^$^A:?I46M7
M.L^#KBY\VV2\.9+2958;,],%6)X !QT&.?LCP/\ \B5X?_[!]O\ ^BUKQC]M
M:ZAC^%NGP.RB:35(S&IZG$<F2/S'YU[/X'_Y$KP__P!@^W_]%K4TVW&=^Z_(
MJ?Q1MV?YFW7Q7KEOXCU3]J?Q1H_AG4#I-]JK?99KY!\T$'EQO(RGJ#A.V#[C
MK7VI7RQX*_Y/4\2?]<I?_14=$%>JK]I%2_A/U7ZF=\6OV:H?ACX.N/&'A_Q)
MJ[ZSIS)-/+<2J"^6"ED90&4@G/)/%:7@+P-X@_:<\/0:[XV\17MIHD8%M:Z?
MIA$?GL@VO.^X%<EL_P )[XP*]=_:._Y(EXK_ .O9?_1B5F?LI_\ )"_#_P#O
MW/\ Z/DIQUYK]+6^=_\ (B7N\K75M?A<\D\&V>I_L_\ [0VF^#;75[C4?#NK
M!<03G@!PP4E>@=67[P R/K6I^VM_R$/ '_7>X_G!4_QB_P"3LOAW_P!<;?\
M]'35!^VM_P A#P!_UWN/YP5,6Y>R;_F:^XJ247-+^7]#J/VT?^22VW_84A_]
M DKK;_Q]#\,_@'I>ORQB:2WTBT6"%C@22M$@13[9.3[ UR7[:/\ R26V_P"P
MI#_Z!)6)^T);S3?LN^&'C!*0QZ>\N.R^3M_F165VH5+?S+\BK7G"_9_F8WP_
M^!VK_'W2T\7^/_$FI&"^+-:65HZKM3) 8;@51<CA0O3G/-1:]8:_^R5XHT>]
ML-9NM:\$:A*89K&[;)CZ$C'0-CD,H&=I!&.MSX:_ KQ3XG\!Z'JFE_%_6M.L
M;FU5X[.W6;R[?L8QBX ^4@C@#ITI_C3]FN^DL;>/Q;\:KAK-I?W*ZTK&,R8/
MW1)<XW8STYQFNB7N2M%6MT_S,X^_&\M;G:_M2?$[4_!GPYT^7P_</;RZQ,(A
M?PG#1Q;"V5/9FXP>H&<<URVA?LA>'?$GAZUU:?Q?JNHZK=Q"8:C;RQM"S$9R
M 5+,,Y_C!/M7J/BOPAX1U/X9Z3X8\6:O9FQ6WABM[Z2X2W9W1 JRQ%B1GGW'
MS8YS7D%U^R=XO\&7$ESX#\<RV^3N\F9Y+9CZ M&2K_BH%1I&4O71^78J[E&/
M>VJ\ST+X"^&_B)X-N=9T/Q;(VHZ%$3_9VH37*R2'#8P!N+!67! ;[N,=Z^>O
M%_P/T+1?V@=$\$P7>HOI6H+&\LTDD9G!;>3M(0+_  CJIKV#X%_&3Q?<?$*]
M^'_CN-)=6@1VCNE5%<,H#%6V?*P*\A@,^N<\8?Q&_P"3RO"/_7*W_E+5Q5ZM
M)O6]OFM1;0J=+?@]#L_B;XBM_P!F7X-V.D>'I99[QY&MK"2]*NZ[BSO(V% .
MW/ QU(SGFN2\)_LJS^/M'@U[Q_XEU>XUF^C$ZPP2KF ,,@,SJV3@C@  =*3]
MMZ%UM?!=VREK6*YG63TR1&0/R5J^F=/NH;VQMKBW8/!-&LD;*<@J0""/PJ(^
M\I3>][>G_#[A+W>6*VM?\3Y6TO6?$O[,?Q.TOP[JNKS:WX,U4A87N"3Y*E@N
MY02=A0D9 X(.<9Z:O[;\S6^D^#Y5 +1W<S@'ID*AJI^VQ*EY?^!].A;=?M+,
MRHHRP#&-5/XD?I4O[;RF/P]X.5N66XF!_P"^$H3<H1;WYK7^:_(JR4[):-?H
M_P S1TW]F6Z^)^E1>(/'OBG5;C6[^,7"6]JRK#:!AD(%96Z9'"[1V]ZR_@+K
M'B#X<?&C5/AEJFIRZIIJ1N;8RDD1D()%902=H9"<J#C-?3]G_P ><'^XO\J^
M8K3_ )/EN?\ KA_[8K5)\M7E6UGIZ;&2?/2YI;Z/\4;O[0WQ,\07'B[1_AOX
M.N&LM7U(H;F\C8J\:N3M4,.5& 69ASC&.]5%_8MTP:=Y_P#PEFKCQ'C=]N!7
MRO,]=N-_7_;S7"?%+PW>Z]^UHVGPZ[<>&+B^6'[+J=N&+QG[,  NUE/S%67A
MAUKTG_AFWQS_ -%K\0_]\S__ "340U@I=7?_ (;Y&LOCMT21)^SK\2]>D\1Z
MW\//%]P;O6M'+&"\D;<\J*P5E+'EL95@3R03GI7&^,+K4/CA\?M3\#ZEXBG\
M/^'M/W)'9POM-TR;<X!X9VR2,YPHX'6NL^%?P3M/!_Q:;69_B5!XGUZ%)([J
MQD1?M3;DQER9W88X/(["M+XH? ?P7\9/$=U<V&OPZ=XHB4"Y^Q2QSGY?E#2P
MY!!& ,Y7ISFJ>KA)ZZ:^O<E?:2TUT].QR?BG]E/4O ]HFK?#+7]776877-K<
M7,:&521G#@(HQU*MD$9'M7T%X9;6[SP=9?VY#'9Z\]MMN5B<%5EP06!7(P3S
MQTS7S#KG@GXR? C2I]7TSQ4-:T.R7=)"TIE$<8(R3%*"%'^X21S7T)\&_B,?
MBEX!L->>W6UN7+0W$*'*"13@E<\X/!&>F>_6G;FC**?_  !?#)-HYWX&?#[Q
MUX'FUIO&7B7_ (2!+H1?91]OGN?*VE]W^M4;<Y7IUQ7K-%%#=PMJWW*.L:'I
MOB"U%KJFGVNI6P8.(;R!94W#H<,",\G\ZGCCM]-LUCC2*UM+>,*JJ B1HHX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,5Z-12:3CR]"DVI<Q\S>%U_:%\'Z-;^'K?0]'O[2U000:A=3Q,R(!A<8E4D
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MSSX2_!O3/A?X(ET(L-0FO0S:A<,N!.S+M*@=E X ^I[UY#I?PG^*OP.UJ_\
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M9+I\>B^3XENE@:73OM$6$=9%+@/OV8X)'S=,=Z]:HJ.7W.3I>Y?,^;GZG"_
M_P -:EX/^%?A_1]7MOLFHVL3K-#O5]I,KL/F4D'@CH:[JBBM)/F;;(BN5)!7
MS;XR^!OC+P/\0[CQG\,)K=FO&9KG2IF5!ECEU&XA60GG&00>GM])45%M4UN5
MTLSYNN/AS\4OC9J=G!\1%LO#OAJU?S7T[3Y%)N& X^Z[_F6XR<#-=#^R_P"
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MIVV]@D?C#*<%?^!!BOU(KKOAC\/;'X7^#K/0;%VF6++S7#C#32M]YR.WH!V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\G6O^%B_ZSS(_L/_ ![?=PV__4?\!^]^%79J3B^A*:E%274]0HHHI#"BBB@
MHHHH ***\L^)7QK/@CX@>%O"5MIPN;O6)H?,N97PD43R[#@#DMP?0#CKTHZJ
M/5@]$Y=CU.BBB@ HHHH ***\M^#/_"S/[3\1?\)__P >>]/[,_X]ON[GW?ZG
MGIL^]_C0M78'HKGJ5%%<_P#$#5+K0_ ?B/4;*7R;RTTZXGADVAMCK&S*<$$'
M! X(Q4RDHQ<GT*BN9I(Z"BO)/V8_'6N?$+X<RZIX@OO[0OEOY81+Y4<?R!4(
M&$4#J3V[UZW6C7+H0G<****D84444 %%97BOQ##X3\-:IK5Q%)-!86[W#QQX
MW,%!.!GO7*_!/XES_%CP?+KT]E'IX:\E@C@C8OM1=N-S'J>>H ^E"U;2Z ]$
MF^IW]%>6:+_PLW_A=6I?VA_R3[8_V7_CU^]L7;]W][][=UK&_:4^,>L_#6UT
M72_#D<9UK5W94FD0/Y:@J!M4\%B6 YR.#Q2OI%]^G4JVK7;[CVRBO)_A#I?Q
M7L]8GF\?:S97VG/;?N;>VCB#I+N7[Q2->@W="17K%4U8A.X4444AA1110 44
M44 %%%% !1110 4444 %%%% !17@W[4WQ.\2_#E/"Q\.ZE_9QO9IDN/W$4N\
M+LP/G5L?>/3UKW:)BT2$\D@$T+WES>=@>C2[ZCZ**\%^*7Q.\3>'/V@O!7AK
M3M2^SZ)J*VYNK7R(F\S=.ZM\S*6&0H'!'2E]J,>[L'V7+L>]45YE\<O^%C_V
M7I?_  KG_C\\]OM?_'M_J]O'^OXZ^G-=/XN\7_\ " ^ ;SQ!J4$ET]C;+)-#
M$5#._ QGH/F/7^=%THN3Z#L[I+J=-17%_!_QY<?$OP#8>(KFUCLI+MY@((F+
M!%65D49/4X49/'/85A?#[_A9?_"R_$__  E'_(HYF_LK_CVZ>:/+_P!7^\_U
M>?O_ (\U5FI<K)NFN9=['J-%%%(84444 %%%% !1110 45S_ ,0-4NM#\!^(
M]1LI?)O+33KB>&3:&V.L;,IP00<$#@C%<3^S3XWUKX@?#4:KK][]OO\ [9+%
MYWE)'\J[<#"*!W/:B/O-I=%?] >B3[GJU%%>0_%[3OBY>>(K9_ .J6ECI M5
M$T=PL!)FWMD_/&QQMV]\<4F[6&>O45\S2:/^TE#&TDGB/3$C4%F9DM  !U)/
MDUF_L^_$SXG_ !!^))M+_7(]5\/:<7.H2QVL"1-\K*@5UC#$EL$8QD ]JJ*Y
MG8F3Y5S'U71112&%%%% !1110 4444 %%%% !1110 45D^++Z?3/"NLWEL_E
MW-O9331/@':RQL0<'@\CO7FG[+_C[7OB)X O-2\0WW]H7L=^\"R^3'%A B$#
M"*!U8]N]"]YM=M0E[MGWT_4]AHHHH **** "BBB@ HHHH ***H:]J\7A_0]0
MU.9'DALK>2X=(\;F5%+$#/?BDVHJ[&DV[(OT5YU\#_BI-\7O#>H:S)8QZ=%'
M?/;0PJY=M@1""Q[GYCT %>BU336Y*:>P4444AA1110 4444 %%%% !117 _&
MKXJ)\(?!O]LFP;49I9UM8(0^Q=[*S L?0!3T&>GUJ9245=C2;=D=]165X5U6
M77O"^CZE,B)->6<-PZQYVAG0,0,]LFM6K:<79DIW5T%%%%(84444 %%?/W[5
M_P 4O%'PU7PQ_P (WJ?]FF]-P)_]'BEW[?+V_?5L8W'IZUCQZ/\ M)R1JZ^(
M=-VL,C]W:?\ QFE%\RNO0;]VU^I],T5\U0Z'^TD)4W^(--*;AN_=VG3O_P L
M:]*^-W_"Q?[ TW_A7G_(3^T?Z5_Q[_ZO8?\ GOQ]['3FF]%<2U=CTNBJNE?:
M?[+L_MO_ !^>2GG]/]9M&[IQUSTXJU3DN5M"3NKA1112&%%%>5_#SXV'XA?$
MWQ)X<M].%I8Z-&R^?(^99I%EV$X'"KUXY/N.E"U?+U_R#9<W]:GJE%%<_P#$
M#5+K0_ ?B/4;*7R;RTTZXGADVAMCK&S*<$$'! X(Q4RDHQ<GT*BN9I(Z"BO*
M?V:?&^M?$#X:C5=?O?M]_P#;)8O.\I(_E7;@810.Y[5ZM6DH\KLR$[A1114C
M"BBB@ HHHH **\"^/GQ0\3^"OB;X(TG1M3^QZ?J3H+J'[/%)Y@,RJ>64D<$C
M@BO?::UCS>;7W ])<OI^(4444@"BBB@ HHHH **** "BBB@ HHKP3]F?XG^)
MOB#KGC.WU_4OM\.GRQ+;+Y$4?E@M*#RBC/"KUSTH6KM\_P"OO$_=CS>GXGO=
M%>6:=_PLW_A=UY]K_P"2>;&\G_CU^]Y0QT_>_?SU_E7J='1/N-Z-H***\"_9
MS^*'B?QYXS\:6.NZG]NM=/D"VL?V>*/RQYCKU103P!USTIKWI<ODW]P/2/-Z
M?B>^T444@"BBO*M%^-A\0?&V_P# MMIHAMM/@D:>\E;+R2+MX51P%^;J<D^U
M"U?*M_\ ('HKL]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHKRSXN?\+-_X27PW_P (/_R"-_\ Q-/^/7[N]?\
MGK\WW=WW:%JTNX=&^QZG1110 4444 %%%% !17EGQ2^-9\ ^-/"OABVT[[5>
M:U<0JUQ*^(X8FE$9( Y9NOH!QUZ5ZG0M5S=/\@V?*%%%% !1110 45X%XE^*
M'B?3_P!J#1_"5OJ?E^'KB.-I+/[/$=Q,3L?G*[QR!T->^TUK%2]?P!Z2Y?3\
M0HJAKWVW^P]1_LW_ )"/V:3[-]W_ %NT[/O<?>QUX]:XKX(_\)__ ,(S>?\
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M1G\:Q_BE_P GB>#_ *6G_H3UH_%)?^%6_M->%O%B_NM-UM1;7;8PN[ B<GZ
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M^@O'_CC3_AWX1O\ 7]1):VM4!6-"-TKDX5%]R2/YUX%^W)_R!O")[_:I^?\
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M!HGP]M8_!OA#1M3T2::65+NZE19)'W;6W#[0G0KC[HX K25G5FNB_P R(O\
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MH:#-IL!TNUMD D@7:" Y$2Y^7 ^\W3\:R_V5_B;XE^)%KXG?Q'J7]HM9S0I
M?(BBV!@^1\BKG[HZ^E>G?"__ ))?X6_[!-M_Z*6O!?V)V>/2?'31C=(LT!4>
MIVRXK6I+EJ5+[)?K^9C3UIP?=K\F;WC_ ./'BCQ!X\G\#_#/3XKK4;=F2ZU*
M8!EC*\-M!^4*IX+-G)X Z9R_$6O?'GX3V0UW6;W2?%6D0X:ZAMX4_=+W+;8X
MV'U&X#OQ5;]B2&.YD\:ZA+A]0>>%&8CYMI\QCS[G^5?36J6L-]IMW;7*AK>:
M)XY%;H5*D'/X5$KTX7ZVO^IKI*;3VO8YWX:?$;3OBAX/MM=TT-$LF4FMW.6@
ME'WD)[]00>X(/M7S;\/?CY\4/&5SJ?AW2$BUS7I)RT5Y=0Q10V-NN0S$(J@G
M)'+9Z8 ).*W/V'YI?[*\8V_)M8[B!DYX#%7!_15_*HOV*;>/^U/'4^P>:)8$
M#]PI:4D?F!^579.HUTY;_E_7H9W<8:[IV_/^O43QAXX^-WP4:TUCQ+?:7XDT
M6201R+;PH$4G^$E8XW4D X/(SZ]*^D_"OB*V\7>&],UJSS]FOK=)T#=5W#.#
M[@\?A7FG[6 !^!^M9&<2V_\ Z-6MG]G7_DB?A/\ Z]3_ .AM1%\T97Z-?D5)
M6<6NJ?YGH]?#OQ@T?X@V_P ;_#<&K:Y876NSRQG2+J) ([=#.PB#CRADAN3\
MK?C7W%7RW\?_ /DYCX;?6U_]*6J5_%I^H2=J4_0]=L?$FM?"OX6W>K_$75+?
M5M1LV=WFL%"B4$@1QJ-B#<20.E>4^'?&7QO^,\<FL>&9=,\):"S,+=KJ-6$H
M!QP6CD9B/[P55SGTK4_;<NIHOASH\*$B&74U\SWQ&Y%>T?#VSM]/\!^'+>U"
MBWCT^W";1@$>6O/X]?QIQ][FD^EE^ Y>[RI=;O\ $\/\-_';QE\._'%KX5^*
M5I;^7>$+;ZQ;*%7DX#';A63/!P%*]Q7TC7S;^W!:PMX)\/W14?:8]0,:-WVM
M&Q8?FJ_E7O/@NXFN_!VA3W!)N)+"!Y"QR=QC4G]:<7S1=]T[?J*2Y9+LU?\
M&QLUX)^S/\3_ !-\0=<\9V^OZE]OAT^6);9?(BC\L%I0>449X5>N>E>]U\M?
ML:?\C-\1/^NT/_H<]*/Q/T?YH4_@OYHZ+XG?'+Q/JGC]O 7PVLXKC5X25N]0
MF4,L3#[P4-\H"]V;// &>O.^/-<^,/P\\'ZP/&;Z?XHT#4+*6SENM/15>S:1
M"B,=L:<;B,Y4CMD$BF_L?C[?X]^(>H77.H-(H+,?F^>61G_55KZ"^)5G!?\
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M5]G:+;0V6C6%O;@"WAMXXXPO3:% 'Z5\W_&^S@A_:B^&LZ*%FF:W\PCOMG8
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M;M=1JPE .."T<C,1_>"JN<^E7/#?QV\9?#OQQ:^%?BE:6_EWA"V^L6RA5Y.
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M6?XA#P!\/;""ZUI1_I-[<C<L)QN( )VC:,99L\G &:C_ &*?^25ZA_V%9/\
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M$_Q8TCXN>'6U/3%DMY87\JYM)L;X7QGJ.H/8]_8Y%>'_ +,__)>?B5_OS_\
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M\17_ /:-Y#J+0))Y,<6$$<;8PBJ.K'MGFO2?'G_(C^(O^P=<?^BFKQ3]B/\
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M"CGWR*N_M?S'6/''@#PZS8MYI2[KGKOE1,_D#^=>F_ ?X$VOPHTV2^OI%O\
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M;6BZ?J'E^3]KMXY_+W;MNY0V,X&<9ZXJ]113=KZ"5[:GRE\4O^3Q/!_TM/\
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MHJ/L*/9MW]2K^^Y>21\SZ+^V&-'TE=-\3^%=63Q7 HB:"&-46:0<9(8AD)]
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MOMJ79-?>3;W6GU:9\Q?%KP5XG^%GQ:'Q-\)Z<^K6-QSJ%E"I9ERH$FX $[6
MW;@#M8<]LV=0_;*M=4TTV?AKPKJUUXEE79';31JT:.>,C82SX/;:N?:OI2BI
M2]WE>Q3>O-U/"_V9/A'JW@NVU;Q)XF4IK^M-EH7.7BC+%CO]&9CDCM@=\@<!
M?6^O?LL_$[5]:M=(GUCP1K#%I/L^?W.6+ $XPK(2P&[A@>N<X^LZ^7KOX@^-
M?@!\1-:;Q/;ZOXE\&WLK-:77FM*(%+%EVLW (!VE"1T!''5\WOJVFEO+T^8K
M>X[ZZW\_7Y%'XG?M#WOQ9\$ZOI/@OP[J26/V9I-3U*]146&%1N91M9ERP&.3
MD\@#GCO/V-_^2.+_ -A"?^2UQ7CW]HJZ^,GA^Z\*> ?"^K75QJ2>1/<W$:CR
MHR?FX1F R.-S,  37MWPA\"R?"[X9Z=HS[;B^@C>:?RSP\S$L5!]!D+GVIQM
M!3D]K?\ !^X)>\XQ7?\ KYGFO[7_ (9F'A_1/&5@NV_T&[0M(HY$;,"I)]G"
M_P#?1JU^R5X;G_X1G6/&6H+G4?$=Z\V\CGRU9OYN7_(5Y]XX^,FL_M'1VO@7
MPSX?NM.6YN$.H7$S[Q&BG/S8& H."2>3M Q7U3X<T*V\+Z!I^D6:[;6Q@2WC
M'LH R?<]?QH@G&,F^NWX7_%?F*?O-1[;_C;\S2HHHI#/C'1_'!_9W^.GC2YU
M_1[Z:SU.2;R'A !9&E\Q'7=@,".N#P:W_CUINL:#\4/#'Q3TW2Y=:T18+>=T
M52?*VY.&P#M!5@0W0']?J^BE&\8P2WCM^)4GS.3Z2W_ ^>%_:\@\36XL_"'@
M[6M7UZ0;4@DC41(Q[DHS$@>X7@=17"?L]VNK>%_VE-9LO%+*FO7EE,\N&!#2
MR&.8@$<'C/3CCBOL*BJC:,N;R:^\B7O1Y?3\#Y9^(W_)Y7A'_KE;_P I:^H+
MRUBO[2>VG0203(T<B'HRD8(_(U-4<\?G0R1[F3>I7<APPR.H/8U.U/DM?=_>
M6W>?/MLON/D?P[K&N_LD^*M7T[5=(NM7\&7\OFP7ML/NXX# GY=VWAD)'0$'
M'6M\;OCAJ?Q@\!W\/AOP_J%EX5M6CFU#4KY0N_YU"1C!*_?93@,2<#@ &MGP
M[\7?%_P US4]'^(EGK&OZ4\N;350YF.T9^XSD!@1@X+ J:@^(GQ>UC]HS2U\
M(>!?#6HBRNI4-W?7BA555((#%251<@');)Q@"D[SBDM=OZ?H"M&3;T_KIZGJ
M'P5\-VWB_P#9ITC1;S(MKZQG@=AU7=+( P]P<'\*\F\"^.O$O[+-Q>^&O%F@
MW>H>'&G:6VU"S7*@GJ48X5@0 2I((/UKZ>\!^%8_!'@W1]"B?S5L+9(3)C&]
M@/F;\3D_C6]6L_XDI1>_^9G'^'&,NA\I>,/CKXI^.#VWA_X9Z3J^FQM*KW&J
M%O)D4#L70D1KW)W9.,>Q]SUWP?J,GP:U'PX][/K&K-I,MN;J9RSW$QC/))]6
M]>V*[JBLY).#AW+BVI*78^3?V7?C!:>#TM?AWJVE7UKJUQJ$@25E"JC,!\KJ
MQ#*<KCH>M7]0\?>.?@#\2-9F\2PZMXI\'WSYMKKS6D6%=Q*["?E5@"5*G;G
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M;_S-=]\'?^23^#_^P3:_^BEKL**B/NJ2[M/\+!+WG%]DU^(5\H_M$27GP_\
MCUX8\=3:;<7FC0PQ!I(1QN4N&3=T#88$9Z_G7U=12U4HR6Z=RKZ.+ZJQ\T_'
MKX@V'Q._9M_M_389K>VFU"./RK@ .K*[ YP2/?KWKUWX&_\ )'_"'_8.B_\
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MP3WKTNBI:3C**ZE)VDI=CYW_ &(_^29ZQ_V%G_\ 1,53_ML?\DJT[_L+Q?\
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M*_QEL;.QT?X<7FFWEKJ\<EP%F< 1]7E(8$A@W48QVJ+]GW_DY;XF_P"_=_\
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M[5=J2,H41LX5-KJQ!&"O;/6JL&J:G^S/\;/$6KZUHEUJ6AZL\OEWT"]4>02
MJQ^7<.A4D?RS]CT5=W=2ZK3Y:$65G'H]?F?-?B'XZ:Y\:M&N_#OPZ\+:D!?1
MF"YU;456.."-AAAE2R@D9&=V?0$TG[$-PD?A?Q/I[';=P7ZO)&>H!3:#CZHW
MY5]*T41]V]NJ_4'>5O(^6?V9_P#DO/Q*_P!^?_TI->\?%?P#%\2_ >J: [K#
M+<(&@F;HDJG<A/MD8/L3775RGQ2T/6/$7@/5K'P_?3:=K31A[2X@F:%MZL&V
M[@1@, 5].:REI24'T5C1.]1S[L^>?AW\?-0^!>DIX.\?>'-31M/+):7-JBL6
M3)(7YBJLH.<,K'C QQ7G_P ??'WB#XF:AH&MWFB7&A^'/,>'3([KAYCE2\A]
M<_*..., GFO3_!O[4UU\/=(30?B-H.N#6K3*?:EC4O.,D@L)&7G'&02#C-9]
MVWB#]JCXA>'[I-"NM%\%:1)YAN+L8\WY@6P<8+,%5<+G;U)K=>]4C)ZZ[_J9
M_#&2V\OT/9OCM\+7^+'P[;3;1D35+9ENK-I#A6<*04)[!@2/KBO)/!/[3MY\
M,=%M_#7Q!\-:M!?Z?&((KB&)=TJ*,+N5RH. !\RD@]:^IZ*A:-VZC^RD^A\M
MZ7XL^('[07Q#TV[T1=6\(>"[)AYLZ3/$)ER"V2,!W.  !D+GZY[?]KKPUJ'B
M/X3C^SK66\>QOH[J6.%2S",(ZEL=3C<"?;FO;:*F45**BO7\;CB[2YF>!_!_
MXM0?%OP+<^#](%[H/B#3]&2);PLNU751&'0@Y^]M)R!UKCO!/[07B#X-1W'A
M[XF:/K5Y-%,[0ZEGS9'4GIF1@'7.<,&Z<8XKZMHJVVY.7?<E*T>7ML?'OCK6
M]2_:R\3:#I_ASP[=V&A6$C--JU[&!M5MN[)&5& O"@DDU]$?%OXC#X0^!CK:
MZ<=56&6*W%NUQY1.[C.[:WIZ5W5<G\4K7Q#?^!]3L_#$%O-JUVGV9?M,FQ41
M_E=P?502<>W?H9E=0Y8]_P"OZZ%1M*5Y$OPT\:?\+$\#Z5XB^Q_V?]N1G^S>
M;YNS#LN-VT9^[GH.M=/7._#OPF/ O@C1M $OGM8VZQ/*.C/U8CVR3BNBJY6Y
MGR[$1ORJ^Y\I_MT?=\%_[UW_ .T:^IK/_CT@_P!Q?Y5-14Q]V'+YM_>5+WI)
M]E8*^;?VXO\ D1O#W_81/_HIJ^DJ*F4>96+C+E=SPO\ :&_Y-G?_ *]['_T*
M.NM_9U_Y(GX3_P"O4_\ HQJ]'HK5RNYO^9W,[:1796/GSXXWGQ ^'_Q!TOQC
MH;:CK7A>-0+S2(9',2$ JVY%S@%<$,00&'TS0U']LS1M4TF6ST?PMJ]]K<\9
MC2SFB0Q;B,8.UF9A[;1GVKZ2HK+E]WE>Q5]>9;GAO[*7POU;X>^$]1O-;A:S
MOM6E2063##0QH"%W#LQW'CL,=\BO(]'\<']G?XZ>-+G7]'OIK/4Y)O(>$ %D
M:7S$==V P(ZX/!K[.HJVVYJ:[6$OA<7U=RMIU]'JFGVMY#DPW$2S)G^ZP!'Z
M&N>^*W_)+_%W_8(N_P#T2U=5145(J<7%:7'!\K3?0\&_9%LXM0^!\UK<)YD$
M]Y<Q2*>ZLJ@C\C7G?A^\\3_LE>*-5M+W1KK7/!5]+YD=W;+PN,A6W8PK[>"C
M8S@$''-?7M%:.3YN9=K$I+EY7ZGRQXT_:6U?XJ:>?#OPTT'6H]0NRJR7[ )+
M"N>=I1B$S_?+# S]1Z/KGPO\1ZE^SU>^%KW5IM8\2SVXDDN+F8N7E#K)Y09N
MWR[ 3]>]>P45#2<7'N4FU)2['R)\(?VBK3X.>%8_"'BKPUJUK?6,DFS[-"H=
M]S%OG1V4@Y.,C.1BN?\ V@_%'C#XJ>&[?Q%/X=N- \'6$RI;K><2SR29'F$8
M'&!CT&>IS7VW13E[^LMQ1]W1;'D7B+P+;_&7]G_2=.M9T$SZ?;7%E,3\JS)&
M, ^Q^93Z9/I7F/@/]HZ]^#VBP^$O'_AO5(KS35\BVGMXU)DC'"@AF4$ <!E)
M!&..Y^JZ*;;<I26S$DN6*>Z/A7X@>,O$/Q$^*G@SQ%JND3:+I,]]##I=O."&
M,:RH6?D#.2PYQCL,XK[JHHHNE!07=O[P>LN9C9(UEC9'4,C#!4C@@]J^2=-;
MQ#^R;XXUAI-&N=9\#:FX=;BV&?+ )*$GHK@$J0V-W4&OKBBIU4N9%;KE9\G?
M$/XXZE\?M)_X0_P#X<U-DO707=Y=(J[$# X.TLJ+D#+%NV,<U+\>O@?K6E?#
M'P6FD)+K;>'4D2\CC4R,Y<JS2!>I4,I![@$>AKZLHHMI[N][_<%]==MOO/G+
M2_VS-*O=/AM8O"6M7/B$J$^P6J(T9?I@,#NQG_8KS+SO$]O^TEX0\1>-[1=(
MN-6N(YH;?<,01$F-$/H1QG///."<5]M45<7::GU3)M[C@NI\N?MK?\A#P!_U
MWN/YP5]1T45$5RQY?-O[QO5W\K?G_F?+/@G_ )/3\2?]<I?_ $5'6M\=O /B
M/PC\1M/^*/@^R;49X HO[.-2S$!=A;:.2K)\IQR,9^GTA11M&"6\44VI2FVM
M)'S7>_M?'Q)I9TSPGX3U:?Q9<+Y:02(KQPN>-PVDLV/=5]\5E_L5VUS9Z]X_
MM[W_ (_(I+>.?)S^\#S!N>_.:^J**J-HMON1)<T>7S1\L^'?^3V]7_ZY2?\
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9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337635744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 15, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Carisma Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">491-6422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CARM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,726,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,542,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2023. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305339201168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337605664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,605<span></span>
</td>
<td class="nump">$ 24,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,866<span></span>
</td>
<td class="nump">2,596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">80,471<span></span>
</td>
<td class="nump">54,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">6,764<span></span>
</td>
<td class="nump">8,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets &#8211; operating leases</a></td>
<td class="nump">2,173<span></span>
</td>
<td class="nump">4,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred financing costs</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">4,111<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">89,554<span></span>
</td>
<td class="nump">72,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,933<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,662<span></span>
</td>
<td class="nump">10,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,391<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">965<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,908<span></span>
</td>
<td class="nump">19,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">63,022<span></span>
</td>
<td class="nump">107,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">107,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value, 350,000,000 shares authorized, 40,609,915 and 2,217,737 shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">271,594<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(245,102)<span></span>
</td>
<td class="num">(158,223)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Carisma Therapeutics Inc. stockholders&#8217; equity (deficit)</a></td>
<td class="nump">26,532<span></span>
</td>
<td class="num">(157,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">26,532<span></span>
</td>
<td class="num">(142,670)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 89,554<span></span>
</td>
<td class="nump">$ 72,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305449327328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="nump">2,217,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="nump">2,217,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337850768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="nump">$ 14,919<span></span>
</td>
<td class="nump">$ 9,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">74,125<span></span>
</td>
<td class="nump">56,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,525<span></span>
</td>
<td class="nump">9,378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">103,650<span></span>
</td>
<td class="nump">65,996<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(88,731)<span></span>
</td>
<td class="num">(56,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(1,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">1,936<span></span>
</td>
<td class="num">(3,145)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (86,879)<span></span>
</td>
<td class="num">$ (61,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in USD per share)</a></td>
<td class="num">$ (2.59)<span></span>
</td>
<td class="num">$ (28.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in USD per share)</a></td>
<td class="num">$ (2.59)<span></span>
</td>
<td class="num">$ (28.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding, basic (in shares)</a></td>
<td class="nump">33,524,197<span></span>
</td>
<td class="nump">2,128,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding, diluted (in shares)</a></td>
<td class="nump">33,524,197<span></span>
</td>
<td class="nump">2,128,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (86,879)<span></span>
</td>
<td class="num">$ (61,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">440<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Less: reclassification to net loss of previous unrealized gain on marketable securities</a></td>
<td class="num">(399)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (86,838)<span></span>
</td>
<td class="num">$ (61,267)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305339339440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">8,700,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 107,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">8,700,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 107,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,059,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">(81,784)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 816<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (96,997)<span></span>
</td>
<td class="nump">$ 14,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification to net loss of previous unrealized gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(61,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,217,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="num">$ (142,670)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,197<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(158,223)<span></span>
</td>
<td class="nump">14,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Convertible preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ReclassificationsOfTemporaryToPermanentEquityShares', window );">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</a></td>
<td class="num">(8,700,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of convertible preferred stock and non-controlling interests to common stock</a></td>
<td class="num">$ (107,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">128,716<span></span>
</td>
<td class="nump">128,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification to net loss of previous unrealized gain on marketable securities</a></td>
<td class="num">(399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(399)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction', window );">Issuance of common stock for cash in pre-closing financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,730,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction', window );">Issuance of common stock for cash in pre-closing financing</a></td>
<td class="nump">30,640<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">30,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,059,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</a></td>
<td class="nump">42,447<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">42,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,374,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization</a></td>
<td class="nump">72,044<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">72,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger', window );">Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,872,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger', window );">Conversion of convertible preferred stock and non-controlling interests to common stock</a></td>
<td class="nump">107,809<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">122,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(86,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 26,532<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 271,594<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (245,102)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ReclassificationsOfTemporaryToPermanentEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock classified as temporary equity reclassified or converted to permanent equity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ReclassificationsOfTemporaryToPermanentEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to pre-closing financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to preclosing financing during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305432029472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (86,879)<span></span>
</td>
<td class="num">$ (61,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,837<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,316<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the operating right of use assets</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">4,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">1,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AccretionOnMarketableSecurities', window );">Accretion on marketable securities</a></td>
<td class="num">(709)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gain on marketable securities</a></td>
<td class="num">(399)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="num">(1,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,191<span></span>
</td>
<td class="num">(473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(2,899)<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,046)<span></span>
</td>
<td class="nump">47,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(4,941)<span></span>
</td>
<td class="num">(4,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long term liabilities</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(81,177)<span></span>
</td>
<td class="num">(5,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(34,460)<span></span>
</td>
<td class="num">(90,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentsForProceedsFromMarketableSecurities', window );">Proceeds from the sale of marketable securities</a></td>
<td class="nump">108,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,132)<span></span>
</td>
<td class="num">(4,660)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">72,408<span></span>
</td>
<td class="num">(32,560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities', window );">Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">37,903<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities', window );">Payment of reverse recapitalization finance costs</a></td>
<td class="num">(5,814)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing', window );">Proceeds from the issuance of common stock in pre-closing financing</a></td>
<td class="nump">30,640<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of principal related to finance lease liabilities</a></td>
<td class="num">(1,301)<span></span>
</td>
<td class="num">(865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ProceedsFromFailedSaleLeasebackTransaction', window );">Proceeds from failed sale-leaseback arrangement</a></td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">1,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction', window );">Payment of finance liability from failed sale-leaseback arrangements</a></td>
<td class="num">(1,069)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing costs</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(2,450)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">62,180<span></span>
</td>
<td class="nump">33,319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">53,411<span></span>
</td>
<td class="num">(4,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">24,194<span></span>
</td>
<td class="nump">28,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">77,605<span></span>
</td>
<td class="nump">24,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashOrPartNoncashAcquisitionEquityAssumed', window );">Conversion of convertible preferred stock and non-controlling interests upon Merger</a></td>
<td class="nump">122,204<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">Conversion of convertible promissory note, accrued interest and derivative liability upon Merger</a></td>
<td class="nump">42,447<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NonCashDeferredFinancingCostsAccruedExpenses', window );">Deferred financing costs in accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">2,779<span></span>
</td>
<td class="nump">6,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for new financing lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1', window );">Allocation of debt proceeds to derivative liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AccretionOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AccretionOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NonCashDeferredFinancingCostsAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Deferred Financing Costs, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NonCashDeferredFinancingCostsAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashOrPartNoncashAcquisitionEquityAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashOrPartNoncashAcquisitionEquityAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of reverse recapitalization finance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PaymentsForProceedsFromMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PaymentsForProceedsFromMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ProceedsFromFailedSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ProceedsFromFailedSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock, Pre-Closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815-15/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305418320160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background</a></td>
<td class="text">Background<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carisma Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the Company), is a clinical-stage cell therapy company focused on using the Company&#8217;s proprietary chimeric antigen receptor macrophage and monocyte (CAR-M) cell therapy platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company&#8217;s focus is its proprietary CAR-M cell therapy platform, which redirects macrophages against specific tumor associated antigens and enables targeted anti-tumor immunity by utilizing genetically modified myeloid cells (macrophages and monocytes) to express chimeric antigen receptors (CARs), enabling these potent innate immune cells to recognize specific tumor associated antigens on the surface of tumor cells. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2024, the Company and its board of directors approved a revised operating plan to reduce monthly operating expenses and conserve cash. The plan, which will be implemented in the second quarter of 2024, includes several measures such as prioritizing CT-0525 as the Company's anti-human epidermal growth factor receptor 2 (HER2) product candidate going forward, suspending the enrollment of new patients for CT-0508 in line with the clinical judgment of the clinical site principal investigator, pausing further development of CT-1119, reducing the workforce, including employees engaged in research and development and general and administration activities, and decreasing spending on other non-essential activities. The Company expects the reduction in workforce to be substantially complete and to pay the majority of the workforce reduction costs in the second quarter of 2024. The revised operating plan considers expenses pertaining to severance costs and potential termination and exit fees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s first product candidate to enter clinical development, CT-0508, is the first CAR-Macrophage to be evaluated in a human clinical trial and is intended to treat solid tumors that over-express HER2, a protein that is over-expressed on the surface of a variety of solid tumors, including breast cancer, gastric cancer, esophageal cancer, salivary gland cancer, and numerous others. CT-0508 has been granted &#8220;Fast Track&#8221; status for the treatment of patients with HER2 over-expressing solid tumors by the United States FDA. CT-0508 is currently being studied in a multi-center open label Phase 1 clinical trial in the United States. This ongoing first-in-human study evaluates the safety, tolerability, and manufacturing feasibility of CT-0508 along with several customary exploratory secondary endpoints.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CT-0525 utilizes a novel approach to CAR-M therapy that engineers patients&#8217; monocytes directly, without </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differentiation into macrophages. In November 2023, the Company received FDA clearance of the Company's IND for CT-0525, and expects to treat the first patient in the second quarter of 2024. The Company believes that CT-0525 has favorable attributes compared to its initial clinical stage product candidate, CT-0508, and that the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. The Company will also continue to focus on its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mRNA/lipid nanoparticle (LNP) CAR-M programs in partnership with Moderna.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company plans to continue ongoing activities under its open label Phase 1 clinical trial of CT-0508 and its sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities. The Company has also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases, also remains ongoing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using its proprietary macrophage and monocyte cell therapy platform, the Company is developing a pipeline of product candidates with an initial focus on advancing multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> autologous and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies for the treatment of solid tumors. The Company is also pursuing early research and development of multiple assets for the potential treatment </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology, fibrosis, and immunology programs are wholly owned. Additionally, under a collaboration agreement (the Moderna License Agreement), with ModernaTX Inc. (Moderna) (Note 12), the Company is developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CAR-M therapies utilizing Moderna's mRNA/LNP technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's follow-on product candidate, CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2, utilizes a novel approach to CAR-M therapy that engineers patients' monocytes directly, without </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> differentiation into macrophages, as the Company currently does for CT-0508. The CAR-Monocyte approach utilizes a single day manufacturing process, which enables the  manufacture of up to ten billion cells from a single apheresis, and leverages an automated, closed-system manufacturing process. In addition, the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. By increasing the cell yield, a CAR-Monocyte enables a larger dose than a CAR-Macrophage. In addition, CAR-Monocyte has the potential for improved persistence and trafficking, which were observed in pre-clinical studies. The Company believes that the increased cell yield, and the improved persistence and trafficking may improve tumor control. In November 2023, the Company received FDA clearance of its IND for CT-0525 and the Company expects to treat the first patient in the second quarter of 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition to the development of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CAR-M cell therapies, the Company is developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CAR-M cell therapies, wherein immune cells are directly engineered within the patient&#8217;s body. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To advance the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CAR-M therapeutics, the Company established a strategic collaboration with Moderna (Note 12). I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">n the fourth quarter of 2023, the Company presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the pre-clinical data demonstrated feasibility, tolerability, and early efficacy of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> CAR-M against metastatic solid tumors. In December 2023, the Company announced the nomination of the collaboration's first lead candidate, which will target an antigen present on a solid tumor with significant unmet medical need.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to acting as a first line of defense in the innate immune system, macrophages and monocytes are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration.  Using the Company's macrophage and monocyte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engineering platform, the Company is pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. Pre-clinical proof of concept for fibrosis is expected in the first half of 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Merger with Sesen Bio</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio, Inc.) consummated a merger with CTx Operations, Inc. (formerly privately-held CARISMA Therapeutics Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and Seahawk Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). Pursuant to the Merger Agreement, the Company changed its name from &#8220;Sesen Bio, Inc.&#8221; to &#8220;Carisma Therapeutics Inc.&#8221; At the closing of the Merger, (a) each then outstanding share of Legacy Carisma common stock and convertible preferred stock (including shares of Legacy Carisma common stock issued in connection with the pre-closing financing transaction described below) were converted into shares of Sesen Bio, Inc. (Sesen Bio) common stock at an exchange ratio of 1.8994 shares of Sesen Bio for each share of Legacy Carisma (the Exchange Ratio), and (b) each then outstanding stock option to purchase Legacy Carisma common stock was assumed by Sesen Bio, with necessary adjustments to reflect the Exchange Ratio.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, references herein to &#8220;Carisma,&#8221; the &#8220;Company,&#8221; or the &#8220;Combined Company,&#8221; refer to Carisma Therapeutics Inc. on a post-Merger basis, and references to &#8220;Legacy Carisma&#8221; refer to the business of privately-held CARISMA Therapeutics Inc. prior to the completion of the Merger. References to &#8220;Sesen Bio&#8221; refer to Sesen Bio, Inc. prior to the completion of the Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Merger, the shareholders of Legacy Carisma held 74.2% of the Combined Company and the shareholders of Sesen Bio held 25.8% of the Combined Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Ratio</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse capitalization under which the historical financial statements of the Company prior to the Merger are Legacy Carisma. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305336990720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development-Stage Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityAbstract', window );"><strong>Development-Stage Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityTableTextBlock', window );">Development-Stage Risks and Liquidity</a></td>
<td class="text">Development-Stage Risks and Liquidity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$245.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December&#160;31, 2023, the Company had $77.6 million of cash and cash equivalents. Absent any other action, the Company would have required additional liquidity to continue its operations over the next 12 months, which would have raised substantial doubt about its ability to continue as a going concern. As discussed in Note 1, Background, in March 2024, the Company and its board of directors approved a revised operating plan that suspends certain development programs, reduces its workforce and decreases other non-essential activities to extend the Company&#8217;s cash runway. The Company projects this revised operating plan will alleviate the substantial doubt that has been raised by significantly decreasing expenses, thereby reducing ongoing liquidity needs to enable the continuation of operations for at least 12 months from the issuance date of these consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on risks of development-stage and liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305502783280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management&#8217;s estimates include the fair value of the Company&#8217;s common stock and the derivative liability prior to the Merger, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. The Company considered the carrying value of its convertible promissory note (Note 8) as of December 31, 2022 to approximate fair value due to its short-term nature. The derivative liability was recorded at its estimated fair value prior to its derecognition in March 2023 upon conversion of the associated convertible promissory notes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement at reporting date using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; U.S. Treasuries</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative liability &#8211; redemption feature on convertible promissory note</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had no marketable securities. The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated a redemption feature within the convertible promissory note issued in January 2022 and determined bifurcation of the redemption feature was required. The redemption feature is classified as a liability on the accompanying consolidated balance sheet and is marked-to-market each reporting period with the changes in fair value </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded in the accompanying statements of operations until it is triggered, terminated, reclassified or otherwise settled. The fair value of the derivative was determined based on an income approach that identified the cash flows using a with-and-without valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the discount factor used was 12% and a 90% to 100% probability of completing a qualified financing prior to the maturity date of the convertible promissory note was assumed. The estimated time of conversion ranged from <span style="-sec-ix-hidden:f-346">three</span> to twelve months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below is a summary of the changes in fair value of the Company&#8217;s derivative liability associated with the redemption feature of the Company&#8217;s convertible promissory note (Level 3 measurement):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition upon conversion of convertible promissory note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023 and 2022, there were no transfers between Level 1, Level 2 and Level 3.</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Upfront license fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Customer options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestone payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, cas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h equivalents consisted of investments in a money market account. The Company maintained $30,000 as collateral for the Company&#8217;s credit card program at September 30, 2023, which was previously reported as restricted cash on its consolidated balance sheet. There were no amounts restricted as of December 31, 2023 and 2022, as the collateral was released to the Company in the fourth quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Marketable Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities consisted of investments in U.S. Treasuries that were classified as available-for-sale. The securities were carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, a component of stockholders' equity (deficit). Realized gains and losses and declines in value determined to be other than temporary were included in the Company's consolidated statements of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:f-368">two</span> to five years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company did not recognize any impairment of long-lived assets during th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately. The Company incurred $4.2&#160;million and $4.1&#160;million in deferred financing costs associated with the Merger during the years ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon completion of the Merger, the $8.3&#160;million of deferred financing costs were recorded against the gross proceeds received as a result of the Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Noncontrolling Interest</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that ownership interests in the Company&#8217;s subsidiary are held by entities other than the Company, management reports these as noncontrolling interests on the consolidated balance sheet. Prior to the Merger, an investor had outstanding Class B and Class B-1 shares in the Company&#8217;s Luxembourg subsidiary related to the sale of the Company&#8217;s Series A convertible preferred stock (Series A) and Series B convertible preferred stock (Series B). The shares were nonvoting shares at the subsidiary entity level and were presented as noncontrolling interests in the accompanying consolidated balance sheet at December 31, 2022. In connection with the Merger, the Company's noncontrolling interests exchangeable shares converted into shares of common stock (Note 8).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger, and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income taxes </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the deferred tax assets will not be realized. As of December 31, 2023 and 2022, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock and exchangeable shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,936,148</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,356,937</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of convertible promissory note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,258,151</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,551,236</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for fiscal years beginning after December 15, 2022. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to accumulated deficit and did not have a material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued but not yet adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305336975568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger with Sesen Bio</a></td>
<td class="text">Merger with Sesen Bio<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2023, Legacy Carisma completed the Merger with Sesen Bio as discussed in Note 1. The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) Legacy Carisma stockholders own approximately 74.2% of the Combined Company, (ii) Legacy Carisma holds the majority (six of seven) of board seats of </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Combined Company and (iii) Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were 40,254,666 shares of the Company&#8217;s common stock outstanding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net assets acquired in the Merger (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 7, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,588</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,316</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,499)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,308</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,264)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired less transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March&#160;7, 2023, the Company paid $4.6 million of severance and personnel costs related to Sesen Bio.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305336826080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,942&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,628&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Lab equipment includes failed sale lease-back assets of $3.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $2.6&#160;million, respectively, as of December 31, 2023 and 2022. Lab equipment includes finance lease ROU assets of $2.9&#160;million as of December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The accumulated amortization balance includ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9&#160;million and $0.3&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2023 and 2022. The accumulated amortization balance includes $1.7&#160;million and $0.6&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2023 and 2022.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $2.8&#160;million and $1.9&#160;million for the years ended December 31, 2023, and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305336066624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,662&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305339006336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#8217;s operating leases have term end dates ranging from 2024 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2024 to 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating and finance lease right-of-use (ROU) assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company entered into purchase and sale agreements under which the Company sold lab equipment for $1.2 million and $1.6&#160;million, respectively. Concurrent with the sale of equipment, the Company entered into various lease agreements, with term end dates ranging from 2025 to 2026, whereby the Company will lease back the equipment. The Company accounts for such transactions as failed sale-leasebacks, due to having continuing involvement with the equipment. The Company carries this laboratory equipment as property and equipment, net on the accompanying consolidated balance sheets and the sale proceeds as a finance liability. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. No gain or loss was recorded on the failed sale-leasebacks. As of December&#160;31, 2023, the Company had a $1.9 million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of the lease costs were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease term and discount rate information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash used in finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities were as follows as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal year ending:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,251&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing and Sponsored Research Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November 2017 (Penn License Agreement),</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company is required to make annual payments of $25,000. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penn is eligible to receive up to $10.9 million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0 million per product in commercial milestones and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#8217;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement is for five years and shall renew automatically for additional one-year periods unless and until </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminated by either party. In addition to paying to manufacture the product, the Company will also pay $1.0 million per calendar year, payable in quarterly payments, for reserved capacity starting on the date on which the Novartis site is declared ready to produce CT-0508 as determined by the Company. In the event of termination without cause by the Company, a termination fee equal to $4.0 million will be payable by Carisma to Novartis which, pursuant to the terms of the agreement, can be credited in full against amounts due for a substitute product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2023, a purported stockholder filed a complaint in the United States District Court for the District of Delaware against Sesen Bio and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumley v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 1:23-cv-00131 (D. Del.) (the Plumley Complaint). The Plumley Complaint asserts claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#8220;control person&#8221; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the Merger and an award for plaintiffs&#8217; fees and costs. On February 7, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Franchi v. Sesen Bio, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 1:23-cv-01041 (S.D.N.Y.) (the Franchi Complaint). The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February 9, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and its board of directors, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Menzer v. Sesen Bio, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, et al., 23-cv-01119 (S.D.N.Y.) (the Menzer Complaint). The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint. In April 2023, the Company executed a confidential fee agreement to resolve the stockholders&#8217; claim for attorney&#8217;s fees and expenses in connection with the Plumley Complaint, Franchi Complaint, and Menzer Complaint.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company settled and paid the confidential fee agreement resulting in $0.2 million of claim expenses incurred during the year ended December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305335940432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2023, in connection with the closing of the Mer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#8217; equity (deficit) for the year ended December 31, 2023: (i) the sale of 3,730,608 shares of common stock in a pre-closing funding at $8.21 per share for total proceeds of $30.6 million, (ii) the issuance of 5,059,338 shares of common stock upon the settlement of the Company&#8217;s $35.0 million convertible promissory note, accrued interest and related derivative liability, (iii) the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests into 18,872,711 shares of common stock, (iv) the issuance of 10,374,272 shares of common stock to Sesen Bio stockholders as consideration for the Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2023, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on May 2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $300.0&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May 12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $100.0&#160;million under an &#8220;at-the-market" offering program. Through December 31, 2023, the Company sold 226,533 shares for gross proceeds of $0.6&#160;million. From January through March 2024, the Company sold an additional 931,250 shares for gross proceeds of $2.4&#160;million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2023, the Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of the Company's common stock, $0.001 par value, from 100,000,000 shares to 350,000,000 shares and authorized 5,000,000 shares of preferred stock, $0.001 par value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305335987200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legacy Carisma adopted the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten years, and stock options typically vested over a four-year period. The Company&#8217;s stock options vest based on the terms in the awards agreements and generally vest over four years. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sesen Bio, Inc. Amended and Restated 2014 Stock Incentive Plan, as amended (the Sesen Bio 2014 Plan), provides for the grant of incentive and non-qualified</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Compan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y&#8217;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">board of directors at the time of grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the Sesen Bio 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the Sesen Bio 2014 Plan are exercisable for a period of ten years from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2023, the Company amended and restated the Sesen </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bio 2014 Plan to (i) change the name of the plan to the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) and (ii) adopt a new form of stock option agreement and a new form of restricted stock unit agreement for the grant of options and restricted stock units under the 2014 P</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lan. On June 6, 2023, the Company&#8217;s stockholders approved an amendment and restatement of the Company&#8217;s 2014 Plan, which amendment and restatement had previously been adopted by the Company&#8217;s board of directors, subject to stockholder approval. As of December&#160;31, 2023, approximately 4.9 million shares of common stock remained available for issuance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sesen Bio 2014 Employee Stock Purchase Plan (the Sesen Bio 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Sesen Bio 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock. On March 7, 2023, the Company amended and restated the Sesen Bio 2014 ESPP to (i) change the name of the plan to Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan and (ii) restate and integrate a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll prior amendments thereto. As of December&#160;31, 2023, 0.2 million shares of common stock remained available for issuance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the year ended December 31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic <br/>Value (in <br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,356,937</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio options assumed in the Merger</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">765,223</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,716)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,984,152</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(114,454)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(839,772)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,516,594</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date per share fair values of options granted during the year ended December 31, 2023 and 2022 were $4.29 and $1.46, respectively. The fair values in the year ended December 31, 2023 and 2022 were estimated using the Black-Scholes option-pricing model based on the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.92% - 4.76%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.40% - 3.05%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57.77% - 103.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.54% - 56.50%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company recognized stock-based compensation expense of $0.2 million related to the modification of Sesen Bio options assumed in connection with the Merger. Compensation cost for awards not vested as of December&#160;31, 2023 was $11.2 million and will be expensed over a weighted-average period of 3.3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337704368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal tax benefit at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs, net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable assets and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(133,580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,169)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,794)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $317.6&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $120.0&#160;million will begin to expire in 2037, if not utilized. The post-2017 federal NOLs  of $197.6&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $229.4&#160;million and $40.8&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2038 while the city of Philadelphia NOLs expire after three years with $29.7&#160;million expiring in 2023. As of December&#160;31, 2023, the Company also had federal and state research and development tax credit carryforwards of $9.9&#160;million that will begin to expire in 2029, unless previously utilized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company's net deferred tax assets as of December&#160;31, 2023. The valuation allowance increased by $84.5&#160;million and $13.7&#160;million during the years ended December 31, 2023 and 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a percentage of apportioned taxable income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2023, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's financial statements. Tax years from 2019 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305426625104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party TransactionsThe Company has a collaboration and license agreement with Moderna, a significant shareholder (Note 12).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305338128144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Moderna Collaboration and License Agreement</a></td>
<td class="text">Moderna Collaboration and License Agreement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered CAR-M therapeutics for up to twelve oncology programs. Under the Moderna License Agreement, the Company and Moderna initiate research programs during a research term, focused on the discovery and research of products directed to biological targets. Moderna&#8217;s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has the right to designate up to twelve research targets as development targets.  The first five research targets have been designated and all programs are currently in the discovery phase. Moderna funds the cost of the Company's activities in accordance with an agreed research budget. The Company is responsible for discovering and optimizing development candidates, and Moderna is responsible for the clinical development thereafter. Pursuant to the Moderna License Agreement, the Company and Moderna formed a joint steering committee (JSC) that is responsible for the coordination and oversight of all research activities to which the Company is responsible for providing. The JSC is comprised of representatives from the Company and Moderna and with Moderna having final decision-making authority, subject to specified limitations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Moderna License Agreement, the Company and its affiliates are subject to various exclusivity obligations under which the Company is not permitted to research, develop or commercialize particular products outside of the collaboration, including products for use as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapies in the field of oncology, products directed to any target included in the collaboration, or products containing a polypeptide provided by the Company to Moderna in connection with a research program that are directed to any development target. Additionally, the Company has granted Moderna an exclusive worldwide royalty free license to the Company&#8217;s intellectual property associated with the product candidates that permits Moderna to conduct its research and development activities. Upon Moderna&#8217;s election of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also will reimburse the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0 million in research and development costs over the first three years from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments royalties the Company owes as a licensor under one of its intellectual property in-license agreements with Penn that the Company is sublicensing to Moderna under the Moderna License Agreement, which royalties Moderna may deduct in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#8217;s intellectual property to conduct research and development activities and participation on the JSC. The Company determined that there were 2 performance obligations comprised of (i) research and development services and (ii) option rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#8217;s estimated probability of the options&#8217; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna elects to exercise or elects to not exercise its option right to license and commercialize the underlying research and development target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company included the $45.0 million up-front and nonrefundable payment and $73.9 million of variable consideration for expected research and development services to be performed during the five-year contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the year ended December 31, 2023 and 2022, the Company recognized $14.9 million and $9.8 million, respectively, of research and development services as collaboration revenues as the Company is the principal in providing such services. The Company recognized $24.7&#160;million of collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2023. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transaction <br/>price unsatisfied</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total performance obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in deferred revenue (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of unearned revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,834)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,459&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve months. The noncurrent portion of deferred revenue represents the $45.0 million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305426514944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events from the balance sheet date through April&#160;1, 2024, the issuance date of these consolidated financial statements, and has not identified any additional matters requiring disclosure.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305426481536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (86,879)<span></span>
</td>
<td class="num">$ (61,226)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337634064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337603600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant areas that require management&#8217;s estimates include the fair value of the Company&#8217;s common stock and the derivative liability prior to the Merger, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. The Company considered the carrying value of its convertible promissory note (Note 8) as of December 31, 2022 to approximate fair value due to its short-term nature. The derivative liability was recorded at its estimated fair value prior to its derecognition in March 2023 upon conversion of the associated convertible promissory notes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement at reporting date using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; U.S. Treasuries</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative liability &#8211; redemption feature on convertible promissory note</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had no marketable securities. The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated a redemption feature within the convertible promissory note issued in January 2022 and determined bifurcation of the redemption feature was required. The redemption feature is classified as a liability on the accompanying consolidated balance sheet and is marked-to-market each reporting period with the changes in fair value </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recorded in the accompanying statements of operations until it is triggered, terminated, reclassified or otherwise settled. The fair value of the derivative was determined based on an income approach that identified the cash flows using a with-and-without valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the discount factor used was 12% and a 90% to 100% probability of completing a qualified financing prior to the maturity date of the convertible promissory note was assumed. The estimated time of conversion ranged from <span style="-sec-ix-hidden:f-346">three</span> to twelve months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below is a summary of the changes in fair value of the Company&#8217;s derivative liability associated with the redemption feature of the Company&#8217;s convertible promissory note (Level 3 measurement):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition upon conversion of convertible promissory note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023 and 2022, there were no transfers between Level 1, Level 2 and Level 3.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Upfront license fees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Customer options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Research and development services</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestone payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, cas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h equivalents consisted of investments in a money market account. The Company maintained $30,000 as collateral for the Company&#8217;s credit card program at September 30, 2023, which was previously reported as restricted cash on its consolidated balance sheet. There were no amounts restricted as of December 31, 2023 and 2022, as the collateral was released to the Company in the fourth quarter of 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Marketable Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities consisted of investments in U.S. Treasuries that were classified as available-for-sale. The securities were carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, a component of stockholders' equity (deficit). Realized gains and losses and declines in value determined to be other than temporary were included in the Company's consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Property and Equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:f-368">two</span> to five years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company did not recognize any impairment of long-lived assets during th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredFinancingCostsPolicyPolicyTextBlock', window );">Deferred Financing Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately. The Company incurred $4.2&#160;million and $4.1&#160;million in deferred financing costs associated with the Merger during the years ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon completion of the Merger, the $8.3&#160;million of deferred financing costs were recorded against the gross proceeds received as a result of the Merger.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling Interest</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Noncontrolling Interest</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that ownership interests in the Company&#8217;s subsidiary are held by entities other than the Company, management reports these as noncontrolling interests on the consolidated balance sheet. Prior to the Merger, an investor had outstanding Class B and Class B-1 shares in the Company&#8217;s Luxembourg subsidiary related to the sale of the Company&#8217;s Series A convertible preferred stock (Series A) and Series B convertible preferred stock (Series B). The shares were nonvoting shares at the subsidiary entity level and were presented as noncontrolling interests in the accompanying consolidated balance sheet at December 31, 2022. In connection with the Merger, the Company's noncontrolling interests exchangeable shares converted into shares of common stock (Note 8).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger, and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Income taxes </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the deferred tax assets will not be realized. As of December 31, 2023 and 2022, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#8217;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock and exchangeable shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,936,148</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,356,937</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of convertible promissory note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,258,151</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,551,236</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for fiscal years beginning after December 15, 2022. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to accumulated deficit and did not have a material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued but not yet adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredFinancingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Financing Costs, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredFinancingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337328672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value measurement at reporting date using</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents &#8211; money markets accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; U.S. Treasuries</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative liability &#8211; redemption feature on convertible promissory note</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of December 31, 2022:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,843&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below is a summary of the changes in fair value of the Company&#8217;s derivative liability associated with the redemption feature of the Company&#8217;s convertible promissory note (Level 3 measurement):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derecognition upon conversion of convertible promissory note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible preferred stock and exchangeable shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,936,148</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,356,937</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of convertible promissory note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,258,151</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,551,236</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305336039680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Net Assets Acquired in the Merger</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net assets acquired in the Merger (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 7, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,588</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,316</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,499)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,308</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,264)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets acquired less transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305336941328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lab equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Office furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,942&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,764&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,628&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Lab equipment includes failed sale lease-back assets of $3.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $2.6&#160;million, respectively, as of December 31, 2023 and 2022. Lab equipment includes finance lease ROU assets of $2.9&#160;million as of December&#160;31, 2023 and 2022.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The accumulated amortization balance includ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es </span>$0.9&#160;million and $0.3&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2023 and 2022. The accumulated amortization balance includes $1.7&#160;million and $0.6&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2023 and 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305339085168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,662&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,361&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305432249920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The elements of the lease costs were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock', window );">Schedule of Lease Term and Discount Rate Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease term and discount rate information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash used in finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash used in finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Maturities, Operating Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities were as follows as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal year ending:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,251&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Maturities, Financing Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future maturities of lease liabilities were as follows as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal year ending:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,612&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">939&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,251&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of ease term and discount rate information relating to operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flow information relating to operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305341274880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the year ended December 31, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise<br/>price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>remaining<br/>contractual<br/>term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate <br/>Intrinsic <br/>Value (in <br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,356,937</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio options assumed in the Merger</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">765,223</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,716)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,984,152</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(114,454)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(839,772)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,516,594</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,023,370</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Using The Black-Scholes Option-Pricing Model</a></td>
<td class="text">The fair values in the year ended December 31, 2023 and 2022 were estimated using the Black-Scholes option-pricing model based on the following assumptions:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.92% - 4.76%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.40% - 3.05%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57.77% - 103.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.54% - 56.50%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305339084384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal tax benefit at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local tax rate change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Return to provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total provision</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets for Federal Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs, net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Start-up costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable assets and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(133,580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,794&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(524)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,169)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,794)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets and liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305447690544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations</a></td>
<td class="text">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2023 (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transaction <br/>price unsatisfied</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total performance obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,183&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock', window );">Schedule of Changes in Deferred Revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in deferred revenue (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the beginning of the period </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferral of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recognition of unearned revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,834)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,459&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ScheduleOfChangesInDeferredRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ScheduleOfChangesInDeferredRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305426544384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Background (Details)<br></strong></div></th>
<th class="th"><div>Mar. 07, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember', window );">CARISMA Therapeutics Inc, Legacy, Stockholders | Carisma Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare', window );">Exchange ratio of shares of Sesen Bio for each share of Legacy Carisma</a></td>
<td class="nump">0.742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember', window );">CARISMA Therapeutics Inc, Legacy, Stockholders | Sesen Bio, Inc. | Carisma Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ConvertedIntoSharesCommonStockAtExchangeRatio', window );">Common stock at an exchange ratio</a></td>
<td class="nump">1.8994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=carm_SesenBioStockholdersMember', window );">Sesen Bio Stockholders | Sesen Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Background</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_OwnershipInterestInReportingEntity', window );">Ownership interest held after the merge</a></td>
<td class="nump">25.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ration of conversion of the acquired entity shares to acquiring entity's share in a merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ConvertedIntoSharesCommonStockAtExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of converted into shares common stock at an exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ConvertedIntoSharesCommonStockAtExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_OwnershipInterestInReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership interest in the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_OwnershipInterestInReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=carm_CarismaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=carm_CarismaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=carm_SesenBioStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=carm_SesenBioStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305341307728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Development-Stage Risks and Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DevelopmentStageRisksAndLiquidityAbstract', window );"><strong>Development-Stage Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 245,102<span></span>
</td>
<td class="nump">$ 158,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 77,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DevelopmentStageRisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DevelopmentStageRisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337822928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</a></td>
<td class="text">Derivative liability &#8211; redemption feature on convertible promissory note<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents &#8211; money markets accounts</a></td>
<td class="nump">$ 7,794<span></span>
</td>
<td class="nump">$ 62,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities &#8211; U.S. Treasuries</a></td>
<td class="nump">27,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability &#8211; redemption feature on convertible promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents &#8211; money markets accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities &#8211; U.S. Treasuries</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability &#8211; redemption feature on convertible promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents &#8211; money markets accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities &#8211; U.S. Treasuries</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability &#8211; redemption feature on convertible promissory note</a></td>
<td class="nump">$ 5,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305431999152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337302496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note (Details) - Derivative liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in fair value of derivative liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 5,739<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Balance at issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">1,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Derecognition upon conversion of convertible promissory note</a></td>
<td class="num">(5,823)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at the end of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305340287184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 07, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DebtInstrumentConvertibleDiscountFactorPercentage', window );">Discount factor percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=carm_CollateralCreditCardProgramMember', window );">Collateral, credit card program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DebtInstrumentConvertibleQualifiedFinancingProbability', window );">Probability of convertible qualified financing (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DerivativeInstrumentConversionTermForRedemptionFeature', window );">Derivative instrument, conversion range, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DebtInstrumentConvertibleQualifiedFinancingProbability', window );">Probability of convertible qualified financing (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DerivativeInstrumentConversionTermForRedemptionFeature', window );">Derivative instrument, conversion range, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember', window );">Sesen Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentGross', window );">Deferred financing costs</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DebtInstrumentConvertibleDiscountFactorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Discount Factor Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DebtInstrumentConvertibleDiscountFactorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DebtInstrumentConvertibleQualifiedFinancingProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Qualified Financing, Probability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DebtInstrumentConvertibleQualifiedFinancingProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DerivativeInstrumentConversionTermForRedemptionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Conversion Term for Redemption Feature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DerivativeInstrumentConversionTermForRedemptionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=carm_CollateralCreditCardProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=carm_CollateralCreditCardProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305340349808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">6,023,370<span></span>
</td>
<td class="nump">16,551,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=carm_ConvertiblePreferredStockAndExchangeableSharesMember', window );">Convertible preferred stock and exchangeable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,936,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">6,023,370<span></span>
</td>
<td class="nump">3,356,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=carm_ConversionOfConvertiblePromissoryNoteMember', window );">Conversion of convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,258,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=carm_ConvertiblePreferredStockAndExchangeableSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=carm_ConvertiblePreferredStockAndExchangeableSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=carm_ConversionOfConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=carm_ConversionOfConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305340190144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>seat </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfBoardMembers', window );">Number of board seats | seat</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Entity common stock, shares outstanding immediately after merger | shares</a></td>
<td class="nump">40,609,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,217,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Less: Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total net assets acquired less transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member', window );">Carisma Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and personnel costs paid</a></td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember', window );">CARISMA Therapeutics Inc, Legacy, Stockholders | Carisma Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Merger with Sesen Bio</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Entity common stock, shares outstanding immediately after merger | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,254,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of restricted cash from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Board Members</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=carm_CarismaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=carm_CarismaTherapeuticsIncLegacyStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337681600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 12,915<span></span>
</td>
<td class="nump">$ 11,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(6,151)<span></span>
</td>
<td class="num">(3,314)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">6,764<span></span>
</td>
<td class="nump">8,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance lease, accumulated amortization</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">903<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">11,392<span></span>
</td>
<td class="nump">10,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionNetBookValue', window );">Sale lease-back asset</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease, ROU assets</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation', window );">Sale leaseback transaction, accumulated depreciation</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accumulated depreciation and amortization related to the asset(s) sold in connection with the property sold to another party and leased back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479741/842-40-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-50<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-52<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-51<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481192/840-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionNetBookValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-50<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-52<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481266/840-40-55-51<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479741/842-40-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionNetBookValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305336043632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 2,837<span></span>
</td>
<td class="nump">$ 1,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305426574496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 3,131<span></span>
</td>
<td class="nump">$ 4,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related expenses</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 7,662<span></span>
</td>
<td class="nump">$ 10,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305340288160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narratives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ProceedsFromSaleAndLeasebackTransaction', window );">Proceeds from sale and leaseback transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember', window );">Penn License Agreement | Penn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CommitmentsAnnualPaymentsRequiredToBePaid', window );">Annual payments to be made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AdditionalMilestonePaymentsForFirstCarMProduct', window );">Additional milestone payments for first CAR-M product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember', window );">Penn License Agreement | Penn | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AdditionalMilestonePaymentsRequiredToBePaid', window );">Additional milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember', window );">Novartis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AgreementTerm', window );">Agreement term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RenewalTerm', window );">Renewal term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountPayablePerCalendarYearForReservedCapacity', window );">Amount payable per calendar year for reserved capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_TerminationFeePayable', window );">Termination fee payable</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AdditionalMilestonePaymentsForFirstCarMProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional amount required to be paid in development and regulatory milestone payments for the first CAR-M product directed to mesothelin.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AdditionalMilestonePaymentsForFirstCarMProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AdditionalMilestonePaymentsRequiredToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional milestone payments required to be paid per product in commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AdditionalMilestonePaymentsRequiredToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountPayablePerCalendarYearForReservedCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount payable per calendar year for reserved capacity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountPayablePerCalendarYearForReservedCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount required to pay per product in development upon the achievement of certain clinical, regulatory and commercial milestone events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CommitmentsAnnualPaymentsRequiredToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of annual payments required to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CommitmentsAnnualPaymentsRequiredToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ProceedsFromSaleAndLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale and Leaseback Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ProceedsFromSaleAndLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The renewal term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_TerminationFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of termination fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_TerminationFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_PennLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_TrusteesOfUniversityOfPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305418351008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 5,774<span></span>
</td>
<td class="nump">$ 4,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease assets</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 8,833<span></span>
</td>
<td class="nump">$ 6,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance lease cost expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinanceLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinanceLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305341280384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LeasesWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_LeasesWeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LeasesWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LeasesWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_LeasesWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_LeasesWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305426433856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash used in operating leases</a></td>
<td class="nump">$ 5,764<span></span>
</td>
<td class="nump">$ 4,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash used in finance leases</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_FinancingCashUsedInFinanceLeases', window );">Financing cash used in finance leases</a></td>
<td class="nump">$ 1,301<span></span>
</td>
<td class="nump">$ 865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_FinancingCashUsedInFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_FinancingCashUsedInFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305340144432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">2,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305339500944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Jun. 05, 2023</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in a pre-closing funding (in shares)</a></td>
<td class="nump">3,730,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issue price per share (in USD per share)</a></td>
<td class="nump">$ 8.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock under Open Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">$ 30,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)</a></td>
<td class="nump">5,059,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests', window );">Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)</a></td>
<td class="nump">18,872,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)</a></td>
<td class="nump">10,374,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockStockOfferingAmount', window );">Stock offering, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketOfferingMember', window );">At-The-Market Offering | Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_SaleOfStockStockOfferingAmount', window );">Stock offering, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketOfferingMember', window );">At-The-Market Offering | Jefferies LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_SaleOfStockStockOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Stock Offering, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_SaleOfStockStockOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=carm_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=carm_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=carm_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305329160688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Narratives (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember', window );">Two Thousand Seventeen Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember', window );">Two Thousand Seventeen Stock Incentive Plan | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Terms</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember', window );">Two Thousand Fourteen Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear', window );">Vesting on first anniversary (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear', window );">Vesting at the end of each three-month period after first anniversary (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance</a></td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember', window );">Two Thousand Fourteen Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember', window );">Two Thousand Fourteen Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount to the market price (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of stock awards vesting at the end of each three-month period after the first anniversary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of stock awards vesting on the first anniversary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandSeventeenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=carm_TwoThousandFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305340196032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation -Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of December 31, 2022 (in shares)</a></td>
<td class="nump">3,356,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross', window );">Sesen Bio options assumed in the Merger (in shares)</a></td>
<td class="nump">765,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(128,716)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,984,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(114,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(839,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as of September 30, 2023 (in shares)</a></td>
<td class="nump">6,023,370<span></span>
</td>
<td class="nump">3,356,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable as of September 30, 2023 (in shares)</a></td>
<td class="nump">2,516,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest at September 30, 2023 (in shares)</a></td>
<td class="nump">6,023,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of December 31, 2022 (in USD per share)</a></td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice', window );">Sesen Bio options assumed in the Merger (in USD per share)</a></td>
<td class="nump">27.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">6.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in USD per share)</a></td>
<td class="nump">5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in USD per share)</a></td>
<td class="nump">29.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as of September 30, 2023 (in USD per share)</a></td>
<td class="nump">3.94<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable as of September 30, 2023 (in USD per share)</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest at September 30, 2023 (in USD per share)</a></td>
<td class="nump">3.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)</a></td>
<td class="nump">$ 4.29<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding as of September 30, 2023</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable as of September 30, 2023</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at September 30, 2023</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding as of September 30, 2023</a></td>
<td class="nump">5,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable as of September 30, 2023</a></td>
<td class="nump">4,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest at September 30, 2023</a></td>
<td class="nump">$ 5,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) assumed in a merger during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options for shares assumed in a merge during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337657472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.92%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">57.77%<span></span>
</td>
<td class="nump">54.54%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.76%<span></span>
</td>
<td class="nump">3.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">103.00%<span></span>
</td>
<td class="nump">56.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305340142736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,316<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Future compensation cost for awards not vested</a></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period compensation cost of unvested awards to be expensed</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember', window );">Sesen Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,074<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=carm_SesenBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305335163872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local tax, net of federal benefit</a></td>
<td class="num">(8.50%)<span></span>
</td>
<td class="num">(7.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal', window );">State and local tax rate change</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in valuation allowance</a></td>
<td class="nump">28.40%<span></span>
</td>
<td class="nump">22.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent', window );">Return to provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Return To Provision, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337551968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 72,689<span></span>
</td>
<td class="nump">$ 27,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization', window );">Capitalized research and development costs, net of amortization</a></td>
<td class="nump">33,778<span></span>
</td>
<td class="nump">11,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">9,746<span></span>
</td>
<td class="nump">5,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsStartUpCosts', window );">Start-up costs</a></td>
<td class="nump">4,407<span></span>
</td>
<td class="nump">4,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">13,353<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsAmortizableAssetsAndOther', window );">Amortizable assets and other</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxAssetsEquityCompensation', window );">Equity compensation</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">134,749<span></span>
</td>
<td class="nump">50,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(133,580)<span></span>
</td>
<td class="num">(49,105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(645)<span></span>
</td>
<td class="num">(1,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(524)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(1,169)<span></span>
</td>
<td class="num">(1,794)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets and liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsAmortizableAssetsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Amortizable Assets And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsAmortizableAssetsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsEquityCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Equity Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsEquityCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Start Up Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305337777216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narratives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">$ 84.5<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">317.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">229.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=carm_Pre2018Member', window );">Pre-2018 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=carm_Post2017Member', window );">Post-2017 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">197.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2023Member', window );">Expiring in 2023 | Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 29.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=carm_StateJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=carm_LocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=carm_Pre2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=carm_Pre2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=carm_Post2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=carm_Post2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305329138544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Narratives (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>product </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>obligation</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Research and development services as collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,919<span></span>
</td>
<td class="nump">$ 9,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_UpfrontNonRefundablePaymentReceived', window );">Upfront non-refundable payment received</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_VariableConsideration', window );">Variable consideration</a></td>
<td class="nump">$ 73,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ContractTerm', window );">Term of contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Noncurrent portion of deferred revenue</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_MaximumOfResearchTargets', window );">Maximum of research targets | target</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets', window );">Number of research targets, designate as development targets | target</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfResearchTargetsDesignated', window );">Number of research targets designated | target</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_UpfrontNonRefundablePaymentReceived', window );">Upfront non-refundable payment received</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfProductsDevelopedAndCommercialized', window );">Number of products developed and commercialized | product</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts', window );">Minimum commitment to reimburse research and development costs</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts', window );">Period of reimbursement of research and development costs</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_NumberOfPerformanceObligations', window );">Number of performance obligations | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Minimum | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Amount receivable per product</a></td>
<td class="nump">$ 247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Moderna | Maximum | Research and Development Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments', window );">Amount receivable per product</a></td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember', window );">Moderna License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Moderna Collaboration and License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount receivable per product in development target designation, development, regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_MaximumOfResearchTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of research targets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_MaximumOfResearchTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum commitment to reimburse research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfProductsDevelopedAndCommercialized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of products developed and commercialized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfProductsDevelopedAndCommercialized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets, Designate as Development Targets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_NumberOfResearchTargetsDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Research Targets Designated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_NumberOfResearchTargetsDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of reimbursement of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_UpfrontNonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront non-refundable payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_UpfrontNonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_VariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_VariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=carm_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=carm_ModernaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=carm_ModernaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305335904704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationAbstract', window );"><strong>Performance obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount', window );">Research and development</a></td>
<td class="nump">$ 49,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_RevenueRemainingPerformanceObligationOptionRightsAmount', window );">Option rights</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Total performance obligations</a></td>
<td class="nump">$ 94,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RevenueRemainingPerformanceObligationOptionRightsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RevenueRemainingPerformanceObligationOptionRightsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140305429896000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 47,459<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_carm_ContractWithCustomerLiabilityDeferralOfRevenue', window );">Deferral of revenue</a></td>
<td class="nump">13,873<span></span>
</td>
<td class="nump">57,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of unearned revenue</a></td>
<td class="num">(14,919)<span></span>
</td>
<td class="num">(9,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at the ending of the period</a></td>
<td class="nump">$ 46,413<span></span>
</td>
<td class="nump">$ 47,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_carm_ContractWithCustomerLiabilityDeferralOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue deferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">carm_ContractWithCustomerLiabilityDeferralOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>carm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MHS37;8,0VLHX=$FB>N<GM)0PFB'&D<_R3/)W^ SU7,WJLSLM0&-09X"6U.H
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M(TI"RM4)\/V:,;G?41<X_,!C\G]02P,$%     @ XD6!6*6<3- W @  M@4
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MT39HVMUK1J9C(I+HDI23[-,O*3F2+5)TVLU%8LD>CO[A8;XA=7[/Q9U<4ZK
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MI#K.:U+SY(DT>]JAYO43T?(G:6KR4#>U?/6"!PZL D^ANS9@!58!Z-!"A_%
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M=W9O)-N9!R0?F)1L:UYN*%&AT ;J^S53Q;)_HW]@>,;VYO]02P,$%     @
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ML6NJ.C[HRQ,.R1>J;G\X SVGFD?ZLWHQFQ&QV@6 C+)5!4M$/Q/WA%P\[I8
M,/,0XU$GE!.^;18 '(JCK(W!>E>I][J!EX&M3T9%R091N.9.-SD]*&$@M76-
M&*XY/1NSMER/M:'JAPF(7R5JYBUV+*D9P(?] O@%FD6798!? D DDU])\I"
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MI+FP7_&HE<=DAIK<N+\,FT;?(^!*)2HN'-' '5?OA+V6=UZ45<.$!<QK09A
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MBA3Z3LI.NF2&^'0KHE.Z%8&@OSNW5+2[RW@W'@<<J@8A-[7S81JK<:Z[\_!
MV5[+L4/O[,24@[@E#2IX1O>P-B"?&20)<:0[ !31CIK>'IVZR-U19S>1'[C+
M6Y[C).:20(%1CY(60,EOG._F+AOY[,GI[.\#V!P%I\?/'4E]A;"0V=/3YP>%
MG.[DG;KDSZ.REM_?6CJS@D_%3U02/Z!LSS+PNA!["2XTD4-D.-@%<#UIH7$T
M)^R81. X SK#U&71?=_G^^_[=EK$R,NI43>[Q2BO#X85.>&7 ((+DH!%?!,>
MOQMSU>#L%:E1UGV22&;MTX[?)SLBR_L4ZUXH-R;0C"9^B"<U+U.Y>PI^WR>(
M9X-O2;D17LD'8.1Z^:RTN]I]E'LIWZ+VR^6+7E"X)4W:"[/ H^>GSYX>J4:^
MDI4?P=7\9>K<A>!*_A.D'=&C!;B_<# \_J -ND^57_T74$L#!!0    ( .)%
M@5BO-_DA:04  *(,   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULK5=A
M;]LV$/TKA%OT4VK'3IH4;6*@:3>LP#H4;;=]IJBSQ(4B59*RX_WZO3O*CHTE
M&3#T2R)1O'=W[]X=Z:M-B+>I)<KJKG,^74_:G/LWLUDR+74Z34-/'E]6(78Z
MXS4VL]1'TK48=6ZV.#V]F'7:^LGR2M8^Q^55&+*SGCY'E8:NTW%[0RYLKB?S
MR6[ABVW:S NSY56O&_I*^??^<\3;;(]2VXY\LL&K2*OKR;OYFYMSWB\;_K"T
M20?/BC.I0KCEEX_U]>24 R)')C."QK\UO2?G& AA?!\Q)WN7;'CXO$/_67)'
M+I5.]#ZX/VV=V^O)ZXFJ::4'E[^$S2\TYO.*\4QP2?ZJ3=E[ALUF2#ETHS$B
MZ*PO__7=R,.!P>O31PP6H\%"XBZ.),H/.NOE50P;%7DWT/A!4A5K!&<]%^5K
MCOAJ89>7'VB-PO2@.;_\FE$&]<6FVZ2TK]6O]OM@:YNW5[,,5VPP,R/L38%=
M/ ([7ZA/P><VJ9]\3?4QP PQ[@-=[ *]63R)^(',5)W-3]3B=''V!-[9/O$S
MP3O[T8D7V/.'8;F'WJ1>&[J>H$D2Q35-EB^>S2].WSX1]/D^Z/.GT/]_T#\
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ML+6ZS /0FG#K834NS .A0W/.G/(X1,A WA%_O:>52@U<"FP'TX#@*Q!\#7K
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M+JB,&KW%+@/L2H(I.046HJ*HPH.WD[:V0MGZEG@8;/<)*K3"M*<8S\QMS2$
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MZ@8'P/=K"S93_L -PC^']/;_ %!+ P04    " #B18%8$W6SF]\$   A"P
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MGJ$2K+?D]!CS#\N5O*;74A!<AN?B7A!A[5J3;9S?Y? <E<8M7&Y8VD40,Z3
M&IW'N.[IZ ,NRAV%1;)E**3PC78JTJUUU$MW@,R(<9]>,500^6EN^O2Q+#G7
M+6_4&NQ\'"F48TSI,!D?I<ET.B5? '*? E+YM]_,QZ/9>R_CH@39VVQC'T
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M=B* ]VN+#U5W$ .[K7CQ+U!+ P04    " #B18%8S1.A^X\#  #>"   &0
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MY44 NJNF7<>JQE>PI;)4#WUS31\@J-T"FJ^4LKN.<[#_I)G_"U!+ P04
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M.K^\"$!W4Z([6-5X9:Z4)9W[;4F#%;5SH/M"*;L[N 3]J)[]!E!+ P04
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M!<7)2%26_EYLT132>!N$GQH]EX0*7M2(4P=1A71$1I$=6)D*)VNOH('(E*N
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MI'\V/@COSIHOE5WR*_2IA5\*_KA +5".-N#YS-JJ^4(,VO^IN/HG4$L#!!0
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MW.9&-!ZTH0T67ZZX,9QF"('$TN+= BG.'!X6"*R_HH"UPD(95FL#(2L$94G
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MC_L361)Q./@I3!":!G,^7NB-R6DR+%0_9@'\H6]HT,^B$)@6O!RJ1"C&PRG
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M^>G5Y5'0O/OA3<.?P2R,AWG\YUI)A)(>P/VEP: =?] &_7=1M_\%4$L#!!0
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M&8 J7U@C9(0D%>*9D6QGH*!56ZQ,45A">[4LS-I;IDAI9 I+$#F0<==I DV
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MF.0T>4MIGHQ+B;Q3"&2S)&E +LT4;>JO2%Y]Y<",P=J\$ZSQ$X_PQJ!B><Q
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M%B\9;ICBK0XT3<#OB4)?J@<RT-P3%_\"4$L#!!0    ( .)%@5AFT<ZH[ (
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M"- X _Z^TMKN!!=@_VN9_ %02P,$%     @ XD6!6%Z<['1$ P  1 <  !D
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M;D.0M!]&G]E:H!G/(TN9G']4[E'O>]3T%=0DA0]*VJV!=[+"ZA0@(HH#S_3
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;.U7VV[C-A#]E8$V722
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MTO$NFVM(,]"BLI_^<Z'I(F%?5W1S0VDVT/I""+T=& 7M77#V)U!+ P04
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MD(S]9_0RW*)!P('^QM-W_Z/?2?)XW=-OF#YT;5=WX9Z/FY=M)^$3^(-97+S
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M&H4%G6O335C=PNFUGVINM:,9R3^N:"A%PP;T?J&U>UIP@&',G?T#4$L#!!0
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M!%X0GL +QSR$%B]\ ^\!GY&W")D4-26#:TG]0K70!=S8*J"$OZ]C9>7_',M
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M#:;:0%1G?%51?&N/R357^M"UQ5S_%H$P'?3SC'-UJ)B3M_G1BGX#4$L#!!0
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MR,[%$"FI<BB7&R-S-]=6TN"4=,L4_V- 60&\7TM,5[6Q!NH_H^@W4$L#!!0
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M?+LH3B3;Y;OY3TQ*%N>'(1 U^68/J/L;QN3;2>:@^H(T_P]02P,$%     @
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M5IV9@[P31156$P(TCP@/."C:P-4:^T\ "Z'O505.G8 [[!1^C14Z6?IA-11
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M+(AR<&@'A/8CQ&]0-:X+YPJII]VRI*D+VB;0]X52N-G8 _HYGOT"4$L#!!0
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M2O":I$0^Z> 91<Z%5XF-2K$B>C^$TXE:$@_'3"PY[# 9-4Q&1B:+..8Y)$B
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M[@9[?2.E>1JX;6[WE9)_!U!+ P04    " #B18%8>LL8TT('  ",.P  &0
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M+020%:]^%B><KO,7"1\HYS3)#U<$STDF"XCO%Y3REQ.9H'H!=_HO4$L#!!0
M   ( .)%@5C!I^CHO ,  /@/   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y
M+GAM;+57;6_;-A#^*X0&%"VP6*+L."^S#31)B_5#!J-NN\^,=+:(2*1&4G8"
M[,?O2,F24\B,ZSE?;)'B/7SN3L>'-]E(]:@S $.>BESH:9 94UZ'H4XR*)@>
MR!($OEE*53"#0[4*=:F I<ZHR,,XBL9AP;@(9A,W-U>SB:Q,S@7,%=%543#U
M? .YW$P#&FPGOO)59NQ$.)N4; 4+,-_+N<)1V**DO "AN11$P7(:?*37-[$S
M<"M^<-CHG6=B77F0\M$.OJ33(+*,((?$6 B&?VNXA3RW2,CCGP8T:/>TAKO/
M6_3/SGETYH%IN)7YWSPUV32X#$@*2U;EYJO<_ F-0^<6+Y&Y=K]DTZR- I)4
MVLBB,48&!1?U/WMJ K%C@([V&\2-0>QXUQLYEG?,L-E$R0U1=C6BV0?GJK-&
M<ES8K"R,PK<<[<QL863R>&;]2LFM+##9FKEPG9&_F%+,QDR3]W=@&,_U!Z(S
MIG"""W+/\QP7ZDEHD(=%"Y-FSYMZSWC/GC0F]U*83)-/(H7T)4"(#K1>Q%LO
M;F(OXATD S*DOY,XBH<-1P_LL W.T,&.]L!^VTCR+9.59B(E"UB#, ""N)B1
M+R+!,8:'S',FR+_-M"S-OJAX-[/E=ZU+EL TP/K2H-80S-[]1L?1'QY71JTK
M(X<^_,4\]_$<O0'/\Y;GN3?D/T ;+E:D!,5EVL?.;S\BS\"4+_GCELGXK9*/
MXWOVQ(NJZ'/ N^V1X;UHG;HXV6=P\08\+UN>E_[@@RIZ:\AO1J-7TW_5,K@Z
M//V?9:7V9K^/IA?[R-C1J#O3HY-EN8$Z,=4=^:'_L]Y? 7B]X&G<D8D/(H/R
MM^1*&\*$P"PKC?<5\IYIPBQ/F_L/O4QK=%JKE+T/K6?1(#Z?A.L^6IT*4;\,
M;6DQ0TP&!/"#E$L"+,EPK #."JNF30@)6QI0Q_&O:5#Z@G\TWNM!)S[4JQFS
M17UK8&N\1+"'' A>)PG7NF)82;U4:CPZW*$R&ESMX=&)"_6KP^%%?8B>^S<[
MMG0Z?:+CTU7Y6X@.[52'>L7BD"KW QQPL--.6^@KXM+[%7PJREP^ S1YGU<J
MR3"V>X]X_R;'AK23)WIUNNR_A1S%G1S%7@WY]>IO\%Y4/QZD_=4?=UH3^Z7B
MCNM$5@)/4>D.4FQ#'['O+15/X(#CL4'_Z7BG/Q^.X4XS5H!:N993$[=SW9>U
MLVU;^[%NYKKE=4]\S]2*XW4RAR6:1H,+/'!4W6;6 R-+U]H]2(.-HGO,L#4'
M91?@^Z649CNP&[3-_NP_4$L#!!0    ( .)%@5CN/<_PJ04  &$?   9
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ME>[P[&.BFW 49H%^O^%<'09F@Z:M#_\#4$L#!!0    ( .)%@5@?L.MM9P,
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M/( <"](PO1;[#]@9NK9\F6#*_<*^C9V9X*Q16E0=V"BH*&__R7.7B"- /+T
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M-"TN5P3++5]-D-\O*!7/-VJ!ZD>0X']02P,$%     @ XD6!6"'#'\X'!@
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MJ)T#G:^5LJ\;-\_=:YS^!5!+ P04    " #B18%88 $U[/8"   &"   &0
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MN1K4P+6!>KYB3&XW^@7=Z(__ %!+ P04    " #B18%8QG2HUED#  "0%@
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M1!&L*N8-NX)Q)$DP!&K17:-QC,Q.#%_W^F!7210EB1L!S.T@BC $KD8<P1R
M!PR)(O,<W'D>!>OG5+#Y'_3H#U!+ P04    " #B18%8EXJ[',     3 @
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MX2I&Z#*Z.+S^[H-X8?]+&,UJI4J8FK)M0/M]'"W4$5"[C=JZ@="R@<G@VNS
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M[8O^:&3U^G'5ZX=A'_X!4$L#!!0    ( .)%@5@3)^RZ[P$  *4B   :
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M*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MMDLX1
M;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U
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M/AM^(+EZ!5!+ 0(4 Q0    ( .)%@5@'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ XD6!6%^$+-7O
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ XD6!6)E<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #B18%8@<[.WOP'  #L,0
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ XD6!6*6<3- W @  M@4  !@              ("!0!   'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .)%@5@!H<.KW08
M )(=   8              " @:T2  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " #B18%8V 6TBO,"  !+"@  &               @('
M&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ XD6!6#]9
MA/,-!0  DA,  !@              ("!Z1P  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( .)%@5C,+BDPC@D  $A4   8
M  " @2PB  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #B
M18%8PP?-F6T)  !O*P  &               @('P*P  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ XD6!6#9 ."IM#P  MBP  !@
M         ("!DS4  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( .)%@5BO-_DA:04  *(,   8              " @39%  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #B18%8B>A%#"(A   ::0
M&0              @('52@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( .)%@5@3=;.;WP0  "$+   9              " @2YL  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ XD6!6,T3H?N/
M P  W@@  !D              ("!1'$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " #B18%869AY/ID"  "V!0  &0
M@($*=0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( .)%
M@5B.H@*^<PP  %\A   9              " @=IW  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ XD6!6/[#N5VJ!0  40T  !D
M         ("!A(0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " #B18%8@3PQ;6$(  !7%@  &0              @(%EB@  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .)%@5C)%^&F# D  +D6
M   9              " @?V2  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ XD6!6'K ^=)" @  *@4  !D              ("!0)P
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #B18%8?L@D
M:IH,   C)0  &0              @(&YG@  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( .)%@5A8^-<<<@(  '\%   9
M  " @8JK  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MXD6!6/RDM3E# @  FP4  !D              ("!,ZX  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " #B18%89#JB:T,"  "*!@  &0
M            @(&ML   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( .)%@5@KY6CG4R(  "MS   9              " @2>S  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ XD6!6)K@7<0V!0
M,PX  !D              ("!L=4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " #B18%89M'.J.P"  !F!@  &0              @($>
MVP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .)%@5A>
MG.QT1 ,  $0'   9              " @4'>  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ XD6!6+J) ?&F @  N@4  !D
M     ("!O.$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .)%@5@3WL2DQ@(  .T(   9              "
M@:;V  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ XD6!
M6'_L5759 @   08  !D              ("!H_D  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " #B18%88O(Y8WD$  #H%@  &0
M        @($S_   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( .)%@5A+\E:TK@(  '0)   9              " @>,  0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ XD6!6,>WY=Y- P  )0D
M !D              ("!R ,! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " #B18%8O.]W@VT%  #Z)   &0              @(%,!P$
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .)%@5A'O%HL
M5P,  -0-   9              " @? , 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ XD6!6)O873 J!0  31H  !D
M ("!?A ! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #B
M18%8U[V_Y5D$  # %@  &0              @('?%0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( .)%@5@G<+$0<@(  -,%   9
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M970T-2YX;6Q02P$"% ,4    " #B18%8N=IUBM4"  ![!P  &0
M    @(%\*P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M .)%@5CYVY2H6@,  +$,   9              " @8@N 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ XD6!6'K+&--"!P  C#L  !D
M             ("!&3(! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " #B18%8P:?HZ+P#  #X#P  &0              @(&2.0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .)%@5CN/<_PJ04
M &$?   9              " @84] 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ XD6!6)_<\'I, P  # T  !D              ("!
M94,! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #B18%8
M]K:_LIX#  #B#P  &0              @('H1@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( .)%@5@?L.MM9P,  .D*   9
M      " @;U* 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ XD6!6%Y] >PK!   : \  !D              ("!6TX! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #B18%8"Y?M=T,$   0&0
M&0              @(&]4@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( .)%@5@APQ_.!P8   8K   9              " @3=7 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ XD6!6+00"_A[
M @  F04  !D              ("!=5T! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " #B18%88 $U[/8"   &"   &0
M@($G8 $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( .)%
M@5C&=*C660,  ) 6   -              "  51C 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ XD6!6)>*NQS     $P(   L              ( !V&8!
M %]R96QS+RYR96QS4$L! A0#%     @ XD6!6)1:*1FS!   G"8   \
M         ( !P6<! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .)%@5@3
M)^RZ[P$  *4B   :              "  :%L 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( .)%@5AB(^<8V $  $@B   3
M      "  <AN 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !" $( !1(
' -%P 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>122</ContextCount>
  <ElementCount>381</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ConsolidatedStatementofCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Background</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/Background</Role>
      <ShortName>Background</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Development-Stage Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/DevelopmentStageRisksandLiquidity</Role>
      <ShortName>Development-Stage Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Merger with Sesen Bio</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/MergerwithSesenBio</Role>
      <ShortName>Merger with Sesen Bio</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Moderna Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreement</Role>
      <ShortName>Moderna Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://carismatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Merger with Sesen Bio (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/MergerwithSesenBioTables</Role>
      <ShortName>Merger with Sesen Bio (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/MergerwithSesenBio</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/AccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/CommitmentsandContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/StockbasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Moderna Collaboration and License Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables</Role>
      <ShortName>Moderna Collaboration and License Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://carismatx.com/role/ModernaCollaborationandLicenseAgreement</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Background (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/BackgroundDetails</Role>
      <ShortName>Background (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/Background</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Development-Stage Risks and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails</Role>
      <ShortName>Development-Stage Risks and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/DevelopmentStageRisksandLiquidity</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Summary of Significant Accounting Policies - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails</Role>
      <ShortName>Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PropertyandEquipmentnetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/PropertyandEquipmentnetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Property and Equipment, net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails</Role>
      <ShortName>Property and Equipment, net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/AccruedExpensesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Commitments and Contingencies - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails</Role>
      <ShortName>Commitments and Contingencies - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://carismatx.com/role/StockholdersEquity</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stock-based Compensation - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationNarrativesDetails</Role>
      <ShortName>Stock-based Compensation - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Stock-based Compensation -Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation -Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails</Role>
      <ShortName>Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Income Taxes - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/IncomeTaxesNarrativesDetails</Role>
      <ShortName>Income Taxes - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Moderna Collaboration and License Agreement - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="carm-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails</Role>
      <ShortName>Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: carm:DerivativeInstrumentConversionTermForRedemptionFeature, us-gaap:PropertyPlantAndEquipmentUsefulLife -  carm-20231231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="carm-20231231.htm">carm-20231231.htm</File>
    <File>carm-20231231.xsd</File>
    <File>carm-20231231_cal.xml</File>
    <File>carm-20231231_def.xml</File>
    <File>carm-20231231_lab.xml</File>
    <File>carm-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>carm-20231231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="538">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "carm-20231231.htm": {
   "nsprefix": "carm",
   "nsuri": "http://carismatx.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "carm-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "carm-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "carm-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "carm-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "carm-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "carm-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 311,
   "keyCustom": 70,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 23,
   "hidden": {
    "total": 6,
    "http://carismatx.com/20231231": 1,
    "http://fasb.org/us-gaap/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 122,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 642,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 538,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://carismatx.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://carismatx.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://carismatx.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
     "longName": "0000006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://carismatx.com/role/ConsolidatedStatementofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statement of Cash Flows",
     "shortName": "Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://carismatx.com/role/Background",
     "longName": "0000008 - Disclosure - Background",
     "shortName": "Background",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://carismatx.com/role/DevelopmentStageRisksandLiquidity",
     "longName": "0000009 - Disclosure - Development-Stage Risks and Liquidity",
     "shortName": "Development-Stage Risks and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "carm:DevelopmentStageRisksAndLiquidityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "carm:DevelopmentStageRisksAndLiquidityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://carismatx.com/role/MergerwithSesenBio",
     "longName": "0000011 - Disclosure - Merger with Sesen Bio",
     "shortName": "Merger with Sesen Bio",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://carismatx.com/role/PropertyandEquipmentnet",
     "longName": "0000012 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://carismatx.com/role/AccruedExpenses",
     "longName": "0000013 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://carismatx.com/role/CommitmentsandContingencies",
     "longName": "0000014 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://carismatx.com/role/StockholdersEquity",
     "longName": "0000015 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://carismatx.com/role/StockbasedCompensation",
     "longName": "0000016 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://carismatx.com/role/IncomeTaxes",
     "longName": "0000017 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://carismatx.com/role/RelatedPartyTransactions",
     "longName": "0000018 - Disclosure - Related-Party Transactions",
     "shortName": "Related-Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreement",
     "longName": "0000019 - Disclosure - Moderna Collaboration and License Agreement",
     "shortName": "Moderna Collaboration and License Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://carismatx.com/role/SubsequentEvents",
     "longName": "0000020 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-122",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://carismatx.com/role/MergerwithSesenBioTables",
     "longName": "9954473 - Disclosure - Merger with Sesen Bio (Tables)",
     "shortName": "Merger with Sesen Bio (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://carismatx.com/role/PropertyandEquipmentnetTables",
     "longName": "9954474 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://carismatx.com/role/AccruedExpensesTables",
     "longName": "9954475 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesTables",
     "longName": "9954476 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://carismatx.com/role/StockbasedCompensationTables",
     "longName": "9954477 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://carismatx.com/role/IncomeTaxesTables",
     "longName": "9954478 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables",
     "longName": "9954479 - Disclosure - Moderna Collaboration and License Agreement (Tables)",
     "shortName": "Moderna Collaboration and License Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://carismatx.com/role/BackgroundDetails",
     "longName": "9954480 - Disclosure - Background (Details)",
     "shortName": "Background (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-35",
      "name": "carm:BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "carm:BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails",
     "longName": "9954481 - Disclosure - Development-Stage Risks and Liquidity (Details)",
     "shortName": "Development-Stage Risks and Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "carm:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "carm:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails",
     "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Marketable Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails",
     "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "carm:DebtInstrumentConvertibleDiscountFactorPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "carm:DebtInstrumentConvertibleDiscountFactorPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Securities (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
     "longName": "9954487 - Disclosure - Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)",
     "shortName": "Merger with Sesen Bio - Schedule of Net Assets Acquired in the Merger (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "carm:NumberOfBoardMembers",
      "unitRef": "seat",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "carm:NumberOfBoardMembers",
      "unitRef": "seat",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://carismatx.com/role/PropertyandEquipmentnetDetails",
     "longName": "9954488 - Disclosure - Property and Equipment, net (Details)",
     "shortName": "Property and Equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails",
     "longName": "9954489 - Disclosure - Property and Equipment, net - Narrative (Details)",
     "shortName": "Property and Equipment, net - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://carismatx.com/role/AccruedExpensesDetails",
     "longName": "9954490 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "carm:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "carm:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
     "longName": "9954491 - Disclosure - Commitments and Contingencies - Narratives (Details)",
     "shortName": "Commitments and Contingencies - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FinanceLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails",
     "longName": "9954492 - Disclosure - Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails",
     "longName": "9954493 - Disclosure - Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease Term and Discount Rate Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails",
     "longName": "9954494 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9954495 - Disclosure - Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://carismatx.com/role/StockholdersEquityDetails",
     "longName": "9954496 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
     "longName": "9954497 - Disclosure - Stock-based Compensation - Narratives (Details)",
     "shortName": "Stock-based Compensation - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-90",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-90",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails",
     "longName": "9954498 - Disclosure - Stock-based Compensation -Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-based Compensation -Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
     "longName": "9954499 - Disclosure - Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Stock-based Compensation - Schedule of Estimated Using The Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9954500 - Disclosure - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9954501 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails",
     "longName": "9954502 - Disclosure - Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)",
     "shortName": "Income Taxes- Schedule of Deferred Tax Assets for Federal Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://carismatx.com/role/IncomeTaxesNarrativesDetails",
     "longName": "9954503 - Disclosure - Income Taxes - Narratives (Details)",
     "shortName": "Income Taxes - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails",
     "longName": "9954504 - Disclosure - Moderna Collaboration and License Agreement - Narratives (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails",
     "longName": "9954505 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails",
     "longName": "9954506 - Disclosure - Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)",
     "shortName": "Moderna Collaboration and License Agreement - Schedule of Changes in Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:ScheduleOfChangesInDeferredRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "carm:ScheduleOfChangesInDeferredRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "carm-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r679"
     ]
    },
    "carm_AccretionOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AccretionOnMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion on marketable securities",
        "label": "Accretion on Marketable Securities",
        "documentation": "Amount of accretion on marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails",
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "carm_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Accrued Research and Development Expense, Current",
        "documentation": "Accrued Research and Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r90",
      "r153",
      "r527",
      "r548",
      "r549"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r33",
      "r419",
      "r422",
      "r463",
      "r544",
      "r545",
      "r794",
      "r795",
      "r796",
      "r801",
      "r802",
      "r803"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "carm_AdditionalMilestonePaymentsForFirstCarMProduct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AdditionalMilestonePaymentsForFirstCarMProduct",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payments for first CAR-M product",
        "label": "Additional Milestone Payments for the First CAR-M Product",
        "documentation": "Additional amount required to be paid in development and regulatory milestone payments for the first CAR-M product directed to mesothelin."
       }
      }
     },
     "auth_ref": []
    },
    "carm_AdditionalMilestonePaymentsRequiredToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AdditionalMilestonePaymentsRequiredToBePaid",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional milestone payments",
        "label": "Additional Milestone Payments Required to be Paid",
        "documentation": "Amount of additional milestone payments required to be paid per product in commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r679",
      "r878"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r565",
      "r801",
      "r802",
      "r803",
      "r859",
      "r879"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r340"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to reconcile net loss to net cash (used in) provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r715",
      "r725",
      "r751"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r718",
      "r728",
      "r754"
     ]
    },
    "carm_AgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AgreementTerm",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement term",
        "label": "Agreement term",
        "documentation": "The period of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r719",
      "r729",
      "r746",
      "r755",
      "r759",
      "r767"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r384"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r73",
      "r94",
      "r287"
     ]
    },
    "carm_AmountPayablePerCalendarYearForReservedCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AmountPayablePerCalendarYearForReservedCapacity",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount payable per calendar year for reserved capacity",
        "label": "Amount Payable Per Calendar Year For Reserved Capacity",
        "documentation": "The amount payable per calendar year for reserved capacity."
       }
      }
     },
     "auth_ref": []
    },
    "carm_AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Amount Payable upon Achievement of Certain Clinical, Regulatory and Commercial Milestone Events",
        "documentation": "Amount required to pay per product in development upon the achievement of certain clinical, regulatory and commercial milestone events."
       }
      }
     },
     "auth_ref": []
    },
    "carm_AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount receivable per product",
        "label": "Amount Receivable Per Product in Development Target Designation, Development, Regulatory and Commercial Milestone Payments",
        "documentation": "Amount receivable per product in development target designation, development, regulatory and commercial milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r149",
      "r175",
      "r203",
      "r214",
      "r218",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r412",
      "r416",
      "r438",
      "r522",
      "r596",
      "r679",
      "r692",
      "r822",
      "r823",
      "r865"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r154",
      "r175",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r412",
      "r416",
      "r438",
      "r679",
      "r822",
      "r823",
      "r865"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Offering",
        "label": "At-The-Market Offering [Member]",
        "documentation": "At-The-Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "carm_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://carismatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698",
      "r711"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://carismatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698",
      "r711"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://carismatx.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698",
      "r711"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross unrealized loss",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r261",
      "r518",
      "r805"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r671",
      "r672"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r408",
      "r671",
      "r672"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "verboseLabel": "Merger with Sesen Bio",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition percentage of voting interests acquired",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBio"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger with Sesen Bio",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r409"
     ]
    },
    "carm_BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare": {
     "xbrltype": "pureItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio of shares of Sesen Bio for each share of Legacy Carisma",
        "label": "Business Combination, Ratio Conversion Of Acquired Entity's to Acquiring Entity's Share",
        "documentation": "The ration of conversion of the acquired entity shares to acquiring entity's share in a merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable and accrued expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total net assets acquired less transaction costs",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_BusinessCombinationSegmentAllocationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationSegmentAllocationLineItems",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Background",
        "label": "Business Combination Segment Allocation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "carm_Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredRestrictedCash",
        "documentation": "The amount of restricted cash from business combination."
       }
      }
     },
     "auth_ref": []
    },
    "carm_CarismaTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "CarismaTherapeuticsInc.Member",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carisma Therapeutics Inc.",
        "label": "Carisma Therapeutics Inc. [Member]",
        "documentation": "Represents Carisma Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "carm_CarismaTherapeuticsIncLegacyStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "CarismaTherapeuticsIncLegacyStockholdersMember",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CARISMA Therapeutics Inc, Legacy, Stockholders",
        "label": "CARISMA Therapeutics Inc, Legacy, Stockholders [Member]",
        "documentation": "Represents the stockholders of legacy CARISMA Therapeutics, prior to the merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r148",
      "r653"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents \u2013 money markets accounts",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "carm_CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization",
        "label": "Cash, Cash Equivalents and Restricted Cash Acquired in Reverse Recapitalization, Financing Activities",
        "documentation": "Amount of cash, cash equivalents and restricted cash acquired associated with the reverse capitalization during the period ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of the year",
        "periodEndLabel": "Cash and cash equivalents at end of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r96",
      "r172"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r96"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash financing and investing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r202",
      "r290",
      "r291",
      "r292",
      "r294",
      "r297",
      "r302",
      "r304",
      "r554",
      "r555",
      "r556",
      "r557",
      "r666",
      "r774",
      "r799"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "carm_CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreement",
        "label": "Collaboration and License Agreement [Member]",
        "documentation": "Represents the information pertaining to collaboration and license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna Collaboration and License Agreement",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "carm_CollateralCreditCardProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "CollateralCreditCardProgramMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral, credit card program",
        "label": "Collateral, Credit Card Program [Member]",
        "documentation": "Collateral, Credit Card Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r75",
      "r523",
      "r583"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r267",
      "r268",
      "r647",
      "r817"
     ]
    },
    "carm_CommitmentsAnnualPaymentsRequiredToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "CommitmentsAnnualPaymentsRequiredToBePaid",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual payments to be made",
        "label": "Commitments, Annual Payments Required to be Paid",
        "documentation": "Amount of annual payments required to be paid."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r682",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r689",
      "r801",
      "r802",
      "r859",
      "r876",
      "r879"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r584"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Entity common stock, shares outstanding immediately after merger",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r84",
      "r584",
      "r602",
      "r879",
      "r880"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock $0.001 par value, 350,000,000 shares authorized, 40,609,915 and 2,217,737 shares issued and outstanding at December\u00a031, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r526",
      "r679"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r158",
      "r160",
      "r165",
      "r519",
      "r535"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of credit risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r135"
     ]
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "carm_ContractTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ContractTerm",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of contract",
        "label": "Contract Term",
        "documentation": "Period of contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the ending of the period",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r326"
     ]
    },
    "carm_ContractWithCustomerLiabilityDeferralOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ContractWithCustomerLiabilityDeferralOfRevenue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferral of revenue",
        "label": "Contract With Customer Liability, Deferral of Revenue",
        "documentation": "Amount of revenue deferred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent portion of deferred revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r326"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of unearned revenue",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "carm_ConversionOfConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ConversionOfConvertiblePromissoryNoteMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible promissory note",
        "label": "Conversion of Convertible Promissory Note [Member]",
        "documentation": "Represents information pertaining to conversion of convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "carm_ConvertedIntoSharesCommonStockAtExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ConvertedIntoSharesCommonStockAtExchangeRatio",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock at an exchange ratio",
        "label": "Converted Into Shares Common Stock at an Exchange Ratio",
        "documentation": "Ratio of converted into shares common stock at an exchange ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible promissory note",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "carm_ConvertiblePreferredStockAndExchangeableSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ConvertiblePreferredStockAndExchangeableSharesMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock and exchangeable shares",
        "label": "Convertible Preferred Stock and Exchangeable Shares [Member]",
        "documentation": "Represents information pertaining to convertible preferred stock and exchangeable shares."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r284",
      "r292",
      "r469",
      "r654",
      "r656"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "carm_DebtInstrumentConvertibleDiscountFactorPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DebtInstrumentConvertibleDiscountFactorPercentage",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount factor percentage",
        "label": "Debt Instrument, Convertible, Discount Factor Percentage",
        "documentation": "Debt Instrument, Convertible, Discount Factor Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DebtInstrumentConvertibleQualifiedFinancingProbability": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DebtInstrumentConvertibleQualifiedFinancingProbability",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of convertible qualified financing (as a percent)",
        "label": "Debt Instrument, Convertible, Qualified Financing, Probability",
        "documentation": "Debt Instrument, Convertible, Qualified Financing, Probability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss",
        "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNoncurrentGross",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred financing costs",
        "label": "Debt Issuance Cost, Gross, Noncurrent",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred financing costs",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "carm_DeferredFinancingCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DeferredFinancingCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Financing Costs",
        "label": "Deferred Financing Costs, Policy [Policy Text Block]",
        "documentation": "Deferred Financing Costs, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r123",
      "r395"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue, Current",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Revenue, Noncurrent",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "carm_DeferredTaxAssetsAmortizableAssetsAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DeferredTaxAssetsAmortizableAssetsAndOther",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable assets and other",
        "label": "Deferred Tax Assets, Amortizable Assets And Other",
        "documentation": "Deferred Tax Assets, Amortizable Assets And Other"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs, net of amortization",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization",
        "documentation": "Deferred Tax Assets, Capitalized Research and Development Costs, Net Of Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r855"
     ]
    },
    "carm_DeferredTaxAssetsEquityCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DeferredTaxAssetsEquityCompensation",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity compensation",
        "label": "Deferred Tax Assets, Equity Compensation",
        "documentation": "Deferred Tax Assets, Equity Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "documentation": "Deferred Tax Assets, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets and liabilities",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r855"
     ]
    },
    "carm_DeferredTaxAssetsStartUpCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DeferredTaxAssetsStartUpCosts",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Start-up costs",
        "label": "Deferred Tax Assets, Start Up Costs",
        "documentation": "Deferred Tax Assets, Start Up Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r855"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r855"
     ]
    },
    "carm_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofDeferredTaxAssetsforFederalIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities, Right Of Use Asset",
        "documentation": "Deferred Tax Liabilities, Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows",
      "http://carismatx.com/role/PropertyandEquipmentnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r48"
     ]
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect."
       }
      }
     },
     "auth_ref": []
    },
    "carm_DerivativeInstrumentConversionTermForRedemptionFeature": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DerivativeInstrumentConversionTermForRedemptionFeature",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative instrument, conversion range, term",
        "label": "Derivative Instrument, Conversion Term for Redemption Feature",
        "documentation": "Derivative Instrument, Conversion Term for Redemption Feature"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative liability \u2013 redemption feature on convertible promissory note",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r437",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r597",
      "r599",
      "r600",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r656",
      "r877"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "carm_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "label": "Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "documentation": "Derivative Liability Statement Of Financial Position Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "carm_DevelopmentStageRisksAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DevelopmentStageRisksAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development-Stage Risks and Liquidity",
        "label": "Development-Stage Risks and Liquidity",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "carm_DevelopmentStageRisksAndLiquidityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "DevelopmentStageRisksAndLiquidityTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/DevelopmentStageRisksandLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development-Stage Risks and Liquidity",
        "label": "Development-Stage Risks and Liquidity [Table Text Block]",
        "documentation": "The entire disclosure on risks of development-stage and liquidity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r342",
      "r373",
      "r374",
      "r376",
      "r674"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698",
      "r711"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698",
      "r711",
      "r747"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share information:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, basic (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r192",
      "r194",
      "r196",
      "r197",
      "r198",
      "r200",
      "r427",
      "r428",
      "r520",
      "r536",
      "r658"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, diluted (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r194",
      "r196",
      "r197",
      "r198",
      "r200",
      "r427",
      "r428",
      "r520",
      "r536",
      "r658"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total provision",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Federal tax benefit at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r390",
      "r404"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r852"
     ]
    },
    "carm_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Differences"
       }
      }
     },
     "auth_ref": []
    },
    "carm_EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Return to provision",
        "label": "Effective Income Tax Rate Reconciliation, Return To Provision, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Return To Provision, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State and local tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r856"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State and local tax rate change",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, State and Local, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r856"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r852",
      "r856"
     ]
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows",
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liability",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future compensation cost for awards not vested",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period compensation cost of unvested awards to be expensed",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r143",
      "r162",
      "r163",
      "r164",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r201",
      "r254",
      "r255",
      "r305",
      "r377",
      "r378",
      "r379",
      "r401",
      "r402",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r463",
      "r544",
      "r545",
      "r546",
      "r565",
      "r624"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r715",
      "r725",
      "r751"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r712",
      "r722",
      "r748"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hierarchy",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r435"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r435"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r431",
      "r477",
      "r478",
      "r479",
      "r664",
      "r665",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r120"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433",
      "r436"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r330",
      "r335",
      "r431",
      "r477",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r330",
      "r335",
      "r431",
      "r478",
      "r664",
      "r665",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r431",
      "r479",
      "r664",
      "r665",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value of derivative liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of The Changes in Fair Value of Derivative Liability Associated With The Redemption Feature of Convertible Promissory Note",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r72"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance at issuance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognition upon conversion of convertible promissory note",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofTheChangesinFairValueofDerivativeLiabilityAssociatedWithTheRedemptionFeatureofConvertiblePromissoryNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r477",
      "r478",
      "r479",
      "r664",
      "r665",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r436"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r18"
     ]
    },
    "carm_FinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "FinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total finance lease cost",
        "label": "Finance Lease Cost",
        "documentation": "The amount of finance lease cost expense."
       }
      }
     },
     "auth_ref": []
    },
    "carm_FinanceLeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "FinanceLeaseCostAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease cost:",
        "label": "Finance Lease Cost [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "carm_FinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r454",
      "r678"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash used in finance leases",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r457"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing liability",
        "verboseLabel": "Present value of lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Maturities, Financing Leases",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total future minimum payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of principal related to finance lease liabilities",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r457"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, accumulated amortization",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r779"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "carm_FinanceLeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of lease assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r454",
      "r678"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, ROU assets",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r678"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r678"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r288",
      "r302",
      "r424",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r534",
      "r663",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "carm_FinancingCashUsedInFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "FinancingCashUsedInFinanceLeases",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing cash used in finance leases",
        "label": "Financing cash used in finance leases",
        "documentation": "Amount of cash outflow for payment on finance lease."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r719",
      "r729",
      "r755"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r719",
      "r729",
      "r755"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r719",
      "r729",
      "r755"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r719",
      "r729",
      "r755"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r719",
      "r729",
      "r755"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r606"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698",
      "r711"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47",
      "r103"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r104"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r266",
      "r609"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r609"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r387",
      "r391",
      "r392",
      "r399",
      "r403",
      "r405",
      "r406",
      "r407",
      "r559"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r388",
      "r389",
      "r392",
      "r393",
      "r398",
      "r400",
      "r553"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r797"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long term liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity (Deficit)",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r719",
      "r729",
      "r746",
      "r755",
      "r759",
      "r767"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r771"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r771"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r699",
      "r771"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income (expense), net",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r170",
      "r171"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities \u2013 U.S. Treasuries",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "carm_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r678"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "carm_LeasesWeightedAverageDiscountRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "LeasesWeightedAverageDiscountRateAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Leases, Weighted Average Discount Rate [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "carm_LeasesWeightedAverageRemainingLeaseTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "LeasesWeightedAverageRemainingLeaseTermAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "label": "Leases, Weighted Average Remaining Lease Term [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "carm_LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Term and Discount Rate Information",
        "label": "Lessee, Operating and Finance Lease, Lease term and Discount Rate Information [Table Text Block]",
        "documentation": "The tabular disclosure of ease term and discount rate information relating to operating and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "carm_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Cash Flow Information",
        "label": "Lessee, Operating and Finance Lease, Supplemental Cash flow Information [Table Text Block]",
        "documentation": "The tabular disclosure of supplemental cash flow information relating to operating and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Maturities, Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Total future minimum payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r175",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r413",
      "r416",
      "r417",
      "r438",
      "r582",
      "r659",
      "r692",
      "r822",
      "r865",
      "r866"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r125",
      "r530",
      "r679",
      "r800",
      "r812",
      "r860"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r147",
      "r175",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r413",
      "r416",
      "r417",
      "r438",
      "r679",
      "r822",
      "r865",
      "r866"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofFairValueHierarchyofAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_LocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "LocalJurisdictionMember",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local",
        "label": "Local Jurisdiction [Member]",
        "documentation": "Local Jurisdiction"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r274",
      "r818",
      "r819"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r274",
      "r818",
      "r819"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued settlement",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r775"
     ]
    },
    "carm_ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis Agreement",
        "label": "Manufacturing and Supply Agreement with Novartis Pharmaceuticals Corporation [Member]",
        "documentation": "Represents the information pertaining to manufacturing and supply agreement with Novartis Pharmaceuticals Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized gain on marketable securities",
        "label": "Marketable Security, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r337",
      "r504",
      "r543",
      "r574",
      "r575",
      "r632",
      "r633",
      "r634",
      "r635",
      "r643",
      "r648",
      "r649",
      "r662",
      "r666",
      "r673",
      "r681",
      "r824",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "carm_MaximumOfResearchTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "MaximumOfResearchTargets",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum of research targets",
        "label": "Maximum of Research Targets",
        "documentation": "Maximum number of research targets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "carm_MinimumCommitmentToReimburseResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "MinimumCommitmentToReimburseResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum commitment to reimburse research and development costs",
        "label": "Minimum Commitment to Reimburse Research and Development Costs",
        "documentation": "Minimum commitment to reimburse research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r337",
      "r504",
      "r543",
      "r574",
      "r575",
      "r632",
      "r633",
      "r634",
      "r635",
      "r643",
      "r648",
      "r649",
      "r662",
      "r666",
      "r673",
      "r681",
      "r824",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r124",
      "r175",
      "r253",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r438",
      "r529",
      "r586"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "carm_ModernaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ModernaLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna License Agreement",
        "label": "Moderna License Agreement [Member]",
        "documentation": "Represents the information pertaining to moderna license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "carm_ModernaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ModernaMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna",
        "label": "Moderna [Member]",
        "documentation": "Represents the information pertaining to Moderna, a significant shareholder."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MovementInDeferredRevenueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInDeferredRevenueRollForward",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofChangesinDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Deferred Revenue [Roll Forward]",
        "label": "Movement in Deferred Revenue [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r98",
      "r126",
      "r145",
      "r157",
      "r159",
      "r164",
      "r175",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r195",
      "r203",
      "r213",
      "r217",
      "r219",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r428",
      "r438",
      "r533",
      "r604",
      "r622",
      "r623",
      "r660",
      "r690",
      "r822"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently adopted accounting pronouncements and Recently issued but not yet adopted accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "carm_NonCashDeferredFinancingCostsAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NonCashDeferredFinancingCostsAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred financing costs in accrued expenses",
        "label": "Non-Cash Deferred Financing Costs, Accrued Expenses",
        "documentation": "Non-Cash Deferred Financing Costs, Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r719",
      "r729",
      "r746",
      "r755"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "carm_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Noncash Interest Expense",
        "documentation": "Amount of expense (income) related to the increase (decrease) in interest expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionDebtAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of debt proceeds to derivative liability",
        "label": "Noncash or Part Noncash Acquisition, Debt Assumed",
        "documentation": "The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "carm_NoncashOrPartNoncashAcquisitionEquityAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NoncashOrPartNoncashAcquisitionEquityAssumed",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests upon Merger",
        "label": "Noncash or Part Noncash Acquisition, Equity Assumed",
        "documentation": "The amount of equity that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "carm_NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "Noncash or Part Noncash, Unrealized Gain (Loss) on Marketable Securities",
        "documentation": "Amount of unrealized gain (loss) on marketable securities in a noncash (or part noncash) transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r305",
      "r801",
      "r802",
      "r803",
      "r879"
     ]
    },
    "us-gaap_NotesReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesReduction",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible promissory note, accrued interest and derivative liability upon Merger",
        "label": "Notes Reduction",
        "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "carm_NumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NumberOfBoardMembers",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of board seats",
        "label": "Number of Board Members",
        "documentation": "Number of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "carm_NumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NumberOfPerformanceObligations",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Number of Performance Obligations",
        "documentation": "Number of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfProductsDevelopedAndCommercialized": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NumberOfProductsDevelopedAndCommercialized",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of products developed and commercialized",
        "label": "Number of Products Developed and Commercialized",
        "documentation": "Number of products developed and commercialized."
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsDesignateAsDevelopmentTargets": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NumberOfResearchTargetsDesignateAsDevelopmentTargets",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of research targets, designate as development targets",
        "label": "Number of Research Targets, Designate as Development Targets",
        "documentation": "Number of Research Targets, Designate as Development Targets"
       }
      }
     },
     "auth_ref": []
    },
    "carm_NumberOfResearchTargetsDesignated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "NumberOfResearchTargetsDesignated",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of research targets designated",
        "label": "Number of Research Targets Designated",
        "documentation": "Number of Research Targets Designated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r213",
      "r217",
      "r219",
      "r660"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r678"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofFutureMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash used in operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r457"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets \u2013 operating leases",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in the operating right of use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r678"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseTermandDiscountRateInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r678"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/Background"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Background",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r117",
      "r550",
      "r551"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r10",
      "r118"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r679"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r717",
      "r727",
      "r753"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r720",
      "r730",
      "r756"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_OwnershipInterestInReportingEntity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "OwnershipInterestInReportingEntity",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest held after the merge",
        "label": "Ownership Interest In the Reporting Entity",
        "documentation": "Ownership interest in the reporting entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of reverse recapitalization finance costs",
        "label": "Payment of Finance Costs, Reverse Recapitalization, Financing Activities",
        "documentation": "Amount of cash outflow for payment of reverse recapitalization finance costs."
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance liability from failed sale-leaseback arrangements",
        "label": "Payment of Finance Liability, Failed Sale Leaseback Transaction",
        "documentation": "Amount of cash outflow in a failed sale-leaseback recognized in financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "carm_PaymentsForProceedsFromMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "PaymentsForProceedsFromMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from the sale of marketable securities",
        "label": "Payments for (Proceeds from) Marketable Securities",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including marketable securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred financing costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "carm_PennLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "PennLicenseAgreementMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penn License Agreement",
        "label": "Penn License Agreement [Member]",
        "documentation": "Represents the information pertaining to Penn License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "carm_PeriodOfReimbursementOfResearchAndDevelopmentCosts": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "PeriodOfReimbursementOfResearchAndDevelopmentCosts",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of reimbursement of research and development costs",
        "label": "Period of Reimbursement of Research and Development Costs",
        "documentation": "Period of reimbursement of research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "carm_Post2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "Post2017Member",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-2017",
        "label": "Post-2017 [Member]",
        "documentation": "Post-2017"
       }
      }
     },
     "auth_ref": []
    },
    "carm_Pre2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "Pre2018Member",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-2018",
        "label": "Pre-2018 [Member]",
        "documentation": "Pre-2018"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r290"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r584"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r290"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r584",
      "r602",
      "r879",
      "r880"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r525",
      "r679"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible promissory note",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "carm_ProceedsFromFailedSaleLeasebackTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ProceedsFromFailedSaleLeasebackTransaction",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from failed sale-leaseback arrangement",
        "label": "Proceeds from Failed Sale Leaseback Transaction",
        "documentation": "Amount of cash inflow received by a seller-lessee in a failed sale-leaseback recognized in financing activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock under Open Market Sales Agreement, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "carm_ProceedsFromIssuanceOfCommonStockPreClosingFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockPreClosingFinancing",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock in pre-closing financing",
        "label": "Proceeds from Issuance of Common Stock, Pre-Closing Financing",
        "documentation": "Proceeds from Issuance of Common Stock, Pre-Closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "carm_ProceedsFromSaleAndLeasebackTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ProceedsFromSaleAndLeasebackTransaction",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale and leaseback transactions",
        "label": "Proceeds from Sale and Leaseback Transaction",
        "documentation": "Proceeds from Sale and Leaseback Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r16"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r505",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r652",
      "r667",
      "r680",
      "r781",
      "r820",
      "r821",
      "r825",
      "r875"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r505",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r652",
      "r667",
      "r680",
      "r781",
      "r820",
      "r821",
      "r825",
      "r875"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows",
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r157",
      "r159",
      "r168",
      "r175",
      "r182",
      "r190",
      "r191",
      "r203",
      "r213",
      "r217",
      "r219",
      "r253",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r411",
      "r414",
      "r415",
      "r428",
      "r438",
      "r521",
      "r532",
      "r564",
      "r604",
      "r622",
      "r623",
      "r660",
      "r676",
      "r677",
      "r691",
      "r796",
      "r822"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r779",
      "r815"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://carismatx.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets",
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r813"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r789",
      "r814"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r136",
      "r140",
      "r141"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r136",
      "r140",
      "r531"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r329",
      "r337",
      "r368",
      "r369",
      "r370",
      "r480",
      "r504",
      "r543",
      "r574",
      "r575",
      "r632",
      "r633",
      "r634",
      "r635",
      "r643",
      "r648",
      "r649",
      "r662",
      "r666",
      "r673",
      "r681",
      "r684",
      "r816",
      "r824",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r329",
      "r337",
      "r368",
      "r369",
      "r370",
      "r480",
      "r504",
      "r543",
      "r574",
      "r575",
      "r632",
      "r633",
      "r634",
      "r635",
      "r643",
      "r648",
      "r649",
      "r662",
      "r666",
      "r673",
      "r681",
      "r684",
      "r816",
      "r824",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: reclassification to net loss of previous unrealized gain on marketable securities",
        "negatedLabel": "Reclassification to net loss of previous unrealized gain on marketable securities",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r33"
     ]
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r119"
     ]
    },
    "carm_ReclassificationsOfTemporaryToPermanentEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ReclassificationsOfTemporaryToPermanentEquityShares",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)",
        "label": "Reclassifications of Temporary to Permanent Equity, Shares",
        "documentation": "Number of stock classified as temporary equity reclassified or converted to permanent equity during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r700",
      "r712",
      "r722",
      "r748"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r467",
      "r468",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r601",
      "r603",
      "r631"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r467",
      "r468",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r601",
      "r603",
      "r631",
      "r864"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related-Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r468",
      "r470",
      "r560",
      "r561",
      "r562",
      "r607",
      "r608",
      "r609",
      "r628",
      "r630"
     ]
    },
    "carm_RenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "RenewalTerm",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Renewal Term",
        "documentation": "The renewal term of agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r284",
      "r292",
      "r469",
      "r655",
      "r656"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r386",
      "r873"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "carm_ResearchAndDevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ResearchAndDevelopmentServicesMember",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Services",
        "label": "Research and Development Services [Member]",
        "documentation": "Represents the information pertaining to research and development services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r713",
      "r723",
      "r749"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r714",
      "r724",
      "r750"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r721",
      "r731",
      "r757"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash and cash equivalents",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r121",
      "r148",
      "r172",
      "r524"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets",
      "http://carismatx.com/role/DevelopmentStageRisksandLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r110",
      "r528",
      "r547",
      "r549",
      "r558",
      "r585",
      "r679"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r254",
      "r255",
      "r377",
      "r378",
      "r379",
      "r401",
      "r402",
      "r418",
      "r420",
      "r421",
      "r423",
      "r426",
      "r544",
      "r546",
      "r565",
      "r879"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenues",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r857"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development services as collaboration revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r212",
      "r215",
      "r216",
      "r220",
      "r221",
      "r222",
      "r324",
      "r325",
      "r505"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r651"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moderna Collaboration and License Agreement",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r328"
     ]
    },
    "us-gaap_RevenuePerformanceObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuePerformanceObligationAbstract",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations:",
        "label": "Revenue, Performance Obligation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total performance obligations",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Revenue Expected to be Recognized in The Future Related to Performance Obligations",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "carm_RevenueRemainingPerformanceObligationOptionRightsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "RevenueRemainingPerformanceObligationOptionRightsAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails": {
       "parentTag": "us-gaap_RevenueRemainingPerformanceObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option rights",
        "label": "Revenue, Remaining Performance Obligation, Option Rights, Amount",
        "documentation": "Amount of transaction price allocated to option rights performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": []
    },
    "carm_RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails": {
       "parentTag": "us-gaap_RevenueRemainingPerformanceObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementScheduleofEstimatedRevenueExpectedtobeRecognizedinTheFutureRelatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Revenue, Remaining Performance Obligation, Research and Development, Amount",
        "documentation": "Amount of transaction price allocated to research and development performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new financing lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r678"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r678"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_SaleLeasebackTransactionAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleLeasebackTransactionAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale leaseback transaction, accumulated depreciation",
        "label": "Sale Leaseback Transaction, Accumulated Depreciation",
        "documentation": "The accumulated depreciation and amortization related to the asset(s) sold in connection with the property sold to another party and leased back to the seller."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r462"
     ]
    },
    "us-gaap_SaleLeasebackTransactionNetBookValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleLeasebackTransactionNetBookValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale lease-back asset",
        "label": "Sale Leaseback Transaction, Net Book Value",
        "documentation": "The net book value of the asset(s) sold in connection with the sale of the property to another party and lease back to the seller."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r863"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "carm_SaleOfStockStockOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "SaleOfStockStockOfferingAmount",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock offering, amount",
        "label": "Sale of Stock, Stock Offering, Amount",
        "documentation": "Sale of Stock, Stock Offering, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Anti-Dilutive Securities",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r66",
      "r408"
     ]
    },
    "carm_ScheduleOfChangesInDeferredRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ScheduleOfChangesInDeferredRevenueTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Deferred Revenue",
        "label": "Schedule of Changes in Deferred Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of changes in deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets for Federal Income Taxes",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy of Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Assets Acquired in the Merger",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Using The Black-Scholes Option-Pricing Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r108",
      "r109",
      "r110",
      "r150",
      "r151",
      "r152",
      "r202",
      "r290",
      "r291",
      "r292",
      "r294",
      "r297",
      "r302",
      "r304",
      "r554",
      "r555",
      "r556",
      "r557",
      "r666",
      "r774",
      "r799"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r221",
      "r661"
     ]
    },
    "carm_SesenBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "SesenBioIncMember",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockbasedCompensationExpenseDetails",
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sesen Bio, Inc.",
        "label": "Sesen Bio, Inc [Member]",
        "documentation": "Represents the entity Sesen Bio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "carm_SesenBioStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "SesenBioStockholdersMember",
     "presentation": [
      "http://carismatx.com/role/BackgroundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sesen Bio Stockholders",
        "label": "Sesen Bio Stockholders [Member]",
        "documentation": "Represents the stockholders of Sesen Bio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/MergerwithSesenBioScheduleofNetAssetsAcquiredintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance and personnel costs paid",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting at the end of each three-month period after first anniversary (as a percent)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Percentage, Each Three Month Period After First Year",
        "documentation": "Represents the percentage of stock awards vesting at the end of each three-month period after the first anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear": {
     "xbrltype": "percentItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting on first anniversary (as a percent)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Percentage, First Year",
        "documentation": "Represents the percentage of stock awards vesting on the first anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount to the market price (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "carm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sesen Bio options assumed in the Merger (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Assumed In Merger in Period, Gross",
        "documentation": "Gross number of share options (or share units) assumed in a merger during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable as of September 30, 2023 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable as of September 30, 2023 (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding as of September 30, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding as of December 31, 2022 (in shares)",
        "periodEndLabel": "Outstanding as of September 30, 2023 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding as of December 31, 2022 (in USD per share)",
        "periodEndLabel": "Outstanding as of September 30, 2023 (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at September 30, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at September 30, 2023 (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at September 30, 2023 (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails",
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ]
    },
    "carm_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sesen Bio options assumed in the Merger (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Assumed in Merger, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options for shares assumed in a merge during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r346",
      "r365",
      "r366",
      "r367",
      "r368",
      "r371",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofEstimatedUsingTheBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable as of September 30, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable as of September 30, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding as of September 30, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest at September 30, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue price per share (in USD per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r173"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://carismatx.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "carm_StateJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "StateJurisdictionMember",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State Jurisdiction [Member]",
        "documentation": "State Jurisdiction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r30",
      "r143",
      "r162",
      "r163",
      "r164",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r191",
      "r201",
      "r254",
      "r255",
      "r305",
      "r377",
      "r378",
      "r379",
      "r401",
      "r402",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r463",
      "r544",
      "r545",
      "r546",
      "r565",
      "r624"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r201",
      "r505",
      "r552",
      "r566",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r605",
      "r606",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r624",
      "r685"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r201",
      "r505",
      "r552",
      "r566",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r584",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r603",
      "r605",
      "r606",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r624",
      "r685"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r716",
      "r726",
      "r752"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r110"
     ]
    },
    "carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued upon conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-Controlling Interests",
        "documentation": "Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "carm_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger",
        "documentation": "Number of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r29",
      "r52",
      "r110",
      "r286"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of common stock, net of issuance costs (in shares)",
        "terseLabel": "Shares issued in a pre-closing funding (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r83",
      "r84",
      "r110",
      "r554",
      "r624",
      "r644"
     ]
    },
    "carm_StockIssuedDuringPeriodSharesPreclosureFinancingTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesPreclosureFinancingTransaction",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash in pre-closing financing (in shares)",
        "label": "Stock Issued During Period, Shares, Pre-closing, Financing Transaction",
        "documentation": "Number of shares of stock issued during the period pursuant to pre-closing financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://carismatx.com/role/StockbasedCompensationScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r83",
      "r84",
      "r110",
      "r352"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Sesen Bio shareholders in reverse capitalization",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r30",
      "r110"
     ]
    },
    "carm_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Preferred Stock and Non-controlling Interests Upon Merger",
        "documentation": "Value of stock issued during the period upon the conversion of convertible preferred stock and noncontrolling interests upon merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r30",
      "r110"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock under Open Market Sales Agreement, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r83",
      "r84",
      "r110",
      "r565",
      "r624",
      "r644",
      "r691"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r30",
      "r110"
     ]
    },
    "carm_StockIssuedDuringPeriodValuesPreclosureFinancingTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "StockIssuedDuringPeriodValuesPreclosureFinancingTransaction",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for cash in pre-closing financing",
        "label": "Stock Issued During Period, Values, Pre-closing Financing Transaction",
        "documentation": "Value of stock issued pursuant to preclosing financing during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Carisma Therapeutics Inc. stockholders\u2019 equity (deficit)",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87",
      "r88",
      "r100",
      "r586",
      "r602",
      "r625",
      "r626",
      "r679",
      "r692",
      "r800",
      "r812",
      "r860",
      "r879"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets",
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r143",
      "r144",
      "r163",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r254",
      "r255",
      "r305",
      "r377",
      "r378",
      "r379",
      "r401",
      "r402",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r439",
      "r440",
      "r444",
      "r463",
      "r545",
      "r546",
      "r563",
      "r586",
      "r602",
      "r625",
      "r626",
      "r645",
      "r691",
      "r800",
      "r812",
      "r860",
      "r879"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity (deficit):",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r174",
      "r289",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r305",
      "r425",
      "r627",
      "r629",
      "r646"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r472"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r472"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r472"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://carismatx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r473"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://carismatx.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Axis]",
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period [Domain]",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxYear2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2023Member",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiring in 2023",
        "label": "Tax Year 2023 [Member]",
        "documentation": "Identified as tax year 2023."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://carismatx.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/ConsolidatedBalanceSheets",
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r175",
      "r253",
      "r438"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "carm_TerminationFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "TerminationFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination fee payable",
        "label": "Termination Fee Payable",
        "documentation": "The amount of termination fee payable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r288",
      "r302",
      "r424",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r534",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r808",
      "r809",
      "r810",
      "r811"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "carm_TrusteesOfUniversityOfPennsylvaniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "TrusteesOfUniversityOfPennsylvaniaMember",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penn",
        "label": "Trustees of the University of Pennsylvania [Member]",
        "documentation": "Represents the information pertaining to Trustees of the University of Pennsylvania ."
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandFourteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "TwoThousandFourteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Thousand Fourteen Employee Stock Purchase Plan",
        "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]",
        "documentation": "Represents Two Thousand Fourteen Employee Stock Purchase Plan."
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandFourteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "TwoThousandFourteenStockIncentivePlanMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Thousand Fourteen Stock Incentive Plan",
        "label": "Two Thousand Fourteen Stock Incentive Plan [Member]",
        "documentation": "Represents Two Thousand Fourteen Stock Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "carm_TwoThousandSeventeenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "TwoThousandSeventeenStockIncentivePlanMember",
     "presentation": [
      "http://carismatx.com/role/StockbasedCompensationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Thousand Seventeen Stock Incentive Plan",
        "label": "Two Thousand Seventeen Stock Incentive Plan [Member]",
        "documentation": "Represents the Two Thousand Seventeen Stock Incentive, a Legacy Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesNarrativesDetails",
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r668",
      "r670",
      "r874"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "carm_UpfrontNonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "UpfrontNonRefundablePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront non-refundable payment received",
        "label": "Upfront Non-Refundable Payment Received",
        "documentation": "Upfront non-refundable payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://carismatx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r133",
      "r134",
      "r137",
      "r138"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "carm_VariableConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://carismatx.com/20231231",
     "localname": "VariableConsideration",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/ModernaCollaborationandLicenseAgreementNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable consideration",
        "label": "Variable Consideration",
        "documentation": "Amount of variable consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://carismatx.com/role/CommitmentsandContingenciesScheduleofLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r678"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares of common stock outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r198"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://carismatx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares of common stock outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r198"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481192/840-30-45-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-50"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-51"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481266/840-40-55-52"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815-15/tableOfContent"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001485003-24-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001485003-24-000005-xbrl.zip
M4$L#!!0    ( .1%@5CS90=V(;0# &+"'  1    8V%R;2TR,#(S,3(S,2YH
M=&WLO7EWV\BU+_K_^11XRKV)O2XI$YQ$VMV^2RW;B4X\Z$GJY)S[UEM>1:!(
MH@T"# 9)S*>_>Z@J%$!2HF3)!&4FG8Y(8JAAUY[W;__ROV]FH7,EDS2(HU__
MXAZV_N+(R(O]()K\^I?CBY/3T[_\[[?_\<O_TVS^UV_G'YUWL9?/9)0Y)XD4
MF?2=ZR";.ME4.O^,DV_!E7#.0I&-XV36;/)M)_%\D023:>:T6^VNODS_FKSN
M=#NCP;C=;[8&HUZSV^_(YJ W&C7=4;OM=4?=OC<>-B:OY:@W[K1;O69?2+_9
M[0Z&S<'1$?S5:?G]@8#_=D<-_[48'@T&+MPRE-WN:.P+T1V.QK+5'@Y;XY;L
MTGNG&<P9YAVEOQY,LVS^^M6KZ^OKP^O.89Q,7KG#X?#5#5YSP!>]OADE85"Z
M%+^AB]NM5N=5$*69B#RIKP_2N-MVCVZ[@Z_0-_BR>#Q=F$KO<!)?O8(?X(9V
MQSSY)FO";Z4GZVN#* PBB;OT*DM$E.(FB RV%9[@]F!YFQW7GI%?>:<:7/\5
M_Z@O39/,7#<6Z8BN@R]+X_)$,C-7P8<@A5??''KQC"YSV\6K80JK%^:V\;=;
MS5:[Z;;U0^#*;[<L+_X\$JG9$.GYJ]<7?BC-(T^;$R'FRQ-6/Y0NODF#5?0#
M(W!?_=>GCQ?>5,Y$LTH<-TMC+]$=_EHLU;HYNAUKN>CRUZ& $WL@H^;O%P=O
M?YE*X;_]928SX> 3FO)?>7#UZ\%)'&5P>IN7BSD,R.-/OQYD\B9[113_ZNU_
M_,=__)(%62C?XJ8V]?;]\HJ__.45/WH4^XNWO_C!E9-FBU#^>N 'Z3P4B]=1
M'$D80'#S&B^4"?\9^+Z,Z$_X_3.PD"3P^/TWV;D<_WK@-8%"(C'#)\G@]?L(
M7K<X@=$E(CR-?'GS=[DX< +8QW&STSEXVX)5[@YZL-N_O"H]]1XO.09.YB,W
M^Q"*R8'#!/?K 5#HZW%P VQF+$(D(O76[L%;^N+A+]3<\T.0>B+\;RF2#_!-
M:M[0.WB+Z_U8+SB#RV.__(K^P=L/_WVO%W2[^@U($*_?P257<"ZOY"E0=D*O
M [)2(N12)K,/<7(N?3F;X^'] &(B3ZQ%A &<=3[=:P2]MAZ!.H:OSY)X+I-L
M <(FRHXC_SV0]QQ'\GLJQWGX,1@7;^P/X(WMY3F_*M-E(L<R =$GTQ7'"4_E
MZY0.-(S)H5/Z.H-#].M!&LSF(9YN^FZ:T)#MDW-XD_IPKNA]Q4O4.],X3^@3
MR9C7:MXT=-Q:_;VDXZ _!3Y^'@<R<6A,<J4\.#G]>_F85&]^J[\J/WU.5*,_
M ?-*LG<@ZHDRFRT7_M'W%;^98?K%I6Z[V7&+5_ O^K-^R:O2O%<O0[L&R\!<
M/%.+T&]V6N9!ZI?-9I9' 4\K!Z+07\ZD2.&,O%5:P>O?+][IV_5/^C/>OWJ5
M.O5:I6ZS!230^\Y52J<"SLC20BGRHQ_OOU+=IUXI-3PY08[$'WUXV<T\#+P@
M^R1G(WB%'\"OI'4;KG8*BO=,7HJ;XSR;Q@D,[?@F@-GKW]_!KVD6>"=Q#G)Q
MP0_ZY=7*YYMU,,.X+Y67SN_]]J^\WKVZKC=J05_&QPEHFQ.)]_)RDYC[)*)\
M+#R076 )@82YR.?S<'$\221=^4\P>S['5\#_@O0,Z' F/)G#UH!^<!(G\S@A
MS?6)=PA.V./L4+]>O.,1:>^H7C-K?\_,;-D!JMT%LC\S/=#$85CVI:3HB"Q.
MJMQS0S&S=#]^^4Y&\2R(5CUV4Z9<>L2K\NCOY-V#&NQG225J;ZX2M1]/)1K6
M8!DLLG8?[\"ZK;I*BXL,=@OO06,#;--X-@=3-\K2LI"&[V=Q=)'%WK<G9?^/
MN>9/;F@\\9H?^WZ \A9,7A'XI]&)F >9"'=F_9_<PGGJ]?>\?):'Z!#^DDUE
M@M<E<HI/0S<!:K4[LQ=/;D<]\5Z<RTP$D?3?BR0"U37=F86OK5FVX<)_CB.<
M41*'(:S[*<P-%*%L9Y:_ME9:'>1N#50^]\F-M.<BI.NP64]N=SY'B5Z'C7MR
M W/GQ7\==NG)[=]=%E:/Y6^J1&%VW3#?AI'XF.N_\T;ZEHW$Q]R+73?8?ZB1
M^)@+O^O6^1:,Q,=<_EVWT7^<D;BE5(E=M^*W8R1N:;-VWJ+?NI&XI8W;=>O^
M1TFA.NS5WJ#?A5W:&_0_/#6FLS?HM[O^>X.^/GNQ-^BWM/![@WZKRU\[@SY-
MLM=?KB.9I--@;N7CGG!1V27P&3&G5-L46,SA'0M]Y^NP:.:CG(CP/4W_SA?B
MM=Z"Y/PT#GT8YO>.0!/2;WD*!SA-CSV@MY0$FS6:"YG*Z+<@AB$\?5)QZ^AA
MM&425*,<Q[(F;7\.?^H'W*.\H7:>C>=&J8]@.=BD<[OE4+KT>RR'3NV<*.LW
M2A_B/?O89&-KZV3Y((+D'R+,Y6\+\^??X(DB\::+C_)*AF45P5QT&LWS+*4K
MW,?:=VLPGYB94OUG(O^5R\A;K!F)=6EZ+KT\P2J7G5%::NO2>0S*:.\IX^&4
M45LWTF-01F=/&0^FC&YMG5U[:?( RGC$F':WMFZXO339,F74UBFXER9;IHS:
M>BT_!)&(O  Q<S0X2WD#?K^X3&CI%Q>XZF HRIW)_NK6TEMYCN@!O,CX\5,0
M!;-\]BSSKKNU=,)5-T#</-\-J)VW:X44^!B(41!BS"04:25<4J!'K>!4J;YS
MEWC2+KBIZK\CCUC)V-T%]U!-=Z0&J4#=7?#A[,+V;4="]7;!T5+3[7LLUU<!
MG\8O7PK$4DQ(_7C_4&ROMAZ3<PD;%7B9]$]$.CV.Z/\P?^-*A+A[J[^U0ZEQ
MB/E,B0A/$ND'V8E(_+,DGB3B"?3)<MQL^&!,P<KNU,YK\2.-I"="L*N=O?\C
M[9XG6M/:&?-U"Z4_WE+7SFROUU(_HCG8JZV!7H^E?L0$D5YM+>]C>((?A#DJ
MD867]?V-%^:^]#\D\0RS2?.,,$*_C'7.KL9T_&VQ^@$E/04!M[-@%,HSPI0&
M;86RBA +^\:;HF00\",][WG:B;W:FOD_V?9OR<ZLK9O@2;=?O^3];![&"REI
MU[_,GP9LN :GO%];=\(SW>;MG.9^;5T*/XJ9IW1[B;''LR!-XV3Q.<Z>9QUU
MOW:NBI]KU[=TUFOG3-G,1/I1!4'W+?2XJ[)DBP:;Y8@6:[W0X@$NZ/Z3.X^V
M9M;V:^>LJ0%!/KS0Z/'85FT].VN;8?VVP XG98WR(AYGUR"BWF$.8$R7[8H;
MLU];AT^M=^ 1O9O]VOI<[K4#YL>=H?S:.CMJN.Z/2.]'M?4^W&O=/^1@GF 7
M1KCP0W"#?]4X>Z&R!;7U#-1["Q[S%-363+_7%GP$ZT*BC78ZFR?Q%9<>[,PQ
MJ*W17/,]>,QS4-N,A7OMP4E,Z6P>NC=.(\INDNGN'(3:F<>[L@F/>1*>ARW\
MA/IH#;SK1\_#7/Y1F[0=9_A1;2WJVYKCGLDH^AAX<(LT'7$?JYST7!*BX!DL
M_^(27IX*8I+I;PO[%VLPETF>9E*F7\:_1P'%5++%ES$.,5V$5R(*Q/,\WK7S
M"3PX)W5/D_75MP:U<X'LR>QG9WV#VOJ$=K"C_(K0VH;[66H__UW[^>0.IB<-
M,3X:EN'@R9T\]Q4CK6[3?92H]J"VOI.+?)0&?B"2Q84(X?!R'FUQ;(^SRZG\
M)))O,OLR'LL-8$HVDF G<8Y8P7/DZ)_%3%IO_$])[Y'IQX\G3YW;\6C[6UNW
MS,^VOW60S[5U#R$Q$"Y1]OX*_K4B.%^^X+$TNY^:"+N;$V'W$96*)W=_W9O9
M]INMWJ,PVR=W&CUD:OU'F5KMO!HF)?A:)/X*]^2],_0W.KE/:^"BX[7"#RZO
MX\MIG*<"#!.)K$]*;F=S&GFX>%<2;WJ6XFI8.Q?'CZ>Y/66LI(S:.AINWZ</
M<9[\3-M4WP25VFS3TWB'A[5-2ZD;Z_S9CF1M_3V;;5.)3L[RQ)N*]!GO5FV]
M-[7;K2?BH[7UF&S7[/DA6+I;.G.U3<_9 4MW1[>\MLD^/\$IWTY^UW#OS_K9
M,+K=UO/W)^TF_W5;M?7GU&9GMG5F:NO"X4;6%[H;\,?8$P4PA 4\*['YRC&L
M05'6^_YFCGEBS_0LU=;U4_L=V]89JZU/9J,=^ZN,$)@9-NS8GX'*F&8)P70_
M[U-66\_,#NS9MLY9;9TY6\2 K<5AJJW+Y5+<G-%,[$SS1+9;[N"QPA-\7N%%
MQWDVC1,#Y&/Z'L"O:19XE#.4+';%<^JV:NM46;FI<9K!KA[M=_6.7:VMWV3=
MBC,+17'XGWD2I'[@/8VU]D0+[M;6:7'K@J/:$>[F@M?6%_&H"_Y0;FE]_=]@
MJ.'B[\[6UM:9 :MI&MLDBW&<H-MIM6&\.ZM=6T?$O>OY/L6^3**[BO8VW^U;
MJM&HT]%(596!?7;/FL8?:IK!I0^U  P"*;Q@(M=@D/)O^@F;HY"Z;NT\*AA<
M.4MB/_>R+\F%3*Y@6ZU=7^WU4M=]-W+MGN[K1_=S)H;5A*]^? CEU\XO]>#
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M[P4SH(Q?#UK+)'5&*ON',!85)+HHGS7]F*"]\>X#!\<EZ1D*B[!U\+9]U&N
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MZ^_$'LR*LB<#=G!Q@1+%O>S*$O)0J](&F'*<(&!I0Z]=4;.A5Q&7]THDP*^
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M,E<5[.V\_$:'#F'VK8=H@O4R$+@"-.F,ZQ<K#!X%F+Y<N[Q,WKG2O>S"E7$
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MMJKHL45($F";.#BX7!=OBA8,)@@\H^Q0+'7'H\P;1AG1!0U3F!,I)+Z,XJL
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M=R_8.3UY*A),LN?TGO(>E='_P,Z@1KGE33#+7F78Z_FSP^V=/@01MW<QP']
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M(H46)">DLB"B4?WO6^!GR3K]Y,87OX'=/<P\S.\4Z\M__?J_OQWD+/S+ ;^
M >-^^BC1/CW(_];-.Q?B(Z0/TRG(1[Z#9?Y9ESY\$+X1+]H@4YFOT]"6(E_>
MFR'^/8:?#]1E\!8Y<0]FBZLP.G*&^24SO&=9< )G@?5'-07(+V!5_?3RKR?A
M7RHUS"2<;;DI]_X:/WOS\J^9"<;\=?M>VCBC<7?5(RX>02LP7$"2)=V5 MH
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MS0C9",Z:%]2L3.N8?"[9,O!IN'D17Y^0.59D81<];]EY#(QD$L,-S>D"VBM
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MZ(#Q""1(7*C)_V/Y1:PTY4WA:-$UX,#$>F!.V%/X6\P#L";E=^%J<CF9$%3
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MB89 E-HJUV5QK>GDNF]&::5PJPVY0>OR';&BQ R#-:'[SF"*NR==O,C!<U/
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M9K<GA5)D31P=+[/9IZ4A$S$T38Q!16[/"2BGGAR&EX[.F]NK$@?3@^-$H=O
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MJL(Z(1KS,/@7>)=IU=V3_2:---2:BD5'9"9PUYR_]$O/8Z5$P,0JW+-D+A.
M24-\XK%&"L-@["<Q/^1:WY$V[J*EW)0R[E.IA%>:/^/_-=WN7OA3?O9!0,I!
MWN/-AX1B)(G-2$#/MD49_B6_PD-H08.QDC<!-Q<[*=P?XNPZG2_[.+1)^F&)
MB<^BN.>BK'<(MNN(?[^\@H[:1;Z3'BZ#;6.<#[CT-Y3(Z094O-^WM-F!:J<%
M)#F9(TTY'&X+0D[/2*WI:NO$SU&BN$MKU/FL:C3ZR \9X8)\"T.@C*0P6MD,
M#>H0S[*E -JVF[4E?.X?G5W <M [Z3QCO(G"EKANX?9#[/&E2 @@GUVPB>$.
M6%)W=H"Z;4H\9#0A1 HW\-AK4MGNOA\WR+B78J>*"JP^;VPA7%X!S0#L.(P&
M/(]'5JLF@VJ7PZJ)K#UA%0XEF^^^(>1"C)*ELQ*[508RCX%WI'-(P[QJ4/&O
M2)D*OB)2\+P4O'IG6X?\KU**R#)ZP B-H1RHQ7M7*@K&;C2Q,8@6GD)K8ID/
M3:YV>NY(87X@IQ, JOH872*M>93ALM-'H47BXQ2%&K(V?)6*6I'$&XEJ_,&%
M+Y@@I%Z7U5IPD2+RC&96+!JSZU<MD3ST0U;#.S?2C@6+O^:U3-+?J-!P!LEG
MV()(2\""N_4/RC$%8Q!@HM5&W<&T=9BR\47XY\-'G$WXB D?<6QO\4#P$9]?
M2GH/+:SMPSL+SWTUR(6NA0<P4Z!LC+\7":<,\:;.6-8\KQE]:D#P6B*U30*&
MNJ]7:T"D7M:(QHT^U0;D]ROWADR8$RMD[@PT.';1<%47JHT4JA(NM![N.^%&
M781_QA7M]I8F]J14Q$;X.$/@??>_&4;!J QR\S^\M>,\[C=IY7R!QX_.A 23
MUHU7X'%N"*,3HO![.*7I)=<ZHS<*,O?U1P[Q>SWED=.BB!VK3Z0W"BN5UZ(
M!#IZP9V.]+P0.43W7LZE]N_:P8SFEAK^C,?HQW:YSAJ,$JV;<T95\]^'1D8E
M'[7[@YM7E*^5\ GL7SK'78<>'9O_7CI/;/:!.;H@00[E!0*OO,J0 6N<T9+O
MN@=+ZT^J5QW1=*;N3\Y?Q ,LY6O^EN26H1D>V_4O9Z>/@07?;*P&!&]@]W+N
M;T*9^?C18_>F&+.VT/:NBN(5#RA:EY1?P#!DB$RK?+W.@G4(.CU!_*)U#EN*
M=KCP=-16?-F-9\.2^(B6);_NTO4:=H:Z]OR0NA?T7FX4L8:(5%5:'O]WE-$L
M"4RDDLE2'T9=,0S'DS.6"$\Y^4TIH+(JB_0RKUP =@ZG^KT+[+,5+<R?M$_Y
M@\:,D3;L^?N?/N W?V2U3,"RSK?HUG+W_IC^YJ;&#;V,4=A0C_T,A V*&5!]
M7/>1)\-[+D;_+(<7@2XNDRD+)2*3)G/G*_$?<%R@< 8$T94A]H[^&H/OA#(3
M;V6Q0D9Q!Y\R:YQV%+=BX_^&5Z[T@KFX/Q89,IW$#-1(ZSI=!_V=8B6AL#<?
M*D7F3=WCQ\S^#=7/<!JHN@H3AKAEHS)'L*&@O,M;]T#I;[!XRYR0)=YB?(?M
M2B*U[;S.J<?@*B,ZCWR=4P.VO;[_VF.; -8%\SZK%VTV>[=A*281+CV+!%&Y
MXT%[5TR'@S$.[@]1"-S+6R&(UIZ/4#5(=?][W&P<^TM[PDT06\-$08.7&V(,
MDH6S(N5NI,YION4B[M;#/?=,;^,9>Z2D]P#]EP]TB)-=L.(%Y*DTL1.;>' N
M@1DI+Y3 K\V(K]&=2,CHABYG?%H7/J^;5!8-)T8S\5;=CYM4V=BM@"R+$4:^
M!#>&=I_66;_9RU8* /]>SFMC_[[WI\+'E_]^;HTA,DJ<ZGNG:M2SCU6[W;%[
ML! A\\>)7,9O8GYVV<0BI6O0%EMPG379J8KJ?J0<-+TN/:\R([%X5%2-<7L.
MH83N4DZ+IQ76ZPS9K2W2M\H78'E^F-Q_GBW J1\TPTC![^RYI468_7M;9#.\
M#_L@WF/]T,+\X-AU'T:.#-R>5*:&,6C17$OPU55NN,MI T/%PBWAE0M?2.);
MVIW!^2852;\JQ)TM?--Q:L'G;M5!.5GE #AG;00)R9BKPTG(+,]7I<M2EDA;
M[& _%PU3&;CK>'(R);AX@)L5*XE7J$UVDI=7?@(5\J)E(8:PS\CTN\\2[(#:
M#T.O;J0V1CM^3DR#.&+T$G3 P-#E=*S0X )^K\R&;A!^\O=]RX@BXUS\H,LL
MVF4_XC\^80_(4QVB8FBR^X*BY[XG_4USPOC&9%J&#/CWVT:."/<21 GEKB1[
MQ1]3@5-_8?+22D %?7@)SRNW:IN+3-1"^8+@G^8#U6WESMLG_1?!/?DMN>I3
M92?,^)3]M?,:8;)V7J1>0"E9"=D" 8WB J$W7NCENJSG@<+15)Q>OOW/UZ].
MSIZ_,&0^'I5YE>:D'L?N@J_-:G(:F\ZG[P42[B-3G(#^Z:5II,=8<%56GZ+2
M](O1 :":+T_::]^3\X;*7GQ:>$X@9>NC%IN.2>Q>GY$1#7?0HU2$#H6&24]<
M'+H)[DS\WB\X\HZN)2.0H@2T-%TT=D@,&)4TF42#Q0\(,Z(AC"60ZE%:I%OF
M ]_%B:=WY-T=Y8M=:VH-^\>A]OL@RSLW&II4MZ+E(!HG.(C0-]36*G38SW_U
M\H8:7E74O,0']2+RJ?*":M%9#$6(LC@:]1G.$[%1]G!E=E@R$\/QX)R2#[1U
M(JQ)GYEFIP2GPMPM57@V-<!':#^*;0BW16B#)%<KPIXB;3GMI1XD9K'&JU.6
MH_HXB]5T/3X1K='A#D<I@61CQO=->25N2'B(H?XF/FC$Z3#.+<]\[:\=9ML9
MAK*"&A['Z%R(C[2+@D"U7$H(\UAXJ\JWHK2(XS*FE$G9M228EKNZT&!M2^<3
M2"J1)73H'*0V-3<#81S?@2GIQQ#ZXRO^W12Z<*)N"=&J=6=&TCH8OEJ;[G<P
MM)YG51NS*)1-EY<I-:H9]M7@V:J'<9;XN!4VN460<.'N<(FCV/=660)C>760
M#&#>-E1#KM!)]P_G(ZK?F<1!P'/K+K]\\R'H\)GQYA9W>$KNC#F=_=KUE<A?
MX$?4R]"67/*HY^* 0!>NK(0%<><].;,X!-%$*R2:D=YT#70D$C"05EQ!N4P"
M%_8]I@P9$O?@)W-*P>"JX^?3YR;3_GR5Z<=397JJ3!_;6]RB,GTT#EH$=7,G
MR-M%4Y*I]F)T?_O;!^_#D^Q-2W3&7:N=2NN6;V'W,:9O0B#N4R&,1L6!#HD?
M'CV=O2:U(CY*W[&K0NFF#Z_?<;L._=TX <9-X (K):!?ID6Z3-F>#SJ%%&[H
ML4_)*Y]163*;D.9H!,/8\<+?.\>!JI3D#G61OA(WL]S,Q?LW/A& )E\HM+G[
MA7P0<9^J \F*2$0NT!+.<?9S-J^DL/#XB:2,V%?"!P12AA>B.[D++(=31NCP
MEUD\G?V"D%#FYYN76&'ITGFI/[L?\J5[\#?HG$YH:?TMW>Z<CUG)/]^X2'GA
M/OJ+FX>+V:OT4]FXSW]T ;AS)_[3!9NE= S_BI9^YZH7W_*S(.,/#F,&+<H2
MT3)#;N9=H=)V*D]G+V7*/49.GI[?TTO 7[.8##* RK'P"ER43@X=EG3H+7T;
MDB[?D:_R)"@R^FYF&:^004?V'^]$3PW"68*#FK?[\D?^T1@0FQ/]Q0T/.WJ/
MDHX%(4OA+KLD6@*_!ZML6UZ2U4A7"-BJ.9?C)6L37&I;+&&VUFL@PS0I7KN9
MPQERYUXEVNUGFP:UT".7W8M?UPB)!(II0LWOBRVF/)P;!HOYGA/NE*]FRPAJ
M*:J\HSX#/@7[MH.OZ(Z=#6>Z-#N,"OQ)N3H10NH0HZ:]JZF=7.6_9:P5$O7O
M^ZAQ[%5[<21X'TQ5F6U0R7DZ#DJW5 1BK(, O)5Y'+AEBIY*1,7F624K2ME4
M])5Q:+I@3OP04!/7.JV;+5,PHK17%B/Y5QIQ%^CDFTYL\XQGA.J(6I*56P]>
M2F(,O&]TH2>/_YB;^>PQ.!M%+-W':=UDL^0VNKGJLZ>/GCW1(@SQN!*=]G "
M)&R@?MZ!)XDOJBEM-2&-[B+P#F!W2U_+T^]F2P#1N?=A[C:,%).RWXA0_3+&
M>1W*07&:YX(BS66YS8@4N0O>;PER[3R''-EBBE9]/D7"?XK'Q_L@F#)V<=&]
M?Z*$2&X356IKJDR(ZV 7G9N\#12R:V>R(#>D)3(W?1^R7<,VV,\AQ@[-&Q2
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M+&M!_2^[HK0&83G$J$<7%.2/LEF-$>L%5J6 61V"Y3T\K../&8L.2&6]:-T
MH'XXIL+0A2GNT'"0+JCRQ_:Q.]!)OP4VA1P"=]Q)7YY29,O)G&[+EHN/H7G'
M0QLI<,T*H?F,&C'"#:X%H+^U:$GNG?!PR7FV+V7"&0@J4XZ[N4?#,W)9')KN
M]02AO$\K(HM)V-668+VR[:)M<U&*1I3 DO]>Y%BM'QINT?RIK:@Y6C/>_W"'
M1HTE2#,,7)#P(FCB#5&CLS1\03V*5"%UF:](!:DAQJK$$RZP]JE!%M$RFGR%
MNUP9S/>;5NS[$ZD$S9G/IOFDUJZ"!>ND9B-.AL ;0=124M[JTAD>XC=#:]DT
MW?<VW99W8W&!IC^2MV>F@1$?7AJY"VH? ;%JM@+Y>KIVQT7-M)2#7SQ1%:C%
M)LVW#_#05XY"9Z(.][E3FT!EJTL"M/1N$AW8!9^TH 8_P/=W9=LJI)5BF,+Y
M>E6+@'2A,]Q]T_EO,HF!,D(Y$L.5AVDSB'A_%S'O E5CD&ZZW?F*F7\H:L1
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M=O6!E(6-;J("&Y=)AQC<2/X3R5P.,]S +D*4$8W\X=&V;Q'EH^.475_&XW6
MPB0WJB3?L)E1=KB,DAS1GO+ LFT/UY-M"J*_!W5@JT HJX_02;Q>VW5U.ON9
M[08.L(!!&Z.AOAVYW_G"^7FPB9M]N#29T,!,?XTQ'5D77\2V>L$5?Z[BKO6H
MT94SUOH5':,+2]M8V^OU4&Z8_;/&%^OK6D GZ$LKJB(QD'\8.3"0,51L%V="
M W<T$Y..7 =J%R#=Z>Z<M&F(4)I%=NILT<9P9T]"RI3SR&QZJ"0;+URAL-D/
M Z.ENO0RW;M#Y60)T$"\J6DYIXLF,*?>.,OZ (^QMP$&H0O9*K1:0(20:^\'
M!&4GK.<]0[QX9U-!(!"A"Z.YKSJ,5^X"IL;['\5R).:[-3KSZTX< 2^^[L2Y
M1QB?.)%8/CQ%$T'C5Y_$@[N/E*22ZS;A]5"&_L[LP!2,VPZ<PL0W]W7F.X"-
MR$,P)W]T6(YC3+K._NH:R,,TI7>^A>/R;M3C6D?]I[XI8IJ5.YV5KN*=Y8WY
MPL@EX__T0YE^L&TV?1QM3POBKK<I':R)]L Q'*8A) [59GV'4Y5=YNY)?M\<
M4S0YS?-]S[.'M@!@2OTI,OAF?K/B,J_*PG<Y2%LZG\'M9CHQ[]4V&R8F YX<
MHXRH$T,(X3L,8[%? 5Z$K#GER;"?W4%]$7UXFND[3RXP00A&7TF85EEF6W&B
M*-8(SNK'I_FZ]T.2]Y#TBJ_&4[W#P/W/3?@G463S)<_</H1[O'0^+;%[-/Y:
MY;"6/^Z2(*RSHAT]$'*^]TFLA 5EP7' 28YM6^#J? R$EE5GB,HI[+I[ R+$
M$K$%$21&PL)8>X_]67)EI(L][OK>A](;MRAHQF9@,@%'Y*+W2$[R1>B?,HBB
M#A7G-%-WOITOTWSC^US<3DZO9I!RYSP(29[4A)&0G6GJI%,J\CC<-\;ED ]F
MVA+=[* :SD+):4/!<-2)&/6Q^3"9KCG*]R 7=MLW:U*D4KCTSTDO4#]H<]T-
M6!_JB2_L/E8,:+0+*@OZD_$+$.8^0/C".;D=JNG[K__M[-FC%RKL*\*]2!!+
MHH)^0,'&^0M,2;F:_>7[[T^?><5@A;',LPT!6IGEPX-3;6.A;>\U]&><D"8@
MA>FRB>M$;B.QI!#YNAUIV.].9W\KKQ@WJSWL<Z+ZHL[MJ9/$=Y+\,'623)TD
MQ_86?X1.$D 5MH0R+(#1;+<[H8%3GAT*[84LXJHJX:5TJ"#AH&R@D9/N)61@
M3"?#(S#+%DIF0"W*[>,NWG9Q@70A@C[GU:+=UI1P4)I")FQD#HN%>]IV&R!M
M!@ +G@<7BRA_2D1'%Z2C^7U\"SZC,VM"P5%K!G.O='CLT"@1>"/C9S3<B<*_
M>CH[#P-B4/C+C$5*Z*,>DJ<0\KHLB\%GYT?H#)@^SGBCY%#4'F/%F>2O'.=I
M\8>F0,[=(77A%A/-I?1# M+)QQ<A-*]\RR10W"6PM?M96'3,],3$FRF#FDW]
MSZ>>R1%2"7EZ!.E6+3*\*%Q9YN/@\1QAJNN]SY&2,QUN4UH2<>^>MIT/U4?4
M3P38SUE?"VX?0";E6**8LQ/>4A20,&"<.H@L$:J6Y7DRFO23NQ\W#)EIZ&RL
MB-N")MS/G7M@@EXHH,KBI ^3>9ANI, ]U=D98VQLR'5)YC+Q+4MZ09ORXMU$
M30J,0R^;P;Y\3]C1%AL,#@]9DV^TZ=_W;VD231.F27#NER4_1Y"V)P#1( D2
M^L WF]^'EO?X:DL::]NR2V*GR0FZ?:YP]U&$MK9]<5J"<?3M"# >[T5O$*T4
M]VU09K"-W?/6=RNRW*+6N&&[88#E6.*Y@/A_1L_2;RF6GQ8R9I<EW&)*C_#R
MHD8K9#5Y"C>SOY]^."4TO##<Z\V(JZQS#UM',3T4L"X76;II7,RQRY>9^SJU
MFQ3\8S"I.!#2=0Y^X;)MR%>M9]^$:^)">,QJG4F"'>__\NU_OGYU<O;<7_';
M1$X0MW%+0X7' ]=OV:.]JB=,RBL3#,*T2+*EF]@-B36Q^)UO62"2BH'^AR4W
M[:W22^="84)[X\2DL:%$[&S(,O,E8D-_H]&7AC\F N.6"M\3Q\>?:5B-W8\C
M#6EOV2T(C#ZU@H10T[V?.TT)&8$Y(6F'O E\BC1"^[*E8CVX:-2^=F!O?D.C
M04,W$58'T%6U)4F\S*\E$1H=P@?$UT>MOB Z!B:^GKU$AAM,:D$Q^C_^XZ4S
M3:1)4>\WEVF1IWYV-CI(VK1$W&#GN\J9^\>/SI[I^8N&%3$2LU?.8ERE5*JM
M=BJRX;[UQLVK^\[W0N''WI!SGEZ>OW_]X<UY_%"OBP4=<-WF)GSK3>8,1R4^
M\9:L$UT>ZAN<)QF_Y!;?E>XL1AW3,U]=E)O-_L3YZ=*_FB]SG-EN57W(:K>/
M?\Q+MB<I#FX\]W)&^;1'+UY^_&WV=A?V/>Y#?SI[$;[\_]3\LO@^AP\T6GJ)
MM,KK[KS8Z_SLR;B$$HZHTSC+'8:$JY"!:H3]HG#"Q/UGY$QOX56XXZ8" \GX
MMUMV#(CUQ?M4)\1[&$M0Z[5Y@,=W^>GL9:1</="#1*Z:.-[H&F@Y\\/+QWEC
MZC\S'0!\P>CX7V808J%J05Y_8A86D]=R;\V,L&9%<6H*C*[ZW/ LJK7;$O_T
MY&Q-ZDR2F0C:%'[4*(-&3J4/==*\9B\SXJ?N<+3=0($$=\DW2_WT8<:KQ'K%
MRZI=VZ8O YBP@QDYSY[R9A"I&DV4_ZBY98;N4UT@7<X%2=!?YO0RZJ&0I[MT
M'CGUJ]%4*_)5&'WJ+.IF?,LN+W64U,Q@.<_\,<Q680-KJ+LDDCA(6/L@B8EN
M+8&O<Z"<(ZBM*<+[R_N!)SZPS^<5O[%2@>(T,D_JF66=W[C/L,RW[O=-Y2F8
M+$S8\DV$'L.!P"X9#QNB>:,]:SQ]PB'KU4H/7!,7G%.X#%? (>J>J(1G2Z=K
M=I%N5@FWOA<A%CFH6VC:$4,PA'N9 -Z_6Y^]]*4;*9V&1 8B\T3^< E8!VKN
M7$U[OGO'H I'?>2\UUZ? C^[2=P'V@!VVY!K=S:L+& <^HX*#9?_QVIPYFCG
MWX@QM<NV[4FQCM+C.QR]1[VO=>R8@64Z] O? 9\V!Z3"K8WS8+');%PK$:/;
M?057"!"?U4!@[\I<VVG3[DEV0&$YRC.LR@6G[,(5",_/F6 Q:#DSR^J.##LD
M4&SR(HT)V1DY:I[\ :Z-<Z5_8,X$I%QQJG5((:\BIH0 HO6Q%\^ZWY*:4T&\
MM@$JHT,BC"0IIE4K4^YS^B,NA&0#?D?_E;@OG5VFJ"#3UO8=PEL1@^!,!ORA
MP42H357 1-479%DX0XA$XDXIV$-W':X\1-_I7C(OER1$U&&J[X>(K&F"#.UQ
M+HU;!HHO#7P^_6VV(=C' "M^6ZO(@W,&,QCDAV@VP6]-T']GV9CFF&P/96Y6
M&3(+FP0.AD2UFW)!/7G4/.*&1]"P%;M 32K5!\1:TDP"P"*I:-7J-"M[[VR3
MK?-:'&SU\7 3B1Q>%R)S_5[8C#YDU66^R +#(#WE1Z2_6V<C7P'LT< [= >X
M3")L+D]B/?N&]X]BKS"IY"!5F=M *5-U&R#(MYH(&IYX%[RYMS2M;]LM9?K+
MQ2<*(IFS7E.*M(7)E.KM@]^_39="%B-_PG!N\D^XI25P0EP YR&&]KF;-88[
M4?R4C+)0.* 2$;1R7[I"2IGTAX &Q#33;P)1N50B9,"\#IZOR;N%XE9(K<E$
M%Y+B3M3"NVTW:_8L089:M_BUC#>-HI2L"/(:F&<$ B#[B 9/QA5!Z-GW+_AA
MO"M%F6P&972Z7+8 $53\EI+O91.51<3B\/2W)%Y1N9^;?,T+VV]O&8Q:B-H[
MAN!T]DY<?Z9UEVVOEI:2 ^XE)W2!1Q<\G] %$[K@V-[BCX NX/@?=LE9KKR&
M%7+6.B4'D/-N 6RLP>PB&[%K/M36>"EEHAI<!^G)JK[(=QIDJQ4://F.T@'Z
MC$J!R8T0$H&DO!KC]4+JR!V[5;5W!^J5&W>NNOWR]C\DUQ2TF3MD!QCS!4[I
M)OX^G>^K59TUZF/#O\)^$W=+3ET1M2#70&K&E#D\9E;Y@TOY73\KFH1,B,EU
M+-JMYF-%:8K!%KZ>Z_FS$'-;OZG/X"874%>JQ]K=!Y9(^9A0%>);J5RHOV>H
MPL=3%X$I6A1-_\F+"NM%ZO.W6RWT? :U.>L!-D>]=[[G:O:7)V??GSYCN*=
M-Y/97QX_?G[Z-/HE??4O3Q^=_M#YK!#K2&63R(_XGI^U^!L./_[R_/1Y=)\'
M"24I-,,LV6X7NW!!Z<D/CWWMN52_OZPPE&6A383.H&NXS9/G;'1"R9U0W**U
M3M=>E[03M*X3##8;^D3K.?)$E"=<Y077YM+9VCE>'LGUW2-$:_ 9D43GW)0@
MS[YQ81D)<GRK;CL\<3CE_H9(4HM)LKX\4THBRUMEV0GE.SB_D) .0K!GQH[I
MD60-L=DWE OCYZ+E?"<6-\ZAA]I42M6'O2GQJCWP45YW$B3>H_BM BQ 4F[T
M6V2=JASG\W+LVZH$EM:-;_@,7[OF6_)R$O_*,5*V#4H6-H?T;<?HY2NM9!NX
M/+)D:570<1@/5]*;L/IN)HO>]MK#\:$<BL-.R'O2R'X?@##P2E[Y?/ [2P;[
MWH[EJQB=AZ^]DT+'2U^I.\KQN&V>SM9RJ6[K?LJ7J)LI57OJ3!L9T05MDY X
MHD)(RFF"E/;])P%J:<H]HJL9P "B/DWV2*N)U+[G;KXME\['R+!%%U6YNZ#2
M',G#N&L%#F\"[6VRE/$+VN;K@5&Q1,E13M?! S":G(NTI@HD0YWG;N0Q2Y1J
M$TQPN<G=#^U6"#%7FQ08"[A];CZ0*4(#E_NB&V3]#<:JR%HW1)EX7:P["(!J
M$,(;-3-N59 &7T;553M75*9Q1Z*_44ZG:P84!R'<\FRS]$CME^?O3]Z@ M\@
ML:8YK[P6(@Z(W/!'1!108$1+%@6\:+> 0$>UZD06LZ2%-E@L5X8>0D2UXH*C
MZKH<U'-AQ\.OQ28 /_R&$'E7@HG!578/[ X)'#&&$XI>S0U-'IHC30_RT&:A
MSIM2-=MT?G+>&?,2\C654*)+L4O $.$(+HO-/OJ45C$\P^SUFIRIJ/980FY"
MR+8[?E Y,&L@%;LM14_I=,39DXB(DYPYO=1A )H%'%_TM+2^:$8$$^2UOOM8
MO -0<<GZ2LHW0H<_0)/QMO75>09?FC5=ME'EWF3I3<NM[[T,N]GO<<$RTB:]
M3N02C@9Y<[;R-<>"$R;HK>98F$J2@$+8++(7@ED@E)).H+% (]O$BX//@+2Z
M<"N'=BS,HF7Y1L#K3%Z$F,V+>#LCO>ZKA,5"#(=OB6,VN,.CY'';0(%)2XB/
M;V&27O_RJC;RUC$^2+QW'YLO61\T9V4.,G[H03C)/"A5,O@&NFSK!Z$%(R2V
M(GG "(29+>A.?-IRR_9F3^II\6<]DN<![I?SN!.(36M@E28L&[79Q'A6GDBU
M&1'?-R9D$-D5BX()HKQC?30$$O?*[L_K5IHH_6F!J-MC$B#I$88E;CU!0J38
MSSJ\[<[R;FLM[$NL% =%!FI^DTVAC*.K,7$&:M6BM=K3]ZM9==WN"6G#J:0?
MC 2,!WML#'+#+61@BX)_R&_>70+1)=O:TXVH6O @<W)'J<'T+7610H/@L%H1
M-NHXDSRH" -SM[2*?9(^J&VU.,H->'M%&D03C,I3==$A48XA381(YFFDM8:D
M8_Q2'M"0K&\@(MFQB ]24NK&(STB/'F]K\A:E(_H"IZS)YU]H,P/8.7O@%C(
M"%]#4T#6CMT[MX%_?G4>D7JYR_WB3 6E:CE-:YQ1'W*$!Q22)SXI1Y[V&F]U
M*D/K:GGZ:"I#3V7H8WN+/T(9NE,K[2NLDT&,>DC['9EB!>E\8H33>&.F4'H8
M097?)V5+_E$K_'GCFK;=2&LH>*0"<$=ZD-!-HT)?(2'/^4!Z>4G!A!:SB!?R
MP/5N*#,C!4_I[9E$9^Z3=JBKZZG.^)#7/5&&W=M,B(=(V=TO(]\SS<7GS@7K
M\0@W6RY,3S?)[XJ%-+MJFL3[G,0%XS?:W5WH3!S@09VF]2ZG%:D\8D31EC&.
MA8?[RL3=D_0?ESV\^$#:(J5-$S]-V9TR3<\M>:5M^!UI]JW*1M!)/,%!+^(W
MYS/6:!/;]QC*;\],/ F#?)7EL)6N=:L4(;0&@2/<-.Y6C&2-.L=-WV!LW*TY
M9Q9[JN;&;8J6\(>*_K6IVDU$N?>X%J))O;Z+.CJLJ2J?ML6BNR(\YY*9T=JC
MQP@?&]B@/%)N4_I28*1S(GK"DU38W1_MD=S 36W[V,1.P@1'.<F^N4\2#KS3
MPQX3V,#DE'TUIXPJR.D:Z$3E@+,B /Z7L1J %)JZF\GF^=:X,(M]33OM/OPL
M/Z=)H(Q/(OKWI7>VI0(O-/&2X;B&C&>:O[N</U0BH+&1$SNN\XORFDXWMQDY
M-:A4@U=Y#28W8C_$K\E5T7[EX2DL8X :S_K$\G^/6Y(@--P0MK2$F76ZRC@&
M7N6;K.O%ACH)YSUVGO%V(/GQ &$4C$-18E3E*(U+6#&J*#>(G@'$GO(OV]Z4
M01P4L0!<ST"UO!$LQI<4Z=Z'$'_2X>(YU)0<4P&[,4XL@(1#)9'15I8.BEF@
M#*9LD 7*N-@"(OO=>9//8I:R_92!.JV3?CW.I7Q+--8K8J"SY'Z!M&^3%>OF
M8N]!.,S$+*GJ1&'9AI99!'.Y.#LF3Z]X.;HJ09.Z:6TS8[J$+C-#JR-7]OUA
MW+@::=D+8M"LU(#\"L4/RN& PPJ[84,X]0AJ)CS20UC+0Y5PI>H8BP[_V+RF
M0TBR:Q%D7:37LA0@\\V!7F;\K\%\O3V$#X!I(89QLV0CRT9K.Z\_,?M4OE'E
MN!LC$(2UGCAIW,_Y=E?6=2ZKSB"%"\K\]"SB-8 )!CBP;$(@K0&IGSO$\6;4
M3E,SNPU!BL=T[DYG/V8K.M\.LN0AQAJN8"@[)"6_&*$[0)4(-"P8(CU]_MC0
M:V-:X2D.J=N2C%+7A!"^W5,YRD.0$T/K#%CO=*'<@!<#8&X_4*>SEP/F"1/?
MOXD[X6\Y6:3Z@XG!4,G,R!/*S*U*WV/AME1;@XKN)R&P)HQ-Y^G2RL)[$MOF
M.C![.Q<R+3!52TY5=TV=MB";J\B<$J_15MIP/+>1&$)CB]&;W9+[88F2P'?>
MNC&@O%IE+]]76L<(9.A#K-NY<T":H/098>@#J#R8>M_&2%AX, C\(_,B=&EA
MOW^<I_E!QU2VI[#[TXF$\>RN",:)W63GA?T4[<$&@AF>9??V[+.<+4TW^Z:W
MI=49H+VC96XK>$7],X%(TFK08?^-&!Z9^K\7Y*]^:!067CL/=I-V+H,U31?_
MAWN76CU6\BX"99AW<5:^'<2@D\J"SWQR?T)\='@,I=0?-8C(IK[ME<B2&T<F
M:D)L*WJ[3K?$C1OIF+Z#+C$RVG1W#A=]FUE99X9[4SL_^H0AUCN7(Y"W>6^J
MU:\8##B&N985[JA=576@KS1=%:'CF>Y<UX&^N\[BQ]"G#7TX(T.2:D0\<##-
M,V=.3F<_\[P@@DQ&CP9#8^,#\]B;YE/-[[6(OB"P,;B?@H /)[:CUA9>4^S<
MR.*KPQC$-Y%8R]E8)BBD<A<MJ4J 21)(C.#$Q']&V#4L&&%):?2H'^C$&;?8
M?S[L_MF$W9^P^\?V%G\$[/[+[K'K(C:?"S$TV!P,((W'T@?P"QA3#]\,$E4,
M->_)5/'':Y-%26MED_'YE."*K%TPF[IAE7##=L5WK*QVLAE*GCKHB%;^ 0@&
M7R\NLF4+W2*?J'1GM8]O<0N3\.S>"J_(/0GR2"PO@/.#1\V>2W)V"IGW%EZ+
M.U>RB,S9U^<2",9K_0"EO&(-" U1U>:%4 SQN"><-*BSC;CXQ+ *':1-NLCF
MI5(/)#Z;8 ZKA3NWD0]E@BYYZTY\%W@*Y#S$>:>1I/M(_B [I-^X"2VI7V2<
M.IWH'U):!VY#0Y@6OIZF+"[3:J_ N<I=1,FIO-M?:Q"P%<T_46B@%2P4OR3#
MM!3%A@%O2 BT0?[D+E_S2LFYKW$TO=A=IT)35<";)8DTS/1U.F_L!86GJCNN
M&_G889^8'3G$2A$OJ:&<!+'_=I.BXB\5V5KY3L1UHF9_D)'M+-'#:+X!^YYB
MY!&_E4*J 4%GMGUS#CAY:+3!>?1E'^!FD(2R21L7[3:KH)=F51 N"1_(*1.V
MF!'-0-+W^K'25703CC,WD5/;><?Y'<_'=3O,LY$"B3&?4^/2?592_9ZJ&;-7
MXV23+:1$[Z5G07W]_L?:"#_R)OQGUJ/,!_UVZ7T&3O&DO>1WT'WI_2UM./WC
M.;GYUR[&R<)I/\$F[G)E7/7L2LA15LAMJB'1O#+]TAV:4,KB_$:D8-D[' IW
MG@BM4N=OP-*4[MT%SSR\#B;4TWT9!LZ=0($4W#NL7XLC7/QR"2%&7'H7)L#U
M%0&!0E%OT^3=Y>0--%V-.'>B5^Y^G7E/C6<*Z3=J$O'%ZTASUL7:^9)CK\Y2
M46>L!5XX9,-LK;M/3Y/.W;7+8E"[3S.QTYJY!WL?X0E\6T&8LJQ8$GNP.(C7
MMH1Y"3U_"0",LA2U62KVE54B.!;6SG4GQB9C,3OU(I/9/"_)N331Z^<_2)!@
MT1*&?[MY5F2KO)E6VEVNM,'2D#5$"L/Q])*>6.+W6I[!L'ON:Y([H?XAMT-S
M6SW%2<*4<?%E4>ZRD9,O<:$[0JMB70X552:;=P0K$7,8R$A\7[JLHR65H6]W
MELY17"+]5Z)=!^[/T\(EG5(3%ZJ&D&0@O-Z45X-7H3@\K?B?>%K:$Q5(V5I#
M&-@K8#4B@(N:J$ _.E>>UMK=KK70TZ'!CQHN#:$HORW%S@A40NN16SR1T,ZR
M1A)\>B6@TDMW5*]#\;D= O4F4_A\K^[4\&$EJ92A0ZMN:^;Y<7N?(JX(/G"M
M#8+%@M0DTG_@BBUC.MD"G+'0/244TW7K+(58IE +:=!G+0\K5N+OV6^,GL"R
M*TS0?Y&Y,_""Q9&G]79_B;R!U47^+E<DK$?4IR[MHS^DT&"3NE=#R@S6T0('
M<,@'JY<7K3#(]DDCQT#J>%HN]YC>0:I7T,O1%!$.SY=.QIHT6'[[(OYJW,,P
M.1KWZM0JX_.MG==(-&B:M'N=-"+1H#K;?SEWSI#.#Q=%N6"J35%UK$6FL>^M
M%T!>U*VG;I]2MO?71SX^*P0! *"IS@7+ 7TGHTK!*Z$M&"::D> P@@+W=&[L
M%Q"[3]$GMS:%.K\PHHI=,N2ECGFE!%.=&-CN^ZR&U[ZLTBN) "/>?+^$L'/1
MI$/)-#=)"R^^E@,&8,A@/JM;^>M.%K5M?=W)<H\P/%F>E9V@156[XX'GE";Q
MK1&(K-AK;)3MW&[>TBYUK\ _ADV-^#Y=4SA7M@T!8>O9-R&@PX5P[6J="=\+
M*1"^_<_7KT[.GOLK?FMA;'#EN](V0SJQ.Q%?>HBHF$#$[Y-Y-ZY%"7!/0I;Q
M$U-D6)H+;OP3[1X/6<?495LH3&1:X8B% 89(8V\3ZW<?-=%6#-/&RLG \&[X
M* ?NU,)!J'&N^!%6KF"A,_<AB#+)7_6Z5>9[OSB'M<@J[HOBMQNH$9=S-W^7
MA(#KP0^U-9^;N[5GA:EL1(==%. 1&A(B4MLO)HS0?9X_W*O<%EKPIU;EZ<B_
MRR&?"]J&]>0.-[.*0S=1[MWO%,%@C2-PIQ3[?5%O#8T^8/;H15R4;=%4"JUF
M(J!K*0C_?)U8CZ=.K*D3Z]C>XA:=6),Q_6+&-'(KK$XFH0ZX!VE7[CPI F.O
M))R -"5$@/$#PE\WV)0RHLQ5MIQ.P_N<0"KN;E*T*6D!E],&62POU[+D<L0/
M'.>,*HW>KM(*7NCD6-ZU[__9-=47;K:FR;G#R:%</ $A)-QR T\*[UX@D"=H
M1C[2P<CM 6;5WIHXTZ(5F;R,.36@\.P,3<42ZZN.2&OH(1D5).TGY$9"8)__
MLH!?3]J(!F0A0/Q4E%>!H-SV_]WL$:0M><V-SI(&$;&R(N/4XEPR[2UQ[2\]
M5Y7DM YW+4L/GZAC^RQ:*21#0G'$;1:5;X_IMCB/X5"-0AC9D\BF*.:1,H#;
M.A9G#@ECG5&5M@W\>CQD/*^GLP_F9.D-[WZ@UT<6!+TZW[2^*"NT[%*G('$Y
M>:JG" ?LMZ*J663,OWH;S576P*91D\2CM*W-E2*(Z4()JD+[.H"%W>*2MODT
MK[HMD=W<[O5/P\W&0V+6+-[A4[H/.R]?^-67J)ZJ4.Q:SJ1A"+]R\7H&, &P
MU4K!-X2EE2W$E-M^W1L.;<OQ)45P(@K+EE;/MZ:%4IGT?;I,=TW8I&34LM_R
M :"3T(^ER])W/$-GO?L9_UK\< .H\:2GAPMC%&KWU%^-Y_Z9B"13V!WL_]FK
M;.$E:A\G*A,".%]=*^T!3<;;]^?)S(5>ZPHKS]=.ZIT;'=D:EL15>8^<^XB"
M$HD!,),!'BS0H.V(__#)0 MHD"2@$__1BUU^639J,.AW9R^XMHDQ6X+[$VHD
MN5NP:R5J8K7LCU3KX!'!E*'+A";(G3QNW%(QI :$#0US5E+G<MA0A.-&#R6<
M$^:'&*C.N!5\(FLHT+S!%+I52:;0F8#$#DO-%&;BC7,C 8^OWPGK4EG0PM/R
M?N%PFL@+V J IY!)"U&&HB\J?1DLM+N?I[B[**_LW21&8^LFD.*M6_-ABPJI
M1QVCPOA!-NX\K'F0W/A55$94@6107X')@J8LD.85P\OD(=JQ#\S*AIGEBINW
M5^Z%EO4BW442]+VN2"YM_=2"2-P]_=\+#KL67#K,B,]VR=Q6/_T]T#E^Y*^_
M]R8K4>/RT]]/7GY\[PF3T=T/<\,%A/-=E6_<WC][*H>)N^FFEN_UKOZ*9I,*
M?_-LD6XSVUSE'O/?TZ(%S.C)64+VQ/DO%RCD4>5Y[%K!EJ2S.MNEU(,0?]H]
MIN<MH_=Z^?$\$=\J\"C"RL*D;-F@@:LQXT^58M3X*,<^+F2':*U=SY*];A $
M.@"V$+5*<X'2.PYKW$EH,GA<L56X.8E8IC. [G&8+SV+()U=*)_*>]8#[&SN
MS=V^W40$;722.#_1ODZMQ=6P!.@AR%NI(V.\!4N/OZZYW?" ] :@^](CP[O)
M4N] ZLT ;:=;[0!#,Q_G9TXA#5AK,]/".;U5P"=\/'=^#BKHSL^#PU,6-)@$
M% 6[G0$XS/Z!+C][N?G^T(B)\0N++/YF[^5Z3D0M=CL^G\UF!H*FO"J A*K@
M,.[M\\J 5L[%!^MI]V[>POO1RVM5TEGH#:R-OLQ3GD.SYMR>!54BZ&[?PK#J
MD+I+!=V>CN=MG0;IM4.KFW5Q*(77=6Z$4=![9L?G[#R\PT.X>(AG:V&E>MC3
M++=90[<+,#[9',0L?8(+)L(4+?^@04=_$?]3R2%Q%C/_D:R+FN8BW(\)*C>D
MLKUA+4!SW?BRR!3"U(/,F)\[KRE:)<@ATZ)G1=FN+Q+SH'(SMT?:NF7N_A+[
MW?R!T$O8194S,F(4^6_<A&(EN172DN#F8:2\F [.6N+!NLCT*3EBWH"2:Y.O
M>+^C52ZE3SH_C5_8J%B9Y]9)29<N)'?+/1,DD8^;B?3:':]EY1_:/1FIGRL?
M,KOC?=XAR9XS[[4><XJ])6IW-",C;"3<RY478! [1>W2@149!I[GDJA]AJ9@
MWC8'% IDJR5$%D1<H]Z86#"__)(6R]!-W#43'9&2J=70'. S,TD<P-\$E?6P
MV>=O*6\@R: Q!#=(AW-*7[0- 8%[K,%\_F+O>Z8>)KHE3C1.5 H)GN?90\4<
ML[0II> 3C(BG,UWYH&?LSIK!D?0U-QV9:=5D3T@>G<X>]-3>A)G+C]\!-D*F
MMS4?,#PWH<9&DT,B!0=GWNC_S??A'!C*EAIZ!/#*LZ?@5TF/,]$O%_,$>4Q"
M/= 6YAOIW==S7U.R)H4>&$><Y$-?XXA!9O&*4(?AB9![0Q9TB$'>5QS)-E:7
MJI?BC@GGT\S3.N>(>A@O0F-Y^N'49Z4X?;MV-K@BHTK[:"?&^B+VX86SF>\!
M4DAY3"8A)$7,MB#VOF_R;SF;J_2$)K02SP]/83(0M%OH=RJ\N(-3D"^R%^YJ
M<CE=1ABM0#LXWX_ _/&,+BXKU^QV:WRP8$=OUU;NJ.;4R?]\^<XFR @LCMO:
MUPC,S<2OX2[HQC1?^H.6NNPS.3% NUF<$)%77C"MDWO'L$X3P9/J+.A5:[9/
MYCM\8OJNES!Q<(,]S^.&M1'\PS87%5R4D>?PFR0HA'$>J;X#0_7G QH]F8!&
M$]#HV-[B%D"CHW$MHC(*N>M\4A*QJQP^YC37Z/ZF1V0@7HH.0^-*AC.L]LH-
M8M[MP3ARWLIA2'>FI\PY\7/"14YX L0TYGX3N:CNYF6U#-P%?#J9Q((-? \>
M [Y<S_>/3H7NH>!.HR4H#9?AL#F=O4%@HT,]XE)1@&/T._CE[0-'V?:$CSB]
MJ)[I*O9F/"KC?^ -X1=N9D0P+0DVO48D#V+6B'&;_ "3\UBQ, L.UA*9L[9*
M.<,D#1WB27I29&Y(/# .^TAJXT $HBZEO %Y/)I+"J]J7XAR5Y_Y4,LRJ^UZ
MII''TR6SO)$Q#]7OV(,Q),.2J+(U\SEW7V]$%MOM>JSANMTR-3@);'=XQ>$;
MWT361'N,K' @2WN ?[?7%=#7>POR0H/C^<<-Q5Z.*B+&P106'4$1F-"D[H>P
M1&5B$[[T"VR5<L$2<K!,?_WRWN)=H[?.,1QCH_SX06*VGIS2")C9&[ ),7QN
M&OXO/OPZYMEO L58;0"2TH!R&O$O/N)=BB>=@4C_+'%G3NTB26?,ZHL\J!5"
M119(AVE?W/4LN:/?N5<;$F1QCE>QX+):-\T3RT* SS^M%A?3E-S!E"QSJO)<
M<%V_";J+P^KOO38S3H]-$_/%)R8F4_!X4T(&MY6Z<AV2A756HLK,"HXL@"$A
M%G &:25L)I6+".KM<9:1;UDZ^A@W_U--=@2X1HG>(?SSC96L7W/MV*NB]ZER
M[;6TEXBOY1^28-UPFE%&C<@*.#;UR.E*@7@$I%AGUU8&C[;Z_S$6RQP5RKRE
MT#C#C42@?B5#U8-4R+2#PK@ ADM0@%6^M0NGI\<A0'K-?T#$2+FS5SEKA?A5
M8?(9^1=?(K1]AU8(W9G9*9UG7W'FJMX"*#3 \"MV0\F90]0]/NB$M#K$KD$I
MK?Z<F*D>G),.6%=K[U8/N7-7//GU@N('%XJYFFJM#B!;;R<,S2+E(QQ6%%0K
MS6VM0%1I#!S3E!I4377?V2%!Y[E+]%T.])1<I)0=B4#YZ?(2'O+2Y_YTL=X8
M>W"T%F;21[N]/MK;06WA,6ME=(OG5KN<J3 E'=[=6!WMW\.J:R*U(1**E(G-
M9ONRG7D-Q4'!KJL8<T"Y5ZO>1N74NI&W]+ IO^LH N3=2%TL_"H#S6N2+$:2
MG6C%O9X<ZPZ6PS/.H$-N2.5=U[.&;^(%)2G+>5[N !1-%UG;2$%[Z399)3 B
M *>H]&Q;6^NLF:>+3]=A^,GD<K\>9(VR2VG]V>8UHQN'[4OWK,ZS:O@&26<R
MC32WSIDOK[A-$$H&^ORGLW-%4=E7BIJ]XG8\)**5&7+S!^@INJ4?_%I<FJZW
MHV],X<&06I'.!R:JI9X%MXY;ED#ALH5[<*K X+^VO:AFW([AQV83.\_H]$\O
MW?:@C#N9T%@G.W7FC9,OEQ@!+9YYV/1H5YY.L47E4OF'?#+<_SBG\S ZMCO.
M'C X-"OJO;(ZX8UGVF;PQ_VIX 4]^H'F1SPB.)NQTSR(EXHMLFKG5KU2'DH(
M_.%..R?![_2B7N.<O5&_N<,*M(O/"L66K$TN/88W6J;4DTI.&W<8N/-GNQ-@
M(.S>5E&"[LD6B@Y*1":=A:/(7^"'TG-.70?\FXMM1E$*YH]LN<A)+MESXX)N
M20=16TA[);MPF3N(Z/B"ET^K??;N<&Q#;U1EH!V_U0;DV8E+=O%&$R)\,R^:
MUFM"L=FN4/H2:<ZX Z=L:X14O*81S)P'=<[$OT77G-$EG#,M94>H-7KQFI29
M'%HW]9ONHQ+N+,STN9!!VCSD/&NN,D(V#XXG7P:ZP^&JOOSIK1*O!D*$AE/9
M'D=5MFN;@'+SIY,J_H6N6%: Y=(UMZ+LJGP1>I[+[1;-U4VY^$3K0TH,67SG
M<6OXY\-B/9VP6!,6Z]C>XA98K(?DCHZP8!#M#B(OA)/!>XL;E+LYJZZ3L:)&
MR=LD:A*QO>Z4W37<GZ7,\?U KPYV71DI@Q#T@^R^>HW2BKN]QFY$ML__]&--
M'3Z5E]P:'/IHY#DQLA]7,5>'@?,*:/JKI#*!3$5;:1+A=/8A9!,4013X@:4>
M-<A0HEHOZG;R.D(K9&#T'\B%7EUXET@>DE^/70<T.P:/SE.5*')?\D6<.V-Q
M,G4W!U?J2+9CB!Z9NQTXO#[X)LY#65/BZL#TQ:4%PVP0=TAHY#W6(]'!J,6]
M%YT$],"*,3E5- KLLJ+3X^\!C-18Y?D(W(<]MS_#WAO2Z5CJC''3'I9RU?"@
M/'[T^&D772AIZ"[="3G=8SJ%(YD<!@3B(?C^Z!*W='%I/:H60UZL77R,MJ.=
M<P45&A!PZ)3JFAE*Q$&M/$O]ZA@H+O1?UE.(#*2O?_49&JUM($]MDGN:J,'"
MUPB+\\H42= F'TX<NL!$IM)* +IAHAY!7H8I"7=E(OM!=H13HC98G9BO[Y/M
M2V(V=PSZYI@Z0XC(DT0E#+=BD3H@C\=TV4!986)BN^.Y83/!I$LX3Q%V"AF*
MGF)N2_Y7BSF9YN,>]DI62>I&4+$(ZEE2V4/3>Y97M@Y-US1%=SU%,0_#RNP4
MI96;Z#WO?!(D^9:KR)=GTB"/*DCOX;/6J\+O/ >>:=X8<-RF2;SS20QL?RZ6
MKMJ\VZO?Z;GUI&NVM]2WWFI].V0)IAF\<_=AY384AXO.T\9L4H\8!]RQ5O>T
MN[[>[LHE81.8F89X^N;$3HHB@'X*O?LN&I]M6X6O^/9N":RF:;QSCU!FJLI6
M65495#LY'[N+?0V"FV*:B?O<4*!;:P*A?Z!/0M62F78IGTF0&.^23%-TU_J?
M9HJ4S9_*GZ*1K7L)&"[JRIDFY,YS/^5O^=;3)7:\]HZWQV0]DB_EYO'+D).>
M)NON-:\]3U4W#SS?1PGOS\QI<^]WY9D+\/<A3V0T]SVM@7O1/6]*(A':I(M/
MA+-5D"LM@:+VS!3)\$:=]'"_I!XNI3"(JE,QS_>J>_L Z]- HN>%\05N7 CU
M_MQ8U:S+:V'!THQ)2#S&E&O)PG\P=S<GGK-Q"CLWJ>5:)384]T47-8"!6R$/
M3F<_A1@\;O@;*@<.B57T14K&B] QR#8 S@ R]'53#U$C(OP%,5_B=0&2:[HB
M$.K$&?X!-['%PKWE<:[+V^-:<"UL4B\H+6V6A^3JQX7JF<>/P_T<T\?!"+<*
M1<T3MT6\*,94U%K\@J[,S%W7L,$,^P.5X]Y</BQRE(\>;T#,1YZ8&X'Z):$,
M-!=]?=?9E\8O]&=Z>(JIF!YSL(RL35Z!(ZMS"$-0,4"BNU0]*Z=9SL-?'^H:
M&5V1G35'31_]M_7KUGZ<(GLP?:5555Z!KIG%V]IY1\^"[1R/^Q??OMH&247S
M)N%_4]4\G!W"4$H #V"C4ZH7GDBI$&5$=<L851-W_IAW3D+_6=F2E 7KW"FK
M-74:<BN/4-N'CNA(BTA[>? "U*6YPO6(O90.@F@0Z":]HTW-1\]J9/[YN'-=
MM+%H_$D02 JCO5!"ZCT"'O<7X0,J;D%S#U$OJGS>$W^Y(FD&[6'P>SOPFH)E
MS;WG!@U  *)H&M4BORW[1-Q6,6P1I,U>/SW2BAH$)D-CZN^YJYX"JQ(Z"2<,
MX(\W3J+FQ.MF&'A/9UWU-9WA@&&J00+1)]<*5O X#_>#9\"Y]U$@:9*ONOW&
M7;.&-4\8P6$[ ?.6C*+H>.1?O_^1V*RYR.E>OFD[%HI@D=K[::GJ/,]T#?$.
MX7' JFFRX6:?D2?ARY05\ ?LZ2YH:PX8<>>4[*,&TA$DXTK/*1(7FS5NPC,^
M&J)$PE46<+7N*PL^!$SWR+9<HN2A7=+K8F0F3F<?-4%[HAH5D;'BVU#C"Z/-
MO*&9FB%\,\1W4S/$U QQ;&_Q0)HA#NXL049LI>'<%J* >Z'X/EM&R.W0*1D"
MNP&#',)]+WWA?&*]^&*3YMLN'0F#P"/KV!6V8%@&R3AY>G3BL"W<YO=H<8I>
MJ-U/N+J<1[E:/:QCGY*&K[DQ?O8&E&(4<R6L!"(:I,P4+,=LW)<"(1G;FW)-
M;"@-M-SI,#]AVEUWX#OW"0.IGR&9@"#W0G'<+MO.W9WS?[;;=$YRAI1V\7@:
M?\=_M,MUY'9[ @DB#*GR @T!,2Y'\>AP\D<\>/=L9V=GSQFJS[(5;GD0[@H^
M9EL15:@J*66@"6,Y57NT#_HJ?1J'<<\BT2! W$[3)#D>)RI<'0&42F-UDE0<
M"309N734)4QN=NW"MYM<V30%B>=.9#SGA2*D(2^^8&:-A7>Y#G$3'.<VNGUJ
M[#"_AS0YUV.!QA6K.E&ZP\T]!Z7+O%Z V"7P,9,>9B[D0UYQ"'\O;&>Q)V-!
MT)M29F TQ)?V(:$,-Q<)B;FDNXA$'-<_D:%"WDKX_1!;Q7[-5--/A!FUSVDY
MFB2D )237R/!YZ,?$D\"(==3%@+^XGAVS9N\.+WV>;FU7S-Y! V\^]0FE"@)
M.?-QYJ>7G?,Y2%\;]O:%NQTW[B^S%1TN[B2H,S9@44<0)=S2=26Y,0H-T'O>
M$](\A59MG?U72]-#W-UN,SA[7#.3$7$JC+8/4426"6=]6G'R15BE>#<P&5K?
M^G&:J9ZM::@KWF_DW A%9'P9BJB=/6#1[XW[1D&Q%"37A!/+@]S&]B6=+P-R
MW[>S+<DMC,L^Y/.NMRR)-RT'D@*I+589P3);ARJR-6>$%CJSX=@(A A3.]17
MJ+##_"RK]"K=^ 1TJO(]XZI2H9.XXTU,<(B[G*PZ<PYS91*K;"9&IVJ:C;N<
M#6>2D0Z,)V,:\KL=\MJ=]B)](@IMX4#L; O)340,Z5[;67.Z5($IJ-0&\KMR
M-4W@W4Z@;U6[YH0) (NKE+2$_81O4N>@3--T7].DU!,Y4GA,:,#L9D+5I4Q/
MSG.0)ND9$U.NJ6*R('?:?8?S:O3W=4N,"VT#%U[ (-Q=JNY$%+VNB%0%.W_>
MJDS@A,&]CW7 &O**1.!$&0$KR[HY"8;7%_1JBJPR6CZ4H#.^XN']/CF1]PR"
MIR.293Z))I!B0D54HR8X3<(=3H(FB1AC8+9%Q#;![:-K1/#%EIE&*/O,5IC=
MH&F>[F^>-MD:J5PN$J3K%! ' 1E<E,#OU%2N$HX;RH)3^B22E_\L,/HT:;>8
M-!IXH>#JT%$&.1']D.]7G(7N.2NW':?DCK22<1@'9.LV ICDW)O"W%HI$ 6J
M;*J/<H\:4Z!2+2 >EM108PUEQG,]^[5*=9 W5$M%B0*J"9!5:)WWCTUN+0QL
MY&!Q-8\R<1F]L_LGTJ58JU#QSJX9> O"DU6O">E%NJ-' D!Q $E7QU\U#+E@
M@"U9P'*5,\@3A/J>NJ()Q/&:/M_DG[)-?E&62W'O%H-UP <#JZ;:^H\9I\.O
M,JYGZ"R%)2OZ">F:Z7+]]%$-?E4N6@IC-2\/R95R7:5;%>\9U0?UM00,NF^'
M-Y/5X1?6)U2RW9BK$.IQZ]*++G':!(LKYX*79V:&=TX5JE$21%D'_/?>XN$R
M!!D!.B7Q2+I";-U;"P>$[K@>OB #Z?;)'9\]H_MX>'UDO\TN\\ORKI_JX#.4
M!>ZTW@^7,Y4?HRRNP]4&6.W-P"(WD+#Y$P!&Q)+[OI,6HA";A"^>!(0Y@U*[
MA>:Q32;R( )R[PA,E2/M+1[V';$0]OD':3YTV%!I7*<5_9Z[JY!&!0AD;96%
M(ERU>^"Y08 9Q:JAYXJ0NY:Z*AFT"/@XHU0#[1@[$W53BS:T:,,<X&DE%\XM
M?+?>\S)@9F"#D<-?E&[^"#&CJ2M6CU'S#=QO*0?JTME>9L(/).:M$,X,';.7
M'!'$*!_R);G3P)^HXF1%QI<?@[8?S4!0E:9SG:UY.$WL(6*7PG6GS-BAXK%T
M^SS;+#5A+N_AO#=YMR"YPW@ID19+@1%BZ)VG]>\"GCS.#\N,@-4Z#I2AO\;%
ME(8;-!@42#E=4&<?/5,%DUBS'$,Z@-P(:C7.IJ5S 78FSJPLD.1B'YB75%7N
MTPT( ZH*L@Q;M7B+M,X,M-V+C(M64E9(9PQ4J;!ST96#M^+5 @4F4IO<Q':
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MRPPC=FKP6.<J06A! P\3R19/_61?!7MU:*ZQ9!)X7UI%I#@PH45\@7-!$0(
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MVC\Y"MH=#@$O\N59BHD 6^HRN=&AX@P>K!2YYCXCG5AA3 GA+LL-0PST,#D
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M!L8]% .KRVS/$9\2>P?-)U)+=/X*PRTU,,3+%>G&Q89Z)**]USW$-1=&5^G
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M%G\$Y.0;JSCJCY 4%)MU$U!SHK.V\]CWWB>8DQ*?R!0'*=542GT8WL7-WA,
M!Z&&.(-!6/Q&!)"\0T.)AU$'+XFE*IJL9F2-T7KJ$,$G4D=F'ZX+O>Q6_GT7
MN$UD23BLP#P]E8E7%*>UCHC"+NEU(IPDXX7PK_]JW8+@%B6J@F&XY!F 5."
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M+(?IEOZ%PTLQEL/2!>^,Y@=M&$AMAYA@TU"B!J2W0-A/P*&2]Q!F1II7I<9
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MZD)\^%Z)#UW\-COG+FRQ[W7L*?3<#,&H[Z("?*IW-304"E1>#U410Q% 2<$
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M#D(;V4@SM:OFD;4#N6)3)L-BI3O*)'22Z@V+IO+2HAWE=&$Y12FVXT>W=<"
MI;@09JL2R1PA&/>X\",*)KT,S*:^#W;RQ08X]Y2\I"K40,9&M5/,,J]KPLE%
MIG1:=RG&EY=A,/B+TD:<SZU,J(4!-!GJ2DJ$IW:WQ%F2/><UH^G;=(#0 0E;
MK"43?F:2^^$$^M,\7AYY@+]AQ$BU^G(BDQX>2?-HX^KE#?4UPGI^^<W+*AH,
M;/Y!9[,AV$H9:"(;6ALDD S9A3"5D[&#H_W?"@BI[M =T]8W71]&:DW.&X6G
M-1 95L?PN!?5>RM@2[C;$S?'W*LSYN"4BF;'8N=U$,PP28V&!4O+*=_MRG!A
M>1)>PFQ+W#"47Y1C\OE[%JJO\=2R&I#09Y=*$DJJEC0_P6V.R$>'[DM0-K8%
MYN"*)[G&SY7!QWK;J/H:FTXF1K'41BP?E[@YD>;C">F>F(XD=$>/P^\K)!E7
M+=*CG<'.8J8*H#X3&W#B'FY7;+6'*5Z-6-H[W>OS35)I;G^D'D).ARL5-MV?
M;T1;?:%N\X9A?*J2QYM6#A3(:AA0S5D@Z5):Y5U*XY& 5Z]*FUG=HB@$$3EN
M\,3AFN16"W!&<7?+RS;<;N#C5ZDY57Q7W[."\^,TNL04H?1BR,"*++EO1WNP
M)0^3LH=.XTY,LI[S/,=C0]<Y)KRBT>B)AV7/;)]P9W\FNBY=J'(TD1_PKNVG
M<7</?@*C3;CLS+G$:_%D07Y_PR"/48 D4>8WA#RWO6Y8K#!F:2A"->68"U/R
M0M$,,I5P#UZ3FS"V^^ >U5W#<Z;$LW;0(XIPB\$A^6C*PS5TCWJD.OTJQ$ZW
MC.U"<:%Y8?!8[$@#2]?'VE"[84?L0P 4P0\4B24[@O"?0(IH?]U],%',?-5W
M-_"JC]JH3Y9I:&_Z(;R;'P6Y[(:1K[SY77Y^M9]0':1-TBBJ )9!39?@5JVU
M@QBD!J])P9O.X,9D*X[WJ;5 S,!UNVANHKJ&>E+TA2,31_==ROE;!F#+#QF@
MG#&]<MP;//N&L.(AO*:<-^#?^$VP<X==O8[JZCQ>%36%*PV'UQ5TB,8%@F*_
M)A+BXAN*^;JLJ:%2S9K98WL"4=>WC13&ON>_ZFN%>^ZI>%6!@H?^=Z#$[>;%
MVZ8YV" 8-.<=\Y>BW!7&Y/FY4'^AQ81#5)5)8O<(*VEB@%W#KMEN!@3X@]"(
M!+3A1=WF96-%*!P)<X^WDTCOHL%?"[!:&@S#Q"6W=6\QI=/=-3HEZ0!)RZ#S
M-XD.0>*P'T7FL_"\EJS)$@2^,C_35JYU^P]^/!8"(&8(;<JT-V&3F*BZJ44M
M(U= 3++$?E+^";>0@V;N 9UH#K&6MX[1 /_!H)XS",*C'HK!* +^*>&.)>FY
M)H570NJU5'.?N$K]F&DO3WK"N0FFZX090KNXVN/]'Y3K" JJ=9BC>X9:2Q0)
M,P.I^_"&G%CA@-L.L_A%SET*LG4 :)+>NR@,X,DMAD)PFI_'Y;TH"7J]XV%@
MT^9_? (AE2)8YL^($?8BX^F<R57YF=ST.?))\LC#XC=B%K!GG'HC-M37/<LD
M)+$R4CW)C6YT33!^U9W%XI4O#UR8D\/M_1BFO7Z6T!D&[1>,44IGY"=0'+W@
M2^ZEC8[9FETBV^0<G="0%/0\1)+2L,I?DS04+8VW59:"VQ"&G$HAJVGDCHZ9
MS7P09\\)4XB"WXPH?X[_S 8'^>:CL@-:_?*7'1^=Y2[L$)$MCCT@W5B$%G8M
M/Q<@AP$Y_N4"Y+@ .9[:6WP,0 YODT/<=<IW+7$W/<(6/TFO]"D?].7RS_>@
M-?M> #3A'"$4ZM>^TO]:*OU/\MT>6>PJ=<CEK.P</0I5N* JA)0=-5%Q 6(;
M<=(DDBY0$7&TQC+)NF67--A^.S+:P'J;J!(T]/6F2F '4;#2%Z!2KZK\>*/U
M1-+#05A@S1RS1$M9643E.C!+LI&%^SUL2+1K>$8JDA>M,IP'83$LRX6"NU!V
M4-+F2>^ZY>875XN3,;;"4\N-K5IX=K-Q>K&Z);45W$.)\$+1#W?AO?N=X@E^
MZMLN*I22?VFB HHH0!J?/ZH<6H?PYEC4B(NU]X)F]8>C"9MJN2'$=H/1DWA6
M8"[@&AWVV<4$SUGY>+QJ@K^*^J84D&U;1!6R_X0=62$8"T]=8_L9P%" &C,T
MQZ+P$:$1D#ET[.V&[D HZL!(TH)>HBB)]Y<*]=D'\/1#)XP=M4TNVKI'S%%?
M. ^K#-)7Z$>,&LU),Z*^$W<R.J( (7E&)6C8-QM)B;"HLA3K07OJB-FM .93
M#4:HZ42<ET0I^/9-)QW3T0B'F_W/U*[?DF6<>#DAG@U/<JC',5LK*%.P$M9>
MV2ZF<=6$84.TNP LRXS=ZIM^:"C37?G3)%G-=PVW]Z[[%[3''6F+EP6,I+;(
M8&UT#Y<W W-@\R;60J%MYF=H@=\D)[$*='AB2I-%JDYP5%8G#JY@;YK*ZX]$
MW9<H]V)@K=W.-2G#'QU;KLN6IIALBW=TJ1@M<V08$H.$H=H,L%=84V.+QY.$
M"1+KNB)$:4BMN92A> O*?DGZDQ)'>3H>)GI]6AQ@_*7MT:]V6=TPMS%^/5/Z
M@CJ!$OTC7T"8ZZQH9Q73\W )&F9%C+W:$9U?*AO.A[.2)-1,F$=>$Y,5=QNT
MR(1CPIE '=/DM$RL#NJ; X:HDII"Q*K%#8B#Q\^V6UQ20MS@#>E_;'UMX@(#
M73>>6CPK>1WA\."%P;PPX]&Z+)G:<Q1]-<) Z:P;2^SSWN=J4,-;G:(^B2"6
ML(9OP[6HCU@9AJI8"%9N%Y9'HF'>2A?A_TQ4<]1SC# +2+Z#EH5KRR!P\51+
M1)Y$)WM4]9BSO\0XHA!#3$<B^5''+S7>[1A?0,JU=YC<F27WHE7F4,4>8H/>
MA.G%)F*U"+U<\=A &9C\_?IJ]977G## H;Q-N(I1]XQNNZG[2T/4'&_[#=^+
MT#J>"NQVVI..?;^Y9Y(0-.;]>/7#%2Y, DK!8\P<&A0"")Z\D;)YOAE-?/!N
MADI5:J,3I["&4WQ1Z#53G6H:!H[MC,4.9IA1VF%(W4$,CRO"XG^:AG:DNPNP
MVS_#>E>WD5\J.]-Q X4<..X,']B2N7+>C;4JSB#0=S5SL-"9]6!Z/2\RYFME
M#ZH?'= M&D4:%0+>1H$&UV\?5@LYDA.>,MPU+(";\."WK5AQV:7N(GR,/RHR
M8%?(3PC/[O'^0/9D)]MH4K[ L,'"*?OIOX;%V1UOPW>!D^!C2NADY/2K1];Z
M<C_6W@5W?'2Q=[23E$1<9H1H(2B=*')&<C19+TG?:?K3NT9PNJRCAE/QK<H8
MO6-@^,B++3:Z^I-KV2/->H/H^:*T"A=QA6,]O.^C'I'.0F1F"H912*KCPX>8
M 2@>^+]L6&FWU&#&A(FMN.B*4JP<G6J$TLP'!!RC_&VBWD:+(3\]O+>CQ'2;
M=%BH;8 Q?CA1N+1=&M.([U4_7F>!B1;$ A@.T<SYV<BZ8G6&?J?2-[2]*[8W
M=#&?B=&2L"0,U(@D<! ?U2Q%KD2?!K%*;#F9?&=:^8@99MJOV]F7'IR!0&%2
M^OGPD\)D1FK<0A)&!K7@V/NLS&QEA+U;#T-_EQ[I[FMN]=;$B8GCS+R22A/9
MVL)@#SZ<NS#?_QEZ<7'7E.R!9!4=C*Q.SJ6P7'2#>S0@((2$/J54FS@WJQ]_
M>/WF.ZSUZP:T!%Z@IS_$;J]->)-WAM]XUZ_MO\G!,>V>IX91!; BO' S_JXX
M589+5N23'U_<# SW X)2]_@V&/ENW22RHTJHJ>F2U.#VB<&(<GILFBA39 @]
M[3\T351K@(CKHW*WYDC=]/;6>;.;;K8JU4"M2IN_)@Z&+!LU!T6D=KJ478L,
MK)0=9QX13=]"+$@82H6G0^E,C%Y6\TIA%*)IBWB+)J]]&6?H:)<6)42&9KC]
MEE@;RD,BM P.^^8(UG-MI^22[065(*B$?[V@$BZHA*?V%A\#*L$Y5!(#;Q0U
M>2YRH33F+<C8D55CH/Q.VH?(K 4[2'X" .W&9Q"<C4WC4DKB%AM#$4)^IC6.
MK/651VRFEE=2!DY6\)F!#Y;+H!8"Y9D7(ML_-LJ0/I9F!YA^)(8X,$%OQ1$M
MTZA*CMQ^OO4I8&7*IDZ/F\8'LG7A%HBDKQ.= ^0OF 19LMW.ZVA'B;LJ:[-@
MWT"N0TIO$L!06(\<@/JF5ZLO"77?;D^$AL45FJ:-A+%,PT/^&*\'&0O.4OMT
MT&2HPO"KIB;(*VD;QDU3693GBU\^7^36L_8( ^98ND51(X%GQ;QTY@NV(>6.
M_DXY#5D\DWT7>JP>Y *SV-W5-FL%5FLT=RKG9P&%\;=;GB-L\($]37DXIG([
M6T"^6OT ?*A><!39./7#B.J 7EIY&^7IMR&8V/2@CN7:: S(<7=)^7&\S[$?
MK;SH@&(!W38[2C_94.R:A0#?PZ2*;-SCD8R3B_099)N9*T^]G<),RIB4BG<_
MW0_PJVDHQ?9I2N=!>0P9=1]!H J6CGWP^*G4) S1JFQ@;8VN(0E-H(R!F"OI
M-?O#KK\'?5XCVQA$ [1 P2S(YP0MYXQ"[FK%[39(3>XI/6'*P];J6! [M,ZF
MG*)/ RGF="RE=W2=ZYAJSZM'ZJ#"!KZ]1NT<>>ZW_7 $;N=HNK$N(!F:].#:
M9'QW.8I)\4 *]4'AC_-)ITT@$/:NB<.M-P]Y3K)-CH>&[2%)-+H01NNE27;0
MIV7"JV_[7=O[(DEBWEQB/=9,L*<WS<D,V6/16JZ+_?PN>))^P2.!>Z]Y"IB'
M459-"%PW87^HAHC+<!9A%"5AD(?X54(OL;*;I7OT:0[O2;?KM6PAH<K6%K]=
MNVWH<5![F9UF3&BVV\WH0KGJP9"#0]UN.*/>4?V%&>0]8Z<[U&.9];-/I"J*
MO0'Y^."^M52*1OV.]BFVVB@T+US;YX[A_ZX'Z@WGBN3H&9>,<:9:77,'+ N[
M=+UKKDT98-Q%M.50P9E1L9/&R;],HN6I9Q0)=%,'X@;2K3K&T<53,V9 @@<O
M1Q3?[*'Z;ITXH'@XJCBSZ=Y8\8Y>Y=!T$5'9SJM^3A@F:7'#5(&B9*#*N5BE
MC_S@^AV.@0>A=)^AP2G;DT.TZ0B/5+ZGWM#3AB^*7AJ0^0*H[-?@0>-V,)=H
M7P3V1'T*[&W>I[BE-T?7S3W1'J@ADD(KJT"1\+=A>T# 2_50X9IC I,&G6XR
MJ<Q*O!YB^9WOQZ\%$N!G.(,<AQE #:)=]Z:.-*>0QF0.S;89!L:M$J=+UTTB
M0C(8S3*.$*M]:W&.#A'PPRMW =DU6!8_;;62!$C-((0]*6_3@5LZ1CFI:)4Q
MKV2]0M'!31%Y$,T>J('=O=B/F$2ON?@S'*>.8J$M7N!=&VYX>JU<>_"M@6[+
M704ZF![^L5-M-E,/A*B>'6Z&C'GBG)>_69^&IHG& KSN;">0=DT;?:2BW2G8
M<,SO3.3.W+!.D*VLD"I Y"<Y[.?VM"S1N*^Y7XOC4N]7<!RVA/W>/J2<Y1T+
M$]X+-R$4JHZEN0U.C2C'4X)@,T55EI:+_BK%RW-O?=0H%UCD\O=I34W=G$^T
MN!0*\/03*[EVXVXIX)+=6$P+P_'2#IJ9O_0/XS^F.9WL\>;-"$S,D^RHN\Z<
MK)/P+KX#VC$$O %2TI^FSO+NM^UU>U17U^2UR++:UM..EX.4Y,E^1W4!Z=0S
M$#JCW>"\=J-@)M6_ED&?#7EAH"F\,,$4D=F[OE_=M.]R6#X0?-RJX\&0298A
M$O<BM_,,S<+RBHW>;-RH#\7_]4[L^NBU$4[^ZH[ID/UT>1O!JFOS)!T'%H[G
M.WQ?U%63E$F)K[A2((&"3;<E'H*]\A;$O6G*N T8C[CH[FY%A[F5*AR><AM.
M*8#RF0"2?@%_/]GNS A9MB=H@WVDZ;B4W:WL_F^7LONE[/[4WN)C*+LG[LD#
M4*>IW&'FH/R*]L&D>/L,3^27QG!-Z,\V4<P\'\90/F*N?*RU&% M>?ZE>8]5
MHK617<1<>:X/TQ&$GV6M<'(,53F^3,D >U.=CP[Y&KSBL<:3$?@ETJQ5PO^L
M!*LI"7PJ_"QW#)=3J8/@28B?60S_I)A([NJ:\[3K9NY7S]@E$ERQY(@S5DTN
MW\J+FF:UY:2==M3S6[IO',S2%*72:0"80AM:&DJ4Q^^[[B,>E?D*9#PCFH:X
M.V36,T]5=)J0D1W P6N/S6Z0S3IU3'32SBB.JW;'Y<UQSA-+"\P3*BVYY/=*
MQ&P&QKEL9AION=H8!YZ<OA+<4%]Z@](FU41^VLT5.]/+/GB?8U###X(?S82
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M4HU@.W#D65$IA5/,?Q2)PX9FWQM=ZX/*(.J^7 !T!J#[XP5 =P'0/;6W^!@
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MZ[8_$%% <(,G!F]8+2BG7/%8$D*2EL@Y4RW#(WN6#=$Z-6>7<?Y&4D2@VJA
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MK]]\!WR=A#9*.5%/P8X,K8$!@H-"ZC\@]SB&M5 /S-3!RU$;T5%2,R0F?J(
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M>SMN"M9$!;66DE[P,/"VO*M)7CVV3*-^]#)^15:T-K>#>)=@W@A@9YCF&MB
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MYJX,R@31FX_Z $?C;;=,XMJ+CMW[&#;HFT2R([5<;M1SS!N.V52O<2<9QU/
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M4A[EBQ!E $[\05#..N0>^DP%T'U-?"$E-?';%D%O7=-(F105MQIJ-+PF?<J
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ME-H4( HV);IYA49R/!IV,JJDE?HHS[X0;N7GS_@A], <'Y<D]>@H^+[TFTG
M8AY"!H1-VI$]F:&:3*NNT7YVD3+P4KH\\2)'Q+PAYC\](N:/B/G']A9/$3%?
M]N_$T<NX!BF]U,BFVU$5#.2WU9+MX[-/O8%,KR9 ;FE330U@YHQV4->*Z>N2
MVWZ\[N.;'(4X%1,/>F;/-(1;)/K=/]B!H#.73Z!R7OZ['S44N];@10<2+K0&
MN*#%M0S+ XV:$>Q>Q0@!VY>\S:=:=]IS(6T67^5(F,)[F:L2L<DBN!;BDLN:
MP>)4DV6 .'=;($@DU6ICY2:(,6/5&<:=C(AOD'-MQ@+^1M ;%:V^SK3>T7A'
M?V/ZKH7#A09;1]X#-T5'K\'>,PPTB6Q!SXI(6PC5^;4YO[? SMT3 %OLJ5%X
M73ET^\I63BK?C2$@[PAR&HD,^$O>\,AV,%882VX&DCJ,>+M(1]PO*9H1W"3;
M&6U=J+R&)%WYM$W +^@>SC5MQV[LQ!!HWR6<<W;;(Z9>60Y'W;SDAQH=$*NB
MA%5Q[<'Q8UX8,U&1/22NP.2!UH 26:)PC\;4FWQ3\S317"1=R:AN1OBU+0A.
MU95;4#;>$+_1TUXB=S;?I%,QUWK@>U RTX!)9VF3]])XD^T%3QD17,X80CP%
M:]C?*JHTI3-_%NFNHMPH\Q;Z=V/+M4*[Q 5S8 V''5/964;24F4E2V6DA'AU
M8TE87:Q&!44Y2IR1/JU[NG@5.]@X9TS=&R'JIT!3>C<NJG25Q_82GH7:)<@\
M;Y,VM833CAZP1Z[.CKFT->=T\;,^:]I?YDY(G <=$SS0TP17:]LG[%"^\X@>
MF4YB+S_)/Z1.F24$4[($(6Y.3A<_M@/]W=*PXM;)S>/$VC[-Z5)PZ]BFNL2I
M3;D*S]<3'T<(4ROC*ZI6#S,V&$6<,)'#-QV1*&\D*R<. :L*'5)%Y/RXC!HD
M[[T+/V)+E5DH:8M*"AR*>\@&SXL>W-ZZR^DA)P,527S)P^G"-]?[3;%HVN9D
M6_?D;1@;)7WFR0YZ%$#("1FWM@E!E[Q,G3K@JKR5* 1-I;]^6@ZM6,%/<U9P
MU97K(5(LM7M2>-#A8Q-G3B(]N3":QC4:*R'93MWX<KY%.?S_\?% *H?H)$/.
M7PH '=R]NA\_)E4L'3?$:-S8J9B?!7B_8+: NMU%C8((MS5R]S7!^OSSIJ)N
MN>?D5CHYNB1WV8%ZJ!<.%%;VE5T=?*IZ54M'=Q@MKP>4]'*#FHT^3<=K1*7,
M]9V^W58+S<<Q<R=901LU2]IZ,;97+[[CID(QXB ?#(XVBE=EQ*6<1S&3%<7H
MP8'O:AGP,Z[\\AJ+F\(:=GFYIV^F9U/N9-)C+]?9'JY5:@FI#S'$.W"XA:\0
M>^,A$D=9Y8HL(L" SF9"P%R:0-W XF#.N"Y,Y)I\#8:>7M!M>YQ,U-VWE\9]
MI6SBM2D19F[U%/J(T?#H820G6(9IDQ:I.QTH.$IT/6W>>66+0/@%R1;;F8?7
M8/9/(?JF!PN[A@B(R^OZ4K5K?/X^=O4YQK;D;FH=PA:#\+CT"RZYTBN4;Y$6
M#J;7G(?Q>R:6.YJ;V7/Y8Z[YO1B+.:8:\1&,,-*'ITE)> W=-HVDPO!XRXX$
M:<,EZH8B9_5#1GW"#E<Q;0F.B[#PO[NND*CIJR6)T"H99;DB9YDY*HBLD1I!
M;,6G]>\'!ARQLQI>J"WZ>_7FBYGF5T32\FP(3]U4!^M$9XD)\4&CWL0+5FL,
M3_17<)-91?*''][8$2S_(4/W%F+Q&8WL[]^*1K8^"0^P/8J[Q9KWL^:WDMEB
M93@XP*M10_?\+%KS=K+/X] )\26Q<W>2' I3UU'5,=ZB&-U.^]Z+F=9V'$D3
M8967%CQ 607L?T-]\JY>OKLHE^_BHPH)P_1-?^UJHI5;+S4%]I*2;25K,I.,
M*_^[IJ&JMQ?[KJ^8'/,EN?/\UM-)$603D3[T*ESS@7%[L]F@O+4)^S_8@^WO
M*>^IZCVEV/\(\AFOG=/%/V;_5J!@[\1.(-HM !RN_E*NH;HJ-VM=I3Z.I/7D
MJMN1+1S6ZB#B(&&.47D@=1"ZOURX4VQ*^CE[J=RH,T1$C5>3!O#EL(WDSWQ?
M/#@_^W&]C+5H@:6J&3&"AD(6/+TJF0&\;)C1GOD7PM%0#<-&=NOC&LS_[Y$,
M)IRX'NG;+<AA@G]8=5+'B9;K)H1I820OB'B_DQ_:YL78!Q\_+%TBGQW(?5 ]
MW1;ZBL0*8JD1CFX>V7P\EL5=C,W$EDY<%G:*($F)1J^)U%O")OA=E4&'D)ZO
M#?@C;HRSD5!^"F?9/OX&[OP3YU.]W;^.\E.BL3).*I*+I#K2$)F"IYDC E)
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M]93NFEFA*>>*PL0K=I<-]H7@/>'+M(9X"47J!;J5W%CV=CN]:GCA2C<Q_!9
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M/[3Q("9BRH[>,@M(HXHV;(A(JPU<9;F.KYK:K)TU=RV'.IG(=)6@.:G2.\0
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M;XR>ZO#3 TX\_N"2JX=%+]H%OVK#[MJ"Q.TWU4G9;37,C=C6]%E@#"31/^.
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M!?WH08P<)Y /4G74;J@P 86N9JZ[G.;=E]050V&<A]7-74%Z<[@MDH9ESZ8
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M9$?XA5 >0SR887VI/*@5"Y%!YF0[Y1C[\9&GCRGX<*#[_UA0U$0-$6DE7H^
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M+[HQ3.+.>K9MF;[<&#1_-M+_F(\M6^+4:"1STU7@O.!3B_,T49'%?)^QS7+
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MW.=-Z0+]Y^),AD==[@?%'X]?7J0)X;\2'7GC' \3^/WD^:<<XB>#0K<R[TJ
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M/J@- ,@?\C"-?S&^_I:DF\+Z0/W;$$0,3PZQRR8ZE>E[?\UEJ>1:,@)E4J4
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M7DRFT<W?^+%RD;)__=P@_C&<ZP3D%^(/%"Q6:A/8MDFO"=MPK+%?YXX]VC+
M-\!]B(&/7LP=]5N4TBX[=AVB^(HC^U*7MN*RCQZY .INVA94NBSJRL<C$B/;
M=D6J!XZD45"4BU5-=0 ALZ86ZDV]G/ +.:P 3C,W0^K".^;J>V (+EK)6*8<
MUZ(&&=Z$4%QP_PDBFL4!N,:D2'UO+6*6]W5)61%5XG3KN+-10XY8JIQO"GJ*
MR]%2[$K\(2TSG0*W$SUU5;7G,U/W\Y@!)J'R&?UE"X@NY51C1Z=RDX03'@N
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MJQJ60)Y9VA[][66D8@8SAY$468(GHKK.A"/I %&AO:KQS"VCK$NP*HCU*:)
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M>6G 'A(<>)_*(:YOXB?N-IN]JYO0@0"7&4IL-"4Q/_Q73M:63G3H_ Y95F3
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MW7G<$G!Z_\?$^T2EEYU6I^=38=8X#3*J0^82O#3+O6 ^S])++.@C2/G+"//
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M)+WH(DZ$YQRO $RQ+%(+2H;EF,JCF*;KP9("<_^$HD&S%959T:&AHLP.X?V
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MB$HS+?VT'PGBHC48\ X&?+_!@&\PX/=M%D\! _Y[15N%*3S;46FDR"VI"HP
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M@\ZD/SX][:MV3_7@A$[[PV%[-.QT!YU>./BC,Z!3VFE.Z4&>TO[&4PI_HAU
M1_V+*62@0GJ.C>"_+M(8._0$$/9PXUNX%K_^J\ BX9<'/8GW:AI-HL5!S^%5
MH__W0O^'T]YDT.X%W?&XV^M/.T&_UQVU@[!SVNZ/6T'W#SCS= %TFPO@(,_:
MZ<8+X'!U",X+:T\^Q.E58TSNAS(Y'7>[[4ZW/9ZV1KW.<'@:AE.P'T=!MS\=
MM[JM/WJGI$MZC2XYQ#/7;1^]Q98.0FHH*96ZY%IS)O?B3(Z#[K ;=-N3;KO;
MZYVJT2 (IV$WG/0#U1ZHR1_M4;O?P5,YV'0J5]G+MTR)WBH/>O,BSN8QS6.:
MQS2/:1YSSX^YIS\^X\+ 45,8^%0LYF=8&+A]?7[YF)$YN6WJ_I&[0=8U]]^P
M:F9WI;DW'3""W>3F"2AQ\.>44&.FWGNB/$5*KWV?RCOL^)L%V#F5!7-5@+^9
MPTY.3E[O^P[1J[:GN/D\CQ)J&N!.C2T<^9M<W/N/4*'A?0*L[U*A1M=#DH=$
M &&<E2DUPG+R;)W :/BN/ HCAO9[R0M-3WXEL(6;VK)<Z+K2*/)2]#8M)]DG
MI21[G&*WR,3)\,U-AB\W&;Z\)L.G)$D6<I[I%0-_4J??%*.MI28S O%)N*_$
M-PB<>O )A8M>8K6O;C/S#5G01C"05]15S.U))*];?@]GF1/_7A!E^#:$P(EC
MVU<C+6]"%NBT?(NIJ'%U9+NVV"T[:=."0\S Y=TAYJ5MUI 1@1'Z!W?A!MR6
M3Y/);T<M]V?#]2CZ[FFNRG5P7/DV1T8S!1K*8(;2*A\$0PAK:06X8[3RK8C"
MP^KGG#!\D<2R=-]L-: 23RSIY]SP&@?>G.TH1_BG6-6;64O+P&B+R:7/LF-Z
M?0:UF.-:B:WR\N])9/)C^2OOY9=W9Y___(IA("O4W(24;TT\>INH%8TZIM]8
M ]^,?Z8#/54A]<[:'FDO#JX<&&.+5Y05L=+4L\0^SP2>O$'?[/>)@E@W9,(8
M9I%E[J7UP$D]406Q!0L6(HNB8!FI6K<_N6$NE#7FA8.['N$X[%\UU8:&HT!H
M9H:@8^0_WD>J/$?(*>+;<XEL$;,MHU<S >W5A2+@CNVN.I3+::;(N[0<<[#E
M^B.^>6#(;.AP_2,X")+%PJB8-<*(:BY$ME;0T3[RX;<90Y1<*0.#@6BB/$5B
M'>0IRL5G4<!3X15$?$8[ T.91'W("+5B$)YI4WP-[.$.1=8.:=K1A:4M$,CE
MK=_GC6&)<8XU^"JBL!C]MJ*SI!<7^;H(E[Q>+^XR;0O>3)/5VC))&9Q<7O\<
M#^IG]VP*<J)(FD"Z351(4""$MY/CLM'=15 7ZPZ"WK.M.,<WG!C?/=S5\3 C
M)EZ&3!%'NH+&=>)]PVUU/FQ1(7_"*B8$3T/XI@L$1R!84]]3B(V/R@&4?D#R
MXB#\YAJ%VV"C6.[$Z\B\G44.XCQU1L/LU.9-=?8E(TN2\^!@&%BT=H00%OH7
ML1,(J_A*(9!Y7GU%2OP^L3;;2V2 6]*2N^WTCFH7;@%BKS$*UU* .Z[%$SUG
M.UK,[S0)(7=*?2+&Q$?@;WET%606@F^U&2^$P&/K?T=T51C,?L'XT$#"YC[<
M[B*W*& (0EL@>L2"(>HK9F?ISYJ%B-Z%?XE@<$)$! ]\[;ULOQ)/G)0E'^:<
MB9>LVC T]D9SRH.W,$"0G+7S2K"\Q+)2 G;&3$_@^"?GI-XLPJ_/U//(Z/'3
M,I&7F4LLB'^FD50<FDQW8VX%5_[HPO9+_LONO8B_PR]T)V*O=?16]SU6VQ$/
M>F5T? ZAO)GLH<[J"GA%X"["B[+3:I\>]*1W%H7?4J:3-N+0/GI;:7Y529(O
MX\L@B8(M!61OEN,,S([8XY!;KTD2FR0QMJZN2Q+O4)QE\86;S/(^C*7)+-=F
MEG<M56'QWZX!]3&Q:=Z=??WX[=.9]_VOOWX]^_+KW[]_?/?-^_C[NZW\D4<%
MC-G8?KWG8W])?G):P#-"=+)_8C+%RR\HN,S>O?P$TPM>K9W/@2+>#-LGHV[]
MGW9%O&EW3EJGFR%OMO]]KS6XNT%U[PV'9[1O.#RG6PF]F[^\"1S/-9A$(NQT
M%O PH6[P<%)O#FJ5,+%;6IV;SO;9+%=G%V%:=2<F$Z7 2-FQ_6,6A6&L'NGZ
M.".4XFVD9-UL;R\^UZWC3;^_P\AVWFKQ'/=SJ]<$ B6HQ\#4KV^TYY5I[[PS
M]_7].SJJ'OVWM>\;B74WIHC)@2NO;NDNLV]YAR##+VXU17=J&3YUK^8FP;(/
M"'2-::,BB3A45N3A425V-CCRP%F-9D&<_^GHN*LC:45^?!X$\]<H(6=)B/_Y
MU8K'V>)=D&58#/@_R'IVY#$A&SB7/Q>ODV)V'*;D ^-CX>C LB@Z1!**ZQR]
M'0[]0<O Q.F1OF70]MMLC3Y[6V_1W=PFS0%YJ@=D^ @'I LV9,]OCWI[<D#N
MR*@YC$OQ4QU+QUH;I[/;*M2>_<,^(-?<('8Y;3V>&)#E8S&-?JKP^-\J2VM.
M1._H+:6V.F]N>R0VB.9]W!G;V*F-#%VC9+>6H>M5:Q]4Z] _;77V1(Z>E;_Q
M)5/S( HU<S472C E6[ Y?+#IB&QK8AWV$;E&S<K2_LHK"Q;)9UQ6#LK<\*@,
MX*CXIX/!GA@A=QGS:<3I&HU[#^(T1''JC_9%G.[4IAWMN>+]GBZP +L4M[N-
M2;M=H/X)'IMKM/"M#LCIT=O3EM\;MN_(--DZF[+OQN^SE;9KE/2MI&UT]+;?
M WU\5X;P_4G;T\J>K;.,L2UVL22+& /Q<VX02-2BL8EO;A/SHGZ)@V0!-LRO
M>EWAW]S1KWY30:Z^XNL_3_\.A@Z>J#,L[SN;3(I90=W:[]4\P\IM' Y\\VR&
M[4K_ENK2G0Y=OW7T=N /!_L2UVM,Z@<UJ?=-&MM@</B#SNF>2.-S2)W3YF)M
M:F&)G2FPV7ZC@1&2<R]&.6ABSC=6_)_U2M8=J%U/20?]UO:PNR<!PR;P_( Z
M^TX%J7OTMN>?=IY8Y'FOU>U[C>PC;7J$7I0W<>:;JU:]HF*QO,/5_#U-)+3T
M.YZ*%<'O';UM]_8E[M?8O ^H/[>0EMUT:!]U*)&C[84P/<,@<GWP^!Y#>'NW
M#MM71NTV^:>C%;:*DN]Z] ?@K8[\?O_6P9-#"(\WYZDY3SOF 78]3\.CMT-P
M;/MWY=C>>P) C\ L(S<7/EHK2!>F$J8%%@KN6Y?*M4-[6K&V^HZDWZ* L!<C
ME?L[43K^IZ?Y$(52\%73XK*W>[^Y12FV,G"S/J4[.IMW_OUG59)]IB&:YL$2
MJT!O$RI[HC;1$[5\KO,D1#"^L%S<K!2B?WKTMNN/ND\HPM\<B*=Z(*YS!>[D
M0(R.WK;]X>T3P_N5J3B8NRXKE*V1;U(5M[@<<"4=-^!FQV'0 D_9'PQNG;AK
M,AA[*$37*]2[$:(V<ICYW<&33%WLNU(U>>!,7:JD6'$@FHJ(7?._7WDA;W@8
MD%C7[[6?D,7=2-"N.>';21"VR/N]_FA/).A9F:B?RX6*;I"ML5;OIF91VQO+
M&QX/++GQNZ-],38:D_71BA9O*TE]#([UNL,]D:1G9;9*V=0=J=GG87U<HV;=
M3HO5H[$B_0/LDKNKBI/&3-TG0;E&BVX6E-UTZ!!OX_;M TB-L7H#8Y7@12:K
M^>#&5+VQJ8I+6A<16Q'\TZ.WH\$3@OEK9&1K(W1K&<%&],ZM(T'[:%X>1D'W
M7:G&VU>F'O:!N$9IWCJ#,&R!%='W1ZV[2LON=0%T(W*WU\&W%SE,6HW\P;"U
M]R+W'(H:[R2+]3RLD]VR6+8E;=<#TCEZV^O[,.\]L5_^+WO?VIRXDB7X5Q1,
M3[0=(?OR?KAZ'>%R5?5XHF[96Z[JV?G4(:3$5E^0:$G8Q?WU>\[)3#V0  D$
M",B-G;XN0*G,D^?]5#KNX2)9FV-1JV)8=%K5 4LRQ&,% 5//Q:G8KC?',>@J
M.V#S<0$14+^ZSLL/YDV^ 4!E.F+^AL\]U?#YI/%H75?](GBTGK]B#*NE]QI;
M![&JY8"M-'_]!(^]T:39T+,P5PKKY@JKA&;,J%NF<*QDK-W2&*M262N(1VM5
MU@)XM)ZQ]FJW';W7VCH+2^FM!TN^.@]]8[/DJSAAI' ?VS5WRW*,*>VT2MBR
M68+52FP9U&X'O:U[8"G]\T"Y4^>A/&R2.[4*Z_MU,+PJTU]6*9J'3I]:B2O8
MC;A7E1J[L] D*3-J[#HO5P'S)DJ3W$5NU$J4;X)2T*R*4J!4R .F1VUL@O=;
MF%M:;Y<U-*8BJN4Q)5"5I%N>;19+_L2IHK31KMUV6WI]^Y;;A:[H"'33L\6U
M_!E317&M@_7]/;W>*"O=N4*Y4D>HW-Z[DXD=X'@5/F44T0#VSAP3[E:[P&BB
MUMNJK]_Z^^'46907_O+M&\<>_Y]:X.'D\,7 :'@LG#H>/U2(B5U^Q_OO5+@3
MB/1*@$@OA,@Y>+Z2F2TR9]#'!I?*][6I%O*#3::N9WASWAKTWO"\.4#C;H+M
MMAX<<SQ#X#SA,";7N0L"SQ[.:&+U#Q=U>WB5YXYAAR\/\%*/^8O]>E?%;/M]
M%;,]9=1;HY3L&O76ZS8#KMOTMR\]4.ZYW!@4[TA,U-_[0),AL2^Q)?H2;];3
MMJ"XWG_+X@([VY- '[I!X$X $RS[3:XMEKC"W]\TNM<=N8SM6*".W%RU\:.#
M#11-"'[M+ZL8TA/SGE\-CZUD3 _?OF1,"><O(5Q],KQ'[SG (87_,,8S%JTJ
M&$I=,I1!?36#7+:?[J[VTZC=UJ_K];03+?6!-C4\[0V7T[6E1_#Q-?YVT*2M
M^G>SX-7UX-ZM?#P[.E)S!8BS]U<,NMONKX6I0T #F6GO:;#S+6M&^+Z]@/_!
M]V>+1\O0U*)3M?<"]<=9X =@U0+W*;"WSE[V5AADW<+;VN0F-P-9KW8+^V+K
M\3,'!ML$&,WU-#?:2RB_0:[LTRP+Y5G5=>.U(Y[C5TUL/K]=-:B(724NXUCL
MJJ/!G;4#F;?!G4'5<&=/-M'1:<+H('2=;=3@=6*0OZ&@SMFH;Z@$KY-^&^ZF
M$BIP;.];ZI>->OD*<)F[ _6WU:GO50$N?+PL52['T<K7@5,[6ZK-Y=@>CA"M
MZ]WZ0!]DQ.K2@,?HT:[1?$-(EZ\ZEPKI'O;H;39Z>B^C?>12#!=Z,H(]IBAK
M1J!]8B:;#)G'Y6NKH6O->K-%OX0_FKH&CT^9B=4MX_D6FO56&4I'HQVM+>4-
M,4&H1HLJ4*/>1U(Z:.)1<=7YH.EK1X,<:^MSUR,'*,B';7BXA6I\S T/[V#/
M"&MC#(J:;8$.KIG&U Z,L8K^;CQ*)H3I$X#TP;GG "T81VLT0.5O]AIZ9[!U
M2UD5R*T@%JV;)5,2%C6HG>Q M>0^!'<US=ED-D:36G-Y:UEW,O78*W-\ZG7@
M^JIZ8IN171*ZE"%_'X?M@P.@9E\!P-]8\#CZ8?S*[ZYK-)JJH<RQ(=;%5KS7
MA_W#7UNC6!J5L%U7VD^62B8]JE*+8^*[(OOES-390M20XK-+J.$["PQXD_79
M\!R AQ\#LYA]7E@[:8..V^[HC7K:^LM/(DJ]K2)6Y>6Q.\ J+*_H]/5F1J?P
MO6/5&38)OS<\VY\8V@^0F,:4S6![O@;2\IK'U=:D*:I^XN6KRO'T4)X87)BF
MNL"INWJG59:;[O#E<27IRB>%<SOA\"5@'P[%Z?3T>L9\D,*J=(5JY8Y9R4Z6
M"VBVK!<X,TV[1"[]N^VX'E"'++THXK&H2'::TJ8/XBQ>C3DY^"L6[;3UUJ J
MXY?.4&M6NG%5=.--RN2*4ERSKO3I,\#3/>G3>\%8C"2VFYD#?DY5!S\.R1'K
M*:0C2BTKZ*?DMTW$3,[N(SR'YJ8%T+/<&6Z ;G0+@JX<P/]R$-!4F\?MIGW3
MG6-M[S=H-FNW_8'>Z9250E/&=1[(FE)$K(AXWWVQRB'B5NVVU]0;G;+FOAZ*
MB$DU^8V4,IEJ'JN+FAC>B^WP]S:3%&0RU-D.U5J",<TP,7')<+"5"$V]\K7
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M(Y()(\^=:.Z4H=( Q@ :8F\T#_AFFR2B[9%KQTEP>7:V^^K\"J'$LE+\K6M
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MX 3X%UR2#Y'&E7+1\4X&F.\<F3]%<[;GS/ TYB"$4I$^'K;%6>'8*P$NT P
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MTZ:$Y5?W7=3^D!,>74CNS#.%TF['\P9BCNBD7O)FLW>1:QX-F,+'X;<&#9[
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MD:(<U:60_Y+<*KPH)2S'C/=OHKY.\)-7&PU%](\E^CY03WE2I:(8G=R>;*Q
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MGOB26%^7[\S[:-L__X;3"\J6U"L8MF[FR2!15U_-L8([\0T4?#GZ*<K=[?
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M=S43"(4O42/!GA0CMO5BA]I<)'=16#E8;:US[0ENUA=  ZA0!>'B>O1R0X0
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MQ6%94\HK<MREZ \**G,D%50?/"23U. LTIOA3:3G"9.>'=@AXU71V'ST-\L
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MQ+;@IWQ?<,^H8:#:PHTETDAP3M?$ -7*BRLA(,L8ZA^P:U-%]0KXOSZG*R'
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MC"^V\R?$TK*)+>T!-F9:TE X)\'/85.5)X0&.R!J"5+03\>G\%G84H(O/?C
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ML52BFU$<)(6YY@DU!F/"KC]%<1F 0LA*-RT?W7PWAY":*\Z?Y^=X$,JD<.L
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MJ!@;;E!. ^L@1X\5)887\T]??Q$<GY]OA%)^"JB&\0*>9P0 1T%K\TQP<9P
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MS/\+>PO<SAS#Y)?+B]\[O!^(X>)8*O@-/<TM-I<E<Y^S1B]'\^J0:F-M%FG
M4#AO!?LC>3C(WH$M&]2P1 \'\-99U$NSJ#OY6=3%.9K<&@Z[LMQ3!IV6'#*W
M#;*PZ086@9>?X;LP8(OO>J".9&7(NL-6M]O1AVRHLU9_I"JZTNNKXT[_=[DW
MO @7.D0N[3V@N31L2G=1ZB;B^R?#C55'H/R5;GE)A(H?  L2?P;3Y:+LVT]Y
M:+]J^-BADHFMLAM= R,'%SD8HG0UUANWNDQN=3O#?G\T'HR&>J?3U15U.&BI
MORMM/M?YT"AR*XI9P):F"W]P;-!,X9:KW?HS^TB?N9 12FV$L7E'K/()<RJB
M?2?6X[$1F\.5;'([EFS?B35$$AW)J977V-! A:7AB8EG(C$9/),4W.06'8]Y
M$R<+&T:*UT02,>A3*1KOAH 694O41Q58T:./G<GEMGHM=R_9%3TL=W7Q5]1/
M^PDV[?#BJL^_>!8Z,"BJL)*';=  L*1K2HW#&I+HE!I_L+&T>X[HLHGS!S$-
M16E]6'V0!CTI?U@X4/K%4Z9:;G(5&UL*QX%"@\.T8()<.!".QBAP"X)9M!D^
M$=/BYA#OU83:2&AEB'US@S!:4FP,;#FP]$1[(<.#>Z:^\ YJ8C2C+0)X LJB
M;:I#T*5M8W.P1E0=H(N1Q;@\?A&S<*B=*W><N[$1EN+;I\]W896:0[B "^'Q
MP$K]M!J;1#LF_D;;]V*C,1NY/ZH27%5-\Z>^&<ZAQ<Z7/DZ6B[7OU!;*^>)D
M'_7NQO>L(O,E),[''H*"B_VG1 DY]4P#@.(X2S"1>9M_3FLS[,/MT,!KG#R#
M52-TU5BC*::9(M*\X%!FZMDIP!G3F:5OX3DBZSCH?07 S2,\T-.%,BY-X*UO
MS#2C*^6#<+$9(^*AI@;MWP .ECF/]U56P5YP>)$\4)\V,=BKJ,4TP*RG^08T
MUU4,N YV:C'$?L!Z6(U/R78)]$%S7<0)P2F#TD[TW%R/@%&.<3@#:?H G8DQ
MHVZ*MLO'SN8<M]+"-R^ %F\KG9#$Q85$+K-N%!)HRX09O#7LL:J&HH&: _)Y
MC05W2:VT0SD8Q LS4<S$EC.5OLIL/2HBT?]RI5O+P@[\C\3M\'[OT:I$VUAH
M5=(/[$8=60K\22"#*A^\B'J5-2*:N>@?-(".A86$[0W"6;$Z,#QDCD8 HK!O
M-X(($2S"2R< 4S.":.+QC$=Q1WEZU#BA1XVO\L0/S4L1XCSBH*,YB8+H-ZX_
MPY:9+B=A3AUWP"['L%I >C]BI,>_B[#@1R!@\$M.+ER.XD(C&R0$.9YID)GM
MN(TXW&/:$HDFBYD-:IPHF'HFL45BA]-C4)H_#SA0%CR#;O8S^$AU$@PKRVLD
M^OR*VYKY#O#Q[ 'O+\#X'6I> -^P&0GZR+06?,H,IK.'_25!G7$93AP&79ZE
M6 \RKL(EEDDW;[M7P,TK#U)NWGU1'NG5O0_[,8@SJ\T3X)([S2["XD&,)!(Z
M&1$[LP+]@:O'KA H-,\J1$R=P0\!;5'50[W$Y#-PQJKAD$8R-FF44K)_,K]Q
MK'D5_CYN)(#>[;D?ZHO?X\4O935\0$SBVA9Z= 3ZXEST>P5[8)''9/*7C3D)
M;8W"B3,QB 0C4I9N>%S%<K#X#G](PT%).\YX)S7K]H$9@9FGAGBXP*%#WOT!
M_ZRQLRK8F12$,PKI<J1S(F/-BZ:H^U9PU81:8+*Y8IB;S\<YQ/A1Q(XXI@$>
MFAA&044XFB7!Q3WJBGF"M% WBJ0N6+S_1E7F]<95*"28Y<ZZ;/M^;;7KC06#
MLL@^7K#(<GUYV9IKENJ4&",T=M0I>[.=G]%<'"/#4A#E7O3%B\/[>X2_O%1:
M<ON*(GJ)U ;@G1XC>?N$JKA-4;@?SHMJQ9D3/OP,]*"_J7/^*Q<!WY1B=JGA
MQL#06(#Z@H%8$AJ+5F'"E V'&1RA+1B+(*6NTSX9P^^['>]R4N[J+Y<XMPL:
M95=\L).3' 7"YXSR))'<\1B$J\2  _:+FH*PM\BFX[J)$!1SR31^H@CP[/0/
M&N5.OO/XFMS)C:_U6MU1IS?H#K1V9]P;CKI#61O*BMYIC8>=?N]WI=6N0GCM
M8U/Z08;L?>1ESF<"9Y@DT-U)J[7-@OS[#F33BN\-#RY$*X!9GX3>39PET 6>
M'97TA=B D71X\Z!Q^CS&RT?U<N>K,"B0:PFWK;MB>HBB!-E<3-/?XYPK8+]R
M:]25 1*WNHWVTA=3?<FJ2Q^KILNB'*_.JCYAR7>M_Z+NQ8W*?Y!.#UN8R 2
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M\T$>8"4 >\KCXS%HVMBR,0Z[<)@[+B."XZZ@ C1#7-?6#/(+A*^-7Y/80.)
M^=?*DS@PWQC3&[FA@UD5)O,XK- WJ\Z%9_^?MA--+'9S%PU:.XLD$)>AEV5!
M-@AL"X:%\5EK;N S>TM=1B.,0WDTSXP/'\>H&]IN<(!_BJ=!T-'D<.&&\Z>S
M*&K NV4C[OBFA^DB<X K4)-#T,(_00X'M\^C:V" .B\\9X580<)5C'G1HA+#
MY&D9>(E\5#1O]BW2M^E0N#[9L#R^R'?! X?.XK4VEES:D4K54"=_I( JX7=%
M3E)6U-U-#-W^M\&DWU[> -E0MQ*I\3XYM284@^;)/F+^-HH$2N+/B^U&CK$%
MIGSK):9_3WC$/8!@0_H&V!OLXXTP:\H" N!!"D!72I\B)V$S\0/<I1X."5^Q
MR06\I:V$&7MC1LY$\HG@JT1W>2H;\@)R4-%1'J972Z16S8.<I=CX/WR_D+*4
M6!5&>S$5BVJ6:$[E,:#/Y^Q[A7L#D: R4WJV'?MG,%,:8,?'.M]-5"/_"K^$
MW8ACEQGE"\;1(^/WO!#KC1B]8[A<8TANYY+>#^+X$=M0JM*?;5@!+N)ATOS4
MY+SX245]0Y?^'QQ_K&J38V=+M[.9#4H6(69)KUV%XBMY+"N'HFD,.2# 7^R)
M!9<\L=A/C(Q\@UOFU!X\&J"BT(\;*4?^ M?Z!'@9K,?9$@>O&#(AW9D@\:3[
M:'T>_0$BP#&T+"OB2HHR3V466;44+,,XR+6IOF$RJ0=;P,=P#_ ,965-&?-$
M&U77L[6?$]O4T6DB] G0M-%?)GZ,+,WU-8Q,PYZ0C?L@V0,HJ5R-,3FOM^,_
M F74-& 9'13W22-.@OB<PZ8VF)*+8(F.*V)$ELTU/Y%V$RFJ+^A@CC18%Y@A
M_CLDZ1.-%A(VWV>C OHS0ITY1"/D:8RF;:))B&(#<#4-=5%-+%T:5P&>D'J7
M^#E@S']T6CBPBY*:"#?XC.0%VB#=THK7Q'&S$?-;+ P,T#/SV'7AA7.C@!1D
M)\BGO31@0PXSIB/?<;F0'!/^A$%L,-NN[?'U##"9>=+(=PV*38:6:%CXG&6/
M>VCG4FH#)XHPIIDE[$72M=BPT+<Q$R\\:"./3->^&X#KBZ-R-L')-2@DCJ)"
M=V!#N5,5[0='G3$?E '@));6!+*7.])MC$4\!BSBB9:"A] @A7M_,%72S&8^
ML$D53)GVH 'R07)!W6<A5/#XMB7V@<G7F*?"G\'L6@<T/";FN6-6HQGFI9NV
M*S)/-):Y&):1)=4!_%U0H$D@X :2.#TA[2MZ!%2:_Z T^_W^X(\!5UZR;3X1
M))RF(]9+MO!A*H[_YFR/\H6!!"FF%C2=IO"6RJ-MUS2*7GP1&XNPN/]&W"H+
M*X-#"@J-5Y'$?]H,;)$22628_!-*1*#2PQ2;HL 3NGZX2HQ&NHZ$BHX>!#2F
M_TPM$$?:PERG!M5BS,A6#XOOL?J"Q._G7Q-C!!JAW&H..,X:&4G,7_ E<NOZ
MKTWI ;B1KUI>@.")T5)+-O'&K6JJ\N=U#@WT#J T)KL!BV%>W :W\ODJ\R08
MJ,%#X B*>]NXMX!'_A#] ,=,U9BZB';H,+%%'1'3B<\AS^#)(J'IDLW+PWE9
M'"N)RS!R,EAVW%?NAKG ="OTDA'SWABSDB?@PF&>R-:-)2#%,2$ ;PXW3BRK
MV\(!(3*+^*.X*8 D_W>8;!3X#GF-ZSRTM##)9A[/TLNO[N'L5P0$.I=J1D!@
MY[%NI947Z^XH VT@=^1>6^EVQEI;'<FCOL:&O19CO<&@][NL5**4]"Y1N_48
M(@&0&D/C^R\^H*EN:+%A]P\\.0UD%]:(T1=5L;161"T]7@:DH=I2%C?.-]K?
M.YYH?T$*[LI*5LN57)#3JBV%C8>#(1OK7;W3[0P'+670'>I]901_]K7Q[^T#
MMP]X -XIW=_?KPN57K>7YF;+*9@#IJ=WV\IX-.[VNIU^=SR0Q\I(T;5A3U,T
MO3/^7>D.*L#J0+60/D7>S51FIBL"JH&!^Z?0P%V3551!V^,5]K\P!3T0Y11:
M]**4SQ$#?5GT9<FJJ@W,'- *!!Q1<P.C+H 4I7TZV(R*/ !",Z2@O4$ QIC5
M/,HC)@TJ](D()>];Y!-YBOE$@D#5&R_/XN$?U!HC;3U6;XX7&&;H1>FDI)2@
M?D&S2BT)H *&P1R>'WO"@HMU#AT;V*1*(ILB)W_O-"T#PI6_8R&3RQ-I[VR=
MC*>/@4E_QW.3.9P!([3P?H+RVN#R(SJSX]051C<7LZ67U(@VEI="1U_&"BR"
M\E$R\2D?TBQ5-BWBA*+#0,0)J&KRU6!O04<!,"@!TF%6?N:/PF>CY[A-''":
M-S8"K8"J4G?,)7,]T=G(,/&\V?MW[][>WIH:=W%XOYI@AQRNLN+BA@*C$2\(
M[($@;R&$)7:$0K\+MXP\FV[_307$<GCSJH;P'J_$\:C+0ZXM,ENP1F,5R>(W
MPD ;<Q[:;;:Z^ <9M(,]&"KMW*8W'465QZK>ZK7[2D?KL.%PH+18;]QALLI:
M\N!WN2M707K+S9C(OHOY[8Y=.C\7%KSR 03OXA)5%\0%M-:M$54G/],=*$CK
M=P8ZZPT[G9:F=@>C;D?N*OUN?\A:X]_E7B6(2FD&MS:7?KQ9<.^BU<6=<'!]
MI&P?7J1$W]/5?DO6%#X*YTT,?^ 1:L%W/L2IU,19*>+LYKKF=";WU;ZLM94>
MZ_1!Q WZNMP'V2>W^^JHT_E=&2I5(,YV,R3#QU@G&C=!<\^Q@N:&:!<H_,;W
M<"V8&L9.P(0M3H?MF@ZK18<93B71D+,S:K68 H(2(#W6%!4(4QNW55D=L8&N
M]']7Y"J4@\F=IO00&IFQ5IM?F+C$)QZV.2-AUZD"D?'\-!%#W"Z!"9-R?&AJ
M.]^@0W_+?8A[$1LZ0-!B%7R+<XB,P$2_V^MW1Z-^6QW+P$<[(PVL][:L:4P;
M=]6Q@F"H0F3B;VM+$T7."M>@X^T:((/9M^]Y?\OYA^+%ZEP&*3)3.DP9='76
MZ>F]P:C='[6&'=;I=N6V#+#K]*H@@[K-($7"76CQ_!0RQ"=MPG2L8]]"PX(5
M"'DL[6 HV45N'NC^X.T+G6!:O!-,QNV5*=E+0!:AOVZ,(6^A?;/[+U0.:AJN
MMZ3'DJB?P^07PVI(+F-DX?P*?*YW\>D!61!&%S%R?.G+M<P%^O(<H]W?R%&1
MD7(,9!0QP7.FIUO3S*(BR0V PU.T1I@99E,Z+8:!-15;1P$IS45R63Q=ID%_
M1SESHG%WIKF F6P3^\T*PF@KYWH$J\$K@KQ>SZ[I+TE_[<K17Z"1++^HTZ K
MNH)GZBL0Y!=C2_!0:+% .PM36C&5<5MBAFO]F_.IY>OL5[7EN]"Q_R+QC_<\
M+QR> LSZGS_??[Q_ENZ_?_K\/T6U63@%'P,6VK\T!0].8ZHSE[T/_H$3 V:F
M.G]O6+0G^E%@. BC&>V\Q2FWN%W^=60"-EO<#!1#=L6;Q==-^.I=QN?PA2)G
M?M5JEOV\T^J5^D7>I@:]IMQO+UUJQ33A)4.#!=H=9E)DSM013J]$.=^I/'MQ
M!./1'S%[LN31'^L3<S7'F"6*M?%LJX9=%YV)6=UIU^VF7.(V,Z?$[P >(3)$
M[OTT7,;CG<%EF1SY;S73622$]8>#;U":.-BG"?.L7)%H!?MLOMBO[VX=;8)#
M+=XQ_45UWH'RK+Z3.X-NJ]5^!_N5Y5:GUQTJ[98R[ WZ[[RITAYT^P-=_IW]
M:E_+S8D'=Q)6FV$@D=?#D%O[/G3=BX2TW JVAL35=EZ]VQ?]"R^7^OZ#8A[
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M'VDO=+-+5E:TX*M8==?>>HM4A2+DCIS?1N3=R-;G\#\3;VK>_/]02P,$%
M  @ Y$6!6,M:'T"L%   0=D  !$   !C87)M+3(P,C,Q,C,Q+GAS9.T]:W/C
M.([?YU?HO%5W<U7KSK.[T[E);SE.LINMO#9QS^Q]FJ(EVF:U+'I(*HGWUQ]
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M?$*%8E3FEQ6-8"3HX*R%BTL[M9>_3P3] )2D30H=S$\"_!EZH!(,MA[OS6Q
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M>WX:C0=X=HCW#R9[-06C@;Z.MB81=7/URF"M4CA<E$**2=NN#->?/<"V0[(
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M MHLEC]//+\.XPGFCQ1*+;'&D/[\U(7I/*1EJ[DDN!<U&YV$(F,8>()06(!
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M,;#9LZ.GUJ!(UK)W\*W&?<\AU[HH24LF:J3EBYL ,9<$R7ME2$"#KG4(U*M
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MI95>FI'FIXCU DZN4=(Z6EN6^D@BQA@@N6Q2XB5DV[KGU,&V<+>R$LL)E0[
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MO5.P5N'9:S--D86A([%2W282VI"[3\.N)?,Q1QX+[K>W?,V+AN@C'J#PRUR
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MG#?5U+BP%(+^^:>F13*C8X8?=7/.W^.DF4'ZQ\_S]@*N?]A,Y\CJWR;="W'
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M:1Z-]QH,W?X).00-FF.RX0"+XGV92K< "<ZYH!@)R@A2BKT3JW P9IZU=#2
MM+77PK5 3HI#]51^-!&KO_OV3^AJ[EVWFA@\]O2AE^XGBK2WV)7B0:^S+*_Z
M"[YHVO>W^@M>KZ1!28_,L:2$ Z";S7#C'X&2[$T2U+,0':T\>+<"N/N4%>8W
M^BK>>>'BYC$;J7(RAB@1.9%" ?'6,G0KF3+,BIQX;1WT@+6O&,SA^')_+JMK
MBZ.)GEPMYB^G..-?="D,Y8;(6LHT>J@$)^ENM8XX7PM-4L[:\!1E=+7/K#9
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MA\/M75^YZW%V59'W4?6'T92=T9YPR4LA;19(D/B/4RZ;($3.RE>>)XZJZH_
M00&..I)4J=\:<>0&$8'D+)B(1@KG:LO_35;]V88G.U?]V<8HQW+$NZGVA-),
M48N.A$T)YV0P'!<$(PCS-#"NP2F_C^(<1W&T.H3Y>U;]V<8,!RGBT@?@CZH_
M6YMRZVHN3['#00CC=.1,.4J"*]DE%H>*9283=#XE3X9EFVM[^-]6U9]A>;*-
M^JN?'"P<SP^?H/6? 3<-L106?@4??;SLSC@^-1-\S>K("]=IQ51BQ-"NS"MS
MQ!GN"-5.49,<-3'T.SS8ZKU'$6>TB]6:_:B\XBEC@O&H8)K\AOO)^64W# 1Z
M:%8+24RBMG1[HL1[Q8DR+$I&1?#^H?OA&<2_?6R^_(*/7DP1^,7US+#FA2?M
M9NRJX(KG107* L62VWUP]/ @'C?XS;?NUS786?U-1=U5G-7OX<DY:BMT*)VF
M$ ^WCOC"S>1]CD8$)^Q#NX9CL.&&57LP$VZCLOTLR'];73D9IHT3 1<#"KCH
M>" VQM**GL><C+(N]KSP>^@U^UMN=U/]XZOJ4_0VP%7=FF7D.K_V3?YG4R)4
M7T[GT,+L^E!O)#0'QA!K%"*7+(9(;/$XL@F6XWHC!0O#^^4]D!Z%?U;GA&D/
MIJJ=([W*IGO6^#8M"#\;>28RY\83T9590YL0G]$O<59[FBSN7EB_XIWKGGX"
M]JZCN0&VZ\^;\_-FVFT$%M$&;R[FL[F?)N3="&A.5'LDE_222&5P"F.XQJD0
M:&0RR!1KGS$_A.<$>%!=[0/<XZZ$1HQA/%WU/FD^3L?_!>EEPKEIG,=E(W+[
M4NALFF[T>\'/+LZO$BMO)566M%I-/3%EFRD#5<0%+8A6-B@P@@M1.UQD6(E.
MB)9'9/H!TJVK2K?(U%K\YN^^_1/F7<36U17X2'A/7:*21*9Q%.N42+#H6T85
M@.&N 43U"H![%? '[?= C &RR@<3]FT+G_TX_?;U,^ZD 7__S1RW1XO/1KCO
M809*OBO84GA,&'1S)",,J.?,<2W<4<_Z?07],2KV2)2*N?2=@[Z2.%Y+W%Y)
M/+XAL>^P^J7$[54=B8AKWBA*ZT3"S1DN=R68*3EB$UB2-;/!F)"HE[WV0E7@
MG  A#V2; 7+O!QA2-SX8"4H%!>N)XZ5<<JE#X22U1*%_)83P5)G:'<"'E>@$
MR'N$IM]8+. XB+U<"#1X)HS.J%T41MJ<B,U1DP@VTM(>Q;#:M8_J2_&#P+5,
M?)^T=H!S\E*(XTU>85_<%7QH_137D]7'18N>@629!$8S0?T)8BW7A"9;#OQU
M3&ZH:79+J"=(OR&-=9]C[D 3X[\W3?IK/)FL'3VO83[*(BK*(GHNUMC%L;$U
MAA.G<Y!1B*A=[9H< XER@AP]I+'7W!'L?*'X'KY >U6GB(VTT@GG:2#"9D.D
MEY0$4)HPIA2.,H:^1NV;PCL03H@TNRAWC;%9[62850$\?Z/VW13F.^2Z//+$
M75-9M@%<*5-E8Y' :XID[[+2D9*8N5NV<DQ9$9Y$-"H)RDWM)KJ/HZJ7M;+Q
M78N0-<-UYIX#H5Y((K,2Q >I2%26XR),LZU^D]@7V[ZR5"IS9'.N2D53'$N.
MRD:1GEU^P$=TL5C4>.J4M$2H@(Y>!$FL2PF%BX)**IRZ6U-[N %V#>OP0:4U
MZ="W-NH3S3) ?,-FZ?$!JUZL/2 .E,'2 ]YA<EBJF[8O=7:TRX$HY)D+45L@
M7)ARIV<2"::4S=+2I$R35"J>"G4>R6HY!N9L8XX!&/.^R?._? N_HFL_:3IP
MJ\A0:[2E*+,7"7=R@%N&8($3+QFETF;F=>V@@(U@]K^'JFZZNSY0%;T/43QG
M)>BJ*2GH$%(RY?(IEFNHLJ&/0,!QZJT(N #7WD#?@7!ZQM]%QP/, 2\N6M3H
M15ONMU^,OY:O5CE6RGMPPFF2=2GL;&4H;04,H30)E76P5-6N KL9S>D1H9+F
M!XBL? 5^!B7?[N7YY[;YTNV15M B+_?2AA*@&J$QAL2UTA'F*+>:"TE][>W+
M W!.CQ6U=#] 7.+SINM>U%U:O)QV_?)@ML*610"PGA&NLBIW9(QXA0R.UMC$
MM1&Y^D'_0WA.CQC5M+_/#C#=U-:U#NAX_6[\\=/\3?YCMKA9> :YP>DOQHOS
MB]*/,?T*GUN(X^Y& O_T[+QIY^/_ZKX=61X29XJ6Z3 1Z9(L;1\C<2$'GK/(
MN7I?D#V(=40\K7.^=VQ4&,!+?J*(/863.7*M9;E(<3A'1(I[3H'",0_2!):-
MY[6W7H,*](/A@YE_GX=(CPB7Y]#VE##SA&,7?1<54$Q9[A]++0<"-I@0=!+:
MU@Z8&EZJ'RP?E@@#['+>^\E"A.#CGS?B<5[C:M0T?_[33RY@Y'C04D1!E 1<
M;[03N$_WEE#/L^/>1ZYJN[5]<)T<W:H;8X#]SS;NRRVB)_3MT067)#$'I:HN
M*B9#+MT\G1:&>95J'Z,]%>O)$6LO1AM@2[5I0&R86T>6)6-Y*;&3>'<V4+I+
MNT@XER[&F$W2M<L@;@GQY*@UI(D&:+_9SS>]O=&RT5D)G"@5<*-E8R(^V4"R
MM!8LE"N)VJ3:'N7)\6I@0VW,%ZH7BU?*!HSGW=&EGZ;G3==K$*:Q*S;?METK
M]%U:+&[U_%WC])XN3*6HO5=-"=6]\=H;-*->TH!V9\8H(E$_Q#L>B8.<RUFQ
MM:YV6^7-:':^=KC[Y$7DC_;*REP"BETI(\=E(H$92:*,/BB?DL^U(Q+7(]E7
M!%XE>]^[6=A=O<<29U>.U-_D,QQ\*$NW*2W1&A!]HLX8$CGU1 I-<7M !=&<
M:J>CQ^UF[7R7M4 .%4M7P\!-;44/T7+L&LX,5]_7S=1?_^2&'[:Z'.D#=ZB>
M=]M!/4P,704CW^VVL0<+'0&Q>#)2*,6(X(8A;,]("-&2DJ"M6;8J^.H]8(Z!
M4(]$UAV>3]L8IG:IRK<P1>\R=B4C/K8 -T)]) BJO4V$9U'.KY@B5E!*-"L'
M6QY5D/O5J=S\C@.T]QG2-DU]Q=:N,_B[GUYD%/&BQ747%?#^XO/GR>45PO\8
MSS^];KYXW*O-WG["/_"QJ\/I)[A6MY^;MMO +>4(R7%)A29)EGJ)%K>.+O%,
MG/,R!L["O82U#02I".J$&74HTPVP=+V#[E#@+8*]F5L\>W9Y\Y-%4'..S(J2
MI2G*68%4G@2?$Q$L:.N$\[YZ#'A_="?D.P]DD@%NPF[B6>4T]$ TD,]\'\UA
MW.*A[/< 3790_L!SRA)9N?S F19(B!IG.0V:>"EQYM4I\A2%SU#[O&E?='C$
MJ3T<&[;1>6UG]D-[,9L#S-[D/Z;CKL'G_/)-+I[8['+RQ4_'?K4&4V.M5H[0
M+B3+XQSI-!-$YABT$-:RGJYMWS?NWRW9U33-T'JMZ-G.VOGH77&Y.D+' "+Z
M(F9I&H!+(26!IT"RU]%F"%%QUV?4XU-OC'C\[GJTWWKA"3@!3U=@Q<"%*Q"K
M^/$>,+99U/O8\Q '6SLH_Z[Y=M!<Q;GX+AQJF/;,<\)RPED!MSG$ED+<I84#
M"XXF<+T"2@YMP UK;GW[;:.PRG;[W7\=GU^<K[*]:-;>ZT"4H(%(53IY!,25
MG(S1"T/!]*HO^XCE;KUT?TOE3FIO:NALG^'>-Q*%O?;.4VM(5*HX KEDYJ"@
M-'1GFS2*5+MNR!$7=1A@,UW;"/M,@KF9 -0#XH\2#CN:]BF)^$^PRX%*. 3<
M6ZCD,E%2.QQ*@A''<6*ED#,SX'&EW%L>U#=0PF%HYFQCC@$8<S>;7$K<$HHH
M"2BEB#16$.]0>A:CYI)Z [+V0O1-9.QO9:9',O:WT7'MVR:4-0*DV0O40HD_
M+;48UX2@CAAE)AB:B<@"Y8TE_M"7ZJ)*&\D4%3S>:4JZZ:JQWPOW;_7*45*#
M:7< C_1F@.BJ$N?E"(QTWB"[K4[E@(@%8@4O'G?4T4A%%>UU2O/$8-TK(-\\
M%>JIN?9Q[(U0U+/I],)/WOK+[KMWL"C1^J%Y!F_].(TTC=IZ%7"GI$J[-L.(
M=3(3KR$GH5Q2L5]SA]ZO_.;-/J"&*][9=2C/SIN+Z1RAE7W5'Y]+RL&G,2R*
M1;S)SW$Q1/T]QS\ME]7OX&.)&&_:R[,2OGQ^CANYL9_\/I[ ;-Y,X;<O1;Z1
M8<Y1IW ZHTR6S&KHZO82JPSCC"<.=_..-S!F '"GP:U#6ZWBR?)"GI0Z*]Q
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M[ALMPIY=7O_*L@C.V5^^3=>D,SDHZ7'/BPM(:8Z-BTJ % A+P?O 5**V>N#
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MZM2V''CLI2=!@:J:'7 :6.'\#7?(S27 XC1@F5IW ZZ)06@=.)% *9'.>YP
M(SI3#A"Q"S(8\50B//+ND^)#33T/$.BY\%RO4F-\PO_AW)1Y,"BXT"08;0B3
M2087P$E)*R_\MP!\W^[_TVTQ1 3PDQ5Q+<8TW1E8?60:*EEQ 'D.LQ?9@2;K
MLA2.P<9#)#H,(1L >(DCF_ 42_(&PS7<2TM<DH8[2"[RVA<4WPYO']E>'3EM
MMS'M$(W(;KH);SX7@98.@N>)!H7KB+9>$TFM)$YE0"\!_1)<3SC5M6.Y-H(Y
M0![GP6U]MYM9%4-5+AAUW>W7"N:<EXDHZQ*1T@D2H@S$,) N&"L09!^V''NO
M\<-Z;$_7><7,F;O=@OO .+WVY%LI?T-[ZZ=HKG9AIQMPC+->&1?+M;XE4D @
M3B:%&@F1)9ND3KV.7P]MP%[MR6O8;QN%5;;;[5;;DAO>U1V$KK$A!$<L#YH8
MIV34P4?N>[4/_3;:DV^E]HWMR;?1V5 Y\?>",^Y?/8>[J\=O7S^/%R&[BZ20
MD0#N&;>4),UQ_4\YD$ 5+84H,Q4.^  U66N!/T+';N K_X.8?2C^/D6/W3__
MA-G\*JV)C8R(G@MF2)8BE_A13JQ1DC!K6.;:&%,_[[\B_N^3Q8<P?NT+BEJ"
ME&L7_Q&Z%FZEI=#(6Z 95";<EH*/#.5Q+ N2</$*N$ 9V[/_UE (OQO.'H^=
M*YZ6#R'4;SY^^H!<A-^;Z?S38G2>Y3FTU])2'(LY"=2Z+T5D',KM2I!NQM7&
M".NR=/VJ>NX=^@^Z'P\SAJCB\52!;^=0GGWQXTDYG7G1M/^.?SL?!:T\"\(3
M)7%HR\1Q<1*I=)S"O:,ST0BV]Y/W)\KRW0R!HR)%Q1HB.\OUZW@62T[Y"[34
MHO? HD;8,CK@5S^'44P1A:"2>%&:Y1E>#I(EKF^!>@:6TI"JAXT/*,\/TA^*
M'!L+E R=H[,ZHF_R;[B.G9=4HS]FN)Y]^ 3/)C[^B9_C'\\6=RA%QM)[HTDP
MJ9[2LS.283* ZBKH>!*&K'=,NL")XAZG98%CQZN02"J3-5!@M'KX\"DE#*'C
M9B+N9DCH6MXF7_)WHR&E@@1()2C-KK;ZOL.$H6U8.ES"T#;&/I:$H=N1'!'
M2%^"FAW(16T3IVT@Y6; F*ACI+6/O4\L9G K#CP8,[B-+;Z5F*L^,OV(&=PJ
M9G KFNPC^.HI-OY6^)MC,MZ$,KI+KVPM+ E>1L*]\%'YA'[[(*6UOPG>;A4S
M>'2TW<:T>XT9S J<]RZB1V-QX^J5P8VK **2SM9IK9VN?5IVZC&#6]FZ=\S@
M-H8:+&90"NJ"24! "O0_- _$II2(\8I*ZH/VK)<']_W$##[%8WNZSBO>5]T-
MX>D#X_1B!K=2_H:8LZ=H;L"807!)Y!*V:IC#!=)(1YR)C%CPJ51WTJ)?)>!#
M&[!7S& -^VVCL-HQ@ZBIZ_@W9B35U$:2F2\+"P=< E0B-AI'<S;*0XUHSULO
M/5S,X%9J;VKHK/*R>3MXT:I@F'*,<"$$D5'CDF"](=1$X;5@G-D:39F/).#S
MR<9[LLX.L<G;M/2_\..VJY5V-IM=G'=>W.S=>/;GBQ9@53O^7;F= 1]!>VV(
MTHD2*8,ACAM** U2,)J-D8,$@@XIU!%Z\0,?\1X538XI\'F=@+]]_0QQ#ND#
MM.=L9*)D(09!' 6/[C$X8JFQ)<W/*?2.@Y6U2WP.)\WWR?S#$^/8I_Z59/]L
M)OB8R7A^V8UJ&2V+(FD2(L4UDO$2CB)%B4[!52]%;_W>C_MV%^O[' 1'1)5#
M5'AXBHB_CK^,$TS38H7+''AP&5T[BVYZ.2$)I=VNT?B!53F%4+ON]^!"_1@)
M!Z7)QIC5_44SK?^\2#:=P8"Q2[W>.W2DTO;"5XI+NCI#A_;+.,(&5DZZ!XU+
MXZ]W$)N/TU+^?!$H_;R9S6?70X(# Q5H(#PDG'(%5\1JG(OQY]P)X[/@O5(U
MGW)%4D>$>A%+=8 MCL:#",*7/A02?":24D^L88EDHZ1%LE-?_[IS"$'V%<ET
M2%YO#FLZ%"..)<3IY11G1.CJXY?'O5K*V9T^N\ATUCF0) 24=N^X;Z?<E7;O
MCEK)? ZU+U<?@'/XR[2#<:49QF8#;#PW0%M>+?<!-U"$TX/ #A.J5,V,_>BQ
M@PWV3I001'0Y2R*D".@H6]PZNF")]CE1FPUWMG9.R $(\DA,T&'XL8WJ!^#%
M.Y@!/O#3V33]"E]@TGPN&)=N]ZK$,.[E4E) :&8X@=I2O-HBV."TX=2 ZGD7
MM04[>L#:_WZYHB&;8:TPP*G^O\,46C]!A&?I'%4]FR^:S-P&Z96P02E!0 =7
MEMD226<L439Z893C.%XJ4Z47L%,B2WU+##"O/+N8X<YA=K.7<3>1:DMS"KR<
M$"$VJ44B@6I#,M512@1G[Y:"WYD@&Z#\\&]KVFJ 8^1UL,J7+:Q")_L ',B_
M?13<87S<*J;L08_=[;"G.><.T$154.6&4 :-0&,D+I9RG3AHC,(E5%7O)'L@
MHCSBZQZ()UNHOWHA('2QIL_&#:[+RQ52B0C.&/3D,T59C8G$"UI:$]*4@DX\
MT#OQ<9MJG=Q]]/Z]C<JZ;ZHI;@!/=+DB0EJ_8"[=H!$$J[6F% UF<44L]SZN
MU%!C/&L>7-1"U#XO[H=L_^PXIJ/@ :PW ,=Z:>QU,_T",Q2ENY6<?6CF?G+S
M\Z*UU\W\_\+\6I\C%0!,]):@HDI58!N)E3D3[C1HB4-4AWR(ZZ&G"/-],_DX
M.#)D^E=MP18F>-&TRQ^5WV,C&9))DEIB@XPXU!W: !(EB?)@HG%"0NW>,/N5
M\,<P.5(V;=RTUHOY6!P#??!?85:EM?2#S]LU1J,_V$JQ%V\^0WG+]..K9C9[
MCJ^\S$W;,>":>\%:L"8QHCKNN5(&%[U5(I).UDD98ZKMQ_6 M>L<N_D5B_.<
M3%UP2F;B7$8:(P&(I;@B*)G <V6=$K7=A$<@[2MNH38G[LY'-35_+%$%.&27
M11O+)IY3 <EP3RS'?[H#02>S)UQF!CIJ9G3M$7,+P*%.5JM:MJFEX0$<M"LP
MR[U]'S@#G8/>@7*84\\=C+/)S#MH=@\&S^C,L!@5B8*7^I3HF5DA+$G.&J=%
M2*YZC.%>#/W(J>5P=MY&H;5/)M^VP"FSR\,UC>ZK"EVP?HG=EQ:7-FX,R9I1
MIWG2V?5KCWKKL?O?@NRDX::*>BJ>"RV0X"8$H9@EE."-M<$K0DWB1"H:B0LY
MD0PZ2%Y^D?6TU*WG?LNF>KJ"AIDT2^7JHN_5G7BV.2F+*[X.Z #XG(DU8(B
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MW5X;''=]@2!N'",HB$40;ABCX3M?[(TK*&Z)DOG&G"P2?:EN;WTW*V43B<'
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MT.JI4#)%7/I$#1T\U>:P^!R,TN9X2/7_-#B' O&],\P=%%0"X^!=DV3 =)K
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MD9TC29Y/:SW['/7ACH/"<6-R%4//Z!2[0FUQQ$69US==JP+7P7:7%+E\:\@
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M9]/.?:Q]MI<X)1'[&< C_-)($ES\#+3^IW7-X=^)[BO%NZVJ=D1+_B1)0L>
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M*])D' [2\JQS'KBO$SBU4#0URUJ"R4O;]9U/;+6>>K <C%VH-^\=,Q^K.()
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MZ[K_($-F0&(W1Q@- %3VR(Z]<A*XIXDA8FUORXFIF,2^,"O7#6VU%-X,\=:
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ME1M2D-6/-$H9+RH45W,6^\XFI?GX%:>KR@,7E*D_7; ]]?D?7X21([^DA,*
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MPOS=5(HT<?&NB%T<YK3<%&9/D2"GH2]$8+]Q7QX :G+AD=LJ>*TN("-5_7=
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MW!1"9 @T=:;8 [=/O.4IEV@ %:F,[4GD(92Q=NM[\J$K)@*Y')"*Z! PWR?
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M1;;7\-X$*!'O#7I+%EL<=%4[;73))7,2D6>C+] -E5[)>U">ZI[ R+@J.-&
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M<A:J2XK$?4!/1"*ZJ[W&J:QMG&M-Z32 D._3TH<<&::E;-GPXTN1E&;U6S1
M9RDE6U5']E*@56YEGG9-U[.&Q^?\@-K=D9L,,".BPGQ"Z9)4&$R9^/8E<-N.
M)W-4X=ZWB\=EC][!&^7O$EQ/W*C,^7A#4O"BW=MY-\L&JW7Y@IT-4SPANNI-
MR*2<"5T_L87HDVZ2&6K&X/;6ABRN7@PI/=/0HP92.N+@:Z?3[/,]%%=9Y5@
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MX8RU[+BT^^H+BP+<P3-\XVK9.DK8[D.2!>&^T?;6H>*A('=A"5I$0!^;;L'
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M8F361F=GA.F T+FB_0HR3X$+[Y1!:/_68K>;L]ME@SO#@C>NQ51Q_0&P(-N
M_+;6T-\,/9>7+Y$0*Y8I16")^WTC_>BM08V"KJL$RWX+TI!PN&5 6"%6EWNP
MKAV_KG1&7[+*D&NU=)UVY%_H?S6L-??TN5P!KKF<&D8'V#4@/_IU+V"$=<]!
M:CN-VPQBVZ/SI4\*S7R8&O[\F%+'RK+X97<C-*<2?5/[75WI:XS(4(!<[2#?
MB^4H%5>U('1#<#V4#YK_@$']DBA]D4D=*Z>P:^'&%;&ZY6(<2R -QL:3I5TF
MZ>.XYSCY.K3XAAH?R9@8D8%$U"<+6\,%+X96SG=_5^8UP33<G/4O5(JD;TU
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MY:@]D=M8YA++!C["438R&6LAE#;0K##&^!!5R@,L\,Q&YM7R\9M7,OWW@Y7
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MC.4R)HNB1@A'>""-@AW\.<*W'0QZ/0<%H[]&E?\ZY<L\VV1/XYOX=U!S=U
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M0,S$YQ4C(1SM4Q(IK#:1'KY"PKC92X=6CXOK9D[&) "ZU[7M0Q)-"7Z!^70
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MDWJ63TU8^&;VD.T#I^?&C.5J/ =]UL7ZGGKA2Y?CU[IV.!-YPW6%?'YJO+\
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M Q\4D"1'MC[V7SPSQ2'+)\&7&"^QO4T$&_Y@.Q)$[,1]A^ZH0[S_KO2N&H@
MN@A&62$BFO4#BYY,6*X:!O.E/ZKHON8EZ7SBMO:\Q[_V9MTT)/K(M(..KC2[
MT #O:F'D&+MX!SZAHI8FEZF"@9\[KQL<A+1!%M&NE, )_ZQ%7#>ABFB"3^L\
MA6QEPUL0NLKM ]^Y4S+]&+90O/&KS\SFA6*76EQ=DLYE65X1=L[[_&D.H"R,
M^HT^";4'G8 ,0%0%)'%;<*SJS#_6NBZ+KFD*.YH5^.3W[U@A1K/50 ^9:">,
MX<8\UJU>=*=&W>AL\@NS\JFE,Y81C=U+BAB0:F28F%(WXU1K^H$'VK=[U'[1
M.K'O<E)MH^]#&F )X@">-VZFE #=W,*J?<%DK3*1E&(9#=MOY7'6*]=MN_%P
MO[_':01=K<6E109=Q):*#UJOHA1.::<X7#%U>Z66N"^;I)&("J%V([C(_#@Q
M[ ZXN^NR2FT.9^;'H?'.7.2E^*J>]]*SSR,![)\93G\IAV=#W62FDC&@37:<
MYV-<37P4-L/6T2EZV["AI:J674=<435Z^@[@<2..S>HH8'1MJ# B[%S=.<_=
M ^B9PIV/XD,=)AVC<.$\]5:['=)L5N21-?4\&F]"O:RSL9@W/JV_Y KA2:R.
M>J=VZ'KJ+B3+6IPN/5F"54')"-PCF6@8+H+\J@F7]VM*4LW(^9F6V"+)]&H/
M-]FD'_2Z'?&DN+/?F22IES1I10/ YKVG>R5(+\5C9E6@:7.7C+3 R__-]9W_
M,T%/ )M^\[KD$R0%XL&3FD]3,W'*I4\3#;CM7EP(4>\B4SG_);[Z<?(%,0B7
M,Z,R]I8C=T=$1^TM;-[)/H_B75/K$AI\&VB!!M7Y1BBTD&X2=R1\I$1:FBV>
MLVUURGG\/=I#L+U5@,[.8KU\%5%]MJ*@[WK.F@ISSSF'OD:]BYL")$U!XGGX
MUSXYY#/A5@E@4QJ52<-;'L4>'C-) Q31 &\A9:@X,ICR4>T\2<MU4B '.[Y-
MIH@(1P/+#<H/?R[P5_+G19Y^_C36P].*\'">[(\/;(,R;55G0"\3DY#(@:*F
MO!Q7#G^7:W>9' =ZOWKP59Q*QQ4V=+F,$!NMCS:"SVAQW^LJ0/XA<9!EB?:8
M[=!9UFH<(JQ4I'*HU'+VAF-]TFON\2K^WQVQ208,?%D2BVQ$<5"G#%&;RK%"
M9:KY)(6.+"-/A3' JNYJ"O[6%*3LN&U09,PK4)+76D?@4OM,-]/>6"A4EB36
M[YL;WQ-\2/:D(#3$H>V_*;GR"R&>BH\&[PYM^M9:R"8OE1_]!.%.MC!S*C_S
M2ES^,[M["&VK6)XOZF8*30Y/.S!KI@'F;(X8""R4+T_QW1M]^-L'1F_/-]OS
MI=M^C-58NY];G$#R@"J%!>V3V,@ZL+F!3?5LY/?4JIK1_& &HW@#!>XKXEM[
M4[>[87=9@A5QUE3&FS@H1K =QD34$&0CMFOFCG>?KM1Q<*G5K6BTX&Y8^?V$
M*H^C ;H3>(A^=$G"W:R+19R]!\U?Y4E9GIH+/Y*+!CL^Y3%@GV:;]1!B&8Q/
MV7N38CDO(5X!^?T0[0N+]M.PJ_Z./*,UG$3XX$?:AWKK"C:G$)M($!9T34$\
M0_%D CDU&F$!=()&]>!CYNK>-S_A4^_?3XIIAK+T!B6SD3:M!<;AO893ZU2#
MJ2[T_C"*!M#]!A>ZF;NZ9-<;F#M"P@8V9&I92Q,2)^H1;9^AC&1W+'0<08AE
M*VP3?KU:E<%OUWMG9V92^4ST44C3<\TUKEG$?83G3 "R$U01#R]9M3":7:W;
M+K"9LM%^7:E]P%Y9?A1JPT6^%/JWV^3]R ]?Z$4Y5=NC/V$O*]:\NI2S?GHC
MIKMT@5NIU!5X EW+:NGZD(3!2(QHC:JJII=;</;/9:#89(Y+*0W _)EKC1K2
MF%EUSJ2D5>GAS2-O&2*TY8T:43'M8=Y-*&NN, HN,;)'^KR'(G,H4M5:16D
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M.Z !'CZ'_^W-+(7MJ 2IT2=5,(H:^_#(A'J^FSXO81C8T5'+W\/E)/Z =L1
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MSG^Z!8L*4+]@"PWP =KQH!>Z/&;8""1__A\;:",J_!DB'1A( URE 2(3/](
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MFX3^^,>/DTY,QR*+LNZD+[MF*XU&?^0?V7"TBK-1UWE8;?.\3M\2;MH>+=&
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M>]\/[SGO&>/EP_]#,N:::Z[UF_.9_V>NK)D^\<99<M"'QJ9>*L\Z^@E-0W\
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M/<_1^@U=(9(F<X/EV9;>0>;8 >DQ_X'9#3<)5%''05:H6I4BPQF>&8K6[V0
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MMGHGKQ3R+E%B*VR71MP7VG]53TK1Y44I1O[V8'Z#8][16TEJQYP=?N#A)O1
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M;\VVO")%#>:=\#KF/OX2L*X[=?;XZ+W5Q!""/A]R1. <H;HAON*QB;5(N6:
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M[%L8JKKHU"D:,VY/NQ^R)Q!)]M;_P[P/PFZ&_T)M:L!W+'6H%-0K%7KY!P:
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M9&KV18<ZJ/L#D*EL7WJQBQ-5B5 W.6:<-!N8JZ13S1NI/R$L%[_OD@UY@RN
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M;N(=;GI5I'IRU+]6&.1F;41Q0<@=S!69%&5R;AT78D+G81#%O$.LW>>3;;#
M:LKS ].<U8*=2L)RK\$A=DSP^P.YMP^"@63OW0X?"V7C+Z8TKOO@$(F/2B8R
M7I,Q6%JE#%D5$;$DJB,;:O'$F &4IC& 8T2[K_3A:,C:)8H= D+6<[B2\* W
M[#GU2HO1U:ME$(.CHM,/7-&$)V(VI>0YO%BJ5H0858TE5>S/(VE1X.PVABSZ
M,M2+")W1:<"%[1<Y=2MNFH]R+CC%8#]/H<IYFK ZF!L'GB0;U>I-**6%$AG
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MO DD!JVR0\*0JT"V::B+A*CV9AG"O>5Y=;%>]S;+S=0K-";V)B7$?\_V,J7
M,X<_\J*EG>P^I(JQ??$ZS)\<Q41(T$P XP:2TCB*\>Y%35*W#.P!=.^;GO]S
MCHR#:!"B.KGE/GKCX*5;>$6)V..H7<68/E6.PV$_!3KALJ)'W#&Q=;:UCTR,
M3_!>=#6N 1R:<WZM]*&6!IU&B3=;MS![2*B4+IJN6=[\/DHT2L_>H1X$&@@F
M@S^CEQ+1-%I8V\RU3;E0_ZUZ(M0/WV!D1P5(CJY^ <W'62+/_HHMP-_"(]'8
MGR!')+OK]8'5+9.7<(>IZ^\68--/-.I+-VB^F&Q'7QM'OX$31 S/V#[.$/Q,
M&UW9!B^ZN?<X,0\+'K2"=F1](5B#08Y%F :A9(GY(S?+X5YTW*"XV-#<W/W8
MZ_!YJ^Y-H4#3:,4N6V>]R_-%CB<PG3V2V=IR.3-=>,DE=&""<\#B<D@RW//Q
M/N$N<VN/##0T<"/*1T=D/;G3J[K*8TZ=R[I/HO?#Q57IJCJ^BT:H#)#[(*,3
M/R>YM%$BUVF&/RUGTW-Z<T H,2;G7=M:J> 5;1$F+0!=MSQJ# (@/.I>7OP@
M(W7%N:BF6ZLB\H_D?=,[87/!O?1(3]=#'0H3"VUX9RY+G1V,@H[RM"<O?SKK
M<LJK@6*UIMHY(\Z:]45D"TU.:U 4C4U(> @?X57+(5@N B:=[73C3Z9#@DY9
MY'2.?L\5??4G)ZC^?39P<<@BJ$:,X%&M4*(DD#\@\R[@.7M-^4>,UG7O0Z'7
M*K;,DG4]EB9;-545-0A8V>KOUU_N*N[->)Q-8B)VZK!HC%2GU*>STF3L?F?O
MTN(-BZE>I1/= LNIJK+/^M;WL0(/3B-OY,=*3YD\,JXK'"L2+A;(/;,^(Y40
M*BME85\+1B)'/"?F#6J0CRF,6QL1H#>@4.N;0[8C;A1>0L@>FU7>BD%Y[-X:
M62OUR2 R\^9N) &,[R,P_;L'[%,(.R$9V[;E=J-K??>#>82D^)ZA^U1.O/D]
M5E_]RN&(IP!:V5R. ;F"SR3AIWXNBR2'<B43&CJ0R3F- 39\B,\AHLXA=RIB
MP;(2U=#K6R;Z1?\\>5WQY(F\H"/J;NT/<J*]$89UKWJ<=YP*"%(;,75H<,O^
M&_(/[ XA#(JS6$:$PZS>?A Y#KJY9RZDP-*C+OB""JA83L:6-C?FXRT)9B4P
M=@+/,OH"(7RK[\1H5&5(, WLY\_4>*"9J9/UH.T7HZ@"(\K\V 7GP<12(JNS
MW%";_VRN73'V(Q\DLH_2]#12I-0KY_]YMJ/(Q3RF)BY_'K+PH@;O6RYS2&N"
M#XNJ@]T.X&YJPS"3@;YN[9M8* ;:,<^S;!)N/WX<$&RP,'[Q4%*P^V+V:<8_
M)BUP]N9'_@F8A9P1%[^[B[H:=Q=?O/\4?CM#FHSOQ@';Z2(AL4!VR68)_ZWM
M5UZU>K4#U1\%;@G>CKU)!51-SWD-WO(^WTA!:_0=]-C<*C0T22,IQ9':.V$F
M%O(EXH^XC3/Y9(C6T/X*,JT[J!\@A?_NLR;_9YOB8@2<C:2!19O$$I\V.WU]
M9%_Y-:GVN\>7S;CO2Y[W-6S%]L$?T-Q5J&AK(%&M>5;7=OY)TVB_?39H 6*H
MC' /1\L591."5IITEM%1XCZ[$CT9\Q1_O^L)72%'T-A"C>W0,2:<-&]-QL-K
M^L:ITY1H8C,7)EI=PUIF2ZLO=$&Y<66]P8<$'C,7$VBSOEN)0X9[SWN!@_%^
M0^*]6W6\!2>,MXBAYL>G.5F8.>N_E+Q\ ]G7A:KSLMZD;_IJ['??_^=XRF=^
M?E?#BB?E'N9P8+.U!"MX146XQ,&O 2A> BO1S%\*_PDG]^D(>FEV:[;J?HG$
MV@Y+-T.;=$71\^?1'7QUIXEZ%\^,O^2+)GN8U!3_\1'0Z].;' [(&%5C;X,9
M$]:6(!_,+?T6I''LI='QH:LMLSF_D'R^S_]IN+(B>.7*@=I3/5VA.K>?14VQ
M>Y&$]6T*4R;VP\+Q#X0VSNVW:IFD;5DM"_(=]](CT)(L;40SHEW X4@^02+H
M(TGG:M?/HKJJABK7H!\/XI^[7\ ^_CK'6.*C<\GZ>T NHUW\S=_*6I[JSNA7
MXW^S(E<?GX]4?UVH)4\7KPL;P$E3F(2P?LNEY2K)Y.R?_EGX^=]>J(C=)*<5
MF[& >$4!.W*2;*ZB5Y&DN<O.GUQ-?82RAOUZL*P:;!,;A2<0M'"AYJ'JE6/[
M2LI%<[]B9T8A[U\?3AT9Q?&MS('/Z9S7:KG0'%58H)[+Z1)7+E/TJABEIQ7&
MCD'R4@%O@>'HREW,YH+@N'##Q#0]<IK;4"6XK^"OA9"^]!CC:\U5ASKF,"H
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M'6_%W_66?UTJ_Y;_X4,Q]S0]Q0=W,W[2,N(9D]CO9H608>M+Y(PCMC&864&
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MO>H X:6LX)NZU8%<(7>J-3$*Z_/9/FLX7JYPCC"YB-4/)ND9:27,!?#E*2J
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MSEA*M^DAR2+7]?K<PN:B0PKLYT##EP4;51YXL1X=ZV YZ@<5\ 8QP[I,!71
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M'XUO!1V:9_VJ>4-8>9N&645 )RCRU.\>#V-/.>,NO%$Z%=\^QZHFE<\''(,
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M%HJ/#-_P/R[43>FL2)PPF-@Z*@^PMY^L29A"TV2I2$,#6$F![#BDFZ1O22V
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M*9-Y?5N&T.3B<C:\3'[\=WX+4J2RZY(NN]'][X;T]P'=8DN>>%&I#G<E6[R
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M*_)+E/ B?:OPZ/<OZ,BII_#6E0NJ9J&6GLZPK7T5/=PXN80$PX!PD9CNF)S
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MZCR(R @Q\%KSV*IVFJ]>J[V[4U(8YEU0,IH4:SNQ104 TNN[&.+C%.[U>GK
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M\0M$@.<UBLC<Z3[8#5$9#\O#W-B($4L"8G->X!$\@]G27#3!7'8BEX(X -T
MV0,GF[3(!<I^%2\LQTM#\]KL"L@U0M_.6V0,/&R;.=_-2S$]BJ Y<"8-@TQ_
M69H7>&!>B^K976ZIB7Y1O6[J#^P$_FJNIER@)4U"R5U_M_B""$;LT#PSJ$MT
MN69CW#T+*]*@S*WVWX@'QJ4\393W))T$='P448GD306\<UZ"12!J;/CE;0;S
MYF1O"8I#K=Y=#]#]1+]R*>Z#IAHGXH]4&(47 XI4ILN7ZNCG4QUL/S8L'RAU
M*=U_7'9.T(GXJ]->O+..]Q A0JX#.=7#7@##J_L+K:YCX]_'^>3WL7E\LI?R
M,,A]TY-[]AB1 EM(IP'=Q];+6&74!8B^DGKAIHR,"Z-7SV3%R?RI0;6;3/3'
MW8HMCK?ZI3ODX2C&"<VF:<)F$]^5PDL(MA14@ K<O'5BAQ LLX6:&L'ET^24
M%8;RI@36?H<*N' 75SZ:.F<V3>E=<;\_7;VBTZ1RYPU8F@KHF*4"-I.I@)4>
M*F FY1@1 SF%A@&MIML688P;_ )O9V,Z.,KMV8>[.Y]51;&]UMX5^TQ[LN??
M\I(/F]I@> -+&+;QX-71[=_AI4]6H;4JRAKB)JN9#%]*A]> Q)O0$2H ,VK+
M,7X$QVNBT%R4@18K V$:U;D=2+\Y]MC/[;&V/]?*BK>G FXI-U(!E0@36MKH
M(7;$W X]C1E\[>Y<@^F)](4S63VF.'S;D+]CF9<0ZV''_?JQ0B^B?S "M)_<
MCR!R'QF0SRTV8:0+Q6VT=.43!)%4P/?'XKZN6O3Z3]-D&Y80E#/!"21V=32Y
M.Z$$S[/HG\I]L4B0\K.^/M8NZ>%--__!HANVH>&A*6AP;*-M'8:C9]%A6#S8
MYP5\JHY3^;IYOS;<L*__B#V&: 6A=6=X'5$UL$,M7DJ>[,ZX\V%OK8/824?>
MR8<M:*)D#H%3-LC!/V%6>#M< 7?SU'#;:;H#1M5' S=5FCL=04>C3]E<^KG"
M? 6P#W3GDOU)1X>:-6N\_')F:1T*32?U8A1+*?E0 =J@_HUI68M7IJ6E2QS(
M KT=W9WMKXD-)\LPU26NPY_7H#>:TWK@^Q]#/(G<OO-D]K.A1*((28KFG!J&
MKHW"GRHE2K*\V+^@R3QUD[S\F@IHM/(<TH"<71H\T56I(\<I>E*BW[9<4M$>
ME$Z*[.!40#Q<1"UDV4JRQ)OD@Z*?&$/+=6B="'HB%Z.O>*Q?GV :,1ZJ?-TE
M%<N>,W5.Y]G,LY")7LHU,JKU%(3+!0EB^#-0?#^INA?X#OGC.9+EBX?[SZ%2
MUC<'-Q>\QLMA;8^:34OQGCA/>8)U4AM3:8FZ?:CX([5]!NV5"WR?$]6.N/BV
MWM&0*H#RBR:]2$:8Q]-=A-JP?#RB,\#,I\N/7'QZ5BBUY_H-\QEV8S.WW>ZE
M5;_O["MV+Y[X"K\OF1?UK]HDD6I4OI@&)R(,F#4DG1 !0Z[(@]\_1T$+)6:J
MUUJYG=^TLL]O$MYU7+X8T[[/L4-\G_M\/BP:B_@C9CPJAYCVV#,<*P=5'UG5
MC DW(?>G0#><9GYE6*W:E&FW+=NGD^]B[[Y7OH[1:[M+&*,!"2P">?'\SZ2@
M.X(BCQ4T3.E\6+\;]0JSGX03S^&S(?I$#]6J(:2S.66TT61I15JL/PSOX&4;
MSV12R##7G5E^P6:.+*_<[.LZDL+L_O3XR\NR--,#%24*PVR%-17@0E(<ZDA\
M<;VYR6$;[/N">>$4:6L7_":8$1%.N8CGT:NZGXJ;DLB)O>3PR:0Z5$<0[@.^
M3@6TF4%Y9S?G&#&1<1+77.R&)86JFAVY]I<R7#15IY,]Q[I"Z8A<),=AZ&T(
M/68TM2ZQM\R%PW"C,;\ N]HAKGU9AJG)6N19,&_B**\7R<(A"/HSDPK@@3*&
MKOD<^VBNX+Z6X\%8_:R>11#3QISD;SD^5K,:O1TIP[H0JU*7"Z>U9W6KEB]K
MJBF')5JO=0##5!GP<G9^S@N#S);K\L<:EEZGG%QTW[)5WQ'_T[L9DMY'SFZ]
M[8*BH[!NS0FW-L7/;8H%)!A$O9]5&;EUY4;Q9L"S+ 5 \O>_Y7_?0DDO\)G8
MP?8YP7%20,A9RF<W+[X"N'>JT71S%<#RN3_@O*$]+U,>P8Q=U%18-U^[2<.2
M EOS'-TK?_I1=*10+D@7M[]+0A" $M VPB/+M)VVBAGM[/0N/ZOW!Y.Q6;9:
MZ.N(L6A2[=^?H@)Z-P-[*"UR!F31>)2Q6S5MMJ>!%L#%76F"+4T4$DI]/Z,#
MAX7HTF[^JL]1U@HQQ*>NEX $R$RW+JEO?&)!/77;CUF:28-5[>V<,,?MECLH
MJHSGI+<KN\)"/*4_-ES<_([,!1I8DG4P/5&'<.X7'(ISD;!SQ7GS#V_6-=6^
MZKV1M4# "11="QM0MO1N1Q<"PS6DTN=)K0_:Y7B=;K+@OR#V ^K6\%EF1,<7
M'- ;Y$_0&VI!+'VI!).TQ%VN:4'S1,Y@WB)$)F@AB3#6U?-:F9;ZL[JY%%O-
M:.9AN,T_6U$!&A+!!B0VI:7X!,S>@@<";13$@T_K_$V.G^OEO*I]D5G^*5^:
MAPGK:!T?TVW00AJ<R5-9&'/W"9;QD-%3.$J.67%&<:&E6:^29]VZ/\$C9"CR
ML0+#?HA\TI$^&$-J#H\^KKZD;-^XZCE4Z-E#&,6@POEY:K#")/:+8**UF[@_
M=VLNI&A)X*?VM!TA0G0^')HUL1P",:O&T\#K+-L$R:BX22NO:Y&GR6W-\/$/
M1T8>57IACX4_O*0:PE#A)D=C35S+3DJGF7_ E;)O,_?12XF<CA;FK]3H[[$K
M_.C?Q+OX+NNMT42)W4(^L&PQ%]>2!^^G\*]U 3&F ^?&MQ;FP_W\S;M6LFJO
MQ0W.3PI*<QCM?/I-.=VBCC,=KY#;^Q/947=5O]7\4*S)L'-M.:H@"H0=-<*;
M#="(S,0SUM(S6JI9!M.O7F^C]Z2JZ6[C.__"H.CGK=:WL6,__(6"8Q'EH2&8
M4O0,Z@)-F95+M=>)51T;8$@H5[#.W-TD([S2-Y*HZ-P]O56B<>-AM0&6-."B
M"EE4ACO)0RMT$!W[JC=I0^O1QM,)($NS3U&S7<4.LL@N:A!3EK1"!8 D8*)D
M)<0 ,UX03HK_NV"\#72C G+Y47I;A0I40)!MS-$];U-*_P$L^\0>*RH726%(
M+#AQ90UX?UBK%-A[1ST97# G'JF6?+\IK7/(9?]%[;I3O;O1E?(E4WIQ(L40
M,'@3)4T1I@+ZC&511$XDBLS.&.),8K?O4FQ-QL#;IU0^5JD5N#9FD.N[7PGN
MC_AZU17U2B28\'\L51O+#BMHS$.=491CYWTJG;N^1P7D\UA.D-CL%\S:ZZF
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M6X('O)?RUJ(R/KXDVI*9FEOO1' S2#?NN?DQB.34,]__S]_!^7M2AIC!>7R
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MN<DCYN(A*:0M@5873.IK,V*[E"J( ? N3]@Z4HY 6]D=--9L?')">9D:?8#
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M%<7G""19]FR;@/M#''EXN[&,X6/BFN(/JS2C>163K^T7.A=E:398N((JGN!
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MB^I!,T =\#0F1 3IOZ U*9V>J_X=XUJM=4TY/-&Z+^C91'L7A?];]%AQNEA
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ML#"UODG^UD0+'@%KE,.A'\>9X-41-M_7PCPI^4>ON!,5V=W[[[<>JFO";XR
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M0/X,.F6MU2!'FW.IP./<K\:]<6H26#*)UZCI*4M0<!I:Q+)\#Q%7B8PY:L*
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M&BE._9ZW,E-^SQ][0U@D;%F_O(ZK_4R/TG=4"ODII:#Y*AG8+*-T%Y^1F>_
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M&K-;P8WC7]7O56@X_WT$5-47!A$%X>',7Y V8$819+),ZJW?&>15GMMOE6D
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M_;X%-X%1>-$LE[^?2ZKIZ;)ZVO+@G7S2Q&X()4,)"(PXL_#RCP*29U70,)R
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MD@QG^8$A76>/PX? K ]ZIDIBH^528,8-^>"\4A3"L\9=]V)UU5M-&P^5%^R
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M!1'B+!FT\_1#VJJRNFZI.6R^BLP<BL2$0KQH &672S3 _%/:L8B&$5^A>6F
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M.GZ=++/J]*(NK][='"R<ZT3N<1^5A_?YC,LXS(SO/5G/:IEDYW*7?V;U$YJ
M6G"EGB%J8$ A%3]PU*B+N8/I![K)MU_Z^41J6T]<,WZEQK[X+'==^Y_M#"0'
M3M\'9@X)]'<Z/VCU;RFKL1GR_KM?@)S@!/\=P/3V1_9$)AK@G$C,$M!V2.F&
MJ=:KKY$W4AYQ)5&VE8#D<$7'K2.1[& 7:UD12ZF1/>BPK=)-&"(P>'-$Q[>
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M0GU"?4)]0GU"?4)]0GU"_3]+K3J%C)!EEM4U?]L]BP!+/]D?5" 9@&H4=&D
MI5WHO"P-8-90?.=,,'4"#R*3!FB CVB*P\GUD^O_.U]OREHWPW85G?7ZVI/8
M[4FP\X35N_Y6=+6T^;<7EC[!"4YP@O\" >S482.#=6!5:,<$=L$^U])/+[[X
MPM<O M'8/<;<S%>6M0JRX\7UD/&AAB-S\N]KSH+K\?[%4?M:<T4T0 RI2 W2
M2@.<72.FTP!,3 2GX5+!I%^C"K*2:Q*!/CLH9H8C'^<2&@ @O4>Q"<O&[=MH
M[E'C#E,P):4ZG&-FX*-7:MXP;#H>1&4';:XNS.H+-::K[*!)$CU%AXUKU*<P
M#WTL#7 *WL<\^7;*7'?*$1.KPZ.Z:E'Q5222MW2]+R#X"?\$ZBW3:7RX_LI/
M,&BC8,[U+5=@RTZYU=OM\:D/V\U(5U*J&IMQHF_K?]I&R&ZNWR@?D.KQ@<,G
M4##)V37]>UI ?.ZHP;O"SM["\KP4D07Q"2]"#AZ.O8&/ZXHC1B^(.-T>T=:H
M&-I$O;MZ^.W"$ODW<?V7_WO  [@=I98&6!JEWJ !4/'0(WGY];+0##[7 @,O
ME\XT;XB.@J'%VF8ZS".[680&"-2']I[!"U(BXZ!KTM7^12_"L_8=?B=L.P88
M7V6]LE]\O\S1B@9(#PR_4_ZX]#\*;"+OT@#S>9D['ZBL-,"/%YG4^'Y+[Z>@
M\9*V8.P :LEUT15HT&[8848N)DP7@XN.DM7<0!Q5(MML$"%\1E2^,B%=^_D0
M7%0T:ZYH10M7G[WU&M![_<U7D1404=!XD[2X_4FF65[WVE_0A%.18G(5\!VB
M=O<T X(&*([!1VV@>!V$1B+71M/R;'E,O1IJ,E+WQ:I-#=(?=,GJ.V]7)X'!
M,807;'H6JT_^PZG<E42)Z?/;@$$GYB]DTRRBFV."^%G?FKR+)5K?YQ-8[LV<
MXB\HDTI+3UQP4K/<_#"J+W+^N7*/0J"0_85_]WG _^MH=%DLP-KC%@G^-( &
M7JP<Q3UR/4;*\O[9@W<%62)?"YE?;]9A4PJ[#&(C7TS?UH^\N2SX!O8F&ZFX
MKTL424R_N%N>BNM:WQH$W468#;?>X,N[2G>&>B2]#J+[QP7 %YH%'(RFK)HN
MKGZJ%NHQC-.WB>VI>,"T6BY#L7SAO]&T3"SL3HT[VIO9';?Y'%_GGTUM)"@A
MLE-*?]ZQN9$0\OC,5S7YQL5A1I%$8B:>YPE18U[4MG,*_\W>UT+I0XES5E[
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MR#W# 3;VGD4X6?4NTXO3'?X+W%]>W57=DG>L-2[+6""%9-5=,JM16Q#T9I%
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MO[CJZ^4G9*$ZI#Z:P/OP??8/P +^B.)*K=.7H""(1 +7CQ+'7IU+65\2]_L
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M2'U< !W@P;L%LD?Z_\WT95,/HJ.0)D,'5DWV"BE:1^#N3]$4[F6:1<$RK>T
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MBF.<WJ5E,ZVY/%],DRS;TL\/=A-2GI5T-#]P0<U9OGO%\L(4:6@_G/#<?<2
M 1S_%N_;@L)J'.!0@3#P@B!92*S>?M*O"1_L!KRCNM*%K/6<#-ER['IW-SH0
ML8#$\\^%$AGRQ3,7=*+KG4)+.!Y=G;&O5_ 88KOQ*3,#>VF>1[$(2.O5?E1#
M2CR(G?\(^4MS@<3SJ\*XGY2D5,BLNX28T7R[\3AM230M<I$FUPEO=/06/T-X
M@9]ZB@-V0\,/@+3CM:F7/P8'JO^UU,W%\-.DBT-="?;RTB'W<&G8JJO!</Z<
MYE1U:=WJ2&;(D7UJIH#AE'TB8?:H_%!GZR,6K(UGP":ZF4MTWO'ZT?>LT4]/
MS&*,)4(H[I\HHY<F?)>^/_2\T-H/VZ5.,S^^/!M?@5;#RWQ=?],Q*]O0'+CH
M\%W\2-3KGQ?NGQ^.3TUHZ^A"GO@/PZ\2GV#-,$&RX,NP:\5>,1W7.D0/^AQ
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MR$\!9)G/HX@"I6#\C&>*=;)-UOI8O3_"[GQP<(DF8U-I"93K65<V?5@1P
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M^!2A68XALY#"_2]ZR1G'Z(_X@XQEIFU<.-=7&Y7O]]RZO^1^SF<Q8KV9SW\
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M@QO;WE9?&;_<R+Z95Q(WBCR5[GN=0+>#TD*5@ERGI,!D2<BW5PX!3#/I#C3
MV/H"']V]6KQ(J5/VZ+T7=;6)]M%T>9J&W_GT-DZA4GI+1F=+.4*:<P;+DVW,
M#A$FS2GE#[MN'(T((UO+IKL>P45\0,Q!],0P;&+:XG02P:>BHO>Z/%@]LY8U
M'EEN)<3DM"9Q$$L#.%%\Y]!A$Z;#Y8]XFY>D])C8'@QTMI<$<]*]-;1]BQE-
M/X>+1KPEB]MECNT""_S\62QX=[:"?B1L#C3<(=( >&&JD-_$1M+%01>U )X
M[=@X^8303V^VKI[:H,M#P94Z?ED8G.<]2/1W+A^@V-1*)_\YG,S5ZI8O&/#(
M<)Z;1PY:O<;4H9D#^'V_$^%/\#JY[&G9%H_@ >*'=B%>0;F_SE1K,!P(L%#;
M:Z86JQ+,,-(*U9RGKU>&%'$&R'9&4>CY]S=GSFNQCY/E<04WR^Z/MPX4)&,
M7E9%O^$UU>UHT?I78$X:P+D6'&89[#QND^F:VOE3+H4WW&U'[HQ#TLMGLP[O
M53=MAKR8:B6;"@R@DI4#6YB-0B3L*+!<1=;Z4<J++YC@#L%,DNFC6F_,/;3
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M8^*K7CH]8+7:/(^B_:8MF"1%1+6H"8?FN?UT[H &G#X.DCUB'D49;Z_>T_&
M0<X00LKU05&V0C&R(2Z"G^:',W1 >8H$F6:60Q$J^W'^XUA)C; \C H3:G;P
MY(S@_(I^L9E5>5SCK[\BTP <[[IP576*"?D)OF;3X@@!9QH $&A22*Q]\K<P
MJ](A]_[UZB'&7Q4Z$CRG(A9C+LS>@%^$#'(0Y)([SM59O[>&]>=>KCXZ1 _4
ML\V+MG7)?( P1R=&^=;TS+J0XR<$H_4$NP.]]*[BU&9W5/HT<5:$3]7X@X]L
MMS%2TF[0&\#4\0#-SJBG[F(FD9<\Z'L#'(#K=CO=H3&B:\"O:::DLH3-;#3/
M^G+&W$A/53(PF/JWN?7.9S/GBLVZ@NT<DI4!*?T<7F9V)ER+HXMGS:C]E9V\
M6\314%)4)4CR^>G"& \8SH#9H_R(!7_W5EC+#(LW1>NYV8R38'M<6HE$D@[_
MW%O4V[TT.1C$I'1PT\R[9[+CK&M Z4VCH]3#EP=B%CYR"C</7%T4:K8A N!F
MU87=0*$U^Y>Y=$@K1<A,5V%/WRFR,H8JN,8,R1P[1/)KK*=<_&-'1^JAG-=;
MCB!\%1CM7=-_#>D#WCU+/(QG9),(WFC3%MT![G&\(_/9S8*8QE:. NWLWVGY
MRX8FT@ ?)R81*^IFP7XD0D7UX'['1IULKL7DN-4?!^7DVLE',?3:IM9,>T+?
MCAB.4IZ/:3VZ<[E[XO/B^FZ):;\O',<23P.8RQ?L M4LY(P^O"FK6)E('*F_
M#%YZ116GQ 7>S;8L.U+*=2O\S'53CL??:NRV5"[>SI;#UT4S9*@"<[,#ZLEX
M)5[\*5+PXH6K>XH''(V(J(H9H$)DM4B%C;I1L<2-:RR?)7YO>HL6-WN\L:\+
M)I3T*ZC**% "#!M*W)[HD!07R^2O)?X^^R/D=A^GA('ZSTW;%][QLQG!,7;)
M^I,PF?Y5;]CK@%RB^=Z.!@T@2_WK;PL1@-=8J8.M7%Y40/8'ET.>; !OOQ %
M7,RI3VX$E?1%U#V" J>SA;0$RC\YFBYP?'LOQY*D!N,,WK11WLC"M<T\29UO
M'?]\VJ0B^<^OF-MQ2P!&O1CB'\#1UM:Y &@K-&(<VE3/?&-K7MFW\FQV8;S2
MR.>8'^D>68*B=#\+O>J"Z9D$"#$NDK?7DL9?NX_7[MV7[Q5N;>>A)']NVU>"
MP@(D5W--:8"[;=F4J!_F';&MG3L.(6XJ/\GD03*R(^@:F1.OW&S]*&\\NS68
MEW%=2>8BC/,3 ^(GUV;J7@\/H6488T)G\G?CQZ#%+]/NFH>1Z=4OKH7S_:K>
M!^YEIXTDSB.8VC7L-77O#WWOQ5@7A#=_NDT.W]#VO2O:49HJ1^UQ9XM%8=/V
M=L$X%HDBWQ8N9G-]A8@T57@8SK,<D7?8!7X1U G:>6!&1><<YP.0)404F(4&
MF+,BKNT^B"JU4.%@CVH7:FF9%?"X*],PB1F8*8DEQQ];&6H53;#<)>I\7GF1
MZ/+4]+/]X/Z3CQOXT.OIDD(A;PSPGS,Q/?+O*"7H!>$YZ-&\)PV0H0M6P?3/
M5)B1/]0=)U/6[J ]L74V@A71B2ZB?!UQR?5QP0BWE40SVUM3O3]_A-Z(-;8C
M9;(]7G!RIR0%&#,;ZDQ3$A/',/'SJX[?E TYK)QS<WV[-QI>MN$$-@:Q:"[+
MY@"OZW_W#L\OQN]J0?*VBF/@VYD-P]/*&_8D>C!''OQNSFQ0D%L O 41GNK;
M#&+NR%\[E6T_;5-?YL2L\.&YF&;8V831B^0SNYNHS<C"(F3#\NW!F4?2U!Q1
M[R\L1RMZ9VF W[ISX+O@4\W5ST=X@/Z&R+JR_<42<,JN2N!@A'RVE,$YL<:7
MA7R!"8D3^_V\+"V&;ZEBQ%>,MC:W^3-RSO1LQDGEK=9=8J!XQGBF[N93@+B^
MCPIH :+MA'%):V]: -=YU:>7U4)U^>0NW@;B<]O[0HO)RGBD]O.H&NT=6.80
MO\^KT%A- J(_J8Z)="T4? '[JV0I6R8-55%O3$6]6B&^^BBQ!,Q^VZZ;5 9=
M#'!/7<'L0WC/)_R8AJ1&UX<BW(2G%IM?1G F2[63J2;;_ *46._(=>%D<XS;
M7MZHTP;NEOL#?'_,(M?1\P",'4F$R,"LW+1+S/0;WBZG<WYF+^<0<O&B)N--
M58))T>"\<EL *(0;5E.()H2B?.C?#U4,F_!RO%I-#T8O03!=.[SG.4X7'R('
M]-1MD*(5XQ4T0&&LJ#)6HZW!?J<[+:!CG/"HHG+F7MSLM KE,_GN7)J6_I3(
MCLRENY>3XCFQLH;O,*Z.P9ZCO$=G+*B<E"^!)E@TR^@:(?GHGBDFCMY(--7$
MFZ[T%"N JCCMQT*HK!I2_"E%-LP9M[*TOG_)UH+=Z*+?N>&4$LW[@F>*43\R
M(E0<&"_GB^@#@L\DQ,/E;:IX(T6Z)U"A"1X32=NZNYC=?8V-YO!7Y'39C*B(
MY3=Y%@H8DYRO$Y49.+Z#)HJ^ ?%3 V-5_:]88Q>'#]9< ANDM#,_ITI]U=^2
MZ@WG;=_/E+!$)>IQQX2V,&VR]230 )^0Z92,HNQBXGR1]:TE\;GX\?M3;Y 7
MKE^-;6MHQBE_Q.*3/[Q.<Y6NJJNTX'NZ(#E_$1U\&L2P*Q>(D&DW;9E;R^TQ
M,!BG?!V#C9 -P>I]\AKG&>FC,H?SM5^Y$%(-\9@MD/I2R.:27[9.S/U1I"33
MI=N-Y\OJ).>^SG 2(YJU!YM@13N&TDP?/MC*682?G07H_=:4+*=DD,5I@ NY
MK9I&#H^2,$1TI,#F,IRJ);!7U$ZXAZLDA$662WL][;;T1B>R"E(M]=IN[S,4
M@&9-=HA,)>91O2K<]4)#]8+H&3<65.L2+ONS1B^??>I^@$S]VI,J2AS9!G(V
M03]_1?R*J\U8D<AOP'/$O@GVH5(Q8(MK31TS,5,6%HF> Q+!<%YHQ;KQ]3:9
MK-/6-,#,J;"A".+[FJI(N@]=>'V6$$-M7U\8V+!V5V,+V"T[EL/N]\W!M#[+
MT:T2GOM'+#/BT&'SSG^#UITG.M'_+F+Q^I=/)P5*Z,B?"PVIC9=I@)459]2D
MBCY5.Y+\D.H_#SWDZ2++:O3]VV>3@X&&-$!\(G:&Q#AU?-5RT0LT5RN\[ND^
M/(74RT@922::+5PQTO9*RXY6:K,Q?EQ>\M8]%6L20H>4!03EH'7W)CCW>K1&
M>H&,P#K]RV(KP%MG#LV:08 ]652@)8[\, 3[WN$U==HR^9]8_9[J?:"4#>-/
MR9VR?>C3"F5[L$!@H =UHFUFUQZ$,E1(O!$Y=H4HHA39.+;X8HY(*+LF&YS(
M5D*.#0W2@J G: #VNML2'0UB(NP?5S3*+]RB =Z=!T7#M$DJ*T[WB+I9[K?B
MIPZ3H3&DT4W0P1]+8OH:=MYZ.">M/<777UV506NWUBFV!;.""BO[LL=']VC0
MGC.F=US=^T@BA)K8WL2:) C\V-;G2P-4JJ,[^+Z]&&&4:EK$[]  '8+0H<-<
M0B/^:0*$6SG,(>[#S7O0%T;]:1^?]E4QS!Q,^<F$O4["D&_GN(1[8))E)X)7
MZ]\O[Q=5SE=4TP#T=*VQK 9%EBKN6IWI33<OS>.?P+F'*:FO!0L#+0=YW]H7
MZ]V8T>HJA^.7+ \M*K\ZO5G+5H=/Y!W/5T\7,VM?\O*]_%C;1; 2ZK!6P*V9
M>Z(I[OMX>,:M/8#9<FZ+S2OJ94-^R-$7CU7/ $F=YIKSUT#XOY);,^%OELF"
MMN<PY3=O!4!4;36^!9+N&]$ ,%9P.G"OSBV\WE+%NU\5E!ZYX]3N!P^E ?Q:
M06*H'NH[[2MF2TX;0DF8RQ:3VAJ/2LR_J=W<N/U'\>CNCS5ZI(NI63]?OW53
M@CA?LYC@(69I&+:,$S7GQC2!F?NFU:&EO$=M;2!*$MI@-G6:\H8EWW"K!IX*
M$L.?8>D)RPC?&"<-'R??R]*OYEXV2%*RO.$L+05)\;8\$RD<Q&L>);+\RT']
M6]HP*,P_UP_47&K=5=+W<+#PP,THY'Z_'P!V'I!CX?>BK;W%,JF2%XR_B;Z/
M33(D/+[T/0C>-5!WAE!&C"Y1A]*-Z7=M5J/' [QCY(GD]I6&\BV26J#\6Q1X
ML]=@)F 1+(P\1 AO(CU-Y1G?1P]=NX+HN.$?%+DXB9/A\ZM9;[>5'/*NK0NK
M21#G]Q*,\@C7>GOJ"#, +R:$2@<*%JP5?-!<' TQ/[B/T0BZ,9,8F ;V)]/_
M/:[(M=B(7DR!NU:4O(:2!-&=9R"&0UN6; GBT9>/ZYWI#5YPW/(4/OO^LYUP
M.Q=)<87XG1ATIL8VH0FCC0I1L!&V#JNK=1G3]8[V#";^02?ZH3=V"^'V@=9_
MOW242"8'F-$ D#>7LJA'$S:@34@1#> <J%,Q.'R@FSN6F4C=B-$7(/LZ^E&#
M\[7"BER.HN!! UCUD"/D>6KB\CR>T#<M<G3')3#K.0T@XK/@[TWTMDL=^7'\
M#B<Y@2L^\&V#B4% #&1#=S-_*]$4,Z[#+,HLY:E9;% '@KFIU7.>9[1DLV;\
M]\T5-;VK-,!?W?YZR KRB_V(0K6=Z$V;.\:@C9+Y0^Y>Z>Q =1Q<R-*%^U&1
MID<X.@^4(H(V:G$<2K<OE1B7\*CLW9Q9^$J-(Q(X% OO2N4E&1FF_DB>@BBN
MC>L/+'\-&IAA0\\QX7()FE$3BC"+!XZ&/4Q\?)2/I*PU0]?#TMF81/9RO$.S
MZ2!S?R1*)18L_3!XW\@"=$G#Q1=_IC7Y:'CZ:2\Q0FI!FW/N$HQN24]SW6'6
MO9@][/@:7_F*/]'MG\SW^.W+'/;MP$E]<M2AWA4,HK'O2K)C-UISC"3"*.ZO
MI6OZF6/;6FB&6&V+D$Z>&2*5/D4_DM2OJT^FV)3)R,. >L<^2U41]N38N4 5
M>2IW;[CGN&1#3>WUJ-Y'TB@7](0E?U;N]@YU&"K$4Z\L;DTM/QPK<DYNX!TN
M*NO1F=J$NGUK%S)0/>M[0/=3L_%\?:\2H6$D&E/M=+!/E@I$AU&[*%E@^!2I
MG.)[R!'(>#;95@E'EG7JAMV9,N/S>FY) :+BX8[HD /+RO!YO,T>,WN*0^U&
MP?QI_W#)N#5D0E^1)C., Z_?YD%D_#V>4R@8DG)==D)\;?=FTRGB#NP=RBHT
MKZY2,B^RQ3EM<4??$&WE.UB]A$_T_K+T^I<Y](W1('4Z86(QNR^X[FF':(1B
M:"2_L>U#8^??;;L179D19$_GV,EK_/=_$C3!!+NAR^U80AH/GO!%Y(, +.2X
M"B5)@@=["S-<E>X6]I1]BB5>CJ- =KN:&JY^;6H0&E2,]'A884:O\MBSZDQ\
M]9Z@(![U=XK.J@PO$NV4;_Y I+3VHV-T>P8?2P;?A7T@B8Y^.#>B:^W98@UT
M*YX&"".SM!#7F9_$*,4H2>H4[D9"=^#!(!6AZ+FX+&^QM0<EOQK/>I__"KX;
M"*,@]L7*:]&L1-=>?9)ZI=SDV"UE_2L?%E.>>G4:JG!=39C(?7<CQ>]@QMY*
M;WS7IZ\T?*)[:K62JR?((>JW_4W%-(9^W]6QPZ+E=2YWE]!N'+[%*'["9-CW
MH5OTMYK$_?H?%VS]%\RSC(9*+P'(/4'QELV$ &=[WD-GCAU.5 K<"?WV36)1
MN1L6?GF\/,HGM[NT.,53L&-LRG"*<>A,[RV-4WW]_%)X141PH"J\8*9*'W(_
MZH/3N3[<SP-10$ JQ2STIE?731-9E>RNGJ)ZP2O[\ #0U7FIIG2GJ*S@)JT@
M_4+%NFPW#ECR=* 9Z:Z-\'(;Z+*&DT2)-M=1@5CN_OF&%J(=#2 TTS1#8#JN
M]?KUP:<@:@5'2RA8GO4G=QE1_X7V1]VM,2 V<!#YYG$2 )V#DLY;P5>R4>H?
M)&J(WVS,"*GP@ 1-+?GON.H7%X-)W+#^^X<@0D:5?X.,*T/[=4D_5ECH;WB*
MXD?<Y;L<K=M,O[AH@/N.Y'D["L2*\.UXR,9\&@ C!MI[,@+ZC3B43.>D 5 H
M2AQR01S^YQ".V:;\@:5=00^7H5?[J*.P+A3\#\MQA$*Y@/;8P"R!IRKT45'\
MW'H "5%_5:Y%!Q^!G\"#B_4TP%5-76K]CV,?]"B0&5?;PDJTPO*_RW]XI_'<
MN'_!%)!GT8%X7A2'*L.*ZZ1#WW^K> 2F 4[K_L9]$#63[A8?)'Y[66_]'+:,
M[4J1(DL76&LG2)F^4MM<__0ARFQ9..CSM&7[3_,^J&C/%7R9VQ;G,QI C;R)
M=PK9)G-A&7L$C4(RJRN\J@5/8334CMZK AO;RG(W?PZ3E"#+ 32 ;9AOV'Y>
M=G@6/& J" GNVI<30STCLN"T6")DU\QJRI*3WCA6F<\E#>6G"(L*.7Y>.(6A
MS/78$(=Q+'I$\-S*OI6-%]8GR?N]I'KXT])X>E$_0< IRLPR^.K.2_O&@H#8
MK8,I6TS%-(P%G01[&Z-.4NT[2*[H0=:[>1,)6N^(9QR!L4T"S#_N7<*5%>@>
MI.HX''T+ LZ"RH<W2@/OEU0XB7 JK'2*/K.8$<7_)B-'T8XSK*V%@=(5)2PU
M\P]3]?VOI-])NI&[&MI./HL!DBP#->L;XMM;?6XJX"8:"9"_;Q.X0Z5B8PU3
MWFE6H?I?C=89W'WP&HC]S)]6"&U&.>Q,IGLV>3XRQ]I\_3R ]MEJV*_,VP7"
M$DBBKI>G Z7]G@ME%Y*+==MQB;KM2YN'F';3D4%;:VTHE*U/H^"RROR3[@T#
M ,!;I&&;*#CKWR! 5A_<6R^CAU^#?,T6:!:D 5B&Q$S(DHVS-2;\<MG/ZX=Y
MP#UEFT0!DW;O5=T;T5R@-T\>R=S;H@$,4^;1%8XETMLA[@!^A_97//Q$8RZ!
M(]:B;<*QB<4_0>]3E*E=MOHD2V(FGT.[DMI#)EX7GX4'MU>%/LB"&^\$>:^#
M_Y\G:P2YU$]Y+7YYQA.)U(OB5-'>%PK+^A\\^O/0<G"1!<QL_V_J&'CG,JZ2
MXEEU;)E9*%U*LA2V@GC70>@9755UNMZ%K<;.7:(82N4_'L'9@#>BL>;[+&=F
M5KKG-X^WF$<:.>_\;1J@(9CZ>>>P34/_XY.IUNSC1T9WR'E^7M9B:>Y4US$+
M^C8 _JHK0'IN^V=\.4R:7NNAST GAX;["P"B0SMP$VP5-#S#LAVHF^%R1$ P
M6NME;UN%9W%!A7_YOIMQX27):B(7?NC$#;/JJ_.>,XHWS [4935"&BH@-SE:
MMNH&)[8F%F S%S#99J+9W%#S*9"H#PW ,WG43-"HCP?307P*JUJ9<:_[#%-E
M/X&VXPZ'P!6*WPSGX"Q3GS16MOF%-0DEE^%/+3?@3B# %)%M[J@HB^WV3U<V
MGCP[N]"/]QDB8#@Y7?O135L;DIU?CF2:_CT<6>Y\@$D ,D2@R>H4'>94+/F"
MV=0+ESD_=P4(^=%MJ][5B87D.8?9FT_,>Z6]/7KQ3]S7(6)CZ*_D/@^BS&DK
MLCBNY/MX3ILRR)0+E*>X*[-IX2DTPRZDVSOZ,N/>46 />1133^T)$HYM$6!X
MO>(;6C68LK$(?LB;2U7I.N3>W1Y'S@7E(L&61*1^13Q!99;](.Y.=MKI>-.'
M%^\W7X+=U%S%GU.=EWN@*.::+)56ZU5^6+ZBH_V$DU^XD$F_U-T%7.L+AAL:
M+ZE16(C^OM(';P.5/=7]$_1SK6J+U\S;JA5QF&8:(+0&T^+FRB.M-F)8FGPZ
MH.WNXJWZ+N6'\YG[B@=;7W.;?ZQ65"BMETR/"X4J[ID 3ATR+,_6:9H;%UH^
MZ$^6KML,H#IEMX_FRSV]B7?I49J)'X2#_Q)C"9^.S:,?*U.(IB:TVU:3KA+;
M-RVUD'-Y"]U)*$*MMT-?TJ3*F;]*+.2+=?_QCRU YP./@\0%4(N;@)&_1JU.
MPL:!J@J_,?D'PN[3#([[L.Z\\IKJWA*5R\ H*)H:T[< TQ*5H0[,Y;]^4I>H
MHKB6B9BO[#Y C1\T(=QQO<FHEI3X)H>S+? ^536V/<<S5#H;IXW!.8<Y=$B2
MW)^O-Q25(9B^ ZM3('RK,1'S:A[,V#@/IE][([7!KC[*9']'OK@&Z3#V%A1B
ME:0OPT"$I55,K!YY5Q@^BVM#_V6@W$BR8KKA")9-^M@:B!@G7R:-'3+MNHQT
MK#I"3'-FNC*/:\ROI+B=W$T7[/8FE,?2.4[+;B"C^ZW (42$<WDE R1ORV%I
M*X1QPBN'*_)9+E-@&]OJ3,ON6(/^#3J!D!>8N=&-I\55J5\^POX9[E":9<4:
M>;9D R@E<9S3V,S,__/OLA_V[_PWJ/Y/=*+_7?1?>]*56TGMK!R_\1$;[6 R
MH@CADVIU_75'QOT)W^*$E)DGU^_;@Z3A#01W@[B?+Q48A+Z8@EI]$[+9+?!"
M/\!J=,&+[WTQ0X$A@SD5B'<$[G\)NHH,ZTH',[CV* 8U[.^3#2/;<#V\/HZ\
M;86ZK[&'+PNW)@P1:]X@AKD2!%8F#%WF/EM<$H,720I(85<9?KS=^.(JTV;[
M/-AM.M 4!RO\MBL3\=KBH6=I^/S0M1<OF68!DPE@Q.NGCOX4:R2+VI7O7Q/J
M9S+![_PQS .]ZW<*+6,D)$;T?*LU]Q>.2Y;6R>77F,L*1=,%+0E'J0>Q8W>-
M_@9J>J/64MN*<U83Y'3= '4U,:*.'4Y797F?BR[:GM+VMW!77:SZ@G7@=^(9
MI[JV5Z8LXKM_O6JL]LJS,AE3H 'NKH/'C;&F(3#<R"/E^R-E% ,L84EL6EVR
M:M%16[CKTH]9QRM!BCLF5TQ>I$0_'+R,!P++'DR'<BD9&XHTPRP_?RMWWZX]
MCHP,8IEU"5,,1[D$,#$D<U7K5,U@>334<-"QLOX5DV^E'JML2=X?)AV=S>&=
M<N#&HD7:P]Q+ZX/16X5..S2 8'.O7+Y_&\=:N7!G41HF[@ 3KB7G=_=NOPQT
M'L^>"!>N>[@*@<"NQ'?^]LC/*-%3085HW"ZR(7ZUK!^&+NRZ;RVZ/'<?$_U.
MX -L /*OF.E TTQ[A>F,O'[NV<P8!PO.;6CI]JYV=#Y9(_F(_JK@2!XA;$K<
M*KU?G.+X+#_EJKO0WIF1!DHI,7(6R:,BG8FW_5!\)Y);;"AC]M0[LNWPX8$V
M)&$YH6->T2 U6;'R^('#F';#5I?3^\:?>CYNZ/"N/.0S:S6\)!.A=9T89AP]
M8OZBUCOBGJII=-"]JZ3\8.O"*V:]0U_SE%7=][7B0SCG5N]$*47H!2;&5C5P
M'MM%]PQ+H"8E _OHQ@!!706;RH-<F?\DQQSF5?K<R=U_'W6=DDN5L22^M?)S
MNM,0>F!H;6UK/?Y'*,:4>J%9O/%,WD%[!BK])ZJP6^4K6VP3Q:156]UF_SCE
MDY^_J2'\H7&>6M^],.@F"A&A ;IRIZ_DMW+*Q1=<O,VG+0S$KY;G:ZT<'<S2
M )O"/_R"'U8>;S1__N2".QG,PXWTYWKIIJ?Z>89XF?;6WZW[3@O@:("(NDAD
MC_*C$26F5@6<KA:=-?(2_ %Y.1-]JQD?XCSP%/_41-^[OH'"C9X,<HJ:C0!"
M:HAJO8E'ENN+^2[^KD'!?DBL64C=N1<&>?GCXV60'<M[C3F"WQFY=V.;3S=H
M$-OQ[TG8HI+HXHT]R!/MPI27"'\!/O/8WQ?IO )W(G;DW:^U+!43'GG=+5E?
M.Z+2H>)Q16RBB$JO5WE3JU#MHZF0*T9@"=A/L_Q #N(F#-=@[.#+L\8OD'A0
M7Q.W=*<=J9NNNI4;O-D;6!2QV3@O.2LI0?2WU#\J_>?[&1)<(71A+>VI,D<U
M&WU_P0SDI[C<Z.LZ ^6U%H[00Y^XEE<LX+A?,^&<14B/B5I!_O+##.V@=X;1
M^6+CV6=G/A<2+:A.2R9UH&SQ2MU+ QOSO@=30;HSU!O$ZCF9L\V2KI8]U57'
MQ0&_SY;PMV\>2C*"6KEGIAOTCN>,?$S,"_Q4X&:7,5'M+'7@^&5O5TAS@J^&
M:3Y=;]=5<FG7]GKKBSB"X528(V9XG\RZ-Z;,,+OS,?_@>-I[>S:@2Z@:+;Y
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MPA+7MY_V\Q(F;(NO3$LW%N'2"+<]Y;H D@Y1OTGI,NP]E2_@B20)&<#!PA_
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MK2)K_)F?N32G9S6Y6%G<LFM\.+WZ<9W[SC^@]]0 Z1WV20.HSGEWTWN9^<:
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MEE^HC81N0[0%KK*(-75Q$0T7GY)<&?[$Q)9ZV>RB,_U'>EF3*ZY:[(7?%S/
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MZRUCBKL?\?2#V.F')UXY[=GGP 0NQ ^) SC^#.=_TN<]"]<B^']#YF:9?MS
MWNPW"5852T<RY<,-):<:Q8&6W;_@^DOY5("BXZ%<[[)&652.;8N,!<4*F3)&
MVR<@J!J$EW !2P6\A/<L2MDH]E@-;=R;2[RW9\_1JA>3"?&Y]S4CI5&]-\2B
M@C*V5)>Y0P7@RM"9<1!1SJ14/6*9O4CTEX*E'YRR.;BW=BN2>6P;^H%X,-;
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M/\/= 0"DRQ]<R*.A9U(U$OT%>.".I]$E9RO%]64C#5\9CBM(5$"AP=='M)W
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M07X>L^FR(,M'BFD!3\Q>JJ,-[4#0.%<9.N#6DT%*F)3RKWU[U04T*;MF/KR
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MMK3Y2\GE"AF=OW]TM>HN;9@&T0;?SJ(%J/68)9)"_X$GDGK*<HT*>P2;!>]
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MJVC5^'??/'V:0!A-2 &3N+:UK"1?-X\2<>Q)B%Y-N!U*R)6MO'70#*9Z"VV
MZ2",4X.C'Z0IQ-^R$G[-9V6HP?+U9-%+W [;W^;NL@S%G4;"T%A19 -X<\ \
M$WZJE=>&HO&EJ<X@S>*PM#CD9)]?A143M1DS<PT],(I9XO&G VS!=("&XOPB
M?J>Y9CC%36UPZ\G-FVWM/ XXL!@5QK*\33G;03-D;T,0CZ73 7I/D".3E)^,
M>7E,!W0V^9;3&N7AJP]YCM+MJR 4!KX$PU[M_(R9'Z$#^"EQRXB*@S9SDCQ>
MJ0TF9G7"9V RW9_+?[IS1SOFJQM.\V]C=3SQH!7,!-7 KR_T=0H-K3]*\^47
MDR\^>VJ+"T%,FH"? ULS$,A,7:RWB!34##KMV>Z2I?;2YW5'O+USS^MKJAD0
M93K@E:4/V1364Y #:YX%#FY>MAREL+MQ4** A'C0\"FBZ 0=,'>\HM%06>4F
M4I&B:T.;L33:<M_^U7WC8UEEEA GR>,-0P]DIH$5*G9KB*7!)5:DA ?#^VXJ
MCC7#VYN+M:A4/S7WKTFA(]R614L@TK68MMW%[0_(^8C.^E[3YK?41/?;3I4)
MTJR44W'JGZ36NW;*S-1+K,WJ8'8@IK&F!?7R>XI^#50_FN@=9PO4@*?_IMYF
MJW?RZSNM??!@;OV;E _((,Q<VI%!1PSM"H-@H+[G\$=I;4QJ"+\-NA[R+D6]
MY1?/%@;5WPK\6]58#@Q_^.:=3UJCP57.]!.'^6<=:!-ADI!QT/PV10HW$=%L
MK,N;\JY(:[*AXZ)(GX\V@OQ<&!@,":7.7JIT)P92</,.IXVV;RJ\(-;CNG5H
M2NI7TVDF'T$;;F#JB7^19O^Z:'T?5MD.KWN*:<:(/ VB _S;Z( HVBO)O!*&
M%"O"'2W0 4>L15ZF%G1 K/DVU0-./8$-M22]V7-N,%J,*6"L/&HAN1P/7@A)
M7Z"R&:!J SJ=/L6?]0V[JH.@)MO&N.?$2AWPST-:2_@7#MY[0B[\D7\WZ9T+
M2#*+0XO](6!RI([G3ULNI6R\Q6OK4[^H@0DLS7Z?'I>*#%S+:B:$&)0,3=]?
M_G6G1E+;RXEG%?RCOYUJ2H20N@NA8H3V39#>""0JY]MF<-G(L<E2UL7G",F$
M8:J-YTDT#JBEG+NQ2-$I0BJ.PL$%>-*EH>81+T?*;=VVPSO#M'HRL&#TT)B0
M0#/Q8A".\<X<1BB^L'^$!"<!^4#+8M80:F0:B/8!8B]C3#ND ]PQ?6*H#'AU
M]R@L?W4E&K2DC_T;_3WH@.Q)S#FX$V8":T[-K7?\[NNC.UJ\%[:Q87V8UZ#M
MZ'CVJAN_UML48!)LPG>1]J !3FLZ !Y)%^T"::RZ=(#H5"N&*,MXD\MED6H[
MH[P@)CAB29MV2&\S2[YT=J(32;T\QF"N#TE86F@4"XUB1./I(RT2+Y,6R<I_
ME-#2>&1XVTQI5HA-T'P=.<*U>L$X^:T0[YOH-TSGHCW&,)9KI06*E>AT'^EU
MK2H7]HI-V6GN8-$P8KLKJ]/X][PIHU%!=O%F)<<+#?PU.Y8;[&3[EV"ABE[M
M9K1L\NUZ\+=F&9-]+K&I$A3S]:XO@#]M&HV $--HC@ X.!Z(-ZS.6B=B=CV]
MI'([7+[KS+_]X*[%!73KY8&A1IT2O^I5V/+4Q'MOUE)9N];Z<B6TW"D_7U+'
M8O;_WG<=-/$_?:3LO[8=Q*1I$W*A/R3%U*;M]ZR+NRS7F3K U;N@.1$$B<.O
M4E@\3N_'Z>(;&GPG+(7D.02<A'S?;8I"U@>V&A=6/K0.MYG.<H!(P#LQO6Q2
M(S005 P>JB[N6B3^^8]*4$7R1M%.8VO\4[$I$GQBOPEY';FB9G^AE*W^QWY2
M+G"= "K /^YZ3%&[J2"X*$J5-?M[RZE@T__+222F[+"5..&H2[H"P6;&\:U[
M !_%@X-F\$EX,S.>#M 9 J8GQO16OX)W6ZI^#CBFJOTS_!!'="1IBGW:_U1O
M6?#@9(*#!%G!Y)IF3V/ /*WK[!G_'QT.8%O+]8PKR7I1MQT*BVZ[  V1*\/#
M/13M:'E?;($ .J(VJ![3-@A-IC4,&&OR'-T^_-]Z-OZ/_6/_SH[U4S2PG,$4
ME@6#)X+Y1L/N[DU]-TRN05;!64"\;J\P67N!I54:]JK; _(4 OF-$I/7Z\.E
M?K3$8?CV5A7A033ELM!K-IEGB.<;.[OOSGF0L,T@O,[ZG^''I-071MO/ YO-
M@1M%AIQK"PW0,XDW#2#=P%X<7BVRQ7K<C/@[9;[;82\0(PZ"R!ZJ<\A39Q@Z
MZ1[/$0:<B,";%-VF2)/-7DP2HCZ:KE;Y&%<+6DO8Z? M"K^@M/'IZ_,;TN )
M%UZG-YK__(-1@)4,FBMD&N*LAS;VV6];N.I7FRSP<2VIR(68W/ETM00;/QQ1
M?N=%IZZ$=.KA"D/N,)A*K$^+[-'Z=[B4WU$Y\2X=D/",Q-"93U[ XY QH+F2
M+.% -Y_YWX&1)6_=(#[^5X.ZBJ,NR<#0IC!SXLH&[FOW//(]Z,S>Q.).Z>6!
M5ZT%D6YOV<I/^RVE$6]U?4%88?JTX] OL"]@;J!.1"I,C>3C1G"@L4D4DBS(
MUUH>$61D$L_F?GUP5N=+],?"&_T-,-2+6NG04,]T WF]GT&&PR7"7%.3D^W"
MT2),Q\RU 9:_@:'P94E31A2%K=,!NO88DQ?MNE1+CC,98;13-UZ#;=J,D*K@
M") ,9JXPBWT8JD0P;;87'B[)*4>/O7(DV\9&Y5E=\6*_TD%PBSV]WQRC1X8L
M'+1)X8[3.H^04<_B4LS G/>ORYV+1YW3^A1%4GM/X]D1H_"TT+1D0S#[ZP%T
MP-<F\'W8$!J8WHKX8?$5XLZ7&]12Q9MN6=MZ)0Y#&'UI4K&SQN;_5G'GMPL-
M&'L/W^O*F.3KX/YD4,$\$*]'!WR\Y%0&#$.+OJSJ#"BTL8<[K0Y- WZ?'!=)
MT^PGQ%V5V?KB+M@+"UZ;-$ANR)UQF4SZID3D-:Z0G[*][+M\[X9Y(EZ#AV!)
M.1O:FHQ"L$#-OQ9'$*<$73=E@7"9QPZG<!$/%O'(:@FGWGJS'.EX"W+L\]7K
M(L]1;KBQ#4I0)<G2#>],8Q.<IP/8QJ5D4MT6_&\7)_7I-4F)?*K9KE"?9G!"
M<  ,!]QQ@:DS=( %YLB2 ^I/<+"OQ&+FOJL<J_"X:K5>:Y?^,R/FYH4;BWB1
MF._('QA(S*$"!@C'2H&I4B%(GMMF.4&)!U!,AM=AZMP\FV^QV=-*;+<_,F%@
M-X8D"J>D5S$XGP-'!^U3(-IRK/XEIAR^25W@/.^[K5T]NOELM+0TY2636((R
MY)IO$->WPI]SSSV%+T>K?V=(!<N_#_!]20<0;TS#_WR2&J@W5]H@DVU(T6!F
MW/0J3)IP 0$167,[439MHU5<2)8Y?ZQ%;ED)Z*5<FC8:$/W4Q+:^.[EO:B+7
MAR0P[B?%G3P<JB1E4HO&&DS 0/@S08V@*J4F3)BJ\%"]3Y[-C#K+A*+3+;DM
M4/.)ION( ]U2EA;0C[S0><3D#8K5H)KQK<QC]:[K 6?:>\_R[ I+2;Y+[S,^
MN-UH'#4N*-6EQE!$)](&(&J=]7R+_M2;/_0FURTZ/;\1A9[[L\44EB&/XT$1
M-'%:,PBHT'_*U:_(]@52X=JN?N!R?EEM91(Q]9D%DT/D+?Z7598LEV.=@MG,
MK]%RS0LJ1M-FO#?LA;FM,WBQ!6(GAFO];9 PM/8H"&\6\PD%XR5)Y9#<NYP^
MDF(>3;RMB+4^9:8J.U 3 ]+;Q#P!!M9JMX#>IYVI3C:F YHU%VP<1R"05.W/
M#F]K+WY8X[HV')T>IKB(P5OT7GI7+XP_,#>_-CEYM#;1IZ(0ER.[>LYR!/33
MHL%U078B?[YR-+TXKB/;QOK6<(8NVZF,@/O"E@JR F756RO(Z4V22%]!KEJ7
MI-T5KX,M3\0E=0:IOJ1^:3WK[.B7<)WMDHDG:9J=J RFY:Y\ 9Y70JK/?9 "
MU#",$_ "K:=6Z5.QVOT%:56+RE&1<-^-O?W8W/I"/JN6:MLMD_>4G"VV(Y.=
M+2EVW2UG#P&N'%UAE.8C.:,EJ7;T,1I6Z"0UI]) WQ!?;%VAE :]NN YXG;A
M!E?5P'VIGTM90;?75VT5G*U,"]C\VJ;2*70 9^-6"9M,[NW1(3T*!@LFJ3NW
MX!CR^EN.'1WPH[2&H81[[<,8:/F$%./OG$>2;R26*WBGY-D9[O-\VKW%%2>Q
M#TA1W@<0D:K45/BRZ*5M:K!7/_7D2X92#"S_4]ZRN'WLY?+%R?Z\_E<ET4H=
MXL] $LS^T+)DJ1.YJ*N4\VD4(PX]XY;?9U3)NC"U,!H'PI'6"6;RC/F .[DG
MQ:\OGC.VSZZ#5'3MS>G-FA^X:3+CG;=0J *0'XGWQX4#3U=P1LRRCM3++JB*
M;WNNCW=1NMCOD0X=[U-D\F,U]?'=K=XP&=+;^2A7HUA]9WC>U/2#KK<M6OE
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MQ,';]^Q3/;>CS0\LF@[X!-=WA8FO2"4EM':X0+TF?K>]>*R68Z_$X?M)L>Y
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M$KL[@#NB#"@C<E8SF(X;^#,=@-<S.I2999#$,C\CJGA@?4^IWLU6W:)<QD9
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MXBC8YP!,N)%/TGE%Z9@71V3 F9$+V!SR/_J)M0OTI !J-3R)\R)I9@P0],D
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M+.6!0E+<_GW"!?:#'?#L_A+_&G)6 W.>.3[VU^A6744^$?LKC&I1YH!^EPS
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M=Z87GF[0H/%(D7XY1T6CN);[JXWB]^M2B-=4D61 +ST;:31+*G;H9EG,^ZJ
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M*_)42BB^&^_B)OI76L4(RE6X//2&)7I^55BHJ<ZMJLI64N^2K;O^/QS <(W
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M&(WQ/Y\^;\Z$H&_V[4P!U1PI<XA2,44/8LY*4%]^V_#T:T89:L2"KT!=OO[
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M6,A/M0H.()9#SJFW\N!BEI,QK.$,2?,BM=B7:MP!*G:IDMRSN1?.:U#G6>+
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M\N6,H[C>YQSZ1!;A-M!2?A8 HQ'73+_T64ERN07<Y36[+:4TXBA[;U[:Z05
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M[\3OU?O3$>UGQE5^>5R^&P8M+)]^:WC?\OS&EO5 N_:?975)@FK:J1\6B[E
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M0V'T=1$^ SW5T=Y&COZJJCB^)FIBE<Q9/)@*VOZTE0.X*WXY6+/<C8<,>-Q
M&JQ/OBF\^[J/CFKJ[C81A$!9OP(;&'4)#BRG>4"5$5PJ]OF?1WTD1I-4!(,&
MUB@L?'_5O96QQFVFBD0K6>!4"9]1DE^V2/G\,KA5-_W"!VC;QNV*.1;XF *N
M]X^C*"5(H2.,,"T$>[Q.MXE==CSI9-I&I BZ9,BF7S_CO+O='/0DR7TDT$@K
M^ QA37IOMS4>C;FWD.,VX@U>^[.\$&!?]+\\U\'?\K?\)RO_[U8'>?Y,L<F
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M^V(8FN4^G=&._*.05N[ WE3CQ&F+HMV)HX7>B2234"=8';"=J#+71_W!U4<
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M_OU)JD=7AF7?KD),6[9I;IO2 VK_ZU-._"W_*<H+W%B';Y8".@6^O'-Z)WS
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MO:9&OFHP]T_I.:Q+%XP-<H8$"UU"L?>V8<[KG2ZVVO/ZKC;%<7)F86\(H+\
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M[AZJM-3[6.*O/GA^P^?%Z$=[BP5'SQO=O21LXNBH9@586J5]_F-OIX&[&I.
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MDL4ICA-0=0K[,,4).6V%<0M(M-,3M?'P^O16H/CCFVW<L"[4JPI.?@B==+A
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M=&/B/TM0[AZ()0G\C>*$%RI:E&.W3=V?O:N9ER+T3/:"V7V)G!NM3,<@6QT
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MRLO1-H(?5Q29323'DCONA$_K)G0O:/!.A.Z(B\_=T/?T*QL-N2//G554M1?
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M('9EMIWO@AW$(>6-4L<=%DHS-:_Q*$6-Q$Q^H$6(;=HWV.^(DZ<#Q%J,D_-
M84$/4DG"'_));0R:]"ZHXS9J8$5"Y?H%$X>\@ILW]>7;<'.A&<LZ(WWI6P,,
MI?J^P*'V^_WL,=AYY..1Y)<F3O*V+IL^P>TUSNC69"+&9U-ZW+:)$7.E2*R/
M2>V$Z]_![,NF3T+9P*V-9B(?VJ^$9E+2M-1DC-T?>,9&_O4N:CA4HDCQNT%6
MMEI,V YT>*JHO*8-[^'0/(!Z\ETZ3<,'TE!5LJ5 .9W>%N^SNY:/RS>S-_PM
MEQ^6K_RI>0&$\0; !M$<<Q"QOTM2>*:NAC5GFV%1.B%7 N+L7,=N(OA27D5!
MH?E2W<0>-(MF";D(GT:4/L)V;G \\8IM*>F8ENNSMAN>^B0VL=XUM>"LPJP?
M4Z.X]TGP2U3!ZBQHPIKXD91/ODXQQ:__BE#A$3P\N'XR22OLTM3#I<7>VU(_
M5]I93L4+)\\5NEM:ZQG.Y"IK[OMBYSUF,[45O6OS")5HQ-*.2D(3&J\+#D$R
ME7NIB!*$FWCXAS.?O3_F+'\\8P#*(LW4,W4ZA(-W$A#CNW%#+)R:7O^$D$1,
M)B%R8+<(TD$8/]HYTIONF.\M!E[M/TIK.P18WPY<!VW," 'ONFY0F?&0=3^\
M>\<X6V,N<YL LQ:GD&WYL/1L:75(R?=2S>\:S.'A?J/1D(N(YMM@1]0QV!V\
M'(*MGC5'+*0(ZCP;OT_LTFH*C:@19GC]0GK9^HVG;X_*QKY;N^,6?T&E^HWV
MRH:9I,?K,3NO4G_+H(3K%[;[7YN:+Z<U[J.;=E DT9_"1/OJ;QT>JP4(;+5C
M +42;0WA<IA6@H1!6/J?R.]X_98N7[T^YK[8&5%UU:?J>XUNE["P2#3D'JT#
MP0*EL=,P@KP_*^P>59:(=R'>L/HN97SN]H<2XS0O[^I;3#WU2GZ8.Y=I&C:D
M[+--+E?"?S(9;%(+>)%N3)X:P>AO.=YG..<7KXTF)1^[:562+1%[LNGZS=9)
MC<RZZ Z+,P$TJ'F=^A?NME5^4"<'Z9)G5'E2RMU[L:V")\K%OE7''+]07!X2
MU;N"\7.]#' D3/P^D4@U2TMV+<_M'M=/^TB>FI@/NL+F$$TTE%!@'S;>:^AU
MQV'?;J,"!9G[8!)I]ZP&Y/)?5/HK3+_T>+UC8_6/PB!UI#WH'&(,3/PV!!<U
MM;LXIU,]:#-XQ;GHPNNRFD@<KP:?![E(H;K#[1CS86MPP;:Q%(A;7#[%7LHQ
M"YFRJU3"^\#H2X[ZE$96?6'5+U@[7FLV$[F.PS-U&/'3H@7]RS!2L?(-Y1U.
M;]NBSC5]N'%BC&E(8HX.'&;PO+/HF53XE>&7SC!)L6"8@.<E[Q2KZ +G:RT]
M7$L<<>?/G6Q5[## /:":IY4'2LEE@VTYW(SJ+>J\Z0#DO6RN7YS)W7$=;,1X
MC!&VNVIG")DT7D7AVNJ$G)+;>Z431 =8$R?:%,2M0[V<,X9$'H8[/]#CZF8?
M$['-D5\&%3.O)<SJ!"3&YQ-X.OODLT,\3/A9'ZD:L\F=JF..T2AIBOX&2;BA
MF[SIHCJ6EF?R38TS4! I??WW>AVL*Y+=+=DV.!?3G6>D 6E\QXAXGWS>_==;
MX85/&*16\V6,A]8=LD-]H)VD \WW80ISW1 ^+"G_;E0SOW'@;$1/MX,:X7?*
M5)SU@[9+G@+UAU*IP,7Z508E?E]E-[Q?UID!4VAL'&"R=(;*/Z_\%*7/V2X$
M>K2SI'XHY&,-E_P>_,VYTYV6N47VO>,5(]GQBTMLW#@D,QUX&14$XJD_5$#*
M$GBP='+)-<3#\9%)GI9==CK^@8?5,;WZV(Y#BB@D[ 4=.&*#GTXHZ(;B4(>P
MCOMNUW3?O,DI#(EEWKAB=9F=X^4'WULYD1RGQ"-C_&JQ^Z.YUB[XK+R:(N.J
MG9K=0F_(ND[!BJ @-04NM&)JN-/[.6=\65;CR$)R#U>?XCD9I0\&9+^G56L#
MY!<D66*<8P18.W#Q#D&RP.+5^'V"D=1GH%Z/7>3Q ^8 2V1=I*,GL9$.Q%K]
MV5]\9H_^4."@FZL&B^/^W, _N-J9FE0+5H#_M80NCUH7L"V8)*G/)@3[^QA$
MJ[L2Z0"WQ1UW(:LZETZPRT@^HE6,-@K>-JB0IEQ!.>8R)E.=#GRK(TC0&M<0
MV\?SM]D;*'!Q+]B]W#OBWZ>4,S#)W2X?VBVMC3)2)GPA&O+[H+A4.3QT/8@,
M7M[RBEELAPL-E=?);]G6^3U1RM"5=L/_>%(9.?]5=W)D$%2,78\#KY^R]<6A
MN=JA3G./9$ZY+IH5?=N8^:8OI(/S$/4\U#QY#'C.D>],\7.\6C-&=(KXM5<]
M475N\68))!I=3,.0G+5T2.K@^>/$"'UH7 KR^6;6)ATXL>>%J;"]D^&ZO=)2
MP.D:9I_I5$<'S,EGK2YW2Z>(?\P:_QAC7[<QL3_=B454&8=X(([1?L EAEY)
M&I'O#^(<(>*[VM5>%Z,43OE5_ SD.QS)<1?"36N%5 8%PY0)-U44"!SM_*EU
M7U;7XO%81^/^IQ41O:Y\',*<)8VOBWL/B7LUHXK1,U^1F_:-U^@ ?. ?FX6]
M;$Q$5V0'LM1WMVV=_?+%(3D!AUFL7I6>SN?G%P+\0V]:VUBY4J[HX/OBQ:79
MC"<DSQ7"1W2I=^4\&DO41\$^/?MC57N^9%#%D+'!ZZA'=2^L"HIK3F0?%LA.
MW(/2CI/)CQ MJR1G%?DB<^_4:_AY+:X>X1<;DO U=W(Q#H2U!\,;TX?0\]QO
MZ,!3"!VX+8^SMM,YL:AM#LY/_<UZZH2!I=%-!(?P%O)/,5BSCFDETL*L(P>G
M5R>$P!:N=*6TTS%O)7:R+5+J_*'W=2?9C_,)A*#ZE2BE#!\QH0-=S5YEM"99
MQ/)#[OTDBTHG;OX^#;,I2))*09:VP8J[,AFSJ<Y$F)M]#F)N/$G*;A^0"1HH
M2"D<BE3HQ5[1(M5=0G71@4!(>6<[(JCQ.EX]0N71')C+@7:F%NTN64@L5"'N
M/D[WKX9<3LX5!T4J*G9J[IO16$H(S]JS26:XAO"Q^&4Z4(&:N]L[]/V6_YNJ
M3Z-TX(4#:-R=: D] 6]1938I="WRNJZX ;T37BFE[9RP5*J$3#.JYK -RL@?
M,EZ,B>HV1* 1PE=:QZT<ZF^>&?!_6KZ1F3!5E62[=#]EGC\@F<>HOX XD-;-
ME>-65"##"[K#]@C"4.[-RHV,8TLO-76;*K,"D37&,USMA4YL]YVCSZ!9F-A5
M/E2.1%=;GY=/?\8^W!S,--PR8I)X+:^6YHO@/-O][17YQN^B<_</GRHO57YE
MJ!NC,R,Q"QYE[;2X1NHC:,TF1,HC.1V-&\]J]#0F99I#OA-=/F?:7_T0/YHI
M?,^"^1"F\,V?GDBL-.[.-<R<\M+\-0N(&9O4:&XS]L9F%^B>%()ED9%,$!P(
M'!/U$P4L5^+MF;A=NK+UW.U>T$O(WG%A< 0T2%/19PCYT3A_B':4-W[1(H)[
M46RI'!*F:AD[NQBI3N&R\[+S&F@3;D7B8\,0:XCU)[2N!2>06"S:!OO2"OUP
M=?/]?RP FK]3*779LKA'<A8M8ND7ZU6O![5']P08#@FD#SB/F>1?D;I[N9G9
M_E>AX2,SVFUC]$X[@_.=MI#4>6\15*,S9Y$]N]&"GC@["VE%A(S;U.1Y=;99
M7.R7+-*<ME=*S;_9)MND?>Y(]/= IKB7+K?6$ZEQ^* P.;0 ":)%8 ]Y556K
MG>F<<'T@6TV-;_%GI+_'X5.0<'29=!-#T]M%G?3::BU!QQ:,+\5"EMWB6\(^
MI@KE8=>*;?27ZV[F+^F0Q!36.3SQ6QW&R*/USS:?-'MX7%@.\]A,TIIY$#.Z
M^,6-G7FW6<"BL1L4E&UQ/:M0,7^BE@Z\HSI'A37-.CS.6]"=3LX8(LO3/&D%
MF/X5R@ )17#LY/>D<.GHX*>RP^MO.^*&"4?C6.U/KL1F?HT89ENRY"AS?#YO
MS2PFO_\$$@?B R^(F4*IX8E@VCNHA:H^]Q7S#-1O=*]865)7YQ$Q'B?C%3B2
MU.(M"1,N[#D1P=4WVKLL\M(PSO_E[<.OA$;FLIM]W8F!)/*L5@-K"XA3Y8E[
MCNEX4I?18CO/U9QPI:\W9-S<5MOA;5YSM'L-"%KS+FA?,G\+]/?JOT8UUKJ1
M%U[7Z>I R%Z=U^OB^7E*/R:^I@-5;/]:5,J2E#=";*,F;8_!-')7]ZF_HJ!1
MJIOFFC>MCG7F=PH_,/1NMOK"81&W7V:P$W;VD;Y&0^G@A<@WK,&"$L$+?&H1
M'P.91]\[\GP>#*W_>J:!+=Y89ZU78Q^I F=X1L4@(RH$;A3L.-K)8?GLSYMN
M3F,OG W^A+,)YWS ATL0.QP)MXS*6-V\2SL^(I((78<YR278#@AB'K]78SY?
M..A\!S&C)0"OZONL&\"?.V"DIS%120?F^9P<XNPUY<TG1>;@Q'_<V;?07?VW
MN^S8>"6U$E,E\%1:-*RN$'K>#CGXW*5U\MRIWT?L^W05.S*>BA1]=DG.[=)F
M[W&(ZD7Q>ZF1FQHO-O9Y'):X6>XO,<<JCC@1MM;*O*WB9Q*W*]:!\;N.YMJ.
MBS]J9N[3=ZRB&EH[AXJG VNQ/W>8D8_A5P@<0?+@XRL#]K4-R?$*Q<ER>AR#
MIUJ91M_?1C7+UB<6&9J/6221($N4D;D:ZN76O9USB^Q%ZT9@3JIQ+.6Z;$Y:
MZ%[ZZG^M[KK$W=MX8N9LA+:DLD9I/(VH4W="(C9RG@CXI(K/\6EK7C-^&=(K
M-[NH\+RV=,0/)N8[A^ T61J'O1QX^BVOEZLX1';K 78M9WYD23KHE3+DQ-)K
M)<.8EQ5E 9;A;PZ-K/C0Y%LHITDWG/ H-6^QY[4C4&[XD$OZPJT;I[+)0CO@
M-C6=6\R9(^L4A5B54K_\)_#--WM2V$4Z -!\9NOW;U2>U_U"!SS8ZK'&^]*D
M\PRR.8H\]C]>V>C #NQ_P+C?S44!),]9XR!G.1"7';%V.M9U=[THUN7;TG>?
M?/8?&:=&AZE<AS:/5C$$9A7I1CZDH;T0&RIG]VG>='3EE)SCVHGB;]@D_FV4
M'[H$TA+UWO0C?U'8E\:O1;=_F&:57*M)E%WQ.W0*/6[(/-TP'+KJ]>->^O=?
MZRNN!8+\,HL&0U1&R"BZ6_Q_8F?D<@P=R$=\S1X0I0-&=.#N$T/:N0;>X<4Y
MT)HK7DN;M$Z^S\;S5 UY:V#85X\V>DU720UG)*-NM2GEVCLUBAIQ1 ; V>KP
M^20;'9:EQ=9U4!PUL?):P2'7R)-2AW;/A5)F&(S5G,%8.[RZ:4T)H'U#-GB&
M<=^OK=CDRUAMP_W4,T^.;1GE.GF/[X%"D2?@S..D5F(5$F<Z_;05-U<X96KN
M[19G[R29,B^NXW;O%M/HAS?&:^QA^/SF1@%\-?Y7"L[IPLB=34K6P'"O[.FB
MJY[O5=W>Q'?=7-WR)#)$X\>/CF@B]PAXFR]_1R;[6OX-_:]G=M]#>] D*[?Q
MQQ$O'Z85=BMPS\<A5^ Z=G"!\C^53H^(#VSKL*N]?)4YDEX5."VCF:'P.*)O
M$[ZT]4#P+8<F]1 5A9X?;11%C/)#YR5PX! ZL/DQ0IK6(<F@IO?O0E[#1[";
M+R&<Z#4VA4WNU&LUEL4#\87M\ <#1S]>\\I1O]^S-TEIH#+$HQTT%,2T30=.
MW<9OM5R?%@O2C>>I?Q,AL[+1]9S])-.)L*KS247ND1)C'AC29>9.AM2:*.PH
MP>_>ZG]F7?&BL4_^F 'RENG,B1$/AI]%_>E3,&M,]65P\:73QEBEK(071?8C
M2O!T>[:=B.^\6975X1KG@M582E./J>Y,?;*Z/-#V738C8WMD/DKY2JM!OG_X
M5\-V"U-I ICDOEFI,RY&C*>6ED_=;57E'G#"#9C#"F_#P"?+HZP1)\IZSHMG
MV+Z=<_FVF.GK3N:F=433>FI]?U>AS,U6X/*#:2<U1(L>7G=Y?BU4YM85+>!)
ML>H2\(P3*P@?!#'#[I(Y*0X#*A[XS15?A=:1+;E$6'![_+1VZ9/OX)!C\TQ#
M;DJY\OL29$685S_:#A&PCPA]M6/FB"'M#KYD<KY>)7YT?E?_P_<W^>Q[.6T8
M:L*X):?! OH5&;S:;5LTZH!8AV-X)W(%K#W3S4>0.[4#[Q@N&(CHRB)U4LDZ
MU,NAU2"2:'NY KK,N0;JRJES>)SZPTW]0J"Q_F'@SROIGEC\8\R>'):7#J#M
M_W$[GY4QO2B&XG\]A%ZSK*8#?2>-!4%/:VL1/]"74CZA]G@M&T"T25@)H:J)
M04_7>,B/EALE\'D/5!0\9,V7FS_MN35IBY5^(#.]2W71K8T$ZU!X"*?52"A\
M!Z;=YTCGN%R#=E=6.!W@%,B0>ZDL4RRNGB/?2^N'_%6.&3^-L\C&O>D[IS!*
M5DORZ8YU<ONR!MW5$6^MMH8@&1I NM-<A^A+BD!1A G-L3H#\JPA3D;*?N\L
M<PX5NU.[KG*E?A[U>3Z00+GT;(&98FH_T0M>W*<#P9!-J0ZUM/XX-11U#!%+
M:^2$DD2C*,D\8> U)@7:QV9(KMN##QV;#YJ%'S_Y' DPY<KO,2;C< EC&MX3
M;*EO;>A _R>)-?1$]NP(11PR-M(F.]$SOU+;1/M6*C[ZK/^]0%!MQSGJK4)W
MN^\FP6K*Y3$[3I\79,+M#3]6ZCGMBQ3!P#-@66(S%6UF'&>ZVCJ<L.[KMW5A
M=/S9';2Z):_J)C]5B^ 9^++>'F<.N368SCGJ$!\SUNMO>VG%@ XH46*HGQ$O
M0!'PF_@P+RP.$VJ)]\V<CWFRUYT_.8IQR6GUO/KUNS/O_(Y^)_<:'<!W8BLP
MU#/>:#QJD$&AIUY9%V\__QI$S!-G&5Y=W3M7?>Z^7<VL;ZRS\ZZ96=J>@S=V
M#3S'NC&&)98/TD"K;GMG:@O;:KE_(N+@ V>KQN8[R0]9HNSS=P+17&A[CK<@
M+H0M]I1=XT5"8X5@6;Y#V>>OPX70K-J$WB!+P>>E:97XZ]$C 434",<[,)=D
MHPQ,&-\9MO[9T^&ZP\@Q]&8O#JX1B_>PW&Y_\:G9,%/G--]EW_@1Q I#ZA29
M*6A6/)1+FT4V<)$11A2=:/!,-O_Z2%@%'0B@ RSEE5-O\K%AV>&@V=<G;T<O
M)R1LHFKJ%;Z,D\Q::RTBK%+-XU,<N3-8EZ*__.G.CE</0,Q2&3KZ486Y5E@$
MJ/F:XMVAVU6ZG#2P7=PG1!WDJWRKV:Z7J5QM71>%2(ZYR0*N;Q_.[[_^?L]1
MNJ'L[\IS[_9_Z%TQM#_"1UL/9 R*$AW(0=W@H2GL%><E5E'>HQ"K88R@=+%P
MZ)\DJ  $U]V7N@..5,U>V*!P=M*T6=N1Q$-)=$#S65$WC46'K*"3YE ,L\9G
MR)C%BC@6LD+BOGXZ>:&6=_[YVP)UE^P:^0[&3[F"F)^I9PBC9WSH[2P6ZDW"
MT7?9I/R[Z+X=,Y.-5Q-+@M.ST[IQ,==YGR&8(+J?C%)!/-J%-_LA-RV0([F;
M>[Z\5BY#.8-C791R4PIZ1A!$YJ'U7Z7U@5B^I.X_%Y3L:QEWP(?_M1X5XP*N
M$SI,OFHY:MS^S[KQZ<ZDZ@5&D/&B#6F)6/@N!MK>T/WIP/\RXON^=[ Z=?OM
MMLHT82/D'R&E60UVH\AN5\,W<X7_=YB[DRM(/2*]2HC6H&QLQ!]^1D8Q$7QX
MEJ9-J*75C]R-XC9%Z*:>07<>;70T Z]V[8#U*:YTX((%FO%SR5'4,T.D.O(E
M6C\8_\-">;">(26/;5!$T"\'$EO7T,[DBS^ZSFY,+33"?UV+I#H2PSI!FZ*K
M=(#(\2>&.4$20'@M+,<R7)@T-2OA:_:P;$CHT5_J)JAG&G%FZR=/O&UZZZ*C
MNK/XPEE<,4C4XSN:.-?7,_"Q^+L4YC/C+&\%4^@ AR<=R-.A PD@.N!F?(B@
M0V.1)YR><XX"^U&X<:+XK95OPQCB\>?H01&CF8S[NM?GGW.>3/6Z@-9$XPQ)
M$K0 -F9&POV (,A79"PIV?AQQ&;9#R>^ F_U]A\)08C^5;+?P>:0@YC_@5T9
M'4EO0\SG[#'3CJ^2+SI@C[R:4N](O59.Y@C9\3I249G:QG=EW8VO_L<KSQ=Z
MQJ0[;UTTF-;&+Q6I:%_PRHO,Z)V4XN<U=4@&XUH8Y$F_X+]"DB02":A6) ?E
M5ME)1Y]7GE?23TU>FI"#+;+,?;A9"])<MBO(Z\\V94\QR>;I2](MU.>0-PI/
M?E[IJ ;[.B<]=MJDY%,WKD%-0'N";U.:(TX&>0N^ZJN-S?;9NJDU@XHLCW^!
M;-D/BU,$VX1A0.^B7ON,8%\9M\]ZW3UDJFV0_'4^960.->M+Y(F4%3^E6Y"N
MWY,/;M5I^O.J18#EG/0^5P6&<J:'#K3U,2Z]U@[(]F5')$F2<16%H'[F2011
M-5OI &;9]]LV8E;("KW8!B?"?>A 2S$A@<IBNDAC943R6;N_GVMDR9 +D6N"
MV*-*US!3[ITPII"BIC$8",E(4(8.?-5ZRO#DEUC*(Q"^0(7!L^[$US#\?PQ-
M2J2RI$7M2'#0 7#FKA CS[P+I0/(4^2QO=6_CRZ=QAT4CE[2&P'CS13HP&G(
M5P-=6J8E'5C<;IP'$4Y>@VS-@M^ ;R)P)@SN&"#ISO"4,@1!#O'/0W?<%@\%
M#Q: *;2$23_:A:,2-)CZANTBBB+!P8?XF5F$F*F$TBY&_7W@\ !=]?VX(,;@
M^LD?$&VWVA&88.K:OS>IE^B 7C$=V-J'N'&0@GE1>P10 S(5_?>I /_SP.7W
MN>^#5HQ -(36[]L,TL?$30=4A7?+MD;^-A'J_SQT])V<]/]G$<'_'ZRAW3+Z
M,,PS[ZH)3!H>!-"!C"]OW3?.FY)_A>;@C<[0=IZ8+3 R?X@K[1K*+5Q_#[VI
MJH./6@LJA&B<:SP_^&5 "-,#=20O!V]CIIBQB?O2372 ?1L4Y.,Y)F?&];98
MT*G5,BL)A(5GY\Y]P0#&6O=]U2 Q,Z4C/7<$=SWS&4ENLX2PEW#2AJ]TH<U@
M%Q%GAYZA_&;HK#?9O?_V+:(#.[ #^W\W&<@.=%MN7[N>/Z0S4>IF!_PIHEF*
M#LS/_0E;S[2BJ.*!:#V)>#RZ!77$"Z27]!B_Z+?-P8']$7C9N;Q!AM7^^9W;
MXC]"CQ]F\(+'$KDH+;X0D]P.#=/OG4=YV/$KGIZ_8A'>>[9D1G#YKBF/);.L
M(O=/#.U_?EJ4@,]N5I(.>4XXDS*S_E=K&Z=*C&JA8V:SP(3LXAL^P[N<8S=N
M+(K)#QG,.N:M)&I.ENB2BWA?*G]5ZG>F;+F1^P?PX"LT,<9I]>309-YR-)6;
MS7>,#$%TE< TZ4"Q'/:;L9,' T-A^C+D]%.2\JUJPH5OL5(E4@E,%LR/_ZK^
M5$1M.N27',XR/2SG!&Y3,N]-RAN=</#QZ.==+*L/>!%H<-.P[]V)F\%I1><-
MTM5B(']5+=!NJ[,OSTH8037J:(A?L%/_*K&7!-RG3Y&\<9 @PF0G#G%BB78V
M<BE?N_:^OU&:7LWX4[5T5SY%S,/$);N.V3/B=7EQ*&BSB#;3";R75U]LG3'%
M#)'; G,FJ6=0W$BV!:2[)N;%TYV?I(!N,^WZ3G%R/MQ:N '^%/X#<48>-=I)
M#!VLEYV=(29>V06/^4SRB0J?1WN\:OSJ7G>S;V(<_2P_BJ#0C 9( P9..FVJ
MS/CIAER9//E?V1EFDP\-7AV9.MZT)FOLUWX%+'<1=5S2>)7J_?J,PC&"^&F_
M\MEM1/;.XB0!2[HDU^5*%O&J-4EY'M*3)/'UVS-G*R&_2>-3_ZJ A_:CWL.4
M"[SL8<J(+\L)C2"3?M%^YRMS,3\O6%L%AZZWS#RS#C^A1S)NA@OBI9+W$8'E
MDK*MPQSG/Q>^RE=<3[,5^FO!^C'K20!C<>21RCU[W,KCJK:-/42TX=7-W.!,
M<_0[.1J#7<K:-#(Q\NDG^ _TA,]C4@ENXC:1S&7B\<W*XL5;EP1> 4V7 D2=
M'T5^=^&NMRTTQU3'T>.PY_6R]/M79(5>11]K-M)O/LQY3+Y'K2#'(,+$&9T/
MZ\T;_&J1G&LP1@>,]T#Q$+PF9$]J6I0A:WQTJ)?>%S+2HE:CL#E,G83#T8$@
M_FN.7]/S[CT+7OS16",1T)D#N>+[)'_;LP5QG')J1GD/6B\[@^4@O2::4#Y+
MO4J18GTB</SP5[N?G#7 7/9?Z;$S&V^S" H4$3<OX=88KR ,#V2\)V,B":UX
M+D1E*JGJ/7-/,L&BGK"]8H4+^?@J= (#V4+(MF<G#&7ZI?++&L=BNW4VR46@
M8W#!<<IEDC4.>6S\R&9Y$N_ZV*"KR%L;]3]%ZFTHCJBT4$*>MN'%1<GI["KM
M9/L[<G.E1N0H@%JCREB]EFEJ"N6N(Y0Y)=^>E8JR+H>USQZNC=I-E[JV<A\6
MS5C>56IZ(0U$ 9.B<846+D+]+\4(DF_=1ZR.)%[;N7"!N<YX.3WM6WCDU[Y
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M@'. <X!S@'. <X!S@'. <X!S@'. <X!S@'. <X!S@'. <X!S@'. <X!S@'.
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M]A'+QY$HR76)!5T^%*YNZ'7JC=X5%C!1^#X" K+U9KCEP7\&&\+-:1GV#S]
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M/(]??93Q4^<[+81YFYP5O00)AW'Z+B9$-.$)D18=Z$U$\#O_*/:_\"ENACC
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M?>!KCA5P,H+7Z(7?WM@.MFD <EPB"#6+%FV6H^ 6W*/P<U^<Z!YF\3?"!S9
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MV@CMQ/*MU(NW.SG$\]N-_M20K3JO<<6/FTL%KW]$9F,><NLU!=**'V<#NK!
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M/F_PZ#V]=O]^C)L+8RV*Y4X>COBQ9ET V3B):D0P_IHW4"P-"4K$>Y(2XFG
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ML4<(#DI.K$9I3Y8\=;H^Q<5J8&9_QOKC29F=$XUU'>MB:^L;5F?XDB5C'W@
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M<;>;TX-Y=09]O-9Q(8(@M79$A#=#*Z'I DXLK,*,<P"L!8$&C0C$;(2H#:M
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M'XJ].' ]4=E 7_B!3VS>6>@31UGVJV<DO:4*YZO3/AI'> @_<QEF>VD^NM4
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M;TT7NU<Z.?E@'G8_^ZC<Y]ZN>X2;IUD(QD:=SVLD530J+L9L*TX(==3UOW2
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MK.<^9 -#=A"7#7-TR,JQNZ$@Y#I0"-:JI X"0RQ(YB&X)G_\COP<<Z,GHF/
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M;(;IJ]C=Y !(X%N/7USMUCO.\"")F;>N'1I5(*)B"\*A<ZC;</;4I)U7?X%
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MK7-L4 Z2C\V(G+B >6=]?YIEQ$!>J'NEZBU3MG+-6H$/IN]5O&J7<EL<'R>
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MA]O>4_LQ^V-6Z+=9VT=%V'X_/SG_L7]Y*1:%KW[&GM>75@5<\ &G@6K,M^B
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M',D<E$#J=XA1T0:<7]56CJHPC4.8+3S8YO)6E)!^K!K=9W=N/[G+M#R6>IX
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M7T)@(?;4QGS!RP[-%GXYZFWB<3[I63J-50%G_0"ED-FXW/23Y_]#X]$B@]6
M6SQ%-$Q]"0G949\F>'/W4T)^^-9/3<3[UY'2&:=R_OR9?3Q_Y?21^B;Y4:#Y
MB]UN!FGQDV!/JLGNR&+GZPHU&;0WVBLZ?QZ7K=[4,O)^6)!0JC\YU#X8\,SJ
M*!B6_)+7-+3 VL"A=V4L)Z4)+<OP+\)@"@3RG [P,: %F)[(@E- [# ',!:#
MTP K?I2SH@/8^>;#5K>4MW-SW?NG%*%TP%=WC[_CKT7;05/?[9VP^QU,OQ12
MFH5^&\MNB_ZAB ]V/RN*+=OH^F7LOSDI'/291?/I/79'95GW'7OH1\@K4A-N
M+LSVW(BJT8+*!!Z!6+1CK?,4J<\$2CQ/6G@#DRQZ[[KO0>0BV")VR<32D681
M%T*EA;.YK.MUX^0T1>^,O3<71JY)J)W5&$-529%$/;J0<5GXFH)=HRYQ1R9*
MA3[L9T\)6.P0&RX"8/COK\&\U',D%8)/._ TA<,9!V.:I&9U76VV^'&SL#[M
M0[W%RU-UB1=>_;=@X.DZ.S$E)A]/N+RNN',%>'Q]?_.KZ]NK'QW9]+P" F::
MLV!6Z$P/34[SR)#6_ZMM8_^_&B_5)79W(B%G7,^-QU T?Y"\L0%["]EFS;&C
MPA!'ER_<I[T&SGF8MZ'_V^5.))?A6W_WT0%KD8B?[=B1>*!9<H)+8OK=%S97
M85Y$8M*O==K-(7SU/;&3*9/ALD^ZYY:_]DG(Y*W]V=!YO<UJC012/X&6)IIY
MZ8 )7N"2Z\3=A;LE\D4&OFZA?U\&)U9SOP@UA@4SW?G^6_'_<8<99?J_[O1
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M_GMMVD80CY#\,:YJ\/.G%?[MPOV(-/[HQ:<Y,;E&PJD]JH '38F"*6D%\O>
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M5_GR?5?H+BS1*0Q[^@%K81@@6L]AK-42MR F0>F1(9BI/]QS)-EV];E]1)9
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M 32.R(8-]&3MZI%%E 8:&28!<ZT40YMWN9EZ2 0/N>G^7FK(F:2N?Q>C;LE
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M]I@1SM3ALD7I=[-GDX'((5A]V@\X0[O0]G3RW1#Y+B6-(3[C_DPO>+_/YS/
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MU!:^H"'PY1(177IK470N:\9V)XB;A65J\I[9^)R-[CMUQHP42W;1O#<I.JH
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MKW*E.<$1H&#^I.,Z%4?GCKZS&6M<]29%IY_2#WY5L8=$1IN^VK*>1NP.S04
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M4R3JR96%T..Z,5=JBC6=Q'&Y7RI\X[)WO6\YU#U7N*GTNZ]<X,"L*Q2]'Y3
M;&;YY.K19BN(T5Q$XS7V9L<,^T!NU-WFQ$E<)4:@+^+-S+V4LV&6E?+\JBPF
M6<F'1C9&1K.N7?29T>RK&3ZS(8S[0:+,*!+E>7$S(PKMR7UW 7K4-!@Y!YCZ
M\<S4Y.CE[[U+2C7Q1[M&1%."N3]]9V!WX[N@<QL3DX*4[<K\[C+YA)%=2,E:
MT"2B<W&S5M^B[R+T,1STW6A6 E"MB?!,""D0JSXG(AJ/]D$?K_'T9O1!&!25
M,#,ZYN=A+\T?SR<SJ;*DVW,G:PK"E:YH:.59[2^W7$B!6(P++U*AG35CD++2
M14;_44=#[K_%_Y2<S8OAP"T(&E?/U")#GNHUQAX.K%#T*(HV6(:H%3FXQ)[-
M-J@'@(A211^MIQ5U[$($%K]ZL[]@9;34:+)_MR[3S9SY-:7@B,NK3WIDFPRH
M<W@O[D-9ER)J,W#/M<VY'@:\'Y13,9R$IWL!EL[:,9ST6MB]-]H3J/$#:KGU
MI_$3JWSA-QN=.,=LKR?7VA<2+XW:CL+L\4VK]U*7R0"*T=7^+-VG6K&/U^FL
MZS22+=->59A<5GX=> 1-:KU*?#?6RD-4PUI5_4(X2YJ[2%3!S4U0#I83-70K
MWRYU<%\KX@TL$H0NC5\C<NT.DJZ=Z#)-N^ZP>?-)[5"U_E /H$YH<PZ[["]H
MF H,RBZWV;F'%-KV$(GC]*.:2],^8XQMPQS@$C'@[APU*0)-PY[T Y5I,^='
MT8M@N]O5%TV2H,\;9-WFYS6Q[V93 T]?#6!ANVMPJ+5YO>2*MF#EY6;E7=QO
M#)=\<34<_L>]+W.]O*>E-M3\&XK/.W:6*#2*EL9ZZ6# $>Y$:2^JO\[R?W(D
MS'7<HFU>$-OD1*[NSG(<'LRYK_9]\E:2U<.$C"1XB;44@R6R874Q>:[=E//K
M)Z\OG2_>+SKHQQ$7T-:C"PEG)#->JP?SWU$\O1<<RAT!7K7KZP)'26@7#:[M
M(+Y WM0EZW&(A%NI[0-08Y72$AE"]2@>!]NG?61 K6!X*->"ML.O'5>?7WU=
ML[.".7>#'OTV4N[^:!&907"XJ,HF+8>+JK2U_:@T7<($AJ;O+15*XOSP-'E;
MK8Q56)86:Y;25;KGC[RMCBGSJ-PSGT2B/"@9%CP]K*I6H5&AG-B?&:*1T'R$
MY9,=(_,!??[0K78[8'WI%PNIP&I&@^FWSEN-"U'1M;^EN24..7?99[R]VE?2
MHF9FD##_U@:"#5Y2]0_T:#!!TBI@;S,H@$/8_WFZAI#6O=<>R=LO2:-M-,%.
MF/R>1E*.KVU&1W53MD.*C]C0U;F[WT<F0)'4W-2%0:]R.2;N)1>D/J_RLVW(
M+!]+ 1KH/5!.>#LV\^I$48'$Z=6^='0=2T^B4",#^G[QULU\B*$@"'>KX.FH
MR0">"N$^,\MOX#K!J'*&"4J8M?M7%H&K7IP.Z[W".T"\NC?XC-(D;%DB+.+Q
M+K/L K1>H* A.&/52?-VNK3'^'L^Y:,=O6\WJ$3O"",-4_%1V*==;31'OP]\
M"$LUIP71KBB#PR'-ER4JF>WL7#,Y^#!<)^9*0[&FPX.IV@]W$'".B,:K-4@!
M[NBSY"2SY6 Y6_K>442&)<1$O65"4;F:GZ4Z81PBVNU\/?=[E0-? ]0=/XB9
M>8[_L,RM,1#T.'3._>VAR<@OBJZ[Q4),.,/X6Y-7\K/3K^?O0@>)@^O-"]*3
MP,Q%=2$@AS9G67(];471G0];:OO" Z$"H1.++'CS5?NQ8QTEXQVLC79FV8^8
MY*<.@/1D/8]1O=4J%5LR@!VXZAY)5[2@-3&:/\_YREY.6?_2YU!VZR-]"]#'
MM4HL"&V$<G4Q#M(OW,+T,VK[OWI6Z/M$POS#>(+3?41>> CGJ=F:AA4JU0JL
M,+O=M@)7I",#5*$WR8!E*5YB8$M^1ZA(+78FXN@\L%-NI:8U:2A![)7(^S>)
MJOR^>[IV6_#%RUCN+O-M61ZN:4']5.94Y%![X(JG\TD\[&LS_;*EPZMPME5=
M^1%35 P3U7S)\_@;<ST/M#5$J_.^%:3(\49?)+_#QU"V'4V]*3<Q<9A 1\HH
M,%H+^^:-F\C =X*#\E2PW'F^(CM6\B5'*,3+P[I8]JQ)2>,1Y^!N;:2=(%(.
M!U4X_ZS(Z5[L> 9-]#'Y0P:8M[8D\S7D^,E?"A\J.!(9\M0L%$0'+ ?IBFM.
M!OL4=-=QK"?LN8@.-^XY7>HW?NMC][I>Z9W']M/SA88S! G$VA>JET&D+Q3N
M#0833"_P0;ZL,2P[I&R8ABGYJ%X?9<RML>E#3:)(-K.2POJ<1+<Y*#WMYK!:
M;VD>?T8&-(P8>B;)\JJ"#RL,<8_'O=E('#G/)]CX_ZPUI"C,15]YU7'*J/0$
MW='GJ:L,&KW?5D/R9958BV\B ])&R( 5:!_P6O KOX\:S2FB:JQ!)E:"&3)+
M!Y=2V,(:]11FOH/Z53AK";PTI D>FGI,K3YRUT_RR8DO[OM]D0DTU?LM4QJ'
M*:_%UKH?9B\-K5SVJ?W[^\;/5]29#-@[@E_BA_.( MF:<2!86X.K_L(= I-C
MQ_,T:M]-BQ#LI-)N"U0,/XT:I?(70W5MKQ[<( /<M0/XX^R7K,-1_:\-/<Y1
M= WS;7Z3LR!-K,*J;P8&TE6U*]_2LMY3.E*W(I+,?O+0Y@;[%]MUI1U#"WA(
MG^O;IK#,&7TKV54HHJD]ERGEZIMT@GYCBE2*3M!5(P3W )MPNH]EE^)[/7KF
M\6!)_/8*,'9"YTJ2EY0LM@)7U1*O>?'+:1G80J[U!=9FSV;/'@D)1394.)$X
M)RJD10WVA3EI?)9$_LHP:QXKO_?4]2\_0/]8YC2?";\OG?T[K5+,&J;&&?3^
M4-AV!R8+JC*>V&R>H<:0 :A[<5@^\(QW@L0?$DT.#U!LI0*EKJ$P%_JDHONP
MZ!=SS;)[M#Q]MRLO04>U30?YSO=W_?]G()B#4IRGJ:P5$_7( &@J&9"_7AI[
M<@JV)P/N* 0IVRV(-Y^%QBX?_:-J8H78)W_;/<R6*J N[,D;_I-[:U3&*_#]
MK2Z\2]4T['ZMJ]#)RTS+'["(39_XRSU&.C<E-!\S\]KI?-\[&)R"JWM :$*%
MME58I11R0)KPECHXO%YF"/X[>CV\] V5/5O7C6,(5A+5]ZF5>2@=T3(/YX@#
M=';V4*92*;%7/_EU]AGH?"'[F4+0B?F]K6(U&,$(&%T@26ZCIDJ-/^9MR<1-
MDQN7;OLH_2ZQNHZ/*O+_V_'(/Z^3YI?W*0OHUGQ>67U"IOG[;A_#1)?NT#NA
MXSPW\868U)Y&WVSIZ?1"W,M^IU_/JIJ_:Q6D"0T54=1YH2TA>SU2QF1 S7ZR
MR/;&DSC?D:_4GC$%_*^/5Z-\V&7'Q6>('W4Z1-W0>&Y0)R3N3+:73O[L1*.N
MM2YV1)\V+H2#CT'#'X'N\9/>"*,(]E@^X'+B^$:BNU@O(A^N4J]8$6P3B1SR
M;*"+_OJQS^O5ROG/9A8Q177FO8RLUV,;!,51'X95)UF)B&@^R4<#/-\]^@^,
MA 7=[VB@+8YCA3N]EY#B[1R1>>D3?:6S&L-P-$BF>)W>JVKNWY0 ^JZF^>/+
MVLB=/V_JZS(IDP<YKX ,)*[R_;J;EE/!"JJ2OI!VMU2<Q*F"9:>6=%L:&J9\
MV$8$8),V#%)60Z9I:KB1D%*A21P,P[T9>0!S7"1J.]2V9F'RYJMKJ.:_M_8"
M<M_-\:3)ZEHR.P3QC*N_P1MVIR\^Q"QFE\_UB1C#,2)8_F7JZUVW'U+&GU\K
M=_[YS3+SP8(E%?,F1U]?&PT^J"^CE7D*L=.[,;*$E@2_^"5JY$O=BR;$= #H
MFG.I/)8P<XL TCA!-JTL0 %W7K-7O&Y+F%UJX\5P$5[]S"DS[FO6MW)"N2/X
M.I2I)M^Z[?O<F](]TE&"M7[+,^61'#^]?9\,\/_8<23-V@5&2':0 4S23W\Z
M32R8[#QC29QY&6/KI,JN\+SFP6W?D9#Z$K.Z##4EYKD=)B,EL$GUF#<RX:E^
M8^S P(+?H.(0,U-0JI7@K]"+.ZIJ\;\;9=*6H$<UW%)R%3GOGFQ^5-S8$N4J
M%M3#/!"L@H>LC,8@O!:V.,(7 OP959<+QADG/7G">**X.$:P?;VZ]"O_'MJK
M1&$8B9G?6;OJ$&%[:$O5N:'A0 G0\Z>._5DV$7(A#W$* \)=/J-(UG8.F4*!
M A5$5LD/A-M;U[%N8#"KC^#.%27A"2(%EE<5GYF?HZ/:PJK/]S9=QB"E<W9D
MQG!R=PQW+V7:DFYK;R0W=D,Q ,O7M43GW=.*O9*7[K@6G0=HKDZ>N^D9VG(E
MX&YS]2!N#$,WO=HAT ISX.3BC/E_)TUX [W]W^[JOD'3;^;QI5HU6*K<*+$?
MEW=.G$?I/K\=&"@QJ=(?>\VC1\WT.]BR<-'?&'C+9$$LOU"@:>%:N9;K3HDV
M1?(HY6M4[@WA5;RR@N,CTOC?8%69K R<9$^EZMTD-#OA8=S^ ?(DZJ0Q]%5(
MJ[%XS5!2>>@#(FA"^=9676-NE7N0%U4W&>"@7O7,EZZV3LM!/_[!@:5QVJ^^
M,B=?/TRIB.S+@JUJ )OP_=<WZ"TX3HMPU5@!>+PR#1YH7I-H4NY^8."?\HXB
MPO';^W8&R:-[C;[GQ<'TRTKTZA,;Z2=&+>&]E#E2OXW^W+M5\:I&(EPSF#$Q
M*LL%7>R6TW:IK1I5 R(" _+J52+#.(BB6!NYC&>-R>)W+ ]G%XHR)"H\F@"?
M-8+"/9)S85/XN.XL\"?OF&-=&YRH<N>MC"S;#WN '>T]ZGM1^_L"!V^=QJVN
MR:(+E]F@M,*NY;H\>R$_1&T/?Q]W?)9169:#6F'<$Z6 T1Q"SEET1#_<6]^4
M!MJ$!5.@4$ATD?UT3Y "9RTHQ[\4!8\,9D5%8'JAN%+SI&K.WI8WP)J[5/8=
M"G"']=N (OX/IE: BQ8BB.7MT7?DL*PKY5[[,>1I87X_(3Q<>Z#A]FN_RRDG
M=5PM"Z-F><V#JX)HYN6V2/BH]:_%X8!BP;-!)>5'PGTD+/]]Y>Y-1$,./:X7
M<Z4JA+L6]6K":$1Y/.1MKHGRAJRG<OW_FCGL>QMQ/S6MFSQ2R#'W0XBLP%W*
MQVXBQQZ\A3Z6HTCTL-)3<:&_#/V$FK%SP5/6--]R.KC.67P]0B"\-(WF[PV=
M&VJ%"]29>U.@9']&7!Y&)<G'L?:W8-,$U-[U<U]Q=U6,>76DL=WH=WX'F#<9
MP*PLXA1V]2A;5P=4-26&%KMW2#&KD515J477,,,.0+%O.;7Y6(9/SW'#F VU
MID6/AX5&]6O#)/[L,^7>.S9^V74DW8O?18G%+?,R.>;R-,':VJ9]?&DH91[E
MNPY^,B#DO+LV^N)(:F^J(3#VQ&+A!B[V0;76Y]X)K8'H[S627 !J ]T[B7G-
MAMUML,T+Y7QCJ=^%"7XVJ?&\MO'M]?&U0,G&R+/XI, _^"""CK_PJDPY3Z:#
MAT^1LR1W)7)'_^I0T;BI:89R]QIN^-9)'?7^?F Y\V^B'CZGD"B(V0L<@;H'
M>#C_+:_7X=<(&6+[&&G'=@H,7 TV(H#\&3M3U&A3EIQE#312M-VMKS<];7A*
MY3E26N_P^5K':MK87I  \V8;+4G>WW"U-J4C?WZ8CNC24N9N>VL83NBBC.1]
MXK'81'_+/^D%)C?)H\3YI,K$Q#R^7[$/$'AI/G7VAJY<4&.5>- S)]"E0J+C
MN+1[S,DB9>3,2TNK8=."3)2:V[N2/EI>/PW>+@M%E3J'KE-I 9CCL?\/43@Z
MR;GU)>]BNR?^/R:P^K#(L[2**H*-2\8?P\+IG)[:E!XI!Z$=Z_APNL=B3H43
MHQ@UX?NR?[;.6JN:;5=+@91X6_T9]_PL<QVVYCF&A:=:&JJG:K<=<M>,A[V6
M;OHD"':1:*:/N3W["#I:\$\MPT4I*:?%R;U]=X!C63&.V4+RM=&MW$352=(]
M?[,EJXF5QO 1!^]7S4:FEXR%/)F_^O# )D'TF+:>12XL==?L,93.231_*];>
MKL;<<?GV#X5HK7XK+:7=U)KSTN9K'BNFTG.%K=7Q%M*UOH:=D1OV1L8"1MR1
M\X_7H]G+!=X@T#9\08*+F]7Z5L(K8 2JW>K^=-[DW#$=C_97?B_GEWG/3(ZH
MDI'N4\M!,S"#FGGQL?MY#4!>(A"SU"6J)'9\KN8:/!3]6EU<I"#,AUHEIIU]
M;:HN?9U_L0^D[J^1^=\1E4Y WA\I_.SR_(+9CX20D?Z++@R".S5>!-6:"IW6
M[>?K]3WEP<KKWSN!-]6-<BITCZOL8[$'[*3I7 J,6Z' A_JF/VXV-M5D@%UW
M]=V'.S0U0A#\->EBS"XN%N/0/;A>.7EPKWH*<FZ9^X,M5EMEX7::X"P7P2"I
MI7*IJ6&[%B2*%5P5R\; N\0K=BHM+<Q$BJ_I2!FGBOBO9&JH<"P3M0DF_HQ=
M[TPE^T-"/+PH_>A<[*XK?J9^V?%&H#.R8^T*OT']J%U>\TP'I%8V/-@ESUG^
M&T>JT_CV^"G\Y8X07XK4",5K!C;&#X>I_13%S/WBZ$S,.4R\^NMQ1%3H4AVG
MT6'5^9[[TK^-\>+CRD:+$WO7$F#A.\AUDH1C&VO^-*\FK*V.(ZC \[Q12O<_
MN\_N^[GU%6W :5'IX7LT!)KH_;T*&X8N*4VA'0TU9BP9L->'U>E:H@E60-&@
M _>Z-BU5*\T[FS:^?KCW!%JGH7V;-C&@&+CTQ6X\M(X'J^MWSJD\7-;&B ]?
MZ@SEGO+)KDW7,6?C67WUZ?+ZJS<1E!\@Q<SKN;?.RQ6I5H>-%2A$<0DB92QR
MTEKZ?/:"@/_NKI] =;$_BXL<%QFF#XY=P/!M7URUCI?K>EGN6VMM.T2W\!M?
M1<.T*7.NMVO).9C)58U,K&'74XN)UTWPVK^Y=!G1I??6>_68O]I"S'9V(_ *
MJZ.T^+8."$*9:9P,J#R"U&I![ @B%YST<>_&'+OPB*;<*/.@$QD <_C@KJ@0
M4 84P$&8F\D >_.@7X:C.;A]9;/\.E6V?OY+R;O_R"/_,[?Q/6]0--X+UXZA
MCY;6*BN03T_>D)FNG[JM'B?XTY2[ZO@VO8$PTNCC+[L[7^+#Y3E$T.]:ZUAB
ML4MLH=.+ES"AA0))"+?C[.BO!9"Y=V71\0KN]D8J& :G8$:"D3]K+Z)6_JV7
ME9.L5Z46R#!"_XW-.R8)20"PX9__2BZH*;=%:ASYY'#X;@^3L^F:Y^5?W-J"
MW__C[<AX@;6"X,[OXI2># XY?L)\RY?X)D/OD8N*/00B\E?U,E> ERWQ@?LT
M#>(^2%,&A);^"T>C#(7^UYI6[3.\!'XB>#Q#?2*8 N=R@(X,BKD(@JCR*'PC
M]<!]X1O]_G$>SXELQE&GU8Z50Z6_.THY9C4I&M$6CG;UN7JL^^B-T\\LJ9LR
MO48*6IY]Z=RO_"K.FN$=)$6,7A76"SSF#;UQ'M?#$O>@>8K411GZ#J3:-6R\
M."< Y/L&LD1!HW-Y\>Z%=$_!4WS5,3$FJ XG ?=G:OVDIXJK<85L\.F0E=(O
M*?O>7T#A"!*"YU)]L\F;NC_EMH)75LU-!NB#12(N"AWFJ'Q[LEF_ +D3J+L&
MPK'2-,JMO"W&X?CJ%6-]?>NAY0G7A0<+SO,5>1U6Q6]M<WS*,+/=NM,ZZ>7#
M<6IP<\6W#Q8GR>#/&4AAT0/]YSU-4'-=Y+99O(L,G1$M86LG86GNO UK]T)K
MN[C0;0?E8M5?3<#,E;QTZ]HF]VV;JNO5^ V[YT"&8Q^-M]'Y=)VQRU)+"1QB
M^=@G!^UA;Z9$8:4^]G\%$R@9 #](!EQ5 ]_B?VVY.*P*=M-)KF1$5$BC31U2
M)EBUB$U&QLES7P%,DI<.9KY+RQH;;/4YA%H5Z:I[A=$'!_TD/L>4U[45E&$1
M>B/A"FE&R>PFQ;1,G^4=H$^$[^ZB6!+<L1KTEP3*ST=J1&PTTMG&.F[.@C=M
M5J(&)#MS\TI&B"W:C<YK@;R]"8S=O PP<4ISQ,ZU4A-J)_MTJ9O<35ZU4:+$
MIR6Q.[!19B<>#A?^:>FK(@4MF:[H_.36@ (;)B&H83^WO$/6LJ(DZH!R!\PN
MG42_3>(BB,>BTY]ZE81$4OY513:=E""1<MR:SJ>3J*A>4<[N, Y%V1*DV5)A
M6Y18NC L7>K&AG#X\/K[M9NJ*/Y0IK0V7XCETHZ<H!-L\JP*]W^RX<NVATI7
MX6-6S'EO.E59J#GXL_5Q3Y3\EJDR_%RF::2TVZ\L&*PUJ2P4.JPL."/U50R-
MEJA\VZQN*BLROK9B&BEW7.&W D1?6J&/@%P)EK0MF1_U*69*&T[X9*.M_V(T
M?.X.2/G39NL#\=K"B:5HR!P<LARBH![@W@5!/.UH8Y16GQ01;*R<@B@;5>0S
M]$XLOT$+#140')2G=XR,'<68]*V>NA,,_._IB'INK!_4'D\XL(QD/+I'B+EF
M'9UF&1?2U=_.SE[<H G5M^);:4,0VGEN3_-5)\.X>8=<2__9?EB +ZH57,\^
M4Q=#WR:J9TE[O][J\JS^%D[_A.X_H%6Y(SS8>C=T@N<ZWOV7<DZ(G_*/?[[\
MG]ELR:LX&]-7O&\W$:5X:EPN1J6;SEA48G%U5Z<MLZ[K1A%#WP8\K[I&+.32
M[=RI_]HY X>98U!@5E,\8R<BLB6,ZZ_I[/>49W5&3E=%J &?Y7/70%D[$%C4
M!RDH_7;CMQ2PMO21_:O)'Q$<&]*T( DZ NOCWYS5:E?2^FSG'*'B^!""IK_X
M*I]EGY.?3*:'*Z,>9B>V2C8]7V0YTN[V#:!<W^,>+Q 94 =Z+P(3A"5(N_Q.
MJSNO7IQ6S-^7?7Q17D[_P2VSY6 Z;/XS_(=5M%=7HT_%#[K]SQ9 @2G'JKJ9
M65]F3Z#R=P]+4&2P[D__KF>PZ:.@VI;)?9"WUSV-@ Y*'C7J</J[K;IX%=0P
MX\I2SVA,8UV3?YUOG,CO9I8 KOF46Z\\M3N(U?[YSM^J]RZD_@$P2VD<)\V\
M@N!%QRS3.1CH:.L5%0KGY&V<+3PS1:<D=M-[/MJ-Q<5(7V74#5KS4*J,'N*Y
MRR:/DC,<6_/^L=60VVGU=]T\W1%Z2P6V^0'4Y53:Z!S])N>[#@6E_7I=A "&
M'\&Z02$0J??N<05AY:!'E'%5,^(G]DH.+DY)F9U'SORE&DOG=Q;^M0J DEH/
M-S$".;1W'TJ/I49'+=/1OPPRT2LL_:2@VPMQ^RE"8/49G:(%N6*64* (92&1
MF#RP+)+/\M!D03!#'EHA&<FSHW??"O?+7;=K-:.7CG.%2_Y-8P_L>&"'H58_
M)%+*\_I[/?1(LZ>\/92H@4_Z27R$J7$Y*V %L;C<5:\>9BX8]/X/6<'2(UU(
M:JVT9 !TKNV("?H:#UM-HL.KM+<AE(4F5.J.TM+Y78 UFAX9*MY[GR-0,](J
M=FT*H> -E=J,5 ?M%2"#N7]75Z ;W(&KRFRIO:8[]3V7,.U_A22L=%1<60CO
MU=%V[8@,8%7_N6".#\C[U&'G0.G"[[A&]3([G-;AN_0F&8!!YEXA [Z#HL,P
M'/0D);/G\\-BGTH/?YY!U,:MV%?( "1%QR+_3"WZWHS.3/K&V:J"8Y:._Y-(
MW^O7N@M0@M\H+/OB0Q\YME[%_ORX$K=K?NI^G!*^J.,_GF<Y6NDNT,%U1M$C
MK*38N0OF:\J+_1]DG8Z?]5'#DKZ51UEP$*8MJCD@:,52MZ+,[2V:-"E]-! ^
M#7H=[+94_^TF -F_#.(F ^ARENG1O#4!9GVI;>Y(Y8%<8Y66!,(%M;HT"N.?
MA$55'3"!LOR1N&@,\(,WDK,I1QO&&,(PZNI>=#]=,_XH5.NZRN)M3 B=.F8&
M%X\)ZZ%[N9WE#3>63Z;*ATW=-4&\O*(W43:@Q5T#<1-*+R\< ZK[!D;\\X]=
M2#[:;= _ QES1$3C?GI ]O7\L]2Q2_W2JUE1_V:BPD6QG"'.).G'C$C$=XT3
MSC5C8H_N])Z"@L5)R;)BR+](^*RZ,CZ9*O>YMG_L:_0!;:N1X+ER977DZAKN
M2B'>!5O4N<2<8C1VP&7UI&F]JA$H]L8"Y2NAQKY?@.)3<NE6<2YFX(T'WWB3
M_.?Q.,K>_C& )J+_7H7PR>?XNK?9A!07[Z021RC='Y6W[@ G^8)TCP1#@V>N
M/_='YF@%9Z@63)+>*:?M6%W';D1@Z34M@6IMB6<S"F! :>_2@H]B\1F)ZU6Y
MT=ABXM#6__3(G_][_<^O<%POT@#N$M3D7U&.I,K+I"CN^/U;T0= 8M*V=15=
M P'=&1>>E"6/_*;)JY,%+*@^9N^SN)[[W\^>&BY#B#D926T++63 1/1.$=HU
M/^E6L#5&YLOH>OF1/I*%^^,\\^BN,>D:&= _YT\X1RZ=WT\L.B]065M19@^;
M,7<_%\I+T;6>/#S7SG9!PC;/>)]MMUX;\TZBI[L^HUT;ISVW#BM**>3Z7_\]
M4LPZ[<.!8> ;P>[XF.^F-?=RW.Q?Q2F&[J-L0M6BH24NZZ-S)R0]\U5WPDG8
MF7%MWE*=E3/XAX%QH;M4B*85F/#BXC[HL9KGGG%D@*9 8$1 &%J2#.!7Z>$]
M'A _YTI+<_^098@?7X:WTBO?/4_T%M6C&MZ(\Y)&5!\?#G>5)DW)$J^TQF%X
MN^-"S)>GD^(JUJBL)[-<\B&G3@S)M\_2#4]CU]OLAX7H_' ^D][(PB77 .XU
M!O&2VHD'YW3!2_1Q,)7K1$6L9F=J\TZJBP>B\[O/DVXMZBI'%!G0.NS]JDU)
M2]//OL7WW/!AD9O)\%XV< *=,_/16R<..H=:=4B0OI1-!MR22J&V'DVO]L6)
MC9(!P;''87/2IJU7M@<2JH9.[IBS=_SE_&8$C6EEC^IHJS$NSU-+$NO3-O%4
MB?E@.8S_!NEM.)@[>-DT$6;/&8>D6@IQI2..B4EF,C58*1Q2,7C$%KM^ <W'
M64R\0B[TD^XG=?+08ZCW"!7.C4DQ1$OKXMV3E(!2@355"]4B_A4*!;N8_K>T
MJ_7N"!"*MRLIVNJ6B]*=;,,9@U=!06LUCL1*^J'">>'7%?Z ^-4?Y^F*%,L'
MT6.[\I 88HM7M\T6I'KQA?:LJK+]/)'PM4Y[Y)%Y&XRE:MG]*I[!G08?.J@-
M^^/^,VDXZD4XOV.^!NV+"$W*SP#JU!F8@[ZINLZ@^^Z!4+9!JLMHV.Z^0AO-
MHG8(02#SC;T?&?#);5VB3Y"&\=<YH *$>X#)^61%,T54Q6'[?XT&_AF4O"^2
M7/( 0?\V7:[/2DDX#P,F9O&%S;8$7(#0H!$98$M_RG^1&+,&[N>7Y:?) !YH
MWD6&9Z:0F%7 8^WG5<=.(MZ\M/Y W5>U\*G]7&W;B"</KH,<VU%4!2(A[=+[
M5E?Q07G^]%T/'1&NGVZU5U'F$*L:5ZHBG>BQC*/@HN=87N33KA,';<QH3+FM
M$]]$A>F]/H6G:??[D)ZV)$IA))$92Z&.G8ET/2Z7/[LFBKC]5_RKI-OL:5H?
MYK/7S.Y$31%&I^7X7(5"FZA_-'DPA5(4)ZC,XL5784OQ4J[:92+[^LE')JZ=
M/7_OS\NZ;==? 8AS"W=+A5$Y+<J=0YO5'$K:X<8R?X=]<8>T985&3R*Y>TVX
M_'J%_]3R)G%$Q;<^O@#V&TB3'67VNGC8R,^2O2YG8H^)S$13["]4;H-T)U&:
M#$CMQ4:=>]63 0B?5ZV/E;]5PX]W=(&1.N4H+V2KJ+_"<RQU%YUOYVKO?(^[
MM51ZUR#%;^\G X9)&90W(,__7@2W]\P%^BGUJ7"Z3LASQU7*\VFAA*3A&*++
MC.+%,MQ5B6[;X_8@ _*RFMUQ#\B %-"OL%ECX#DK-Q/IP9GXD) K/>B45W5<
MW7\3S8YM)@J-OZZ<Z!Q>U=76@M/*7F7\\25Q4_'^OM?V1P;?!\+IRO+!@95X
M4)%T1+(Y&< T_U.T;&;CL*8]Y87OD57YT49EF_WHQZR,"#-"K[*0&$EPNL-=
MS,V*TK8A[DR!ZXTO!4]>-8F**# >+/>N50R;"+,MP3=NG:ZXB4VH.?=]2P$.
M"Q:CQP)G6A&[9W9'@W2M^4X>DMZ)#Z:_G@.D\RP2EL(&^T,+X*-OZHBCF<W"
M$+QK@M?PR(&8Y=<^(N&G)-Z^]1<TC23V(I0Q=-**%PN;J-Y"I(AX#3%]K@?>
M W8_T(#^\#F(MN+!'$2\P3(OECI[_V!/D4.EF>CVT?#0#_55,M_RS6<Y<SJ1
M*/0SM@J$J 1?M-S4/'S2^N8@&:"S /\9.I$3QC4SY?,7N/<Q;V'GK"A>T2>
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M!<&[JMF9%&-%UY"A.VV3W</28S7RIC)7CG>#\W.3QA69S>+E#T87$-6@>"O
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M]AWI1:]IZ;P-.Z:#P_JJ\+R1+<N%<<./"K?J1%TV66_K9"-EJ%GPI>66&Z<
MM.\I( ]L.T0<H9,SW7QN"M$#!%KA!\XK1=1%PND@)9I"343F-Y,E\V_]MGZ@
M3L@WTF+5!18A-:C)IX"E"J@^W<A5P=<>8;U/@'2DY*FA=XH^!/52TRF 9-\4
M@EG4Z?1[+Q%_T=;"1RS^ZD]9 95!ZS=F=&7TLYN''^O?MFN#+]BE:Y8BY:DY
M% O/.7R8ZLS,MSB6Z7F9ZPE^TBNW347Q[]?W<7MR.+5V7\T[Y$?E%I/=(S:M
M1;Z"KO)6?:\ZV8(:2Q(+Z%:@3#7]!3GU8)6>Q56#'382'7!6A6:OR:X;J.)K
M=8F[C\\_?JC[TABVVGIVL0BDOX(&GP(B&[R$>4*[ [PNVI=-VFA734]]C).J
M;)6)+RU#,2$MUT".65$!1E$PP;4T]L9X&;#!(S?QW'C&AC/Z#:&'$1>8A"X<
MFRF?O((^&GE+:!*^/++-<6+9W!"7AT)=PXF_^"P@Q)?^GLFVMC9PK]QV'0\_
MXAM"2:]L[FR< EB]9T6)"BWRU!2WVO3X][+[-_P1I<$?,'OG2VB84\"NUA9H
M8W?Q%/"P1%.4,-W"1C^NQK];5D:!6^_^UC7K"DIO\?^:R3'4*+.".-+CR4G'
M#I=C=*_PI-TMV,P9HPJR.KVNV93^^IY,((#YX/6 73C.:KX6TXF(&.FRY\DH
M7MME[G,>A0Z_NK*J\2L)87S.T\C H%HI@J0A_6@W/J;@2/ !R8_2DN7KC#%R
M;:9W7#5HT)#BX$47&A#K?<&K.= P#N(SJQ+WGAUF(C70O?F*:R,A[0#$"WU*
M& SVJI>K#7H]?N[EK<^EQ<-]J^P,?9Q' 0NHXN&DU$>77'8+#W1>:$$K3^B^
MQ8WRA(Q: 'Y2EK>Q<.[?+@(DA'G4/ROBX^MX]\0)#PDR>O$VT<W'9 QGP_8%
M2J]WB>SYP3PT+<;UN*'E.7&'DAD9J9ER"CB6*5E?=Z==.DA=I9^4_5B4T8P<
M/ ]GPRNF%"T8BAHV/>,KVY%;B+Y_H4?<(GC)>)6F2<!\0FIE)B]H2+QHE#*W
MFL1KW?I'Z.G8ZP_2'\EQ)_)^=@N^T4[86@.J[>SN&]W)6RM1#NWEYQFU,=\/
M"BB*U#3H'0*JL[=\S>RXM@O720AK2KN!8(DE5!8-"M?>H1T>3(@O^2,VT[/(
MEGCVIFEJ3C]DY@ZM>>\8.^IKI3D@]Q4A9S^3^0]&<1<5>2 -#P'5WD"S5E^?
M=*:)F"4*%,',L?WNUQ,# 6V?,\>V\'R:-UQL&0CG<P(5-T'@^I]^F_9FYU82
MOH1+J05_2QHY4YU2YW<*B,!K>,F ;0U^T]/A+X+6,86NACK%;IX8MN"?+!C1
M:@WG@1/4;77#XG5;I3'141E9">6+3OD#UZ.^57,XOOX>^V9.3CU3!Q9*,B!X
MT\\&XYAQ/2\>\VQ</+#$^YM0XQG(IPHF%3'.?07H96JVG+K] HM#Q^Q=)57-
M9C?9/F?VRU)D,55HO\=<<+<_4'\UD;K<D(LV^.IIR[+O=N!S#QUG5ZT4-6_'
M/$TN: .Y#BG*7(.-VL>OZ)AJ+7^UB')\=:]'93'/V9#(O;/@M)F,7/=]HU1P
MKM'21OXC8Y6J(W$[EW/[J705-;?EQIKF9;)WJ4N53>=Q=\$[TF>+$L8;@A G
MT:IPB23\F0K8!8I, X+DWC+D]JS-%]GAKJ*G<N?H$[<Z[5(9>9R_P9M['1=
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M:%HF8D_@Q'K=+/,ZT2V$PNQV5\NM\$EB/P_YZQ)[MF8CS('>^6QY"9J1<Z<
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M#R\<+TS__E..OQ/>:CP0GUOBH$&T06^ZT<V7.WSS&FC7<AGD CJ2 S+#-U:
M5$G]#3BF@,[\633KT7WXUW6X4 N/#M&@PV<\%48WA&&!3ZN^S!B)/A96;FV]
M95 (.#-],JY5T T/ ['N.^];R;QODQ%!].V^@\RZWS@O;W$U0J)>(FUO<,K
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M4EN!E]=4X=UXX5D_#W#)%C>O5O6L]95'UDW!2R;7S$2X1 D["7;:H]P^2K@
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MTE(7"MH-@0ND9$?[4FN\U2,P*#/.X;HH-\Z,R4.95W%JR' #?6"?/]) *W<
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M::;'5($"BVZF\IPOM!)OI>Y^B!'"\303/S76-T[R8_XS2+"O]3_/_1<@Z_R
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MU=%9H:K]5A,AF'=K#)W,F;&K/$KHD4MX8T;_DLD?W77+7FFN8E^H2[4,-P)
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M+EL+V@68$Z8G$<OJ)9%0+!#>W^\-$#90ND/E4J] NV_>A7. Y7I.?!<J7M(
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MALM 9Q315<=J.NIF$Y IZ5W2/8OVQ?SCXP *3#=-\UZI5^@I6 &)[]Y&+K9
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MI(R$U)>_QE1)'@8$Y-X:EM)T_'*N_W6-[''=PI?E/PG ;^4U:;ISFRHG1S2
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MM'JQ@;-SOBZJ"/X4NF6L+,WQ*[O"C.'"&N4 T58B2[*C!\C97M@N)8N*=C/
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M'"7-W\Z8?8%O3&[5+E3&+C[3-?/M52ZA%!^;;C"DO&7\Y)-&\08\F*J7 F7
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M Q'=R-0AR[Y-%:TD094_%45"-\2G2/J#IE%!&NS<!^S;7W#(-LSE&@ILJT/
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M73_G!ZQ&1$$9ODQOI1+9'<>4?KB^2%F?2V">U.;^N9^W]>/TD$MO1X8&^'G
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MHNI[F"46-@0#X@(B%@6'B ^4XF?=#'XTN06C="_^XM8"!+O_D?/8WY,'A=,
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M\78M?-DB6-GQ ?[F-X>>"_R[S/Q.X;>9!\+.\> %+ERL^2@8EW F=,$*\N2
MYS#C^@'F_UIK=!S%K5$-]J) V[P0&N!K>K,=@1Z *8%?:8 _C^#K12AWHB_]
M@.-V((&EEGZ D2&R'61YPE:(.X1G#ILZ>N+;6S5OX[NBBZ:#U!RI/YNC5GH5
MYU]F34-#]:<_?DCM96**PV^!W\ %%QLC_Q(1:"5_5_!.W_)[=G$1!]7-[4.N
M&FN]D;E_;4"7=A0W3@<^A$3&)KO<-LHI^_6Z ;"O\ ?OR$1RM]5RPO7=KZ^+
M4@L-.I*TB).X&'/6Y U@X>+I [0?I1Z^DK..(7 "3Z]OW4"R#\!>3" []^&I
M&NW_NSC.?4X4%Q"[U%#F/*'X1TG<Z6KZ["O>$/$K"3OJG$?G/RW 3SB:033
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M]!)R66]!5M" 5>!T[[&-4\SK:5,^3D3I-S(DE5("50@L@$H17TOJ3A<]K,L
M;C=$JM)-JJ?-;*.GQH>4$XV^VA*I] U,DU,ET9UT+>BY%^O4IHA<W++]Q-Z2
M76Q_AIENE4+B'T$^'G'U=&FI!IE93:])MV6>>)ZT,!^5"/+]5JF:'YYSX'YN
M=('*]4O8LQ&Y%*;H?T\RH]%2O_TH5D.VV+]US6^E=>T^,K>S+E-,7B$CG8D(
M0B@1M" ;:CQZ!.>!U-FF3;)[,B0+80;>'LL.R@?Q=P57))949$W-?XD[+D8W
M>IVF@SPW"NJC6\W:?!0#>5FC^=L9K@#+_7-Y*1^:9?R_E&/C>0X<\<+[P=C
M48>> LEGZ5-<;[Q-K&:S8=R]U&FGEYK,_$.G#\E(D@O81(M:"#K6VR\K+NB9
M_T1A284..X*+]Y$_G[RB\E)_YU[%<?&FS+X83)&7B&XLZ4$D?:I+R4_"I+V
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MFI[CFN>@3X@Q5>YS*OB=U/4O$09LGX!R$=G<5W39JY[[8+DW3X_;53D7+]$
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M:($&Z!9F_W_8^\ZHIK]NS2C- D20(E*" B)=0&D"$94N1KI2 DH3$)'>"45
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M. =\KJZNN>H^_;S)$CSD=FE"WN8AAR6C9#?W\O6,%WZ*$0FE.NZ*[U,6X9U
MII<_0C!FG]Q+T"-[FD<O!N7#U[KZ'D^= VP'ETPA6P0L6 ^O4(C/W14MWA%V
MHXE\]=F+<UE/)8[+>ED[5>Y@4!;Q-JO@(>/86-*2V0V8S5M_;OL/^$2E,;,V
MY-TP6U;MX'(=E&ML#O/KD0^#G%'.-Q-;S**X[I7=!']"<J^? R9+I31$GK!Q
M^MVXE"UV8(W(O5N@SO<^1&J^Z;DF&MZFP(\V"[T]5!EOP][8LV/5E23_T7D
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M%XKJ8W-6M*;-K'V_H1>YNOX,$D "X[;*.G#\78\):E'!4BDY8@EQB\O4MWA
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MS[SH^#_G $Y%U@THPRCQ@6(=1D!>'3-GC6X\XMUZJA,1$; ?6;9%8TXM-':
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M;/[-5_GOVLQ,V$3^.6#8UK;$,GN!6"K@\_,_=FG35F8*_0_KZ?YMT(V$GD7
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M'YI0$OXPK&.(V^YTG_'8@P6&36EOFQ 1FWLSMD>1<HN<A?1ZUW*LNGGC3OR
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M>Y//QE.55<XN=M/TVZ_71&E:+\KMZS062$'&=4RJ2N5G*@WJYK6PG6?;QAB
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M&%PU1N3NPW?7Z^AQ"96;S%EU/4__?<[W&8#=% H#X$R:E[=E;G97XPS^T#(
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M6)+L8\82LHXEE&)""#%D&>M,&(20/>M@+-DR8QW,\OC<QWT\Q_W]Z7Y^>OZ
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MD#QB3^XA;K0W?<'<SC EF<5M>TO6-7PTT[63_?76RG8K15-![]6%K;0T*SK
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MD>7;<D[O[D832\-/)4GA6$OOGWTN*SWB9Z+\IS^-NE +6N2+<SV]'QN.%\9
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MWE@,Z@)%-\F-BDFE]UDXC.UL!FQ<*+QR,?82\Z:5>$2PJ]CG3\^:X'\*AN=
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M8JGQAG1%93:!"DUZ0OT2TC1%!\3M[VI,=\]IC-!$R*H;X#&!]T^TZZ^>C!C
MUN4;0:D]6\Z\"W@N2B"YU3.@__RJ,3$O\?JUR9O/=%:^$L1K7]VF \*8V3U!
MWGVE&6T8OGJ+!URSS0V;=BYGX'O7RE79XS&@M2:Q7(^G\R#V\%B68$+TX1KM
MFS0+'2#O4G]#HCPC7#1[1I'8%F1S%P:D^)!LXBCA3)&8:W8=OE]GG]AY!J[S
M7GOV\O/6D8'+#W%6L0M[2UBO?J7.-7?1K:[2%S36L 8+O*F56*ACB%FV5-^
M,IR@H2_V <NESD]"+V:5%. ],:PCW_[=+9%C;0J?D>Z6+5F1>SG+3$H*4)RC
M37U$M(??:NB >W:F;2_UV8W2A'S#:&6='00/KZ%&HA44L@ Z9UQ.GG"J'E57
MX\M@ZW]S+RWR:HN,V*(PYS73_L+R5R"A174U CX)*2*T;44,[\I><#I[/4?
M?HWWUYLG\UDI]VW/*MS_BGI)S,L\WTI$ZH[X1$(@_5PL(??W;Q!O(']/#!S
MV6 *%*:<?R F,S[LY[O%OI?/:OZ;?(%D%8BXLYSQZ1+$$]F9GC6KX3LZ .PP
M\:4#&/*'_P+Y_]<YY?@BLLVB+%]3;F5QV]/1S4) 4OUOPA/ 5PUM<ZW5C0VP
M /31HAD3^::)?GN3_L'<MYJN1(\##Q^%-[G=KJY*8HTH"2)BRSL(@IK^"P,1
M?V%$FS*CA+_H)[M(SO,E:#?(GV@CAC'I3!(2:8;%B]C;Q>^02_X@-L5^=UP>
MTW"=/,<:'3!IW]]^Q]'N2)X]2Z>*P26](X)=JO7UWB.=L1F^A.Y>.%I_E@@^
MF8"?Z+7^FUB<B!P?YX"Z+1#O2XNOIX;"L<X73U[O8%B _[6(;PEM>],!KJ X
M"P?<RC =(/L9N=>U][4$_IQJN^Z0(X8L73LVP\FS0 Y[W(K(V?JC*!&N^H-L
MDK$$0,' ZIDID^(*J,X,Y\L)52)6)H<L].N<J*XL[G7(')VZ*K1>N:/\S$]1
MF<]$_<V->7P<Y@IZ?"\LK&%[WL;2P\=N@K7(C.E/SBYV.I'VP)<=_N<!'?"W
MN.BQ07D([/F[_0RL^Y$HOLM,! +C)0O-B0^C8'WE1_<J#A#7@=FN;#O?,U>E
MZD)0;R@NIX&W$NE='OS\T'1H[\36FB]K1YK2?S_ _.H3]7H&N;Q(K;4\M@!L
MK1+EHQH=,-&*H,6(!H!KWABRM\DS,YI_GJX1"?T@DN'0<S,48_&[B[8,NNN'
MY-94"&YN/W06()HF0B!?@W<MZI,K2US/2N=&,GFN"OYT27\)^.O?=>__KV-2
MCYN\__ZCJB<+U1AZ?FN%#EH32Q!U=$ 2G.GY:,O=WV1X)RLT8L*X2:#(V@+G
M)GS#DI2IX3>MN O^_]CF5J')3;$=UKP9'%"G<=L5G<6_4^E]K8L,%EQ7C?YS
M>*#">YJH_T>36ZW1V,%?.N J64'^Y.-V&14NL6[0<6%4I6_>1Z*Q$KR(IJ33
M ?SP/U>VZ8 '=0%6O13K_[8%%[=/&$\C[V_6-QGX)>>DX83:Q5;V>]242YIL
M4<' *>[3*WYC\R7$)=.DR,.''4@6N8K%FFKOF@T;Z6^M!K.[9\N^1$?6?:A.
M6WM(1?XK_D[-@AK[^1@-<GFR"SKGO['C70775):2]'6)E?E2D5"Y+QM\W+,T
MVOJ!E9UZI^Z12JXR8+6$) 8I<-[70SY SKD! R]65N32&@F#25C&+^@Q]2=3
M08GJJL,W'$U<$V)E\R+*]"R/^2Q:FW(.IT'":_QS+&!>'?]<P0JV[4_Z5VY]
M^81X%'5[_;8S X$%A< H$0<*\STU&7Z/#QQ+\"2SX9Z.!IPS;!+GT%*/=D*W
M.5W:74"T"9>#@/;Z+M[/#KGZV#JZ5<,_+6#?5*E<Q3@W;O7K4GN<IJ9!&]LR
M6WJS0<K)+(ONG?@4&_[LO(M.2NW'YUJ*)1M;=5^M5EYTA=9?D/*,N),TIA&T
MB.X<C&P:SZ.IA+%SO@AZ%?(\[,60ODB5WH/[ I=@;FVKZS=?P('JABC)<3B+
MI@"N25VARB[OMLA5A&2FR=MOH6DM.;MTP-25C<6\PH5DS8WNP*GGF27"/ZIL
M[=X]W[VGU)\Z\/(\'($U,MF9+)I^E;[B#=) 5$+="%MWVC19FDB*&]G5L;R9
MO)I[1=75-C/I,FWJBHNH%*2 W-)$"RB@B Q^$ AZGK B>>7))4V+H6:EXNUW
MW)\L8*-!V2Q$IK:T4A>1'?L/#A-\FUH@Q X*1O:'L&5WT %LVC[Y3TWNS4@[
M(]<G<C!6_2 I5UV\K/K88 I&(K@9EW>%C)K/!74>/_/ B _[+$3YLQ^7CA7K
M&?)GC+J7 $VC_X4>P0]*:F(T9:$*359G%XTSDZ<;K?(4L.5*JV#S1_RA,N/@
MSTL5CX[E1V56V7F@KTA(!"4H;$$^YB!PP<NV8@#UJNP'K_)SX>]EC?.NM[U>
MRN!;]/WD4'%UA@N2)J+?*M_ @R]+[*/RX$^G@[$+O"3%N3--Z4><TYC?'X#E
MB@]M[N8>&-$!R7'R@=?W?3I].8-/"* ?1]X!9OS&Q6245KINBH><A.5.SU:C
M2U*YR$NCS"WG$A(#H3AC'A]SD'>KS@Q=7/!55JYGRC6(<:%I7IH)]- FWS/'
M) 7M=C6OT-T7[G&-97KVP7>]/RJ"UHPB'.P+SG!21J<S,QDR/QVBKEU@MWXO
M_U>@JLVDR\O!I-2R#L_(F8-!_\C'4O]J3VC \8Z$PPS]CW]7#]Z05C[PH3V^
MO< (US5IR_+=T8I,X,P4%_@B(7'2GU-'+">X)WVC2<';L>1HB$_ =880_M2R
M?+FJA@%\9N8[$8XS3-%;EY"D1 (P<:OP8P>0;<NK]HA' &S^[/ROEY8UN O=
M#UEM<B?I@'8P<,MXX1[IRSBJ4B7I7<WT=^E>S*B:WIV)B:\K=0G4Q>1:GZD/
MV(5&L!5J?RET8@M$<@"3P>'S1W?##FIJFW)<PH3:>&(M=?@90C^)W'DM4>'6
M70H-)<<]"]CB\I9ISW'M6YGRF&!.5J_.LTPG825=2LT^\Z:=>'5]GPN^*.!C
MG;/$N7XQ%E.0HABKF,QS0YJY3!6@9FVY7Q(T2P> EQR1+>E;QS4=('<Z($4(
MGU1'M6D7DZ]-F<:%>M:$5!</WH&<"W 3.<^88A.EYM>/3<&*RK>PE_T)MFFO
MERD+KC%G>/8]VU9'1+Z773;DASI  1)%U.\[\0A^=XDI4\GL>%E4*M9P%.N=
M[+9]?K4^Q4S\]MI;7AL@D0NN6G<RZ+Y22=.:J#G(]=K$/!]9!P+5S[EB+H^[
M#U-,BMLQ;G,99_6NI6A^TS:82 4U]>\IQIUPS\K]JR-,OSEGX8Y./;]^QB,Y
MW*)7T$!"G*@+[3ZY/-7I0C"+SQHG<.@$B?A%3C[(B#Q^''V8LP//N5) G:5,
MK+P6DN]DYW:BC>8@WEP=/20'"LRF#_Y\^^0M;]P /WQ.<K_"%P$4V=8$XCUH
M0L2QA/4\F=&(G4*WFU7EHF6!B!;<*D.)H":%*0Z^=+ //UZ6HF7(*9D,%)WX
MS(57!PF_F/YIO97XJ!;Q*V= <Z>$?\R)4@F1#QB%%!I"-[WJ5K?.S)?SDBZ5
M:V8NR@C8]#<-Y1O@>@26JRP4E]C_U82S^>.K,W?687=(LXLR5QQ#7I6AS84,
M+S#MHLHW5H"3IL/"[ E@;KF*45F.F1"_KW]Y3*09=BJN8^<<>C[TP_[17OS%
M2%'\2+)T $=<A*;8'^V "FDZP+"U43B+.QD',!VJ=9&=7)IG'9?ZOTK4& G?
M+2?1CN>HW(.?"[X&X@KN7DE8_S<.2&$_]^[[]9!;6K,_ 2DMUL];%\T0L&N_
M?7$8L2'*G6+A$"%(O*#QVX/T'[%I@P_I , WWW_^<B=[I_9V%XWMI?W#$E<_
M4Q3)'\J@S\G&X:4>0/<ABE&!@U;_K@[O#W.K+ATH5N$3A]_/%8P',26>=(5
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M4JH6<Y"W%AN1?O=%G;V^LCDZ-U6>_S&_1OT6RRLZ!R/AQ)MQ*XFAZL%5,GP
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M:BE9_BI!]D-!-_&;Y7"GD7*B$G:[ _V1<^2SE)>+FNF#A;@(+CL=,6%;>^_
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MX>/][B8;OO%6 13]MCFT$TCW_6/2MLOB>**T4-P_L:O]59J<Q<_Z'^]=$(A
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M[;(UT/5,BA>!TO#$5]*';R0#H,\DZ'$)\F?0?Z[E%"A6+\"&V38RT^+MM6T
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MID_!AZ744?,G)DE^8@\Y*V=9EJ><)3[$"1-JQ.<9Q&&"(&%!DF0TC7*NWU7
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MB@%Y:_P9E&HY\*IC7=E$'DN21?F@"O>WI,TKKAR2>UC+61#93$6-E]:H-LJ
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M9HJD)=Q9)D>Z\5R -:=@YXV&6?!#< LZ=FU>V%O'T-K%OCW.)@X L [I?J"
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M8A2?B-C-7>0&0[OWD*.0<7L'J6X?%4_37S_NP3'QU>.&_JN\=MR#9^R5X_Y
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M?=9GJ.1Y&<41E(E((,HQ@J6,.<SCB KU?U3$5N7V; F.O)6T!/<*G3K$R=H
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M!-CI6!Y9@W1\N!G2$TR4G1W^<\'OIK[ZM=?V6BKU"[#15W"R1IMF[09T4MR
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MZ!Y@G02]!F#_RS$YX]I)LCO<30F]F^K1G '-FCEY&9 _[6!5(&_Y SL&Q^X
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M1'%:0E)$L=(X)(L)PSE+,Y=3P@5Z(Y\5=M3!?%-6Q$U[7,++3F4$1,%-3_0
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M!2.3*J_K 3O49P%&=+=6E)[\MIZ+.*)9?%O7MWSYK!CX.">/MK;*^1'&/^-
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MQDYX6KK_ Z/DZ,B_'B!W5[R#Q*&<ZC8DIW6/.X!PY.AV>=<W-&2EJR"]4QM
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M9BM+!$LI='_$6%"2,<)2IY.?.PL3Z9MYN[S(C@F/I@Y7 .VND,+#=Y5B,NS
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M>(XH33#".&>(1BQ"><'4SI"2B$AJ'*P=IN4[W:6^&ERU)*\" @  ,-&4P0'
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MT10;;@._WL0!-PB'D$\]87ZE;G5NI^ 7 80RY?I_%#P4<"I<@T5!R5_>(_J
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MM#"11&G"*1)%HG%#0X)(7A!42,YYD?&"" Q9OZ,4O3L3O4" ]A?6;9?O-B@
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M??US7LUPCFF>)AQAD<<:;ZM 98PU&C 53.2$AXE1_XX38WM>%C6UH'/1-$&
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MKD"49 G+*,T)J.VI"5'/=J)CX73%LN8C:!D!P@P:*=3,<+A6$\QNN- 0V&Q
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M<9B!VRI;,=5 Y >W/5U_[.MZ+VJ[[8QR?M. PU]?JA]7(-C6?$P+A7VINHX
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M/G@U@[X#-.O9H]3^7^'1Q7K153>+527N5U^6SW,-X?IYR;^2)R.$KK$Q//M
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MJEF6%UD8ZH2H)&;*QRDB1&3($,TX93S"&8,!_ITGY3_[X6F^:0)Z=;?A/A-
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M[I]\V>AN T_SY?SIY2EX;HD#D09,U6BVKSE5CQT*0<V!+B'J3@1#T"4.00F
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MT(43@+;OU2\VO;RSA:(./4A#]&CI,KC1C@-WH5?F6+=?[K/BT5$8E]^7DS!
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M#]%T]&%GI=G?Q4/=U7A1JU_]XD_UQ.>->*IF..=4\J1 1.BD?5[$J"@H1YG
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M>!(R3-,D$'Z/L*5DGE,?=EI<5[#[^+F"H9GD<QZ'>B;,!3/@ /AP I1X4^%
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M<&Q5&L%(298Y7T_%LU*#NZ\/MWTO E#+>)B,<1MAAP>8)="EP.YSL_&9FE5
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MX9T%QQT'I25/#.VBMS7<T!U+[X>,AK.9=83:$C)>X%_?S3_-_IR.E")&^V1
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MY1A$)5PO1HX9Z;D0$!EB60AJP2G-T/EAZ/JZ9$Q.%4"Q>_7]L-%\#K*":)N
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MV"T#=V\K1DPSE9+B0)3/@(&\ *.( 2FUHE8D%$IO3<#NR&CFJO)\OM&1.F@
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MXN7^H_OGR&9FB:,4/(^EE(\S,"QZ<!Z=6"9YDJ3VH[XGR!G6N@Z/E5D_BFL
M@__NQM,BP'?3CVZ2WF44(0IM^?W]Q*W:7'TI<A_AMB8Q: TV$=SJ699V\S)
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M2J&CGE#4X*#9!Q:'H.Z)\23G5G(#9_Z)//_R??<'K*9J1>X\T1(PIDNE45$
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MFOO]#:4.*9>[?SU6R,&?(*H559Y906VO!M@CCV#WD%;''Q4$P0$3L(_52&-
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M>YOP6=D4Q%Z!8\>1)"R/N(\<+$)P9*T@T=MHP!4/#Z!6$J635?TR?(Z0>WL
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M?+JVDP_V)O[:Y3.A4?)!6>6R-)5 >>H><I9[1"VS7MA >1+GCNN/X*,NN$^
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M60FEVP,+1NX;+.5P,A!M@R81$9^/%_,8>*V41BPZIY.(UM#!&V8>D]3, =Z
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M!GSZ-A[63VK>927<3K,J1PI+++!WR'(:$+?2PJ]RFZ_,AZ")>,%* [TG:?U
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M1WYM9),P_+O7.SIZ>K] CPVQ/<ED]C/HM/+RO2Y<RQ=N@3HL"GEOP4NLV"U
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MMY@L(/Y($71 "T 7Q95O;K6]YR^W)?'^\1>M>8'$BR,0RU[RKR%X)X5S!C&
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MT:#SNU$<S.'/Q$S#BW\#4$L#!!0    ( .1%@5@QO.<=X0(  -$.   8
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MCW%55VYUR!<N"=8_PWW% W]/\G]02P,$%     @ Y$6!6+P5-7X'"   1RD
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MB:!<,@%@CA)IQC2#Q%)42*J2]!Q)$R;*%)A'M5.KQ(,EURH4$3XV[ #8B 3
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M44'>A2MW0(Z[IRXA5O%M4&83E4P$]<*,WY?7[;JLD"+-$S43&)V.E:^)? 7
M -PW(0JU5WS19]U)JAP> 8!"5Q'KA.=&=.9_G*%VYPF?=63F(N8FG97*1LI:
ME7;H6_T)]0"0A_(+4P<I/[SXPK]6]U_Z6XW_T7SE<KCFAHYLM#[6:M<:Q\T7
MA^NUX,6QWU-[7 M.&M]<JS.VO97:(Q<('PS$V^0\^[#7W)M/* '9:>2/+%A]
M98 P^CSD/MK+[U3\V?OW"CO"=3W6Q8DW>;<?'-?/@HI[[>39JQUE:+ZAU]_#
MX8^SU2;_-KQZM]]"S7$_GWTKO^+HENBM,]>QMPG.%J)EF7)5+$=DZ(J244C.
M=C/"+[RZLF-1W<W8;4;GY5B*F'UZ:GTW_L3Q5Q!?Q;0^^QM)Q&\MDHYR+L:[
MBVO,4N!P/=9'CA9L8!W++_[ERKAO:#O^6XB)6'L5<+'+':^H+Z;P$;9Z8=>G
M?.'MP?*G?Y'QR+U ^3]02P,$%     @ Y$6!6)TL*HA_!   ]A(  !@   !C
M87)M+3(P,C,Q,C,Q>&5X>#,R,2YH=&WM6&UOXD80_MY?,25J+I$PV.8ML4DD
MCA 5716B0'3MIVJQU[ Z>]?=79*XO[ZS:SLO1])RTO62GHH0PIZ7G7GF\<S(
MP[7.TM/AFI+X](?ACXX#9R+:9)1KB"0EFL:P48ROX&-,U2=PG$IK+/)"LM5:
M@^_Z7?@HY"=V0TJY9CJEI[6?8;N\'K;M(<.EB(O38<QN@,4G#>:Z'<_ONLOC
M/AUT/3HX\JGG'_<'<=\]&I"(_.XUT!352QNEBY2>-#+&G34UYP?=7J[#6Q;K
M=>"Y[D\-JW<Z3 37>)A$X_)OZ6/;$Y$K=*9%'G@^>M+T3CLD92L>V/P:I:M:
M/1*ID,&>:S^AD3@)R5A:!.\6+*,*+N@M7(F,\'=-1;AR%)4L*145^Y-BC'B(
MO;PMXQ^@GY1Q6N?C^2:)R=V:+9F&CM_RGF:P6^P1(D_E*P4_GEPMIN?3\6@Q
MG5W Y?75_'ITL8#%[,5,WDKDWA%<M^:M<0OFD[&-WNOTW":,YC ZFUTN)F?_
MJ73J)([=/LS.8?'S!.:CJ_>CB\G<F?WZR^0W&(T71N*[KK\KS?[U7+K/YC+E
M$ G.::29X'#+]!KTFL*(\PU)X8KF0FH0"8R)9"HCL%A327*ZT2Q2,.51"PZ,
M_O[>D>^[X5AD.>&%O?+"0T"7YT)FX+G.!TB$M+X+2B10'F,3/*,1S994[N]Y
M?3?L>$W3]SI %"0L1?E]/',:;233#!,G/(;)7;0F?$6Q86894\K$CE^C&6-W
M!0R28M"/0RM3J2-KPA0B*C5+BB;D&ZDV!+'7 AZH:F(:A!53,2(2B]PT[L?:
ME8XA AYG R5R23A5SNPNI06,(HN>(4(3Y40WC5E6P"<N;C'#%=W?ZQV%._>B
MG,0QS@TGI8D..OVZ.S%$D^O ,7=>B4@'WF&=Q;<__BDN?K?5Z1H@D*PUA9--
MFA9(]2Q/#8GNB27I'QLFJ1FIRE1*54^"USD@R%\)7N\@/KRO[@,-[RE8E=@[
M[G2QEL>A(>CW4$__;=:3<>PC&;%%PLZE"9K&>-?6IRXV81*KG4NJ3%V;1DS2
M%- ,H\&^AH(<"ZV:UBIAG/#(W$>',;.N39=!K4U:TD+DV/:,0-54J%I=ZPOZ
MNR;+E-;BI9 QE0[BF9)<T:#^$\9,Y2DI L8M*M8HK)PMA=8B"\QN=F.Z5T32
M:B!:VI3BA[6MY9:KF\9]3<?UR96X945M'6_+NKV6W^^\*'9;WHNROW/;;WD#
M_ZM[M<'V=G+;MD"48"#>"@MXTN@T:H.*=(&?WX'W=/$S//P<\A+MQYOQMWY&
MSY#/=G[ *)<L+:=H.42[GRWH%31?,>O72/A]\71<?A]9[>]U!Z&ROS#7](9R
M^$!Q7#U)<T?NNB;;QD[0[*!:-2G;PW+$1:0L!@-(^#;Q?6%??U.8ODWDGF?F
M)8Y 9E81.P_':T837'QP"=+LAL(L21@NT?]#^D5[U:5DN&SDN&UL(7FX#67;
MSO]GUHO'[VERH>S6$DB:$N-PZ\W-PP-M%PCWP80L\:G>Z&V3?WC94_V6[YW:
M]GW77U!+ P04    " #D18%8C)8= (,$   -$P  &    &-A<FTM,C R,S$R
M,S%X97AX,S(R+FAT;>U8;6_B1A#^WE\Q)6HND3#XA9?$D$@<(2IJ&R(@NO93
MM=AK6)V]Z^XN2>BO[^S:#LF1M)QTO:2G(F39GI>=>>;Q[&C[*YVEY_T5)?'Y
M=_WO'0<N1+3.*-<024HTC6&M&%_"AYBJC^ XI=90Y!O)EBL-ONNWX(.0']DM
M*>2:Z92>5W[ZS>*YW[2+]!<BWISW8W8++#ZK,3^(_"APXZ3;.6W%'8^0A7MR
MVNYTNBYU6VWW=Z^&IJA>V"B]2>E9+6/<65&S?MAJY[IWQV*]"CW7_:%F]<[[
MB> :%Y-H7-P6/G8]$;E$9UKDH>>C)TWOM4-2MN2AS:]6N*K4(Y$*&1ZX]M<S
M$B<A&4LWX;LYRZB"*WH'4Y$1_JZN"%>.HI(EA:)B?U*,$1>QCW=%_%WTDS).
MJWP\WR0QNE^Q!=,0^ W_:0;[Q1XA\E2^4O##T70^OAP/!_/QY JN;Z:SF\'5
M'.:3%S-Y*Y%[)W#3F#6&#9B-AC9Z+VB[=1C,8' QN9Z/+OY3Z51)G+H=F%S"
M_,<1S ;3]X.KT<R9_/KSZ#<8#.=&XKONWC3[UW-I/9O+F$,D.*>19H+#'=,K
MT"L* \[7)(4IS874(!(8$LE41F"^HI+D=*U9I&#,HP8<&?W#@Q/?=WM#D>6$
M;^R3USL&='DI9 :>Z_P$B9#6]X82"93'V 0O:$2S!96'!U['[05>W?2] (B"
MA*4H?XAG1J.U9)IAXH3',+J/5H0O*3;,+&-*F=CQ;S1C[*Z 05(,^G%H12I5
M9'480T2E9LFF#OE:JC5![+6 +55-3-U>R52,B,0B-XW[L7:I8XB R]E B5P0
M3I4SN4_I!@:11<\0H8YRHNO&+-O 1R[N,,,E/3QHG_3V[D4YB6/<-YR4)CH,
M.E5W8H@FUZ%CWKP2D8Z\XRJ+K[_\4US\5B-H&2"0K!6%DW6:;I#J69X:$CT0
M2](_UDQ2LZ4J4RE5?@E><$20OQ*\]E%\_%#=+0T?*%B6V#L-6EC+TYXAZ+=0
M3_]MUI-Q[",9L47"SJ4)FL;XUM:G*C9A$JN=2ZI,7>M&3-(4T RCP;Z&@AP+
MK>K6*F&<\,B\1X<QLZY-ET&M=5K00N38]HQ 550H6UWC,_J[)HN45N*%D#&5
M#N*9DES1L+KIQ4SE*=F$C%M4K%&O=+806HLL-+/9K>E>$4G+#='2IA!OQ[:&
M6XQN&N<U'5<KE^*&%35UO"MKM1M^)WA1[#:\%V5_Y[;3\+K^%_=J@VWOY;9I
M@2C 0+P5%O"L%M0J@Y)TH9_?@_=T\#,\_!3R NW'D_'7_D8OD,]V_X!!+EE:
M[*+%)MKZ9$ OH?F"6;]&PN\W3[?+;R.KPX-6MZ?L%:8,MQ49PR]"XL#U)-$]
MV>N:?&M[@;.':MFF;!?+$1F1LA@,)+VWB?#S$_M;0_5M8O<\.X<K1A.X?-@C
M)TG"<'3^'\3/FJ:N)4/X<L1O!TD[:VSE@R@2:Z[-Z5"I<+R+==..!<],'8^/
M;W*A[# 32IKB\')+=PYTME^YG2O<K0E9X*>^UKLF_W &5%Z+XZBF/0;["U!+
M P04    " #D18%8#RAMH#8.  !C2@  %P   &-A<FTM,C R,S$R,S%X97AX
M.3<N:'1MW5QK;QNW$OU^?P6OB[8V("F27TD<UX#KN*B!-@GL%/EX0>V.)-:[
MRRW)E:S^^CLSY+[TL.6BL147:&MI^1B2,V<.9V9U.G%I<G8Z 1F?_>?TO]VN
M>*^C(H7,B<B =!"+PJIL++[$8&]%MQM:7>A\;M1XXL1^?_]0?-'F5DVE?^Z4
M2^"L'.?TE?]\^HHG.1WJ>'YV&JNI4/%/.^J-/(S[;X[CM_U!='@\BMX>'.Y#
M?/3Z2![#T?#X[?\&.]@5F_L^ULT3^&DG55EW C3_R>%1[M[-5.PF)X-^__L=
M;G=V.M*9P\D,=O9_^C&61Y)FC(,YG9\,]G$D!W>N*Q,USDYX?3M^J+)YI!-M
M3K[K\S_OZ$EW)%.5S$]^_*Q2L.(#S,2U3F7V8\?*S'8M&#7R#:WZ&U!&G(0_
MSKS\KW&<1&50KF>P3XNXO)NHH7+B[>NV_)M)'N&^@WDFT2_.KZ]N?C\7GW^]
MO#[_=/G'YZN+&W'UX:*WQ2LY7%S)8/][+T8,D3;2*9V=%%D,AEKMH'+'<?<7
M([-;M(0TA\QR$W&-K:=@YN*33E0T7UKQ6KVLGCWM&G?./D^4O7<-8M=1DQ^^
M>[._WW_GO^,/@W=[ A_(6.<$$\.YN)!&V52*SQ,P,H?"J<B*JRSJT1A0#D&3
MR:PQ1B9DA)L<RRP",5-N(CY(&\N_Q&_*.L*>ZR(!<73<?R-VPQC5-^4H'3&;
MJ&@B5)HG0+!C?:]!_WUW(/CD!,EP U%AE%.X@9=WT41F8Q#GD1-Z) 8(/1TA
M<478/\85-85N-JXDW\7&N=%ID8P9*?/"V$+B&3I-$_%NOCTZI,%IJ(;2?)%)
M(FZ< 7"XWR-M4B&S&,\ALPB:1GPRVH4!@G3[_4%_KR?XN,+!X%\P&E&S*9#<
MV.ICY/00^^]W")</VDNHVKY':<M%+%OE?3I::F<NXQA/IIO "!7I36FS"O<M
M<R==^N;IT><!FQU42WT&N=H;UN\=E5NV!E]@I#)%W]I_YWR>!4%WSN3V[/F@
MUW]-^Q"LX1PAI\@\O(!U:!&$&L$JGD;HU5LF4L#>0@H#?Q7*L%@('](QA@3P
M1-B!7!HT>P^>826F7HF("R <HDXI?F>43$2FLP@'2!1#;8"E<DA&7OH#50^?
M4WN<1)LP<BU,C:9_]&YZ8@3X$1O;&EH3.;,=!/8H*>@$>-0P0KQ.7I05+<$@
M1-&BP!AMR#7@0J=*%S8AO+,%]J_%JSI;OT$(B-52P](WZ]X1VO@A9KI(8I*K
M2!Q[IGK$% >HI%5^[[R8,\"3",+C#-B-GN%N&&J:8W<=TPRDB+A[#[3LB0MV
M-;9<0\-A#EZ_L_=L0*SQB!T=&ZZ 1O3RA0D)300I#;61Y%E6F4#CW'[X[NC-
M.[%[OH<C.J-M7OJ:'%4H\FP!E4B*X!M52QES@P,I=,<XS%L<YN?%8>AH+(V!
MZ_2:)H?HLBV,_19GY!?]+$&9FS/1SEAGBL@59E&7JZU2Q!XSW"EMQC)3?_-H
M09Z+97FB1%JK1N7:JEEC92--JR(%TGA,S7'>/V)[:H/"%2HW[PA;(&M!YSU"
M'L%&WY24NG-#,BIO=FB_*3X@<8Q.O A$'78OUVXO;B/NE(YNA47!2-OQ$1@+
M"]_Z3^A%%'KQV)+&:MQ4$^2GW121S)5CS0L[OY[5M^#WX+CR0=^&YQINC^=B
MME Y+E3Q5#D')8,3S^FLO*\J+:^Z0E0RKK/+G[4T,3U\KPB9M+$MJLJ/US/4
MAW3EV]"P:'LT;($;7=#]#Y'N$X($P=RVZ)DD#XD2X5U/HYLP4V(3EES9Y1V2
M#T:]CR.$;\0LZ9AU.)0"<=P0Y#(? ,->A?A/<,PC[<E,@&UR07AG)=B=0O=G
M:2%N*?=+5<=X>]2Q#7B7R&$R\!SN?(; L' @VZ.?K$4I\1^"MON4*)!-5-YK
MB$"1(O,W<!<!Q(\?B?WT3*%+]P1V(M$4A@!9/?Y$QH\9ECO'@/0IQ=7&8LA-
MM.==@;?'83#D#G2M*.@;ND7H@CCHF"">Z!.9H;S#S<ZEXCB1]PA-C"&N43WP
MUY$PU3(6L0,9PD0FHY[X!3O>OXY2;L]ND)32S0<M7C.-F2 ?GNB$F!6RI\)D
M%$@B.M_>JH=TD*X>Q*IM,?R3;C"X;&2N$R#Z&O%%"O\;%4G@E>ST<"@F?313
MD^L2BUY/SA\IUTPE"6Y6O0U$,27N).,<#JSH?M/8^[;?]O&E\M-JF<J3VG"#
M19$S@E.TCKK=>WI-"Z'@5_.VB@M+)1)\_!<O/C[94+%F&KG4WL:7TJU</A'H
MW&@BOIZ0M\?#T_01R9>*_; ]V+] 198<^]:@_?/MV,[9LZY^%9_7_G LT;&8
M8I<^N.%#\,>R.]@=[37B1LUH>D^\4*,:;8]1[?<&3:/ZI0H@75?QB-\1%O$Z
M;[?&OCCNE :I/'13[*I!23QJ<Z#+J]MB&HE]Y8J E!6%]3U\&+6\'&P2:.OP
MM.2!5LEFF&KA]21!AQP"F-(X[^C9LU2]=I%G<'0%FWGJT'Q*P]5KH]6H;&,9
M_<P4Q O[@JT26F0JX\;6</2VD1"CA566R53 4OQHK\.QNZ9[YX#3Q=Y:']\3
M+]6HQ]MCU.U;TGTT:GMLFNPF6KJ]('D>&TF:WA$@34;_1Q6>(C^K;A[+-L4\
MDDW<$0?T5)3"K?? VTLE<),G4LN5=1(KU?)>6J^()2!6\?T0;R?/R:7*BH)P
MR]@&6UD+]9;NDB%L%8):]47J'K47E!10(U6GG#8,=@E)ETHN\V C8PN=0E;F
MOW(Y]W9GO 675Z][Q]01NAP<<>0"'80LKJYG=;8,)VU<ITG'J#>E]G"ONQX5
M""(6TI/VI=JXVA[7L]][?=#P/77%$!_>]B312;G<Q "PTTG <?Z7K6B.CL8*
ME2((*>1-":?4(XA++HB/$T7L;%1G03FH0/$"^H-S%!W*[BT&3<*3$%8.5R/.
MII6WI(7,NRS<1!M<'N.AD[<A"B%]!1#:FL^7E)]MR/+ZA#H%WSS9\WGL*L Q
M1V961P/+1G%GN9H 1ZS2\RA!H[A@79D$I1UQ+B*&U:[05A3&47IQ3*$N;3IU
M#C&!L20'WE@K58*&6)AMB8,BK+7&9M5GKBUCPHD!BJQ-8:D.M.PUU,[I]*1?
M=Y%#JY/"+7=YH'34_W=B:G08(QCAGM]V&=!.9#*3<[OSE<I5MP6,'E21'OJ
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M2P$"% ,4    " #D18%8\V4'=B&T P!BPAP $0              @ $
M8V%R;2TR,#(S,3(S,2YH=&U02P$"% ,4    " #D18%8RUH?0*P4  !!V0
M$0              @ %0M , 8V%R;2TR,#(S,3(S,2YX<V102P$"% ,4
M" #D18%8[(7/GUP@   ./0$ %0              @ $KR0, 8V%R;2TR,#(S
M,3(S,5]C86PN>&UL4$L! A0#%     @ Y$6!6)OIZ@\01   \^H" !4
M         ( !NND# &-A<FTM,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M .1%@5@;##AW^J8' !W3"@ 4              "  ?TM! !C87)M+3(P,C,Q
M,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( .1%@5@R.9EPCB0! #%;"P 5
M      "  2G5"P!C87)M+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4    " #D
M18%8[O/(I_^9  #Y*P< %0              @ 'J^0P 8V%R;2TR,#(S,3(S
M,5]P<F4N>&UL4$L! A0#%     @ Y$6!6+<)S X4%0  TJ\  !D
M     ( !')0- &-A<FTM,C R,S$R,S%X97AX,3 Q-RYH=&U02P$"% ,4
M" #D18%8,;SG'>$"  #1#@  &               @ %GJ0T 8V%R;2TR,#(S
M,3(S,7AE>'@R,3$N:'1M4$L! A0#%     @ Y$6!6-@_>6GD @  '@D  !@
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M &-A<FTM,C R,S$R,S%X97AX,S(Q+FAT;5!+ 0(4 Q0    ( .1%@5B,EAT
M@P0   T3   8              "  <C$#0!C87)M+3(P,C,Q,C,Q>&5X>#,R
M,BYH=&U02P$"% ,4    " #D18%8#RAMH#8.  !C2@  %P
M@ &!R0T 8V%R;2TR,#(S,3(S,7AE>'@Y-RYH=&U02P4&      \ #P#\ P
&[-<-

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>carm-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:carm="http://carismatx.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="carm-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2024-03-15</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:SesenBioStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">carm:CollateralCreditCardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">carm:ConvertiblePreferredStockAndExchangeableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">carm:ConvertiblePreferredStockAndExchangeableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">carm:ConversionOfConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">carm:ConversionOfConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:CarismaTherapeuticsIncLegacyStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">carm:CarismaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:TrusteesOfUniversityOfPennsylvaniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:PennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ManufacturingAndSupplyAgreementWithNovartisPharmaceuticalsCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">carm:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-17</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">carm:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">carm:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">carm:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-06-05</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandSeventeenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">carm:TwoThousandFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">carm:SesenBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Pre2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">carm:Post2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:StateJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:LocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">carm:LocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">carm:ModernaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:ModernaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">carm:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">carm:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>carm:segment</measure>
    </unit>
    <unit id="seat">
        <measure>carm:seat</measure>
    </unit>
    <unit id="target">
        <measure>carm:target</measure>
    </unit>
    <unit id="product">
        <measure>carm:product</measure>
    </unit>
    <unit id="obligation">
        <measure>carm:obligation</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001485003</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-35">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-36">FY</dei:DocumentFiscalPeriodFocus>
    <carm:DerivativeInstrumentConversionTermForRedemptionFeature contextRef="c-44" id="f-346">P3M</carm:DerivativeInstrumentConversionTermForRedemptionFeature>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-52" id="f-368">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36296</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">Carisma Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">3675 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">491-6422</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CARM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-30" unitRef="usd">275726423</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">41542534</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2023. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c-4" decimals="-5" id="f-37" unitRef="usd">317600000</us-gaap:OperatingLossCarryforwards>
    <carm:TerminationFeePayable contextRef="c-5" decimals="-5" id="f-38" unitRef="usd">4000000</carm:TerminationFeePayable>
    <dei:AuditorFirmId contextRef="c-1" id="f-39">185</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-40">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-41">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-42" unitRef="usd">77605000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-43" unitRef="usd">24194000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-44" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-7" decimals="-3" id="f-45" unitRef="usd">27802000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-46" unitRef="usd">2866000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-47" unitRef="usd">2596000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-48" unitRef="usd">80471000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-49" unitRef="usd">54592000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-50" unitRef="usd">6764000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-51" unitRef="usd">8628000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-52" unitRef="usd">2173000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-53" unitRef="usd">4822000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-6" decimals="-3" id="f-54" unitRef="usd">146000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-7" decimals="-3" id="f-55" unitRef="usd">4111000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-56" unitRef="usd">89554000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-57" unitRef="usd">72153000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-58" unitRef="usd">3933000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-59" unitRef="usd">1728000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">7662000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-61" unitRef="usd">10361000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">1413000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c-7" decimals="-3" id="f-63" unitRef="usd">2459000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-64" unitRef="usd">1391000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-65" unitRef="usd">3437000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">544000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-67" unitRef="usd">1162000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">965000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-69" unitRef="usd">523000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">15908000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-71" unitRef="usd">19670000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">45000000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c-7" decimals="-3" id="f-73" unitRef="usd">45000000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-7" decimals="-3" id="f-75" unitRef="usd">33717000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-76" unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-77" unitRef="usd">5739000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">860000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-79" unitRef="usd">976000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-80" unitRef="usd">328000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-81" unitRef="usd">872000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-82" unitRef="usd">926000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-83" unitRef="usd">1041000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-84" unitRef="usd">63022000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-85" unitRef="usd">107015000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-86" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-87" unitRef="usd" xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-6" decimals="-3" id="f-88" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-7" decimals="-3" id="f-89" unitRef="usd">107808000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-90"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-91"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-92" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-93" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-94" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-95" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-96" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-97" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-99" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-100"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-101"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-102" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-103" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-104" unitRef="shares">40609915</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-105" unitRef="shares">40609915</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-106" unitRef="shares">2217737</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-107" unitRef="shares">2217737</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-108" unitRef="usd">40000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-109" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">271594000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-7" decimals="-3" id="f-111" unitRef="usd">1197000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-112" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-113" unitRef="usd">-41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-114" unitRef="usd">-245102000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-115" unitRef="usd">-158223000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-116" unitRef="usd">26532000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-117" unitRef="usd">-157065000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-6" decimals="-3" id="f-118" unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-7" decimals="-3" id="f-119" unitRef="usd">14395000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-120" unitRef="usd">26532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-121" unitRef="usd">-142670000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-122" unitRef="usd">89554000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-123" unitRef="usd">72153000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">14919000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-8" decimals="-3" id="f-125" unitRef="usd">9834000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">74125000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-127" unitRef="usd">56618000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">29525000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-129" unitRef="usd">9378000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">103650000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-8" decimals="-3" id="f-131" unitRef="usd">65996000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">-88731000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-8" decimals="-3" id="f-133" unitRef="usd">-56162000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">-84000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-8" decimals="-3" id="f-135" unitRef="usd">-1919000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">1936000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-8" decimals="-3" id="f-137" unitRef="usd">-3145000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-139" unitRef="usd">-61226000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-140"
      unitRef="usdPerShare">-2.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-141"
      unitRef="usdPerShare">-2.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-142"
      unitRef="usdPerShare">-28.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-143"
      unitRef="usdPerShare">-28.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-144" unitRef="shares">33524197</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-145" unitRef="shares">33524197</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-8" decimals="0" id="f-146" unitRef="shares">2128069</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-8" decimals="0" id="f-147" unitRef="shares">2128069</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">-86879000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-149" unitRef="usd">-61226000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-8" decimals="-3" id="f-151" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-8" decimals="-3" id="f-153" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-86838000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-8" decimals="-3" id="f-155" unitRef="usd">-61267000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-9" decimals="INF" id="f-156" unitRef="shares">8700885</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-9" decimals="-3" id="f-157" unitRef="usd">107808000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesIssued
      contextRef="c-10"
      decimals="INF"
      id="f-158"
      unitRef="shares">2059072</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-159" unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-160" unitRef="usd">816000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-161" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">-96997000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-163" unitRef="usd">14395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-164" unitRef="usd">-81784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-15"
      decimals="INF"
      id="f-165"
      unitRef="shares">158665</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-166" unitRef="usd">106000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-8" decimals="-3" id="f-167" unitRef="usd">106000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-168" unitRef="usd">275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-8" decimals="-3" id="f-169" unitRef="usd">275000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-3" id="f-170" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-8" decimals="-3" id="f-171" unitRef="usd">-41000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="-3" id="f-172" unitRef="usd">-61226000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-8" decimals="-3" id="f-173" unitRef="usd">-61226000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-7" decimals="INF" id="f-174" unitRef="shares">8700885</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-7" decimals="-3" id="f-175" unitRef="usd">107808000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-176"
      unitRef="shares">2217737</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-177" unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-178" unitRef="usd">1197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-179" unitRef="usd">-41000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-180" unitRef="usd">-158223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-181" unitRef="usd">14395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-182" unitRef="usd">-142670000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-24"
      decimals="INF"
      id="f-183"
      unitRef="shares">128716</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-25" decimals="-3" id="f-184" unitRef="usd">187000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">187000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-186" unitRef="usd">2316000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">2316000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-26" decimals="-3" id="f-188" unitRef="usd">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">440000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-26" decimals="-3" id="f-190" unitRef="usd">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">399000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction
      contextRef="c-24"
      decimals="INF"
      id="f-192"
      unitRef="shares">3730608</carm:StockIssuedDuringPeriodSharesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction contextRef="c-24" decimals="-3" id="f-193" unitRef="usd">4000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction contextRef="c-25" decimals="-3" id="f-194" unitRef="usd">30636000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">30640000</carm:StockIssuedDuringPeriodValuesPreclosureFinancingTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-24"
      decimals="INF"
      id="f-196"
      unitRef="shares">5059338</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-24" decimals="-3" id="f-197" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-25" decimals="-3" id="f-198" unitRef="usd">42442000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">42447000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-24"
      decimals="INF"
      id="f-200"
      unitRef="shares">10374272</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-24" decimals="-3" id="f-201" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-25" decimals="-3" id="f-202" unitRef="usd">72034000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">72044000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <carm:ReclassificationsOfTemporaryToPermanentEquityShares contextRef="c-1" decimals="INF" id="f-204" unitRef="shares">-8700885</carm:ReclassificationsOfTemporaryToPermanentEquityShares>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">-107808000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger
      contextRef="c-24"
      decimals="INF"
      id="f-206"
      unitRef="shares">18872711</carm:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger contextRef="c-24" decimals="-3" id="f-207" unitRef="usd">19000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger contextRef="c-25" decimals="-3" id="f-208" unitRef="usd">122185000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger contextRef="c-27" decimals="-3" id="f-209" unitRef="usd">-14395000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">107809000</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterestsUponMerger>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-24"
      decimals="INF"
      id="f-211"
      unitRef="shares">226533</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-212" unitRef="usd">597000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">597000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProfitLoss contextRef="c-28" decimals="-3" id="f-214" unitRef="usd">-86879000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-86879000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-6" decimals="INF" id="f-216" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="c-6" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesIssued
      contextRef="c-29"
      decimals="INF"
      id="f-218"
      unitRef="shares">40609915</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-219" unitRef="usd">40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-220" unitRef="usd">271594000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-221" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-222" unitRef="usd">-245102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-223" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-224" unitRef="usd">26532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">-86879000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-8" decimals="-3" id="f-226" unitRef="usd">-61226000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">2837000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-8" decimals="-3" id="f-228" unitRef="usd">1893000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">-159000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-8" decimals="-3" id="f-230" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">2316000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-8" decimals="-3" id="f-232" unitRef="usd">275000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">5428000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-8" decimals="-3" id="f-234" unitRef="usd">4197000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">1283000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c-8" decimals="-3" id="f-236" unitRef="usd">2537000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">-84000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="c-8" decimals="-3" id="f-238" unitRef="usd">-1919000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <carm:AccretionOnMarketableSecurities contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">709000</carm:AccretionOnMarketableSecurities>
    <carm:AccretionOnMarketableSecurities contextRef="c-8" decimals="-3" id="f-240" unitRef="usd">0</carm:AccretionOnMarketableSecurities>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">399000</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="c-8" decimals="-3" id="f-242" unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <carm:NoncashInterestExpense contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">139000</carm:NoncashInterestExpense>
    <carm:NoncashInterestExpense contextRef="c-8" decimals="-3" id="f-244" unitRef="usd">93000</carm:NoncashInterestExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">-1046000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-8" decimals="-3" id="f-246" unitRef="usd">1361000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">2191000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-8" decimals="-3" id="f-248" unitRef="usd">-473000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">-2899000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-8" decimals="-3" id="f-250" unitRef="usd">4230000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">-1046000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-8" decimals="-3" id="f-252" unitRef="usd">47459000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">-4941000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-254" unitRef="usd">-4659000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">213000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c-8" decimals="-3" id="f-256" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">-81177000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-8" decimals="-3" id="f-258" unitRef="usd">-5116000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">34460000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-8" decimals="-3" id="f-260" unitRef="usd">90900000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <carm:PaymentsForProceedsFromMarketableSecurities contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">-108000000</carm:PaymentsForProceedsFromMarketableSecurities>
    <carm:PaymentsForProceedsFromMarketableSecurities contextRef="c-8" decimals="-3" id="f-262" unitRef="usd">-63000000</carm:PaymentsForProceedsFromMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">1132000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-264" unitRef="usd">4660000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">72408000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-8" decimals="-3" id="f-266" unitRef="usd">-32560000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">37903000</carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities>
    <carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities contextRef="c-8" decimals="-3" id="f-268" unitRef="usd">0</carm:CashCashEquivalentsAndRestrictedCashAcquiredInReverseRecapitalizationFinancingActivities>
    <carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">5814000</carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities>
    <carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities contextRef="c-8" decimals="-3" id="f-270" unitRef="usd">0</carm:PaymentOfFinanceCostsReverseRecapitalizationFinancingActivities>
    <carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">30640000</carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing>
    <carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing contextRef="c-8" decimals="-3" id="f-272" unitRef="usd">0</carm:ProceedsFromIssuanceOfCommonStockPreClosingFinancing>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">1301000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-8" decimals="-3" id="f-274" unitRef="usd">865000</us-gaap:FinanceLeasePrincipalPayments>
    <carm:ProceedsFromFailedSaleLeasebackTransaction contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">1183000</carm:ProceedsFromFailedSaleLeasebackTransaction>
    <carm:ProceedsFromFailedSaleLeasebackTransaction contextRef="c-8" decimals="-3" id="f-276" unitRef="usd">1626000</carm:ProceedsFromFailedSaleLeasebackTransaction>
    <carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">1069000</carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction>
    <carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction contextRef="c-8" decimals="-3" id="f-278" unitRef="usd">98000</carm:PaymentOfFinanceLiabilityFailedSaleLeasebackTransaction>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">146000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-8" decimals="-3" id="f-280" unitRef="usd">2450000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-8" decimals="-3" id="f-282" unitRef="usd">35000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">187000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-8" decimals="-3" id="f-284" unitRef="usd">106000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">597000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-8" decimals="-3" id="f-286" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">62180000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-8" decimals="-3" id="f-288" unitRef="usd">33319000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">53411000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-8" decimals="-3" id="f-290" unitRef="usd">-4357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-291" unitRef="usd">24194000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-9" decimals="-3" id="f-292" unitRef="usd">28551000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-293" unitRef="usd">77605000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-294" unitRef="usd">24194000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">352000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-8" decimals="-3" id="f-296" unitRef="usd">98000</us-gaap:InterestPaidNet>
    <carm:NoncashOrPartNoncashAcquisitionEquityAssumed contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">122204000</carm:NoncashOrPartNoncashAcquisitionEquityAssumed>
    <carm:NoncashOrPartNoncashAcquisitionEquityAssumed contextRef="c-8" decimals="-3" id="f-298" unitRef="usd">0</carm:NoncashOrPartNoncashAcquisitionEquityAssumed>
    <us-gaap:NotesReduction contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">42447000</us-gaap:NotesReduction>
    <us-gaap:NotesReduction contextRef="c-8" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:NotesReduction>
    <carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">41000</carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities>
    <carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities contextRef="c-8" decimals="-3" id="f-302" unitRef="usd">-41000</carm:NoncashOrPartNoncashUnrealizedGainLossOnMarketableSecurities>
    <carm:NonCashDeferredFinancingCostsAccruedExpenses contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">0</carm:NonCashDeferredFinancingCostsAccruedExpenses>
    <carm:NonCashDeferredFinancingCostsAccruedExpenses contextRef="c-8" decimals="-3" id="f-304" unitRef="usd">1661000</carm:NonCashDeferredFinancingCostsAccruedExpenses>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">2779000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-306" unitRef="usd">6440000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-8" decimals="-3" id="f-309" unitRef="usd">2898000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1 contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1 contextRef="c-8" decimals="-3" id="f-311" unitRef="usd">3820000</us-gaap:NoncashOrPartNoncashAcquisitionDebtAssumed1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-312">Background&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carisma Therapeutics Inc., a Delaware corporation (collectively with its subsidiaries, the Company), is a clinical-stage cell therapy company focused on using the Company&#x2019;s proprietary chimeric antigen receptor macrophage and monocyte (CAR-M) cell therapy platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company&#x2019;s focus is its proprietary CAR-M cell therapy platform, which redirects macrophages against specific tumor associated antigens and enables targeted anti-tumor immunity by utilizing genetically modified myeloid cells (macrophages and monocytes) to express chimeric antigen receptors (CARs), enabling these potent innate immune cells to recognize specific tumor associated antigens on the surface of tumor cells. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2024, the Company and its board of directors approved a revised operating plan to reduce monthly operating expenses and conserve cash. The plan, which will be implemented in the second quarter of 2024, includes several measures such as prioritizing CT-0525 as the Company's anti-human epidermal growth factor receptor 2 (HER2) product candidate going forward, suspending the enrollment of new patients for CT-0508 in line with the clinical judgment of the clinical site principal investigator, pausing further development of CT-1119, reducing the workforce, including employees engaged in research and development and general and administration activities, and decreasing spending on other non-essential activities. The Company expects the reduction in workforce to be substantially complete and to pay the majority of the workforce reduction costs in the second quarter of 2024. The revised operating plan considers expenses pertaining to severance costs and potential termination and exit fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s first product candidate to enter clinical development, CT-0508, is the first CAR-Macrophage to be evaluated in a human clinical trial and is intended to treat solid tumors that over-express HER2, a protein that is over-expressed on the surface of a variety of solid tumors, including breast cancer, gastric cancer, esophageal cancer, salivary gland cancer, and numerous others. CT-0508 has been granted &#x201c;Fast Track&#x201d; status for the treatment of patients with HER2 over-expressing solid tumors by the United States FDA. CT-0508 is currently being studied in a multi-center open label Phase 1 clinical trial in the United States. This ongoing first-in-human study evaluates the safety, tolerability, and manufacturing feasibility of CT-0508 along with several customary exploratory secondary endpoints.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CT-0525 utilizes a novel approach to CAR-M therapy that engineers patients&#x2019; monocytes directly, without &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; differentiation into macrophages. In November 2023, the Company received FDA clearance of the Company's IND for CT-0525, and expects to treat the first patient in the second quarter of 2024. The Company believes that CT-0525 has favorable attributes compared to its initial clinical stage product candidate, CT-0508, and that the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. The Company will also continue to focus on its &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; mRNA/lipid nanoparticle (LNP) CAR-M programs in partnership with Moderna.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company plans to continue ongoing activities under its open label Phase 1 clinical trial of CT-0508 and its sub-study utilizing CT-0508 in combination with pembrolizumab, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities. The Company has also elected to pause further development of CT-1119, a mesothelin-targeted CAR-Monocyte, pending additional financing. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases, also remains ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pipeline&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Using its proprietary macrophage and monocyte cell therapy platform, the Company is developing a pipeline of product candidates with an initial focus on advancing multiple &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; autologous and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CAR-M therapies for the treatment of solid tumors. The Company is also pursuing early research and development of multiple assets for the potential treatment &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;oncology, fibrosis, and immunology programs are wholly owned. Additionally, under a collaboration agreement (the Moderna License Agreement), with ModernaTX Inc. (Moderna) (Note 12), the Company is developing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CAR-M therapies utilizing Moderna's mRNA/LNP technology. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's follow-on product candidate, CT-0525, a CAR-Monocyte intended to treat solid tumors that over-express HER2, utilizes a novel approach to CAR-M therapy that engineers patients' monocytes directly, without &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; differentiation into macrophages, as the Company currently does for CT-0508. The CAR-Monocyte approach utilizes a single day manufacturing process, which enables the  manufacture of up to ten billion cells from a single apheresis, and leverages an automated, closed-system manufacturing process. In addition, the CAR-Monocyte approach has the potential to improve upon the potential anti-tumor effect of a CAR-Macrophage. By increasing the cell yield, a CAR-Monocyte enables a larger dose than a CAR-Macrophage. In addition, CAR-Monocyte has the potential for improved persistence and trafficking, which were observed in pre-clinical studies. The Company believes that the increased cell yield, and the improved persistence and trafficking may improve tumor control. In November 2023, the Company received FDA clearance of its IND for CT-0525 and the Company expects to treat the first patient in the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In addition to the development of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; CAR-M cell therapies, the Company is developing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; CAR-M cell therapies, wherein immune cells are directly engineered within the patient&#x2019;s body. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;To advance the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; CAR-M therapeutics, the Company established a strategic collaboration with Moderna (Note 12). I&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;n the fourth quarter of 2023, the Company presented pre-clinical data from this collaboration demonstrating that CAR-M can be directly produced &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP. Additionally, the pre-clinical data demonstrated feasibility, tolerability, and early efficacy of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; CAR-M against metastatic solid tumors. In December 2023, the Company announced the nomination of the collaboration's first lead candidate, which will target an antigen present on a solid tumor with significant unmet medical need.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to acting as a first line of defense in the innate immune system, macrophages and monocytes are found in all tissues in the body where they serve key regulatory functions such as wound healing, termination of immune responses and tissue regeneration.  Using the Company's macrophage and monocyte&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;engineering platform, the Company is pursuing early research and development of multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. Pre-clinical proof of concept for fibrosis is expected in the first half of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Merger with Sesen Bio&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;7, 2023, the Company (formerly publicly-held Sesen Bio, Inc.) consummated a merger with CTx Operations, Inc. (formerly privately-held CARISMA Therapeutics Inc.) (Legacy Carisma) pursuant to an Agreement and Plan of Merger and Reorganization, as amended (the Merger Agreement), by and among the Company, Legacy Carisma and Seahawk Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into Legacy Carisma, with Legacy Carisma continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). Pursuant to the Merger Agreement, the Company changed its name from &#x201c;Sesen Bio, Inc.&#x201d; to &#x201c;Carisma Therapeutics Inc.&#x201d; At the closing of the Merger, (a) each then outstanding share of Legacy Carisma common stock and convertible preferred stock (including shares of Legacy Carisma common stock issued in connection with the pre-closing financing transaction described below) were converted into shares of Sesen Bio, Inc. (Sesen Bio) common stock at an exchange ratio of 1.8994 shares of Sesen Bio for each share of Legacy Carisma (the Exchange Ratio), and (b) each then outstanding stock option to purchase Legacy Carisma common stock was assumed by Sesen Bio, with necessary adjustments to reflect the Exchange Ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except as otherwise indicated, references herein to &#x201c;Carisma,&#x201d; the &#x201c;Company,&#x201d; or the &#x201c;Combined Company,&#x201d; refer to Carisma Therapeutics Inc. on a post-Merger basis, and references to &#x201c;Legacy Carisma&#x201d; refer to the business of privately-held CARISMA Therapeutics Inc. prior to the completion of the Merger. References to &#x201c;Sesen Bio&#x201d; refer to Sesen Bio, Inc. prior to the completion of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the Merger, the shareholders of Legacy Carisma held 74.2% of the Combined Company and the shareholders of Sesen Bio held 25.8% of the Combined Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Ratio&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the Merger was accounted for as reverse capitalization under which the historical financial statements of the Company prior to the Merger are Legacy Carisma. All common stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <carm:ConvertedIntoSharesCommonStockAtExchangeRatio contextRef="c-34" decimals="4" id="f-313" unitRef="number">1.8994</carm:ConvertedIntoSharesCommonStockAtExchangeRatio>
    <carm:BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare contextRef="c-35" decimals="3" id="f-314" unitRef="number">0.742</carm:BusinessCombinationRatioConversionOfAcquiredEntitySToAcquiringEntitySShare>
    <carm:OwnershipInterestInReportingEntity contextRef="c-36" decimals="3" id="f-315" unitRef="number">0.258</carm:OwnershipInterestInReportingEntity>
    <carm:DevelopmentStageRisksAndLiquidityTableTextBlock contextRef="c-1" id="f-316">Development-Stage Risks and Liquidity&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$245.1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of December&#160;31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. As of December&#160;31, 2023, the Company had $77.6 million of cash and cash equivalents. Absent any other action, the Company would have required additional liquidity to continue its operations over the next 12 months, which would have raised substantial doubt about its ability to continue as a going concern. As discussed in Note 1, Background, in March 2024, the Company and its board of directors approved a revised operating plan that suspends certain development programs, reduces its workforce and decreases other non-essential activities to extend the Company&#x2019;s cash runway. The Company projects this revised operating plan will alleviate the substantial doubt that has been raised by significantly decreasing expenses, thereby reducing ongoing liquidity needs to enable the continuation of operations for at least 12 months from the issuance date of these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants.&lt;/span&gt;&lt;/div&gt;</carm:DevelopmentStageRisksAndLiquidityTableTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-5" id="f-317" unitRef="usd">-245100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-6" decimals="-5" id="f-318" unitRef="usd">77600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-319">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant areas that require management&#x2019;s estimates include the fair value of the Company&#x2019;s common stock and the derivative liability prior to the Merger, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. The Company considered the carrying value of its convertible promissory note (Note 8) as of December 31, 2022 to approximate fair value due to its short-term nature. The derivative liability was recorded at its estimated fair value prior to its derecognition in March 2023 upon conversion of the associated convertible promissory notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative liability &#x2013; redemption feature on convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, the Company had no marketable securities. The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated a redemption feature within the convertible promissory note issued in January 2022 and determined bifurcation of the redemption feature was required. The redemption feature is classified as a liability on the accompanying consolidated balance sheet and is marked-to-market each reporting period with the changes in fair value &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recorded in the accompanying statements of operations until it is triggered, terminated, reclassified or otherwise settled. The fair value of the derivative was determined based on an income approach that identified the cash flows using a with-and-without valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the discount factor used was 12% and a 90% to 100% probability of completing a qualified financing prior to the maturity date of the convertible promissory note was assumed. The estimated time of conversion ranged from &lt;span style="-sec-ix-hidden:f-346"&gt;three&lt;/span&gt; to twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below is a summary of the changes in fair value of the Company&#x2019;s derivative liability associated with the redemption feature of the Company&#x2019;s convertible promissory note (Level 3 measurement):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derecognition upon conversion of convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023 and 2022, there were no transfers between Level 1, Level 2 and Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Upfront license fees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Customer options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Research and development services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Milestone payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, cas&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;h equivalents consisted of investments in a money market account. The Company maintained $30,000 as collateral for the Company&#x2019;s credit card program at September 30, 2023, which was previously reported as restricted cash on its consolidated balance sheet. There were no amounts restricted as of December 31, 2023 and 2022, as the collateral was released to the Company in the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's marketable securities consisted of investments in U.S. Treasuries that were classified as available-for-sale. The securities were carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, a component of stockholders' equity (deficit). Realized gains and losses and declines in value determined to be other than temporary were included in the Company's consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:f-368"&gt;two&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company did not recognize any impairment of long-lived assets during th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately. The Company incurred $4.2&#160;million and $4.1&#160;million in deferred financing costs associated with the Merger during the years ended December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Upon completion of the Merger, the $8.3&#160;million of deferred financing costs were recorded against the gross proceeds received as a result of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Noncontrolling Interest&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that ownership interests in the Company&#x2019;s subsidiary are held by entities other than the Company, management reports these as noncontrolling interests on the consolidated balance sheet. Prior to the Merger, an investor had outstanding Class B and Class B-1 shares in the Company&#x2019;s Luxembourg subsidiary related to the sale of the Company&#x2019;s Series A convertible preferred stock (Series A) and Series B convertible preferred stock (Series B). The shares were nonvoting shares at the subsidiary entity level and were presented as noncontrolling interests in the accompanying consolidated balance sheet at December 31, 2022. In connection with the Merger, the Company's noncontrolling interests exchangeable shares converted into shares of common stock (Note 8).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger, and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger, the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Income taxes &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the deferred tax assets will not be realized. As of December 31, 2023 and 2022, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#x2019;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock and exchangeable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,936,148&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,356,937&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Conversion of convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,258,151&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,551,236&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for fiscal years beginning after December 15, 2022. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to accumulated deficit and did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued but not yet adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-320">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). Any references in these notes to applicable guidance is meant to refer to GAAP as found in Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) promulgated by the Financial Accounting Standards Board (FASB). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-321">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant areas that require management&#x2019;s estimates include the fair value of the Company&#x2019;s common stock and the derivative liability prior to the Merger, stock-based compensation assumptions, the estimated useful lives of property and equipment, and accrued research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-322">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. The Company considered the carrying value of its convertible promissory note (Note 8) as of December 31, 2022 to approximate fair value due to its short-term nature. The derivative liability was recorded at its estimated fair value prior to its derecognition in March 2023 upon conversion of the associated convertible promissory notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-323">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative liability &#x2013; redemption feature on convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, the Company had no marketable securities. The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated a redemption feature within the convertible promissory note issued in January 2022 and determined bifurcation of the redemption feature was required. The redemption feature is classified as a liability on the accompanying consolidated balance sheet and is marked-to-market each reporting period with the changes in fair value &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recorded in the accompanying statements of operations until it is triggered, terminated, reclassified or otherwise settled. The fair value of the derivative was determined based on an income approach that identified the cash flows using a with-and-without valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, the discount factor used was 12% and a 90% to 100% probability of completing a qualified financing prior to the maturity date of the convertible promissory note was assumed. The estimated time of conversion ranged from &lt;span style="-sec-ix-hidden:f-346"&gt;three&lt;/span&gt; to twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below is a summary of the changes in fair value of the Company&#x2019;s derivative liability associated with the redemption feature of the Company&#x2019;s convertible promissory note (Level 3 measurement):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derecognition upon conversion of convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023 and 2022, there were no transfers between Level 1, Level 2 and Level 3.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-324">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value measurement at reporting date using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents &#x2013; money markets accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative liability &#x2013; redemption feature on convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-37" decimals="-3" id="f-325" unitRef="usd">62999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-38" decimals="-3" id="f-326" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-39" decimals="-3" id="f-327" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-40" decimals="-3" id="f-328" unitRef="usd">7794000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-41" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-42" decimals="-3" id="f-330" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-40" decimals="-3" id="f-331" unitRef="usd">27802000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-41" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-42" decimals="-3" id="f-333" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <carm:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-8" id="f-334">Derivative liability &#x2013; redemption feature on convertible promissory note</carm:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativeLiabilities contextRef="c-40" decimals="-3" id="f-335" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-41" decimals="-3" id="f-336" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-42" decimals="-3" id="f-337" unitRef="usd">5739000</us-gaap:DerivativeLiabilities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="-3" id="f-338" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-339">The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of December 31, 2022:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss contextRef="c-43" decimals="-3" id="f-340" unitRef="usd">27843000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-43" decimals="-3" id="f-341" unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-43" decimals="-3" id="f-342" unitRef="usd">27802000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <carm:DebtInstrumentConvertibleDiscountFactorPercentage contextRef="c-8" decimals="2" id="f-343" unitRef="number">0.12</carm:DebtInstrumentConvertibleDiscountFactorPercentage>
    <carm:DebtInstrumentConvertibleQualifiedFinancingProbability contextRef="c-44" decimals="2" id="f-344" unitRef="number">0.90</carm:DebtInstrumentConvertibleQualifiedFinancingProbability>
    <carm:DebtInstrumentConvertibleQualifiedFinancingProbability contextRef="c-45" decimals="2" id="f-345" unitRef="number">1</carm:DebtInstrumentConvertibleQualifiedFinancingProbability>
    <carm:DerivativeInstrumentConversionTermForRedemptionFeature contextRef="c-45" id="f-347">P12M</carm:DerivativeInstrumentConversionTermForRedemptionFeature>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-348">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below is a summary of the changes in fair value of the Company&#x2019;s derivative liability associated with the redemption feature of the Company&#x2019;s convertible promissory note (Level 3 measurement):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derecognition upon conversion of convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-46" decimals="-3" id="f-349" unitRef="usd">5739000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-47" decimals="-3" id="f-350" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-48" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="c-49" decimals="-3" id="f-352" unitRef="usd">3820000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-48" decimals="-3" id="f-353" unitRef="usd">84000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-49" decimals="-3" id="f-354" unitRef="usd">1919000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-48" decimals="-3" id="f-355" unitRef="usd">-5823000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-49" decimals="-3" id="f-356" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-50" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-46" decimals="-3" id="f-358" unitRef="usd">5739000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-359">&lt;div&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 606). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration and licensing agreements with strategic partners, which are within the scope of ASC 606, under which it may exclusively license rights to research, develop, manufacture, and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: (1) non-refundable, upfront license fees (2) reimbursement of certain costs; (3) customer option fees for additional goods or services; (4) development milestone payments, (5) regulatory and commercial milestone payments; and (6) royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (i) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Upfront license fees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the license to the Company's intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the customer; the retention of any key rights by the Company; and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Customer options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised. If an option is not exercised and the research and development target is terminated, the Company will accelerate and recognize all remaining revenue related to the material right performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Research and development services&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promises under the Company's collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company's research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. Reimbursements from and payments to the customer that are the result of a collaborative relationship with the customer, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Milestone payments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-360">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-361">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-362"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-363">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, cas&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;h equivalents consisted of investments in a money market account. The Company maintained $30,000 as collateral for the Company&#x2019;s credit card program at September 30, 2023, which was previously reported as restricted cash on its consolidated balance sheet. There were no amounts restricted as of December 31, 2023 and 2022, as the collateral was released to the Company in the fourth quarter of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-51" decimals="-3" id="f-364" unitRef="usd">30000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-6" decimals="INF" id="f-365" unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-366">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's marketable securities consisted of investments in U.S. Treasuries that were classified as available-for-sale. The securities were carried at fair value with the unrealized gains and losses included in accumulated other comprehensive loss, a component of stockholders' equity (deficit). Realized gains and losses and declines in value determined to be other than temporary were included in the Company's consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-367">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:f-368"&gt;two&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets. Lab equipment that are classified as finance leases are amortized over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-53" id="f-369">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-370">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events indicate a triggering event occurred, the recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company did not recognize any impairment of long-lived assets during th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;e years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; or 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-371" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-8" decimals="INF" id="f-372" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <carm:DeferredFinancingCostsPolicyPolicyTextBlock contextRef="c-1" id="f-373">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs that are directly associated with in-process equity financings until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. If a financing is abandoned, deferred financing costs are expensed immediately. The Company incurred $4.2&#160;million and $4.1&#160;million in deferred financing costs associated with the Merger during the years ended December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2022, respectively&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Upon completion of the Merger, the $8.3&#160;million of deferred financing costs were recorded against the gross proceeds received as a result of the Merger.&lt;/span&gt;&lt;/div&gt;</carm:DeferredFinancingCostsPolicyPolicyTextBlock>
    <us-gaap:DeferredFinanceCostsNoncurrentGross contextRef="c-54" decimals="-5" id="f-374" unitRef="usd">4200000</us-gaap:DeferredFinanceCostsNoncurrentGross>
    <us-gaap:DeferredFinanceCostsNoncurrentGross contextRef="c-55" decimals="-5" id="f-375" unitRef="usd">4100000</us-gaap:DeferredFinanceCostsNoncurrentGross>
    <us-gaap:DeferredFinanceCostsNoncurrentGross contextRef="c-56" decimals="-5" id="f-376" unitRef="usd">8300000</us-gaap:DeferredFinanceCostsNoncurrentGross>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (ROU) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating classified leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="c-1" id="f-378">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Noncontrolling Interest&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that ownership interests in the Company&#x2019;s subsidiary are held by entities other than the Company, management reports these as noncontrolling interests on the consolidated balance sheet. Prior to the Merger, an investor had outstanding Class B and Class B-1 shares in the Company&#x2019;s Luxembourg subsidiary related to the sale of the Company&#x2019;s Series A convertible preferred stock (Series A) and Series B convertible preferred stock (Series B). The shares were nonvoting shares at the subsidiary entity level and were presented as noncontrolling interests in the accompanying consolidated balance sheet at December 31, 2022. In connection with the Merger, the Company's noncontrolling interests exchangeable shares converted into shares of common stock (Note 8).&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-379">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Up-front and milestone payments made to third parties who perform research and development services on the Company's behalf are expensed as services are rendered.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-380">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company's common stock prior to the Merger, and, for stock options, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management's best estimates and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Merger, the fair value of the Company's common stock was estimated by the Company's board of directors, with input by management considering the Company's most recently available third-party valuation of the Company's common stock. The expected term of stock options for employees is estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to nonemployees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-381">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Income taxes &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities, and the expected benefits of net operating loss and income tax credit carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's consolidated financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that some, or all, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the deferred tax assets will not be realized. As of December 31, 2023 and 2022, the Company has concluded that a full valuation allowance is necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest, or penalties in the accompanying consolidated financial statements. Although there are no unrecognized income tax benefits, when applicable, the Company&#x2019;s policy is to report interest and penalties related to unrecognized income tax benefits as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock and exchangeable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,936,148&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,356,937&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Conversion of convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,258,151&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,551,236&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-383">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible preferred stock and exchangeable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,936,148&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,356,937&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Conversion of convertible promissory note&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,258,151&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,551,236&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-57" decimals="0" id="f-384" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-58" decimals="0" id="f-385" unitRef="shares">9936148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-59" decimals="0" id="f-386" unitRef="shares">6023370</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-60" decimals="0" id="f-387" unitRef="shares">3356937</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-61" decimals="0" id="f-388" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-62" decimals="0" id="f-389" unitRef="shares">3258151</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-390" unitRef="shares">6023370</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-8" decimals="0" id="f-391" unitRef="shares">16551236</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. This standard is effective for fiscal years beginning after December 15, 2022. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to accumulated deficit and did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued but not yet adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2023-07), which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 on a retrospective basis. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2023-09), which expands the disclosures required for income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this pronouncement on its disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-393">Merger with Sesen Bio&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;7, 2023, Legacy Carisma completed the Merger with Sesen Bio as discussed in Note 1. The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Sesen Bio were cash, cash equivalents and marketable securities. For financial reporting purposes Legacy Carisma was determined to be the accounting acquirer based upon the terms of the Merger and other factors, including: (i) Legacy Carisma stockholders own approximately 74.2% of the Combined Company, (ii) Legacy Carisma holds the majority (six of seven) of board seats of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Combined Company and (iii) Legacy Carisma management holds all key positions of management. Accordingly, the Merger was treated as the equivalent of Legacy Carisma issuing stock to acquire the net assets of Sesen Bio. As a result of the Merger, the net assets of Sesen Bio were recorded at their acquisition-date fair value in the consolidated financial statements and the reported operating results prior to the Merger are those of Legacy Carisma. Immediately after the Merger, there were 40,254,666 shares of the Company&#x2019;s common stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net assets acquired in the Merger (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,588&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,316&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,499)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,308&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,264)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net assets acquired less transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to March&#160;7, 2023, the Company paid $4.6 million of severance and personnel costs related to Sesen Bio.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c-63" decimals="3" id="f-394" unitRef="number">0.742</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <carm:NumberOfBoardMembers contextRef="c-6" decimals="INF" id="f-395" unitRef="seat">7</carm:NumberOfBoardMembers>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-63"
      decimals="INF"
      id="f-396"
      unitRef="shares">40254666</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-397">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net assets acquired in the Merger (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,588&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,316&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,499)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80,308&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,264)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net assets acquired less transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-64" decimals="-3" id="f-398" unitRef="usd">37873000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities contextRef="c-64" decimals="-3" id="f-399" unitRef="usd">44588000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-64" decimals="-3" id="f-400" unitRef="usd">1316000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash contextRef="c-64" decimals="-3" id="f-401" unitRef="usd">30000</carm:Businesscombinationrecognizedidentifiableassetsacquiredrestrictedcash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c-64" decimals="-3" id="f-402" unitRef="usd">3499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-64" decimals="-3" id="f-403" unitRef="usd">80308000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-64" decimals="-3" id="f-404" unitRef="usd">8264000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-64" decimals="-3" id="f-405" unitRef="usd">72044000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:SeveranceCosts1 contextRef="c-65" decimals="-5" id="f-406" unitRef="usd">4600000</us-gaap:SeveranceCosts1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-407">Property and Equipment, net&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Lab equipment includes failed sale lease-back assets of $3.4&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $2.6&#160;million, respectively, as of December 31, 2023 and 2022. Lab equipment includes finance lease ROU assets of $2.9&#160;million as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) The accumulated amortization balance includ&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;es &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.9&#160;million and $0.3&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2023 and 2022. The accumulated amortization balance includes $1.7&#160;million and $0.6&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2023 and 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $2.8&#160;million and $1.9&#160;million for the years ended December 31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lab equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Office furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Lab equipment includes failed sale lease-back assets of $3.4&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $2.6&#160;million, respectively, as of December 31, 2023 and 2022. Lab equipment includes finance lease ROU assets of $2.9&#160;million as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) The accumulated amortization balance includ&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;es &lt;/span&gt;$0.9&#160;million and $0.3&#160;million, respectively, related to failed sale-leaseback assets as of December&#160;31, 2023 and 2022. The accumulated amortization balance includes $1.7&#160;million and $0.6&#160;million, respectively, related to finance lease ROU assets as of December&#160;31, 2023 and 2022.</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-66" decimals="-3" id="f-409" unitRef="usd">903000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-67" decimals="-3" id="f-410" unitRef="usd">1062000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-68" decimals="-3" id="f-411" unitRef="usd">11392000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-69" decimals="-3" id="f-412" unitRef="usd">10260000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-70" decimals="-3" id="f-413" unitRef="usd">267000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-71" decimals="-3" id="f-414" unitRef="usd">267000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-72" decimals="-3" id="f-415" unitRef="usd">340000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-73" decimals="-3" id="f-416" unitRef="usd">340000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-74" decimals="-3" id="f-417" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-75" decimals="-3" id="f-418" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-419" unitRef="usd">12915000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-420" unitRef="usd">11942000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-421" unitRef="usd">6151000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-422" unitRef="usd">3314000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-6" decimals="-3" id="f-423" unitRef="usd">6764000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-424" unitRef="usd">8628000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:SaleLeasebackTransactionNetBookValue contextRef="c-68" decimals="-5" id="f-425" unitRef="usd">3400000</us-gaap:SaleLeasebackTransactionNetBookValue>
    <us-gaap:SaleLeasebackTransactionNetBookValue contextRef="c-69" decimals="-5" id="f-426" unitRef="usd">2600000</us-gaap:SaleLeasebackTransactionNetBookValue>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-68" decimals="-5" id="f-427" unitRef="usd">2900000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-69" decimals="-5" id="f-428" unitRef="usd">2900000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:SaleLeasebackTransactionAccumulatedDepreciation contextRef="c-68" decimals="-5" id="f-429" unitRef="usd">900000</us-gaap:SaleLeasebackTransactionAccumulatedDepreciation>
    <us-gaap:SaleLeasebackTransactionAccumulatedDepreciation contextRef="c-69" decimals="-5" id="f-430" unitRef="usd">300000</us-gaap:SaleLeasebackTransactionAccumulatedDepreciation>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-6" decimals="-5" id="f-431" unitRef="usd">1700000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-7" decimals="-5" id="f-432" unitRef="usd">600000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-433" unitRef="usd">2800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-8" decimals="-5" id="f-434" unitRef="usd">1900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-435">Accrued Expenses&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-436">&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt;text-align:justify;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <carm:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-6" decimals="-3" id="f-437" unitRef="usd">3131000</carm:AccruedResearchAndDevelopmentExpenseCurrent>
    <carm:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-7" decimals="-3" id="f-438" unitRef="usd">4326000</carm:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-439" unitRef="usd">1366000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-7" decimals="-3" id="f-440" unitRef="usd">2100000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-441" unitRef="usd">3100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-442" unitRef="usd">2809000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-6" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-7" decimals="-3" id="f-444" unitRef="usd">1126000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-445" unitRef="usd">65000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-447" unitRef="usd">7662000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-448" unitRef="usd">10361000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-449">Commitments and Contingencies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for its laboratory and office space in Philadelphia, Pennsylvania. The Company&#x2019;s operating leases have term end dates ranging from 2024 to 2029. The Company also has obligations under an arrangement for the use of certain laboratory equipment that are classified as finance leases that commenced in 2022 and have end dates ranging from 2024 to 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating and finance lease right-of-use (ROU) assets and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company entered into purchase and sale agreements under which the Company sold lab equipment for $1.2 million and $1.6&#160;million, respectively. Concurrent with the sale of equipment, the Company entered into various lease agreements, with term end dates ranging from 2025 to 2026, whereby the Company will lease back the equipment. The Company accounts for such transactions as failed sale-leasebacks, due to having continuing involvement with the equipment. The Company carries this laboratory equipment as property and equipment, net on the accompanying consolidated balance sheets and the sale proceeds as a finance liability. The ongoing lease payments are recorded as reductions to the finance liability and interest expense. No gain or loss was recorded on the failed sale-leasebacks. As of December&#160;31, 2023, the Company had a $1.9 million financing liability recorded in other current liabilities and other long-term liabilities on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The elements of the lease costs were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease term and discount rate information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities were as follows as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal year ending:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing and Sponsored Research Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under a license agreement with The Trustees of the University of Pennsylvania (Penn), entered into in November 2017 (Penn License Agreement),&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company is required to make annual payments of $25,000. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Penn is eligible to receive up to $10.9 million per product in development upon the achievement of certain clinical, regulatory and commercial milestone events. There are additional milestone payments required to be paid of up to $30.0 million per product in commercial milestones and up to an additional $1.7 million in development and regulatory milestone payments for the first CAR-M product directed to mesothelin. Additionally, the Company is obligated to pay Penn single-digit royalties based on its net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company entered into a manufacturing and supply agreement with Novartis Pharmaceuticals Corporation (Novartis) for the manufacturing of the Company&#x2019;s CT-0508 product candidate (Novartis Agreement). The Novartis Agreement is for five years and shall renew automatically for additional one-year periods unless and until &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;terminated by either party. In addition to paying to manufacture the product, the Company will also pay $1.0 million per calendar year, payable in quarterly payments, for reserved capacity starting on the date on which the Novartis site is declared ready to produce CT-0508 as determined by the Company. In the event of termination without cause by the Company, a termination fee equal to $4.0 million will be payable by Carisma to Novartis which, pursuant to the terms of the agreement, can be credited in full against amounts due for a substitute product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2023, a purported stockholder filed a complaint in the United States District Court for the District of Delaware against Sesen Bio and its board of directors, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumley v. Sesen Bio, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 1:23-cv-00131 (D. Del.) (the Plumley Complaint). The Plumley Complaint asserts claims under Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder for allegedly false and misleading statements in the proxy statement/prospectus filed as part of the Registration Statement in connection with the Merger and under Section 20(a) of the Exchange Act for alleged &#x201c;control person&#x201d; liability with respect to such allegedly false and misleading statements and seeks, among other relief, an order enjoining the Merger and an award for plaintiffs&#x2019; fees and costs. On February 7, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and its board of directors, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Franchi v. Sesen Bio, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 1:23-cv-01041 (S.D.N.Y.) (the Franchi Complaint). The Franchi Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint. Additionally, on February 9, 2023, another purported stockholder filed a complaint in the United States District Court for the Southern District of New York against Sesen Bio and its board of directors, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Menzer v. Sesen Bio, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, et al., 23-cv-01119 (S.D.N.Y.) (the Menzer Complaint). The Menzer Complaint contains substantially similar allegations and claims and seeks substantially similar relief as the Plumley Complaint and the Franchi Complaint. In April 2023, the Company executed a confidential fee agreement to resolve the stockholders&#x2019; claim for attorney&#x2019;s fees and expenses in connection with the Plumley Complaint, Franchi Complaint, and Menzer Complaint.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company settled and paid the confidential fee agreement resulting in $0.2 million of claim expenses incurred during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <carm:ProceedsFromSaleAndLeasebackTransaction contextRef="c-76" decimals="-5" id="f-450" unitRef="usd">1200000</carm:ProceedsFromSaleAndLeasebackTransaction>
    <carm:ProceedsFromSaleAndLeasebackTransaction contextRef="c-77" decimals="-5" id="f-451" unitRef="usd">1600000</carm:ProceedsFromSaleAndLeasebackTransaction>
    <us-gaap:FinanceLeaseLiability contextRef="c-68" decimals="-5" id="f-452" unitRef="usd">1900000</us-gaap:FinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-453">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The elements of the lease costs were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-454" unitRef="usd">5774000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-8" decimals="-3" id="f-455" unitRef="usd">4764000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-456" unitRef="usd">1187000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-8" decimals="-3" id="f-457" unitRef="usd">560000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-458" unitRef="usd">139000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-8" decimals="-3" id="f-459" unitRef="usd">98000</us-gaap:FinanceLeaseInterestExpense>
    <carm:FinanceLeaseCost contextRef="c-1" decimals="-3" id="f-460" unitRef="usd">1326000</carm:FinanceLeaseCost>
    <carm:FinanceLeaseCost contextRef="c-8" decimals="-3" id="f-461" unitRef="usd">658000</carm:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-462" unitRef="usd">1733000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-8" decimals="-3" id="f-463" unitRef="usd">920000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-464" unitRef="usd">8833000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-8" decimals="-3" id="f-465" unitRef="usd">6342000</us-gaap:LeaseCost>
    <carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock contextRef="c-1" id="f-466">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease term and discount rate information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseLeaseTermAndDiscountRateInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-467">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-468">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-469">P1Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-470">P2Y2M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-471" unitRef="number">0.098</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-472" unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-473" unitRef="number">0.090</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-474" unitRef="number">0.090</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock contextRef="c-1" id="f-475">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash used in finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-476" unitRef="usd">5764000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-8" decimals="-3" id="f-477" unitRef="usd">4750000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-3" id="f-478" unitRef="usd">139000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-8" decimals="-3" id="f-479" unitRef="usd">98000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <carm:FinancingCashUsedInFinanceLeases contextRef="c-1" decimals="-3" id="f-480" unitRef="usd">1301000</carm:FinancingCashUsedInFinanceLeases>
    <carm:FinancingCashUsedInFinanceLeases contextRef="c-8" decimals="-3" id="f-481" unitRef="usd">865000</carm:FinancingCashUsedInFinanceLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities were as follows as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal year ending:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-482">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future maturities of lease liabilities were as follows as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fiscal year ending:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-484" unitRef="usd">1510000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-485" unitRef="usd">600000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-486" unitRef="usd">219000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-487" unitRef="usd">339000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-488" unitRef="usd">226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-489" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-490" unitRef="usd">233000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-491" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="-3" id="f-492" unitRef="usd">240000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="-3" id="f-493" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="-3" id="f-494" unitRef="usd">184000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="-3" id="f-495" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-496" unitRef="usd">2612000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-497" unitRef="usd">939000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-498" unitRef="usd">361000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-499" unitRef="usd">67000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-500" unitRef="usd">2251000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-6" decimals="-3" id="f-501" unitRef="usd">872000</us-gaap:FinanceLeaseLiability>
    <carm:CommitmentsAnnualPaymentsRequiredToBePaid contextRef="c-78" decimals="-3" id="f-502" unitRef="usd">25000000</carm:CommitmentsAnnualPaymentsRequiredToBePaid>
    <carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents contextRef="c-79" decimals="-5" id="f-503" unitRef="usd">10900000</carm:AmountPayableUponAchievementOfCertainClinicalRegulatoryAndCommercialMilestoneEvents>
    <carm:AdditionalMilestonePaymentsRequiredToBePaid contextRef="c-80" decimals="-5" id="f-504" unitRef="usd">30000000</carm:AdditionalMilestonePaymentsRequiredToBePaid>
    <carm:AdditionalMilestonePaymentsForFirstCarMProduct contextRef="c-78" decimals="-5" id="f-505" unitRef="usd">1700000</carm:AdditionalMilestonePaymentsForFirstCarMProduct>
    <carm:AgreementTerm contextRef="c-81" id="f-506">P5Y</carm:AgreementTerm>
    <carm:RenewalTerm contextRef="c-81" id="f-507">P1Y</carm:RenewalTerm>
    <carm:AmountPayablePerCalendarYearForReservedCapacity contextRef="c-5" decimals="-5" id="f-508" unitRef="usd">1000000</carm:AmountPayablePerCalendarYearForReservedCapacity>
    <carm:TerminationFeePayable contextRef="c-5" decimals="-5" id="f-509" unitRef="usd">4000000</carm:TerminationFeePayable>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-6" decimals="-5" id="f-510" unitRef="usd">200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-511">Stockholders&#x2019; Equity&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;7, 2023, in connection with the closing of the Mer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ger, the following is reflected on the consolidated statements of convertible preferred stock and stockholders&#x2019; equity (deficit) for the year ended December 31, 2023: (i) the sale of 3,730,608 shares of common stock in a pre-closing funding at $8.21 per share for total proceeds of $30.6 million, (ii) the issuance of 5,059,338 shares of common stock upon the settlement of the Company&#x2019;s $35.0 million convertible promissory note, accrued interest and related derivative liability, (iii) the conversion of convertible preferred stock and exchangeable shares previously presented as noncontrolling interests into 18,872,711 shares of common stock, (iv) the issuance of 10,374,272 shares of common stock to Sesen Bio stockholders as consideration for the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2023, the Company filed a universal shelf registration statement on Form S-3, which was declared effective on May 2, 2023 (Registration Statement). Under the Registration Statement, the Company may offer and sell up to $300.0&#160;million of a variety of securities, including debt securities, common stock, preferred stock, depositary shares, subscription rights, warrants and units from time to time in one or more offerings at prices and on terms to be determined at the time of the offering. On May 12, 2023, the Company entered into an Amended and Restated Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Sale Agreement) with Jefferies LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock with an aggregate offering price of up to $100.0&#160;million under an &#x201c;at-the-market" offering program. Through December 31, 2023, the Company sold 226,533 shares for gross proceeds of $0.6&#160;million. From January through March 2024, the Company sold an additional 931,250 shares for gross proceeds of $2.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2023, the Company's stockholders approved an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of the Company's common stock, $0.001 par value, from 100,000,000 shares to 350,000,000 shares and authorized 5,000,000 shares of preferred stock, $0.001 par value.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-82"
      decimals="INF"
      id="f-512"
      unitRef="shares">3730608</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-64"
      decimals="2"
      id="f-513"
      unitRef="usdPerShare">8.21</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-82" decimals="-5" id="f-514" unitRef="usd">30600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-82"
      decimals="INF"
      id="f-515"
      unitRef="shares">5059338</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-82" decimals="-5" id="f-516" unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests
      contextRef="c-82"
      decimals="INF"
      id="f-517"
      unitRef="shares">18872711</carm:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStockAndNonControllingInterests>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-82"
      decimals="INF"
      id="f-518"
      unitRef="shares">10374272</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <carm:SaleOfStockStockOfferingAmount contextRef="c-83" decimals="-5" id="f-519" unitRef="usd">300000000</carm:SaleOfStockStockOfferingAmount>
    <carm:SaleOfStockStockOfferingAmount contextRef="c-84" decimals="-5" id="f-520" unitRef="usd">100000000</carm:SaleOfStockStockOfferingAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-85"
      decimals="INF"
      id="f-521"
      unitRef="shares">226533</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c-85" decimals="-5" id="f-522" unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-86"
      decimals="INF"
      id="f-523"
      unitRef="shares">931250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c-86" decimals="-5" id="f-524" unitRef="usd">2400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-525"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-87"
      decimals="INF"
      id="f-526"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-88"
      decimals="INF"
      id="f-527"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-88"
      decimals="INF"
      id="f-528"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-88"
      decimals="INF"
      id="f-529"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-530">Stock-based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legacy Carisma adopted the CARISMA Therapeutics Inc. 2017 Stock Incentive Plan, as amended (the Legacy Carisma Plan), that provided for the grant of incentive stock options to employees, directors, and consultants. The maximum term of options granted under the Legacy Carisma Plan was ten years, and stock options typically vested over a four-year period. The Company&#x2019;s stock options vest based on the terms in the awards agreements and generally vest over four years. Upon completion of the Merger, the Company assumed the Legacy Carisma Plan and the outstanding and unexercised options issued thereunder, and ceased granting awards under the Legacy Carisma Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Sesen Bio, Inc. Amended and Restated 2014 Stock Incentive Plan, as amended (the Sesen Bio 2014 Plan), provides for the grant of incentive and non-qualified&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; stock options, restricted stock awards and restricted stock units, stock appreciation rights and other stock-based awards to the Compan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y&#x2019;s employees, officers, directors, consultants, and advisors, with amounts and terms of grants determined by the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;board of directors at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding under the Sesen Bio 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the Sesen Bio 2014 Plan are exercisable for a period of ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 7, 2023, the Company amended and restated the Sesen &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bio 2014 Plan to (i) change the name of the plan to the Carisma Therapeutics Inc. 2014 Amended and Restated Stock Incentive Plan (the 2014 Plan) and (ii) adopt a new form of stock option agreement and a new form of restricted stock unit agreement for the grant of options and restricted stock units under the 2014 P&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lan. On June 6, 2023, the Company&#x2019;s stockholders approved an amendment and restatement of the Company&#x2019;s 2014 Plan, which amendment and restatement had previously been adopted by the Company&#x2019;s board of directors, subject to stockholder approval. As of December&#160;31, 2023, approximately 4.9 million shares of common stock remained available for issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Sesen Bio 2014 Employee Stock Purchase Plan (the Sesen Bio 2014 ESPP) provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The purpose of the Sesen Bio 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock. On March 7, 2023, the Company amended and restated the Sesen Bio 2014 ESPP to (i) change the name of the plan to Carisma Therapeutics Inc. 2014 Employee Stock Purchase Plan and (ii) restate and integrate a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ll prior amendments thereto. As of December&#160;31, 2023, 0.2 million shares of common stock remained available for issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value (in &lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,356,937&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sesen Bio options assumed in the Merger&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;765,223&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(128,716)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,984,152&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(114,454)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(839,772)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,516,594&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date per share fair values of options granted during the year ended December 31, 2023 and 2022 were $4.29 and $1.46, respectively. The fair values in the year ended December 31, 2023 and 2022 were estimated using the Black-Scholes option-pricing model based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.92% - 4.76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.40% - 3.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57.77% - 103.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.54% - 56.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company recognized stock-based compensation expense of $0.2 million related to the modification of Sesen Bio options assumed in connection with the Merger. Compensation cost for awards not vested as of December&#160;31, 2023 was $11.2 million and will be expensed over a weighted-average period of 3.3 years</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-89" id="f-531">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-90" id="f-532">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-90" id="f-533">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-91" id="f-534">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear contextRef="c-92" decimals="2" id="f-535" unitRef="number">0.25</carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageFirstYear>
    <carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear contextRef="c-92" decimals="4" id="f-536" unitRef="number">0.0625</carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageEachThreeMonthPeriodAfterFirstYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-93" id="f-537">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-92" decimals="-5" id="f-538" unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate contextRef="c-94" decimals="2" id="f-539" unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-95" decimals="-5" id="f-540" unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-541">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate &lt;br/&gt;Intrinsic &lt;br/&gt;Value (in &lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,356,937&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sesen Bio options assumed in the Merger&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;765,223&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(128,716)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,984,152&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(114,454)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(839,772)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,516,594&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,023,370&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="INF" id="f-542" unitRef="shares">3356937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-543"
      unitRef="usdPerShare">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross contextRef="c-1" decimals="INF" id="f-544" unitRef="shares">765223</carm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerInPeriodGross>
    <carm:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-545"
      unitRef="usdPerShare">27.94</carm:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-546" unitRef="shares">128716</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-547"
      unitRef="usdPerShare">1.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-548" unitRef="usd">134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-549" unitRef="shares">2984152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-550"
      unitRef="usdPerShare">6.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-551" unitRef="shares">114454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-552"
      unitRef="usdPerShare">5.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-553" unitRef="shares">839772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-554"
      unitRef="usdPerShare">29.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-555" unitRef="shares">6023370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-557">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-558" unitRef="usd">5929000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-6" decimals="INF" id="f-559" unitRef="shares">2516594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-561">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-6" decimals="-3" id="f-562" unitRef="usd">4950000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-6" decimals="INF" id="f-563" unitRef="shares">6023370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-564"
      unitRef="usdPerShare">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-565">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-6" decimals="-3" id="f-566" unitRef="usd">5929000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-567"
      unitRef="usdPerShare">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-8"
      decimals="2"
      id="f-568"
      unitRef="usdPerShare">1.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-569">The fair values in the year ended December 31, 2023 and 2022 were estimated using the Black-Scholes option-pricing model based on the following assumptions:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.92% - 4.76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.40% - 3.05%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57.77% - 103.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54.54% - 56.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-96" decimals="4" id="f-570" unitRef="number">0.0292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-97" decimals="4" id="f-571" unitRef="number">0.0476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-98" decimals="4" id="f-572" unitRef="number">0.0240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-99" decimals="4" id="f-573" unitRef="number">0.0305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-100" id="f-574">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-101" id="f-575">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-96" decimals="4" id="f-576" unitRef="number">0.5777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-97" decimals="4" id="f-577" unitRef="number">1.0300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-98" decimals="4" id="f-578" unitRef="number">0.5454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-99" decimals="4" id="f-579" unitRef="number">0.5650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-100" decimals="0" id="f-580" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-101" decimals="0" id="f-581" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-582">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories in the accompanying consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.125%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-102" decimals="-3" id="f-583" unitRef="usd">1242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-103" decimals="-3" id="f-584" unitRef="usd">143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-104" decimals="-3" id="f-585" unitRef="usd">1074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-105" decimals="-3" id="f-586" unitRef="usd">132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-587" unitRef="usd">2316000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-8" decimals="-3" id="f-588" unitRef="usd">275000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-106" decimals="-5" id="f-589" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-6" decimals="-5" id="f-590" unitRef="usd">11200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-591">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-592">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local tax rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research and development costs, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable assets and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(133,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company has net operating loss carryforwards (NOLs) for federal income tax purposes of $317.6&#160;million, which are available to offset future federal taxable income. The pre-2018 federal NOLs of $120.0&#160;million will begin to expire in 2037, if not utilized. The post-2017 federal NOLs  of $197.6&#160;million carry forward indefinitely. The Company also has NOLs for state and local income tax purposes of $229.4&#160;million and $40.8&#160;million, respectively that are available to offset future taxable income. The state NOLs will begin to expire in 2038 while the city of Philadelphia NOLs expire after three years with $29.7&#160;million expiring in 2023. As of December&#160;31, 2023, the Company also had federal and state research and development tax credit carryforwards of $9.9&#160;million that will begin to expire in 2029, unless previously utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company's net deferred tax assets as of December&#160;31, 2023. The valuation allowance increased by $84.5&#160;million and $13.7&#160;million during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOLs and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOLs may also be limited, including Pennsylvania, which limits net operating loss utilization as a percentage of apportioned taxable income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense/(benefit). As of December&#160;31, 2023, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company's financial statements. Tax years from 2019 and after remain subject to examination by all of the taxing jurisdictions. The NOLs and research credit carryforwards remain subject to review until utilized.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-593">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal tax benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State and local tax rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-594" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-8" decimals="INF" id="f-595" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-596" unitRef="number">0.085</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-8" decimals="3" id="f-597" unitRef="number">0.078</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal contextRef="c-1" decimals="3" id="f-598" unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal contextRef="c-8" decimals="3" id="f-599" unitRef="number">-0.062</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal>
    <carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c-1" decimals="3" id="f-600" unitRef="number">-0.004</carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="c-8" decimals="3" id="f-601" unitRef="number">-0.020</carm:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-602" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-8" decimals="3" id="f-603" unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="3" id="f-604" unitRef="number">-0.284</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="c-8" decimals="3" id="f-605" unitRef="number">-0.224</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <carm:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent contextRef="c-1" decimals="3" id="f-606" unitRef="number">0</carm:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <carm:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent contextRef="c-8" decimals="3" id="f-607" unitRef="number">-0.011</carm:EffectiveIncomeTaxRateReconciliationReturnToProvisionPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-608" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-8" decimals="3" id="f-609" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-610">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's deferred tax assets for federal income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research and development costs, net of amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortizable assets and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(133,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-611" unitRef="usd">72689000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-612" unitRef="usd">27021000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization contextRef="c-6" decimals="-3" id="f-613" unitRef="usd">33778000</carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization>
    <carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization contextRef="c-7" decimals="-3" id="f-614" unitRef="usd">11907000</carm:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCostsNetOfAmortization>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-6" decimals="-3" id="f-615" unitRef="usd">9746000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-616" unitRef="usd">5643000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <carm:DeferredTaxAssetsStartUpCosts contextRef="c-6" decimals="-3" id="f-617" unitRef="usd">4407000</carm:DeferredTaxAssetsStartUpCosts>
    <carm:DeferredTaxAssetsStartUpCosts contextRef="c-7" decimals="-3" id="f-618" unitRef="usd">4744000</carm:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-6" decimals="-3" id="f-619" unitRef="usd">13353000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-7" decimals="-3" id="f-620" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
    <carm:DeferredTaxAssetsLeaseLiability contextRef="c-6" decimals="-3" id="f-621" unitRef="usd">668000</carm:DeferredTaxAssetsLeaseLiability>
    <carm:DeferredTaxAssetsLeaseLiability contextRef="c-7" decimals="-3" id="f-622" unitRef="usd">1451000</carm:DeferredTaxAssetsLeaseLiability>
    <carm:DeferredTaxAssetsAmortizableAssetsAndOther contextRef="c-6" decimals="-3" id="f-623" unitRef="usd">21000</carm:DeferredTaxAssetsAmortizableAssetsAndOther>
    <carm:DeferredTaxAssetsAmortizableAssetsAndOther contextRef="c-7" decimals="-3" id="f-624" unitRef="usd">59000</carm:DeferredTaxAssetsAmortizableAssetsAndOther>
    <carm:DeferredTaxAssetsEquityCompensation contextRef="c-6" decimals="-3" id="f-625" unitRef="usd">87000</carm:DeferredTaxAssetsEquityCompensation>
    <carm:DeferredTaxAssetsEquityCompensation contextRef="c-7" decimals="-3" id="f-626" unitRef="usd">74000</carm:DeferredTaxAssetsEquityCompensation>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-627" unitRef="usd">134749000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-628" unitRef="usd">50899000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-629" unitRef="usd">133580000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-630" unitRef="usd">49105000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-631" unitRef="usd">1169000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-7" decimals="-3" id="f-632" unitRef="usd">1794000</us-gaap:DeferredTaxAssetsNet>
    <carm:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-6" decimals="-3" id="f-633" unitRef="usd">645000</carm:DeferredTaxLiabilitiesRightOfUseAsset>
    <carm:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-7" decimals="-3" id="f-634" unitRef="usd">1430000</carm:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-635" unitRef="usd">524000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-636" unitRef="usd">364000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-637" unitRef="usd">1169000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-638" unitRef="usd">1794000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-639" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-7" decimals="-3" id="f-640" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-4" decimals="-5" id="f-641" unitRef="usd">317600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-107" decimals="-5" id="f-642" unitRef="usd">120000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-108" decimals="-5" id="f-643" unitRef="usd">197600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-109" decimals="-5" id="f-644" unitRef="usd">229400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-110" decimals="-5" id="f-645" unitRef="usd">40800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-111" decimals="-5" id="f-646" unitRef="usd">29700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-112" decimals="-5" id="f-647" unitRef="usd">9900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-648" unitRef="usd">84500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-8" decimals="-5" id="f-649" unitRef="usd">13700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-650">Related-Party TransactionsThe Company has a collaboration and license agreement with Moderna, a significant shareholder (Note 12).</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-651">Moderna Collaboration and License Agreement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company entered into the Moderna License Agreement, which provides for a broad strategic collaboration to discover, develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; engineered CAR-M therapeutics for up to twelve oncology programs. Under the Moderna License Agreement, the Company and Moderna initiate research programs during a research term, focused on the discovery and research of products directed to biological targets. Moderna&#x2019;s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has the right to designate up to twelve research targets as development targets.  The first five research targets have been designated and all programs are currently in the discovery phase. Moderna funds the cost of the Company's activities in accordance with an agreed research budget. The Company is responsible for discovering and optimizing development candidates, and Moderna is responsible for the clinical development thereafter. Pursuant to the Moderna License Agreement, the Company and Moderna formed a joint steering committee (JSC) that is responsible for the coordination and oversight of all research activities to which the Company is responsible for providing. The JSC is comprised of representatives from the Company and Moderna and with Moderna having final decision-making authority, subject to specified limitations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the term of the Moderna License Agreement, the Company and its affiliates are subject to various exclusivity obligations under which the Company is not permitted to research, develop or commercialize particular products outside of the collaboration, including products for use as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; therapies in the field of oncology, products directed to any target included in the collaboration, or products containing a polypeptide provided by the Company to Moderna in connection with a research program that are directed to any development target. Additionally, the Company has granted Moderna an exclusive worldwide royalty free license to the Company&#x2019;s intellectual property associated with the product candidates that permits Moderna to conduct its research and development activities. Upon Moderna&#x2019;s election of a development target (and payment of a related development target designation milestone) for commencement of pre-clinical development of a product candidate, the Company will grant Moderna an exclusive worldwide, sublicensable royalty bearing license to develop, manufacture and commercialize the product candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Moderna License Agreement, Moderna made an upfront non-refundable payment of $45.0 million to the Company. Assuming Moderna develops and commercializes 12 products, each directed to a different development target, the Company is eligible to receive up to between $247.0 million and $253.0 million per product in development target designation, development, regulatory and commercial milestone payments. Moderna also will reimburse the Company for all costs incurred by the Company in connection with its research and development activities under the Moderna License Agreement plus a reasonable margin for the respective services performed (with a minimum commitment to reimburse $10.0 million in research and development costs over the first three years from execution of the Moderna License Agreement). The Company is also eligible to receive tiered mid-to-high single digit royalties of net sales of any products that are commercialized under the agreement, which may be, subject to reductions. In addition, Moderna has agreed to cover the cost the Company incurs for certain milestone payments royalties the Company owes as a licensor under one of its intellectual property in-license agreements with Penn that the Company is sublicensing to Moderna under the Moderna License Agreement, which royalties Moderna may deduct in part from any royalties owed to the Company. The Moderna License Agreement terminates on a product-by-product basis upon the latest of expiration of the applicable product patents, expiration of regulatory exclusivity and the tenth anniversary of first commercial sale, unless terminated earlier by the Company or Moderna.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At commencement, the Company identified several potential performance obligations within the Moderna License Agreement, including research and development services on research targets, option rights held by Moderna, a non-exclusive royalty-free license to use the Company&#x2019;s intellectual property to conduct research and development activities and participation on the JSC. The Company determined that there were 2 performance obligations comprised of (i) research and development services and (ii) option rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the research and development services, the stand-alone selling price was determined considering the expected passthrough costs and cost of the research and development services and a reasonable margin for the respective services. The material rights from the option rights were valued based on the estimated discount at which the option is priced and the Company&#x2019;s estimated probability of the options&#x2019; exercise as of the time of the agreement. The transaction price allocated to research and development services is recognized as collaboration revenues as the research and development services are provided to satisfy the underlying obligation related to the research and development target. The transfer of control occurs over this period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $45.0&#160;million allocated to the options rights, which are considered material rights, will be recognized in the period that Moderna elects to exercise or elects to not exercise its option right to license and commercialize the underlying research and development target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company included the $45.0 million up-front and nonrefundable payment and $73.9 million of variable consideration for expected research and development services to be performed during the five-year contract term, inclusive of passthrough costs, in the transaction price as of the outset of the arrangement. During the year ended December 31, 2023 and 2022, the Company recognized $14.9 million and $9.8 million, respectively, of research and development services as collaboration revenues as the Company is the principal in providing such services. The Company recognized $24.7&#160;million of collaboration revenues since inception of the Moderna License Agreement through December&#160;31, 2023. The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Transaction &lt;br/&gt;price unsatisfied&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#x2019;s consolidated balance sheets. Contract liabilities consist of amounts received prior to satisfying the revenue recognition criteria, which are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in deferred revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the beginning of the period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of deferred revenue represents advanced payments received from Moderna for costs expected to be incurred by the Company within the next twelve months. The noncurrent portion of deferred revenue represents the $45.0 million upfront, non-refundable and non-creditable payment allocated to customer option right which is not expected to be recognized within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <carm:MaximumOfResearchTargets
      contextRef="c-113"
      decimals="INF"
      id="f-652"
      unitRef="target">12</carm:MaximumOfResearchTargets>
    <carm:NumberOfResearchTargetsDesignateAsDevelopmentTargets
      contextRef="c-113"
      decimals="INF"
      id="f-653"
      unitRef="target">12</carm:NumberOfResearchTargetsDesignateAsDevelopmentTargets>
    <carm:NumberOfResearchTargetsDesignated
      contextRef="c-113"
      decimals="INF"
      id="f-654"
      unitRef="target">5</carm:NumberOfResearchTargetsDesignated>
    <carm:UpfrontNonRefundablePaymentReceived contextRef="c-114" decimals="-5" id="f-655" unitRef="usd">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:NumberOfProductsDevelopedAndCommercialized
      contextRef="c-114"
      decimals="INF"
      id="f-656"
      unitRef="product">12</carm:NumberOfProductsDevelopedAndCommercialized>
    <carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments contextRef="c-115" decimals="-5" id="f-657" unitRef="usd">247000000</carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments>
    <carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments contextRef="c-116" decimals="-5" id="f-658" unitRef="usd">253000000</carm:AmountReceivablePerProductInDevelopmentTargetDesignationDevelopmentRegulatoryAndCommercialMilestonePayments>
    <carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts contextRef="c-117" decimals="-5" id="f-659" unitRef="usd">10000000</carm:MinimumCommitmentToReimburseResearchAndDevelopmentCosts>
    <carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts contextRef="c-114" id="f-660">P3Y</carm:PeriodOfReimbursementOfResearchAndDevelopmentCosts>
    <carm:NumberOfPerformanceObligations
      contextRef="c-118"
      decimals="INF"
      id="f-661"
      unitRef="obligation">2</carm:NumberOfPerformanceObligations>
    <carm:UpfrontNonRefundablePaymentReceived contextRef="c-119" decimals="-5" id="f-662" unitRef="usd">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:UpfrontNonRefundablePaymentReceived contextRef="c-119" decimals="-5" id="f-663" unitRef="usd">45000000</carm:UpfrontNonRefundablePaymentReceived>
    <carm:VariableConsideration contextRef="c-119" decimals="-5" id="f-664" unitRef="usd">73900000</carm:VariableConsideration>
    <carm:ContractTerm contextRef="c-119" id="f-665">P5Y</carm:ContractTerm>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-5" id="f-666" unitRef="usd">14900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-5" id="f-667" unitRef="usd">9800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-120" decimals="-5" id="f-668" unitRef="usd">24700000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock contextRef="c-1" id="f-669">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied as of December&#160;31, 2023 (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Transaction &lt;br/&gt;price unsatisfied&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount contextRef="c-6" decimals="-3" id="f-670" unitRef="usd">49183000</carm:RevenueRemainingPerformanceObligationResearchAndDevelopmentAmount>
    <carm:RevenueRemainingPerformanceObligationOptionRightsAmount contextRef="c-6" decimals="-3" id="f-671" unitRef="usd">45000000</carm:RevenueRemainingPerformanceObligationOptionRightsAmount>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-6" decimals="-3" id="f-672" unitRef="usd">94183000</us-gaap:RevenueRemainingPerformanceObligation>
    <carm:ScheduleOfChangesInDeferredRevenueTableTextBlock contextRef="c-1" id="f-673">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in deferred revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the beginning of the period &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recognition of unearned revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,834)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</carm:ScheduleOfChangesInDeferredRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-674" unitRef="usd">47459000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-9" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <carm:ContractWithCustomerLiabilityDeferralOfRevenue contextRef="c-1" decimals="-3" id="f-676" unitRef="usd">13873000</carm:ContractWithCustomerLiabilityDeferralOfRevenue>
    <carm:ContractWithCustomerLiabilityDeferralOfRevenue contextRef="c-8" decimals="-3" id="f-677" unitRef="usd">57293000</carm:ContractWithCustomerLiabilityDeferralOfRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-3" id="f-678" unitRef="usd">-14919000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-8" decimals="-3" id="f-679" unitRef="usd">-9834000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability contextRef="c-6" decimals="-3" id="f-680" unitRef="usd">46413000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-681" unitRef="usd">47459000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-121" decimals="-5" id="f-682" unitRef="usd">45000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-683">Subsequent Events&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated subsequent events from the balance sheet date through April&#160;1, 2024, the issuance date of these consolidated financial statements, and has not identified any additional matters requiring disclosure.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-122" id="f-684">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-122" id="f-685">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-122" id="f-686">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-122" id="f-687">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
